PMID-sentid	Pub_year	Sent_text	comp_official_name	comp_offset	protein_name	organism	prot_offset
2616041-2	1989	The activities of MAO-A and MAO-B were estimated radiochemically, in-vitro, in human hippocampus and rat striatum in the presence of various concentrations of THA with [2-14C]hydroxytryptamine binoxalate (100 microM) and beta-[ethyl-14C]phenylethylamine hydrochloride (20 microM) as substrates for the respective enzyme form.	Tacrine	159-162	monoamine oxidase A	Homo sapiens	18-23
2616041-2	1989	The activities of MAO-A and MAO-B were estimated radiochemically, in-vitro, in human hippocampus and rat striatum in the presence of various concentrations of THA with [2-14C]hydroxytryptamine binoxalate (100 microM) and beta-[ethyl-14C]phenylethylamine hydrochloride (20 microM) as substrates for the respective enzyme form.	[2-14c]hydroxytryptamine binoxalate	168-203	monoamine oxidase A	Homo sapiens	18-23
2616041-2	1989	The activities of MAO-A and MAO-B were estimated radiochemically, in-vitro, in human hippocampus and rat striatum in the presence of various concentrations of THA with [2-14C]hydroxytryptamine binoxalate (100 microM) and beta-[ethyl-14C]phenylethylamine hydrochloride (20 microM) as substrates for the respective enzyme form.	beta-[ethyl-14c]phenylethylamine hydrochloride	221-267	monoamine oxidase A	Homo sapiens	18-23
2809594-1	1989	Twenty analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were tested for their capacity to be oxidized by pure monoamine oxidase-A (MAO-A) prepared from human placenta and pure monoamine oxidase-B (MAO-B) prepared from beef liver.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-62	monoamine oxidase A	Homo sapiens	124-143
2809594-1	1989	Twenty analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were tested for their capacity to be oxidized by pure monoamine oxidase-A (MAO-A) prepared from human placenta and pure monoamine oxidase-B (MAO-B) prepared from beef liver.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-62	monoamine oxidase A	Homo sapiens	145-150
2809594-1	1989	Twenty analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were tested for their capacity to be oxidized by pure monoamine oxidase-A (MAO-A) prepared from human placenta and pure monoamine oxidase-B (MAO-B) prepared from beef liver.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	64-68	monoamine oxidase A	Homo sapiens	124-143
2809594-1	1989	Twenty analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) were tested for their capacity to be oxidized by pure monoamine oxidase-A (MAO-A) prepared from human placenta and pure monoamine oxidase-B (MAO-B) prepared from beef liver.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	64-68	monoamine oxidase A	Homo sapiens	145-150
2809594-6	1989	The corresponding pyridinium species of MPTP and several of the MPTP analogs inhibited MAO-A competitively with Ki values at micromolar concentrations; in contrast the pyridinium species inhibited MAO-B competitively at considerably higher concentrations (i.e., 100 microM or greater Ki values).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	64-68	monoamine oxidase A	Homo sapiens	87-92
2809594-2	1989	Several of the MPTP analogs were very good substrates for MAO-A, for MAO-B, or for both and had low Km values and high turnover numbers.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	15-19	monoamine oxidase A	Homo sapiens	58-63
2809594-7	1989	The data provide information concerning the structural requirements for the oxidation of tetrahydropyridines by MAO-A and MAO-B and the inhibition of these enzymes by pyridiniums.	Pyrrolidines	89-108	monoamine oxidase A	Homo sapiens	112-117
2809594-3	1989	These values were similar to or even better than those of kynuramine and benzylamine, good substrates for MAO-A and MAO-B, respectively.	Kynuramine	58-68	monoamine oxidase A	Homo sapiens	106-111
2809594-3	1989	These values were similar to or even better than those of kynuramine and benzylamine, good substrates for MAO-A and MAO-B, respectively.	benzylamine	73-84	monoamine oxidase A	Homo sapiens	106-111
2809594-4	1989	MPTP had relatively low Km values for oxidation by both MAO-A and MAO-B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	monoamine oxidase A	Homo sapiens	56-61
2809594-5	1989	In contrast, the turnover number for MPTP oxidation by MAO-B was considerably higher than the value for MAO-A.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	37-41	monoamine oxidase A	Homo sapiens	104-109
2809594-6	1989	The corresponding pyridinium species of MPTP and several of the MPTP analogs inhibited MAO-A competitively with Ki values at micromolar concentrations; in contrast the pyridinium species inhibited MAO-B competitively at considerably higher concentrations (i.e., 100 microM or greater Ki values).	pyridine	18-28	monoamine oxidase A	Homo sapiens	87-92
2809594-6	1989	The corresponding pyridinium species of MPTP and several of the MPTP analogs inhibited MAO-A competitively with Ki values at micromolar concentrations; in contrast the pyridinium species inhibited MAO-B competitively at considerably higher concentrations (i.e., 100 microM or greater Ki values).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	40-44	monoamine oxidase A	Homo sapiens	87-92
2633172-0	1989	Correspondence between 3H-MPP+ binding site and MAO-A enzyme: pharmacological evidences.	3-hydroxy-1-methyl-3-phenyl-2-piperidinone	23-30	monoamine oxidase A	Homo sapiens	48-53
2509446-3	1989	The preincubation of platelet MAO-B with purified MAO-A from mitochondrial membranes of human placenta resulted in appearance of excess octopamine activity.	Octopamine	136-146	monoamine oxidase A	Homo sapiens	50-55
2619973-2	1989	Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally.	Moclobemide	18-29	monoamine oxidase A	Homo sapiens	82-101
2619973-2	1989	Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally.	Moclobemide	18-29	monoamine oxidase A	Homo sapiens	103-108
2619973-2	1989	Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally.	Tyramine	195-203	monoamine oxidase A	Homo sapiens	103-108
2619973-2	1989	Administration of moclobemide--a relatively short-acting, reversible inhibitor of monoamine oxidase-A (MAO-A)--to experimental animals potentiates the pressor responses to intravenously injected tyramine, but such effects are moderate, short-lived, and much less apparent when the tyramine is given orally.	Tyramine	281-289	monoamine oxidase A	Homo sapiens	103-108
2619973-3	1989	The ability of moclobemide to potentiate the pharmacological actions of amine substrates for MAO-A in in vitro preparations is very weak, unless the drug is "activated" by prior incubation with the tissues.	Moclobemide	15-26	monoamine oxidase A	Homo sapiens	93-98
2619973-3	1989	The ability of moclobemide to potentiate the pharmacological actions of amine substrates for MAO-A in in vitro preparations is very weak, unless the drug is "activated" by prior incubation with the tissues.	Amines	72-77	monoamine oxidase A	Homo sapiens	93-98
2619974-0	1989	Effect of a reversible monoamine oxidase-A inhibitor (moclobemide) on sleep of depressed patients.	Moclobemide	54-65	monoamine oxidase A	Homo sapiens	23-42
2619974-1	1989	The effect of moclobemide, a short-acting, reversible, preferential monoamine oxidase-A inhibitor in a 4-week therapeutic trial, on the sleep of ten depressed patients, was assessed by polysomnographic recordings.	Moclobemide	14-25	monoamine oxidase A	Homo sapiens	68-87
2673623-2	1989	Moclobemide is a new, reversible, preferential monoamine oxidase A inhibitor with antidepressant properties.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	47-66
2695130-1	1989	The antidepressant efficacy, tolerability, and safety of moclobemide, a reversible, monoamine oxidase-A inhibitor, were compared with those of imipramine in parallel groups of patients with a major depressive episode, in a 4-week, multicentre (17 centres), randomised study.	Moclobemide	57-68	monoamine oxidase A	Homo sapiens	84-103
2511580-1	1989	13 patients with major depressive disorder, who responded well to the reversible MAO-A-inhibitor moclobemide after unsuccessful initial treatment with tri- or tetracyclic antidepressants were monitored under naturalistic outpatient therapy conditions with moclobemide plasma level control for an average of 7.4 months.	Moclobemide	97-108	monoamine oxidase A	Homo sapiens	81-86
2506486-8	1989	The results suggest that most of the HVA in plasma is derived from deamination of DA by MAO-A in peripheral neurons; that DOPAC in plasma is derived from cells outside the central nervous system; that DHPG in plasma is derived virtually exclusively from the metabolism of norepinephrine in sympathetic nerve endings and that residual levels of HVA after treatment with debrisoquin provide an improved but limited indication of central dopaminergic activity.	amsonic acid	82-84	monoamine oxidase A	Homo sapiens	88-93
2817346-1	1989	The monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, is the precursor of 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol, metabolites of noradrenaline.	Norepinephrine	38-51	monoamine oxidase A	Homo sapiens	4-23
2685852-3	1989	The objective of the present review is to evaluate the pharmacokinetics of five MAO-A inhibitors (moclobemide, toloxatone, brofaromine, cimoxatone, amiflamine).	Moclobemide	98-109	monoamine oxidase A	Homo sapiens	80-85
2685852-3	1989	The objective of the present review is to evaluate the pharmacokinetics of five MAO-A inhibitors (moclobemide, toloxatone, brofaromine, cimoxatone, amiflamine).	toloxatone	111-121	monoamine oxidase A	Homo sapiens	80-85
2685852-3	1989	The objective of the present review is to evaluate the pharmacokinetics of five MAO-A inhibitors (moclobemide, toloxatone, brofaromine, cimoxatone, amiflamine).	amiflamine	148-158	monoamine oxidase A	Homo sapiens	80-85
2685854-0	1989	[Brofaromine--a selective, reversible and short-acting MAO-A inhibitor].	brofaromine	1-12	monoamine oxidase A	Homo sapiens	55-60
2685854-3	1989	Brofaromine is a MAO-inhibitor of the second generation, a selective, reversible and short acting MAO-A-inhibitor, promising that the dangerous "cheese effect" will occur only under extreme conditions.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	98-103
2685855-1	1989	Moclobemide, a benzamidederivate, is a reversible, selective MAOI with a predominant effect upon MAO-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	97-102
2685855-1	1989	Moclobemide, a benzamidederivate, is a reversible, selective MAOI with a predominant effect upon MAO-A.	benzamidederivate	15-32	monoamine oxidase A	Homo sapiens	97-102
2685856-0	1989	[Treatment of depression using MAO-A inhibitors: an open study of a direct switch from moclobemide to tri-/tetracyclic antidepressants].	Moclobemide	87-98	monoamine oxidase A	Homo sapiens	31-36
2685856-1	1989	In an open study 13 depressed inpatients received moclobemide, a selective and reversible MAO-A-inhibitor (300 mg/d) for one week and subsequently were switched to a three-week course of a tricyclic or tetracyclic antidepressant (TCA) without medication-free interval.	Moclobemide	50-61	monoamine oxidase A	Homo sapiens	90-95
2587674-9	1989	The results suggest that the two reversible MAO-A inhibitors moclobemide and brofaromine carry a much reduced liability to tyramine-related hypertensive reactions.	Moclobemide	61-72	monoamine oxidase A	Homo sapiens	44-49
2587674-9	1989	The results suggest that the two reversible MAO-A inhibitors moclobemide and brofaromine carry a much reduced liability to tyramine-related hypertensive reactions.	brofaromine	77-88	monoamine oxidase A	Homo sapiens	44-49
2587674-9	1989	The results suggest that the two reversible MAO-A inhibitors moclobemide and brofaromine carry a much reduced liability to tyramine-related hypertensive reactions.	Tyramine	123-131	monoamine oxidase A	Homo sapiens	44-49
2587675-0	1989	[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].	Moclobemide	73-84	monoamine oxidase A	Homo sapiens	56-61
2587675-0	1989	[Psychometric findings in treatment using the selective MAO-A inhibitors moclobemide and maprotiline].	Maprotiline	89-100	monoamine oxidase A	Homo sapiens	56-61
2817346-1	1989	The monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, is the precursor of 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol, metabolites of noradrenaline.	3,4-dihydroxyphenylglycolaldehyde	53-86	monoamine oxidase A	Homo sapiens	4-23
2817346-1	1989	The monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, is the precursor of 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol, metabolites of noradrenaline.	3,4-dihydroxymandelic acid	108-134	monoamine oxidase A	Homo sapiens	4-23
2817346-1	1989	The monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, is the precursor of 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol, metabolites of noradrenaline.	3,4-dihydroxyphenylglycol	53-78	monoamine oxidase A	Homo sapiens	4-23
2817346-1	1989	The monoamine oxidase A metabolite of noradrenaline, 3,4-dihydroxyphenylglycolaldehyde, is the precursor of 3,4-dihydroxymandelic acid, and 3,4-dihydroxyphenylglycol, metabolites of noradrenaline.	Norepinephrine	182-195	monoamine oxidase A	Homo sapiens	4-23
2496202-1	1989	Monoamine oxidase (MAO) A and B are important enzymes that metabolize biogenic amines throughout the body.	Amines	79-85	monoamine oxidase A	Homo sapiens	0-31
2747630-1	1989	Monoamine oxidases (MAOs) A and B, flavin-containing enzymes found in the outer mitochondrial membrane, oxidize many important biogenic and xenobiotic amines.	4,6-dinitro-o-cresol	35-41	monoamine oxidase A	Homo sapiens	0-33
2747630-1	1989	Monoamine oxidases (MAOs) A and B, flavin-containing enzymes found in the outer mitochondrial membrane, oxidize many important biogenic and xenobiotic amines.	xenobiotic amines	140-157	monoamine oxidase A	Homo sapiens	0-33
2764901-0	1989	Monoamine oxidase A from human placenta and monoamine oxidase B from bovine liver both have one FAD per subunit.	Flavin-Adenine Dinucleotide	96-99	monoamine oxidase A	Homo sapiens	0-19
2744764-1	1989	Monoamine oxidase A and B (MAO A and B) are the central enzymes that catalyze oxidative deamination of biogenic amines throughout the body.	Amines	112-118	monoamine oxidase A	Homo sapiens	0-25
2744764-1	1989	Monoamine oxidase A and B (MAO A and B) are the central enzymes that catalyze oxidative deamination of biogenic amines throughout the body.	Amines	112-118	monoamine oxidase A	Homo sapiens	27-38
2496202-5	1989	Similar to the endogenous enzymes, the expressed MAO A prefers serotonin as a substrate and is sensitive to the inhibitor clorgyline.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	49-54
2496202-5	1989	Similar to the endogenous enzymes, the expressed MAO A prefers serotonin as a substrate and is sensitive to the inhibitor clorgyline.	Clorgyline	122-132	monoamine oxidase A	Homo sapiens	49-54
2920501-8	1989	The data suggest that the selective reversible MAO-A inhibitor brofaromine has a larger therapeutic safety than phenelzine.	brofaromine	63-74	monoamine oxidase A	Homo sapiens	47-52
2495232-7	1989	The mode of action of the various steroids on MAO A activity in endothelial cells seemed to be that of affecting the number of MAO molecules, as binding of [3H]pargyline, an MAO inhibitor, changed in proportion to changes in enzyme activity.	Steroids	34-42	monoamine oxidase A	Homo sapiens	46-51
2495232-7	1989	The mode of action of the various steroids on MAO A activity in endothelial cells seemed to be that of affecting the number of MAO molecules, as binding of [3H]pargyline, an MAO inhibitor, changed in proportion to changes in enzyme activity.	3h]pargyline	157-169	monoamine oxidase A	Homo sapiens	46-51
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Steroids	19-26	monoamine oxidase A	Homo sapiens	37-42
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Steroids	19-26	monoamine oxidase A	Homo sapiens	250-255
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Steroids	88-95	monoamine oxidase A	Homo sapiens	37-42
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Steroids	88-95	monoamine oxidase A	Homo sapiens	250-255
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Carbon-14	137-140	monoamine oxidase A	Homo sapiens	37-42
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Thymidine	141-150	monoamine oxidase A	Homo sapiens	37-42
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Carbon-14	196-199	monoamine oxidase A	Homo sapiens	37-42
2495232-9	1989	The specificity of steroid action on MAO A activity was also supported by the fact that steroid-induced changes in total cell division ([14C]thymidine incorporation) and total protein synthesis ([14C]leucine incorporation) were seen after changes in MAO A.	Leucine	200-207	monoamine oxidase A	Homo sapiens	37-42
2715286-1	1989	A sensitive gas chromatographic assay for the simultaneous determination of brofaromine [4-(7-bromo-5-methoxy-2-benzofuranyl)piperidine hydrochloride], a new monoamine oxidase-A inhibitor, and its major metabolite was developed and validated.	brofaromine	76-87	monoamine oxidase A	Homo sapiens	158-177
2715286-1	1989	A sensitive gas chromatographic assay for the simultaneous determination of brofaromine [4-(7-bromo-5-methoxy-2-benzofuranyl)piperidine hydrochloride], a new monoamine oxidase-A inhibitor, and its major metabolite was developed and validated.	brofaromine	89-149	monoamine oxidase A	Homo sapiens	158-177
2495009-1	1989	The concentrations of monoamine oxidase-A and -B were determined in homogenates of human cerebral cortex, caudatus and placenta and in human platelet-rich plasma and platelet membranes by determining the specific binding of tritium-labelled pargyline.	Tritium	224-231	monoamine oxidase A	Homo sapiens	22-48
2495009-1	1989	The concentrations of monoamine oxidase-A and -B were determined in homogenates of human cerebral cortex, caudatus and placenta and in human platelet-rich plasma and platelet membranes by determining the specific binding of tritium-labelled pargyline.	Pargyline	241-250	monoamine oxidase A	Homo sapiens	22-48
2495009-3	1989	Determinations of the minimum quantities of clorgyline, (-)-deprenyl, J-508 or pargyline necessary to give complete inhibition of enzyme activity was found to give overestimates of the amounts of monoamine oxidase-A and -B present due to nonspecific binding of these inhibitors.	Clorgyline	44-54	monoamine oxidase A	Homo sapiens	196-222
2495009-3	1989	Determinations of the minimum quantities of clorgyline, (-)-deprenyl, J-508 or pargyline necessary to give complete inhibition of enzyme activity was found to give overestimates of the amounts of monoamine oxidase-A and -B present due to nonspecific binding of these inhibitors.	Selegiline	56-68	monoamine oxidase A	Homo sapiens	196-222
2495009-3	1989	Determinations of the minimum quantities of clorgyline, (-)-deprenyl, J-508 or pargyline necessary to give complete inhibition of enzyme activity was found to give overestimates of the amounts of monoamine oxidase-A and -B present due to nonspecific binding of these inhibitors.	N-methyl-N-propargyl-(1-indanyl)-ammonium hydrochloride	70-75	monoamine oxidase A	Homo sapiens	196-222
2920501-8	1989	The data suggest that the selective reversible MAO-A inhibitor brofaromine has a larger therapeutic safety than phenelzine.	Phenelzine	112-122	monoamine oxidase A	Homo sapiens	47-52
2924086-4	1989	The results demonstrated the presence of MAO A and B in human thyroid cells which oxidized 5-hydroxytryptamine and 2-phenylethylamine, respectively, and were selectively inhibited by the MAO inhibitors clorgyline and (-)-deprenyl.	Serotonin	91-110	monoamine oxidase A	Homo sapiens	41-52
2469451-9	1989	Due to the rapid, reversible, dose-dependent and MAO-A specific effect of moclobemide on plasma concentrations of DHPG, it is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man.	Moclobemide	74-85	monoamine oxidase A	Homo sapiens	49-54
2469451-9	1989	Due to the rapid, reversible, dose-dependent and MAO-A specific effect of moclobemide on plasma concentrations of DHPG, it is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man.	Moclobemide	74-85	monoamine oxidase A	Homo sapiens	215-220
2469451-9	1989	Due to the rapid, reversible, dose-dependent and MAO-A specific effect of moclobemide on plasma concentrations of DHPG, it is suggested that DHPG in plasma may be a useful indicator of the magnitude and duration of MAO-A inhibition in man.	3,4-dihydroxyphenylglycol	114-118	monoamine oxidase A	Homo sapiens	49-54
2924086-4	1989	The results demonstrated the presence of MAO A and B in human thyroid cells which oxidized 5-hydroxytryptamine and 2-phenylethylamine, respectively, and were selectively inhibited by the MAO inhibitors clorgyline and (-)-deprenyl.	phenethylamine	115-133	monoamine oxidase A	Homo sapiens	41-52
2924086-4	1989	The results demonstrated the presence of MAO A and B in human thyroid cells which oxidized 5-hydroxytryptamine and 2-phenylethylamine, respectively, and were selectively inhibited by the MAO inhibitors clorgyline and (-)-deprenyl.	Clorgyline	202-212	monoamine oxidase A	Homo sapiens	41-52
2924086-4	1989	The results demonstrated the presence of MAO A and B in human thyroid cells which oxidized 5-hydroxytryptamine and 2-phenylethylamine, respectively, and were selectively inhibited by the MAO inhibitors clorgyline and (-)-deprenyl.	Selegiline	217-229	monoamine oxidase A	Homo sapiens	41-52
2924086-12	1989	It is therefore apparent that even though thyroid MAO A and B enzyme reactions result in the generation of H2O2, this H2O2 does not seem to play a significant role in T3 biosynthesis.	Hydrogen Peroxide	107-111	monoamine oxidase A	Homo sapiens	50-55
22156310-0	1989	Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers.	Tyramine	59-67	monoamine oxidase A	Homo sapiens	107-112
2677240-0	1989	Therapeutic and side-effect profile of a selective and reversible MAO-A inhibitor, brofaromine.	brofaromine	83-94	monoamine oxidase A	Homo sapiens	66-71
2714732-1	1989	We investigated the pressor response to oral tyramine before and during treatment with moclobemide, a selective monoamine oxidase-A inhibitor, in 10 depressed patients.	Moclobemide	87-98	monoamine oxidase A	Homo sapiens	112-131
2794993-10	1989	The results suggest that the two reversible MAO-A inhibitors Mocl and Brof may lessen the liability to TYR-related hypertensive reactions.	Tyramine	103-106	monoamine oxidase A	Homo sapiens	44-49
22156310-0	1989	Potentiation of the pressor effect of oral and intravenous tyramine during administration of the selective MAO-A inhibitor moclobemide in healthy volunteers.	Moclobemide	123-134	monoamine oxidase A	Homo sapiens	107-112
2483108-2	1989	In this investigation we demonstrate in these cousins deletion of the MAOA gene, undetectable levels of MAO-A and MAO-B activities in their fibroblasts and platelets, respectively, loss of mRNA for MAO-A in fibroblasts, and substantial alterations in urinary catecholamine metabolites.	Catecholamines	259-272	monoamine oxidase A	Homo sapiens	70-74
2601584-0	1989	The effect of debrisoquin on MAO A and MAO B activities.	Debrisoquin	14-25	monoamine oxidase A	Homo sapiens	29-34
2622533-3	1989	While dopaminergic neurons of the substantia nigra revealed no staining for monoamine oxidase, noradrenergic neurons of the locus coeruleus stained positively with the monoamine oxidase-A substrate serotonin, and serotonergic neurons of the raphe nuclei were stained by the monoamine oxidase-B substrate beta-phenylethylamine.	phenethylamine	304-325	monoamine oxidase A	Homo sapiens	168-187
2508163-1	1989	The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide.	Moclobemide	79-90	monoamine oxidase A	Homo sapiens	36-60
2508163-1	1989	The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide.	Moclobemide	79-90	monoamine oxidase A	Homo sapiens	62-67
2508163-1	1989	The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide.	Moclobemide	210-221	monoamine oxidase A	Homo sapiens	36-60
2508163-1	1989	The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide.	Moclobemide	92-102	monoamine oxidase A	Homo sapiens	36-60
2508163-1	1989	The concentration of the reversible monoamine oxidase type-A (MAO-A) inhibitor moclobemide (Ro 11-1163) was determined by high pressure liquid chromatography (HPLC) in the plasma of 16 depressives treated with moclobemide.	Moclobemide	92-102	monoamine oxidase A	Homo sapiens	62-67
3244725-0	1988	Characterization of MAO A and MAO B in human placental mitochondria by activity, immunoblotting and radioimmunoassay with monoclonal antibodies and active site labeling with 3H-pargyline.	3h-pargyline	174-186	monoamine oxidase A	Homo sapiens	20-25
3137566-0	1988	Importance of monoamine oxidase A in the bioactivation of neurotoxic analogs of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	80-124	monoamine oxidase A	Homo sapiens	14-33
3242595-0	1988	Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine.	1-phenylcyclopropylamine	76-100	monoamine oxidase A	Homo sapiens	16-35
3242595-0	1988	Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine.	1-benzylcyclopropylamine	102-126	monoamine oxidase A	Homo sapiens	16-35
3242595-0	1988	Inactivation of monoamine oxidase A by the monoamine oxidase B inactivators 1-phenylcyclopropylamine, 1-benzylcyclopropylamine, and N-cyclopropyl-alpha-methylbenzylamine.	N-(1-methyl)cyclopropylbenzylamine	132-169	monoamine oxidase A	Homo sapiens	16-35
3242595-6	1988	The reaction of 1-BCPA with MAO A was too slow to study in detail.	1-benzylcyclopropylamine	16-22	monoamine oxidase A	Homo sapiens	28-33
3242595-9	1988	The results with 1-PCPA indicate that the active site topographies of MAO A and MAO B are different.	1-phenylcyclopropylamine	17-23	monoamine oxidase A	Homo sapiens	70-75
3242595-10	1988	The ability of N-C alpha MBA to undergo attachment to a cysteine residue in both MAO A and MAO B may lead the way toward peptide mapping of the two isozymes in order to determine differences in their primary structures.	Cysteine	56-64	monoamine oxidase A	Homo sapiens	81-86
3137566-4	1988	However, the neurotoxicity of these two analogs can be prevented by pretreatment with a combination of deprenyl and the selective MAO-A inhibitor clorgyline at doses that are sufficient to almost completely inhibit both MAO-B and MAO-A activities.	Clorgyline	146-156	monoamine oxidase A	Homo sapiens	130-135
3137566-4	1988	However, the neurotoxicity of these two analogs can be prevented by pretreatment with a combination of deprenyl and the selective MAO-A inhibitor clorgyline at doses that are sufficient to almost completely inhibit both MAO-B and MAO-A activities.	Clorgyline	146-156	monoamine oxidase A	Homo sapiens	230-235
3137566-7	1988	The data support the conclusion that both 2"-MeMPTP and 2"-EtMPTP are bioactivated to pyridinium species to a significant extent by MAO-A.	2"-memptp	42-51	monoamine oxidase A	Homo sapiens	132-137
3137566-7	1988	The data support the conclusion that both 2"-MeMPTP and 2"-EtMPTP are bioactivated to pyridinium species to a significant extent by MAO-A.	2"-etmptp	56-65	monoamine oxidase A	Homo sapiens	132-137
3137566-7	1988	The data support the conclusion that both 2"-MeMPTP and 2"-EtMPTP are bioactivated to pyridinium species to a significant extent by MAO-A.	pyridine	86-96	monoamine oxidase A	Homo sapiens	132-137
3399053-3	1988	Neurons in regions rich in catecholamines were positive for monoamine oxidase A, including the nucleus locus coeruleus, the nucleus subcoeruleus and the medullary reticular formation.	Catecholamines	27-41	monoamine oxidase A	Homo sapiens	60-79
3266532-3	1988	Brain selectivity would overcome the risk of tyramine interactions which have been shown to occur with selective MAO-A but not MAO-B inhibitors.	Tyramine	45-53	monoamine oxidase A	Homo sapiens	113-118
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	35-45	monoamine oxidase A	Homo sapiens	167-172
3346666-4	1988	The apparent Km (30-90 microM) for milacemide oxidation by mitochondrial MAO-B preparations is significantly lower than that for milacemide oxidation by mitochondrial MAO-A (approximately 1,300 microM).	milacemide	129-139	monoamine oxidase A	Homo sapiens	167-172
3346669-1	1988	A series of methylquinolines (MQ) were found to inhibit markedly type A monoamine oxidase (MAO) in human brain synaptosomal mitochondria.	methylquinolines	12-28	monoamine oxidase A	Homo sapiens	91-94
3346669-1	1988	A series of methylquinolines (MQ) were found to inhibit markedly type A monoamine oxidase (MAO) in human brain synaptosomal mitochondria.	memoquin	30-32	monoamine oxidase A	Homo sapiens	91-94
3346669-2	1988	4-MQ and 6-MQ inhibited type A MAO (MAO-A) competitively and 7- and 8-MQ inhibited MAO-A noncompetitively.	4-methylquinoline	0-4	monoamine oxidase A	Homo sapiens	31-34
3346669-2	1988	4-MQ and 6-MQ inhibited type A MAO (MAO-A) competitively and 7- and 8-MQ inhibited MAO-A noncompetitively.	4-methylquinoline	0-4	monoamine oxidase A	Homo sapiens	36-41
3346669-2	1988	4-MQ and 6-MQ inhibited type A MAO (MAO-A) competitively and 7- and 8-MQ inhibited MAO-A noncompetitively.	6-methylquinoline	9-13	monoamine oxidase A	Homo sapiens	31-34
3346669-2	1988	4-MQ and 6-MQ inhibited type A MAO (MAO-A) competitively and 7- and 8-MQ inhibited MAO-A noncompetitively.	6-methylquinoline	9-13	monoamine oxidase A	Homo sapiens	36-41
3346669-2	1988	4-MQ and 6-MQ inhibited type A MAO (MAO-A) competitively and 7- and 8-MQ inhibited MAO-A noncompetitively.	7- and 8-mq	61-72	monoamine oxidase A	Homo sapiens	83-88
3346669-3	1988	Among these four isomers of MQ, 6-MQ was the most potent inhibitor; the Ki value toward MAO-A was 23.4 +/- 1.8 microM, which was smaller than the Km value toward kynuramine, an amine substrate, 46.2 +/- 2.8 microM.	memoquin	28-30	monoamine oxidase A	Homo sapiens	88-93
3346669-3	1988	Among these four isomers of MQ, 6-MQ was the most potent inhibitor; the Ki value toward MAO-A was 23.4 +/- 1.8 microM, which was smaller than the Km value toward kynuramine, an amine substrate, 46.2 +/- 2.8 microM.	6-methylquinoline	32-36	monoamine oxidase A	Homo sapiens	88-93
3346669-4	1988	On the other hand, MQ were very weak inhibitors of type B MAO (MAO-B) and 8-MQ did not inhibit MAO-B in brain synaptosomal mitochondria.	memoquin	19-21	monoamine oxidase A	Homo sapiens	58-61
3346669-4	1988	On the other hand, MQ were very weak inhibitors of type B MAO (MAO-B) and 8-MQ did not inhibit MAO-B in brain synaptosomal mitochondria.	memoquin	19-21	monoamine oxidase A	Homo sapiens	63-68
3346669-7	1988	The relationship of the chemical structure of structurally related quinoline and isoquinoline derivatives to inhibition of the activity of type A or B MAO was examined.	quinoline	67-76	monoamine oxidase A	Homo sapiens	151-154
3346669-7	1988	The relationship of the chemical structure of structurally related quinoline and isoquinoline derivatives to inhibition of the activity of type A or B MAO was examined.	isoquinoline	81-93	monoamine oxidase A	Homo sapiens	151-154
3340083-0	1988	Photoaffinity labeling of human placental monoamine oxidase-A by 4-fluoro-3-nitrophenyl azide.	4-fluoro-3-nitrophenyl azide	65-93	monoamine oxidase A	Homo sapiens	42-59
3340083-1	1988	Our previous work has shown that low concentrations of 4-fluoro-3-nitrophenyl azide (FNPA) (0.01-1 microM) photodependently inhibited only the type B monoamine oxidase in rat brain [Biochem.	4-fluoro-3-nitrophenyl azide	55-83	monoamine oxidase A	Homo sapiens	150-167
3340083-1	1988	Our previous work has shown that low concentrations of 4-fluoro-3-nitrophenyl azide (FNPA) (0.01-1 microM) photodependently inhibited only the type B monoamine oxidase in rat brain [Biochem.	4-fluoro-3-nitrophenyl azide	85-89	monoamine oxidase A	Homo sapiens	150-167
3340083-5	1988	FNPA acted as a competitive inhibitor for human placental MAO-A in the dark (Ki = 10 microM) when [14C]serotonin was used as the substrate.	Carbon-14	99-102	monoamine oxidase A	Homo sapiens	58-63
3340083-5	1988	FNPA acted as a competitive inhibitor for human placental MAO-A in the dark (Ki = 10 microM) when [14C]serotonin was used as the substrate.	Serotonin	103-112	monoamine oxidase A	Homo sapiens	58-63
3340083-7	1988	The specificity of the photodependent incorporation of FNPA to MAO-A was shown by the protective effect of serotonin during the irradiation.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	63-68
3335842-1	1988	4-(O-Benzylphenoxy)-N-methylbutylamine (Bifemelane, BP-N-methylbutylamine), a new psychotropic drug, was found to inhibit monoamine oxidase (MAO) in human brain synaptosomes.	bifemelane	0-38	monoamine oxidase A	Homo sapiens	141-144
3335842-1	1988	4-(O-Benzylphenoxy)-N-methylbutylamine (Bifemelane, BP-N-methylbutylamine), a new psychotropic drug, was found to inhibit monoamine oxidase (MAO) in human brain synaptosomes.	bifemelane	40-50	monoamine oxidase A	Homo sapiens	141-144
3335842-1	1988	4-(O-Benzylphenoxy)-N-methylbutylamine (Bifemelane, BP-N-methylbutylamine), a new psychotropic drug, was found to inhibit monoamine oxidase (MAO) in human brain synaptosomes.	Bifemelane	52-73	monoamine oxidase A	Homo sapiens	141-144
3335842-3	1988	BP-N-methylbutylamine had a much higher affinity to MAO-A than an amine substrate, kynuramine, and it was a more potent inhibitor of MAO-A than of MAO-B.	Bifemelane	0-21	monoamine oxidase A	Homo sapiens	52-57
3335842-3	1988	BP-N-methylbutylamine had a much higher affinity to MAO-A than an amine substrate, kynuramine, and it was a more potent inhibitor of MAO-A than of MAO-B.	Bifemelane	0-21	monoamine oxidase A	Homo sapiens	133-138
3335842-3	1988	BP-N-methylbutylamine had a much higher affinity to MAO-A than an amine substrate, kynuramine, and it was a more potent inhibitor of MAO-A than of MAO-B.	Amines	16-21	monoamine oxidase A	Homo sapiens	52-57
3335842-3	1988	BP-N-methylbutylamine had a much higher affinity to MAO-A than an amine substrate, kynuramine, and it was a more potent inhibitor of MAO-A than of MAO-B.	Amines	16-21	monoamine oxidase A	Homo sapiens	133-138
3335842-5	1988	The inhibition of MAO-A and -B by BP-N-methylbutylamine was found to be reversible by dialysis of the incubation mixture.	Bifemelane	34-55	monoamine oxidase A	Homo sapiens	18-30
3335842-6	1988	MAO-A in human placental and liver mitochondria and in a rat clonal pheochromocytoma cell line, PC12h, was inhibited competitively by BP-N-methylbutylamine, while MAO-B in human liver mitochondria was inhibited noncompetitively, as in human brain synaptosomes.	pc12h	96-101	monoamine oxidase A	Homo sapiens	0-5
3335842-6	1988	MAO-A in human placental and liver mitochondria and in a rat clonal pheochromocytoma cell line, PC12h, was inhibited competitively by BP-N-methylbutylamine, while MAO-B in human liver mitochondria was inhibited noncompetitively, as in human brain synaptosomes.	Bifemelane	134-155	monoamine oxidase A	Homo sapiens	0-5
3335842-8	1988	The effects of other BP-N-methylalkylamines, such as BP-N-methylethylamine, -propylamine, and -pentanylamine, on MAO activity were examined.	bp-n-methylalkylamines	21-43	monoamine oxidase A	Homo sapiens	113-116
3335842-8	1988	The effects of other BP-N-methylalkylamines, such as BP-N-methylethylamine, -propylamine, and -pentanylamine, on MAO activity were examined.	bp-n-methylethylamine	53-74	monoamine oxidase A	Homo sapiens	113-116
3335842-8	1988	The effects of other BP-N-methylalkylamines, such as BP-N-methylethylamine, -propylamine, and -pentanylamine, on MAO activity were examined.	Propylamines	77-88	monoamine oxidase A	Homo sapiens	113-116
3335842-8	1988	The effects of other BP-N-methylalkylamines, such as BP-N-methylethylamine, -propylamine, and -pentanylamine, on MAO activity were examined.	pentanylamine	95-108	monoamine oxidase A	Homo sapiens	113-116
3335842-9	1988	BP-N-methylbutylamine was the most potent inhibitor of MAO-A, and BP-N-methylethylamine and -propylamine inhibited MAO-B competitively, whereas BP-N-methylbutylamine and -pentanylamine inhibited it noncompetitively.	Bifemelane	0-21	monoamine oxidase A	Homo sapiens	55-60
3335842-9	1988	BP-N-methylbutylamine was the most potent inhibitor of MAO-A, and BP-N-methylethylamine and -propylamine inhibited MAO-B competitively, whereas BP-N-methylbutylamine and -pentanylamine inhibited it noncompetitively.	Bifemelane	0-21	monoamine oxidase A	Homo sapiens	55-58
3335842-10	1988	Inhibition of these BP-N-methylalkylamines on MAO-A and -B is discussed in relation to their chemical structure.	bp-n-methylalkylamines	20-42	monoamine oxidase A	Homo sapiens	46-58
3045798-3	1988	The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66.	Moclobemide	40-51	monoamine oxidase A	Homo sapiens	19-24
3045798-3	1988	The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66.	Moclobemide	40-51	monoamine oxidase A	Homo sapiens	95-100
3045798-3	1988	The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66.	brofaromine	56-67	monoamine oxidase A	Homo sapiens	19-24
3045798-3	1988	The most selective MAO-A inhibitors are moclobemide and brofaromine, with ratios between their MAO-A and MAO-B inhibiting potency (estimated in in vitro assays) of 1: greater than or equal to 1000 and 1:500, respectively, whereas the least selective drug is cimoxatone with a ratio of 1:66.	brofaromine	56-67	monoamine oxidase A	Homo sapiens	95-100
3045798-4	1988	If in vitro findings are considered, the most potent MAO-A inhibitor seems to be cimoxatone and the least potent toloxatone.	cimoxatone	81-91	monoamine oxidase A	Homo sapiens	53-58
3045798-4	1988	If in vitro findings are considered, the most potent MAO-A inhibitor seems to be cimoxatone and the least potent toloxatone.	toloxatone	113-123	monoamine oxidase A	Homo sapiens	53-58
3045798-5	1988	After oral administration, however, cimoxatone, brofaromine and moclobemide appear to be about equally effective in inhibiting brain MAO-A.	cimoxatone	36-46	monoamine oxidase A	Homo sapiens	133-138
3045798-5	1988	After oral administration, however, cimoxatone, brofaromine and moclobemide appear to be about equally effective in inhibiting brain MAO-A.	brofaromine	48-59	monoamine oxidase A	Homo sapiens	133-138
3126263-6	1988	The selective inactivation of MAO-B, e.g., by l-deprenyl prevented the covalent incorporation of [3H]Ro 16-6491 whereas selective inhibition of the MAO-A by clorgyline was without effect.	Clorgyline	157-167	monoamine oxidase A	Homo sapiens	148-153
3126263-7	1988	The covalent linkage to membranes of unlabelled Ro 16-6491 and Ro 19-6327 (a selective and reversible MAO-B inhibitor closely related to Ro 16-6491) after the addition of NaBH3CN at pH 4.5 irreversibly inactivated MAO-B activity whereas MAO-A activity was unaffected.	Ro 16-6491	48-58	monoamine oxidase A	Homo sapiens	237-242
3126263-7	1988	The covalent linkage to membranes of unlabelled Ro 16-6491 and Ro 19-6327 (a selective and reversible MAO-B inhibitor closely related to Ro 16-6491) after the addition of NaBH3CN at pH 4.5 irreversibly inactivated MAO-B activity whereas MAO-A activity was unaffected.	lazabemide	63-73	monoamine oxidase A	Homo sapiens	237-242
3257699-0	1988	Substituted phenylpiperidines and phenylpyridines as reversible selective inhibitors of monoamine oxidase type A in rodent brain and liver.	phenylpiperidines	12-29	monoamine oxidase A	Homo sapiens	88-112
3257699-0	1988	Substituted phenylpiperidines and phenylpyridines as reversible selective inhibitors of monoamine oxidase type A in rodent brain and liver.	phenylpyridines	34-49	monoamine oxidase A	Homo sapiens	88-112
2451963-4	1988	Selective inhibition of intraneuronal MAO-A with MDL 72394 (0.5 mg kg-1, i.p.)	beta-fluoromethylene-3-tyrosine	49-58	monoamine oxidase A	Homo sapiens	38-43
2451963-8	1988	Selective inhibition of MAO-A at all sites with clorgyline (5 mg kg-1, i.p.)	Clorgyline	48-58	monoamine oxidase A	Homo sapiens	24-29
2451963-19	1988	The results demonstrate that inhibition of MAO-A and -B both within amine neurones and elsewhere in the brain is essential for the development of the 5-HT behavioural syndrome.	Amines	68-73	monoamine oxidase A	Homo sapiens	43-55
2452231-1	1988	In this paper the preliminary results from an ongoing investigation on the effect of the MAO-A inhibitor moclobemide on clinicolaboratory variables (antidepressant effect, platelet MAO activity, urinary MHPG and 5-HIAA excretion, plasma prolactin and growth hormone levels and TSH response to TRH) are reported.	Moclobemide	105-116	monoamine oxidase A	Homo sapiens	89-94
3184554-9	1988	These results indicated that MAO-A inhibitors potentiated the ocular hypotensive effects of epinephrine, and that the coadministration of a reversible MAO-A inhibitor with epinephrine might be useful for patients with glaucoma.	Epinephrine	92-103	monoamine oxidase A	Homo sapiens	29-34
3184554-9	1988	These results indicated that MAO-A inhibitors potentiated the ocular hypotensive effects of epinephrine, and that the coadministration of a reversible MAO-A inhibitor with epinephrine might be useful for patients with glaucoma.	Epinephrine	172-183	monoamine oxidase A	Homo sapiens	151-156
3045798-5	1988	After oral administration, however, cimoxatone, brofaromine and moclobemide appear to be about equally effective in inhibiting brain MAO-A.	Moclobemide	64-75	monoamine oxidase A	Homo sapiens	133-138
3045798-6	1988	All these drugs are short acting and their MAO-inhibiting action is reversible within 24 h or, in the case of brofaromine, 48 h. Due to the selectivity and reversibility of the MAO-A inhibition, they were found to be less likely to induce large increases in the pressor responses to tyramine, both in animals and in man.	brofaromine	110-121	monoamine oxidase A	Homo sapiens	177-182
3247497-4	1988	Inhibition of MAO-A of human placental mitochondria by L- and D-DOPA was non-competitive with the substrate kynuramine (Ki = 154 microM and 133 microM, respectively).	l- and d-dopa	55-68	monoamine oxidase A	Homo sapiens	14-19
3247497-4	1988	Inhibition of MAO-A of human placental mitochondria by L- and D-DOPA was non-competitive with the substrate kynuramine (Ki = 154 microM and 133 microM, respectively).	Kynuramine	108-118	monoamine oxidase A	Homo sapiens	14-19
3266532-13	1988	Selective inhibition of brain MAO-A can be achieved by using the bioprecursor amino acid MDL 72394 (E-beta-fluoromethylene-m-tyrosine).	beta-fluoromethylene-3-tyrosine	89-98	monoamine oxidase A	Homo sapiens	30-35
3247497-5	1988	L-alpha-methyl-DOPA competitively inhibited MAO-A (Ki = 121 microM).	Methyldopa	0-19	monoamine oxidase A	Homo sapiens	44-49
3247497-6	1988	MAO-A and MAO-B of human liver mitochondria were also inhibited by L-DOPA (Ki = 152 microM and 275 microM, respectively).	Levodopa	67-73	monoamine oxidase A	Homo sapiens	0-5
3266532-13	1988	Selective inhibition of brain MAO-A can be achieved by using the bioprecursor amino acid MDL 72394 (E-beta-fluoromethylene-m-tyrosine).	e-beta-fluoromethylene-m-tyrosine	100-133	monoamine oxidase A	Homo sapiens	30-35
3363166-4	1988	Acute oral administration of the selective reversible MAO-A inhibitor brofaromine but not of the - in low doses - selective MAO-B inhibitor pargyline increased daytime melatonin with large variations in onset, degree and duration.	brofaromine	70-81	monoamine oxidase A	Homo sapiens	54-59
3363166-6	1988	Further investigation of this selective action on melatonin might help to better understand the action of the therapeutically effective antidepressive therapy with selective MAO-A inhibitors.	Melatonin	50-59	monoamine oxidase A	Homo sapiens	174-179
3432361-0	1987	Results of an open clinical trial of brofaromine (CGP 11 305 A), a competitive, selective, and short-acting inhibitor of MAO-A in major endogenous depression.	brofaromine	37-48	monoamine oxidase A	Homo sapiens	121-126
3432361-7	1987	The specificity of brofaromine to inhibit deamination is limited to MAO-A, since no reduction in platelet MAO activity was measurable.	brofaromine	19-30	monoamine oxidase A	Homo sapiens	68-73
3601232-1	1987	The effect of 1,4-benzoquinone (BQ) on type A and B monoamine oxidase (MAO-A and -B) in human brain synaptosomes was examined.	quinone	14-30	monoamine oxidase A	Homo sapiens	71-83
3432450-1	1987	Moclobemide is a reversible, short-acting monoamine oxidase inhibitor (MAO1), specific for MAO A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	91-96
3665338-0	1987	Disposition kinetics of moclobemide, a monoamine oxidase-A enzyme inhibitor: single and multiple dosing in normal subjects.	Moclobemide	24-35	monoamine oxidase A	Homo sapiens	39-58
3632718-5	1987	Thus, also in species where the MAO-B activity (as estimated in a conventional way) was dominating, the intrasynaptosomal deamination of dopamine was brought about mainly by MAO-A.	Dopamine	137-145	monoamine oxidase A	Homo sapiens	174-179
3601232-1	1987	The effect of 1,4-benzoquinone (BQ) on type A and B monoamine oxidase (MAO-A and -B) in human brain synaptosomes was examined.	quinone	32-34	monoamine oxidase A	Homo sapiens	71-83
3298420-0	1987	A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.	Moclobemide	50-61	monoamine oxidase A	Homo sapiens	34-39
3298420-0	1987	A clinical study of the selective MAO-A-inhibitor moclobemide (Ro 11-1163): a comparison of 2 different dosages with particular reference to platelet MAO-activity and urinary MHPG-excretion.	Moclobemide	63-73	monoamine oxidase A	Homo sapiens	34-39
3298420-1	1987	A new selective MAO-A-inhibitor (noclobemide) was used in a double-blind comparative study of 23 patients with severe unipolar or bipolar depressive disorder.	noclobemide	33-44	monoamine oxidase A	Homo sapiens	16-21
3494215-2	1987	We studied the effect of MPP+ on type A monoamine oxidase (MAO-A) activity in mitochondria prepared from various sources.	mangion-purified polysaccharide (Candida albicans)	25-29	monoamine oxidase A	Homo sapiens	59-64
3821373-0	1987	Quinoline and quninaldine as naturally occurring inhibitors specific for type A monoamine oxidase.	quinoline	0-9	monoamine oxidase A	Homo sapiens	80-97
3821373-0	1987	Quinoline and quninaldine as naturally occurring inhibitors specific for type A monoamine oxidase.	quninaldine	14-25	monoamine oxidase A	Homo sapiens	80-97
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	quinoline	128-137	monoamine oxidase A	Homo sapiens	7-24
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	quinoline	128-137	monoamine oxidase A	Homo sapiens	26-31
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	2-methylquinoline	142-152	monoamine oxidase A	Homo sapiens	7-24
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	2-methylquinoline	142-152	monoamine oxidase A	Homo sapiens	26-31
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	Kynuramine	160-170	monoamine oxidase A	Homo sapiens	7-24
3821373-1	1987	Type A monoamine oxidase (MAO-A) in human placental mitochondria was competitively inhibited by naturally occurring substances, quinoline and quinaldine, using kynuramine as substrate.	Kynuramine	160-170	monoamine oxidase A	Homo sapiens	26-31
3821373-3	1987	MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline.	quinoline	83-92	monoamine oxidase A	Homo sapiens	0-5
3821373-3	1987	MAO-A in human brain synaptosomal mitochondria was also competitively inhibited by quinoline, while type B MAO (MAO-B) was reversibly and non-competitively inhibited by quinoline.	quinoline	169-178	monoamine oxidase A	Homo sapiens	0-5
3821373-4	1987	Quinoline inhibited MAO-A much more potently than MAO-B.	quinoline	0-9	monoamine oxidase A	Homo sapiens	20-25
3821373-5	1987	Of several compounds structurally similar to quinoline, isoquinoline noncompetitively inhibited MAO-A and -B activity.	quinoline	45-54	monoamine oxidase A	Homo sapiens	96-108
3821373-5	1987	Of several compounds structurally similar to quinoline, isoquinoline noncompetitively inhibited MAO-A and -B activity.	isoquinoline	56-68	monoamine oxidase A	Homo sapiens	96-108
3806102-3	1987	MAO-A in human placental mitochondria was strongly inhibited by N-MIQ in competition with the substrate.	N-methylisoquinolinium	64-69	monoamine oxidase A	Homo sapiens	0-5
2952905-6	1987	Among compounds structurally related to QUIN, 4-pyrimidine carboxaldehyde was the most potent substrate-competitive inhibitor of MAO-B, while 3-hydroxyanthranilic acid and xanthrenic acid, other metabolites of tryptophan, inhibited MAO non-competitively with the substrate.	Quinolinic Acid	40-44	monoamine oxidase A	Homo sapiens	129-132
2952905-6	1987	Among compounds structurally related to QUIN, 4-pyrimidine carboxaldehyde was the most potent substrate-competitive inhibitor of MAO-B, while 3-hydroxyanthranilic acid and xanthrenic acid, other metabolites of tryptophan, inhibited MAO non-competitively with the substrate.	4-pyrimidine carboxaldehyde	46-73	monoamine oxidase A	Homo sapiens	129-132
2952905-6	1987	Among compounds structurally related to QUIN, 4-pyrimidine carboxaldehyde was the most potent substrate-competitive inhibitor of MAO-B, while 3-hydroxyanthranilic acid and xanthrenic acid, other metabolites of tryptophan, inhibited MAO non-competitively with the substrate.	Tryptophan	210-220	monoamine oxidase A	Homo sapiens	129-132
3099392-0	1987	Mapping human brain monoamine oxidase A and B with 11C-labeled suicide inactivators and PET.	Carbon-11	51-54	monoamine oxidase A	Homo sapiens	20-39
3099392-1	1987	The regional distributions of monoamine oxidase (MAO) types A and B have been identified in human brain in vivo with intravenously injected 11C-labeled suicide enzyme inactivators, clorgyline and L-deprenyl, and positron emission tomography.	Carbon-11	140-143	monoamine oxidase A	Homo sapiens	30-67
3099392-1	1987	The regional distributions of monoamine oxidase (MAO) types A and B have been identified in human brain in vivo with intravenously injected 11C-labeled suicide enzyme inactivators, clorgyline and L-deprenyl, and positron emission tomography.	Clorgyline	181-191	monoamine oxidase A	Homo sapiens	30-67
3099392-1	1987	The regional distributions of monoamine oxidase (MAO) types A and B have been identified in human brain in vivo with intravenously injected 11C-labeled suicide enzyme inactivators, clorgyline and L-deprenyl, and positron emission tomography.	Selegiline	196-206	monoamine oxidase A	Homo sapiens	30-67
3099392-3	1987	The anatomical distribution of 11C paralleled the distribution of MAO A and MAO B in human brain in autopsy material.	Carbon-11	31-34	monoamine oxidase A	Homo sapiens	66-71
3494215-3	1987	By kinetic analysis, MPP+ was found to inhibit MAO-A in competition with the substrate, kynuramine.	Kynuramine	88-98	monoamine oxidase A	Homo sapiens	47-52
3494215-4	1987	The Ki value of MAO-A with MPP+ in human brain synaptosomal mitochondria (1.3 microM) was much lower than the Ki values of MAO-A in other organs.	mangion-purified polysaccharide (Candida albicans)	27-31	monoamine oxidase A	Homo sapiens	16-21
3494215-5	1987	Among the MAO-A samples, MAO-A in intrasynaptosomal mitochondria from human brain was the most sensitive to MPP+.	mangion-purified polysaccharide (Candida albicans)	108-112	monoamine oxidase A	Homo sapiens	10-15
3494215-5	1987	Among the MAO-A samples, MAO-A in intrasynaptosomal mitochondria from human brain was the most sensitive to MPP+.	mangion-purified polysaccharide (Candida albicans)	108-112	monoamine oxidase A	Homo sapiens	25-30
3494215-6	1987	The Ki value of MAO-A with MPP+ in striatum (1.6 microM and 2.0 microM for MAO-A prepared from putamen and from caudate) was similar to the Ki value of MAO-A in synaptosomes from cortex.	mangion-purified polysaccharide (Candida albicans)	27-31	monoamine oxidase A	Homo sapiens	16-21
2436247-5	1987	These dose-dependent reductions are consistent with in vitro biochemical and anatomical data from primate brain suggesting that at low doses of deprenyl, MAO-B inhibition might be expected to selectively affect dopamine and serotonin-containing neurons, while at higher doses (which lead to MAO-A as well as MAO-B inhibition), noradrenergic neurons may become relatively more affected by the drug.	Selegiline	144-152	monoamine oxidase A	Homo sapiens	291-296
3030067-0	1987	Localization of MAO-A and MAO-B in human brain: a step in understanding the therapeutic action of L-deprenyl.	Selegiline	98-108	monoamine oxidase A	Homo sapiens	16-21
3295117-1	1987	MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a selective nigrostriatal neurotoxin, is bioactivated by MAO-B (and less effectively by MAO-A) to 2,3-MPDP+ and this intermediate undergoes further oxidation to MPP+, partly through the activity of MAO forms.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	monoamine oxidase A	Homo sapiens	141-146
3295117-1	1987	MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a selective nigrostriatal neurotoxin, is bioactivated by MAO-B (and less effectively by MAO-A) to 2,3-MPDP+ and this intermediate undergoes further oxidation to MPP+, partly through the activity of MAO forms.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	6-50	monoamine oxidase A	Homo sapiens	141-146
3100771-5	1987	In vitro, SR 95191 selectively inhibited MAO-A and was less potent than cimoxatone, clorgyline and harmaline, but was more potent than moclobemide.	SR 95191	10-18	monoamine oxidase A	Homo sapiens	41-46
3100771-6	1987	Ex vivo, SR 95191 also preferentially inhibited MAO-A in the brain and was 6 and 13 times less potent than cimoxatone and moclobemide, respectively.	SR 95191	9-17	monoamine oxidase A	Homo sapiens	48-53
3100771-7	1987	Like all MAO-A inhibitors, SR 95191 in vivo caused a dose-dependent increase in striatal 3-methoxytyramine, dopamine, serotonin and in hypothalamic norepinephrine contents.	SR 95191	27-35	monoamine oxidase A	Homo sapiens	9-14
3100771-12	1987	Like all reversible MAOIs, SR 95191 antagonized the long-lasting MAO-A inhibition induced by clorgyline.	SR 95191	27-35	monoamine oxidase A	Homo sapiens	65-70
3100771-12	1987	Like all reversible MAOIs, SR 95191 antagonized the long-lasting MAO-A inhibition induced by clorgyline.	Clorgyline	93-103	monoamine oxidase A	Homo sapiens	65-70
3108930-3	1987	L-Deprenyl is a monoamine oxidase (MAO) inhibitor which may selectively inhibit MAO-B at low doses, while at high doses it nonselectively inhibits MAO-A as well as MAO-B.	Selegiline	0-10	monoamine oxidase A	Homo sapiens	147-152
3030067-8	1987	The exact locations of MAO-A and -B in human brain are important to understand the mechanism of L-deprenyl action as an antiparkinson drug.	Selegiline	96-106	monoamine oxidase A	Homo sapiens	23-35
3480939-2	1987	However, availability of other selective MAO-B inhibitors have clearly shown that this is not the case, since the "cheese effect" is associated with the selective inhibition of MAO-A, the enzyme responsible for intraneuronal oxidation of noradrenaline.	Norepinephrine	238-251	monoamine oxidase A	Homo sapiens	177-182
3480939-3	1987	Following inhibition of neuronal MAO-A, noradrenaline in the cytoplasmic intraneuronal pool can increase to high levels.	Norepinephrine	40-53	monoamine oxidase A	Homo sapiens	33-38
3480939-4	1987	Since tyramine releases noradrenaline into the cytoplasm and not by exocytosis, its action is potentiated by inhibition of neuronal MAO-A.	Tyramine	6-14	monoamine oxidase A	Homo sapiens	132-137
2877718-2	1986	Catecholaminergic enzyme (tyrosine hydroxylase and monoamine oxidase-A) activity was consistently increased with development and the increase was significantly greater after aphidicolin-induced elimination of dividing, non-neuronal cells.	Aphidicolin	174-185	monoamine oxidase A	Homo sapiens	51-70
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Kynuramine	62-72	monoamine oxidase A	Homo sapiens	0-41
2879023-8	1986	Thus these results suggest that amethocaine preferentially inhibits MAO-A and the nature of inhibition is reversible and of mixed type.	Tetracaine	32-43	monoamine oxidase A	Homo sapiens	68-73
3097589-2	1986	Further, utilization of specific inhibitors, deprenyl and clorgyline, also provides evidence that serotonergic neurons contain exclusively MAO-B and catecholaminergic ones contain MAO-A.	Selegiline	45-53	monoamine oxidase A	Homo sapiens	180-185
3097589-2	1986	Further, utilization of specific inhibitors, deprenyl and clorgyline, also provides evidence that serotonergic neurons contain exclusively MAO-B and catecholaminergic ones contain MAO-A.	Clorgyline	58-68	monoamine oxidase A	Homo sapiens	180-185
3489461-3	1986	Both MAO A and B catalyse the oxidation of MPTP to the 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+), which undergoes further oxidation to the fully aromatic 1-methyl-4-phenylpyridinium species (MPP+).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	43-47	monoamine oxidase A	Homo sapiens	5-10
3489461-3	1986	Both MAO A and B catalyse the oxidation of MPTP to the 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+), which undergoes further oxidation to the fully aromatic 1-methyl-4-phenylpyridinium species (MPP+).	1-methyl-4-phenyl-2,3-dihydropyridinium	55-94	monoamine oxidase A	Homo sapiens	5-10
3489461-3	1986	Both MAO A and B catalyse the oxidation of MPTP to the 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+), which undergoes further oxidation to the fully aromatic 1-methyl-4-phenylpyridinium species (MPP+).	1-methyl-4-phenyl-2,3-dihydropyridinium	104-108	monoamine oxidase A	Homo sapiens	5-10
3489461-3	1986	Both MAO A and B catalyse the oxidation of MPTP to the 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+), which undergoes further oxidation to the fully aromatic 1-methyl-4-phenylpyridinium species (MPP+).	1-Methyl-4-phenylpyridinium	168-195	monoamine oxidase A	Homo sapiens	5-10
3489461-3	1986	Both MAO A and B catalyse the oxidation of MPTP to the 1-methyl-4-phenyl-2,3-dihydropyridinium species (MPDP+), which undergoes further oxidation to the fully aromatic 1-methyl-4-phenylpyridinium species (MPP+).	mangion-purified polysaccharide (Candida albicans)	205-208	monoamine oxidase A	Homo sapiens	5-10
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	87-91	monoamine oxidase A	Homo sapiens	60-65
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	87-91	monoamine oxidase A	Homo sapiens	138-143
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	1-methyl-4-phenyl-2,3-dihydropyridinium	93-98	monoamine oxidase A	Homo sapiens	60-65
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	1-methyl-4-phenyl-2,3-dihydropyridinium	93-98	monoamine oxidase A	Homo sapiens	138-143
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	mangion-purified polysaccharide (Candida albicans)	103-107	monoamine oxidase A	Homo sapiens	60-65
3489461-4	1986	These bio-oxidations are blocked by selective inhibitors of MAO A and B. Additionally, MPTP, MPDP+ and MPP+ are competitive inhibitors of MAO A and B.	mangion-purified polysaccharide (Candida albicans)	103-107	monoamine oxidase A	Homo sapiens	138-143
3489461-6	1986	Both MAO A and B also are irreversibly inactivated by MPTP and MPDP+, but not by MPP+.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	54-58	monoamine oxidase A	Homo sapiens	5-10
3489461-6	1986	Both MAO A and B also are irreversibly inactivated by MPTP and MPDP+, but not by MPP+.	1-methyl-4-phenyl-2,3-dihydropyridinium	63-68	monoamine oxidase A	Homo sapiens	5-10
3094536-1	1986	The selective monoamine oxidase inhibitors clorgyline and (-)-deprenyl have been used to determine the activities of monoamine oxidase-A and -B towards tryptamine in several human tissues.	Clorgyline	43-53	monoamine oxidase A	Homo sapiens	117-143
3094536-1	1986	The selective monoamine oxidase inhibitors clorgyline and (-)-deprenyl have been used to determine the activities of monoamine oxidase-A and -B towards tryptamine in several human tissues.	Selegiline	58-70	monoamine oxidase A	Homo sapiens	117-143
3094536-1	1986	The selective monoamine oxidase inhibitors clorgyline and (-)-deprenyl have been used to determine the activities of monoamine oxidase-A and -B towards tryptamine in several human tissues.	tryptamine	152-162	monoamine oxidase A	Homo sapiens	117-143
3776120-2	1986	The monoamine oxidase was found to oxidize at a high rate MAO substrates and revealed high sensitivity to clorgyline, a specific inhibitor of monoamine oxidase type A.	Clorgyline	106-116	monoamine oxidase A	Homo sapiens	142-166
3090204-2	1986	Both L- and D-threo-DOPS were found to inhibit MAO-A in human placental mitochondria in competition with the substrate, and the Ki values for L- and D-threo-DOPS obtained were 68.3 and 125 microM, respectively.	l- and d-threo-dops	5-24	monoamine oxidase A	Homo sapiens	47-52
3090204-2	1986	Both L- and D-threo-DOPS were found to inhibit MAO-A in human placental mitochondria in competition with the substrate, and the Ki values for L- and D-threo-DOPS obtained were 68.3 and 125 microM, respectively.	l- and d-threo-dops	142-161	monoamine oxidase A	Homo sapiens	47-52
3090204-3	1986	The inhibitory effect of L-threo-DOPS on both MAO-A and -B activity was confirmed in human liver mitochondria, and MAO-A was found to be more sensitive to the inhibitor.	Droxidopa	25-37	monoamine oxidase A	Homo sapiens	46-58
3090204-3	1986	The inhibitory effect of L-threo-DOPS on both MAO-A and -B activity was confirmed in human liver mitochondria, and MAO-A was found to be more sensitive to the inhibitor.	Droxidopa	25-37	monoamine oxidase A	Homo sapiens	46-51
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Dopamine	74-103	monoamine oxidase A	Homo sapiens	0-41
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Dopamine	105-113	monoamine oxidase A	Homo sapiens	0-41
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	amsonic acid	115-117	monoamine oxidase A	Homo sapiens	0-41
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Serotonin	124-143	monoamine oxidase A	Homo sapiens	0-41
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Serotonin	145-149	monoamine oxidase A	Homo sapiens	0-41
2420928-1	1986	Monoamine oxidase (MAO) type A and type B were measured using kynuramine, 3,4-dihydroxyphenylethylamine (dopamine, DA), and 5-hydroxytryptamine (5-HT, serotonin) in 20 brain areas.	Serotonin	151-160	monoamine oxidase A	Homo sapiens	0-41
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Serotonin	8-17	monoamine oxidase A	Homo sapiens	71-76
3954792-0	1986	Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.	Deuterium	15-24	monoamine oxidase A	Homo sapiens	132-137
3954792-0	1986	Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.	alpha-	45-51	monoamine oxidase A	Homo sapiens	132-137
3954792-0	1986	Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.	Carbon	51-57	monoamine oxidase A	Homo sapiens	132-137
3954792-0	1986	Stereospecific deuterium substitution at the alpha-carbon position of dopamine and its effect on oxidative deamination catalyzed by MAO-A and MAO-B from different tissues.	Dopamine	70-78	monoamine oxidase A	Homo sapiens	132-137
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Serotonin	8-17	monoamine oxidase A	Homo sapiens	254-259
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Norepinephrine	22-36	monoamine oxidase A	Homo sapiens	71-76
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Norepinephrine	22-36	monoamine oxidase A	Homo sapiens	254-259
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Serotonin	125-134	monoamine oxidase A	Homo sapiens	71-76
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Serotonin	125-134	monoamine oxidase A	Homo sapiens	254-259
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Melatonin	217-226	monoamine oxidase A	Homo sapiens	71-76
3008207-7	1986	As both serotonin and norepinephrine are preferentially metabolized by MAO-A rather than MAO-B, an increased availability of serotonin (the precursor of melatonin) or enhanced noradrenergic function might mediate the melatonin changes observed to follow MAO-A but not MAO-B inhibition.	Melatonin	217-226	monoamine oxidase A	Homo sapiens	254-259
2412565-0	1985	Effect of superior cervical ganglionectomy on melatonin stimulation by specific MAO-A inhibition.	Melatonin	46-55	monoamine oxidase A	Homo sapiens	80-85
2875125-3	1986	In humans treated with the MAO-A selective inhibitor, clorgyline, or the nonselective inhibitor, tranylcypromine, increased plasma melatonin also occurs; in contrast, the MAO-B selective inhibitor, 1-deprenyl, does not affect plasma melatonin.	Melatonin	131-140	monoamine oxidase A	Homo sapiens	27-32
2875125-3	1986	In humans treated with the MAO-A selective inhibitor, clorgyline, or the nonselective inhibitor, tranylcypromine, increased plasma melatonin also occurs; in contrast, the MAO-B selective inhibitor, 1-deprenyl, does not affect plasma melatonin.	1-deprenyl	198-208	monoamine oxidase A	Homo sapiens	27-32
2875125-3	1986	In humans treated with the MAO-A selective inhibitor, clorgyline, or the nonselective inhibitor, tranylcypromine, increased plasma melatonin also occurs; in contrast, the MAO-B selective inhibitor, 1-deprenyl, does not affect plasma melatonin.	Melatonin	233-242	monoamine oxidase A	Homo sapiens	27-32
2414414-6	1985	MAO A-4F10, A-7B10, and A-7E10 immunoprecipitate catalytically active MAO A from Triton X-100 extracts of human placental and liver mitochondria, but not catalytically active MAO B from either pletelets or from Triton X-100 extracts of human liver mitochondria.	Octoxynol	81-93	monoamine oxidase A	Homo sapiens	0-5
2414414-6	1985	MAO A-4F10, A-7B10, and A-7E10 immunoprecipitate catalytically active MAO A from Triton X-100 extracts of human placental and liver mitochondria, but not catalytically active MAO B from either pletelets or from Triton X-100 extracts of human liver mitochondria.	Octoxynol	81-93	monoamine oxidase A	Homo sapiens	70-75
2414414-6	1985	MAO A-4F10, A-7B10, and A-7E10 immunoprecipitate catalytically active MAO A from Triton X-100 extracts of human placental and liver mitochondria, but not catalytically active MAO B from either pletelets or from Triton X-100 extracts of human liver mitochondria.	Octoxynol	211-223	monoamine oxidase A	Homo sapiens	0-5
2864393-5	1985	When neuroblastoma cells were induced to differentiate by the addition of sodium butyrate to the medium, parameters of cell growth (protein, RNA) and enzyme activity (TH and MAO-A) increased in both cell lines irrespective of the presence of thyroid hormones.	Butyric Acid	74-89	monoamine oxidase A	Homo sapiens	174-179
3091762-2	1986	MPTP can also act as an inhibitor of both MAO A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-4	monoamine oxidase A	Homo sapiens	42-53
3029514-11	1986	For example some oxazolidinone derivatives showed a selective inhibition toward monoamine oxidase A.	Oxazolidinones	17-30	monoamine oxidase A	Homo sapiens	80-99
2416297-4	1985	Desipramine hydrochloride, a norepinephrine uptake inhibitor, reduced 5-HIAA as well as MHPG concentrations; zimeldine hydrochloride, a serotonin uptake inhibitor, reduced MHPG as well as 5-HIAA concentrations; and clorgyline, a selective monoamine oxidase type A inhibitor, which might be predicted to most affect 5-HIAA, dramatically reduced MHPG, moderately reduced homovanillic acid, and only modestly reduced 5-HIAA concentrations.	Zimeldine	109-132	monoamine oxidase A	Homo sapiens	239-263
3875898-2	1985	The reagents recognized different populations of neurons: those that recognized MAO A were located in cell groups containing catecholamines, including the substantia nigra, nucleus locus coeruleus, nucleus subcoeruleus, and the periventricular region of the hypothalamus, whereas those that recognized MAO B were observed in serotonin regions, including the nucleus raphe dorsalis and nucleus centralis superior.	Catecholamines	125-139	monoamine oxidase A	Homo sapiens	80-85
3875898-2	1985	The reagents recognized different populations of neurons: those that recognized MAO A were located in cell groups containing catecholamines, including the substantia nigra, nucleus locus coeruleus, nucleus subcoeruleus, and the periventricular region of the hypothalamus, whereas those that recognized MAO B were observed in serotonin regions, including the nucleus raphe dorsalis and nucleus centralis superior.	Serotonin	325-334	monoamine oxidase A	Homo sapiens	80-85
3985989-4	1985	Both molecular forms of MAO, MAO A and MAO B, are present in single nerve cell as shown by clorgyline, a selective inhibitor of MAO A molecular form.	Clorgyline	91-101	monoamine oxidase A	Homo sapiens	29-34
3928010-2	1985	Both selective MAO-A and MAO-B inhibitors markedly potentiated nictitating membrane contractions in response to beta-phenylethylamine (PEA).	phenethylamine	112-133	monoamine oxidase A	Homo sapiens	15-20
3928010-2	1985	Both selective MAO-A and MAO-B inhibitors markedly potentiated nictitating membrane contractions in response to beta-phenylethylamine (PEA).	phenethylamine	135-138	monoamine oxidase A	Homo sapiens	15-20
3928010-4	1985	The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors.	Tyramine	25-33	monoamine oxidase A	Homo sapiens	68-73
3928010-4	1985	The pressor responses to tyramine were potentiated by the selective MAO-A inhibitor clorgyline (2 mg kg-1) but not by selegiline (1.0 mg kg-1) and AGN 1135 (1.5 mg kg-1), selective MAO-B inhibitors.	Clorgyline	84-94	monoamine oxidase A	Homo sapiens	68-73
3928010-5	1985	At the doses used selegiline and AGN 1135 caused a near total selective inhibition of liver and brain MAO-B, while clorgyline inhibited MAO-A only in the brain.	Clorgyline	115-125	monoamine oxidase A	Homo sapiens	136-141
2862247-0	1985	Monoamine oxidase-A selective inhibition in human hypothalamus and liver in-vitro by amiflamine and its metabolites.	amiflamine	85-95	monoamine oxidase A	Homo sapiens	0-19
2862247-1	1985	Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy.	amiflamine	0-10	monoamine oxidase A	Homo sapiens	133-152
2862247-1	1985	Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy.	fla	12-15	monoamine oxidase A	Homo sapiens	133-152
2862247-1	1985	Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy.	fla	48-51	monoamine oxidase A	Homo sapiens	133-152
2862247-1	1985	Amiflamine (FLA 336(+] and its two metabolites, FLA 788(+) and FLA 668(+) were found to be competitive inhibitors of the activity of monoamine oxidase-A in homogenates of human hypothalamus and liver obtained at autopsy.	fla	48-51	monoamine oxidase A	Homo sapiens	133-152
3985989-4	1985	Both molecular forms of MAO, MAO A and MAO B, are present in single nerve cell as shown by clorgyline, a selective inhibitor of MAO A molecular form.	Clorgyline	91-101	monoamine oxidase A	Homo sapiens	128-133
3156909-0	1985	A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.	r011-1163	61-70	monoamine oxidase A	Homo sapiens	33-38
3872126-6	1985	We reported recently that both monoamine oxidase A and B oxidize MPTP to MPDP+, the 2,3-dihydropyridinium form and that the reaction is accompanied by time-dependent, irreversible inactivation of the enzymes.	2,3-dihydropyridinium	84-105	monoamine oxidase A	Homo sapiens	31-50
3872126-8	1985	We now wish to report that MPTP, as well as its oxidation products, MPDP+ and MPP+, the 4-phenylpyridinium form, are also potent reversible, competitive inhibitors of both monoamine oxidase A and B, particularly the former, and that the order of inhibition for the A enzyme is MPDP+ greater than MPP+ greater than MPTP, while for the B enzyme MPTP greater than MPDP+ greater than MPP+.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	27-31	monoamine oxidase A	Homo sapiens	172-197
3872126-8	1985	We now wish to report that MPTP, as well as its oxidation products, MPDP+ and MPP+, the 4-phenylpyridinium form, are also potent reversible, competitive inhibitors of both monoamine oxidase A and B, particularly the former, and that the order of inhibition for the A enzyme is MPDP+ greater than MPP+ greater than MPTP, while for the B enzyme MPTP greater than MPDP+ greater than MPP+.	4-phenylpyridinium	88-106	monoamine oxidase A	Homo sapiens	172-197
3872126-6	1985	We reported recently that both monoamine oxidase A and B oxidize MPTP to MPDP+, the 2,3-dihydropyridinium form and that the reaction is accompanied by time-dependent, irreversible inactivation of the enzymes.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	65-69	monoamine oxidase A	Homo sapiens	31-50
3872126-6	1985	We reported recently that both monoamine oxidase A and B oxidize MPTP to MPDP+, the 2,3-dihydropyridinium form and that the reaction is accompanied by time-dependent, irreversible inactivation of the enzymes.	1-methyl-4-phenyl-2,3-dihydropyridinium	73-78	monoamine oxidase A	Homo sapiens	31-50
3156909-0	1985	A controlled study of a specific MAO A reversible inhibitor (R011-1163) and amitriptyline in depressive illness.	Amitriptyline	76-89	monoamine oxidase A	Homo sapiens	33-38
6374037-7	1984	Phospholipase A2 may disrupt the phospholipid microenvironment of MAO-A, the integrity of which is essential for MAO-A activity, but not for MAO-B.	Phospholipids	33-45	monoamine oxidase A	Homo sapiens	66-71
3925487-1	1985	A low dosage of the specific MAO-A inhibitor clorgyline (5-10 mg/day) was administered chronically to 10 depressed patients.	Clorgyline	45-55	monoamine oxidase A	Homo sapiens	29-34
6335034-0	1984	Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.	Amines	28-33	monoamine oxidase A	Homo sapiens	89-115
6335034-0	1984	Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	34-78	monoamine oxidase A	Homo sapiens	89-115
6335034-0	1984	Oxidation of the neurotoxic amine 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) by monoamine oxidases A and B and suicide inactivation of the enzymes by MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	80-84	monoamine oxidase A	Homo sapiens	89-115
6335034-4	1984	Additionally, MAO A, isolated from human placenta, oxidizes MPTP to the same product at about 12% of the rate of kynuramine, again with a comparable Km value.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	60-64	monoamine oxidase A	Homo sapiens	14-19
6335034-4	1984	Additionally, MAO A, isolated from human placenta, oxidizes MPTP to the same product at about 12% of the rate of kynuramine, again with a comparable Km value.	Kynuramine	113-123	monoamine oxidase A	Homo sapiens	14-19
6388247-2	1984	Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	111-135
6388247-2	1984	Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A.	Moclobemide	13-23	monoamine oxidase A	Homo sapiens	111-135
6388247-2	1984	Moclobemide (Ro 11-1163), a benzamide derivative, is a MAO-inhibitor which selectively and reversibly inhibits monoamine oxidase type A.	benzamide	28-37	monoamine oxidase A	Homo sapiens	111-135
6429130-5	1984	An alternative approach in the development of safer, effective MAOIs is the use of rapidly reversible MAO-A inhibitors, such as moclobemide, that carry less risk of a hypertensive reaction and yet appear to be effective antidepressants.	Moclobemide	128-139	monoamine oxidase A	Homo sapiens	102-107
3929314-5	1985	Reductions in plasma 3-methoxy,4-hydroxyphenylglycol (MHPG), used as a possible index of in vivo MAO-A inhibition, were highly correlated with increases in tyramine pressor sensitivity (r = 0.82).	Methoxyhydroxyphenylglycol	21-52	monoamine oxidase A	Homo sapiens	97-102
3929314-5	1985	Reductions in plasma 3-methoxy,4-hydroxyphenylglycol (MHPG), used as a possible index of in vivo MAO-A inhibition, were highly correlated with increases in tyramine pressor sensitivity (r = 0.82).	Tyramine	156-164	monoamine oxidase A	Homo sapiens	97-102
6508845-1	1984	A partial purification of endogenous modulators of monoamine oxidase-A (MAO-A) and MAO-B from human plasma has been achieved through Sephadex, ion-exchange and affinity chromatography.	sephadex	133-141	monoamine oxidase A	Homo sapiens	51-70
6508845-1	1984	A partial purification of endogenous modulators of monoamine oxidase-A (MAO-A) and MAO-B from human plasma has been achieved through Sephadex, ion-exchange and affinity chromatography.	sephadex	133-141	monoamine oxidase A	Homo sapiens	72-77
6382361-0	1984	A placebo-controlled study of the antidepressant activity of moclobemide, a new MAO-A inhibitor.	Moclobemide	61-72	monoamine oxidase A	Homo sapiens	80-85
6382361-1	1984	Preliminary open trials performed by the authors and others with Moclobemide, a new MAO-A inhibitor, indicated that the drug has a satisfactory antidepressant activity.	Moclobemide	65-76	monoamine oxidase A	Homo sapiens	84-89
6374037-7	1984	Phospholipase A2 may disrupt the phospholipid microenvironment of MAO-A, the integrity of which is essential for MAO-A activity, but not for MAO-B.	Phospholipids	33-45	monoamine oxidase A	Homo sapiens	113-118
6548970-3	1984	The induction of cerebral MAO-A activity, a pronounced influence on the circadian rhythms of locomotion and intracerebral neurotransmitter as well as plasma protein and cortisol concentrations has been reported.	Hydrocortisone	169-177	monoamine oxidase A	Homo sapiens	26-31
6203542-6	1984	These data, which suggest that MAO-A inhibition by clorgyline in vivo is more closely associated with changes in the noradrenergic than the serotonergic or dopaminergic systems in nonhuman primates, are in general agreement with the effects of clorgyline on CSF and urinary biogenic amine metabolites in man.	Clorgyline	51-61	monoamine oxidase A	Homo sapiens	31-36
6203542-6	1984	These data, which suggest that MAO-A inhibition by clorgyline in vivo is more closely associated with changes in the noradrenergic than the serotonergic or dopaminergic systems in nonhuman primates, are in general agreement with the effects of clorgyline on CSF and urinary biogenic amine metabolites in man.	Clorgyline	244-254	monoamine oxidase A	Homo sapiens	31-36
6203542-6	1984	These data, which suggest that MAO-A inhibition by clorgyline in vivo is more closely associated with changes in the noradrenergic than the serotonergic or dopaminergic systems in nonhuman primates, are in general agreement with the effects of clorgyline on CSF and urinary biogenic amine metabolites in man.	Amines	159-164	monoamine oxidase A	Homo sapiens	31-36
6538844-0	1984	Effect of a reversible and selective MAO-A inhibitor (cimoxatone) on diurnal variation in plasma prolactin level in man.	cimoxatone	54-64	monoamine oxidase A	Homo sapiens	37-42
6538844-3	1984	The effect of cimoxatone, a reversible, selective MAO-A inhibitor, on diurnal variation in plasma PRL level was investigated in healthy adults after a single 40 mg oral dose, as an indirect approach to investigating whether DA is preferentially a substrate for Type A or B MAO in man.	cimoxatone	14-24	monoamine oxidase A	Homo sapiens	50-55
6202347-5	1984	The alpha-methyl substituted monoamine amiflamine has been shown to inhibit MAO-A within serotoninergic neurones at lower doses than are required for inhibition in other neurones.	alpha-methyl substituted monoamine amiflamine	4-49	monoamine oxidase A	Homo sapiens	76-81
6698662-5	1984	MD 770222, which is also a selective and reversible inhibitor of MAO A although less potent than cimoxatone, is the major plasma metabolite and its plasma elimination half-life is about three times longer than cimoxatone.	cimoxatone	210-220	monoamine oxidase A	Homo sapiens	65-70
6863305-2	1983	A strong inhibition of monoamine oxidase B was observed with phosphatidylserine and a moderate activation of monoamine oxidase A with phosphatidylinositol, while cardiolipin had no significant effect on either form.	Phosphatidylinositols	134-154	monoamine oxidase A	Homo sapiens	109-128
6649522-0	1983	[Selective inhibition by pyrazidol of monoamine oxidase type A in different human and animal tissues].	pirlindole	25-34	monoamine oxidase A	Homo sapiens	38-62
6847697-8	1983	Furthermore, when SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from these cell lines were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained.	Tritium	36-38	monoamine oxidase A	Homo sapiens	57-62
6408492-5	1983	Enzyme titration studies and comparisons of the substrate specificities of MAO-A and MAO-B across the brain indicated that dopamine was metabolised by the same MAO active centres as other monoamines.	Dopamine	123-131	monoamine oxidase A	Homo sapiens	75-80
6408492-6	1983	In the cerebral cortex, the Km values of MAO-A and -B towards dopamine were found to be 210 and 230 microM, respectively, indicating that the relative contributions of these two forms towards the oxidation of this substrate will not be significantly affected by changes in its concentration.	Dopamine	62-70	monoamine oxidase A	Homo sapiens	41-53
6847697-8	1983	Furthermore, when SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from these cell lines were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained.	Pargyline	39-48	monoamine oxidase A	Homo sapiens	57-62
6675426-0	1983	Studies on amiflamine, a reversible inhibitor of monoamine oxidase type A, selective for serotonergic neurons.	amiflamine	11-21	monoamine oxidase A	Homo sapiens	49-73
6368197-0	1983	[Antidepressive action, pharmacokinetic characteristics and biochemical properties of cimoxatone, a new reversible MAO-A inhibitor].	cimoxatone	86-96	monoamine oxidase A	Homo sapiens	115-120
24875606-8	1983	Clorgyline injection selectively and completely inhibited MAO-A activity, while injection of clorgyline and deprenyl inhibited both MAO-A and MAO-B activities when embryos were assayed after either 2 or 7 days of embryonic development.	Clorgyline	93-103	monoamine oxidase A	Homo sapiens	132-137
24875606-8	1983	Clorgyline injection selectively and completely inhibited MAO-A activity, while injection of clorgyline and deprenyl inhibited both MAO-A and MAO-B activities when embryos were assayed after either 2 or 7 days of embryonic development.	Selegiline	108-116	monoamine oxidase A	Homo sapiens	132-137
24875606-5	1983	Two types of MAO activity similar to adult avian and mammalian MAO-A and MAO-B have been demonstrated by differential clorgyline sensitivity of tryptamine deamination.	Clorgyline	118-128	monoamine oxidase A	Homo sapiens	63-68
7159481-0	1982	Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin.	Norepinephrine	61-77	monoamine oxidase A	Homo sapiens	0-24
24875606-5	1983	Two types of MAO activity similar to adult avian and mammalian MAO-A and MAO-B have been demonstrated by differential clorgyline sensitivity of tryptamine deamination.	tryptamine	144-154	monoamine oxidase A	Homo sapiens	63-68
24875606-6	1983	In addition, SDS-PAGE of embryonic quail [(3)H]pargyiine-labeled MAO demonstrates that the quail MAO-A and MAO-B flavin-containing subunits have apparent molecular weights of 63,000 and 62,000 respectively.	Sodium Dodecyl Sulfate	13-16	monoamine oxidase A	Homo sapiens	97-102
24875606-6	1983	In addition, SDS-PAGE of embryonic quail [(3)H]pargyiine-labeled MAO demonstrates that the quail MAO-A and MAO-B flavin-containing subunits have apparent molecular weights of 63,000 and 62,000 respectively.	(3)h]pargyiine	42-56	monoamine oxidase A	Homo sapiens	97-102
24875606-8	1983	Clorgyline injection selectively and completely inhibited MAO-A activity, while injection of clorgyline and deprenyl inhibited both MAO-A and MAO-B activities when embryos were assayed after either 2 or 7 days of embryonic development.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	58-63
6865966-0	1983	Neurochemical effects in vitro and in vivo of the antidepressant Ro 11-1163, a specific and short-acting MAO-A inhibitor.	Moclobemide	65-75	monoamine oxidase A	Homo sapiens	105-110
7159481-0	1982	Monoamine oxidase type A: differences in selectivity towards l-norepinephrine compared to serotonin.	Serotonin	90-99	monoamine oxidase A	Homo sapiens	0-24
7159481-3	1982	Serotonin was a more selective substrate for MAO-A, being inhibited by low concentrations (less than 10(-7) M) of the irreversible MAO-A inhibitor, clorgyline, more consistently and to a greater extent (80-100%) than was l-norepinephrine (30-85%).	Serotonin	0-9	monoamine oxidase A	Homo sapiens	45-50
7159481-3	1982	Serotonin was a more selective substrate for MAO-A, being inhibited by low concentrations (less than 10(-7) M) of the irreversible MAO-A inhibitor, clorgyline, more consistently and to a greater extent (80-100%) than was l-norepinephrine (30-85%).	Serotonin	0-9	monoamine oxidase A	Homo sapiens	131-136
7159481-3	1982	Serotonin was a more selective substrate for MAO-A, being inhibited by low concentrations (less than 10(-7) M) of the irreversible MAO-A inhibitor, clorgyline, more consistently and to a greater extent (80-100%) than was l-norepinephrine (30-85%).	Clorgyline	148-158	monoamine oxidase A	Homo sapiens	45-50
7159481-3	1982	Serotonin was a more selective substrate for MAO-A, being inhibited by low concentrations (less than 10(-7) M) of the irreversible MAO-A inhibitor, clorgyline, more consistently and to a greater extent (80-100%) than was l-norepinephrine (30-85%).	Clorgyline	148-158	monoamine oxidase A	Homo sapiens	131-136
7159481-3	1982	Serotonin was a more selective substrate for MAO-A, being inhibited by low concentrations (less than 10(-7) M) of the irreversible MAO-A inhibitor, clorgyline, more consistently and to a greater extent (80-100%) than was l-norepinephrine (30-85%).	Norepinephrine	221-237	monoamine oxidase A	Homo sapiens	45-50
7159481-5	1982	Serotonin also had a 2- to 4-fold smaller apparent Km for MAO-A than l-norepinephrine and was deaminated 2- to 5-fold more readily by MAO in vitro in most tissues.	Serotonin	0-9	monoamine oxidase A	Homo sapiens	58-63
7159481-7	1982	Thus, l-norepinephrine, like dopamine, should be regarded as a substrate for both MAO-A and MAO-B in vitro.	Norepinephrine	6-22	monoamine oxidase A	Homo sapiens	82-87
7159481-7	1982	Thus, l-norepinephrine, like dopamine, should be regarded as a substrate for both MAO-A and MAO-B in vitro.	Dopamine	29-37	monoamine oxidase A	Homo sapiens	82-87
6287513-1	1982	Clonidine was administered to nine psychiatric patients before and after chronic treatment (3 to 4 weeks) with clorgyline, a selective monoamine oxidase type A inhibitor with antidepressant efficacy.	Clonidine	0-9	monoamine oxidase A	Homo sapiens	135-159
6214234-8	1982	Current and previous findings concerning clorgyline, a relatively specific monoamine oxidase A inhibitor, suggest that three pharmacologically distinct classes of antidepressants, norepinephrine and serotonin-reuptake and monoamine oxidase type A inhibitors, all reduce central norepinephrine turnover in depressed patients.	Clorgyline	41-51	monoamine oxidase A	Homo sapiens	222-246
7126245-2	1982	Loosely based upon the structure of clorgyline, it is an irreversible inhibitor of MAO A but is apparently indifferent towards MAO B.	Clorgyline	36-46	monoamine oxidase A	Homo sapiens	83-88
7126245-3	1982	This compound, N1-(2,4-dinitrophenyl)-N2-prop-2-ynyl 1,3-diaminopropane, may be useful as a model for the design of more potent but equally specific inhibitors of MAO A.	n1-(2,4-dinitrophenyl)-n2-prop-2-ynyl 1,3-diaminopropane	15-71	monoamine oxidase A	Homo sapiens	163-168
7142171-0	1982	An evaluation of phospholipids as regulators of monoamine oxidase A and monoamine oxidase B activities.	Phospholipids	17-30	monoamine oxidase A	Homo sapiens	48-67
6287513-1	1982	Clonidine was administered to nine psychiatric patients before and after chronic treatment (3 to 4 weeks) with clorgyline, a selective monoamine oxidase type A inhibitor with antidepressant efficacy.	Clorgyline	111-121	monoamine oxidase A	Homo sapiens	135-159
7196439-8	1981	This evidence indicates that the structural gene for the flavin polypeptide of MAO-A is on the human X chromosome.	4,6-dinitro-o-cresol	57-63	monoamine oxidase A	Homo sapiens	79-84
6178382-5	1982	These findings demonstrate the clinical actions of low-dose clorgyline and clorgyline"s specificity as a monoamine oxidase A (MAO-A) inhibitor in vivo in humans, as well as the effects of specific MAO-A inhibition on monoamine metabolism.	Clorgyline	60-70	monoamine oxidase A	Homo sapiens	105-124
6178382-5	1982	These findings demonstrate the clinical actions of low-dose clorgyline and clorgyline"s specificity as a monoamine oxidase A (MAO-A) inhibitor in vivo in humans, as well as the effects of specific MAO-A inhibition on monoamine metabolism.	Clorgyline	60-70	monoamine oxidase A	Homo sapiens	126-131
6178382-5	1982	These findings demonstrate the clinical actions of low-dose clorgyline and clorgyline"s specificity as a monoamine oxidase A (MAO-A) inhibitor in vivo in humans, as well as the effects of specific MAO-A inhibition on monoamine metabolism.	Clorgyline	75-85	monoamine oxidase A	Homo sapiens	105-124
6178382-5	1982	These findings demonstrate the clinical actions of low-dose clorgyline and clorgyline"s specificity as a monoamine oxidase A (MAO-A) inhibitor in vivo in humans, as well as the effects of specific MAO-A inhibition on monoamine metabolism.	Clorgyline	75-85	monoamine oxidase A	Homo sapiens	126-131
7062060-8	1982	The enzymatic activity of MAO A is critically dependent on associated phospholipids, whereas that of MAO B is not.	Phospholipids	70-83	monoamine oxidase A	Homo sapiens	26-31
7130973-2	1982	Concentrations of 5-hydroxytryptamine and phenylethylamine, approximately at their Km values, were used as substrates for MAO A and B respectively.	Serotonin	18-37	monoamine oxidase A	Homo sapiens	122-127
7130973-2	1982	Concentrations of 5-hydroxytryptamine and phenylethylamine, approximately at their Km values, were used as substrates for MAO A and B respectively.	Phenethylamines	42-58	monoamine oxidase A	Homo sapiens	122-127
7130973-4	1982	Of the carbolines which have been found endogenously, tetrahydro-beta-carboline, 6-methoxytetrahydro-beta-carboline and harmane are all sufficiently potent inhibitors of human MAO A, with I50 values of 5 X 10(-6), 10(-6), 5 X 10(-7) M respectively, for this property to be of possible physiological significance.	Carbolines	7-17	monoamine oxidase A	Homo sapiens	176-181
7130973-4	1982	Of the carbolines which have been found endogenously, tetrahydro-beta-carboline, 6-methoxytetrahydro-beta-carboline and harmane are all sufficiently potent inhibitors of human MAO A, with I50 values of 5 X 10(-6), 10(-6), 5 X 10(-7) M respectively, for this property to be of possible physiological significance.	tryptoline	54-79	monoamine oxidase A	Homo sapiens	176-181
7130973-4	1982	Of the carbolines which have been found endogenously, tetrahydro-beta-carboline, 6-methoxytetrahydro-beta-carboline and harmane are all sufficiently potent inhibitors of human MAO A, with I50 values of 5 X 10(-6), 10(-6), 5 X 10(-7) M respectively, for this property to be of possible physiological significance.	6-methoxytryptoline	81-115	monoamine oxidase A	Homo sapiens	176-181
7130973-4	1982	Of the carbolines which have been found endogenously, tetrahydro-beta-carboline, 6-methoxytetrahydro-beta-carboline and harmane are all sufficiently potent inhibitors of human MAO A, with I50 values of 5 X 10(-6), 10(-6), 5 X 10(-7) M respectively, for this property to be of possible physiological significance.	harman	120-127	monoamine oxidase A	Homo sapiens	176-181
7327272-1	1981	One--day cold exposure decreases the monoamine oxidase type A activity by 52--54% (serotonin and noradrenaline substrates); the monoamine oxidase type B activity by 14%.	Serotonin	83-92	monoamine oxidase A	Homo sapiens	37-61
7327272-1	1981	One--day cold exposure decreases the monoamine oxidase type A activity by 52--54% (serotonin and noradrenaline substrates); the monoamine oxidase type B activity by 14%.	Norepinephrine	97-110	monoamine oxidase A	Homo sapiens	37-61
7263710-2	1981	It was found that phosphatidylinositol uniquely stimulated the monoamine oxidase A activity to 80% over that in the original intact mitochondria.	Phosphatidylinositols	18-38	monoamine oxidase A	Homo sapiens	63-82
7263710-10	1981	Phosphatidylcholine might reassociate as the membrane fluid bilayer, which in turn modulated the monoamine oxidase A activity.	Phosphatidylcholines	0-19	monoamine oxidase A	Homo sapiens	97-116
7264664-2	1981	[3H]Pargyline was bound to MAO A in a crude mitochondrial fraction from the placental trophoblast of a male newborn and to MAO B in blood platelets from the umbilical vein of the same newborn.	Tritium	1-3	monoamine oxidase A	Homo sapiens	27-32
7264664-2	1981	[3H]Pargyline was bound to MAO A in a crude mitochondrial fraction from the placental trophoblast of a male newborn and to MAO B in blood platelets from the umbilical vein of the same newborn.	Pargyline	4-13	monoamine oxidase A	Homo sapiens	27-32
7264664-3	1981	[3H]Pargyline was also bound to MAO A and B in a crude mitochondrial fraction from cultured skin fibroblasts of a male adult and to MAO B in blood platelets from the same individual.	Tritium	1-3	monoamine oxidase A	Homo sapiens	32-43
7264664-5	1981	For all tissues, SDS-PAGE of [3H]pargyline-bound samples revealed a labeled protein band of apparent molecular weight 63,000 for MAO A and 60,000 for MAO B.	Sodium Dodecyl Sulfate	17-20	monoamine oxidase A	Homo sapiens	129-134
7264664-5	1981	For all tissues, SDS-PAGE of [3H]pargyline-bound samples revealed a labeled protein band of apparent molecular weight 63,000 for MAO A and 60,000 for MAO B.	Tritium	30-32	monoamine oxidase A	Homo sapiens	129-134
7264664-6	1981	When SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from the same male newborn were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained.	Tritium	23-25	monoamine oxidase A	Homo sapiens	44-49
7264664-6	1981	When SDS-solubilized, [3H]pargyline-labeled MAO A and B proteins from the same male newborn were subjected to limited proteolysis and one-dimensional peptide mapping in SDS gels, different patterns of [3H]pargyline-labeled peptides were obtained.	Pargyline	26-35	monoamine oxidase A	Homo sapiens	44-49
6116758-3	1981	Clorgyline and 5-HT, both known as MAO-A occupants, were able to abolish the second (high) Km deamination of PEA.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	35-40
7225122-0	1981	Dexamethasone selectively increases monoamine oxidase type A in human skin fibroblasts.	Dexamethasone	0-13	monoamine oxidase A	Homo sapiens	36-60
6121956-3	1981	Biochemical studies have revealed beta-carbolines" several actions, including inhibition of MAO-A, competitive inhibition of 5-HT uptake, general inhibition of Na+ dependent transports, binding to benzodiazepine and opiate receptors and probable action on dopamine receptors, which may all participate to a variable degree in the actions of different beta-carbolines.	Carbolines	34-49	monoamine oxidase A	Homo sapiens	92-97
6121956-10	1981	It has been suggested that some beta-carbolines act as the physiological ligands (agonists) of the benzodiazepine receptors, but the physiological beta-carbolines so far known seem to have other effects, such as the inhibition of MAO-A or 5-HT uptake in low concentrations.	Carbolines	32-47	monoamine oxidase A	Homo sapiens	230-235
6121956-10	1981	It has been suggested that some beta-carbolines act as the physiological ligands (agonists) of the benzodiazepine receptors, but the physiological beta-carbolines so far known seem to have other effects, such as the inhibition of MAO-A or 5-HT uptake in low concentrations.	Carbolines	147-162	monoamine oxidase A	Homo sapiens	230-235
7393204-0	1980	Electrophoretic analysis of 3H-pargyline-labeled monoamine oxidases A and B from human and rat cells.	Tritium	28-30	monoamine oxidase A	Homo sapiens	49-75
6771658-0	1980	Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil.	Clorgyline	56-66	monoamine oxidase A	Homo sapiens	25-52
6771658-0	1980	Titration of human brain monoamine oxidase -A and -B by clorgyline and L-deprenil.	l-deprenil	71-81	monoamine oxidase A	Homo sapiens	25-52
6771658-3	1980	The interaction of clorgyline with the -A form of the enzyme appears to take place almost entirely at specific binding sites, and the conditions required for this inhibitor to "titrate" the concentrations of MAO-A have been elucidated.	Clorgyline	19-29	monoamine oxidase A	Homo sapiens	208-213
20227955-0	1980	Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies?	phenethylamine	0-21	monoamine oxidase A	Homo sapiens	62-81
20227955-0	1980	Beta-phenylethylamine and benzylamine as substrates for human monoamine oxidase A: A source of some anomalies?	benzylamine	26-37	monoamine oxidase A	Homo sapiens	62-81
20227955-2	1980	With 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and benzylamine (Bz) as substrates and clorgyline and deprenyl, respectively, as selective MAO A and B inhibitors, their activity pattern has been defined and compared with that of human liver.	Serotonin	26-30	monoamine oxidase A	Homo sapiens	152-157
20227955-2	1980	With 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and benzylamine (Bz) as substrates and clorgyline and deprenyl, respectively, as selective MAO A and B inhibitors, their activity pattern has been defined and compared with that of human liver.	benzylamine	65-76	monoamine oxidase A	Homo sapiens	152-157
20227955-2	1980	With 5-hydroxytryptamine (5-HT), beta-phenylethylamine (PEA) and benzylamine (Bz) as substrates and clorgyline and deprenyl, respectively, as selective MAO A and B inhibitors, their activity pattern has been defined and compared with that of human liver.	Selegiline	115-123	monoamine oxidase A	Homo sapiens	152-157
20227955-5	1980	The divergence between PEA and Bz as MAO A and B substrates may be one reason for some of the apparent discrepancies in the behaviour of MAO A and B noted in a variety of tissues in the literature.	Boron	31-32	monoamine oxidase A	Homo sapiens	37-42
20227955-5	1980	The divergence between PEA and Bz as MAO A and B substrates may be one reason for some of the apparent discrepancies in the behaviour of MAO A and B noted in a variety of tissues in the literature.	Boron	31-32	monoamine oxidase A	Homo sapiens	137-142
6791210-5	1981	Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline.	Clorgyline	43-53	monoamine oxidase A	Homo sapiens	27-32
6791210-5	1981	Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline.	Pargyline	202-211	monoamine oxidase A	Homo sapiens	27-32
6791210-5	1981	Chronic treatment with the MAO-A inhibitor clorgyline and the MAO-B inhibitor pargyline showed significant inhibition of the alternate MAO enzyme as well, although this crossover effect was greater for pargyline than clorgyline.	Clorgyline	217-227	monoamine oxidase A	Homo sapiens	27-32
6791210-7	1981	Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r = 0.92), supporting our previous data indicating the rank order of clorgyline greater than pargyline greater than deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramine potentiation is primarily a function of MAO-A rather than MAO-B inhibition.	Tyramine	0-8	monoamine oxidase A	Homo sapiens	390-395
6791210-7	1981	Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r = 0.92), supporting our previous data indicating the rank order of clorgyline greater than pargyline greater than deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramine potentiation is primarily a function of MAO-A rather than MAO-B inhibition.	Methoxyhydroxyphenylglycol	135-139	monoamine oxidase A	Homo sapiens	390-395
6791210-7	1981	Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r = 0.92), supporting our previous data indicating the rank order of clorgyline greater than pargyline greater than deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramine potentiation is primarily a function of MAO-A rather than MAO-B inhibition.	Clorgyline	210-220	monoamine oxidase A	Homo sapiens	390-395
6791210-7	1981	Tyramine pressor sensitivity changes accompanying administration of the MAO inhibitors were highly correlated with decreases in plasma MHPG (r = 0.92), supporting our previous data indicating the rank order of clorgyline greater than pargyline greater than deprenyl for enhancement of tyramine pressor sensitivity and, thus, suggesting that tyramine potentiation is primarily a function of MAO-A rather than MAO-B inhibition.	Selegiline	257-265	monoamine oxidase A	Homo sapiens	390-395
7406910-0	1980	Progesterone provokes a selective rise of monoamine oxidase A in the female genital tract.	Progesterone	0-12	monoamine oxidase A	Homo sapiens	42-61
729356-0	1978	In vitro inhibition of monoamine oxidase types A and B by d- and l-amphetamine.	d- and l-amphetamine	58-78	monoamine oxidase A	Homo sapiens	23-54
6776235-2	1980	10(-6)M was the most effective (-)-deprenyl concentration in vitro for discriminating between the inhibition of MAO A and B.	Selegiline	31-43	monoamine oxidase A	Homo sapiens	112-123
6776235-4	1980	This suggests that all dopamine oxidation can be accounted for by the joint contribution of MAO A and B and that it is unnecessary to postulate a special form of the enzyme which metabolizes dopamine.	Dopamine	23-31	monoamine oxidase A	Homo sapiens	92-103
6776235-5	1980	In the brain, the striatum has the highest proportion of MAO B, and in several cortical regions, relatively more dopamine is oxidized by MAO A.	Dopamine	113-121	monoamine oxidase A	Homo sapiens	137-142
6776235-7	1980	Km values for dopamine for MAO A and B are similar, 130 and 140 uM respectively, so that the proportion oxidized by the two forms should not vary with substrate concentration.	Dopamine	14-22	monoamine oxidase A	Homo sapiens	27-32
547037-0	1979	Effect of cadmium and copper on monoamine oxidase type A and B in brain and liver mitochondria.	Cadmium	10-17	monoamine oxidase A	Homo sapiens	32-62
547037-0	1979	Effect of cadmium and copper on monoamine oxidase type A and B in brain and liver mitochondria.	Copper	22-28	monoamine oxidase A	Homo sapiens	32-62
547037-1	1979	The effect of cadmium and copper on monoamine oxidase type A and B in mitochondrial preparations from brain and liver was determined in vitro.	Cadmium	14-21	monoamine oxidase A	Homo sapiens	36-66
547037-1	1979	The effect of cadmium and copper on monoamine oxidase type A and B in mitochondrial preparations from brain and liver was determined in vitro.	Copper	26-32	monoamine oxidase A	Homo sapiens	36-66
111275-0	1979	Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.	Clorgyline	15-25	monoamine oxidase A	Homo sapiens	57-83
111275-0	1979	Selectivity of clorgyline and pargyline as inhibitors of monoamine oxidases A and B in vivo in man.	Pargyline	30-39	monoamine oxidase A	Homo sapiens	57-83
111275-3	1979	The differential effects of the two drugs on platelet MAO, which consists exclusively of the MAO-B form, suggests that the in vitro selectivity of clorgyline, and possibly of pargyline, on MAO-A and MAO-B may be maintained in vivo during long-term administration in man.	Clorgyline	147-157	monoamine oxidase A	Homo sapiens	189-194
96466-4	1978	Intestinal monoamine oxidase A was able to oxidise dopamine, whereas in human platelet or striatum the amine is a monoamine oxidase B substrate.	Dopamine	51-59	monoamine oxidase A	Homo sapiens	11-30
708457-0	1978	N-substituted cyclopropylamines as inhibitors of MAO-A and -B forms.	n-substituted cyclopropylamines	0-31	monoamine oxidase A	Homo sapiens	49-61
34012683-8	2021	Comparing the targets of the herbal strategies and three existing drugs (atenolol, pravastatin and propranolol) and the symbols of coronary artery atherosclerosis, we discovered that MAOA, HTR1A, and ABCG2 are overlapping in the three groups.	Propranolol	99-110	monoamine oxidase A	Homo sapiens	183-187
33913699-4	2021	Contezolid exhibited 2- and 148-fold reduction over linezolid reversible inhibition of MAO-A and MAO-B human enzyme isoforms.	Contezolid	0-10	monoamine oxidase A	Homo sapiens	87-92
33913699-4	2021	Contezolid exhibited 2- and 148-fold reduction over linezolid reversible inhibition of MAO-A and MAO-B human enzyme isoforms.	Linezolid	52-61	monoamine oxidase A	Homo sapiens	87-92
33990379-9	2021	We further demonstrated that MAO-A restrains antitumor T cell immunity through controlling intratumoral T cell autocrine serotonin signaling.	Serotonin	121-130	monoamine oxidase A	Homo sapiens	29-34
34054418-5	2021	The signaling of 1,25-dihydroxyvitamin D3, the active form of vitamin D, through vitamin D receptor (VDR) induces the expression of the gene of tryptophan hydroxylase 2 (TPH2), influences the expression of serotonin reuptake transporter (SERT) as well as the levels of monoamine oxidase-A (MAO-A), the enzyme responsible for serotonin catabolism.	Calcitriol	17-41	monoamine oxidase A	Homo sapiens	269-288
34054418-5	2021	The signaling of 1,25-dihydroxyvitamin D3, the active form of vitamin D, through vitamin D receptor (VDR) induces the expression of the gene of tryptophan hydroxylase 2 (TPH2), influences the expression of serotonin reuptake transporter (SERT) as well as the levels of monoamine oxidase-A (MAO-A), the enzyme responsible for serotonin catabolism.	Calcitriol	17-41	monoamine oxidase A	Homo sapiens	290-295
34054418-5	2021	The signaling of 1,25-dihydroxyvitamin D3, the active form of vitamin D, through vitamin D receptor (VDR) induces the expression of the gene of tryptophan hydroxylase 2 (TPH2), influences the expression of serotonin reuptake transporter (SERT) as well as the levels of monoamine oxidase-A (MAO-A), the enzyme responsible for serotonin catabolism.	Vitamin D	31-40	monoamine oxidase A	Homo sapiens	269-288
34054418-5	2021	The signaling of 1,25-dihydroxyvitamin D3, the active form of vitamin D, through vitamin D receptor (VDR) induces the expression of the gene of tryptophan hydroxylase 2 (TPH2), influences the expression of serotonin reuptake transporter (SERT) as well as the levels of monoamine oxidase-A (MAO-A), the enzyme responsible for serotonin catabolism.	Vitamin D	31-40	monoamine oxidase A	Homo sapiens	290-295
33651656-2	2021	Tranylcypromine (TCP), an irreversible monoamine oxidase (MAO)-A/B inhibitor applied in treatment resistant depression, was not included because of strict requirements for quality of study design.	Tranylcypromine	0-15	monoamine oxidase A	Homo sapiens	39-66
33922294-0	2021	Enantioselective Interactions of Anti-Infective 8-Aminoquinoline Therapeutics with Human Monoamine Oxidases A and B.	8-aminoquinoline	48-64	monoamine oxidase A	Homo sapiens	89-115
33922294-3	2021	A major role for MAO-A in metabolism of primaquine (PQ), the prototypical 8-AQ antimalarial, has been demonstrated.	Primaquine	40-50	monoamine oxidase A	Homo sapiens	17-22
33922294-3	2021	A major role for MAO-A in metabolism of primaquine (PQ), the prototypical 8-AQ antimalarial, has been demonstrated.	Primaquine	52-54	monoamine oxidase A	Homo sapiens	17-22
33922294-3	2021	A major role for MAO-A in metabolism of primaquine (PQ), the prototypical 8-AQ antimalarial, has been demonstrated.	8-aminoquinoline	74-78	monoamine oxidase A	Homo sapiens	17-22
33403748-9	2021	Among drugs interacting with hub genes in suicides we found MAOA inhibitors and dextromethorphan.	Dextromethorphan	80-96	monoamine oxidase A	Homo sapiens	60-64
33618250-3	2021	Higenamine shows acceptable potency against LSD1 and high selectivity towards LSD1 over MAOA/B.	higenamine	0-10	monoamine oxidase A	Homo sapiens	88-92
33855088-4	2021	Results: The norepinephrine levels were markedly high in gastric cancer tissue, while the norepinephrine-degrading enzymes MAOA and MAOB showed low expression.	Norepinephrine	90-104	monoamine oxidase A	Homo sapiens	123-127
33855088-8	2021	The norepinephrine-degrading enzymes MAOA and MAOB have significant expression differences in cancer and normal tissue, and their missing or low expression may predict immune therapy outcomes for gastric cancer patients.	Norepinephrine	4-18	monoamine oxidase A	Homo sapiens	37-41
33264068-8	2021	We found increased MAO-A expression in the pulmonary vasculature of PAH patients and in experimental PH induced by SuHx.	suhx	115-119	monoamine oxidase A	Homo sapiens	19-24
33264068-9	2021	Cardiac MAO-A expression and activity was increased in SuHx- and PTB-induced RV failure.	6-thiotheophylline	65-68	monoamine oxidase A	Homo sapiens	8-13
33376014-3	2021	Based on these considerations, the present study synthesizes a series of 22 pyrazolo[1,5-a]quinoxalin-4-one derivatives and evaluated them as potential inhibitors of human MAO-A and MAO-B.	Pyrazolo[1,5-a]quinoxalin-4(5H)-one	76-107	monoamine oxidase A	Homo sapiens	172-177
33360592-11	2021	We detected effect modification by four DA relative genes (ANKK1, COMT, DAT1 and MAOA) on the association between UF and IQ scores.	Dopamine	40-42	monoamine oxidase A	Homo sapiens	81-85
33444985-3	2021	Substitution patterns on both the phenyl ring and the benzofuran moiety determine the affinity for MAO-A or MAO-B.	benzofuran	54-64	monoamine oxidase A	Homo sapiens	99-104
32970293-4	2021	The most potent inhibitor was a 1-tetralone derivative (1h) with IC50 values of 0.036 and 0.0011 microM for MAO-A and MAO-B, respectively.	Tetralones	32-43	monoamine oxidase A	Homo sapiens	108-113
33085988-1	2021	We herein report the biological evaluation of 3-arylcoumarin derivatives (3a-l) as potential human monoamine oxidase-A and -B (hMAO-A and hMAO-B) inhibitors.	3-arylcoumarin	46-60	monoamine oxidase A	Homo sapiens	99-125
33085988-1	2021	We herein report the biological evaluation of 3-arylcoumarin derivatives (3a-l) as potential human monoamine oxidase-A and -B (hMAO-A and hMAO-B) inhibitors.	3-arylcoumarin	46-60	monoamine oxidase A	Homo sapiens	127-133
33085988-2	2021	The result indicated that 7,8-dihydroxy-3-(4-nitrophenyl)coumarin (3j) was most effective against MAO-A (inhibition concentration [IC50 ] = 6.46 +- 0.02 microM) and MAO-B (IC50  = 3.8 +- 0.3 microM) enzymes than other synthesized compounds and reference compounds (pargyline and moclobemide).	7,8-dihydroxy-3-(4-nitrophenyl)coumarin	26-65	monoamine oxidase A	Homo sapiens	98-103
33085988-2	2021	The result indicated that 7,8-dihydroxy-3-(4-nitrophenyl)coumarin (3j) was most effective against MAO-A (inhibition concentration [IC50 ] = 6.46 +- 0.02 microM) and MAO-B (IC50  = 3.8 +- 0.3 microM) enzymes than other synthesized compounds and reference compounds (pargyline and moclobemide).	Pargyline	265-274	monoamine oxidase A	Homo sapiens	98-103
33085988-2	2021	The result indicated that 7,8-dihydroxy-3-(4-nitrophenyl)coumarin (3j) was most effective against MAO-A (inhibition concentration [IC50 ] = 6.46 +- 0.02 microM) and MAO-B (IC50  = 3.8 +- 0.3 microM) enzymes than other synthesized compounds and reference compounds (pargyline and moclobemide).	Moclobemide	279-290	monoamine oxidase A	Homo sapiens	98-103
32970293-4	2021	The most potent inhibitor was a 1-tetralone derivative (1h) with IC50 values of 0.036 and 0.0011 microM for MAO-A and MAO-B, respectively.	Hydrogen	56-58	monoamine oxidase A	Homo sapiens	108-113
33279529-1	2021	Monoamine oxidases (MAO-A and MAO-B) are the two flavin adenine dinucleotide (FAD) enzymes that play an important role in neurotransmitter homeostasis and in protection against biogenic amines.	Flavin-Adenine Dinucleotide	49-76	monoamine oxidase A	Homo sapiens	20-25
33279529-1	2021	Monoamine oxidases (MAO-A and MAO-B) are the two flavin adenine dinucleotide (FAD) enzymes that play an important role in neurotransmitter homeostasis and in protection against biogenic amines.	Flavin-Adenine Dinucleotide	78-81	monoamine oxidase A	Homo sapiens	20-25
32970293-6	2021	Among these 1-tetralol derivatives, 1p (IC50 = 0.785 muM) and 1o (IC50 = 0.0075 muM) were identified as particularly potent inhibitors of MAO-A and MAO-B, respectively.	1,2,3,4-Tetrahydro-1-naphthol	12-22	monoamine oxidase A	Homo sapiens	138-143
33279529-1	2021	Monoamine oxidases (MAO-A and MAO-B) are the two flavin adenine dinucleotide (FAD) enzymes that play an important role in neurotransmitter homeostasis and in protection against biogenic amines.	Amines	186-192	monoamine oxidase A	Homo sapiens	20-25
33097301-6	2021	Enzymatic studies confirmed that pOBz competitively inhibited the activity of purified human MAO-B (Ki = 0.041 muM versus Ki = 0.92 muM for salidroside), and pOBz was highly selective for MAO-B over MAO-A.	pobz	33-37	monoamine oxidase A	Homo sapiens	199-204
32702381-12	2021	In female MDD patients, the minor allele of rs6323 and rs1137070 on the MAOA gene likely lead to a worse response to venlafaxine.	Venlafaxine Hydrochloride	117-128	monoamine oxidase A	Homo sapiens	72-76
32702381-17	2021	SLC6A4 genetic variants, as well as HPA pathway, play an important role in the fluoxetine antidepressant therapeutic response while the polymorphism of MAOA gene involved in the pharmacological action of venlafaxine among female MDD patients.	Venlafaxine Hydrochloride	204-215	monoamine oxidase A	Homo sapiens	152-156
33097301-6	2021	Enzymatic studies confirmed that pOBz competitively inhibited the activity of purified human MAO-B (Ki = 0.041 muM versus Ki = 0.92 muM for salidroside), and pOBz was highly selective for MAO-B over MAO-A.	pobz	158-162	monoamine oxidase A	Homo sapiens	199-204
33339338-1	2020	The beta-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application.	norharman	4-18	monoamine oxidase A	Homo sapiens	114-119
32454163-7	2020	The use of the areca nut increases both brain serotonin and noradrenaline levels, whereas arecoline, a potentially addictive areca nut component, has monoamine oxidase-A (MAO-A) inhibitor-like properties.	Arecoline	90-99	monoamine oxidase A	Homo sapiens	171-176
32454163-8	2020	MAO-A inhibitors prevent neurotransmitter breakdown and increase dopamine and serotonin concentrations in the brain.	Dopamine	65-73	monoamine oxidase A	Homo sapiens	0-5
32454163-8	2020	MAO-A inhibitors prevent neurotransmitter breakdown and increase dopamine and serotonin concentrations in the brain.	Serotonin	78-87	monoamine oxidase A	Homo sapiens	0-5
32454163-9	2020	A reduction of daily BQ use was observed among patients with depression after antidepressant therapy, including MAO-A inhibitor and selective serotonin reuptake inhibitor (SSRI).	bulaquine	21-23	monoamine oxidase A	Homo sapiens	112-117
32454163-13	2020	Arecoline, an MAO-A inhibitor, may account for BQD.	Arecoline	0-9	monoamine oxidase A	Homo sapiens	14-19
33215182-0	2020	Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N,N-dimethyltryptamine with monoamine oxidase A.	tryptamine	81-91	monoamine oxidase A	Homo sapiens	124-143
33215182-0	2020	Quantum chemical (QM:MM) investigation of the mechanism of enzymatic reaction of tryptamine and N,N-dimethyltryptamine with monoamine oxidase A.	N,N-Dimethyltryptamine	96-118	monoamine oxidase A	Homo sapiens	124-143
33339338-1	2020	The beta-carboline alkaloid harmine is a potent DYRK1A inhibitor, but suffers from undesired potent inhibition of MAO-A, which strongly limits its application.	Harmine	28-35	monoamine oxidase A	Homo sapiens	114-119
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	monoamine oxidase A	Homo sapiens	251-256
33339338-2	2020	We synthesized more than 60 analogues of harmine, either by direct modification of the alkaloid or by de novo synthesis of beta-carboline and related scaffolds aimed at learning about structure-activity relationships for inhibition of both DYRK1A and MAO-A, with the ultimate goal of separating desired DYRK1A inhibition from undesired MAO-A inhibition.	Harmine	41-48	monoamine oxidase A	Homo sapiens	336-341
33212830-0	2020	Selective Interactions of O-Methylated Flavonoid Natural Products with Human Monoamine Oxidase-A and -B.	o-methylated flavonoid	26-48	monoamine oxidase A	Homo sapiens	77-103
32924264-2	2020	The present work describes the syntheses of selected 1,3-benzodioxine-containing chalcones (CD3, CD8 and CD10), and their inhibitory activities against MAO-A, MAO-B, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE).	1,3-benzodioxine	53-69	monoamine oxidase A	Homo sapiens	152-157
32924264-2	2020	The present work describes the syntheses of selected 1,3-benzodioxine-containing chalcones (CD3, CD8 and CD10), and their inhibitory activities against MAO-A, MAO-B, acetylcholinesterase (AChE), and butyrylcholinesterase (BChE).	Chalcones	81-90	monoamine oxidase A	Homo sapiens	152-157
33017522-10	2020	RESULTS: Dopamine secretion increased locally in HCC due to an imbalance in dopamine metabolism, including the upregulation of dopa decarboxylase (DDC) and the downregulation of monoamine oxidase A (MAOA).	Dopamine	9-17	monoamine oxidase A	Homo sapiens	199-203
33212876-1	2020	Twelve pyridazinones (T1-T12) containing the (2-fluorophenyl) piperazine moiety were designed, synthesized, and evaluated for monoamine oxidase (MAO) -A and -B inhibitory activities.	pyridazinones	7-20	monoamine oxidase A	Homo sapiens	126-159
33212830-8	2020	The calculated binding free energies of the O-methylated flavonoids (1 and 4-6) and chalcones (2 and 3) to MAO-A matched closely with the trend in the experimental IC50"s.	Flavonoids	57-67	monoamine oxidase A	Homo sapiens	107-112
33212876-1	2020	Twelve pyridazinones (T1-T12) containing the (2-fluorophenyl) piperazine moiety were designed, synthesized, and evaluated for monoamine oxidase (MAO) -A and -B inhibitory activities.	t1-t12	22-28	monoamine oxidase A	Homo sapiens	126-159
33212830-8	2020	The calculated binding free energies of the O-methylated flavonoids (1 and 4-6) and chalcones (2 and 3) to MAO-A matched closely with the trend in the experimental IC50"s.	Chalcones	84-93	monoamine oxidase A	Homo sapiens	107-112
33212830-10	2020	The natural O-methylated flavonoid (1) with highly potent inhibition (IC50 33 nM; Ki 37.9 nM) and >292 fold selectivity against human MAO-A (vs. MAO-B) provides a new drug lead for the treatment of neurological disorders.	Flavonoids	25-34	monoamine oxidase A	Homo sapiens	134-139
33212876-5	2020	T6 and T3 efficiently inhibited MAO-A with IC50 values of 1.57 and 4.19 microM and had the highest selectivity indices (SIs) for MAO-B (120.8 and 107.4, respectively).	t6	0-2	monoamine oxidase A	Homo sapiens	32-37
33212876-5	2020	T6 and T3 efficiently inhibited MAO-A with IC50 values of 1.57 and 4.19 microM and had the highest selectivity indices (SIs) for MAO-B (120.8 and 107.4, respectively).	Triiodothyronine	7-9	monoamine oxidase A	Homo sapiens	32-37
32931665-7	2020	In vivo experiment was conducted to study the impact of traditional Chinese medicine nitidine chloride (NC) on MAOA in HCC.	nitidine	85-102	monoamine oxidase A	Homo sapiens	111-115
32942081-1	2020	Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines.	Norepinephrine	139-153	monoamine oxidase A	Homo sapiens	20-25
32942081-1	2020	Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines.	Dopamine	155-163	monoamine oxidase A	Homo sapiens	20-25
32942081-1	2020	Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines.	Tyramine	165-173	monoamine oxidase A	Homo sapiens	20-25
32942081-1	2020	Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines.	Serotonin	175-184	monoamine oxidase A	Homo sapiens	20-25
32942081-1	2020	Monoamine oxidases (MAO-A and MAO-B) are mammalian flavoenzyme, which catalyze the oxidative deamination of several neurotransmitters like norepinephrine, dopamine, tyramine, serotonin, and some other amines.	Amines	201-207	monoamine oxidase A	Homo sapiens	20-25
33262691-4	2020	Such joint apparent contradictions can be overcome by pointing out that, among their respective signaling pathways, valproate and IL-17a share an enhancement of the "type A monoamine oxidase" (MAOA) enzyme carried by the X chromosome.	Valproic Acid	116-125	monoamine oxidase A	Homo sapiens	193-197
33262691-7	2020	Following a prenatal exposure to molecules that significantly elicit the MAOA gene expression, a daily treatment with the same metabolic impact would tend to recreate the fetal environment and contribute to rebalance monoamines, thus allowing proper neural circuits to gradually develop, provided behavioral re-education.	monoamines	217-227	monoamine oxidase A	Homo sapiens	73-77
33262691-8	2020	Given the multifaceted other players than MAOA that are involved in the regulation of serotonin levels, potential compensatory effects are surveyed, which may underlie the autism heterogeneity.	Serotonin	86-95	monoamine oxidase A	Homo sapiens	42-46
32931665-7	2020	In vivo experiment was conducted to study the impact of traditional Chinese medicine nitidine chloride (NC) on MAOA in HCC.	nitidine	104-106	monoamine oxidase A	Homo sapiens	111-115
32601846-6	2020	MAO-A inhibition with moclobemide may provide anti-parkinsonian benefit when administered without L-DOPA and might perhaps be considered as monotherapy for the treatment of Parkinson"s disease in the early stages of the condition.	Moclobemide	22-33	monoamine oxidase A	Homo sapiens	0-5
32621059-1	2020	Whereas monoamine oxidase (MAO) type B inhibitors are used as adjunct to L-3,4-dihydroxyphenylalanine (L-DOPA) in the treatment of Parkinson"s disease (PD), the enzyme MAO type A (MAO-A) also participates in the metabolism of dopamine in the human and primate striatum.	Dopamine	226-234	monoamine oxidase A	Homo sapiens	168-178
32621059-2	2020	Here, we sought to assess the effect of the selective reversible MAO-A inhibitor moclobemide on L-DOPA anti-parkinsonian in the gold standard animal model of PD, the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-lesioned primate.	Moclobemide	81-92	monoamine oxidase A	Homo sapiens	65-70
32601846-6	2020	MAO-A inhibition with moclobemide may provide anti-parkinsonian benefit when administered without L-DOPA and might perhaps be considered as monotherapy for the treatment of Parkinson"s disease in the early stages of the condition.	Levodopa	98-104	monoamine oxidase A	Homo sapiens	0-5
32621059-8	2020	Reversible MAO-A inhibition with moclobemide appears as an effective way to increase the anti-parkinsonian action of L-DOPA, without negatively affecting dyskinesia or dopaminergic psychosis.	Moclobemide	33-44	monoamine oxidase A	Homo sapiens	11-16
32621059-8	2020	Reversible MAO-A inhibition with moclobemide appears as an effective way to increase the anti-parkinsonian action of L-DOPA, without negatively affecting dyskinesia or dopaminergic psychosis.	Levodopa	117-123	monoamine oxidase A	Homo sapiens	11-16
32574581-2	2020	The best-documented gene implicated in aggression is MAOA (Monoamine oxidase A), which encodes the key enzyme for the degradation of serotonin and catecholamines.	Serotonin	133-142	monoamine oxidase A	Homo sapiens	53-57
32574581-2	2020	The best-documented gene implicated in aggression is MAOA (Monoamine oxidase A), which encodes the key enzyme for the degradation of serotonin and catecholamines.	Serotonin	133-142	monoamine oxidase A	Homo sapiens	59-78
32574581-2	2020	The best-documented gene implicated in aggression is MAOA (Monoamine oxidase A), which encodes the key enzyme for the degradation of serotonin and catecholamines.	Catecholamines	147-161	monoamine oxidase A	Homo sapiens	53-57
32574581-2	2020	The best-documented gene implicated in aggression is MAOA (Monoamine oxidase A), which encodes the key enzyme for the degradation of serotonin and catecholamines.	Catecholamines	147-161	monoamine oxidase A	Homo sapiens	59-78
32716595-1	2020	A number of 1,2,3,4-tetrahydrochromeno[3,2-c]pyridin-10-one derivatives were synthesized and screened against different targets involved in Alzheimer"s Disease (AD) onset and progression, such as acetyl- and butyrylcholinesterase (AChE and BChE), monoamine oxidases A and B (MAO A and B), aggregation of beta-amyloid (Abeta) and reactive oxygen species (ROS) production.	1,2,3,4-tetrahydrochromeno[3,2-c]pyridin-10-one	12-59	monoamine oxidase A	Homo sapiens	275-286
33224618-7	2020	The efflux parameter kloss (corresponding to MAO-A activity) was decreased (P<0.05) by pretreatment of clorgyline, while the macro-parameter Flux/Efflux ratio (Ki/kloss) was increased (P<0.0001).	Clorgyline	103-113	monoamine oxidase A	Homo sapiens	45-50
33050524-0	2020	Synthesis, Docking, 3-D-Qsar, and Biological Assays of Novel Indole Derivatives Targeting Serotonin Transporter, Dopamine D2 Receptor, and Mao-A Enzyme: In the Pursuit for Potential Multitarget Directed Ligands.	indole	61-67	monoamine oxidase A	Homo sapiens	139-144
32875729-0	2020	Potential monoamine oxidase A inhibitor suppressing paclitaxel-resistant non-small cell lung cancer metastasis and growth.	Paclitaxel	52-62	monoamine oxidase A	Homo sapiens	10-29
32875729-3	2020	Hence, the aim of this article was to evaluate a previously synthesized MAOA inhibitor (G11) on inhibiting paclitaxel-resistant NSCLC metastasis and growth.	Paclitaxel	107-117	monoamine oxidase A	Homo sapiens	72-76
32875729-10	2020	G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels.	g11	0-3	monoamine oxidase A	Homo sapiens	43-47
32875729-10	2020	G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels.	g11	0-3	monoamine oxidase A	Homo sapiens	112-116
32875729-10	2020	G11 dramatically reduced the expression of MAOA in A549/PTX and H460/PTX cells, which exhibited relatively high MAOA expression levels.	Paclitaxel	56-59	monoamine oxidase A	Homo sapiens	43-47
32875729-13	2020	CONCLUSIONS: These findings indicated G11 showed a moderate inhibitory effect on paclitaxel-resistant NSCLC metastasis and growth, and support further investigation on MAOA potentially as a promising therapeutic target for paclitaxel-resistant NSCLC treatment.	Paclitaxel	223-233	monoamine oxidase A	Homo sapiens	168-172
32875729-14	2020	KEY POINTS: SIGNIFICANT FINDINGS OF THE STUDY: Inhibition of MAOA might contribute to the suppression of metastasis and growth in PTX-resistant NSCLC cells.	Paclitaxel	130-133	monoamine oxidase A	Homo sapiens	61-65
32971892-0	2020	Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.	thiazolylhydrazine	57-75	monoamine oxidase A	Homo sapiens	112-117
32845149-0	2020	How Monoamine Oxidase A Decomposes Serotonin: An Empirical Valence Bond Simulation of the Reactive Step.	Serotonin	35-44	monoamine oxidase A	Homo sapiens	4-23
32845149-2	2020	In particular, monoamine oxidase A (MAO A) is an important flavoenzyme involved in the metabolism of monoamine neurotransmitters.	monoamine	15-24	monoamine oxidase A	Homo sapiens	36-41
32845149-8	2020	Together with additional experimental and computational work, the herein presented results contribute to a deeper understanding of the catalytic mechanism of MAO A and flavoenzymes in general, and in the long run, should pave the way toward applications in neuropsychiatry.	flavoenzymes	168-180	monoamine oxidase A	Homo sapiens	158-163
32869630-0	2020	Luteolin, a potent human monoamine oxidase-A inhibitor and dopamine D4 and vasopressin V1A receptor antagonist.	Luteolin	0-8	monoamine oxidase A	Homo sapiens	25-44
32869630-3	2020	Here, luteolin exhibited selective inhibition of hMAO-A (IC50 = 8.57 +- 0.47 microM) over hMAO-B (IC50 > 100 microM).	Luteolin	6-14	monoamine oxidase A	Homo sapiens	49-55
32971892-0	2020	Design, Synthesis, In Vitro and In Silico Studies of New Thiazolylhydrazine-Piperazine Derivatives as Selective MAO-A Inhibitors.	Piperazine	76-86	monoamine oxidase A	Homo sapiens	112-117
32971892-2	2020	Herein, novel series of thiazolylhydrazine-piperazine derivatives were designed, synthesized and evaluated for their MAO-A and -B inhibitory activity.	thiazolylhydrazine	24-42	monoamine oxidase A	Homo sapiens	117-129
32971892-2	2020	Herein, novel series of thiazolylhydrazine-piperazine derivatives were designed, synthesized and evaluated for their MAO-A and -B inhibitory activity.	Piperazine	43-53	monoamine oxidase A	Homo sapiens	117-129
33015076-6	2020	The metabolic enzyme for the monoamine neurotransmitters, monoamine oxidases A/B (MAO A/MAO B) are the prime candidates for the investigation into the role of DNA methylation in mental disorders.	monoamine	29-38	monoamine oxidase A	Homo sapiens	58-80
33015076-6	2020	The metabolic enzyme for the monoamine neurotransmitters, monoamine oxidases A/B (MAO A/MAO B) are the prime candidates for the investigation into the role of DNA methylation in mental disorders.	monoamine	29-38	monoamine oxidase A	Homo sapiens	82-93
33479699-0	2020	Novel 1,3,4-thiadiazole compounds as potential MAO-A inhibitors - design, synthesis, biological evaluation and molecular modelling.	1,3,4-thiadiazole	6-23	monoamine oxidase A	Homo sapiens	47-52
32583952-3	2020	The title compound MO10 was assessed for inhibitory activities against two human MAO isoforms, i.e., MAO-A and MAO-B.	mo10	19-23	monoamine oxidase A	Homo sapiens	101-106
32753686-4	2021	Ethanol treatment resulted in decreased 5-HT concentrations in human induced pluripotent stem cell (iPSC)-derived neuron culture media, and the downregulation of gene expression of TSPAN5, DDC, MAOA, MAOB, TPH1, and TPH2 in those cells.	Ethanol	0-7	monoamine oxidase A	Homo sapiens	194-198
32459875-2	2020	We probed the efficacy of DPI on two well-known drug targets, the human monoamine oxidases MAO A and B.	diphenyleneiodonium	26-29	monoamine oxidase A	Homo sapiens	91-102
32459875-3	2020	UV-visible spectrophotometry and steady-state kinetics experiments demonstrate that DPI acts as a competitive MAO inhibitor with Ki values of 1.7 microM and 0.3 microM for MAO A and MAO B, respectively.	diphenyleneiodonium	84-87	monoamine oxidase A	Homo sapiens	172-177
32311818-0	2020	Serotonin homeostasis in the materno-fetal interface at term: role of transporters (SERT/SLC6A4 and OCT3/SLC22A3) and monoamine oxidase A (MAO-A) in uptake and degradation of serotonin by human and rat term placenta.	Serotonin	0-9	monoamine oxidase A	Homo sapiens	118-137
32149402-6	2020	Interestingly, it has been found that TV 3326 (i.e. ladostigil) is regarded as a novel therapeutic agent since it has the potential to cause inhibition of monoamine oxidase (MAO) A and B, and acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the brain.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	38-45	monoamine oxidase A	Homo sapiens	155-186
32311818-11	2020	Together with 5-HT degrading enzyme, monoamine oxidase-A, this offers a protective mechanism against local vasoconstriction effects of 5-HT in the placenta.	Serotonin	135-139	monoamine oxidase A	Homo sapiens	37-56
32792865-4	2020	Additionally, MAOA knockout inhibited HPV-16 E7-induced migration, invasion, and EMT, and significantly reduced HPV-16 E7-induced ROS generation and HIF-1alpha protein accumulation via promoting its degradation.	ros	130-133	monoamine oxidase A	Homo sapiens	14-18
32149402-6	2020	Interestingly, it has been found that TV 3326 (i.e. ladostigil) is regarded as a novel therapeutic agent since it has the potential to cause inhibition of monoamine oxidase (MAO) A and B, and acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) in the brain.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	52-62	monoamine oxidase A	Homo sapiens	155-186
32705963-2	2021	Recent study documented that shifting of fluorine atom from para to ortho position on the phenyl B ring of heteroaryl chalcones shown a remarkable shift in the selectivity and potency between MAO-A and MAO-B isoforms.	Fluorine	41-49	monoamine oxidase A	Homo sapiens	192-197
32705963-2	2021	Recent study documented that shifting of fluorine atom from para to ortho position on the phenyl B ring of heteroaryl chalcones shown a remarkable shift in the selectivity and potency between MAO-A and MAO-B isoforms.	heteroaryl chalcones	107-127	monoamine oxidase A	Homo sapiens	192-197
32589395-3	2020	We produced recombinant human MAO A variants at Lys305 that plays a key role in O2 reactivity leading to H2O2 production.	Oxygen	80-82	monoamine oxidase A	Homo sapiens	30-35
32278045-13	2020	Finally another suggested mechanism is suppression of MAOA/mTORC1/hypoxia-inducible factor 1alpha signaling pathway by curcumin.	Curcumin	119-127	monoamine oxidase A	Homo sapiens	54-58
32670031-9	2020	In MAOA-H carriers endogenous testosterone levels at baseline were associated with increased joystick deflection in both blocks.	Testosterone	30-42	monoamine oxidase A	Homo sapiens	3-7
32670031-12	2020	The administration of testosterone seems to act on the subjective emotional experience in a provoking situation, while endogenous testosterone levels increased pulling impulses only in carriers of the MAOA-H variant.	Testosterone	130-142	monoamine oxidase A	Homo sapiens	201-205
32575435-6	2020	Urolithin B was found to be a better MAO-A enzyme inhibitor among the tested urolithins and EA with an IC50 value of 0.88 microM, and displaying a mixed mode of inhibition.	urolithin B	0-11	monoamine oxidase A	Homo sapiens	37-42
32575435-6	2020	Urolithin B was found to be a better MAO-A enzyme inhibitor among the tested urolithins and EA with an IC50 value of 0.88 microM, and displaying a mixed mode of inhibition.	urolithins	77-87	monoamine oxidase A	Homo sapiens	37-42
32380384-10	2020	Harmine, Clorgyline, Isatin, zonisamide and our title compound including are known with their competitive inhibitory activity on Human monoamine oxidase, commonly named MAO A and B.	Harmine	0-7	monoamine oxidase A	Homo sapiens	169-180
32380384-10	2020	Harmine, Clorgyline, Isatin, zonisamide and our title compound including are known with their competitive inhibitory activity on Human monoamine oxidase, commonly named MAO A and B.	Clorgyline	9-19	monoamine oxidase A	Homo sapiens	169-180
32380384-10	2020	Harmine, Clorgyline, Isatin, zonisamide and our title compound including are known with their competitive inhibitory activity on Human monoamine oxidase, commonly named MAO A and B.	Isatin	21-27	monoamine oxidase A	Homo sapiens	169-180
32380384-10	2020	Harmine, Clorgyline, Isatin, zonisamide and our title compound including are known with their competitive inhibitory activity on Human monoamine oxidase, commonly named MAO A and B.	Zonisamide	29-39	monoamine oxidase A	Homo sapiens	169-180
32589395-3	2020	We produced recombinant human MAO A variants at Lys305 that plays a key role in O2 reactivity leading to H2O2 production.	Hydrogen Peroxide	105-109	monoamine oxidase A	Homo sapiens	30-35
32527030-5	2020	The inhibitory activity against human monoamine oxidase A (hMAO-A) for the DCM extract was almost the same (88.22%).	dcm	75-78	monoamine oxidase A	Homo sapiens	38-57
32527030-5	2020	The inhibitory activity against human monoamine oxidase A (hMAO-A) for the DCM extract was almost the same (88.22%).	dcm	75-78	monoamine oxidase A	Homo sapiens	59-65
32483206-3	2020	Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection in CRPC patients following Enz treatment.	enzalutamide	137-140	monoamine oxidase A	Homo sapiens	39-58
32483206-3	2020	Here we report that high expression of monoamine oxidase-A (MAO-A) is associated with positive ARv7 detection in CRPC patients following Enz treatment.	enzalutamide	137-140	monoamine oxidase A	Homo sapiens	60-65
32483206-4	2020	Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo.	Phenelzine	21-31	monoamine oxidase A	Homo sapiens	10-15
32483206-4	2020	Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo.	Clorgyline	35-45	monoamine oxidase A	Homo sapiens	10-15
32483206-4	2020	Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo.	enzalutamide	106-109	monoamine oxidase A	Homo sapiens	10-15
32483206-4	2020	Targeting MAO-A with phenelzine or clorgyline, the FDA-approved drugs for antidepression, resensitize the Enz resistant (EnzR) cells to Enz treatment and further suppress EnzR cell growth in vitro and in vivo.	enzalutamide	121-124	monoamine oxidase A	Homo sapiens	10-15
32483206-6	2020	Together, our results show that targeting the Enz/ARv7/MAO-A signaling with the antidepressants phenelzine or clorgyline can restore Enz sensitivity to suppress EnzR cell growth, which may indicate that these antidepression drugs can overcome the Enz resistance to further suppress the EnzR CRPC.	Phenelzine	96-106	monoamine oxidase A	Homo sapiens	55-60
32483206-6	2020	Together, our results show that targeting the Enz/ARv7/MAO-A signaling with the antidepressants phenelzine or clorgyline can restore Enz sensitivity to suppress EnzR cell growth, which may indicate that these antidepression drugs can overcome the Enz resistance to further suppress the EnzR CRPC.	Clorgyline	110-120	monoamine oxidase A	Homo sapiens	55-60
32144745-9	2020	Compound 4b was found as the most potent (ki = 0.022 +- 0.001 microM) and selective (SI (Ki hMAO-A/hMAO-B) = 206.82) hMAO-B inhibitor in this series.	Silicon	85-87	monoamine oxidase A	Homo sapiens	92-105
32443652-6	2020	COE-13 most potently inhibited MAO-A (IC50 = 0.88 microM) and also significantly inhibited MAO-B (IC50 = 0.13 microM), and it could be considered as a potential nonselective MAO inhibitor.	coe-13	0-6	monoamine oxidase A	Homo sapiens	31-36
32133483-4	2020	MAOA promoter methylation was analyzed via direct sequencing of sodium bisulfite-treated DNA extracted from whole blood before and after an 8-10-week semi-standardized, OCD-specific CBT.	sodium bisulfite	64-80	monoamine oxidase A	Homo sapiens	0-4
32087226-2	2020	Among the compounds isolated, flavonoids calycosin (5) and 8-O-methylretusin (6) were found to potently and selectively inhibit hMAO-B (IC50 = 0.24 and 0.23 muM, respectively) but not hMAO-A with high selectivity index (SI) values (SI = 293.8 and 81.3, respectively).	Flavonoids	30-40	monoamine oxidase A	Homo sapiens	184-190
32087226-2	2020	Among the compounds isolated, flavonoids calycosin (5) and 8-O-methylretusin (6) were found to potently and selectively inhibit hMAO-B (IC50 = 0.24 and 0.23 muM, respectively) but not hMAO-A with high selectivity index (SI) values (SI = 293.8 and 81.3, respectively).	7,3'-dihydroxy-4'-methoxyisoflavone	41-50	monoamine oxidase A	Homo sapiens	184-190
32087226-2	2020	Among the compounds isolated, flavonoids calycosin (5) and 8-O-methylretusin (6) were found to potently and selectively inhibit hMAO-B (IC50 = 0.24 and 0.23 muM, respectively) but not hMAO-A with high selectivity index (SI) values (SI = 293.8 and 81.3, respectively).	8-O-methylretusin	59-76	monoamine oxidase A	Homo sapiens	184-190
32316576-1	2020	Monoamine oxidases (MAOs) including MAOA and MAOB are enzymes located on the outer membranes of mitochondria, which are responsible for catalyzing monoamine oxidation.	monoamine	147-156	monoamine oxidase A	Homo sapiens	36-40
32499684-6	2020	MAOA-H allele carriers showed greater deactivation of the right anterior hippocampus and greater cortisol response after stress than did MAOH-L allele carriers.	Hydrocortisone	97-105	monoamine oxidase A	Homo sapiens	0-4
31373522-0	2020	Monoamine oxidase A inhibition by toxic concentrations of metaxalone.	metaxalone	58-68	monoamine oxidase A	Homo sapiens	0-19
31373522-2	2020	Monoamine oxidase A (MAO-A) inhibition by metaxalone has been proposed as the etiology of this toxicity.	metaxalone	42-52	monoamine oxidase A	Homo sapiens	0-19
31373522-2	2020	Monoamine oxidase A (MAO-A) inhibition by metaxalone has been proposed as the etiology of this toxicity.	metaxalone	42-52	monoamine oxidase A	Homo sapiens	21-26
31373522-4	2020	We investigated the effect of metaxalone on MAO-A activity using an in vitro model.	metaxalone	30-40	monoamine oxidase A	Homo sapiens	44-49
31373522-5	2020	Methods: Metaxalone at concentrations ranging from 1.56 to 400 microM were incubated with a proprietary MAO substrate and recombinant human MAO-A for 1 h. After that, an esterase and luciferase were added and luminescence measured.	metaxalone	9-19	monoamine oxidase A	Homo sapiens	140-145
31373522-8	2020	Results: Metaxalone demonstrated significant dose-related inhibition of MAO-A activity.	metaxalone	9-19	monoamine oxidase A	Homo sapiens	72-77
31373522-10	2020	Conclusions: Our in vitro model shows that at toxic concentrations similar to those reported in case reports metaxalone shows significant MAO-A inhibition.	metaxalone	109-119	monoamine oxidase A	Homo sapiens	138-143
32772067-3	2020	Its biological activity results from the content of N,N-dimethyltryptamine (DMT), acting mainly as a non-selective agonist of serotonin receptors and beta-carboline alkaloids, which are strong and short-acting monoamine oxidase type A(MAOI-A) inhibitors.	N,N-Dimethyltryptamine	52-74	monoamine oxidase A	Homo sapiens	210-234
32772067-3	2020	Its biological activity results from the content of N,N-dimethyltryptamine (DMT), acting mainly as a non-selective agonist of serotonin receptors and beta-carboline alkaloids, which are strong and short-acting monoamine oxidase type A(MAOI-A) inhibitors.	N,N-Dimethyltryptamine	76-79	monoamine oxidase A	Homo sapiens	210-234
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	3-chlorobenzoic acid	37-41	monoamine oxidase A	Homo sapiens	80-99
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	Moclobemide	110-121	monoamine oxidase A	Homo sapiens	80-99
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	4-chlorobenzoic acid	147-167	monoamine oxidase A	Homo sapiens	80-99
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	4-(2-Aminoethyl)morpholine	186-212	monoamine oxidase A	Homo sapiens	80-99
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	polyphosphoric acid	285-304	monoamine oxidase A	Homo sapiens	80-99
32337091-5	2020	The broader substrate specificity of McbA was exploited in the synthesis of the monoamine oxidase A inhibitor moclobemide, through the reaction of 4-chlorobenzoic acid with 1.5 equiv of 4-(2-aminoethyl)morpholine, and utilizing polyphosphate kinases SmPPK and AjPPK in the presence of polyphosphoric acid and 0.1 equiv of ATP, required for recycling of the cofactor.	Adenosine Triphosphate	322-325	monoamine oxidase A	Homo sapiens	80-99
32403270-3	2020	In this work, we aimed to find potential drugs for PCa patients suffering from depression by establishing novel anti-PCa reversible monoamine oxidase-A inhibitors (MAO-AIs/RIMA); with an endeavor to understand their mechanism of action.	mao-ais	164-171	monoamine oxidase A	Homo sapiens	132-151
32403270-3	2020	In this work, we aimed to find potential drugs for PCa patients suffering from depression by establishing novel anti-PCa reversible monoamine oxidase-A inhibitors (MAO-AIs/RIMA); with an endeavor to understand their mechanism of action.	rima	172-176	monoamine oxidase A	Homo sapiens	132-151
32403270-4	2020	In this investigation, twenty synthesized flavonoid derivatives, defined as KKR compounds were screened for their inhibitory potentials against human MAO-A and MAO-B isozymes.	Flavonoids	42-51	monoamine oxidase A	Homo sapiens	150-155
32077158-1	2020	Monoamine oxidases have two functionally distinct but structurally similar isoforms (MAO-A and -B).	Biogenic Monoamines	0-9	monoamine oxidase A	Homo sapiens	85-97
32155491-0	2020	Isoquinoline alkaloids from the roots of Zanthoxylum rigidum as multi-target inhibitors of cholinesterase, monoamine oxidase A and Abeta1-42 aggregation.	isoquinoline alkaloids	0-22	monoamine oxidase A	Homo sapiens	107-140
32155491-9	2020	In addition, these alkaloids presented moderate Abeta1-42 anti-aggregation activity and MAO-A inhibition with IC50 values between 0.5 and 2 microM.	Alkaloids	19-28	monoamine oxidase A	Homo sapiens	88-93
32357811-4	2020	In the case of MAO-A umbelliferone, curcumin, caffeic acid, quercetin possessed dock score -8.001, -7.941, -7.357, -6.658 respectively.	7-hydroxycoumarin	21-34	monoamine oxidase A	Homo sapiens	15-20
32357811-4	2020	In the case of MAO-A umbelliferone, curcumin, caffeic acid, quercetin possessed dock score -8.001, -7.941, -7.357, -6.658 respectively.	Curcumin	36-44	monoamine oxidase A	Homo sapiens	15-20
32357811-4	2020	In the case of MAO-A umbelliferone, curcumin, caffeic acid, quercetin possessed dock score -8.001, -7.941, -7.357, -6.658 respectively.	caffeic acid	46-58	monoamine oxidase A	Homo sapiens	15-20
32357811-4	2020	In the case of MAO-A umbelliferone, curcumin, caffeic acid, quercetin possessed dock score -8.001, -7.941, -7.357, -6.658 respectively.	Quercetin	60-69	monoamine oxidase A	Homo sapiens	15-20
32357811-6	2020	Compound umbelliferone was observed as the most active hMAO-A inhibitor (IC50= 10.98+-0.006 microM) and selectivity index of 0.607.	7-hydroxycoumarin	9-22	monoamine oxidase A	Homo sapiens	55-61
32223138-4	2020	Here, we designed and synthesized four NIR fluorescence probes containing a dihydroxanthene (DH) skeleton to detect MAO-A in complex biological systems.	dihydroxanthene	76-91	monoamine oxidase A	Homo sapiens	116-121
32223138-5	2020	The specificity of our representative probe DHMP2 displays a 31-fold fluorescence turn-on in vitro, and it can effectively accumulate in the mitochondria and specifically detect the endogenous MAO-A concentrations in PC-3 and SH-SY5Y cell lines.	dhmp2	44-49	monoamine oxidase A	Homo sapiens	193-198
31471933-4	2020	Computational analysis revealed that the malononitrile group can find an advantageous position with the aromatic cleft and FAD of MAO A or MAO B.	dicyanmethane	41-54	monoamine oxidase A	Homo sapiens	130-135
32273550-3	2020	MAOA is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines.	dietary amines	93-107	monoamine oxidase A	Homo sapiens	0-4
32191250-0	2020	Nuclear quantum effects in enzymatic reactions: simulation of the kinetic isotope effect of phenylethylamine oxidation catalyzed by monoamine oxidase A.	Phenethylamines	92-108	monoamine oxidase A	Homo sapiens	132-151
32191250-3	2020	Herein, we present a computational study of monoamine oxidase A (MAO A) enzyme and its substrate phenylethylamine, focusing on the impact of nuclear quantum effects on the reaction free energy barrier.	Phenethylamines	97-113	monoamine oxidase A	Homo sapiens	44-63
32191250-3	2020	Herein, we present a computational study of monoamine oxidase A (MAO A) enzyme and its substrate phenylethylamine, focusing on the impact of nuclear quantum effects on the reaction free energy barrier.	Phenethylamines	97-113	monoamine oxidase A	Homo sapiens	65-70
32065882-3	2020	Among these protoberberine alkaloids, epiberberine potently inhibited LSD1 (IC50 = 0.14 +- 0.01 muM) and was highly selective to LSD1 over MAO-A/B.	epiberberine	38-50	monoamine oxidase A	Homo sapiens	139-146
31471933-8	2020	The most effective was 63, a (phenylhydrazinylidene)propanedinitrile derivative that also inhibited MAO A (1.65 muM), making it a potential lead for Alzheimer"s disease application.	(phenylhydrazinylidene)propanedinitrile	29-68	monoamine oxidase A	Homo sapiens	100-105
31884721-7	2020	The presence of the MAOA L allele predisposed its carriers to higher scores for Negative Emotionality, lower scores for Orienting/Regulatory Capacity, and a lower decrease in cortisol.	Hydrocortisone	175-183	monoamine oxidase A	Homo sapiens	20-24
32241179-0	2020	Genetic interaction between two VNTRs in the MAOA gene is associated with the nicotine dependence.	Nicotine	78-86	monoamine oxidase A	Homo sapiens	45-49
32322429-10	2020	It is also suggested that MAO A and B both are restrained by nicotine.	Nicotine	61-69	monoamine oxidase A	Homo sapiens	26-37
32211356-2	2020	A total of 201 preterm and 111 term children were examined for their development at 6, 12, 18, 24, and 36 months and were genotyped for 15 single-nucleotide polymorphisms (SNPs) in dopamine-related genes (DRD2, DRD3, DAT1, COMT, and MAOA).	Dopamine	181-189	monoamine oxidase A	Homo sapiens	233-237
32211356-6	2020	In the analysis of individual SNPs in each dopamine-related gene, the tag SNP (rs2239448) in MAOA remained significantly associated with the mental scores of preterm children for the interaction with age trend (p < 0.0001; largest effect size of 0.65 at 24 months) after Bonferroni correction for multiple testing.	Dopamine	43-51	monoamine oxidase A	Homo sapiens	93-97
31834986-2	2020	Methylene blue is an inhibitor of MAO-A, while azure B, the major metabolite of methylene blue, as well as various other structural analogues retain the ability to inhibit MAO-A.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	34-39
31834986-2	2020	Methylene blue is an inhibitor of MAO-A, while azure B, the major metabolite of methylene blue, as well as various other structural analogues retain the ability to inhibit MAO-A.	Methylene Blue	80-94	monoamine oxidase A	Homo sapiens	172-177
31834986-3	2020	Based on this, the present study evaluated 22 dyes, many of which are structurally related to methylene blue, as potential inhibitors of human MAO-A and MAO-B.	Methylene Blue	94-108	monoamine oxidase A	Homo sapiens	143-148
31834986-5	2020	Acridine orange was found to be a MAO-A specific inhibitor (IC50 = 0.017 muM), whereas oxazine 170 is a MAO-B specific inhibitor (IC50 = 0.0065 muM).	Acridines	0-8	monoamine oxidase A	Homo sapiens	34-39
32203303-0	2020	MAOA inhibitor phenelzine efficacious in recurrent prostate cancer.	Phenelzine	15-25	monoamine oxidase A	Homo sapiens	0-4
32244397-3	2020	Chemical stressors influence behavioral outcomes by affecting the monoamine oxidase A (MAOA) enzyme, which is involved in serotonin metabolism and the neuroendocrine response to stress.	Serotonin	122-131	monoamine oxidase A	Homo sapiens	66-85
32244397-3	2020	Chemical stressors influence behavioral outcomes by affecting the monoamine oxidase A (MAOA) enzyme, which is involved in serotonin metabolism and the neuroendocrine response to stress.	Serotonin	122-131	monoamine oxidase A	Homo sapiens	87-91
32099971-4	2020	In the current study we have prepared a series of compounds related to piperine and investigated them through monoamine oxidase A and B assay and evaluated the free radical scavenging activity.	piperine	71-79	monoamine oxidase A	Homo sapiens	110-129
32342809-3	2020	MAO-A is a flavoenzyme, which binds to the outer mitochondrial membrane and catalyzes the oxidative transformations of neurotransmitters like serotonin, norepinephrine, and dopamine.	Serotonin	142-151	monoamine oxidase A	Homo sapiens	0-5
32099324-0	2020	Reversible Small Molecule Inhibitors of MAO A and MAO B with Anilide Motifs.	Anilides	61-68	monoamine oxidase A	Homo sapiens	40-45
32099324-2	2020	Based on this general blueprint, we synthesized a series of 66 small aromatic amide derivatives as novel MAO A/B inhibitors.	Amides	78-83	monoamine oxidase A	Homo sapiens	105-112
32099324-7	2020	Results: N-(2,4-Dinitrophenyl)benzo[d][1,3]dioxole-5-carboxamide (55, ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC50 = 56 nM, Ki = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC50 = 126 nM).	n-(2,4-dinitrophenyl)benzo[d][1,3]dioxole-5-carboxamide	9-64	monoamine oxidase A	Homo sapiens	265-270
32099324-7	2020	Results: N-(2,4-Dinitrophenyl)benzo[d][1,3]dioxole-5-carboxamide (55, ST-2043) was found to be a reversible competitive moderately selective MAO B inhibitor (IC50 = 56 nM, Ki = 6.3 nM), while N-(2,4-dinitrophenyl)benzamide (7, ST-2023) showed higher preference for MAO A (IC50 = 126 nM).	st-2043	70-77	monoamine oxidase A	Homo sapiens	265-270
32099324-8	2020	Computational analysis confirmed in vitro binding properties, where the anilides examined possessed high surface complementarity to MAO A/B active sites.	Anilides	72-80	monoamine oxidase A	Homo sapiens	132-139
32099324-9	2020	Conclusion: The small molecule anilides with different substitution patterns were identified as potent MAO A/B inhibitors, which were active in nanomolar concentrations ranges.	Anilides	31-39	monoamine oxidase A	Homo sapiens	103-110
32010186-3	2019	We recently reported that lifetime use of tobacco and cannabis in college students is influenced by the interaction of the X-linked MAOA (monoamine oxidase A) gene and child maltreatment.	Biogenic Monoamines	138-147	monoamine oxidase A	Homo sapiens	132-136
31793911-3	2020	Here, we show that 3,4-dihydroxyphenylglycolaldehyde, which is produced exclusively in noradrenergic neurons by monoamine oxidase A metabolism of norepinephrine, activated asparagine endopeptidase that cleaved Tau at residue N368 into aggregation- and propagation-prone forms, thus leading to LC degeneration and the spread of Tau pathology.	3,4-dihydroxyphenylglycolaldehyde	19-52	monoamine oxidase A	Homo sapiens	112-131
31793911-3	2020	Here, we show that 3,4-dihydroxyphenylglycolaldehyde, which is produced exclusively in noradrenergic neurons by monoamine oxidase A metabolism of norepinephrine, activated asparagine endopeptidase that cleaved Tau at residue N368 into aggregation- and propagation-prone forms, thus leading to LC degeneration and the spread of Tau pathology.	Norepinephrine	146-160	monoamine oxidase A	Homo sapiens	112-131
31793911-3	2020	Here, we show that 3,4-dihydroxyphenylglycolaldehyde, which is produced exclusively in noradrenergic neurons by monoamine oxidase A metabolism of norepinephrine, activated asparagine endopeptidase that cleaved Tau at residue N368 into aggregation- and propagation-prone forms, thus leading to LC degeneration and the spread of Tau pathology.	Asparagine	172-182	monoamine oxidase A	Homo sapiens	112-131
31793911-3	2020	Here, we show that 3,4-dihydroxyphenylglycolaldehyde, which is produced exclusively in noradrenergic neurons by monoamine oxidase A metabolism of norepinephrine, activated asparagine endopeptidase that cleaved Tau at residue N368 into aggregation- and propagation-prone forms, thus leading to LC degeneration and the spread of Tau pathology.	2-amino-5-fluoro-4-picoline	225-229	monoamine oxidase A	Homo sapiens	112-131
33132375-1	2020	A series of 2-(N-cyclicamino)chromone derivatives (1a-4c) and 3-(N-cyclicamino)chromone derivatives (5a-8c) were synthesized, and their monoamine oxidase (MAO) A and B inhibitory activities were studied as part of a structure-activity relationship investigation.	5a-8c	101-106	monoamine oxidase A	Homo sapiens	136-167
32342809-3	2020	MAO-A is a flavoenzyme, which binds to the outer mitochondrial membrane and catalyzes the oxidative transformations of neurotransmitters like serotonin, norepinephrine, and dopamine.	Norepinephrine	153-167	monoamine oxidase A	Homo sapiens	0-5
32342809-3	2020	MAO-A is a flavoenzyme, which binds to the outer mitochondrial membrane and catalyzes the oxidative transformations of neurotransmitters like serotonin, norepinephrine, and dopamine.	Dopamine	173-181	monoamine oxidase A	Homo sapiens	0-5
32493193-2	2020	The two isoforms of the MAO enzymes, MAO-A and MAO-B are responsible of the degradation of monoamine neurotransmitters and due to this, relevant efforts have been devoted to find new compounds with more selectivity and less side effects.	monoamine	91-100	monoamine oxidase A	Homo sapiens	37-42
31706600-4	2020	Monoamine oxidase A (MAOA) aids in serotonin uptake and is often implicated in behavioral and emotional disorders, including ADHD.	Serotonin	35-44	monoamine oxidase A	Homo sapiens	0-19
31714755-6	2019	The PcncAAAD-catalyzed decarboxylation products, kynuramine and 3-hydroxykynuramine, could further be converted to quinoline scaffolds through the addition of H. sapiens monoamine oxidase A (HsMAO-A).	Kynuramine	49-59	monoamine oxidase A	Homo sapiens	170-189
31322459-7	2020	Glucocorticoids and glucocorticoid-metabolizing enzymes interact closely with other biomolecules such as inflammatory cytokines, monoamines, and some monoamine-metabolizing enzymes, namely the monoamine oxidase type A (MAO-A) and B (MAO-B).	monoamines	129-139	monoamine oxidase A	Homo sapiens	193-217
31322459-7	2020	Glucocorticoids and glucocorticoid-metabolizing enzymes interact closely with other biomolecules such as inflammatory cytokines, monoamines, and some monoamine-metabolizing enzymes, namely the monoamine oxidase type A (MAO-A) and B (MAO-B).	monoamines	129-139	monoamine oxidase A	Homo sapiens	219-231
31322459-7	2020	Glucocorticoids and glucocorticoid-metabolizing enzymes interact closely with other biomolecules such as inflammatory cytokines, monoamines, and some monoamine-metabolizing enzymes, namely the monoamine oxidase type A (MAO-A) and B (MAO-B).	monoamine	129-138	monoamine oxidase A	Homo sapiens	193-217
31322459-7	2020	Glucocorticoids and glucocorticoid-metabolizing enzymes interact closely with other biomolecules such as inflammatory cytokines, monoamines, and some monoamine-metabolizing enzymes, namely the monoamine oxidase type A (MAO-A) and B (MAO-B).	monoamine	129-138	monoamine oxidase A	Homo sapiens	219-231
31706600-4	2020	Monoamine oxidase A (MAOA) aids in serotonin uptake and is often implicated in behavioral and emotional disorders, including ADHD.	Serotonin	35-44	monoamine oxidase A	Homo sapiens	21-25
31706600-5	2020	When children are exposed to cigarette smoke, bisphenol A (BPA), or organophosphate pesticides, MAOA activity is inhibited.	bisphenol A	46-57	monoamine oxidase A	Homo sapiens	96-100
31706600-5	2020	When children are exposed to cigarette smoke, bisphenol A (BPA), or organophosphate pesticides, MAOA activity is inhibited.	bisphenol A	59-62	monoamine oxidase A	Homo sapiens	96-100
31706600-5	2020	When children are exposed to cigarette smoke, bisphenol A (BPA), or organophosphate pesticides, MAOA activity is inhibited.	Organophosphates	68-83	monoamine oxidase A	Homo sapiens	96-100
31647557-0	2020	Kinetic and solvent isotope effects in oxidation of halogen derivatives of tyramine catalyzed by monoamine oxidase A.	Halogens	52-59	monoamine oxidase A	Homo sapiens	97-116
31647557-0	2020	Kinetic and solvent isotope effects in oxidation of halogen derivatives of tyramine catalyzed by monoamine oxidase A.	Tyramine	75-83	monoamine oxidase A	Homo sapiens	97-116
31647557-1	2020	The isotope effects approach was used to elucidate the mechanism of oxidative deamination of 3"-halotyramines, catalyzed by monoamine oxidase A (EC 1.4.3.4).	3"-halotyramines	93-109	monoamine oxidase A	Homo sapiens	124-143
31714755-6	2019	The PcncAAAD-catalyzed decarboxylation products, kynuramine and 3-hydroxykynuramine, could further be converted to quinoline scaffolds through the addition of H. sapiens monoamine oxidase A (HsMAO-A).	5-hydroxykynuramine	64-83	monoamine oxidase A	Homo sapiens	170-189
31714755-6	2019	The PcncAAAD-catalyzed decarboxylation products, kynuramine and 3-hydroxykynuramine, could further be converted to quinoline scaffolds through the addition of H. sapiens monoamine oxidase A (HsMAO-A).	Quinolines	115-124	monoamine oxidase A	Homo sapiens	170-189
31557622-0	2019	Umbelliferone derivatives exert neuroprotective effects by inhibiting monoamine oxidase A, self-amyloidbeta aggregation, and lipid peroxidation.	7-hydroxycoumarin	0-13	monoamine oxidase A	Homo sapiens	70-89
31754354-5	2019	To better understand the relationship between serotonin and BTIC we expanded our analysis to include monoamine oxidase-A (MAO-A), an enzyme that metabolizes serotonin.	Serotonin	157-166	monoamine oxidase A	Homo sapiens	101-120
31754354-5	2019	To better understand the relationship between serotonin and BTIC we expanded our analysis to include monoamine oxidase-A (MAO-A), an enzyme that metabolizes serotonin.	Serotonin	157-166	monoamine oxidase A	Homo sapiens	122-127
31754354-12	2019	Conclusions: Our data suggests that MAO-A activity is required for tumorsphere formation and that its expression in breast tumor cells is associated with BTIC-related properties.	btic	154-158	monoamine oxidase A	Homo sapiens	36-41
31754354-14	2019	These data warrant further investigation of the link between MAO-A and BTIC.	btic	71-75	monoamine oxidase A	Homo sapiens	61-66
31471184-5	2019	RESULTS: Fluoxetine-treated monkeys with MAOA low transcription polymorphism had significantly lower [11C]DASB binding potentials than control monkeys.	Fluoxetine	9-19	monoamine oxidase A	Homo sapiens	41-45
31471184-7	2019	The MAOA x fluoxetine interaction was enhanced by binding potentials that were nonsignificantly higher in monkeys with high transcription polymorphism.	Fluoxetine	11-21	monoamine oxidase A	Homo sapiens	4-8
31471184-8	2019	CONCLUSIONS: Juvenile fluoxetine treatment has residual posttreatment effects on brain serotonin transporter that depend on MAOA genotype.	Fluoxetine	22-32	monoamine oxidase A	Homo sapiens	124-128
31471184-9	2019	MAOA genotype may be important to consider when treating children with fluoxetine.	Fluoxetine	71-81	monoamine oxidase A	Homo sapiens	0-4
31725281-6	2019	When implementing the bioassay for the screening of plasma, a pronounced receptor activation was already observed in blank samples, which could be ascribed to endogenous serotonin, as suggested by annihilation of this activity by a 5-HT2AR antagonist or after incubation with MAO-A (monoamine oxidase-A).	Serotonin	170-179	monoamine oxidase A	Homo sapiens	276-281
31725281-6	2019	When implementing the bioassay for the screening of plasma, a pronounced receptor activation was already observed in blank samples, which could be ascribed to endogenous serotonin, as suggested by annihilation of this activity by a 5-HT2AR antagonist or after incubation with MAO-A (monoamine oxidase-A).	Serotonin	170-179	monoamine oxidase A	Homo sapiens	283-302
31725281-7	2019	The presence and degradability by MAO-A of serotonin in plasma extracts were confirmed by LC-HRMS.	Serotonin	43-52	monoamine oxidase A	Homo sapiens	34-39
31291696-1	2019	The two human monoamine oxidase isoforms (namely MAO A and MAO B) are enzymes involved in the catabolism of monoamines, including neurotransmitters, and for this reason are well-known and attractive pharmacological targets in neuropsychiatric and neurodegenerative diseases, for which novel pharmacological approaches are necessary.	monoamines	108-118	monoamine oxidase A	Homo sapiens	49-54
31795294-0	2019	Path Integral Calculation of the Hydrogen/Deuterium Kinetic Isotope Effect in Monoamine Oxidase A-Catalyzed Decomposition of Benzylamine.	Hydrogen	33-41	monoamine oxidase A	Homo sapiens	78-97
31795294-0	2019	Path Integral Calculation of the Hydrogen/Deuterium Kinetic Isotope Effect in Monoamine Oxidase A-Catalyzed Decomposition of Benzylamine.	Benzylamines	125-136	monoamine oxidase A	Homo sapiens	78-97
31795294-3	2019	In this work, we focus on MAO A-catalyzed benzylamine decomposition in order to elucidate nuclear quantum effects through the calculation of the hydrogen/deuterium (H/D) kinetic isotope effect.	Benzylamines	42-53	monoamine oxidase A	Homo sapiens	26-31
31795294-3	2019	In this work, we focus on MAO A-catalyzed benzylamine decomposition in order to elucidate nuclear quantum effects through the calculation of the hydrogen/deuterium (H/D) kinetic isotope effect.	Hydrogen	145-153	monoamine oxidase A	Homo sapiens	26-31
31795294-3	2019	In this work, we focus on MAO A-catalyzed benzylamine decomposition in order to elucidate nuclear quantum effects through the calculation of the hydrogen/deuterium (H/D) kinetic isotope effect.	Deuterium	154-163	monoamine oxidase A	Homo sapiens	26-31
30716416-2	2019	The best-characterized of these interplays occurs between: a) low-activity alleles of the gene encoding monoamine oxidase A (MAOA), the main serotonin-degrading enzyme; and b) child maltreatment.	Serotonin	141-150	monoamine oxidase A	Homo sapiens	104-123
30716416-2	2019	The best-characterized of these interplays occurs between: a) low-activity alleles of the gene encoding monoamine oxidase A (MAOA), the main serotonin-degrading enzyme; and b) child maltreatment.	Serotonin	141-150	monoamine oxidase A	Homo sapiens	125-129
31557622-5	2019	Among the compounds, 2 exhibited the highest hMAO inhibitory activity with an IC50 value of 3.23 microM for hMAO-A and 15.31 microM for hMAO-B.	hmao	45-49	monoamine oxidase A	Homo sapiens	108-114
31557622-9	2019	These represent the first experimental and modelling data for hMAO-A/B inhibition by umbelliferone derivatives.	7-hydroxycoumarin	85-98	monoamine oxidase A	Homo sapiens	62-70
31557622-11	2019	Umbelliferone derivative 2 is a promising therapeutic lead scaffold for developing anti-neuropsychiatric disorder drugs that function via selective hMAO-A inhibition.	7-hydroxycoumarin	0-13	monoamine oxidase A	Homo sapiens	148-154
31561103-1	2019	A series of eighteen 2-styrylchromone derivatives (see Chart 1) were synthesized and evaluated for their monoamine oxidase (MAO) A and B inhibitory activities.	2-styrylchromone	21-37	monoamine oxidase A	Homo sapiens	105-136
31736764-4	2019	Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant.	Tyramine	6-14	monoamine oxidase A	Homo sapiens	44-63
31348537-3	2019	The results show that, with the exception of one compound, all indole-5,6-dicarbonitrile derivatives (10) exhibit submicromolar IC50 values for the inhibition of MAO, with the most potent MAO-A inhibitor exhibiting an IC50 value of 0.006 muM while the most potent MAO-B inhibitor exhibits an IC50 value of 0.058 muM.	1H-indole-5,6-dicarbonitrile	63-88	monoamine oxidase A	Homo sapiens	188-193
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Catecholamines	101-115	monoamine oxidase A	Homo sapiens	16-36
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Catecholamines	101-115	monoamine oxidase A	Homo sapiens	38-43
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Serotonin	124-133	monoamine oxidase A	Homo sapiens	16-36
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Serotonin	124-133	monoamine oxidase A	Homo sapiens	38-43
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Dopamine	135-143	monoamine oxidase A	Homo sapiens	16-36
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Dopamine	135-143	monoamine oxidase A	Homo sapiens	38-43
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Epinephrine	145-156	monoamine oxidase A	Homo sapiens	16-36
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Epinephrine	145-156	monoamine oxidase A	Homo sapiens	38-43
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Epinephrine	165-176	monoamine oxidase A	Homo sapiens	16-36
31556016-1	2019	BACKGROUND: The Mono-amine oxidase-A (MAO-A) enzyme is involved in the degradation and regulation of catecholamines such as serotonin, dopamine, epinephrine and nor-epinephrine.	Epinephrine	165-176	monoamine oxidase A	Homo sapiens	38-43
31736764-4	2019	Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant.	Tyramine	6-14	monoamine oxidase A	Homo sapiens	65-70
31736764-4	2019	Since tyramine is a prototypic substrate of monoamine oxidase A (MAO-A), genetic polymorphisms in MAO-A may also be relevant.	Tyramine	6-14	monoamine oxidase A	Homo sapiens	98-103
31736764-5	2019	The aims of this study were to identify to what extent the interindividual variation in pharmacokinetics and pharmacodynamics of tyramine is determined by genetic polymorphisms in OCT1, CYP2D6, and MAO-A.	Tyramine	129-137	monoamine oxidase A	Homo sapiens	198-203
31736764-6	2019	Beyond that, we wanted to evaluate tyramine as probe drug for the in vivo activity of MAO-A and OCT1.	Tyramine	35-43	monoamine oxidase A	Homo sapiens	86-91
31736764-9	2019	On average, as much as 76.8% of the dose was recovered in urine in form of the MAO-catalysed metabolite 4-hydroxyphenylacetic acid (4-HPAA), confirming that oxidative deamination by MAO-A is the quantitatively most relevant metabolic pathway.	4-hydroxyphenylacetic acid	104-130	monoamine oxidase A	Homo sapiens	182-187
30639342-7	2019	Circulating testosterone levels were higher in carriers of the long compared to the short MAOA allele.	Testosterone	12-24	monoamine oxidase A	Homo sapiens	90-94
31539917-4	2019	(+-)-Kavain is a weaker MAO-A inhibitor with an IC50 of 19.0 microM.	kavain	5-11	monoamine oxidase A	Homo sapiens	24-29
31539917-5	2019	Under the same experimental conditions, the reference MAO inhibitor, curcumin, displays IC50 values of 5.01 microM and 2.55 microM for the inhibition of MAO-A and MAO-B, respectively.	Curcumin	69-77	monoamine oxidase A	Homo sapiens	153-158
31539917-6	2019	It was further established that (+-)-kavain interacts reversibly and competitively with MAO-A and MAO-B with enzyme-inhibitor dissociation constants (Ki) of 7.72 and 5.10 microM, respectively.	kavain	37-43	monoamine oxidase A	Homo sapiens	88-93
31539917-7	2019	Curcumin in turn, displays a Ki value of 3.08 microM for the inhibition of MAO-A.	Curcumin	0-8	monoamine oxidase A	Homo sapiens	75-80
31539917-9	2019	Yangonin proved to be the most potent MAO inhibitor with IC50 values of 1.29 and 0.085 microM for MAO-A and MAO-B, respectively.	yangonin	0-8	monoamine oxidase A	Homo sapiens	98-103
31655995-4	2019	2-Nitroxysuccinate 3-hydroxy-6-methyl-2-ethylpyridine inhibited catalytic activity of monoamine oxidase A more efficiently than its structural analogue Mexidol.	2-nitroxysuccinate 3-hydroxy-6-methyl-2-ethylpyridine	0-53	monoamine oxidase A	Homo sapiens	86-105
31655995-4	2019	2-Nitroxysuccinate 3-hydroxy-6-methyl-2-ethylpyridine inhibited catalytic activity of monoamine oxidase A more efficiently than its structural analogue Mexidol.	emoxypine succinate	152-159	monoamine oxidase A	Homo sapiens	86-105
31271801-5	2019	Compounds 1 and 2,2"-dihydroxy-4",6"-dimethoxychalcone (12) potently inhibited hMAO-A with IC50 values of 0.18 and 0.39 muM, respectively.	2,2"-dihydroxy-4",6"-dimethoxychalcone	16-54	monoamine oxidase A	Homo sapiens	79-85
31271801-8	2019	Docking simulations showed binding affinities of compounds 1 to 5 for hMAO-B were higher than those for hMAO-A or AChE and suggested these five chalcones form hydrogen bonds with MAO-B at Cys172 but that they do not form hydrogen bonds with hMAO-A or AChE.	Hydrogen	159-167	monoamine oxidase A	Homo sapiens	104-110
30639342-8	2019	An interaction of the MAOA polymorphism and testosterone administration was identified in the cuneus, where short allele carriers in the placebo group showed diminished activity in the decision period.	Testosterone	44-56	monoamine oxidase A	Homo sapiens	22-26
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Dopamine	86-94	monoamine oxidase A	Homo sapiens	4-23
31051081-8	2019	Incubation of the adipose tissue samples and vascular rings with the MAO-A inhibitor (clorgyline, 30 min) improved vascular reactivity and decreased ROS generation.	Clorgyline	86-96	monoamine oxidase A	Homo sapiens	69-74
31051081-8	2019	Incubation of the adipose tissue samples and vascular rings with the MAO-A inhibitor (clorgyline, 30 min) improved vascular reactivity and decreased ROS generation.	Reactive Oxygen Species	149-152	monoamine oxidase A	Homo sapiens	69-74
31291555-9	2019	In addition, our results indicated that the expression and catalytic activity of MAO-A were up-regulated by RANKL stimulation and down-regulated by TCP in vitro and in vivo.	Tranylcypromine	148-151	monoamine oxidase A	Homo sapiens	81-86
31291555-10	2019	Furthermore, the effects of MAO-A knockdown on OC differentiation indicated that MAO-A played an important role in osteoclastogenesis in vitro and might contribute to the inhibitory effects of TCP.	Tranylcypromine	193-196	monoamine oxidase A	Homo sapiens	28-33
31291555-10	2019	Furthermore, the effects of MAO-A knockdown on OC differentiation indicated that MAO-A played an important role in osteoclastogenesis in vitro and might contribute to the inhibitory effects of TCP.	Tranylcypromine	193-196	monoamine oxidase A	Homo sapiens	81-86
31154274-10	2019	The results of the cocktail experiment using the human liver enzyme indicated that the IC50 value of HAL on MAO-A was 0.10 +- 0.08 microm and that of HAR was 0.38 +- 0.21 microm.	Harmaline	101-104	monoamine oxidase A	Homo sapiens	108-113
31339297-5	2019	We confirm that [18F]AV-1451 is a weak inhibitor of MAO-A and -B and that MAO inhibitors can alter binding of [18F]AV-1451 in autoradiography and in vivo PET imaging.	7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	21-28	monoamine oxidase A	Homo sapiens	52-64
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	monoamine	4-13	monoamine oxidase A	Homo sapiens	25-29
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Dopamine	86-94	monoamine oxidase A	Homo sapiens	25-29
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Serotonin	96-105	monoamine oxidase A	Homo sapiens	4-23
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Serotonin	96-105	monoamine oxidase A	Homo sapiens	25-29
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Norepinephrine	110-124	monoamine oxidase A	Homo sapiens	4-23
30456877-1	2019	The monoamine oxidase A (MAOA) enzyme metabolizes monoamine neurotransmitters such as dopamine, serotonin and norepinephrine, and its genetic polymorphism (rs1137070) influences its activity level and is associated with smoking behaviors.	Norepinephrine	110-124	monoamine oxidase A	Homo sapiens	25-29
30456877-8	2019	These findings suggest that MAOA rs1137070 contributes to the susceptibility to nicotine dependence through its influence on brain circuits involved in reward and attention, and interacts with smoking in the progression.	Nicotine	80-88	monoamine oxidase A	Homo sapiens	28-32
31460269-3	2019	The patterns of protein tyrosine phosphatase 1B (PTP1B) and human monoamine oxidase A (hMAO-A) inhibition by rubrofusarin 6-O-beta-d-glucopyranoside (1), rubrofusarin 6-O-beta-d-gentiobioside (2), rubrofusarin triglucoside (3), and cassiaside B2 (4) were compared with the aglycone, rubrofusarin, isolated from Cassia obtusifolia seeds.	rubrofusarin	109-121	monoamine oxidase A	Homo sapiens	66-85
31177620-1	2019	A set of piperonylic acid derived hydrazones with variable isatin moieties was synthesized and evaluated for their inhibitory activity against the enzymes acetylcholinesterase (AChE), butyrylcholinesterase (BChE), and monoamine oxidases A and B (MAO-A/B).	piperonylic acid derived hydrazones	9-44	monoamine oxidase A	Homo sapiens	218-244
31243972-8	2019	Highlights are given on how new specific recognition moieties of tyrosinase and MAO-A were designed to eliminate the interference by reactive oxygen species (ROS) and MAO-B, respectively.	Reactive Oxygen Species	133-156	monoamine oxidase A	Homo sapiens	80-85
31243972-8	2019	Highlights are given on how new specific recognition moieties of tyrosinase and MAO-A were designed to eliminate the interference by reactive oxygen species (ROS) and MAO-B, respectively.	Reactive Oxygen Species	158-161	monoamine oxidase A	Homo sapiens	80-85
31460269-3	2019	The patterns of protein tyrosine phosphatase 1B (PTP1B) and human monoamine oxidase A (hMAO-A) inhibition by rubrofusarin 6-O-beta-d-glucopyranoside (1), rubrofusarin 6-O-beta-d-gentiobioside (2), rubrofusarin triglucoside (3), and cassiaside B2 (4) were compared with the aglycone, rubrofusarin, isolated from Cassia obtusifolia seeds.	rubrofusarin	109-121	monoamine oxidase A	Homo sapiens	87-93
31460269-5	2019	Similarly, in hMAO-A inhibition, rubrofusarin displayed the most potent activity with an IC50 value of 5.90 +- 0.99 muM, which was twice better than the reference drug, deprenyl HCl (IC50; 10.23 +- 0.82 muM).	rubrofusarin	33-45	monoamine oxidase A	Homo sapiens	14-20
31680079-1	2019	Monoamine oxidase A (MAO-A), an enzyme found on outer mitochondrial membrane, catalyzes the oxidative deamination of biogenic amines.	Amines	126-132	monoamine oxidase A	Homo sapiens	0-19
29667298-1	2019	Monoamine oxidase-A (MAOA) metabolises monoamines and is implicated in the pathophysiology of psychiatric disorders.	monoamines	39-49	monoamine oxidase A	Homo sapiens	0-19
29667298-1	2019	Monoamine oxidase-A (MAOA) metabolises monoamines and is implicated in the pathophysiology of psychiatric disorders.	monoamines	39-49	monoamine oxidase A	Homo sapiens	21-25
31680079-1	2019	Monoamine oxidase A (MAO-A), an enzyme found on outer mitochondrial membrane, catalyzes the oxidative deamination of biogenic amines.	Amines	126-132	monoamine oxidase A	Homo sapiens	21-26
31680079-2	2019	Recently, it has been studied that MAO-A have a role in the cancer progression by elevating the generation of Reactive oxygen species (ROS) and by promoting epithelial to mesenchymal transition (EMT) through activation of Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1.	Reactive Oxygen Species	110-133	monoamine oxidase A	Homo sapiens	35-40
31680079-2	2019	Recently, it has been studied that MAO-A have a role in the cancer progression by elevating the generation of Reactive oxygen species (ROS) and by promoting epithelial to mesenchymal transition (EMT) through activation of Vascular endothelial growth factor (VEGF) and its co-receptor neuropilin-1.	Reactive Oxygen Species	135-138	monoamine oxidase A	Homo sapiens	35-40
30569287-5	2019	Hence, in this study, we have examined the effect of hinokitol to act as a neuroprotective agent against 6-OHDA-induced toxicity in SH-SY5Y neuroblastoma cells through downregulation of the mRNA expression of PD pathological proteins like alpha-synuclein, MAO A and B, LRRK2, PTEN, PINK1, and PARK7 (deglycase 1 (DJ-1)).	beta-thujaplicin	53-62	monoamine oxidase A	Homo sapiens	256-267
31238535-4	2019	Here, we evaluate the multi-target effects of phloroglucinol, phlorofucofuroeckol-A (PFF-A), and dieckol by screening their modulatory activity against hMAO-A and -B and various neuronal GPCRs.	Phloroglucinol	46-60	monoamine oxidase A	Homo sapiens	152-165
31238535-4	2019	Here, we evaluate the multi-target effects of phloroglucinol, phlorofucofuroeckol-A (PFF-A), and dieckol by screening their modulatory activity against hMAO-A and -B and various neuronal GPCRs.	phlorofucofuroeckol A	62-83	monoamine oxidase A	Homo sapiens	152-165
30933784-4	2019	Comparison of the inhibitory activities of 1a vs. 9a vs. 13a and 1b vs. 7b vs. 11b suggested that methoxy substitution at R1 on the A-rings of flavonoids increases MAO-A inhibition whereas methoxy substitution at R2 increased MAO-B inhibition.	Flavonoids	143-153	monoamine oxidase A	Homo sapiens	164-169
30794821-1	2019	Monoamine oxidase A (MAOA) plays important roles in the metabolism of catecholamines and modulates adrenergic, noradrenergic, and dopaminergic signaling.	Catecholamines	70-84	monoamine oxidase A	Homo sapiens	0-19
30794821-1	2019	Monoamine oxidase A (MAOA) plays important roles in the metabolism of catecholamines and modulates adrenergic, noradrenergic, and dopaminergic signaling.	Catecholamines	70-84	monoamine oxidase A	Homo sapiens	21-25
30794821-5	2019	In total, 87 males and 35 females were evaluated and investigated for the possible effect of MAOA-uVNTR polymorphisms on cerebrospinal fluid (CSF) catecholamine concentrations.	Catecholamines	147-160	monoamine oxidase A	Homo sapiens	93-97
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	tetrahydrocolumbamine	17-38	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	protopine	40-49	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	jatrorrhizine	51-64	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	glaucine	66-74	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	tetrahydropalmatine	76-95	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	palmatine	86-95	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	dehydrocorydalin	108-125	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	ethyl acetate	188-201	monoamine oxidase A	Homo sapiens	157-162
30712820-6	2019	Seven compounds (tetrahydrocolumbamine, protopine, jatrorrhizine, glaucine, tetrahydropalmatine, palmatine, dehydrocorydaline) with high binding affinity to MAO-A were fished out from the ethyl acetate fraction extract of Corydalis Rhizome.	corydalis rhizome	222-239	monoamine oxidase A	Homo sapiens	157-162
31239451-0	2019	Publisher Correction: MAOA variants differ in oscillatory EEG &amp; ECG activities in response to aggression-inducing stimuli.	Adenosine Monophosphate	63-66	monoamine oxidase A	Homo sapiens	22-26
31238535-4	2019	Here, we evaluate the multi-target effects of phloroglucinol, phlorofucofuroeckol-A (PFF-A), and dieckol by screening their modulatory activity against hMAO-A and -B and various neuronal GPCRs.	dieckol	97-104	monoamine oxidase A	Homo sapiens	152-165
30849741-10	2019	Moreover, it is possible for BDT to improve PSHS through the functional targets including GLO1, MAOA and MAOB, which are closely related to monoamine neurotransmitters.	bdt	29-32	monoamine oxidase A	Homo sapiens	96-100
30849741-10	2019	Moreover, it is possible for BDT to improve PSHS through the functional targets including GLO1, MAOA and MAOB, which are closely related to monoamine neurotransmitters.	monoamine	140-149	monoamine oxidase A	Homo sapiens	96-100
30794821-9	2019	Thus, the results of the present study indicated that MAOA-uVNTR polymorphism influences CSF Adr and DA levels in females.	Dopamine	101-103	monoamine oxidase A	Homo sapiens	54-58
30868562-0	2019	Behavioral effects of postnatal ketamine exposure in rhesus macaque infants are dependent on MAOA-LPR genotype.	Ketamine	32-40	monoamine oxidase A	Homo sapiens	93-97
30693539-8	2019	RESULTS: We observed that MAOAIs, particularly clorgyline and phenelzine, were effective at decreasing MAOA activity in human prostate cancer cells.	Clorgyline	47-57	monoamine oxidase A	Homo sapiens	26-30
30693539-8	2019	RESULTS: We observed that MAOAIs, particularly clorgyline and phenelzine, were effective at decreasing MAOA activity in human prostate cancer cells.	Phenelzine	62-72	monoamine oxidase A	Homo sapiens	26-30
31178977-1	2019	Monoamine oxidases (MAO) with 2 isoforms, A and B, located at the outer mitochondrial membrane are flavoenzyme membranes with a major role in the metabolism of monoaminergic neurotransmitters and biogenic amines in the central nervous system and peripheral tissues, respectively.	Amines	205-211	monoamine oxidase A	Homo sapiens	0-49
30974737-0	2019	Design, Synthesis, and Evaluation of Monoamine Oxidase A Inhibitors-Indocyanine Dyes Conjugates as Targeted Antitumor Agents.	indocyanine	68-79	monoamine oxidase A	Homo sapiens	37-56
30974737-1	2019	Monoamine oxidase A (MAOA) is an important mitochondria-bound enzyme that catalyzes the oxidative deamination of monoamine neurotransmitters.	monoamine	113-122	monoamine oxidase A	Homo sapiens	0-19
30974737-1	2019	Monoamine oxidase A (MAOA) is an important mitochondria-bound enzyme that catalyzes the oxidative deamination of monoamine neurotransmitters.	monoamine	113-122	monoamine oxidase A	Homo sapiens	21-25
30974737-3	2019	Herein, a series of novel conjugates combining the MAOA inhibitor isoniazid (INH) and tumor-targeting near-infrared (NIR) heptamethine cyanine dyes were designed and synthesized.	Isoniazid	66-75	monoamine oxidase A	Homo sapiens	51-55
31140884-1	2019	Aim: Due to the pivotal role in the oxidative deamination of monoamine neurotransmitters, two distinct monoamine oxidase (MAO) subtypes, MAO-A and MAO-B, present a significant pharmacological interest.	monoamine	61-70	monoamine oxidase A	Homo sapiens	137-142
30967134-6	2019	METHODS: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs.	Dopamine	86-94	monoamine oxidase A	Homo sapiens	148-152
30735822-6	2019	The in vitro results suggested that compound 6d and 7q are the selective inhibitors of monoamine oxidase A, however, the selective and potent inhibitors of monoamine oxidase B included compounds 6h and 7r.	7q	52-54	monoamine oxidase A	Homo sapiens	87-106
30967134-6	2019	METHODS: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs.	Dopamine	39-47	monoamine oxidase A	Homo sapiens	148-152
30967134-6	2019	METHODS: A set of 41 SNPs of genes for dopamine receptors DRD1, DRD2, DRD3, DRD4, the dopamine transporter SLC6A3 and dopamine catabolizing enzymes MAOA and MAOB was investigated in a population of 446 Caucasians (221 males/225 females) with a clinical diagnosis of schizophrenia (according to ICD-10: F20) with and without HPRL who were treated with classical and/or atypical antipsychotic drugs.	Dopamine	86-94	monoamine oxidase A	Homo sapiens	148-152
30337205-9	2019	Treatment with biogenic amine precursors was ineffective, while the inhibitor of MAO-A selegiline resulted in persistent clinical improvement.	Selegiline	87-97	monoamine oxidase A	Homo sapiens	81-86
30167938-0	2019	Vitamin D improves vascular function and decreases monoamine oxidase A expression in experimental diabetes.	Vitamin D	0-9	monoamine oxidase A	Homo sapiens	51-70
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Serotonin	90-94	monoamine oxidase A	Homo sapiens	24-43
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Serotonin	90-94	monoamine oxidase A	Homo sapiens	45-50
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Norepinephrine	96-110	monoamine oxidase A	Homo sapiens	24-43
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Norepinephrine	96-110	monoamine oxidase A	Homo sapiens	45-50
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Dopamine	116-124	monoamine oxidase A	Homo sapiens	24-43
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Dopamine	116-124	monoamine oxidase A	Homo sapiens	45-50
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Dopamine	126-128	monoamine oxidase A	Homo sapiens	24-43
30852703-4	2019	Finally, the density of monoamine oxidase-A (MAO-A), a mitochondrial enzyme that degrades 5-HT, norepinephrine, and dopamine (DA), was reported as lower in the OFC and ventral striatum of ASPD.	Dopamine	126-128	monoamine oxidase A	Homo sapiens	45-50
30852703-6	2019	Furthermore, evidence suggests that individuals with high-activity MAO-A genetic variants compared with low-activity MAO-A allelic variants release more DA in the ventral caudate and putamen when exposed to violent imagery.	Dopamine	153-155	monoamine oxidase A	Homo sapiens	67-72
30852703-6	2019	Furthermore, evidence suggests that individuals with high-activity MAO-A genetic variants compared with low-activity MAO-A allelic variants release more DA in the ventral caudate and putamen when exposed to violent imagery.	Dopamine	153-155	monoamine oxidase A	Homo sapiens	117-122
30396116-4	2019	Among the compounds isolated, rhamnocitrin (5) was found to potently and selectively inhibit human MAO-A (hMAO-A, IC50 = 0.051 microM) and effectively inhibit hMAO-B (IC50 = 2.97 microM).	kaempferol-7-methyl ether	30-42	monoamine oxidase A	Homo sapiens	99-104
30396116-4	2019	Among the compounds isolated, rhamnocitrin (5) was found to potently and selectively inhibit human MAO-A (hMAO-A, IC50 = 0.051 microM) and effectively inhibit hMAO-B (IC50 = 2.97 microM).	kaempferol-7-methyl ether	30-42	monoamine oxidase A	Homo sapiens	106-112
30396116-5	2019	The IC50 value of 5 for hMAO-A was the lowest amongst all natural flavonoids reported to date, and the potency was 20.2 times higher than that of toloxatone (1.03 microM), a marketed drug.	Flavonoids	66-76	monoamine oxidase A	Homo sapiens	24-30
30396116-5	2019	The IC50 value of 5 for hMAO-A was the lowest amongst all natural flavonoids reported to date, and the potency was 20.2 times higher than that of toloxatone (1.03 microM), a marketed drug.	toloxatone	146-156	monoamine oxidase A	Homo sapiens	24-30
30396116-7	2019	Genkwanin (4) was also observed to strongly inhibit hMAO-A and hMAO-B (IC50 = 0.14 and 0.35 microM, respectively), and competitively inhibit hMAO-A and hMAO-B (Ki = 0.097 and 0.12 microM, respectively).	genkwanin	0-9	monoamine oxidase A	Homo sapiens	52-58
30396116-7	2019	Genkwanin (4) was also observed to strongly inhibit hMAO-A and hMAO-B (IC50 = 0.14 and 0.35 microM, respectively), and competitively inhibit hMAO-A and hMAO-B (Ki = 0.097 and 0.12 microM, respectively).	genkwanin	0-9	monoamine oxidase A	Homo sapiens	141-147
30686752-0	2019	Osthenol, a prenylated coumarin, as a monoamine oxidase A inhibitor with high selectivity.	osthenol	0-8	monoamine oxidase A	Homo sapiens	38-57
30686752-3	2019	Isopsoralen (3) and bakuchicin (1), furanocoumarin derivatives isolated from Psoralea corylifolia L., showed slightly higher IC50 values (0.88 and 1.78 microM, respectively) for hMAO-A than 6, but had low SI values (3.1 for both).	angelicin	0-11	monoamine oxidase A	Homo sapiens	178-184
30686752-3	2019	Isopsoralen (3) and bakuchicin (1), furanocoumarin derivatives isolated from Psoralea corylifolia L., showed slightly higher IC50 values (0.88 and 1.78 microM, respectively) for hMAO-A than 6, but had low SI values (3.1 for both).	bakuchicin	20-30	monoamine oxidase A	Homo sapiens	178-184
30686752-3	2019	Isopsoralen (3) and bakuchicin (1), furanocoumarin derivatives isolated from Psoralea corylifolia L., showed slightly higher IC50 values (0.88 and 1.78 microM, respectively) for hMAO-A than 6, but had low SI values (3.1 for both).	Furocoumarins	36-50	monoamine oxidase A	Homo sapiens	178-184
30686752-5	2019	A structural comparison suggested that the 8-(3,3-dimethylallyl) group of 6 increased its inhibitory activity against hMAO-A compared with the 6-methoxy group of scopoletin (4).	dimethylallyl	50-63	monoamine oxidase A	Homo sapiens	118-124
30686752-7	2019	Docking simulations also implied that 6 interacted with hMAO-A at Phe208 and with hMAO-B at Ile199 by carbon hydrogen bondings.	Carbon	102-108	monoamine oxidase A	Homo sapiens	56-62
30686752-7	2019	Docking simulations also implied that 6 interacted with hMAO-A at Phe208 and with hMAO-B at Ile199 by carbon hydrogen bondings.	Hydrogen	109-117	monoamine oxidase A	Homo sapiens	56-62
30686752-8	2019	Our findings suggest that osthenol, derived from natural products, is a selective and potent reversible inhibitor of MAO-A, and can be regarded a potential lead compound for the design of novel reversible MAO-A inhibitors.	osthenol	26-34	monoamine oxidase A	Homo sapiens	117-122
30686752-8	2019	Our findings suggest that osthenol, derived from natural products, is a selective and potent reversible inhibitor of MAO-A, and can be regarded a potential lead compound for the design of novel reversible MAO-A inhibitors.	osthenol	26-34	monoamine oxidase A	Homo sapiens	205-210
30167938-8	2019	Vitamin D significantly improved vascular function, mitigated oxidative stress and decreased MAO-A expression in diabetic vascular preparations.	Vitamin D	0-9	monoamine oxidase A	Homo sapiens	93-98
30167938-9	2019	In conclusion, MAO-A is induced in diabetic aortas and vitamin D can improve diabetes-induced endothelial dysfunction by modulating the MAO-A expression.	Vitamin D	55-64	monoamine oxidase A	Homo sapiens	136-141
30813423-1	2019	The investigation of the constituents that were isolated from Turnera diffusa (damiana) for their inhibitory activities against recombinant human monoamine oxidases (MAO-A and MAO-B) in vitro identified acacetin 7-methyl ether as a potent selective inhibitor of MAO-B (IC50 = 198 nM).	acacetin 7-methyl ether	203-226	monoamine oxidase A	Homo sapiens	166-171
30804379-0	2019	MAOA variants differ in oscillatory EEG &amp; ECG activities in response to aggression-inducing stimuli.	Adenosine Monophosphate	41-44	monoamine oxidase A	Homo sapiens	0-4
30813423-4	2019	However, acacetin 7-methyl ether was >500-fold selective against MAO-B over MAO-A as compared to only two-fold selectivity shown by acacetin.	acacetin 7-methyl ether	9-32	monoamine oxidase A	Homo sapiens	76-81
30813423-4	2019	However, acacetin 7-methyl ether was >500-fold selective against MAO-B over MAO-A as compared to only two-fold selectivity shown by acacetin.	acacetin	9-17	monoamine oxidase A	Homo sapiens	76-81
30813423-5	2019	Even though the IC50 for inhibition of MAO-B by acacetin 7-methyl ether was ~four-fold higher than that of the standard drug deprenyl (i.e., SelegilineTM or ZelaparTM, a selective MAO-B inhibitor), acacetin 7-methyl ether"s selectivity for MAO-B over MAO-A inhibition was greater than that of deprenyl (>500- vs. 450-fold).	acacetin 7-methyl ether	48-71	monoamine oxidase A	Homo sapiens	251-256
30678358-4	2019	Differently substituted flavonoids have been prepared and investigated as MAO-A and MAO-B inhibitors.	Flavonoids	24-34	monoamine oxidase A	Homo sapiens	74-79
29382249-2	2019	The reversible inhibition of methoxsalen and ABT against the P450, FMO, AO, MAO-A and -B, enzymes were evaluated using standard marker probe reactions.	Methoxsalen	29-40	monoamine oxidase A	Homo sapiens	76-88
29382249-2	2019	The reversible inhibition of methoxsalen and ABT against the P450, FMO, AO, MAO-A and -B, enzymes were evaluated using standard marker probe reactions.	2,2'-azino-di-(3-ethylbenzothiazoline)-6-sulfonic acid	45-48	monoamine oxidase A	Homo sapiens	76-88
30700029-1	2019	New N-acetyl/N-thiocarbamoylpyrazoline derivatives were designed and synthesized in high yields to assess their inhibitory activity and selectivity against human monoamine oxidase A and B.	n-acetyl/n-thiocarbamoylpyrazoline	4-38	monoamine oxidase A	Homo sapiens	162-187
30809547-5	2019	Kynuramine metabolism by human recombinant MAO-A and MAO-B leads to formation of 4-hydroxyquinoline, with Vmax values of 10.2+-0.2 and 7.35+-0.69 nmol/mg/min, respectively, and Km values of 23.1+-0.8 muM and 18.0+-2.3 muM, respectively.	Kynuramine	0-10	monoamine oxidase A	Homo sapiens	43-48
30809547-5	2019	Kynuramine metabolism by human recombinant MAO-A and MAO-B leads to formation of 4-hydroxyquinoline, with Vmax values of 10.2+-0.2 and 7.35+-0.69 nmol/mg/min, respectively, and Km values of 23.1+-0.8 muM and 18.0+-2.3 muM, respectively.	4-hydroxyquinoline	81-99	monoamine oxidase A	Homo sapiens	43-48
30774343-3	2019	During early cigarette withdrawal there is an elevation in the levels of monoamine oxidase-A (MAO-A), which removes monoamines excessively and induces oxidative stress and is implicated in creating sad mood.	monoamines	116-126	monoamine oxidase A	Homo sapiens	73-92
30809547-7	2019	Each of these significantly inhibited both enzymes except for zingerone, which only inhibited MAO-A.	zingerone	62-71	monoamine oxidase A	Homo sapiens	94-99
30809547-9	2019	Resveratrol and isoeugenol were selective for MAO-A, with IC50 values of 0.313+-0.008 and 3.72+-0.20 muM and selectivity indices of 50.5 and 27.4, respectively.	Resveratrol	0-11	monoamine oxidase A	Homo sapiens	46-51
30809547-9	2019	Resveratrol and isoeugenol were selective for MAO-A, with IC50 values of 0.313+-0.008 and 3.72+-0.20 muM and selectivity indices of 50.5 and 27.4, respectively.	isoeugenol	16-26	monoamine oxidase A	Homo sapiens	46-51
30774343-3	2019	During early cigarette withdrawal there is an elevation in the levels of monoamine oxidase-A (MAO-A), which removes monoamines excessively and induces oxidative stress and is implicated in creating sad mood.	monoamines	116-126	monoamine oxidase A	Homo sapiens	94-99
30809547-11	2019	The inhibition of resveratrol (MAO-A) and pterostilbene (MAO-B) was consistent with competitive time-independent mechanisms.	Resveratrol	18-29	monoamine oxidase A	Homo sapiens	31-36
31550216-2	2019	OBJECTIVES: A previously synthesized ethyl acetohydroxamate-chalcones (L1-L22) were studied for their inhibitory activities against human recombinant monoamine oxidase A and B (hMAO-A and hMAO-B, respectively) and acetylcholinesterase (AChE) as multi-target directed ligands for the treatment of Alzheimer"s disease (AD).	Chalcones	37-69	monoamine oxidase A	Homo sapiens	150-175
30809547-12	2019	Resveratrol 4"-glucoside was the only compound which inhibited MAO-A, but itself, resveratrol 3-glucoside, and pterostilbene 4"-glucoside failed to inhibit MAO-B.	resveratrol 4"-glucoside	0-24	monoamine oxidase A	Homo sapiens	63-68
30455149-2	2019	The 2-imidazoline derivatives were evaluated as potential inhibitors of human monoamine oxidase (MAO) A and B.	2-imidazoline	4-17	monoamine oxidase A	Homo sapiens	78-109
30455149-3	2019	Among the 2-imidazolines, good potency inhibitors were discovered with compound 9p (IC50 = 0.012 microM) being the most potent MAO-B inhibitor, while compound 9d (IC50 = 0.751 microM) was the most potent MAO-A inhibitor of the series.	Imidazolines	11-24	monoamine oxidase A	Homo sapiens	204-209
30296051-13	2019	Thus, 4,6-diphenylpyrimidine derivatives can act as promising leads in the development of dual-acting inhibitors targeting MAO-A and AChE enzymes for the treatment of Alzheimer"s disease.	4,6-diphenylpyrimidine	6-28	monoamine oxidase A	Homo sapiens	123-128
31258092-8	2019	Among these active COMT inhibitors only morin (IC50 = 16.2 microM), alizarin (IC50 = 8.16 microM) and fisetin (IC50 = 7.33 microM) were noteworthy MAO inhibitors, with specificity for MAO-A.	fisetin	102-109	monoamine oxidase A	Homo sapiens	184-189
31550216-2	2019	OBJECTIVES: A previously synthesized ethyl acetohydroxamate-chalcones (L1-L22) were studied for their inhibitory activities against human recombinant monoamine oxidase A and B (hMAO-A and hMAO-B, respectively) and acetylcholinesterase (AChE) as multi-target directed ligands for the treatment of Alzheimer"s disease (AD).	Chalcones	37-69	monoamine oxidase A	Homo sapiens	177-183
29956632-8	2019	CONCLUSION: Estradiol increases tryptophan hydroxylase-2 and serotonin transporter expression and decreases the expression of serotonin 1A receptor and monoamine oxidase A and B through the interaction with its intracellular receptors.	Estradiol	12-21	monoamine oxidase A	Homo sapiens	152-171
30515636-0	2018	Molecular docking studies of coumarin hybrids as potential acetylcholinesterase, butyrylcholinesterase, monoamine oxidase A/B and beta-amyloid inhibitors for Alzheimer"s disease.	coumarin	29-37	monoamine oxidase A	Homo sapiens	104-125
30747068-2	2019	OBJECTIVE: A series of quercetin based derivatives was designed, synthesized, and evaluated as novel multifunctional agents against monoamine oxidase A and B with antioxidant potential.	Quercetin	23-32	monoamine oxidase A	Homo sapiens	132-151
30747068-9	2019	Moreover, the mechanistic insight into the docking poses was also explored by binding interactions of quercetin based derivatives inside the dynamic site of hMAO-A and hMAO-B.	Quercetin	102-111	monoamine oxidase A	Homo sapiens	157-174
30336354-4	2019	However, the downstream effects of MAO-A mediated ROS production in a neuronal model has not been previously investigated.	Reactive Oxygen Species	50-53	monoamine oxidase A	Homo sapiens	35-40
30336354-5	2019	In this study, using MAO-A overexpressing neuroblastoma cells, we demonstrate that higher levels of MAO-A protein/activity results in increased basal ROS levels with associated increase in protein oxidation.	Reactive Oxygen Species	150-153	monoamine oxidase A	Homo sapiens	21-26
30336354-5	2019	In this study, using MAO-A overexpressing neuroblastoma cells, we demonstrate that higher levels of MAO-A protein/activity results in increased basal ROS levels with associated increase in protein oxidation.	Reactive Oxygen Species	150-153	monoamine oxidase A	Homo sapiens	100-105
30336354-6	2019	Increased MAO-A levels result in increased Lysine-63 linked ubiquitination of mitochondrial proteins and promotes autophagy through Bcl-2 phosphorylation.	Lysine	43-49	monoamine oxidase A	Homo sapiens	10-15
30336354-7	2019	Furthermore, ROS generated locally on the mitochondrial outer membrane by MAO-A promotes phosphorylation of dynamin-1-like protein, leading to mitochondrial fragmentation and clearance without complete loss of mitochondrial membrane potential.	Reactive Oxygen Species	13-16	monoamine oxidase A	Homo sapiens	74-79
30336354-8	2019	Cellular ATP levels are maintained following MAO-A overexpression and complex IV activity/protein levels increased, revealing a close relationship between MAO-A levels and mitochondrial function.	Adenosine Triphosphate	9-12	monoamine oxidase A	Homo sapiens	45-50
30336354-8	2019	Cellular ATP levels are maintained following MAO-A overexpression and complex IV activity/protein levels increased, revealing a close relationship between MAO-A levels and mitochondrial function.	Adenosine Triphosphate	9-12	monoamine oxidase A	Homo sapiens	155-160
30336354-9	2019	Finally, the downstream effects of increased MAO-A levels are dependent on the availability of amine substrates and in the presence of exogenous substrate, cell viability is dramatically reduced.	Amines	95-100	monoamine oxidase A	Homo sapiens	45-50
30336354-10	2019	This study shows for the first time that MAO-A generated ROS is involved in quality control signalling, and increase in MAO-A protein levels leads to a protective cellular response in order to mediate removal of damaged macromolecules/organelles, but substrate availability may ultimately determine cell fate.	Reactive Oxygen Species	57-60	monoamine oxidase A	Homo sapiens	41-46
30336354-11	2019	The latter is particularly important in conditions such as Parkinson"s disease, where a dopamine precursor is used to treat disease symptoms and highlights that the fate of MAO-A containing dopaminergic neurons may depend on both MAO-A levels and catecholamine substrate availability.	Dopamine	88-96	monoamine oxidase A	Homo sapiens	173-178
30336354-11	2019	The latter is particularly important in conditions such as Parkinson"s disease, where a dopamine precursor is used to treat disease symptoms and highlights that the fate of MAO-A containing dopaminergic neurons may depend on both MAO-A levels and catecholamine substrate availability.	Catecholamines	247-260	monoamine oxidase A	Homo sapiens	173-178
30468220-7	2018	Herein, three isoniazid (INH)-dye conjugates were synthesized by conjugating MAOA inhibitor INH with mitochondria-targeting NIRF heptamethine dyes to improve the therapeutic efficacy of prostate cancer.	Isoniazid	14-23	monoamine oxidase A	Homo sapiens	77-81
31502081-4	2019	This chapter aims to evaluate the impact of key DAergic gene variants suggested to impact on both synaptic DA levels (COMT, DAT1, DBH, MAOA) and DA receptor function (ANKK1, DRD2, DRD4) in terms of their influence on visuospatial WM.	Dopamine	48-50	monoamine oxidase A	Homo sapiens	135-139
30558545-3	2018	A prenatal transient excess of "monoamine oxidase A" enzyme is assumed here to trigger persistent epigenetic regulations that would induce imbalanced metabolisms of synaptic monoamines.	monoamines	174-184	monoamine oxidase A	Homo sapiens	32-51
30272370-6	2018	L-deprenyl is known to target monoamine oxidase-B (MAO-B) on the outer membrane of mitochondria, therefore, the activity of MAO-A and -B was measured based on the fluorometric detection of H2O2 produced by the enzyme reaction.	Selegiline	0-10	monoamine oxidase A	Homo sapiens	124-136
30272370-6	2018	L-deprenyl is known to target monoamine oxidase-B (MAO-B) on the outer membrane of mitochondria, therefore, the activity of MAO-A and -B was measured based on the fluorometric detection of H2O2 produced by the enzyme reaction.	Hydrogen Peroxide	189-193	monoamine oxidase A	Homo sapiens	124-136
30272370-7	2018	Notably, MAO-A and -B activity was low in AML cells and the present findings suggested that the anticancer effect of L-deprenyl was independent of MAO-B.	Selegiline	117-127	monoamine oxidase A	Homo sapiens	9-21
29730831-4	2018	One genetic polymorphism that has been associated with ASB is MAOA-uVNTR.	asb	55-58	monoamine oxidase A	Homo sapiens	62-66
29730831-5	2018	Meta-analytic studies have found the low-activity MAOA-uVNTR polymorphism to be associated with ASB from early childhood through adulthood.	asb	96-99	monoamine oxidase A	Homo sapiens	50-54
29730831-9	2018	Findings indicate an interaction between the low-activity allele of the MAOA-uVNTR and peer delinquency in predicting ASB.	asb	118-121	monoamine oxidase A	Homo sapiens	72-76
30167931-2	2018	Both MAO A and MAO B feature a two-domain topology characterized by the Rossmann fold, interacting with dinucleotide cofactors, which is intimately associated to a substrate-binding domain.	Dinucleoside Phosphates	104-116	monoamine oxidase A	Homo sapiens	5-10
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	Eugenol	29-36	monoamine oxidase A	Homo sapiens	86-91
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	Eugenol	29-36	monoamine oxidase A	Homo sapiens	188-193
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	Esters	43-48	monoamine oxidase A	Homo sapiens	86-91
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	Esters	43-48	monoamine oxidase A	Homo sapiens	188-193
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	caffeic acid	52-64	monoamine oxidase A	Homo sapiens	86-91
30413989-6	2018	CONCLUSIONS: The synthesized eugenol based ester of caffeic acid compound 7 exhibited MAO-A inhibition with IC50 values of 07.03 +- 0.022 microM with good selectivity (SI = 0.291) towards MAO-A.	caffeic acid	52-64	monoamine oxidase A	Homo sapiens	188-193
30413989-7	2018	Conversely, two anilides compounds 2 and 1, bearing chloro and nitro group at 2, 4 positions showed MAO-A inhibition with IC50 values of 08.51 +- 0.017 microM and 08.87 +- 0.005 microM, respectively.	Anilides	16-24	monoamine oxidase A	Homo sapiens	100-105
30413989-7	2018	Conversely, two anilides compounds 2 and 1, bearing chloro and nitro group at 2, 4 positions showed MAO-A inhibition with IC50 values of 08.51 +- 0.017 microM and 08.87 +- 0.005 microM, respectively.	Sodium Hypochlorite	52-58	monoamine oxidase A	Homo sapiens	100-105
30043181-2	2018	After the demonstrations that both cardiac neuronal and extraneuronal MAO-A contribute to the degradation of norepinephrine and serotonin, several studies attempted to determine the impact of MAO-A activity in the control of local concentration of the two biogenic amines and in their receptor-mediated effects.	Norepinephrine	109-123	monoamine oxidase A	Homo sapiens	70-75
29279995-8	2018	MAO-A knockdown suppressed the rasagiline-induced gene expression in SH-SY5Y cells, whereas MAO-B silencing enhanced the basal- and selegiline-induced gene expression in U118MG cells.	rasagiline	31-41	monoamine oxidase A	Homo sapiens	0-5
30167931-8	2018	Some structural features are highly conserved in the two isozymes, such as a Tyr-Tyr aromatic sandwich in front of the flavin ring and a Lys residue hydrogen-bonded to the cofactor N5 atom, whereas a pair of gating residues (Phe208/Ile335 in MAO A; Ile199/Tyr326 in MAO B) specifically determines the different substrate and inhibitor properties of the two enzymes.	Hydrogen	149-157	monoamine oxidase A	Homo sapiens	242-247
30043181-2	2018	After the demonstrations that both cardiac neuronal and extraneuronal MAO-A contribute to the degradation of norepinephrine and serotonin, several studies attempted to determine the impact of MAO-A activity in the control of local concentration of the two biogenic amines and in their receptor-mediated effects.	Serotonin	128-137	monoamine oxidase A	Homo sapiens	70-75
30043181-6	2018	Altogether, the results obtained by different groups showed that MAO-A played a key role in the regulation of physiological cardiac function and in the development of acute and chronic heart diseases through two mechanisms: the regulation of substrate concentrations and the intracellular production of reactive oxygen species.	Oxygen	312-318	monoamine oxidase A	Homo sapiens	65-70
29516165-2	2018	While inhibition of MAO activity in the periphery removes protection from biogenic amines and so is undesirable, inhibition in the brain gives vital antidepressant and behavioural advantages that make MAO a major pharmaceutical target for inhibitor design.	Amines	83-89	monoamine oxidase A	Homo sapiens	20-25
30341696-6	2018	Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.	safinamide	58-68	monoamine oxidase A	Homo sapiens	169-174
30341696-6	2018	Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.	Selegiline	31-41	monoamine oxidase A	Homo sapiens	169-174
30341696-6	2018	Selective inhibitors of MAO-B (selegiline, rasagiline and safinamide) have found a therapeutic role in the treatment of Parkinson"s disease and reversible inhibitors of MAO-A offered antidepressant activity without the serious side effects of the earlier nonselective MAO inhibitors.	rasagiline	43-53	monoamine oxidase A	Homo sapiens	169-174
30242487-2	2018	The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide.	monoamines	186-196	monoamine oxidase A	Homo sapiens	32-36
30242487-2	2018	The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide.	Tranylcypromine	267-282	monoamine oxidase A	Homo sapiens	32-36
30242487-2	2018	The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide.	Phenelzine	284-294	monoamine oxidase A	Homo sapiens	32-36
30242487-2	2018	The monoamine oxidases A and B (MAOA/MAOB) are prime candidates for the investigation into the role of DNA methylation in mental disorders, given their pivotal role in the metabolism of monoamines and as pharmacological targets of potent antidepressant drugs such as tranylcypromine, phenelzine or moclobemide.	Moclobemide	298-309	monoamine oxidase A	Homo sapiens	32-36
30341696-12	2018	As consequence recent novel therapeutic drugs for neurodegenerative diseases has led to the development of multi target drugs, that possess selective brain MAO A and B inhibitory moiety, iron chelating and antioxidant activities and the ability to increase brain levels of endogenous neurotrophins, such as BDNF, GDNF VEGF and erythropoietin and induce mitochondrial biogenesis.	Iron	187-191	monoamine oxidase A	Homo sapiens	156-167
30039351-10	2018	Indeed, tyramine antilipolytic effect was impaired by MAO-A inhibition.	Tyramine	8-16	monoamine oxidase A	Homo sapiens	54-59
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Reactive Oxygen Species	77-80	monoamine oxidase A	Homo sapiens	25-44
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Reactive Oxygen Species	77-80	monoamine oxidase A	Homo sapiens	46-51
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Hydrogen Peroxide	119-124	monoamine oxidase A	Homo sapiens	25-44
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Hydrogen Peroxide	119-124	monoamine oxidase A	Homo sapiens	46-51
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Norepinephrine	178-192	monoamine oxidase A	Homo sapiens	25-44
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Norepinephrine	178-192	monoamine oxidase A	Homo sapiens	46-51
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Serotonin	202-211	monoamine oxidase A	Homo sapiens	25-44
30003648-4	2018	The mitochondrial enzyme monoamine oxidase-A (MAO-A) is a relevant source of ROS in the heart through the formation of H2 O2 derived from the degradation of its main substrates, norepinephrine (NE) and serotonin.	Serotonin	202-211	monoamine oxidase A	Homo sapiens	46-51
30003648-6	2018	Using cardiomyoblasts and primary cardiomyocytes, we demonstrate that chronic MAO-A activation mediated by synthetic (tyramine) and physiological (NE) substrates induces ROS-dependent DNA damage response, activation of cyclin-dependent kinase inhibitors p21cip , p16ink4a , and p15ink4b and typical features of senescence such as cell flattening and SA-beta-gal activity.	Tyramine	118-126	monoamine oxidase A	Homo sapiens	78-83
30003648-6	2018	Using cardiomyoblasts and primary cardiomyocytes, we demonstrate that chronic MAO-A activation mediated by synthetic (tyramine) and physiological (NE) substrates induces ROS-dependent DNA damage response, activation of cyclin-dependent kinase inhibitors p21cip , p16ink4a , and p15ink4b and typical features of senescence such as cell flattening and SA-beta-gal activity.	Reactive Oxygen Species	170-173	monoamine oxidase A	Homo sapiens	78-83
30003648-6	2018	Using cardiomyoblasts and primary cardiomyocytes, we demonstrate that chronic MAO-A activation mediated by synthetic (tyramine) and physiological (NE) substrates induces ROS-dependent DNA damage response, activation of cyclin-dependent kinase inhibitors p21cip , p16ink4a , and p15ink4b and typical features of senescence such as cell flattening and SA-beta-gal activity.	2-(2-quinolinyl)-1H-indene--1,3(2H)-dione-6'-sulfonic acid	350-361	monoamine oxidase A	Homo sapiens	78-83
30003648-7	2018	Moreover, we observe that ROS produced by MAO-A lead to the accumulation of p53 in the cytosol where it inhibits parkin, an important regulator of mitophagy, resulting in mitochondrial dysfunction.	Reactive Oxygen Species	26-29	monoamine oxidase A	Homo sapiens	42-47
30143367-1	2018	In the studied a series novel of lazabemide derivatives were designed, synthesized and evaluated as inhibitors of monoamine oxidase (MAO-A or MAO-B).	lazabemide	33-43	monoamine oxidase A	Homo sapiens	133-138
30036687-0	2018	Bromo-dragonfly, a psychoactive benzodifuran, is resistant to hepatic metabolism and potently inhibits monoamine oxidase A.	benzodifuran	32-44	monoamine oxidase A	Homo sapiens	103-122
30036687-11	2018	Furthermore, MAO-A metabolised 2C-B-fly, producing the aldehyde metabolite, which was trapped in vitro with methoxyamine.	Aldehydes	55-63	monoamine oxidase A	Homo sapiens	13-18
30036687-11	2018	Furthermore, MAO-A metabolised 2C-B-fly, producing the aldehyde metabolite, which was trapped in vitro with methoxyamine.	methoxyamine	108-120	monoamine oxidase A	Homo sapiens	13-18
30568755-1	2018	A series of 13 phenyl substituted thiosemicarbazones (SB1-SB13) were synthesized and evaluated for their inhibitory potential towards human recombinant monoamine oxidase A and B (MAO-A and MAO-B, respectively) and acetylcholinesterase.	phenyl substituted thiosemicarbazones	15-52	monoamine oxidase A	Homo sapiens	152-177
30568755-6	2018	Furthermore, inhibitions by SB5 and SB11 against MAO-A and MAO-B, respectively, were recovered to near reference levels in reversibility experiments.	sb11	36-40	monoamine oxidase A	Homo sapiens	49-54
30568755-8	2018	These results indicate that SB5 and SB11 are selective, reversible and competitive inhibitors of MAO-A and MAO-B, respectively.	sb11	36-40	monoamine oxidase A	Homo sapiens	97-102
30153955-3	2018	Among the synthesized derivatives, 12a exhibited reversible and potent inhibition (IC50 = 0.41 muM) and high selectivity over the MAO-A and MAO-B.	12a	35-38	monoamine oxidase A	Homo sapiens	130-135
29423903-0	2018	[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.	Carbon-11	1-4	monoamine oxidase A	Homo sapiens	30-49
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	monoamine	70-79	monoamine oxidase A	Homo sapiens	0-19
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	monoamine	70-79	monoamine oxidase A	Homo sapiens	21-26
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	0-19
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	21-26
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Norepinephrine	118-131	monoamine oxidase A	Homo sapiens	0-19
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Norepinephrine	118-131	monoamine oxidase A	Homo sapiens	21-26
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Dopamine	136-144	monoamine oxidase A	Homo sapiens	0-19
30271325-1	2018	Monoamine oxidase A (MAO-A) is an enzyme that regulates the levels of monoamine neurotransmitters, such as serotonin, noradrenaline and dopamine and it has been used as a therapeutic target for depression.	Dopamine	136-144	monoamine oxidase A	Homo sapiens	21-26
30169842-2	2018	Here, MAOA methylation was analyzed via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells before and after a 2-week exposure therapy in a sample of n = 28 female patients with acrophobia as well as in n = 28 matched healthy female controls.	sodium bisulfite	61-77	monoamine oxidase A	Homo sapiens	6-10
29958841-0	2018	Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.	Endocannabinoids	16-31	monoamine oxidase A	Homo sapiens	75-101
29958841-0	2018	Interactions of endocannabinoid virodhamine and related analogs with human monoamine oxidase-A and -B.	virodhamine	32-43	monoamine oxidase A	Homo sapiens	75-101
29958841-2	2018	In the present study, we tested four endocannabinoids and two anandamide analogs for inhibition of recombinant human MAO-A and -B (monoamine oxidase).	Endocannabinoids	37-53	monoamine oxidase A	Homo sapiens	117-129
29958841-2	2018	In the present study, we tested four endocannabinoids and two anandamide analogs for inhibition of recombinant human MAO-A and -B (monoamine oxidase).	anandamide	62-72	monoamine oxidase A	Homo sapiens	117-129
29958841-3	2018	Virodhamine inhibited both MAO-A and -B (IC50 values of 38.70 and 0.71 muM, respectively) with ~55-fold greater inhibition of MAO-B.	virodhamine	0-11	monoamine oxidase A	Homo sapiens	27-39
29958841-9	2018	A molecular modeling study of virodhamine with MAO-B and its cofactor flavin adenine dinucleotide (FAD) predicted virodhamine"s terminal -NH2 group to be positioned near the N5 position of FAD, but for docking to MAO-A, virodhamine"s terminal -NH2 group was far away (~6.52 A) from the N5 position of FAD, and encountered bad contacts with nearby water molecules.	Flavin-Adenine Dinucleotide	70-97	monoamine oxidase A	Homo sapiens	213-218
29958841-9	2018	A molecular modeling study of virodhamine with MAO-B and its cofactor flavin adenine dinucleotide (FAD) predicted virodhamine"s terminal -NH2 group to be positioned near the N5 position of FAD, but for docking to MAO-A, virodhamine"s terminal -NH2 group was far away (~6.52 A) from the N5 position of FAD, and encountered bad contacts with nearby water molecules.	Flavin-Adenine Dinucleotide	99-102	monoamine oxidase A	Homo sapiens	213-218
29958841-9	2018	A molecular modeling study of virodhamine with MAO-B and its cofactor flavin adenine dinucleotide (FAD) predicted virodhamine"s terminal -NH2 group to be positioned near the N5 position of FAD, but for docking to MAO-A, virodhamine"s terminal -NH2 group was far away (~6.52 A) from the N5 position of FAD, and encountered bad contacts with nearby water molecules.	virodhamine	114-125	monoamine oxidase A	Homo sapiens	213-218
29958841-9	2018	A molecular modeling study of virodhamine with MAO-B and its cofactor flavin adenine dinucleotide (FAD) predicted virodhamine"s terminal -NH2 group to be positioned near the N5 position of FAD, but for docking to MAO-A, virodhamine"s terminal -NH2 group was far away (~6.52 A) from the N5 position of FAD, and encountered bad contacts with nearby water molecules.	virodhamine	114-125	monoamine oxidase A	Homo sapiens	213-218
29925480-0	2018	Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.	chelerythrine	47-60	monoamine oxidase A	Homo sapiens	24-43
29925480-0	2018	Selective inhibition of monoamine oxidase A by chelerythrine, an isoquinoline alkaloid.	Tubocurarine	65-86	monoamine oxidase A	Homo sapiens	24-43
29925480-1	2018	Chelerythrine, an isoquinoline alkaloid isolated from the herbaceous perennial Chelidonium majus, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A) with an IC50 value of 0.55 microM.	chelerythrine	0-13	monoamine oxidase A	Homo sapiens	176-195
29925480-1	2018	Chelerythrine, an isoquinoline alkaloid isolated from the herbaceous perennial Chelidonium majus, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A) with an IC50 value of 0.55 microM.	chelerythrine	0-13	monoamine oxidase A	Homo sapiens	197-202
29925480-2	2018	Chelerythrine was a reversible competitive MAO-A inhibitor (Ki = 0.22 microM) with a potency much greater than toloxatone (IC50 = 1.10 microM), a marketed drug.	chelerythrine	0-13	monoamine oxidase A	Homo sapiens	43-48
29925480-4	2018	A structural comparison with corynoline suggested the 1- and/or 2-methoxy groups of chelerythrine increase its inhibitory activity against MAO-A.	corynoline	29-39	monoamine oxidase A	Homo sapiens	139-144
29925480-4	2018	A structural comparison with corynoline suggested the 1- and/or 2-methoxy groups of chelerythrine increase its inhibitory activity against MAO-A.	chelerythrine	84-97	monoamine oxidase A	Homo sapiens	139-144
29925480-5	2018	Molecular docking simulations revealed that the binding affinity of chelerythrine for MAO-A (-9.7 kcal/mol) was greater than that for MAO-B (-4.6 kcal/mol).	chelerythrine	68-81	monoamine oxidase A	Homo sapiens	86-91
29925480-6	2018	Docking simulation implied that Cys323 and Tyr444 of MAO-A are key residues for hydrogen-bond interaction with chelerythrine.	Hydrogen	80-88	monoamine oxidase A	Homo sapiens	53-58
29925480-6	2018	Docking simulation implied that Cys323 and Tyr444 of MAO-A are key residues for hydrogen-bond interaction with chelerythrine.	chelerythrine	111-124	monoamine oxidase A	Homo sapiens	53-58
29925480-7	2018	Our findings suggest chelerythrine is one of the most reversible selective and potent natural inhibitor of MAO-A, and that it be regarded a potential lead compound for the design of novel reversible MAO-A inhibitors.	chelerythrine	21-34	monoamine oxidase A	Homo sapiens	107-112
29925480-7	2018	Our findings suggest chelerythrine is one of the most reversible selective and potent natural inhibitor of MAO-A, and that it be regarded a potential lead compound for the design of novel reversible MAO-A inhibitors.	chelerythrine	21-34	monoamine oxidase A	Homo sapiens	199-204
29423903-0	2018	[11C]Harmine Binding to Brain Monoamine Oxidase A: Test-Retest Properties and Noninvasive Quantification.	Harmine	5-12	monoamine oxidase A	Homo sapiens	30-49
29423903-1	2018	PURPOSE: Inhibition of the isoform A of monoamine oxidase (MAO-A), a mitochondrial enzyme catalyzing deamination of monoamine neurotransmitters, is useful in treatment of depression and anxiety disorders.	monoamine	40-49	monoamine oxidase A	Homo sapiens	59-64
29423903-2	2018	[11C]harmine, a MAO-A PET radioligand, has been used to study mood disorders and antidepressant treatment.	UNII-C06QCS6OX3	0-12	monoamine oxidase A	Homo sapiens	16-21
27836462-3	2018	Clock genes can regulate the transcription of monoamine oxidase A, which is involved in the degradation of monoamines.	monoamines	107-117	monoamine oxidase A	Homo sapiens	46-65
29679664-4	2018	For this reason, we identify and synthesize a near-infrared fluorescence (NIRF) heptamethine dye-MAOA inhibitor conjugate (NIR-INH) for simultaneous PCa imaging, targeting and therapy.	heptamethine	80-92	monoamine oxidase A	Homo sapiens	97-101
29671581-1	2018	Monoamine oxidase (MAO) enzymes MAO-A and MAO-B play a critical role in the metabolism of monoamine neurotransmitters.	monoamine	90-99	monoamine oxidase A	Homo sapiens	32-37
29963739-4	2018	3-(5-(4-Chlorophenyl)furan-2-yl)-1-(1-methyl-1H-pyrrol-2-yl)propan-1-one (6) was identified as the most selective MAO-A inhibitor in this series, with an IC50 value of 0.162 microM and a SI value of 0.002.	3-(5-(4-chlorophenyl)furan-2-yl)-1-(1-methyl	0-44	monoamine oxidase A	Homo sapiens	114-119
29963739-4	2018	3-(5-(4-Chlorophenyl)furan-2-yl)-1-(1-methyl-1H-pyrrol-2-yl)propan-1-one (6) was identified as the most selective MAO-A inhibitor in this series, with an IC50 value of 0.162 microM and a SI value of 0.002.	1h-pyrrol-2-yl)propan-1-one	45-72	monoamine oxidase A	Homo sapiens	114-119
29963739-7	2018	Docking studies were performed for compound 6 and clorgyline using the human MAO-A crystal structure (PDB ID: 2Z5Y).	Clorgyline	50-60	monoamine oxidase A	Homo sapiens	77-82
25784069-5	2018	Analysis of covariance showed an association between MAOA genotypes and ADHD performance in DCT, with poorer performance in risk allele carriers.	dct	92-95	monoamine oxidase A	Homo sapiens	53-57
29600412-6	2018	SA, not PA, was associated with hypermethylation of the MAOA first exon relative to no-abuse, and the association was robust to adjustment for psychoactive medication, alcohol and drug dependence, and current substance use.	Alcohols	168-175	monoamine oxidase A	Homo sapiens	56-60
29679664-4	2018	For this reason, we identify and synthesize a near-infrared fluorescence (NIRF) heptamethine dye-MAOA inhibitor conjugate (NIR-INH) for simultaneous PCa imaging, targeting and therapy.	nir-inh	123-130	monoamine oxidase A	Homo sapiens	97-101
30109004-0	2018	Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A.	Curcumin	0-8	monoamine oxidase A	Homo sapiens	69-88
29679664-5	2018	The conjugate combines a NIRF dye for mitochondria targeting with the MAOA inhibitor isoniazid (INH).	Isoniazid	85-94	monoamine oxidase A	Homo sapiens	70-74
29478144-7	2018	The MAOA gene encodes an enzyme which is involved in the catabolism of dopamine, norepinephrine, serotonin, and other monoaminergic neurotransmitters.	Dopamine	71-79	monoamine oxidase A	Homo sapiens	4-8
30109004-0	2018	Curcumin-based pyrazoline analogues as selective inhibitors of human monoamine oxidase A.	pyrazoline	15-25	monoamine oxidase A	Homo sapiens	69-88
29478144-7	2018	The MAOA gene encodes an enzyme which is involved in the catabolism of dopamine, norepinephrine, serotonin, and other monoaminergic neurotransmitters.	Norepinephrine	81-95	monoamine oxidase A	Homo sapiens	4-8
29478144-7	2018	The MAOA gene encodes an enzyme which is involved in the catabolism of dopamine, norepinephrine, serotonin, and other monoaminergic neurotransmitters.	Serotonin	97-106	monoamine oxidase A	Homo sapiens	4-8
29892597-2	2018	We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the flavin adenine dinucleotide in MAO-A using a combination of ultra-high performance liquid chromatography, spectroscopy, mass spectrometry, and computational methods.	thionine	30-37	monoamine oxidase A	Homo sapiens	144-149
29788780-1	2018	AIM: There is little information available on the monoamine oxidase isoform selectivity of N-alkyl harmine analogs, which exhibit a myriad of activities including MAO-A, DYRK1A and cytotoxicity to several select cancer cell lines.	n-alkyl harmine	91-106	monoamine oxidase A	Homo sapiens	163-168
29788780-4	2018	Conclusion &amp; future perspective: The current study delineates the structural requirements for MAO-A selectivity and such information may be helpful in designing selective analogs for kinase, DYRK1A and harmine-based cytotoxics without apparent MAO enzyme inhibition.	Adenosine Monophosphate	12-15	monoamine oxidase A	Homo sapiens	98-103
29788780-4	2018	Conclusion &amp; future perspective: The current study delineates the structural requirements for MAO-A selectivity and such information may be helpful in designing selective analogs for kinase, DYRK1A and harmine-based cytotoxics without apparent MAO enzyme inhibition.	Harmine	206-213	monoamine oxidase A	Homo sapiens	98-103
29892597-2	2018	We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the flavin adenine dinucleotide in MAO-A using a combination of ultra-high performance liquid chromatography, spectroscopy, mass spectrometry, and computational methods.	propargylamine	73-87	monoamine oxidase A	Homo sapiens	144-149
29892597-2	2018	We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the flavin adenine dinucleotide in MAO-A using a combination of ultra-high performance liquid chromatography, spectroscopy, mass spectrometry, and computational methods.	N-((5-(3-(1-benzylpiperidin-4-yl)propoxy)-1-methyl-1H-indol-2-yl)methyl)-N-methylprop-2-yn-1-amine	98-104	monoamine oxidase A	Homo sapiens	144-149
29892597-2	2018	We characterized the covalent cyanine structure linking the multi-target propargylamine inhibitor ASS234 and the flavin adenine dinucleotide in MAO-A using a combination of ultra-high performance liquid chromatography, spectroscopy, mass spectrometry, and computational methods.	Flavin-Adenine Dinucleotide	113-140	monoamine oxidase A	Homo sapiens	144-149
29501028-3	2018	The most potent inhibitor among the studied compounds has been found as (5R)-3-phenyl-5-methyl-2,4-oxazolidinedione (compound 1-R) which appeared to be a good antidepressant drug candidate since it inhibited hMAO-A selectively, competitively and reversibly with Ki values in the micromolar range (0.16 +- 0.01 muM).	(5r)-3-phenyl-5-methyl-2,4-oxazolidinedione	72-115	monoamine oxidase A	Homo sapiens	208-214
29550344-4	2018	The best substrate for MAO A and B was 4-(5-phenyl-2H-tetrazol-2-yl)butan-1-amine (2).	AKOS011737149	39-81	monoamine oxidase A	Homo sapiens	23-28
29550344-7	2018	The IC50-values of clorgiline and selegiline against MAO A and B, respectively, also decreased (two- and 30fold) replacing 2 by benzylamine.	Clorgyline	19-29	monoamine oxidase A	Homo sapiens	53-58
29550344-7	2018	The IC50-values of clorgiline and selegiline against MAO A and B, respectively, also decreased (two- and 30fold) replacing 2 by benzylamine.	Selegiline	34-44	monoamine oxidase A	Homo sapiens	53-58
29550344-7	2018	The IC50-values of clorgiline and selegiline against MAO A and B, respectively, also decreased (two- and 30fold) replacing 2 by benzylamine.	benzylamine	128-139	monoamine oxidase A	Homo sapiens	53-58
29448189-1	2018	A series of novel 3-(E)-styryl-2H-chromene derivatives were synthesized and their monoamine oxidase (MAO) A and B inhibitory activities were evaluated.	3-(e)-styryl-2h-chromene	18-42	monoamine oxidase A	Homo sapiens	82-107
29186431-2	2018	Monoamine oxidase A is one of the key enzymes mediating the turnover of noradrenaline.	Norepinephrine	72-85	monoamine oxidase A	Homo sapiens	0-19
29186431-4	2018	Methods: Monoamine oxidase A methylation was analyzed via direct sequencing of sodium bisulfite-treated DNA extracted from blood cells in a total sample of N=652 (441 male) patients with current posttraumatic stress disorder, patients with remitted posttraumatic stress disorder, and healthy probands (comparison group) recruited at 5 centers in Bosnia-Herzegovina, Croatia, and the Republic of Kosovo.	sodium bisulfite	79-95	monoamine oxidase A	Homo sapiens	9-28
29505805-3	2018	Monoamine oxidase A (MAO-A) is an outer mitochondrial membrane enzyme which is involved in the metabolic pathway of serotonin degradation.	Serotonin	116-125	monoamine oxidase A	Homo sapiens	0-19
29505805-3	2018	Monoamine oxidase A (MAO-A) is an outer mitochondrial membrane enzyme which is involved in the metabolic pathway of serotonin degradation.	Serotonin	116-125	monoamine oxidase A	Homo sapiens	21-26
29421700-2	2018	In the present study, two series of 4-substituted phenylpiperazine and 1-benzhydrylpiperazine (1-21) derivatives were synthesized and screened for their MAO-A and MAO-B inhibitory activity using Amplex Red assay.	4-substituted phenylpiperazine	36-66	monoamine oxidase A	Homo sapiens	153-158
29421700-2	2018	In the present study, two series of 4-substituted phenylpiperazine and 1-benzhydrylpiperazine (1-21) derivatives were synthesized and screened for their MAO-A and MAO-B inhibitory activity using Amplex Red assay.	norcyclizine	71-93	monoamine oxidase A	Homo sapiens	153-158
29421700-7	2018	In the ROS studies, compound 8 (MAO-A inhibitor) reduced the ROS level by 51.2% while compound 13 reduced the ROS level by 61.81%.	ros	7-10	monoamine oxidase A	Homo sapiens	32-37
29421700-7	2018	In the ROS studies, compound 8 (MAO-A inhibitor) reduced the ROS level by 51.2% while compound 13 reduced the ROS level by 61.81%.	ros	61-64	monoamine oxidase A	Homo sapiens	32-37
29421700-7	2018	In the ROS studies, compound 8 (MAO-A inhibitor) reduced the ROS level by 51.2% while compound 13 reduced the ROS level by 61.81%.	ros	61-64	monoamine oxidase A	Homo sapiens	32-37
29477889-6	2018	Compound 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).	3f (	9-13	monoamine oxidase A	Homo sapiens	193-198
29549852-0	2018	Elevated monoamine oxidase A activity and protein levels in rodent brain during acute withdrawal after chronic intermittent ethanol vapor exposure.	Ethanol	124-131	monoamine oxidase A	Homo sapiens	9-28
29549852-2	2018	Monoamine oxidase A (MAO-A) is an important enzyme that metabolizes monoamines and creates oxidative stress.	monoamines	68-78	monoamine oxidase A	Homo sapiens	0-19
29549852-2	2018	Monoamine oxidase A (MAO-A) is an important enzyme that metabolizes monoamines and creates oxidative stress.	monoamines	68-78	monoamine oxidase A	Homo sapiens	21-26
29549852-3	2018	Elevations in MAO-A level, especially in the prefrontal and anterior cingulate cortex (PFC and ACC), are associated with low mood states, including the dysphoria of early alcohol withdrawal in humans.	Alcohols	171-178	monoamine oxidase A	Homo sapiens	14-19
29549852-4	2018	The aim of the present study was to determine whether chronic alcohol vapor exposure causes an upregulation of MAO-A activity or level in the PFC and ACC of rodents during acute withdrawal.	Alcohols	62-69	monoamine oxidase A	Homo sapiens	111-116
29549852-7	2018	RESULTS: Chronic ethanol vapor exposure significantly elevated MAO-A activity and protein levels in the PFC and ACC at 24-h withdrawal (multivariate analysis of variance (MANOVA), activity: F2,13 = 3.82, p = .05, protein: F2,13 = 5.13, p = .02).	Ethanol	17-24	monoamine oxidase A	Homo sapiens	63-68
29549852-9	2018	CONCLUSIONS: The results of this study suggest a causal relationship between acute alcohol withdrawal and elevated MAO-A levels and activity, clarifying the observation of greater MAO-A binding in human alcohol withdrawal.	Alcohols	83-90	monoamine oxidase A	Homo sapiens	115-120
29549852-9	2018	CONCLUSIONS: The results of this study suggest a causal relationship between acute alcohol withdrawal and elevated MAO-A levels and activity, clarifying the observation of greater MAO-A binding in human alcohol withdrawal.	Alcohols	83-90	monoamine oxidase A	Homo sapiens	180-185
29549852-9	2018	CONCLUSIONS: The results of this study suggest a causal relationship between acute alcohol withdrawal and elevated MAO-A levels and activity, clarifying the observation of greater MAO-A binding in human alcohol withdrawal.	Alcohols	203-210	monoamine oxidase A	Homo sapiens	115-120
29549852-9	2018	CONCLUSIONS: The results of this study suggest a causal relationship between acute alcohol withdrawal and elevated MAO-A levels and activity, clarifying the observation of greater MAO-A binding in human alcohol withdrawal.	Alcohols	203-210	monoamine oxidase A	Homo sapiens	180-185
29381782-9	2018	Reducing 5-HT destruction by inhibiting MAOA with clorgyline increased the accumulation of 5-HT throughout the villus.	Clorgyline	50-60	monoamine oxidase A	Homo sapiens	40-44
29381782-12	2018	We conclude that serotonin is conveyed from the maternal blood stream through syncytiotrophoblasts, cytotrophoblasts and the villus core to the fetus through a physiological pathway that involves at least SERT, gap junctions, P-gp, OCT3, and MAOA.	Serotonin	17-26	monoamine oxidase A	Homo sapiens	242-246
29477889-6	2018	Compound 3f ((E)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1H-inden-1-one, MAO B IC50 = 276 nM, hH3R Ki = 6.5 nM) showed highest preference for MAO B over MAO A (SI > 36).	(e)-5-((4-bromobenzyl)oxy)-2-(4-(3-(piperidin-1-yl)propoxy)benzylidene)-2,3-dihydro-1h-inden-1-one	13-111	monoamine oxidase A	Homo sapiens	193-198
29655691-8	2018	All nanoformulations conserved the antioxidant potential of AE, while phosphatidylcholine interfered with MAO-A inhibition assay.	Phosphatidylcholines	70-89	monoamine oxidase A	Homo sapiens	106-111
29561824-4	2018	"Brava" oil exhibited the best inhibitory activity against all enzymes, when they are compared to "Mansa" oil: BuChE (IC50 = 245 +- 5 and 591 +- 23 mg mL-1), 5-LOX (IC50 = 45 +- 7 and 106 +- 14 mg mL-1), hMAO-A (IC50 = 30 +- 1 and 72 +- 10 mg mL-1) and hMAO-B (IC50 = 191 +- 8 and 208 +- 14 mg mL-1), respectively.	brava" oil	1-11	monoamine oxidase A	Homo sapiens	204-210
29320717-0	2018	Imitation of phase I metabolism reactions of MAO-A inhibitors by titanium dioxide photocatalysis.	titanium dioxide	65-81	monoamine oxidase A	Homo sapiens	45-50
29222910-0	2018	Associations Between MAOA-uVNTR Genotype, Maltreatment, MAOA Methylation, and Alcohol Consumption in Young Adult Males.	Alcohols	78-85	monoamine oxidase A	Homo sapiens	21-25
29222910-2	2018	Interactions between maltreatment and the monoamine oxidase A upstream variable number tandem repeat genotype (MAOA-uVNTR) are associated with alcohol-related problems.	Alcohols	143-150	monoamine oxidase A	Homo sapiens	42-61
29222910-2	2018	Interactions between maltreatment and the monoamine oxidase A upstream variable number tandem repeat genotype (MAOA-uVNTR) are associated with alcohol-related problems.	Alcohols	143-150	monoamine oxidase A	Homo sapiens	111-115
29222910-4	2018	The study focused on 53 young adult males and aimed to determine whether MAOA methylation moderated the association of alcohol-related problems with the interaction of MAOA-uVNTR and maltreatment, and whether alcohol consumption moderated the association of MAOA methylation with the interaction of MAOA-uVNTR and maltreatment.	Alcohols	119-126	monoamine oxidase A	Homo sapiens	73-77
29222910-12	2018	CONCLUSIONS: Intronic methylation moderated the association of alcohol-related problems with the interaction of MAOA-uVNTR and maltreatment.	Alcohols	63-70	monoamine oxidase A	Homo sapiens	112-116
29222910-13	2018	Alcohol consumption moderated the association of exonic methylation with the interaction of MAOA-uVNTR and maltreatment.	Alcohols	0-7	monoamine oxidase A	Homo sapiens	92-96
29570223-3	2018	Analyzes of the MAO inhibition properties of the synthesized compounds show that among the pyrrolo[3,4-f]indole-5,7-dione derivatives good potency MAO inhibitors exist as exemplified by 10, which possesses IC50 values for the inhibition of MAO-A and MAO-B of 0.023 and 0.178 microM, respectively.	pyrrolo[3,4-f]indole-5,7-dione	91-121	monoamine oxidase A	Homo sapiens	240-245
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	Moclobemide	39-50	monoamine oxidase A	Homo sapiens	71-95
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	Moclobemide	39-50	monoamine oxidase A	Homo sapiens	97-102
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	toloxatone	55-65	monoamine oxidase A	Homo sapiens	71-95
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	toloxatone	55-65	monoamine oxidase A	Homo sapiens	97-102
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	titanium dioxide	146-162	monoamine oxidase A	Homo sapiens	71-95
29320717-1	2018	The imitation of phase I metabolism of moclobemide and toloxatone, two monoamine oxidase type A (MAO-A) inhibitors, was performed with the use of titanium dioxide photocatalytic process.	titanium dioxide	146-162	monoamine oxidase A	Homo sapiens	97-102
29496172-0	2018	Inhibition of human monoamine oxidase A and B by flavonoids isolated from two Algerian medicinal plants.	Flavonoids	49-59	monoamine oxidase A	Homo sapiens	20-45
29395970-0	2018	Selective inhibition of monoamine oxidase A by hispidol.	Hispidol	47-55	monoamine oxidase A	Homo sapiens	24-43
29395970-1	2018	Hispidol, an aurone, isolated from Glycine max Merrill, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A), with an IC50 value of 0.26 microM, and to inhibit MAO-B, but with lower potency (IC50 = 2.45 microM).	Hispidol	0-8	monoamine oxidase A	Homo sapiens	134-153
29395970-1	2018	Hispidol, an aurone, isolated from Glycine max Merrill, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A), with an IC50 value of 0.26 microM, and to inhibit MAO-B, but with lower potency (IC50 = 2.45 microM).	Hispidol	0-8	monoamine oxidase A	Homo sapiens	155-160
29395970-1	2018	Hispidol, an aurone, isolated from Glycine max Merrill, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A), with an IC50 value of 0.26 microM, and to inhibit MAO-B, but with lower potency (IC50 = 2.45 microM).	aurone	13-19	monoamine oxidase A	Homo sapiens	134-153
29395970-1	2018	Hispidol, an aurone, isolated from Glycine max Merrill, was found to potently and selectively inhibit an isoform of recombinant human monoamine oxidase-A (MAO-A), with an IC50 value of 0.26 microM, and to inhibit MAO-B, but with lower potency (IC50 = 2.45 microM).	aurone	13-19	monoamine oxidase A	Homo sapiens	155-160
29395970-2	2018	Hispidol reversibly and competitively inhibited MAO-A with a Ki value of 0.10 microM with a potency much greater than toloxatone (IC50 = 1.10 microM), a marketed drug.	Hispidol	0-8	monoamine oxidase A	Homo sapiens	48-53
29395970-4	2018	Sulfuretin, an analog of hispidol, effectively inhibited MAO-A (IC50 = 4.16 microM) but not MAO-B (IC50 &gt; 80 microM).	sulfuretin	0-10	monoamine oxidase A	Homo sapiens	57-62
29395970-4	2018	Sulfuretin, an analog of hispidol, effectively inhibited MAO-A (IC50 = 4.16 microM) but not MAO-B (IC50 &gt; 80 microM).	Hispidol	25-33	monoamine oxidase A	Homo sapiens	57-62
29395970-5	2018	A comparison of their chemical structures showed that the 3"-hydroxyl group of sulfuretin might reduce its inhibitory activities against MAO-A and MAO-B.	sulfuretin	79-89	monoamine oxidase A	Homo sapiens	137-142
29395970-6	2018	Flexible docking simulation revealed that the binding affinity of hispidol for MAO-A (-9.1 kcal/mol) was greater than its affinity for MAO-B (-8.7 kcal/mol).	Hispidol	66-74	monoamine oxidase A	Homo sapiens	79-84
29395970-7	2018	The docking simulation showed hispidol binds to the major pocket of MAO-A or MAO-B.	Hispidol	30-38	monoamine oxidase A	Homo sapiens	68-73
29395970-8	2018	The findings suggest hispidol is a potent, selective, reversible inhibitor of MAO-A, and that it be considered a novel lead compound for development of novel reversible inhibitors of MAO-A.	Hispidol	21-29	monoamine oxidase A	Homo sapiens	78-83
29395970-8	2018	The findings suggest hispidol is a potent, selective, reversible inhibitor of MAO-A, and that it be considered a novel lead compound for development of novel reversible inhibitors of MAO-A.	Hispidol	21-29	monoamine oxidase A	Homo sapiens	183-188
29473029-8	2018	Fluoxetine interactions with monoamine oxidase A polymorphisms that influenced behavior and metabolomics markers were an important, previously unrecognized finding of our studies.	Fluoxetine	0-10	monoamine oxidase A	Homo sapiens	29-48
29221756-8	2018	A monoamine oxidase A inhibitor, pirlindole mesylate showed only weak displacement of [3H]d-deprenyl binding.	pirlindole	33-52	monoamine oxidase A	Homo sapiens	2-21
29221756-8	2018	A monoamine oxidase A inhibitor, pirlindole mesylate showed only weak displacement of [3H]d-deprenyl binding.	3h]d-deprenyl	87-100	monoamine oxidase A	Homo sapiens	2-21
29278274-8	2018	This unexpected binding was demonstrated to be because of nanomolar affinities of [3 H]AV-1451 for monoamine oxidase A and B enzymes.	7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	87-94	monoamine oxidase A	Homo sapiens	99-118
30108930-7	2018	MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies.	propargylamine	48-62	monoamine oxidase A	Homo sapiens	0-5
29248751-0	2018	Design, synthesis and biological assessment of new thiazolylhydrazine derivatives as selective and reversible hMAO-A inhibitors.	thiazolylhydrazine	51-69	monoamine oxidase A	Homo sapiens	110-116
29248751-2	2018	Hence, in the present study a new series of new thiazole-hydrazines (3a-3n) were designed, synthesized, characterized and screened for their hMAO-A and hMAO-B inhibitory activity by an in vitro flurometric method.	thiazole-hydrazines	48-67	monoamine oxidase A	Homo sapiens	141-158
29248751-4	2018	The compounds 3f and 3h showed promising hMAO-A inhibition with an IC50 values of 0.012 muM and 0.011 muM and significant selectivity indexes of 1214 and 1601 towards hMAO-A, respectively.	Tritium	21-23	monoamine oxidase A	Homo sapiens	41-47
29248751-4	2018	The compounds 3f and 3h showed promising hMAO-A inhibition with an IC50 values of 0.012 muM and 0.011 muM and significant selectivity indexes of 1214 and 1601 towards hMAO-A, respectively.	Tritium	21-23	monoamine oxidase A	Homo sapiens	167-173
29248751-5	2018	The mechanism of hMAO-A inhibition of compounds 3f and 3h was investigated by Lineweaver-Burk graphics and reversible-competitive inhibition of hMAO-A was determined.	Tritium	55-57	monoamine oxidase A	Homo sapiens	17-23
29248751-5	2018	The mechanism of hMAO-A inhibition of compounds 3f and 3h was investigated by Lineweaver-Burk graphics and reversible-competitive inhibition of hMAO-A was determined.	Tritium	55-57	monoamine oxidase A	Homo sapiens	144-150
29248751-8	2018	The docking study of compound 3f and 3h revealed that there is a strong interaction between the active sites of hMAO-A and analyzed compound.	Tritium	37-39	monoamine oxidase A	Homo sapiens	112-118
30108930-7	2018	MAO-A and MAO-B docking results showed that the propargylamine moiety was positioned in close proximity to the FAD cofactor suggesting that the good inhibitory activity may be attributed to the propargylamine moiety and irreversible inhibition as confirmed in the reversibility studies.	propargylamine	194-208	monoamine oxidase A	Homo sapiens	0-5
29268246-8	2018	The flavonoids catechin and cyanidin were not inhibitors of MAO by HPLC-DAD but highly inhibited the oxidation of TMB (or Amplex Red) by peroxidase whereas quercetin and resveratrol were moderate inhibitors of MAO-A by HPLC-DAD, but inhibited the peroxidase assay in a higher level.	Flavonoids	4-14	monoamine oxidase A	Homo sapiens	210-215
29568754-7	2018	Quercetin and flavonoids significantly contributed to MAO-A inhibition.	Quercetin	0-9	monoamine oxidase A	Homo sapiens	54-59
29568754-7	2018	Quercetin and flavonoids significantly contributed to MAO-A inhibition.	Flavonoids	14-24	monoamine oxidase A	Homo sapiens	54-59
29268246-8	2018	The flavonoids catechin and cyanidin were not inhibitors of MAO by HPLC-DAD but highly inhibited the oxidation of TMB (or Amplex Red) by peroxidase whereas quercetin and resveratrol were moderate inhibitors of MAO-A by HPLC-DAD, but inhibited the peroxidase assay in a higher level.	cyanidin	28-36	monoamine oxidase A	Homo sapiens	210-215
29268246-6	2018	The new method was applied to study the inhibition of human MAO-A and -B by bioactive compounds including beta-carboline alkaloids and flavonoids occurring in foods and plants.	beta-carboline alkaloids	106-130	monoamine oxidase A	Homo sapiens	60-72
29268246-6	2018	The new method was applied to study the inhibition of human MAO-A and -B by bioactive compounds including beta-carboline alkaloids and flavonoids occurring in foods and plants.	Flavonoids	135-145	monoamine oxidase A	Homo sapiens	60-72
29268246-8	2018	The flavonoids catechin and cyanidin were not inhibitors of MAO by HPLC-DAD but highly inhibited the oxidation of TMB (or Amplex Red) by peroxidase whereas quercetin and resveratrol were moderate inhibitors of MAO-A by HPLC-DAD, but inhibited the peroxidase assay in a higher level.	3,3',5,5'-tetramethylbenzidine	114-117	monoamine oxidase A	Homo sapiens	210-215
29268246-7	2018	As determined by HPLC-DAD, beta-carbolines, methylene blue, kaempferol and clorgyline inhibited MAO-A and methylene blue, 5-nitroindazole, norharman and deprenyl inhibited MAO-B, and all of them inhibited the oxidation of TMB in the same extent.	Carbolines	27-42	monoamine oxidase A	Homo sapiens	96-101
29268246-7	2018	As determined by HPLC-DAD, beta-carbolines, methylene blue, kaempferol and clorgyline inhibited MAO-A and methylene blue, 5-nitroindazole, norharman and deprenyl inhibited MAO-B, and all of them inhibited the oxidation of TMB in the same extent.	Methylene Blue	44-58	monoamine oxidase A	Homo sapiens	96-101
30430943-5	2018	METHOD: A series of different umbelliferone derivatives was designed and synthesized, and the derivatives were screened for hMAO-A and hMAO-B inhibition.	7-hydroxycoumarin	30-43	monoamine oxidase A	Homo sapiens	124-141
29268246-7	2018	As determined by HPLC-DAD, beta-carbolines, methylene blue, kaempferol and clorgyline inhibited MAO-A and methylene blue, 5-nitroindazole, norharman and deprenyl inhibited MAO-B, and all of them inhibited the oxidation of TMB in the same extent.	kaempferol	60-70	monoamine oxidase A	Homo sapiens	96-101
29268246-7	2018	As determined by HPLC-DAD, beta-carbolines, methylene blue, kaempferol and clorgyline inhibited MAO-A and methylene blue, 5-nitroindazole, norharman and deprenyl inhibited MAO-B, and all of them inhibited the oxidation of TMB in the same extent.	Clorgyline	75-85	monoamine oxidase A	Homo sapiens	96-101
29714148-5	2018	The MAO inhibitory properties of the chalcone derivatives were evaluated with the recombinant human MAO-A and MAO-B enzymes and the potencies were expressed as the IC50 values.	Chalcone	37-45	monoamine oxidase A	Homo sapiens	100-105
29714148-10	2018	Most 2-benzylidene-1-tetralones possess good inhibitory activity and specificity for MAO-B with the most potent inhibitor displaying an IC50 value of 0.0064 microM, while the most potent MAO-A inhibitor possessed an IC50 value of 0.754 microM.	2-benzylidene-1-tetralones	5-31	monoamine oxidase A	Homo sapiens	187-192
30430943-8	2018	RESULTS: Compound 5 with bromo 5-bromo-isatin exhibited a remarkable hMAO-A inhibitory potential (7.473+-0.035 microM and the selectivity index of 0.14) revealing the impact of hybrid coumarin and 5- bromo-2-oxoindolin-3-yl ring with hydrazine linker on the hMAO-A active site.	bromo 5-bromo-isatin	25-45	monoamine oxidase A	Homo sapiens	69-75
30430943-8	2018	RESULTS: Compound 5 with bromo 5-bromo-isatin exhibited a remarkable hMAO-A inhibitory potential (7.473+-0.035 microM and the selectivity index of 0.14) revealing the impact of hybrid coumarin and 5- bromo-2-oxoindolin-3-yl ring with hydrazine linker on the hMAO-A active site.	bromo 5-bromo-isatin	25-45	monoamine oxidase A	Homo sapiens	258-264
30430943-8	2018	RESULTS: Compound 5 with bromo 5-bromo-isatin exhibited a remarkable hMAO-A inhibitory potential (7.473+-0.035 microM and the selectivity index of 0.14) revealing the impact of hybrid coumarin and 5- bromo-2-oxoindolin-3-yl ring with hydrazine linker on the hMAO-A active site.	coumarin	184-192	monoamine oxidase A	Homo sapiens	69-75
30430943-8	2018	RESULTS: Compound 5 with bromo 5-bromo-isatin exhibited a remarkable hMAO-A inhibitory potential (7.473+-0.035 microM and the selectivity index of 0.14) revealing the impact of hybrid coumarin and 5- bromo-2-oxoindolin-3-yl ring with hydrazine linker on the hMAO-A active site.	5- bromo-2-oxoindolin-3-yl	197-223	monoamine oxidase A	Homo sapiens	69-75
30430943-8	2018	RESULTS: Compound 5 with bromo 5-bromo-isatin exhibited a remarkable hMAO-A inhibitory potential (7.473+-0.035 microM and the selectivity index of 0.14) revealing the impact of hybrid coumarin and 5- bromo-2-oxoindolin-3-yl ring with hydrazine linker on the hMAO-A active site.	hydrazine	234-243	monoamine oxidase A	Homo sapiens	69-75
29154867-6	2018	Fisetin (11) showed inhibition against hMAO-A with IC50 value of 4.62muM and no inhibitory activity toward hMAO-B up to 100muM.	fisetin	0-7	monoamine oxidase A	Homo sapiens	39-45
29126721-1	2018	Three series of 4-hydroxy-N"-[benzylidene/1-phenylethylidene]-2-H/methyl/benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides (9-11)a-l were synthesized and unraveled to be highly potent dual inhibitors of monoamine oxidases (MAO-A and MAO-B).	4-hydroxy-n"-[benzylidene	16-41	monoamine oxidase A	Homo sapiens	228-233
29126721-1	2018	Three series of 4-hydroxy-N"-[benzylidene/1-phenylethylidene]-2-H/methyl/benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides (9-11)a-l were synthesized and unraveled to be highly potent dual inhibitors of monoamine oxidases (MAO-A and MAO-B).	benzyl-1,2-benzothiazine-3-carbohydrazide 1,1-dioxides	73-127	monoamine oxidase A	Homo sapiens	228-233
29283399-4	2017	N-Cyclohexyl-2-[4-[(4-chlorophenyl)thio]benzylidene]hydrazine-1-carbothioamide (B24) was the most active compound against MAO-A.	n-cyclohexyl-2-[4-[(4-chlorophenyl)thio]benzylidene]hydrazine-1-carbothioamide	0-78	monoamine oxidase A	Homo sapiens	122-127
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	monoamine	7-16	monoamine oxidase A	Homo sapiens	26-30
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Serotonin	68-77	monoamine oxidase A	Homo sapiens	7-24
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Serotonin	68-77	monoamine oxidase A	Homo sapiens	26-30
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Norepinephrine	79-93	monoamine oxidase A	Homo sapiens	7-24
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Norepinephrine	79-93	monoamine oxidase A	Homo sapiens	26-30
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Dopamine	98-106	monoamine oxidase A	Homo sapiens	7-24
28293733-1	2018	Type A monoamine oxidase (MAOA) catabolizes monoamine transmitters, serotonin, norepinephrine and dopamine, and plays a major role in the onset, progression and therapy of neuropsychiatric disorders.	Dopamine	98-106	monoamine oxidase A	Homo sapiens	26-30
28293733-3	2018	The functional polymorphism of MAOA gene and genes in serotonin signal pathway are associated with depression.	Serotonin	54-63	monoamine oxidase A	Homo sapiens	31-35
28293733-5	2018	MAOA and serotonin regulate the prenatal development and postnatal maintenance of brain architecture and neurocircuit, as shown by MAOA-deficient humans and MAO knockout animal models.	Serotonin	9-18	monoamine oxidase A	Homo sapiens	131-135
28634060-7	2017	However, the interaction between AMG and MAO-A was not verified by the docking simulation.	methyl-galactopyranoside	33-36	monoamine oxidase A	Homo sapiens	41-46
29065322-0	2017	Sulfonyl hydrazones derived from 3-formylchromone as non-selective inhibitors of MAO-A and MAO-B: Synthesis, molecular modelling and in-silico ADME evaluation.	sulfonyl hydrazones	0-19	monoamine oxidase A	Homo sapiens	81-86
29065322-0	2017	Sulfonyl hydrazones derived from 3-formylchromone as non-selective inhibitors of MAO-A and MAO-B: Synthesis, molecular modelling and in-silico ADME evaluation.	Chromone-3-carboxaldehyde	33-49	monoamine oxidase A	Homo sapiens	81-86
29065322-1	2017	A series of sulfonyl hydrazones derived from 3-formylchromone was synthesized and discovered to be effective, non-selective inhibitors of monoamine oxidases (MAO-A and MAO-B).	sulfonyl hydrazones	12-31	monoamine oxidase A	Homo sapiens	158-163
29065322-1	2017	A series of sulfonyl hydrazones derived from 3-formylchromone was synthesized and discovered to be effective, non-selective inhibitors of monoamine oxidases (MAO-A and MAO-B).	Chromone-3-carboxaldehyde	45-61	monoamine oxidase A	Homo sapiens	158-163
29031059-2	2017	Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1.	Tranylcypromine	0-15	monoamine oxidase A	Homo sapiens	74-100
29031059-2	2017	Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1.	Tranylcypromine	0-15	monoamine oxidase A	Homo sapiens	102-107
29031059-2	2017	Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1.	Tranylcypromine	17-20	monoamine oxidase A	Homo sapiens	74-100
29031059-2	2017	Tranylcypromine (TCP) is an antidepressant originally known to target the monoamine oxidases A and B (MAO-A and MAO-B), which are structurally related to LSD1.	Tranylcypromine	17-20	monoamine oxidase A	Homo sapiens	102-107
28836294-2	2017	This work scrutinizes kinetics of decomposition of adrenaline catalyzed by monoamine oxidase (MAO) A and B enzymes, a process controlling the levels of adrenaline in the central nervous system and other tissues.	Epinephrine	51-61	monoamine oxidase A	Homo sapiens	75-106
28836294-2	2017	This work scrutinizes kinetics of decomposition of adrenaline catalyzed by monoamine oxidase (MAO) A and B enzymes, a process controlling the levels of adrenaline in the central nervous system and other tissues.	Epinephrine	152-162	monoamine oxidase A	Homo sapiens	75-106
28836294-3	2017	Experimental kinetic data for MAO A and B catalyzed decomposition of adrenaline are reported only in the form of the maximum reaction rate.	Epinephrine	69-79	monoamine oxidase A	Homo sapiens	30-35
28836294-5	2017	By using multiscale simulation on the Empirical Valence Bond (EVB) level, we studied the chemical reactivity of the MAO A catalyzed decomposition of adrenaline and we obtained a value of activation free energy of 17.3 +- 0.4 kcal/mol.	4-Sulfocalix[8]arene	62-65	monoamine oxidase A	Homo sapiens	116-121
28836294-5	2017	By using multiscale simulation on the Empirical Valence Bond (EVB) level, we studied the chemical reactivity of the MAO A catalyzed decomposition of adrenaline and we obtained a value of activation free energy of 17.3 +- 0.4 kcal/mol.	Epinephrine	149-159	monoamine oxidase A	Homo sapiens	116-121
29027345-3	2017	Herein, we report a new strategy for specific imaging of MAO-A through the design of fluorogenic probes combining the characteristic structure of an inhibitor of the target enzyme along with propylamine as a recognition moiety.	Propylamines	191-202	monoamine oxidase A	Homo sapiens	57-62
29423105-2	2018	In order to identify the mechanism of TAM resistance for estrogen receptor (ER)-positive breast cancer, we screened the transcriptome using RNA-seq and compared the gene expression profiles between the MCF-7 mamma carcinoma cell line and the TAM-resistant cell line TAMR/MCF-7, 52 significant differential expression genes (DEGs) were identified including SLIT2, ROBO, LHX, KLF, VEGFC, BAMBI, LAMA1, FLT4, PNMT, DHRS2, MAOA and ALDH.	Tamoxifen	38-41	monoamine oxidase A	Homo sapiens	419-423
29044737-9	2017	qRT-PCR analysis revealed that chronic BMY7378 treatment upregulated mRNA for 5-HT1A and 5-HT1B receptors in the hypothalamus and downregulated mRNA for 5-HT1A and monoamine oxidase-A in the brainstem.	BMY 7378	39-46	monoamine oxidase A	Homo sapiens	164-183
28097890-0	2017	Novel 1-(2-pyrimidin-2-yl)piperazine derivatives as selective monoamine oxidase (MAO)-A inhibitors.	1-(2-pyrimidin-2-yl)piperazine	6-36	monoamine oxidase A	Homo sapiens	62-87
28097890-1	2017	In the present study, a new series of 2-[4-(pyrimidin-2-yl)piperazin-1-yl]-2-oxoethyl 4-substituted piperazine-1-carbodithioate derivatives (2a-n) were synthesized and screened for their monoamine oxidase A and B inhibitory activity.	2-[4-(pyrimidin-2-yl)piperazin-1-yl]-2-oxoethyl 4-substituted piperazine-1-carbodithioate	38-127	monoamine oxidase A	Homo sapiens	187-206
28034283-3	2017	METHODS: Ursolic acid has been docked with monoamine oxidase isoforms: MAO-A and MAO-B, LeuT (homologue of SERT, NET, DAT) and Human C-terminal CAP1 using GRIP docking methodology.	ursolic acid	9-21	monoamine oxidase A	Homo sapiens	71-76
28034283-4	2017	RESULTS: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.	Clorgyline	193-204	monoamine oxidase A	Homo sapiens	112-117
28034283-4	2017	RESULTS: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.	Sertraline	220-230	monoamine oxidase A	Homo sapiens	112-117
28034283-4	2017	RESULTS: Results revealed its non-selective antidepressant action with strong binding affinity towards LeuT and MAO-A proteins, which was found to be comparable with the reference ligands like chlorgyline, clomipramine, sertraline and deprenyl/selegiline.	deprenyl/selegiline	235-254	monoamine oxidase A	Homo sapiens	112-117
28034283-5	2017	CONCLUSION: Significant binding affinity of ursolic acid was seen with MAO-A, which indicated its potential role in other neurological disorders, for example, Alzheimer"s disease and Parkinson disease besides depression.	ursolic acid	44-56	monoamine oxidase A	Homo sapiens	71-76
28634060-2	2017	Acacetin, a flavonoid, potently inhibited recombinant human MAO-A and MAO-B (IC50=0.19 and 0.17muM, respectively), and reversibly and competitively inhibited MAO-A and MAO-B (Ki=0.045 and 0.037muM, respectively).	acacetin	0-8	monoamine oxidase A	Homo sapiens	60-65
28634060-2	2017	Acacetin, a flavonoid, potently inhibited recombinant human MAO-A and MAO-B (IC50=0.19 and 0.17muM, respectively), and reversibly and competitively inhibited MAO-A and MAO-B (Ki=0.045 and 0.037muM, respectively).	acacetin	0-8	monoamine oxidase A	Homo sapiens	158-163
28634060-3	2017	Acacetin 7-O-(6-O-malonylglucoside) (AMG) was also found to effectively inhibit MAO-A and MAO-B (IC50=2.34 and 1.87muM, respectively), and to reversibly and competitively inhibit MAO-A and MAO-B (Ki=1.06 and 0.38muM, respectively).	acacetin 7-o-(6-o-malonylglucoside)	0-35	monoamine oxidase A	Homo sapiens	80-85
28634060-3	2017	Acacetin 7-O-(6-O-malonylglucoside) (AMG) was also found to effectively inhibit MAO-A and MAO-B (IC50=2.34 and 1.87muM, respectively), and to reversibly and competitively inhibit MAO-A and MAO-B (Ki=1.06 and 0.38muM, respectively).	acacetin 7-o-(6-o-malonylglucoside)	0-35	monoamine oxidase A	Homo sapiens	179-184
28634060-3	2017	Acacetin 7-O-(6-O-malonylglucoside) (AMG) was also found to effectively inhibit MAO-A and MAO-B (IC50=2.34 and 1.87muM, respectively), and to reversibly and competitively inhibit MAO-A and MAO-B (Ki=1.06 and 0.38muM, respectively).	methyl-galactopyranoside	37-40	monoamine oxidase A	Homo sapiens	80-85
28634060-3	2017	Acacetin 7-O-(6-O-malonylglucoside) (AMG) was also found to effectively inhibit MAO-A and MAO-B (IC50=2.34 and 1.87muM, respectively), and to reversibly and competitively inhibit MAO-A and MAO-B (Ki=1.06 and 0.38muM, respectively).	methyl-galactopyranoside	37-40	monoamine oxidase A	Homo sapiens	179-184
28634060-5	2017	Molecular docking simulation revealed the binding energy of acacetin for MAO-B (-44.2kcal/mol) was greater than its energy for MAO-A (-27.0kcal/mol), and that the Cys172 residue of MAO-B was important for hydrogen bonding with acacetin.	acacetin	60-68	monoamine oxidase A	Homo sapiens	127-132
28861918-2	2017	Novel indole derivatives with inhibitory activity towards acetyl/butyrylcholinesterases and monoamine oxidases A/B as well as the histamine H3 receptor (H3R) were obtained by optimization of the neuroprotectant ASS234 by incorporating generally accepted H3R pharmacophore motifs.	indole	6-12	monoamine oxidase A	Homo sapiens	92-114
28722111-1	2017	Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 .	Amines	123-129	monoamine oxidase A	Homo sapiens	0-19
28608626-5	2017	In this study, we tested the hypothesis that the genetic variants associated with decreased citalopram efficiency, 5HTTLPR/rs25531, and increased impulsive behavior, MAOA-uVNTR and HTR2B Q20*, are more frequent among citalopram users committing suicide than among the citalopram users in general.	Citalopram	217-227	monoamine oxidase A	Homo sapiens	166-170
28608626-5	2017	In this study, we tested the hypothesis that the genetic variants associated with decreased citalopram efficiency, 5HTTLPR/rs25531, and increased impulsive behavior, MAOA-uVNTR and HTR2B Q20*, are more frequent among citalopram users committing suicide than among the citalopram users in general.	Citalopram	217-227	monoamine oxidase A	Homo sapiens	166-170
28185143-3	2017	METHODS: Inhibition potential of 1-aminobenzotriazole and ketoconazole was studied in mice, rat and human liver microsomes, S9 fractions, MAO-A and MAO-B expressed enzymes by monitoring the formation of 4-hydroxyquinoline (4-HQ) from kynuramine, a specific substrate of MAO by liquid chromatography-tandem mass spectrometry (LC-MS/MS).	1-aminobenzotriazole	33-53	monoamine oxidase A	Homo sapiens	138-143
28185143-3	2017	METHODS: Inhibition potential of 1-aminobenzotriazole and ketoconazole was studied in mice, rat and human liver microsomes, S9 fractions, MAO-A and MAO-B expressed enzymes by monitoring the formation of 4-hydroxyquinoline (4-HQ) from kynuramine, a specific substrate of MAO by liquid chromatography-tandem mass spectrometry (LC-MS/MS).	Ketoconazole	58-70	monoamine oxidase A	Homo sapiens	138-143
28185143-5	2017	RESULTS: 1-aminobenzotriazole and ketoconazole inhibited both MAO isozymes (MAO-A and MAO-B) with more specificity towards MAO-B.	1-aminobenzotriazole	9-29	monoamine oxidase A	Homo sapiens	76-81
28185143-5	2017	RESULTS: 1-aminobenzotriazole and ketoconazole inhibited both MAO isozymes (MAO-A and MAO-B) with more specificity towards MAO-B.	Ketoconazole	34-46	monoamine oxidase A	Homo sapiens	76-81
28722111-1	2017	Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 .	Amines	123-129	monoamine oxidase A	Homo sapiens	21-25
28722111-1	2017	Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 .	Hydrogen Peroxide	143-148	monoamine oxidase A	Homo sapiens	0-19
28722111-1	2017	Monoamine oxidase A (MAOA) is a mitochondrial enzyme that catalyzes oxidative deamination of neurotransmitters and dietary amines and produces H2 O2 .	Hydrogen Peroxide	143-148	monoamine oxidase A	Homo sapiens	21-25
28722111-3	2017	Here, we evaluated MAOA in 427 cases of Hodgkin and non-Hodgkin lymphoma and in a spectrum of reactive lymphoid tissues by immunohistochemistry on formalin-fixed, paraffin-embedded specimens.	Formaldehyde	147-155	monoamine oxidase A	Homo sapiens	19-23
28722111-9	2017	The MAOA inhibitor clorgyline reduced the growth of L1236 cells and U-HO1 cells, and shRNA knockdown of MAOA reduced the growth of L1236 cells.	Clorgyline	19-29	monoamine oxidase A	Homo sapiens	4-8
28682929-9	2017	In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.	Tyramine	161-169	monoamine oxidase A	Homo sapiens	112-131
29050386-9	2017	Despite suggestions that MAOA (versus MAOB) is primarily responsible for metabolism of dopamine in dopamine neurons, there was no loss of the enzyme in the parkinsonian substantia nigra; instead, increased nigral levels of a MAOA fragment and "turnover" of the enzyme were observed in the conditions.	Dopamine	87-95	monoamine oxidase A	Homo sapiens	25-29
29050386-9	2017	Despite suggestions that MAOA (versus MAOB) is primarily responsible for metabolism of dopamine in dopamine neurons, there was no loss of the enzyme in the parkinsonian substantia nigra; instead, increased nigral levels of a MAOA fragment and "turnover" of the enzyme were observed in the conditions.	Dopamine	99-107	monoamine oxidase A	Homo sapiens	25-29
29050386-12	2017	The question remains whether suppression of either MAOB in astrocytes or MAOA in dopamine neurons might influence progression of the parkinsonian disorders.	Dopamine	81-89	monoamine oxidase A	Homo sapiens	73-77
28682929-9	2017	In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.	rasagiline	249-259	monoamine oxidase A	Homo sapiens	112-131
28682929-9	2017	In view of the observed, considerable heterogeneity of enzyme activities, we suggest to determine activities of monoamine oxidase A and B to reduce the risk for tyramine-induced hypertension and the serotonergic syndrome during chronic therapy with rasagiline or safinamide.	safinamide	263-273	monoamine oxidase A	Homo sapiens	112-131
28577058-3	2017	However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline.	rasagiline	177-187	monoamine oxidase A	Homo sapiens	114-119
28603901-1	2017	Testosterone, a male sex hormone, has been suggested to partly explain mixed findings in males and females when investigating behavioral tendencies associated with the MAOA polymorphism.	Testosterone	0-12	monoamine oxidase A	Homo sapiens	168-172
28603901-8	2017	Moreover, after testosterone administration, MAOA-S carriers were more risk-taking.	Testosterone	16-28	monoamine oxidase A	Homo sapiens	45-49
28603901-10	2017	In the anterior insula, testosterone administration mitigated this effect solely in MAOA-S carriers.	Testosterone	24-36	monoamine oxidase A	Homo sapiens	84-88
28603901-12	2017	While the molecular basis is not well defined so far, our results support the assumption of testosterone as a modulatory factor for previously reported sex differences of behavioral associations with the MAOA-S variant.	Testosterone	92-104	monoamine oxidase A	Homo sapiens	204-208
28577058-3	2017	However, the role of MAO-B itself in the regulation of cell death processing remains elusive, whereas type A MAO (MAO-A) mediates the induction of anti-apoptotic Bcl-2 genes by rasagiline and selegiline.	Selegiline	192-202	monoamine oxidase A	Homo sapiens	114-119
28577058-6	2017	Mao-A mRNA was also markedly increased by rasagiline and selegiline, and Mao-B knockdown significantly enhanced the induction by selegiline, but not by rasagiline.	rasagiline	42-52	monoamine oxidase A	Homo sapiens	0-5
28577058-6	2017	Mao-A mRNA was also markedly increased by rasagiline and selegiline, and Mao-B knockdown significantly enhanced the induction by selegiline, but not by rasagiline.	Selegiline	57-67	monoamine oxidase A	Homo sapiens	0-5
28577058-9	2017	Rasagiline increased BDNF and GDNF, which Mao-B and Mao-A knockdown inhibited.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	52-57
28577058-10	2017	These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes.	rasagiline	210-220	monoamine oxidase A	Homo sapiens	159-164
28577058-10	2017	These results show that MAO-B might function as a repressor and MAO-A as a mediator in the constitutional expression of pro-survival genes, and that MAO-B and MAO-A might regulate different signal pathways for rasagiline and selegiline to induce neuroprotective genes.	Selegiline	225-235	monoamine oxidase A	Homo sapiens	159-164
28851912-8	2017	We found that ASPD + PP subjects with MAOA-L exhibited decreased surface area in the right basolateral amygdala nucleus and increased surface area in the right anterior cortical amygdaloid nucleus versus healthy MAOA-L carriers.	aspd + pp	14-23	monoamine oxidase A	Homo sapiens	38-42
28851912-8	2017	We found that ASPD + PP subjects with MAOA-L exhibited decreased surface area in the right basolateral amygdala nucleus and increased surface area in the right anterior cortical amygdaloid nucleus versus healthy MAOA-L carriers.	aspd + pp	14-23	monoamine oxidase A	Homo sapiens	212-216
28700656-3	2017	Recently, the monoamine oxidase A (MAO-A) inhibitor clorgyline was shown to inhibit the azole efflux pumps, leading to increased azole susceptibility in C. glabrata.	Clorgyline	52-62	monoamine oxidase A	Homo sapiens	35-40
28685208-4	2017	Both ferric and ferrous ions could significantly enhance the activity of MAO-B, instead of MAO-A, in SH-SY5Y cells.	Ferric enterobactin ion	5-11	monoamine oxidase A	Homo sapiens	91-96
28685208-4	2017	Both ferric and ferrous ions could significantly enhance the activity of MAO-B, instead of MAO-A, in SH-SY5Y cells.	ammonium ferrous sulfate	16-23	monoamine oxidase A	Homo sapiens	91-96
28579071-3	2017	The irreversible and nonselective MAO-A/B inhibitor TCP has been confirmed as an efficacious and safe antidepressant drug.	Tranylcypromine	52-55	monoamine oxidase A	Homo sapiens	34-39
28579071-6	2017	Controlled studies revealed that TCP might provide a special advantage in the treatment of atypical depression, which was supported by a recent PET study of MAO-A activity in brain.	Tranylcypromine	33-36	monoamine oxidase A	Homo sapiens	157-162
28655495-3	2017	Pharmacological data of this review part I characterize TCP as an irreversible and nonselective MAO-A/B inhibitor at low therapeutic doses of 20mg/day with supplementary norepinephrine reuptake inhibition at higher doses of 40-60mg/day.	Tranylcypromine	56-59	monoamine oxidase A	Homo sapiens	96-103
28825649-3	2017	The inhibitory activity of compounds 2a-2n against hMAO-A and hMAO-B enzymes was elucidated by using an in-vitro Amplex Red  reagent assay based on fluorometric methods.	Amplex Red	113-132	monoamine oxidase A	Homo sapiens	51-68
28456030-4	2017	An older study reports that 1,4-benzoquinone inhibits MAO-A and MAO-B from human synaptosomes.	quinone	28-44	monoamine oxidase A	Homo sapiens	54-59
28456030-7	2017	The 1,4-benzoquinones were found to be moderately potent MAO inhibitors with IC50 values of 5.03-13.2 muM (MAO-A) and 3.69-23.2 muM (MAO-B).	Benzoquinones	4-21	monoamine oxidase A	Homo sapiens	107-112
28456030-8	2017	These values are comparable to those recorded for 1,4-benzoquinone of 4.82 muM (MAO-A) and 10.2 muM (MAO-B).	quinone	50-66	monoamine oxidase A	Homo sapiens	80-85
28456030-9	2017	Of interest however, is the finding that the 1,4-benzoquinones are irreversible inhibitors of MAO-A since prolonged incubation results in near complete inhibition, and enzyme activity is not recovered by dialysis.	Benzoquinones	45-62	monoamine oxidase A	Homo sapiens	94-99
28700656-3	2017	Recently, the monoamine oxidase A (MAO-A) inhibitor clorgyline was shown to inhibit the azole efflux pumps, leading to increased azole susceptibility in C. glabrata.	Azoles	88-93	monoamine oxidase A	Homo sapiens	35-40
28700656-3	2017	Recently, the monoamine oxidase A (MAO-A) inhibitor clorgyline was shown to inhibit the azole efflux pumps, leading to increased azole susceptibility in C. glabrata.	Azoles	129-134	monoamine oxidase A	Homo sapiens	35-40
28700656-8	2017	However, loss of Cdr1, Cdr2, Pdr1, and a putative clorgyline target (Fms1), which is an ortholog of human MAO-A, or overexpression of CDR1 did not affect the decreased susceptibility to micafungin and amphotericin B in the presence of clorgyline.	Clorgyline	50-60	monoamine oxidase A	Homo sapiens	106-111
28379899-4	2017	Moreover, isatin inhibited the expression level of monoamine oxidase A as well as that of its downstream protein hypoxia-inducible factor 1alpha.	Isatin	10-16	monoamine oxidase A	Homo sapiens	51-70
30108888-4	2017	A series of 2-phenylbenzofuran derivatives was designed, synthesized and evaluated against hMAO-A and hMAO-B enzymes.	2-phenylbenzofuran	12-30	monoamine oxidase A	Homo sapiens	91-108
28416295-8	2017	Several investigated gene polymorphisms (mostly SERT and MAO-A, but also COMT) significantly influenced two factors from the PANSS (aggressive/impulsive and negative symptoms) and one from the CDSS scale (suicidality), respectively.	cdss	193-197	monoamine oxidase A	Homo sapiens	57-62
28599322-4	2017	The MAO-A upregulation resulted in increased 5-hydroxyindoleacetic acid/serotonin ratio, oxidative stress, leading to NF-kappaB activation, inflammation and apoptosis.	Hydroxyindoleacetic Acid	45-71	monoamine oxidase A	Homo sapiens	4-9
28264138-3	2017	On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).	Harmine	19-26	monoamine oxidase A	Homo sapiens	57-76
28264138-3	2017	On the other hand, harmine is also a potent inhibitor of monoamine oxidase A (MAO-A).	Harmine	19-26	monoamine oxidase A	Homo sapiens	78-83
28487125-3	2017	The most promising compound TM-33 showed potent and balance inhibitory activities toward ChE and MAO (eeAChE, eqBuChE, hMAO-A and hMAO-B with IC50 values of 0.56muM, 2.3muM, 0.3muM and 1.4muM, respectively) but low selectivity.	tm-33	28-33	monoamine oxidase A	Homo sapiens	119-125
28377303-1	2017	The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals.	thionine	4-12	monoamine oxidase A	Homo sapiens	64-89
28377303-1	2017	The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals.	Methylene Blue	18-32	monoamine oxidase A	Homo sapiens	64-89
28377303-1	2017	The thionine dye, methylene blue (MB), is a potent inhibitor of monoamine oxidase (MAO) A, a property that may, at least in part, mediate its antidepressant effects in humans and animals.	Methylene Blue	34-36	monoamine oxidase A	Homo sapiens	64-89
28377303-2	2017	The central inhibition of MAO-A by MB has also been linked to serotonin toxicity (ST) which may arise when MB is used in combination with serotonergic drugs.	Serotonin	62-71	monoamine oxidase A	Homo sapiens	26-31
28377303-5	2017	Similar to MB, these analogues also are specific MAO-A inhibitors with cresyl violet (IC50=0.0037muM), Nile blue (IC50=0.0077muM) and 1,9-dimethyl methylene blue (IC50=0.018muM) exhibiting higher potency inhibition compared to MB (IC50=0.07muM).	cresyl violet	71-84	monoamine oxidase A	Homo sapiens	49-54
28377303-5	2017	Similar to MB, these analogues also are specific MAO-A inhibitors with cresyl violet (IC50=0.0037muM), Nile blue (IC50=0.0077muM) and 1,9-dimethyl methylene blue (IC50=0.018muM) exhibiting higher potency inhibition compared to MB (IC50=0.07muM).	Nile Blue	103-112	monoamine oxidase A	Homo sapiens	49-54
28377303-5	2017	Similar to MB, these analogues also are specific MAO-A inhibitors with cresyl violet (IC50=0.0037muM), Nile blue (IC50=0.0077muM) and 1,9-dimethyl methylene blue (IC50=0.018muM) exhibiting higher potency inhibition compared to MB (IC50=0.07muM).	1,9-dimethylmethylene blue	134-161	monoamine oxidase A	Homo sapiens	49-54
28377303-8	2017	Benzophenoxazines such as cresyl violet and Nile blue are, similar to phenothiazines (e.g. MB), representative of high potency MAO-A inhibitors with a potential risk of ST.	benzophenoxazines	0-17	monoamine oxidase A	Homo sapiens	127-132
28377303-8	2017	Benzophenoxazines such as cresyl violet and Nile blue are, similar to phenothiazines (e.g. MB), representative of high potency MAO-A inhibitors with a potential risk of ST.	cresyl violet	26-39	monoamine oxidase A	Homo sapiens	127-132
28377303-8	2017	Benzophenoxazines such as cresyl violet and Nile blue are, similar to phenothiazines (e.g. MB), representative of high potency MAO-A inhibitors with a potential risk of ST.	Nile Blue	44-53	monoamine oxidase A	Homo sapiens	127-132
28377303-8	2017	Benzophenoxazines such as cresyl violet and Nile blue are, similar to phenothiazines (e.g. MB), representative of high potency MAO-A inhibitors with a potential risk of ST.	Phenothiazines	70-84	monoamine oxidase A	Homo sapiens	127-132
28599322-4	2017	The MAO-A upregulation resulted in increased 5-hydroxyindoleacetic acid/serotonin ratio, oxidative stress, leading to NF-kappaB activation, inflammation and apoptosis.	Serotonin	72-81	monoamine oxidase A	Homo sapiens	4-9
28599322-8	2017	In human SH-SY5Y cells expressing MAO-A but not MAO-B, hypoxia significantly increased the MAO-A expression, which was blocked by M30 or clorgyline.	Clorgyline	137-147	monoamine oxidase A	Homo sapiens	34-39
28599322-8	2017	In human SH-SY5Y cells expressing MAO-A but not MAO-B, hypoxia significantly increased the MAO-A expression, which was blocked by M30 or clorgyline.	Clorgyline	137-147	monoamine oxidase A	Homo sapiens	91-96
28599322-9	2017	Collectively, the MAO-A upregulation induced by chronic intermittent hypoxia plays significant pathogenic role in oxidative stress, inflammation and IDO-1 activation resulting in serotonin depletion and neurodegeneration.	Serotonin	179-188	monoamine oxidase A	Homo sapiens	18-23
28273563-4	2017	Analysis of the binding sites of hMAO-A and hMAO-B led to design of linear analogs of 2-aryl-1,3,4-oxadiazin-5(6H)-one with an additional phenyl ring.	2-aryl-1,3,4-oxadiazin-5(6h)-one	86-118	monoamine oxidase A	Homo sapiens	33-50
28299453-1	2017	We determined monoamine oxidase-A (plasma) and -B (platelets) enzyme activity in chronic levodopa treated patients with Parkinson"s disease after first time intake of an irreversible monoamine oxidase-B inhibitor.	Levodopa	89-97	monoamine oxidase A	Homo sapiens	14-33
28068665-4	2017	The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1-oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of human MAO-B, with an IC50 value of 1.21 micro; in addition, it was found to be highly effective against MAO-A, with an IC50 value of 6.47 micro.	Piloquinone	4-15	monoamine oxidase A	Homo sapiens	244-249
28068665-4	2017	The piloquinone 4,7-dihydroxy-3-methyl-2-(4-methyl-1-oxopentyl)-6H-dibenzo[b,d]pyran-6-one (1) was found to be a highly potent inhibitor of human MAO-B, with an IC50 value of 1.21 micro; in addition, it was found to be highly effective against MAO-A, with an IC50 value of 6.47 micro.	4,7-dihydroxy-3-methyl-2-(4-methyl-1-oxopentyl)-6H-dibenzo[b,d]pyran-6-one	16-90	monoamine oxidase A	Homo sapiens	244-249
28418735-8	2017	Patients with parkinsonism with MAO-A TT genotype have a significantly higher level of 5-HT [5-HT (II), p < 0.05] compared to controls.	Serotonin	87-91	monoamine oxidase A	Homo sapiens	32-37
28418735-8	2017	Patients with parkinsonism with MAO-A TT genotype have a significantly higher level of 5-HT [5-HT (II), p < 0.05] compared to controls.	Serotonin	93-97	monoamine oxidase A	Homo sapiens	32-37
28301816-3	2017	The inhibitory activity of the compounds 4a-4o against hMAO-A and hMAO-B enzymes was evaluated by using in vitro Amlex Red  reagent based fluorometric method.	amlex red  reagent	113-131	monoamine oxidase A	Homo sapiens	55-72
28279698-6	2017	Seeds extracts containing both quinazoline and beta-carboline alkaloids potently inhibited human monoamine oxidase (MAO)-A.	Quinazolines	31-42	monoamine oxidase A	Homo sapiens	97-122
28279698-6	2017	Seeds extracts containing both quinazoline and beta-carboline alkaloids potently inhibited human monoamine oxidase (MAO)-A.	beta-carboline alkaloids	47-71	monoamine oxidase A	Homo sapiens	97-122
28163169-8	2017	Boys with MAOA-H had more DB as a function of PSE, controlling for PTE (beta=0.774, p=0.015), and as a function of PTE, controlling for PSE (beta=0.362, p=0.037).	pte	67-70	monoamine oxidase A	Homo sapiens	10-14
28163169-8	2017	Boys with MAOA-H had more DB as a function of PSE, controlling for PTE (beta=0.774, p=0.015), and as a function of PTE, controlling for PSE (beta=0.362, p=0.037).	pte	115-118	monoamine oxidase A	Homo sapiens	10-14
28302559-9	2017	7-Me-AMT provided the lowest IC50 value against MAO-A comparable to harmine and harmaline and was identified as a competitive MAO-A inhibitor.	7-me-amt	0-8	monoamine oxidase A	Homo sapiens	48-53
28302559-9	2017	7-Me-AMT provided the lowest IC50 value against MAO-A comparable to harmine and harmaline and was identified as a competitive MAO-A inhibitor.	7-me-amt	0-8	monoamine oxidase A	Homo sapiens	126-131
28251489-5	2017	A molecular docking simulation was performed to clarify the binding characteristics of eckol and dieckol to hMAO-A and hMAO-B.	dieckol	97-104	monoamine oxidase A	Homo sapiens	108-125
28402333-7	2017	Reactive oxygen species (ROS) produced by overexpressed MAOA plays an essential role in inhibiting apoptosis and activating autophagy in NED PCa cells.	Reactive Oxygen Species	0-23	monoamine oxidase A	Homo sapiens	56-60
28402333-7	2017	Reactive oxygen species (ROS) produced by overexpressed MAOA plays an essential role in inhibiting apoptosis and activating autophagy in NED PCa cells.	Reactive Oxygen Species	25-28	monoamine oxidase A	Homo sapiens	56-60
28251489-0	2017	Evaluation of the inhibitory effects of eckol and dieckol isolated from edible brown alga Eisenia bicyclis on human monoamine oxidases A and B.	dieckol	50-57	monoamine oxidase A	Homo sapiens	116-142
28251489-6	2017	The results suggested that methanolic extract of E. bicyclis and its isolated phlorotannins, eckol and dieckol, have potent inhibitory activity against hMAO-A and hMAO-B.	methanolic	27-37	monoamine oxidase A	Homo sapiens	152-158
28251489-3	2017	The aim of this study was to determine the effectiveness of eckol and dieckol isolated from the methanolic extract of E. bicyclis against PD by the inhibition of human MAO-A and MAO-B (hMAO-A and hMAO-B).	dieckol	70-77	monoamine oxidase A	Homo sapiens	168-173
28251489-3	2017	The aim of this study was to determine the effectiveness of eckol and dieckol isolated from the methanolic extract of E. bicyclis against PD by the inhibition of human MAO-A and MAO-B (hMAO-A and hMAO-B).	dieckol	70-77	monoamine oxidase A	Homo sapiens	185-191
28251489-6	2017	The results suggested that methanolic extract of E. bicyclis and its isolated phlorotannins, eckol and dieckol, have potent inhibitory activity against hMAO-A and hMAO-B.	phlorotannins	78-91	monoamine oxidase A	Homo sapiens	152-158
28251489-6	2017	The results suggested that methanolic extract of E. bicyclis and its isolated phlorotannins, eckol and dieckol, have potent inhibitory activity against hMAO-A and hMAO-B.	dieckol	103-110	monoamine oxidase A	Homo sapiens	152-158
28251489-8	2017	Molecular docking simulation predicted that eckol and dieckol exhibit higher binding affinity towards hMAO-A and hMAO-B through hydrogen bonding and hydrophobic interactions.	dieckol	54-61	monoamine oxidase A	Homo sapiens	102-108
28251489-8	2017	Molecular docking simulation predicted that eckol and dieckol exhibit higher binding affinity towards hMAO-A and hMAO-B through hydrogen bonding and hydrophobic interactions.	Hydrogen	128-136	monoamine oxidase A	Homo sapiens	102-108
28188065-0	2017	Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone.	purpurin	47-55	monoamine oxidase A	Homo sapiens	24-43
28188911-2	2017	To uncover the molecular rationale of hMAOs selectivity, two recently prepared 2H-chromene-2-ones, namely compounds 1 and 2, were herein chosen as molecular probes being highly selective toward hMAO-A and hMAO-B, respectively.	hmaos	38-43	monoamine oxidase A	Homo sapiens	194-200
28188911-2	2017	To uncover the molecular rationale of hMAOs selectivity, two recently prepared 2H-chromene-2-ones, namely compounds 1 and 2, were herein chosen as molecular probes being highly selective toward hMAO-A and hMAO-B, respectively.	2h-chromene-2-ones	79-97	monoamine oxidase A	Homo sapiens	194-200
28109809-3	2017	The IC50 value of 4 for MAO-A belonged to the lowest group in herbal sources and was similar to that of toloxatone (1.78muM), a marketed drug.	toloxatone	104-114	monoamine oxidase A	Homo sapiens	24-29
28109809-5	2017	Furthermore, compounds 5 (decursinol angelate) and 10 (baicalein) were observed to selectively and moderately inhibit MAO-A.	decursin	26-45	monoamine oxidase A	Homo sapiens	118-123
28109809-5	2017	Furthermore, compounds 5 (decursinol angelate) and 10 (baicalein) were observed to selectively and moderately inhibit MAO-A.	baicalein	55-64	monoamine oxidase A	Homo sapiens	118-123
28109809-8	2017	Molecular docking simulation revealed that 4 interacts with Asn181 residue of MAO-A or Asn116 residue of MAO-B by formation of hydrogen bond.	Hydrogen	127-135	monoamine oxidase A	Homo sapiens	78-83
27981510-0	2017	Aberrant CpG Methylation Mediates Abnormal Transcription of MAO-A Induced by Acute and Chronic L-3,4-Dihydroxyphenylalanine Administration in SH-SY5Y Neuronal Cells.	Levodopa	95-123	monoamine oxidase A	Homo sapiens	60-65
27981510-3	2017	Monoamine oxidase A (MAO-A) is one of the key enzymes in dopamine metabolism and therefore may be involved in L-dopa-induced side effects.	Dopamine	57-65	monoamine oxidase A	Homo sapiens	0-19
27981510-3	2017	Monoamine oxidase A (MAO-A) is one of the key enzymes in dopamine metabolism and therefore may be involved in L-dopa-induced side effects.	Dopamine	57-65	monoamine oxidase A	Homo sapiens	21-26
27981510-3	2017	Monoamine oxidase A (MAO-A) is one of the key enzymes in dopamine metabolism and therefore may be involved in L-dopa-induced side effects.	Levodopa	110-116	monoamine oxidase A	Homo sapiens	0-19
27981510-3	2017	Monoamine oxidase A (MAO-A) is one of the key enzymes in dopamine metabolism and therefore may be involved in L-dopa-induced side effects.	Levodopa	110-116	monoamine oxidase A	Homo sapiens	21-26
27981510-5	2017	To investigate the effects of L-dopa on MAO-A transcription and its underlying epigenetic mechanism, neuronal SH-SY5Y cells were treated with L-dopa for 24 h (acute) and for 7-21 days (chronic).	Levodopa	30-36	monoamine oxidase A	Homo sapiens	40-45
27981510-6	2017	Results showed that chronic L-dopa administration resulted in a dose-dependent and time-dependent downregulation of MAO-A, whereas acute L-dopa administration induced upregulation of MAO-A transcription and expression.	Levodopa	28-34	monoamine oxidase A	Homo sapiens	116-121
27981510-6	2017	Results showed that chronic L-dopa administration resulted in a dose-dependent and time-dependent downregulation of MAO-A, whereas acute L-dopa administration induced upregulation of MAO-A transcription and expression.	Levodopa	137-143	monoamine oxidase A	Homo sapiens	183-188
27981510-7	2017	Meanwhile, chronic L-dopa exposure induced CpG hypermethylation in MAO-A promoter, while acute L-dopa administration caused CpG hypomethylation.	Levodopa	19-25	monoamine oxidase A	Homo sapiens	67-72
27981510-9	2017	These results indicated that aberrant CpG methylation might play a key role in MAO-A transcriptional misregulation in L-dopa administration.	Levodopa	118-124	monoamine oxidase A	Homo sapiens	79-84
27981510-12	2017	These data indicated that in chronic L-dopa administration, TET1 downregulation might mediate CpG hypermethylation, which is responsible for the downregulation of MAO-A transcription.	Levodopa	37-43	monoamine oxidase A	Homo sapiens	163-168
27981510-13	2017	In contrast, in acute L-dopa administration, DNMT3a downregulation might mediate hypomethylation, contributing to the MAO-A upregulation.	Levodopa	22-28	monoamine oxidase A	Homo sapiens	118-123
27981510-14	2017	In conclusion, our findings suggested that TET1 and DNMTs might mediate aberrant CpG methylation, associated with the misregulation of MAO-A in L-dopa administration, which might contribute to dopamine release abnormally leading to the side effects of L-dopa.	Levodopa	144-150	monoamine oxidase A	Homo sapiens	135-140
27981510-14	2017	In conclusion, our findings suggested that TET1 and DNMTs might mediate aberrant CpG methylation, associated with the misregulation of MAO-A in L-dopa administration, which might contribute to dopamine release abnormally leading to the side effects of L-dopa.	Dopamine	193-201	monoamine oxidase A	Homo sapiens	135-140
27981510-14	2017	In conclusion, our findings suggested that TET1 and DNMTs might mediate aberrant CpG methylation, associated with the misregulation of MAO-A in L-dopa administration, which might contribute to dopamine release abnormally leading to the side effects of L-dopa.	Levodopa	252-258	monoamine oxidase A	Homo sapiens	135-140
28345608-8	2017	These findings suggest that the low activity-related C allele of MAOA rs1137070 is associated with an increase in the sensitivity to heroin addiction and the damaging effects of heroin abuse on cognition and the salience network.	Heroin	133-139	monoamine oxidase A	Homo sapiens	65-69
28435530-2	2017	The most potent compound, (2-chloropyridin-4-yl)methanamine 20 (hLOXL2 IC50 = 126 nM), was shown to be selective for LOXL2 over LOX and three other amine oxidases (MAO-A, MAO-B, and SSAO).	(2-chloropyridin-4-yl)methanamine	26-59	monoamine oxidase A	Homo sapiens	164-169
28188065-0	2017	Selective inhibition of monoamine oxidase A by purpurin, an anthraquinone.	Anthraquinones	60-73	monoamine oxidase A	Homo sapiens	24-43
28188065-7	2017	The findings of this study suggest purpurin is a potent, selective, reversible inhibitor of MAO-A, and that it be considered a new potential lead compound for development of novel reversible inhibitors of MAO-A (RIMAs).	purpurin	35-43	monoamine oxidase A	Homo sapiens	92-97
28188065-7	2017	The findings of this study suggest purpurin is a potent, selective, reversible inhibitor of MAO-A, and that it be considered a new potential lead compound for development of novel reversible inhibitors of MAO-A (RIMAs).	purpurin	35-43	monoamine oxidase A	Homo sapiens	205-210
27935229-0	2017	Cortico-limbic connectivity in MAOA-L carriers is vulnerable to acute tryptophan depletion.	Tryptophan	70-80	monoamine oxidase A	Homo sapiens	31-35
27926950-4	2017	Based on our interest in discovering reversible inhibitors with specificity for MAO-B, we have recently reported that, among a series of 10 3,4-dihydro-2(1H)-quinolinone derivatives, are high potency MAO-B inhibitors, with a number of homologues displaying good selectivities for MAO-B over the MAO-A isoform.	3,4-dihydro-2(1H)-quinolinone	140-169	monoamine oxidase A	Homo sapiens	295-300
27840401-5	2017	The inhibition of MAO-A using AME was apparently instantaneous.	alternariol monomethyl ether	30-33	monoamine oxidase A	Homo sapiens	18-23
27840401-6	2017	MAO-A activity was almost completely recovered after the dilution of the inhibited enzyme with an excess amount of AME, suggesting AME is a reversible inhibitor.	alternariol monomethyl ether	115-118	monoamine oxidase A	Homo sapiens	0-5
27840401-3	2017	AME was found to be a highly potent and selective inhibitor of human MAO-A with an IC50 value of 1.71 microM; however, it was found to be ineffective for MAO-B inhibition.	alternariol monomethyl ether	0-3	monoamine oxidase A	Homo sapiens	69-74
27840401-6	2017	MAO-A activity was almost completely recovered after the dilution of the inhibited enzyme with an excess amount of AME, suggesting AME is a reversible inhibitor.	alternariol monomethyl ether	131-134	monoamine oxidase A	Homo sapiens	0-5
27840401-9	2017	In addition, AME could be a useful lead compound for developing reversible MAO-A inhibitors to treat depression, Parkinson"s disease, and Alzheimer"s disease.	alternariol monomethyl ether	13-16	monoamine oxidase A	Homo sapiens	75-80
27863747-3	2017	The bis-iminothiazolidinone compounds were investigated in vitro for their inhibition of monoamine oxidase (MAO-A &amp; MAO-B) enzymes with the aim to identify new and distinct pharmacophores for the treatment of neurodegenerative disorders like Parkinson"s disease.	bis-iminothiazolidinone	4-27	monoamine oxidase A	Homo sapiens	108-113
28052533-3	2017	Inhibitors that act on MAO A are used to treat depression, due to their ability to raise serotonin concentrations, whereas MAO B inhibitors decrease dopamine degradation and improve motor control in patients with Parkinson disease.	Serotonin	89-98	monoamine oxidase A	Homo sapiens	23-28
28107736-0	2017	Crystal structures, binding interactions, and ADME evaluation of brain penetrant N-substituted indazole-5-carboxamides as subnanomolar, selective monoamine oxidase B and dual MAO-A/B inhibitors.	n-substituted indazole-5-carboxamides	81-118	monoamine oxidase A	Homo sapiens	175-180
28158205-4	2017	To understand structure activity/selectivity relationships of LSD1 inhibitors, several series of cyclopropylamine and related compounds were synthesized and tested for their activities against LSD1 and related monoamine oxidase (MAO) A and B.	cyclopropylamine	97-113	monoamine oxidase A	Homo sapiens	210-241
27364959-10	2017	Among receptors and enzymes related to CNS action, it is known that oseltamivir inhibits nicotinic acetylcholine receptors, which are closely related to hypothermia, as well as human monoamine oxidase-A (MAO-A), which is closely related to abnormal or excitatory behaviours.	Oseltamivir	68-79	monoamine oxidase A	Homo sapiens	183-202
27364959-10	2017	Among receptors and enzymes related to CNS action, it is known that oseltamivir inhibits nicotinic acetylcholine receptors, which are closely related to hypothermia, as well as human monoamine oxidase-A (MAO-A), which is closely related to abnormal or excitatory behaviours.	Oseltamivir	68-79	monoamine oxidase A	Homo sapiens	204-209
27863747-5	2017	Compound 5a was identified as the most potent inhibitor of MAO-A depicting an IC50 value of 0.001muM, a 4-fold stronger inhibitory strength compared to standard inhibitor (clorgyline: IC50=0.0045muM).	Clorgyline	172-182	monoamine oxidase A	Homo sapiens	59-64
27806193-10	2017	DHC12 inhibited MAO-A and MAO-B activity.	dhc12	0-5	monoamine oxidase A	Homo sapiens	16-21
28294055-6	2017	Selective inhibition of MAO-A results in the elevated level of serotonin and noradrenaline.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	24-29
28084411-0	2017	Ciproxifan, a histamine H3 receptor antagonist, reversibly inhibits monoamine oxidase A and B.	ciproxifan	0-10	monoamine oxidase A	Homo sapiens	68-93
28084411-3	2017	In a screening for potential monoamine oxidase A and B inhibition ciproxifan showed efficacy on both enzyme isoforms.	ciproxifan	66-76	monoamine oxidase A	Homo sapiens	29-54
27666135-4	2017	The most potent flavone MAO inhibitor studied is Az2k19 (1.6 mum for MAO-A, 2.1 mum for MAO-B), while Az1k15 and Az2k15 displayed better selectivity toward MAO-B (SI &gt; 10).	flavone	16-23	monoamine oxidase A	Homo sapiens	69-83
28069007-10	2017	RESULTS: The data obtained indicate that benzopyrones inhibited hMAO-A and hMAO-B with different degrees as confirmed with the luminescence assay.	benzopyrones	41-53	monoamine oxidase A	Homo sapiens	64-81
28294055-6	2017	Selective inhibition of MAO-A results in the elevated level of serotonin and noradrenaline.	Norepinephrine	77-90	monoamine oxidase A	Homo sapiens	24-29
26648064-5	2017	The discovery of crystal structure of MAO-A &amp; MAO-B isoforms helped in understanding the drug-receptor interactions at the molecular level and designing of ligands with selectivity for either of the isoforms.	Adenosine Monophosphate	45-48	monoamine oxidase A	Homo sapiens	38-43
27028260-4	2016	The inhibitory activity of the compounds against MAO-A and MAO-B enzymes was evaluated by using in vitro flurometric method in which kynuramine was used as a substrate.	Kynuramine	133-143	monoamine oxidase A	Homo sapiens	49-54
28828994-5	2017	From this perspective, we applied ligand-based-virtual associated with structure-based-virtual screening of alkaloids from C. sympodialis Eichl and 101 derivatives proposed by us are promising leads against some important targets (BACE, GSK-3beta and MAO-A).	Alkaloids	108-117	monoamine oxidase A	Homo sapiens	251-256
28828994-8	2017	The natural alkaloids roraimine and simpodialine-beta-N-oxide presented activity against BACE and liriodenine against MAO-A.	roraimine	22-31	monoamine oxidase A	Homo sapiens	118-123
28828994-8	2017	The natural alkaloids roraimine and simpodialine-beta-N-oxide presented activity against BACE and liriodenine against MAO-A.	simpodialine-beta-n-oxide	36-61	monoamine oxidase A	Homo sapiens	118-123
28828994-8	2017	The natural alkaloids roraimine and simpodialine-beta-N-oxide presented activity against BACE and liriodenine against MAO-A.	liriodenine	98-109	monoamine oxidase A	Homo sapiens	118-123
29138643-0	2017	Interactions of Desmethoxyyangonin, a Secondary Metabolite from Renealmia alpinia, with Human Monoamine Oxidase-A and Oxidase-B.	desmethoxyyangonin	16-34	monoamine oxidase A	Homo sapiens	94-113
29138643-2	2017	The dichloromethane extract of R. alpinia leaves showed potent inhibition of human monoamine oxidases- (MAOs-) A and B.	Methylene Chloride	4-19	monoamine oxidase A	Homo sapiens	83-118
28738332-6	2017	Elevated MAO-A levels are present throughout the gray matter of the brain, including affect-modulating brain regions, starting in high-risk states for MDE such as the early postpartum period, perimenopause, heavy cigarette smoking, heavy alcohol intake, and prior to MDE recurrence.	Alcohols	238-245	monoamine oxidase A	Homo sapiens	9-14
27650729-7	2017	MDMA analogues emerged as potent and selective monoamine oxidase A inhibitors.	N-Methyl-3,4-methylenedioxyamphetamine	0-4	monoamine oxidase A	Homo sapiens	47-66
27821364-1	2016	The monoamine oxidases (MAOA/B) and catechol-O-methyltransferase (COMT) enzymes break down regulatory components within serotonin and dopamine pathways, and polymorphisms within these genes are candidates for OCD susceptibility.	Serotonin	120-129	monoamine oxidase A	Homo sapiens	24-28
27821364-1	2016	The monoamine oxidases (MAOA/B) and catechol-O-methyltransferase (COMT) enzymes break down regulatory components within serotonin and dopamine pathways, and polymorphisms within these genes are candidates for OCD susceptibility.	Dopamine	134-142	monoamine oxidase A	Homo sapiens	24-28
27686269-4	2016	The first phytochemical study of the plants was performed by standard procedures, while the AChE and MAO-A inhibition by fractions enriched in high MW alkaloids, was measured in vitro.	Alkaloids	151-160	monoamine oxidase A	Homo sapiens	101-106
27852517-0	2016	Regulation of emotional response in juvenile monkeys treated with fluoxetine: MAOA interactions.	Fluoxetine	66-76	monoamine oxidase A	Homo sapiens	78-82
27852517-8	2016	Two potential translational implications are suggested: (1) MAOA genetic polymorphisms may be the source of some of the variability in response to fluoxetine treatment in children; (2) extended fluoxetine treatment during juvenile brain development may result in persistent effects on emotional regulation.	Fluoxetine	147-157	monoamine oxidase A	Homo sapiens	60-64
27852517-8	2016	Two potential translational implications are suggested: (1) MAOA genetic polymorphisms may be the source of some of the variability in response to fluoxetine treatment in children; (2) extended fluoxetine treatment during juvenile brain development may result in persistent effects on emotional regulation.	Fluoxetine	194-204	monoamine oxidase A	Homo sapiens	60-64
27558674-5	2017	Moreover, the compound 12 was both the most selective and potent MAO-A inhibitor among perimidinones.	perimidinones	87-100	monoamine oxidase A	Homo sapiens	65-70
28546851-6	2017	MAOs" expression substantially increases with ageing (6-fold MAO-A in the heart and 4-fold MAO-B in neuronal tissue), and their involvement in cardiac diseases is supposedly related to the formation of ROS, via the hydrogen peroxide produced during the substrate degradation.	Reactive Oxygen Species	202-205	monoamine oxidase A	Homo sapiens	61-66
27662218-1	2016	In the present study a series of fifteen 2-heteroarylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	2-heteroarylidene-1-indanone	41-69	monoamine oxidase A	Homo sapiens	148-179
27450565-7	2016	In addition, 1,25(OH)2D3 treatment attenuated increased levels of MAOA, DRD2 and VMAT2 gene expression caused by the VDR-overexpression.	Calcitriol	13-24	monoamine oxidase A	Homo sapiens	66-70
27734680-0	2016	Empirical Valence Bond Simulations of the Hydride-Transfer Step in the Monoamine Oxidase A Catalyzed Metabolism of Noradrenaline.	Norepinephrine	115-128	monoamine oxidase A	Homo sapiens	71-90
27734680-1	2016	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines, such as dopamine, serotonin, and noradrenaline (NA), which is why they have been extensively implicated in the etiology and course of various neurodegenerative disorders and, accordingly, used as primary pharmacological targets to treat these debilitating cognitive diseases.	Amines	94-100	monoamine oxidase A	Homo sapiens	0-33
27734680-1	2016	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines, such as dopamine, serotonin, and noradrenaline (NA), which is why they have been extensively implicated in the etiology and course of various neurodegenerative disorders and, accordingly, used as primary pharmacological targets to treat these debilitating cognitive diseases.	Dopamine	110-118	monoamine oxidase A	Homo sapiens	0-33
27734680-1	2016	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines, such as dopamine, serotonin, and noradrenaline (NA), which is why they have been extensively implicated in the etiology and course of various neurodegenerative disorders and, accordingly, used as primary pharmacological targets to treat these debilitating cognitive diseases.	Serotonin	120-129	monoamine oxidase A	Homo sapiens	0-33
27734680-1	2016	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines, such as dopamine, serotonin, and noradrenaline (NA), which is why they have been extensively implicated in the etiology and course of various neurodegenerative disorders and, accordingly, used as primary pharmacological targets to treat these debilitating cognitive diseases.	Norepinephrine	135-148	monoamine oxidase A	Homo sapiens	0-33
27734680-3	2016	In this work, we present atomistic empirical valence bond simulations of the rate-limiting step of the MAO-A-catalyzed NA (norepinephrine) degradation, involving hydride transfer from the substrate alpha-methylene group to the flavin moiety of the flavin adenine dinucleotide prosthetic group, employing the full dimensionality and thermal fluctuations of the hydrated enzyme, with extensive configurational sampling.	Norepinephrine	123-137	monoamine oxidase A	Homo sapiens	103-108
27734680-3	2016	In this work, we present atomistic empirical valence bond simulations of the rate-limiting step of the MAO-A-catalyzed NA (norepinephrine) degradation, involving hydride transfer from the substrate alpha-methylene group to the flavin moiety of the flavin adenine dinucleotide prosthetic group, employing the full dimensionality and thermal fluctuations of the hydrated enzyme, with extensive configurational sampling.	4,6-dinitro-o-cresol	227-233	monoamine oxidase A	Homo sapiens	103-108
27734680-3	2016	In this work, we present atomistic empirical valence bond simulations of the rate-limiting step of the MAO-A-catalyzed NA (norepinephrine) degradation, involving hydride transfer from the substrate alpha-methylene group to the flavin moiety of the flavin adenine dinucleotide prosthetic group, employing the full dimensionality and thermal fluctuations of the hydrated enzyme, with extensive configurational sampling.	Flavin-Adenine Dinucleotide	248-275	monoamine oxidase A	Homo sapiens	103-108
26471320-3	2016	We herein describe the design, synthesis, molecular modeling and biological evaluation of a new series of donepezil-related compounds possessing metal chelating properties, and being capable of targeting different enzymatic systems related to AD (cholinesterases, ChEs, and monoamine oxidase A, MAO-A).	Donepezil	106-115	monoamine oxidase A	Homo sapiens	274-293
26471320-3	2016	We herein describe the design, synthesis, molecular modeling and biological evaluation of a new series of donepezil-related compounds possessing metal chelating properties, and being capable of targeting different enzymatic systems related to AD (cholinesterases, ChEs, and monoamine oxidase A, MAO-A).	Donepezil	106-115	monoamine oxidase A	Homo sapiens	295-300
27318273-7	2016	These findings provide evidence that MT-031 is a potent brain permeable novel multifunctional, neuroprotective and MAO-A/ChE inhibitor, preserves in one molecule entity some of the beneficial properties of its parent drugs, rasagiline and rivastigmine, and thus may be indicated as novel therapeutic approach for AD.	SCHEMBL16948183	37-43	monoamine oxidase A	Homo sapiens	115-120
27634040-2	2016	The KDM1 family is homologous to the mitochondrial monoamine oxidases MAO-A/B and produces hydrogen peroxide in the nucleus as a byproduct of demethylation.	Hydrogen Peroxide	91-108	monoamine oxidase A	Homo sapiens	70-77
27754693-0	2016	Isolation of Acacetin from Calea urticifolia with Inhibitory Properties against Human Monoamine Oxidase-A and -B.	acacetin	13-21	monoamine oxidase A	Homo sapiens	86-112
27754693-2	2016	The chloroform extract of the leaves of C. urticifolia showed potent inhibition of recombinant human monoamine oxidases (MAO-A and -B).	Chloroform	4-14	monoamine oxidase A	Homo sapiens	121-133
27754693-3	2016	Further bioassay-guided fractionation led to the isolation of a flavonoid, acacetin, as the most prominent MAO inhibitory constituent, with IC50 values of 121 and 49 nM for MAO-A and -B, respectively.	Flavonoids	64-73	monoamine oxidase A	Homo sapiens	173-185
27754693-3	2016	Further bioassay-guided fractionation led to the isolation of a flavonoid, acacetin, as the most prominent MAO inhibitory constituent, with IC50 values of 121 and 49 nM for MAO-A and -B, respectively.	acacetin	75-83	monoamine oxidase A	Homo sapiens	173-185
27754693-4	2016	The potency of MAO inhibition by acacetin was &gt;5-fold higher for MAO-A (0.121 muM vs 0.640 muM) and &gt;22-fold higher for MAO-B (0.049 muM vs 1.12 muM) as compared to apigenin, the closest flavone structural analogue.	acacetin	33-41	monoamine oxidase A	Homo sapiens	68-73
27754693-5	2016	Interaction and binding characteristics of acacetin with MAO-A and -B were determined by enzyme-kinetic assays, enzyme-inhibitor complex binding, equilibrium-dialysis dissociation analyses, and computation analysis.	acacetin	43-51	monoamine oxidase A	Homo sapiens	57-69
27754693-6	2016	Follow-up studies showed reversible binding of acacetin with human MAO-A and -B, resulting in competitive inhibition.	acacetin	47-55	monoamine oxidase A	Homo sapiens	67-79
27754693-8	2016	In addition, the binding modes of acacetin at the enzymatic site of MAO-A and -B were predicted through molecular modeling algorithms, illustrating the high importance of ligand interaction with negative and positive free energy regions of the enzyme active site.	acacetin	34-42	monoamine oxidase A	Homo sapiens	68-80
27578245-1	2016	In the present study, a series of twenty-two 2-benzylidene-1-indanone derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	2-benzylidene-1-indanone	45-69	monoamine oxidase A	Homo sapiens	148-179
27578245-5	2016	The 2-benzylidene-1-indanone derivatives also inhibited MAO-A with the most potent inhibition exhibited by 5g (IC50=0.131muM).	2-benzylidene-1-indanone	4-28	monoamine oxidase A	Homo sapiens	56-61
27618912-4	2016	METHODS: Differential metabolism of PQ enantiomers by recombinant human CYP2D6, monoamine oxidase A (MAO), and cryopreserved human hepatocytes in the presence/absence of CQ and QN.	Primaquine	36-38	monoamine oxidase A	Homo sapiens	80-99
27618912-4	2016	METHODS: Differential metabolism of PQ enantiomers by recombinant human CYP2D6, monoamine oxidase A (MAO), and cryopreserved human hepatocytes in the presence/absence of CQ and QN.	Primaquine	36-38	monoamine oxidase A	Homo sapiens	101-104
27618912-6	2016	PQ depletion by MAO and human hepatocytes was not affected significantly by the presence of CQ and QN.	Primaquine	0-2	monoamine oxidase A	Homo sapiens	16-19
27597816-1	2016	HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A &gt;MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.	dicarbine	516-525	monoamine oxidase A	Homo sapiens	217-239
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Amines	102-108	monoamine oxidase A	Homo sapiens	0-19
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Amines	102-108	monoamine oxidase A	Homo sapiens	21-25
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Dopamine	117-125	monoamine oxidase A	Homo sapiens	0-19
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Dopamine	117-125	monoamine oxidase A	Homo sapiens	21-25
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Norepinephrine	127-141	monoamine oxidase A	Homo sapiens	0-19
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Norepinephrine	127-141	monoamine oxidase A	Homo sapiens	21-25
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Serotonin	147-156	monoamine oxidase A	Homo sapiens	0-19
26227907-1	2016	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the metabolism of several biological amines such as dopamine, norepinephrine, and serotonin, which are important neurochemicals in the pathogenesis of major psychiatric illnesses.	Serotonin	147-156	monoamine oxidase A	Homo sapiens	21-25
27597816-1	2016	HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A &gt;MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.	dicarbine	516-525	monoamine oxidase A	Homo sapiens	241-246
27597816-1	2016	HIGHLIGHTS Compounds that interact with multiple targets but minimally with the cytochrome P450 system (CYP) address the many factors leading to neurodegeneration.Acetyl- and Butyryl-cholineEsterases (AChE, BChE) and Monoamine Oxidases A/B (MAO A, MAO B) are targets for Multi-Target Designed Ligands (MTDL).ASS234 is an irreversible inhibitor of MAO A &gt;MAO B and has micromolar potency against the cholinesterases.ASS234 is a poor CYP substrate in human liver, yielding the depropargylated metabolite.SMe1EC2, a stobadine derivative, showed high radical scavenging property, in vitro and in vivo giving protection in head trauma and diabetic damage of endothelium.Control of mitochondrial function and morphology by manipulating fission and fusion is emerging as a target area for therapeutic strategies to decrease the pathological outcome of neurodegenerative diseases.	dicarbine	516-525	monoamine oxidase A	Homo sapiens	347-352
27230395-6	2016	The mechanisms responsible for the anti-addictive properties of ayahuasca and its alkaloids are not clarified, apparently involving both peripheral MAO-A inhibition by the beta-carbolines and central agonism of DMT at 5-HT2A receptors expressed in brain regions related to the regulation of mood and emotions.	Carbolines	172-187	monoamine oxidase A	Homo sapiens	148-153
27300740-7	2016	Results revealed a significant interaction between MAOA and smoking during pregnancy, indicating higher levels of aggressive behavior in young adults carrying the MAOA low-expressing genotype who had experienced prenatal nicotine exposure (n = 8, p = .025).	Nicotine	221-229	monoamine oxidase A	Homo sapiens	51-55
27300740-7	2016	Results revealed a significant interaction between MAOA and smoking during pregnancy, indicating higher levels of aggressive behavior in young adults carrying the MAOA low-expressing genotype who had experienced prenatal nicotine exposure (n = 8, p = .025).	Nicotine	221-229	monoamine oxidase A	Homo sapiens	163-167
27064247-1	2016	BACKGROUND: Polymorphisms in genes such as DAT1, 5HTTLPR, D4DR4, and MAO-A have been linked to attention deficit hyperactivity disorder (ADHD) and susceptibility for opiate addiction.	Opiate Alkaloids	166-172	monoamine oxidase A	Homo sapiens	69-74
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Serotonin	209-218	monoamine oxidase A	Homo sapiens	130-149
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Serotonin	209-218	monoamine oxidase A	Homo sapiens	151-155
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Norepinephrine	220-234	monoamine oxidase A	Homo sapiens	130-149
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Norepinephrine	220-234	monoamine oxidase A	Homo sapiens	151-155
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Dopamine	239-247	monoamine oxidase A	Homo sapiens	130-149
26776902-2	2016	In particular, converging lines of evidence have documented that these maladaptive manifestations of aggression are influenced by monoamine oxidase A (MAOA), the enzyme that catalyzes the degradation of brain serotonin, norepinephrine and dopamine.	Dopamine	239-247	monoamine oxidase A	Homo sapiens	151-155
26964906-3	2016	Most of the studies converge in associating MAO-A and MAO-B with impulsive, aggressive or antisocial personality traits or behaviours, including alcohol-related problems, and for MAO-A available evidence strongly supports interaction with adverse environmental exposures in childhood.	Alcohols	145-152	monoamine oxidase A	Homo sapiens	44-49
27135371-1	2016	A series of (E)-3-heteroarylidenechroman-4-ones (1a-r) was designed, synthesized and investigated in vitro for their ability to inhibit the enzymatic activity of both human monoamine oxidase (hMAO) isoforms, hMAO-A and hMAO-B.	(e)-3-heteroarylidenechroman-4-ones	12-47	monoamine oxidase A	Homo sapiens	208-214
27471444-8	2016	Inhibitors that act mainly on MAO A are used in the treatment of depression, due to their ability to raise serotonin concentrations, while MAO B inhibitors decrease dopamine degradation and improve motor control in patients with Parkinson disease.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	30-35
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	2-AMINO-6-NITROBENZOTHIAZOLE	12-40	monoamine oxidase A	Homo sapiens	143-168
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	2-AMINO-6-NITROBENZOTHIAZOLE	12-40	monoamine oxidase A	Homo sapiens	170-175
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	extended	49-57	monoamine oxidase A	Homo sapiens	143-168
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	extended	49-57	monoamine oxidase A	Homo sapiens	170-175
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	Hydrazones	58-68	monoamine oxidase A	Homo sapiens	143-168
27332045-1	2016	A series of 2-amino-6-nitrobenzothiazole-derived extended hydrazones were designed, synthesized, and investigated for their ability to inhibit monoamine oxidase A and B (MAO-A/MAO-B).	Hydrazones	58-68	monoamine oxidase A	Homo sapiens	170-175
27112704-5	2016	Serotonin"s homeostasis involves serotoninergic autoreceptor such as 5-HT1A, 5-HT1B, 5-HT1D, the enzymatic degradation of serotonin by monoamine oxidase A (MAO-A), and a transporter (serotoninergic transporter [SERT]).	Serotonin	0-9	monoamine oxidase A	Homo sapiens	135-154
27341797-3	2016	Monoamine oxidase A (MAOA) and B (MAOB), two isoenzymes bound to the outer membrane of mitochondria, are involved in the degradation of monoamines and were explored for association with ADHD in different ethnic groups.	monoamines	136-146	monoamine oxidase A	Homo sapiens	0-19
27341797-3	2016	Monoamine oxidase A (MAOA) and B (MAOB), two isoenzymes bound to the outer membrane of mitochondria, are involved in the degradation of monoamines and were explored for association with ADHD in different ethnic groups.	monoamines	136-146	monoamine oxidase A	Homo sapiens	21-25
27135466-3	2016	Compound 16, 1-(2,6-dichlorobenzylidene)-4-(benzo[1,3]dioxol-5-yl)semicarbazide presented a balanced multifunctional profile of MAO-A (IC50 =4.52+-0.032 mum), MAO-B (IC50 =0.059+-0.002 mum), and AChE (IC50 =0.0087+-0.0002 mum) inhibition without neurotoxicity.	16, 1-(2,6-dichlorobenzylidene)-4-(benzo[1,3]dioxol-5-yl)semicarbazide	9-79	monoamine oxidase A	Homo sapiens	128-133
27112704-5	2016	Serotonin"s homeostasis involves serotoninergic autoreceptor such as 5-HT1A, 5-HT1B, 5-HT1D, the enzymatic degradation of serotonin by monoamine oxidase A (MAO-A), and a transporter (serotoninergic transporter [SERT]).	Serotonin	0-9	monoamine oxidase A	Homo sapiens	156-161
27079124-4	2016	In addition, 14e also showed remarkable inhibitory activities of both monoamine oxidase A and B with IC50 values of 0.271muM and 0.393muM, respectively.	14e	13-16	monoamine oxidase A	Homo sapiens	70-89
26905291-4	2016	Polymorphisms of the MAOA (monoamine oxidase A) gene interact with fluoxetine to influence metabolic profiles in juvenile monkeys.	Fluoxetine	67-77	monoamine oxidase A	Homo sapiens	21-25
26905291-4	2016	Polymorphisms of the MAOA (monoamine oxidase A) gene interact with fluoxetine to influence metabolic profiles in juvenile monkeys.	Fluoxetine	67-77	monoamine oxidase A	Homo sapiens	27-46
27252617-3	2016	MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.	Nitrogen	117-118	monoamine oxidase A	Homo sapiens	359-364
27252617-3	2016	MTDL-2 showed more high affinity toward the four enzymes than MTDL-1.MTDL-3 and MTDL-4, were designed containing the N-benzylpiperidinium moiety from Donepezil, a metal- chelating 8-hydroxyquinoline group and linked to a N-propargyl core and they were pharmacologically evaluated.The presence of the cyano group in MTDL-3, enhanced binding to AChE, BuChE and MAO A.	mtdl-3	69-75	monoamine oxidase A	Homo sapiens	359-364
27121693-0	2016	Insights into enzyme point mutation effect by molecular simulation: phenylethylamine oxidation catalyzed by monoamine oxidase A.	Phenethylamines	68-84	monoamine oxidase A	Homo sapiens	108-127
27121693-1	2016	The I335Y point mutation effect on the kinetics of phenylethylamine decomposition catalyzed by monoamine oxidase A was elucidated by means of molecular simulation.	Phenethylamines	51-67	monoamine oxidase A	Homo sapiens	95-114
27058977-7	2016	KEY FINDINGS: Our high-throughput investigation identified monoamine oxidase-B, monoamine oxidase-A and angiotensin converting enzyme as potential targets for d-deprenyl.	Selegiline	159-169	monoamine oxidase A	Homo sapiens	80-99
27020523-1	2016	In a recent study we have shown that several indole-5,6-dicarbonitrile derivatives are potent inhibitors of human monoamine oxidase (MAO) A and B.	1H-indole-5,6-dicarbonitrile	45-70	monoamine oxidase A	Homo sapiens	114-145
27020523-3	2016	Among the active compounds two pyrrolo[3,4-f]indole-5,7-dione derivatives inhibited MAO-A (4 g) and MAO-B (4d) with IC50 values of 0.250 and 0.581 muM, respectively.	pyrrolo[3,4-f]indole-5,7-dione	31-61	monoamine oxidase A	Homo sapiens	84-89
27052821-2	2016	This study investigated a possible in vitro inhibitory activity of new 4-organochalcogen-isoquinoline derivatives, containing sulfur 1, selenium 2 or tellurium 3 on MAO-A and B activities.	4-organochalcogen-isoquinoline	71-101	monoamine oxidase A	Homo sapiens	165-170
27052821-2	2016	This study investigated a possible in vitro inhibitory activity of new 4-organochalcogen-isoquinoline derivatives, containing sulfur 1, selenium 2 or tellurium 3 on MAO-A and B activities.	Sulfur	126-132	monoamine oxidase A	Homo sapiens	165-170
27052821-2	2016	This study investigated a possible in vitro inhibitory activity of new 4-organochalcogen-isoquinoline derivatives, containing sulfur 1, selenium 2 or tellurium 3 on MAO-A and B activities.	selenium 2	136-146	monoamine oxidase A	Homo sapiens	165-170
26447226-7	2016	Conversely, some alleles of the 12 SNPs from the DRD2 locus and the 5 from the MAOA locus showed significant associations with excessive alcohol consumption.	Alcohols	137-144	monoamine oxidase A	Homo sapiens	79-83
26447226-9	2016	DRD2 rs1800497 and rs877138 were significantly associated in men, whereas DRD2 rs17601612 and rs4936271 and MAOA rs5906898 were associated with excessive alcohol consumption in women.	Alcohols	154-161	monoamine oxidase A	Homo sapiens	108-112
26684482-5	2016	A related compound, shikonin, inhibits both the MAO-A and MAO-B isoforms with IC50 values of 1.50 and 1.01 mum, respectively.	shikonin	20-28	monoamine oxidase A	Homo sapiens	48-53
26871599-3	2016	Monoamine Oxidase A (MAO A) oxidizes monoamine neurotransmitters resulting in reactive oxygen species which cause cancer.	monoamine	37-46	monoamine oxidase A	Homo sapiens	0-19
26956991-7	2016	The fluoxetine effect on sleep fragmentation, but not on daytime rest, was modified by the monkey"s genotype for polymorphisms of monoamine oxidase A (MAOA), an enzyme that metabolizes serotonin.	Fluoxetine	4-14	monoamine oxidase A	Homo sapiens	130-149
26956991-7	2016	The fluoxetine effect on sleep fragmentation, but not on daytime rest, was modified by the monkey"s genotype for polymorphisms of monoamine oxidase A (MAOA), an enzyme that metabolizes serotonin.	Fluoxetine	4-14	monoamine oxidase A	Homo sapiens	151-155
26956991-7	2016	The fluoxetine effect on sleep fragmentation, but not on daytime rest, was modified by the monkey"s genotype for polymorphisms of monoamine oxidase A (MAOA), an enzyme that metabolizes serotonin.	Serotonin	185-194	monoamine oxidase A	Homo sapiens	130-149
26956991-7	2016	The fluoxetine effect on sleep fragmentation, but not on daytime rest, was modified by the monkey"s genotype for polymorphisms of monoamine oxidase A (MAOA), an enzyme that metabolizes serotonin.	Serotonin	185-194	monoamine oxidase A	Homo sapiens	151-155
27034576-1	2016	Linezolid is an oxazolidinone antibiotic with weak monoamine oxidase (MAO) type A and MAO type B inhibitory effects.	Linezolid	0-9	monoamine oxidase A	Homo sapiens	51-81
26964672-4	2016	Modeling study indicated that the selectivity of our compounds to hMAO-B is determined by at least two residues, i.e., Ile 199 and Cys 172 (or corresponded Phe 208 and Asn 181 of hMAO-A).	Asparagine	168-171	monoamine oxidase A	Homo sapiens	179-185
26871599-3	2016	Monoamine Oxidase A (MAO A) oxidizes monoamine neurotransmitters resulting in reactive oxygen species which cause cancer.	monoamine	37-46	monoamine oxidase A	Homo sapiens	21-26
26871599-3	2016	Monoamine Oxidase A (MAO A) oxidizes monoamine neurotransmitters resulting in reactive oxygen species which cause cancer.	Reactive Oxygen Species	78-101	monoamine oxidase A	Homo sapiens	0-19
26871599-3	2016	Monoamine Oxidase A (MAO A) oxidizes monoamine neurotransmitters resulting in reactive oxygen species which cause cancer.	Reactive Oxygen Species	78-101	monoamine oxidase A	Homo sapiens	21-26
26871599-5	2016	MAO A inhibitors, clorgyline or the near-infrared-dye MHI-148 conjugated to clorgyline (NMI), were cytotoxic for glioma and decreased invasion in vitro.	Clorgyline	76-86	monoamine oxidase A	Homo sapiens	0-5
26871599-9	2016	In conclusion, we have identified MAO A inhibitors as potential novel stand-alone drugs or as combination therapy with low dose TMZ for drug-resistant gliomas.	Temozolomide	128-131	monoamine oxidase A	Homo sapiens	34-39
26818237-12	2016	In addition, urine samples from two patients and a heterozygous carrier of a family with disturbed monoamine metabolism due to a loss of function mutation in the MAOA gene (X-linked) were analyzed and compared with samples from controls.	monoamine	99-108	monoamine oxidase A	Homo sapiens	162-166
25331606-7	2016	Activity in the amygdala and hippocampus during emotional face-matching increased with the level of CLS in male MAOA-L, while decreasing in male MAOA-H, with the reverse pattern present in females.	calusterone	100-103	monoamine oxidase A	Homo sapiens	112-116
26362361-11	2016	The potent monoamine-releasing actions of 5-IT, coupled with its known inhibition of MAO A, could underlie its dangerous effects when administered alone, and in combination with other monoaminergic drugs or medications.	5-(2-aminopropyl)indole	42-46	monoamine oxidase A	Homo sapiens	85-90
26592797-4	2016	Kinetic studies revealed that compounds 18 and 16 (1-benzyl-3-hydroxy-3-(4"-bromophenacyl)oxindole) exhibit competitive inhibition against MAO-A and MAO-B, respectively.	1-benzyl-3-hydroxy-3-(4"-bromophenacyl)oxindole	51-98	monoamine oxidase A	Homo sapiens	139-144
26404523-3	2016	We report a clinical observation of pseudo-pheochromocytoma due to iproniazid, a non-selective irreversible monoamine oxidase (MAO) A and B inhibitor in a patient with bipolar disorder.	Iproniazid	67-77	monoamine oxidase A	Homo sapiens	108-139
26721607-5	2016	Therefore the inhibition potential of MDMA and its metabolites on the deamination of the neurotransmitters DA and serotonin (5-HT) by MAO-A and B using recombinant human enzymes in vitro should be investigated.	N-Methyl-3,4-methylenedioxyamphetamine	38-42	monoamine oxidase A	Homo sapiens	134-139
26721607-5	2016	Therefore the inhibition potential of MDMA and its metabolites on the deamination of the neurotransmitters DA and serotonin (5-HT) by MAO-A and B using recombinant human enzymes in vitro should be investigated.	Serotonin	114-123	monoamine oxidase A	Homo sapiens	134-139
26721607-8	2016	Further investigation on MAO-A revealed MDMA as a competitive inhibitor of 5-HT and DA deamination with Ki 24.5+-7.1 muM and 18.6+-4.3 muM respectively and MDA as a mixed-type inhibitor with Ki 7.8+-2.6 muM and 8.4+-3.2 muM respectively.	N-Methyl-3,4-methylenedioxyamphetamine	40-44	monoamine oxidase A	Homo sapiens	25-30
26481676-0	2016	MAOA-VNTR polymorphism modulates context-dependent dopamine release and aggressive behavior in males.	Dopamine	51-59	monoamine oxidase A	Homo sapiens	0-4
26481676-2	2016	Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli.	Dopamine	6-14	monoamine oxidase A	Homo sapiens	43-62
26481676-2	2016	Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli.	Dopamine	6-14	monoamine oxidase A	Homo sapiens	64-68
26481676-2	2016	Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli.	Dopamine	6-14	monoamine oxidase A	Homo sapiens	142-146
26481676-2	2016	Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli.	Dopamine	250-258	monoamine oxidase A	Homo sapiens	64-68
26481676-2	2016	Since dopamine is among the substrates for monoamine oxidase A (MAOA), this investigation examines whether functional allelic variants of the MAOA tandem repeat (VNTR) promotor polymorphism, which is known to modulate aggressive behavior, influences dopamine release and aggression in response to violent visual stimuli.	Dopamine	250-258	monoamine oxidase A	Homo sapiens	142-146
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	50-58	monoamine oxidase A	Homo sapiens	23-27
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	50-58	monoamine oxidase A	Homo sapiens	114-118
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	50-58	monoamine oxidase A	Homo sapiens	114-118
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	144-152	monoamine oxidase A	Homo sapiens	23-27
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	144-152	monoamine oxidase A	Homo sapiens	114-118
26481676-9	2016	Interestingly, the two MAOA-groups showed inverse dopaminergic and behavioral reactions to the violent movie: The MAOA-High group showed higher dopamine release and increased aggression after the violent movie; MAOA-Low subjects showed decreases in aggressive behavior and no consistent dopamine release.	Dopamine	144-152	monoamine oxidase A	Homo sapiens	114-118
26429556-3	2016	The review also emphasises the structure-activity relationship studies and molecular recognition of chalcones towards MAO-A and B inhibition.	Chalcones	100-109	monoamine oxidase A	Homo sapiens	118-123
26573170-2	2016	This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dendrimers as cofactors and serotonin as substrate, which generates H2O2, quantified by the conversion of the Carboxy-H2DCFDA dye to its fluorescent form.	Serotonin	131-140	monoamine oxidase A	Homo sapiens	62-67
26573170-2	2016	This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dendrimers as cofactors and serotonin as substrate, which generates H2O2, quantified by the conversion of the Carboxy-H2DCFDA dye to its fluorescent form.	Hydrogen Peroxide	171-175	monoamine oxidase A	Homo sapiens	41-60
26573170-2	2016	This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dendrimers as cofactors and serotonin as substrate, which generates H2O2, quantified by the conversion of the Carboxy-H2DCFDA dye to its fluorescent form.	Hydrogen Peroxide	171-175	monoamine oxidase A	Homo sapiens	62-67
26573170-2	2016	This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dendrimers as cofactors and serotonin as substrate, which generates H2O2, quantified by the conversion of the Carboxy-H2DCFDA dye to its fluorescent form.	carboxy-h2dcfda	213-228	monoamine oxidase A	Homo sapiens	41-60
26573170-2	2016	This study explores the potential of the monoamine oxidase A (MAO-A) enzyme-based assay with polymeric dendrimers as cofactors and serotonin as substrate, which generates H2O2, quantified by the conversion of the Carboxy-H2DCFDA dye to its fluorescent form.	carboxy-h2dcfda	213-228	monoamine oxidase A	Homo sapiens	62-67
26429556-5	2016	Recent studies also showed that heteroaryl-based chalcones are potent MAO-A inhibitors.	Chalcones	49-58	monoamine oxidase A	Homo sapiens	70-75
26299850-2	2016	Leflunomide inhibits human MAO-A and MAO-B and exhibits IC&amp;lt;sub&amp;gt;50&amp;lt;/sub&amp;gt; values of 19.1 muM and 13.7 muM, respectively.	Leflunomide	0-11	monoamine oxidase A	Homo sapiens	27-32
25687583-4	2016	The R and S form of thiophene based pyrazolines-carboxamides showed a binding energy and inhibition constant between 7.93 to -8.76 and 1.54 to 0.38 muM toward MAO-A and -6.39 to -8.51 and 20.84 to 0.57 muM toward MAO-B respectively.	Thiophenes	20-29	monoamine oxidase A	Homo sapiens	159-171
26654229-0	2016	Hansch Analysis of Novel Acetamide Derivatives as Highly Potent and Specific MAO-A Inhibitors.	acetamide	25-34	monoamine oxidase A	Homo sapiens	77-82
25687583-4	2016	The R and S form of thiophene based pyrazolines-carboxamides showed a binding energy and inhibition constant between 7.93 to -8.76 and 1.54 to 0.38 muM toward MAO-A and -6.39 to -8.51 and 20.84 to 0.57 muM toward MAO-B respectively.	pyrazolines-carboxamides	36-60	monoamine oxidase A	Homo sapiens	159-171
26299850-3	2016	The corresponding K&amp;lt;sub&amp;gt;i&amp;lt;/sub&amp;gt; values are 17.7 muM (MAO-A) and 10.1 muM (MAO-B).	k&amp	18-23	monoamine oxidase A	Homo sapiens	81-86
26299850-3	2016	The corresponding K&amp;lt;sub&amp;gt;i&amp;lt;/sub&amp;gt; values are 17.7 muM (MAO-A) and 10.1 muM (MAO-B).	Adenosine Monophosphate	20-23	monoamine oxidase A	Homo sapiens	81-86
26299850-3	2016	The corresponding K&amp;lt;sub&amp;gt;i&amp;lt;/sub&amp;gt; values are 17.7 muM (MAO-A) and 10.1 muM (MAO-B).	Adenosine Monophosphate	31-34	monoamine oxidase A	Homo sapiens	81-86
26299850-3	2016	The corresponding K&amp;lt;sub&amp;gt;i&amp;lt;/sub&amp;gt; values are 17.7 muM (MAO-A) and 10.1 muM (MAO-B).	Adenosine Monophosphate	31-34	monoamine oxidase A	Homo sapiens	81-86
26654229-9	2016	CONCLUSION: This study may be useful in the designing of more potent substituted acetamide derivatives as specific MAOA inhibitors.	acetamide	81-90	monoamine oxidase A	Homo sapiens	115-119
26561069-2	2016	1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines.	flavin adenine	14-28	monoamine oxidase A	Homo sapiens	74-79
27725503-0	2016	2-Azolylchromone Derivatives as Potent and Selective Inhibitors of Monoamine Oxidases A and B.	2-azolylchromone	0-16	monoamine oxidase A	Homo sapiens	67-93
27725503-1	2016	A series of 2-azolylchromone derivatives were synthesized and their monoamine oxidase (MAO) A and B inhibitory activities were evaluated.	2-azolylchromone	12-28	monoamine oxidase A	Homo sapiens	68-93
26561069-2	2016	1.4.3.4) is a flavin-adenine type of enzyme with two isoforms referred to MAO-A and MAO-B that function for oxidation of monoamines.	monoamines	121-131	monoamine oxidase A	Homo sapiens	74-79
26499200-0	2015	Curcumin inhibits cancer-associated fibroblast-driven prostate cancer invasion through MAOA/mTOR/HIF-1alpha signaling.	Curcumin	0-8	monoamine oxidase A	Homo sapiens	87-91
26645625-1	2015	Discordant associations between monoamine oxidase A (MAOA) genotype and high alcohol drinking have been reported in human and non-human primates.	Alcohols	77-84	monoamine oxidase A	Homo sapiens	32-51
26645625-1	2015	Discordant associations between monoamine oxidase A (MAOA) genotype and high alcohol drinking have been reported in human and non-human primates.	Alcohols	77-84	monoamine oxidase A	Homo sapiens	53-57
26536532-5	2015	Hence a series of novel 5-(hydroxamic acid)methyl oxazolidinone derivatives were synthesized and evaluated for their antibacterial and MAO-A and -B inhibitory activities.	5-(hydroxamic acid)methyl oxazolidinone	24-63	monoamine oxidase A	Homo sapiens	135-147
26536532-9	2015	Furthermore, the 5-(hydroxamic acid)methyl oxazolidinone derivatives were also less active as MAO-A and -B inhibitors compared with linezolid and the selective inhibitors clorgyline and pargyline.	5-(hydroxamic acid)methyl oxazolidinone	17-56	monoamine oxidase A	Homo sapiens	94-106
26562313-8	2016	In addition, MAOA-L carriers demonstrated higher aggression and the aggression were inversely correlated with dFRN across two groups; further analyses suggested that dFRN mediated the MAOA genotype-aggression relationship.	dfrn	110-114	monoamine oxidase A	Homo sapiens	13-17
26562313-8	2016	In addition, MAOA-L carriers demonstrated higher aggression and the aggression were inversely correlated with dFRN across two groups; further analyses suggested that dFRN mediated the MAOA genotype-aggression relationship.	dfrn	110-114	monoamine oxidase A	Homo sapiens	184-188
28044091-9	2016	These data suggest a close association between MAO-A-dependent ROS generation, actin oxidation, and ventricular dysfunction.	Reactive Oxygen Species	63-66	monoamine oxidase A	Homo sapiens	47-52
26810928-13	2016	The MAO-A and -B activities were evaluated in vitro by an end-point method using kynuramine as the substrate and mitochondrial suspension or human recombinant enzymes as the enzymatic source.	Kynuramine	81-91	monoamine oxidase A	Homo sapiens	4-16
26499200-4	2015	In this study, we found that CAFs could induce prostate cancer cell EMT and invasion through a monoamine oxidase A (MAOA)/mammalian target of rapamycin (mTOR)/hypoxia-inducible factor-1alpha (HIF-1alpha) signaling pathway, which exploits reactive oxygen species (ROS) to drive a migratory and aggressive phenotype of prostate carcinoma cells.	Reactive Oxygen Species	238-261	monoamine oxidase A	Homo sapiens	95-114
26499200-4	2015	In this study, we found that CAFs could induce prostate cancer cell EMT and invasion through a monoamine oxidase A (MAOA)/mammalian target of rapamycin (mTOR)/hypoxia-inducible factor-1alpha (HIF-1alpha) signaling pathway, which exploits reactive oxygen species (ROS) to drive a migratory and aggressive phenotype of prostate carcinoma cells.	Reactive Oxygen Species	263-266	monoamine oxidase A	Homo sapiens	95-114
26499200-6	2015	However, curcumin abrogated CAF-induced invasion and EMT, and inhibited ROS production and CXCR4 and IL-6 receptor expression in prostate cancer cells through inhibiting MAOA/mTOR/HIF-1alpha signaling, thereby supporting the therapeutic effect of curcumin in prostate cancer.	Curcumin	9-17	monoamine oxidase A	Homo sapiens	170-174
26428872-1	2015	The 3-substituted oxindole derivatives were designed, synthesized, and evaluated for antidepressant activity by employing forced swimming test, tail suspension test, and MAO-A inhibition assay.	3-substituted oxindole	4-26	monoamine oxidase A	Homo sapiens	170-175
26263056-7	2015	The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala.	Pargyline	131-140	monoamine oxidase A	Homo sapiens	67-72
26263056-7	2015	The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala.	Clorgyline	142-152	monoamine oxidase A	Homo sapiens	67-72
26263056-7	2015	The developed method was successfully applied for detection of the MAO-A and MAO-B inhibitive activities by model drugs, including pargyline, clorgyline, as well as beta-carboline alkaloids from Peganum harmala.	beta-carboline alkaloids	165-189	monoamine oxidase A	Homo sapiens	67-72
26352677-4	2015	Our modeling study indicates that Tyr 326 of hMAO-B (or corresponded Ile 335 of hMAO-A) may be the determinant for the specificity of these compounds.	Tyrosine	34-37	monoamine oxidase A	Homo sapiens	80-86
26491258-2	2015	The 3-coumaranone derivatives are structurally related to series of alpha-tetralone and 1-indanone derivatives, which have recently been shown to potently inhibit MAO, with selectivity for MAO-B (in preference to the MAO-A isoform).	3-coumaranone	4-17	monoamine oxidase A	Homo sapiens	217-222
25922182-7	2015	2-(2-(Benzo[d][1,3]dioxol-5-yl)-4-oxo-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide 15 showed selective MAO-A inhibition activity (SI=39524) superior to that of the standard clorgyline (SI=33793).	Clorgyline	174-184	monoamine oxidase A	Homo sapiens	104-109
26337020-1	2015	We have synthesized three categories of alpha,beta-unsaturated carbonyl derivatives and evaluated their MAO-A and MAO-B inhibitory activities.	alpha,beta-unsaturated carbonyl derivatives	40-83	monoamine oxidase A	Homo sapiens	104-109
26316187-0	2015	Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.	Moclobemide	33-44	monoamine oxidase A	Homo sapiens	0-19
26316187-0	2015	Monoamine Oxidase-A Occupancy by Moclobemide and Phenelzine: Implications for the Development of Monoamine Oxidase Inhibitors.	Phenelzine	49-59	monoamine oxidase A	Homo sapiens	0-19
26316187-5	2015	RESULTS: Mean brain MAO-A occupancies were 74.23+-8.32% for moclobemide at 300-600 mg daily (n = 11), 83.75+-5.52% for moclobemide at 900-1200 mg daily (n = 9), and 86.82+-6.89% for phenelzine at 45-60 mg daily (n = 4).	Moclobemide	60-71	monoamine oxidase A	Homo sapiens	20-25
26316187-8	2015	CONCLUSIONS: These findings suggest that for first-line MDE treatment, daily moclobemide doses of 300-600mg correspond to a MAO-A occupancy of 74%, whereas for treatment-resistant MDE, either phenelzine or higher doses of moclobemide correspond to a MAO-A occupancy of at least 84%.	Moclobemide	77-88	monoamine oxidase A	Homo sapiens	124-129
26316187-8	2015	CONCLUSIONS: These findings suggest that for first-line MDE treatment, daily moclobemide doses of 300-600mg correspond to a MAO-A occupancy of 74%, whereas for treatment-resistant MDE, either phenelzine or higher doses of moclobemide correspond to a MAO-A occupancy of at least 84%.	Moclobemide	77-88	monoamine oxidase A	Homo sapiens	250-255
26316187-10	2015	The findings provide a rationale in treatment algorithm design to raise moclobemide doses to inhibit more MAO-A sites, but suggest switching from high-dose moclobemide to phenelzine is best justified by binding to additional targets.	Moclobemide	72-83	monoamine oxidase A	Homo sapiens	106-111
26192590-3	2015	The beta-carboline alkaloid harmine is a high affinity inhibitor of DYRK1A but suffers from the drawback of inhibiting monoamine oxidase A (MAO-A) with even higher potency.	beta-carboline alkaloid harmine	4-35	monoamine oxidase A	Homo sapiens	119-138
26192590-3	2015	The beta-carboline alkaloid harmine is a high affinity inhibitor of DYRK1A but suffers from the drawback of inhibiting monoamine oxidase A (MAO-A) with even higher potency.	beta-carboline alkaloid harmine	4-35	monoamine oxidase A	Homo sapiens	140-145
26192590-4	2015	Here we characterized a series of novel harmine analogs with minimal or absent MAO-A inhibitory activity.	Harmine	40-47	monoamine oxidase A	Homo sapiens	79-84
26015071-4	2015	Among smokers with DRD2 rs1079597 GG//MAOA rs309850 3-repeat, the OR of heavier smoking was 2.67 times higher (95% confidence interval [CI]: [1.08, 6.59], p = .031) and the score on the Fagerstrom test for nicotine dependence was higher (4.26 vs. 2.83) than in those with DRD2 rs1079597 AA//MAOA rs309850 3-repeat.	Nicotine	206-214	monoamine oxidase A	Homo sapiens	38-42
26293971-0	2015	Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.	2-Pyrazoline	77-89	monoamine oxidase A	Homo sapiens	33-52
26293971-0	2015	Synthesis and Screening of Human Monoamine Oxidase-A Inhibitor Effect of New 2-Pyrazoline and Hydrazone Derivatives.	Hydrazones	94-103	monoamine oxidase A	Homo sapiens	33-52
26293971-8	2015	Compound 6h showed hMAO-B inhibitory activity whereas the others potently inhibited hMAO-A.	compound 6h	0-11	monoamine oxidase A	Homo sapiens	84-90
26189013-1	2015	A series of methoxylated chalcones with fluoro and trifluoromethyl derivatives were synthesized and investigated for their ability to inhibit human monoamine oxidase A and B.	methoxylated chalcones	12-34	monoamine oxidase A	Homo sapiens	148-173
25581511-3	2015	The C7-substituted alpha-tetralones also were highly potent monoamine oxidase-A inhibitors with thirteen (of fifteen) compounds possessing IC50 values in the submicromolar range (0.010-0.741 mum).	c7-substituted	4-18	monoamine oxidase A	Homo sapiens	60-79
25581511-3	2015	The C7-substituted alpha-tetralones also were highly potent monoamine oxidase-A inhibitors with thirteen (of fifteen) compounds possessing IC50 values in the submicromolar range (0.010-0.741 mum).	alpha-tetralones	19-35	monoamine oxidase A	Homo sapiens	60-79
25581511-4	2015	The alpha-tetralones were, however, in each instance selective for monoamine oxidase-B over the monoamine oxidase-A isoform.	alpha-tetralones	4-20	monoamine oxidase A	Homo sapiens	96-115
26086546-0	2015	Androgen metabolites impact CSF amines and axonal serotonin via MAO-A and -B in male macaques.	Serotonin	50-59	monoamine oxidase A	Homo sapiens	64-69
26086546-1	2015	A number of studies have shown that mutations or deletions of the monoamine oxidase-A (MAO-A) gene cause elevated CNS serotonin and elevated impulsive aggression in humans and animal models.	Serotonin	118-127	monoamine oxidase A	Homo sapiens	66-85
26086546-1	2015	A number of studies have shown that mutations or deletions of the monoamine oxidase-A (MAO-A) gene cause elevated CNS serotonin and elevated impulsive aggression in humans and animal models.	Serotonin	118-127	monoamine oxidase A	Homo sapiens	87-92
26086546-3	2015	To reconcile these different analyses, we hypothesized that CSF 5HIAA reflected degradation of serotonin by the activity of MAO-A; and that low MAO-A activity would result in lower CSF 5HIAA, but overall higher serotonin in the CNS.	Hydroxyindoleacetic Acid	185-190	monoamine oxidase A	Homo sapiens	144-149
26086546-3	2015	To reconcile these different analyses, we hypothesized that CSF 5HIAA reflected degradation of serotonin by the activity of MAO-A; and that low MAO-A activity would result in lower CSF 5HIAA, but overall higher serotonin in the CNS.	Serotonin	211-220	monoamine oxidase A	Homo sapiens	144-149
26086546-11	2015	CSF 5HIAA was positively correlated with MAO-A-positive pixel area (r(2)=0.78).	Hydroxyindoleacetic Acid	4-9	monoamine oxidase A	Homo sapiens	41-46
26086546-13	2015	In summary, CSF 5HIAA reflects MAO-A activity rather than global serotonin.	Hydroxyindoleacetic Acid	16-21	monoamine oxidase A	Homo sapiens	31-36
26086546-15	2015	Androgens lower MAO-A activity via metabolism to E, thus elevating CNS serotonin and decreasing CSF 5HIAA.	Serotonin	71-80	monoamine oxidase A	Homo sapiens	16-21
26086546-15	2015	Androgens lower MAO-A activity via metabolism to E, thus elevating CNS serotonin and decreasing CSF 5HIAA.	Hydroxyindoleacetic Acid	100-105	monoamine oxidase A	Homo sapiens	16-21
26086546-16	2015	Since androgens increase certain types of aggression, these data are consistent with studies demonstrating that lower MAO-A activity is associated with elevated serotonin and increased aggression.	Serotonin	161-170	monoamine oxidase A	Homo sapiens	118-123
25755053-6	2015	After pre-incubation of the cyclopropylamine with the enzyme, the inhibition was irreversible for both MAO A and MAO B, and the activity was not restored by dilution.	cyclopropylamine	28-44	monoamine oxidase A	Homo sapiens	103-108
25755053-7	2015	Spectral changes during inactivation of MAO A included bleaching at 456 nm and an increased absorbance at 400 nm, consistent with flavin modification.	4,6-dinitro-o-cresol	130-136	monoamine oxidase A	Homo sapiens	40-45
25755053-9	2015	The best inhibitor was cis-N-benzyl-2-methoxycyclopropylamine, with an IC50 of 5 nm for MAO B and 170 nm for MAO A after 30 min pre-incubation.	cis-N-benzyl-2-methoxycyclopropylamine	23-61	monoamine oxidase A	Homo sapiens	109-114
25922182-7	2015	2-(2-(Benzo[d][1,3]dioxol-5-yl)-4-oxo-1,2-dihydroquinazolin-3(4H)-yl)acetohydrazide 15 showed selective MAO-A inhibition activity (SI=39524) superior to that of the standard clorgyline (SI=33793).	2-(2-(benzo[d][1,3]dioxol-5-yl)-4-oxo-1,2-dihydroquinazolin-3(4h)-yl)acetohydrazide	0-83	monoamine oxidase A	Homo sapiens	104-109
25349169-2	2015	Our results, from two independent cohorts of Finnish prisoners, revealed that a monoamine oxidase A (MAOA) low-activity genotype (contributing to low dopamine turnover rate) as well as the CDH13 gene (coding for neuronal membrane adhesion protein) are associated with extremely violent behavior (at least 10 committed homicides, attempted homicides or batteries).	Dopamine	150-158	monoamine oxidase A	Homo sapiens	101-105
24451655-1	2015	Up to now, it remains unclear how monoamine oxidase A (MAOA), which has been repeatedly linked to aggression, affects brain activity within resting-state networks (RSN).	(3~{S})-3-azanyl-4-[[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxysulfonylamino]-4-oxidanylidene-butanoic acid	164-167	monoamine oxidase A	Homo sapiens	34-53
24451655-1	2015	Up to now, it remains unclear how monoamine oxidase A (MAOA), which has been repeatedly linked to aggression, affects brain activity within resting-state networks (RSN).	(3~{S})-3-azanyl-4-[[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxysulfonylamino]-4-oxidanylidene-butanoic acid	164-167	monoamine oxidase A	Homo sapiens	55-59
24451655-2	2015	Here, we used functional magnetic resonance imaging (fMRI) to test whether the MAOA genotype might influence activity within the common RSN.	(3~{S})-3-azanyl-4-[[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxysulfonylamino]-4-oxidanylidene-butanoic acid	136-139	monoamine oxidase A	Homo sapiens	79-83
24451655-4	2015	The executive control and salience RSN revealed reduced activity for the MAOA-L group in several areas related to executive control, namely the right middle frontal gyrus (BA 6 and BA 9), and the dorsal part of the anterior cingulate cortex.	(3~{S})-3-azanyl-4-[[(2~{R},3~{S},4~{R},5~{R})-5-[7-azanyl-5-(hydroxymethyl)benzimidazol-1-yl]-3,4-bis(oxidanyl)oxolan-2-yl]methoxysulfonylamino]-4-oxidanylidene-butanoic acid	35-38	monoamine oxidase A	Homo sapiens	73-77
24451655-5	2015	Participants with the high-activity genotype (MAOA-H) showed increased activity in the posterior cingulate part of the DMN.	2,3-dimethylnaphthalene	119-122	monoamine oxidase A	Homo sapiens	46-50
25810277-8	2015	Tumor necrosis factor-alpha and forskolin activated MAOA transcription that was reversed by Sp1 siRNA; in support, tumor necrosis factor-alpha- and forskolin-induced activities were enhanced by ectopic over-expression of Sp1.	Colforsin	32-41	monoamine oxidase A	Homo sapiens	52-56
25810277-8	2015	Tumor necrosis factor-alpha and forskolin activated MAOA transcription that was reversed by Sp1 siRNA; in support, tumor necrosis factor-alpha- and forskolin-induced activities were enhanced by ectopic over-expression of Sp1.	Colforsin	148-157	monoamine oxidase A	Homo sapiens	52-56
25346381-5	2015	Furthermore, compound XZ09 exhibited less inhibition against the homologous monoamine oxidase A (MAO-A) and B (MAO-B) displaying its moderate selectivity.	XZ09	22-26	monoamine oxidase A	Homo sapiens	76-95
25346381-5	2015	Furthermore, compound XZ09 exhibited less inhibition against the homologous monoamine oxidase A (MAO-A) and B (MAO-B) displaying its moderate selectivity.	XZ09	22-26	monoamine oxidase A	Homo sapiens	97-109
25964750-8	2015	To determine whether a pharmacological stressor, dexamethasone (Dex), will result in similar biochemical results obtained from MS, we used an in vitro system, SH-SY5Y cells, and found that Dex treatment resulted in increased MAO A expression levels.	Dexamethasone	49-62	monoamine oxidase A	Homo sapiens	225-230
25770611-0	2015	Biosensor based on inhibition of monoamine oxidases A and B for detection of beta-carbolines.	Carbolines	77-92	monoamine oxidase A	Homo sapiens	33-59
25770611-1	2015	beta-Carbolines are inhibitors of monoamine oxidases (MAO-A and MAO-B) and can be found in foods, hallucinogenic plant or various drugs.	Carbolines	0-15	monoamine oxidase A	Homo sapiens	54-59
25770611-6	2015	The MAO-A is inhibited by all three tested beta-carbolines (harmane, norharmane, and harmaline) while MAO-B is inhibited only by norharmane.	Carbolines	43-58	monoamine oxidase A	Homo sapiens	4-9
25770611-6	2015	The MAO-A is inhibited by all three tested beta-carbolines (harmane, norharmane, and harmaline) while MAO-B is inhibited only by norharmane.	harman	60-67	monoamine oxidase A	Homo sapiens	4-9
25770611-6	2015	The MAO-A is inhibited by all three tested beta-carbolines (harmane, norharmane, and harmaline) while MAO-B is inhibited only by norharmane.	norharman	69-79	monoamine oxidase A	Homo sapiens	4-9
25770611-6	2015	The MAO-A is inhibited by all three tested beta-carbolines (harmane, norharmane, and harmaline) while MAO-B is inhibited only by norharmane.	Harmaline	85-94	monoamine oxidase A	Homo sapiens	4-9
25770611-7	2015	The presence of norharmane in mixtures of beta-carbolines can be identified based on the difference between the cumulative inhibition of MAO-A by all beta-carbolines and MAO-B inhibition.	norharman	16-26	monoamine oxidase A	Homo sapiens	137-142
25466703-3	2015	METHODS: In this study, we investigated the effects of both nicotine (6-mg gum) and pharmacologically induced MAO-A inhibition via moclobemide (75 mg) on P50 event-related potential-indexed sensory gating in a sample of 24 healthy non-smoking males.	Moclobemide	131-142	monoamine oxidase A	Homo sapiens	110-115
25466703-4	2015	RESULTS: Ratio score (rP50) measured gating revealed significant improvement in auditory stimulus suppression after combined nicotine and MAO-A inhibition compared to placebo and to the nicotine-alone condition.	Nicotine	186-194	monoamine oxidase A	Homo sapiens	138-143
25466703-5	2015	This nicotine + MAO-A inhibition-induced efficient gating was consistent regardless of participants" baseline (placebo) gating efficiency, despite the observation that nicotine in the absence of MAO-A inhibition exhibited a detrimental effect on gating in participants with high baseline suppression ratios.	Nicotine	168-176	monoamine oxidase A	Homo sapiens	16-21
25820651-2	2015	Based on the structural similarity between alpha-tetralone and 1-indanone, the present study involved synthesis of 34 1-indanone and related indane derivatives as potential inhibitors of recombinant human MAO-A and MAO-B.	Tetralones	43-58	monoamine oxidase A	Homo sapiens	205-210
25820651-2	2015	Based on the structural similarity between alpha-tetralone and 1-indanone, the present study involved synthesis of 34 1-indanone and related indane derivatives as potential inhibitors of recombinant human MAO-A and MAO-B.	indacrinone	63-73	monoamine oxidase A	Homo sapiens	205-210
25820651-2	2015	Based on the structural similarity between alpha-tetralone and 1-indanone, the present study involved synthesis of 34 1-indanone and related indane derivatives as potential inhibitors of recombinant human MAO-A and MAO-B.	indacrinone	118-128	monoamine oxidase A	Homo sapiens	205-210
25820651-2	2015	Based on the structural similarity between alpha-tetralone and 1-indanone, the present study involved synthesis of 34 1-indanone and related indane derivatives as potential inhibitors of recombinant human MAO-A and MAO-B.	indan	141-147	monoamine oxidase A	Homo sapiens	205-210
25770611-7	2015	The presence of norharmane in mixtures of beta-carbolines can be identified based on the difference between the cumulative inhibition of MAO-A by all beta-carbolines and MAO-B inhibition.	Carbolines	42-57	monoamine oxidase A	Homo sapiens	137-142
25770611-7	2015	The presence of norharmane in mixtures of beta-carbolines can be identified based on the difference between the cumulative inhibition of MAO-A by all beta-carbolines and MAO-B inhibition.	Carbolines	150-165	monoamine oxidase A	Homo sapiens	137-142
25701103-6	2015	The N-substituted-glycinyl 1H-1,2,3-triazolyl methyl oxazolidinones with potent antibacterial activity demonstrated only weak to moderate affinity for MAO-A and -B, supporting further investigation for this group of compounds.	n-substituted-glycinyl 1h-1,2,3-triazolyl methyl oxazolidinones	4-67	monoamine oxidase A	Homo sapiens	151-163
25964750-8	2015	To determine whether a pharmacological stressor, dexamethasone (Dex), will result in similar biochemical results obtained from MS, we used an in vitro system, SH-SY5Y cells, and found that Dex treatment resulted in increased MAO A expression levels.	Dexamethasone	189-192	monoamine oxidase A	Homo sapiens	225-230
25707011-0	2015	Exploring new selective 3-benzylquinoxaline-based MAO-A inhibitors: design, synthesis, biological evaluation and docking studies.	3-benzylquinoxaline	24-43	monoamine oxidase A	Homo sapiens	50-55
25857233-1	2015	The human cytochrome P450 2A6 (CYP2A6) and monoamine oxidases (MAO-A and MAO-B), catalyzing nicotine and dopamine metabolisms, respectively, are two therapeutic targets of nicotine dependence.	Nicotine	92-100	monoamine oxidase A	Homo sapiens	63-68
25857233-1	2015	The human cytochrome P450 2A6 (CYP2A6) and monoamine oxidases (MAO-A and MAO-B), catalyzing nicotine and dopamine metabolisms, respectively, are two therapeutic targets of nicotine dependence.	Dopamine	105-113	monoamine oxidase A	Homo sapiens	63-68
25857233-1	2015	The human cytochrome P450 2A6 (CYP2A6) and monoamine oxidases (MAO-A and MAO-B), catalyzing nicotine and dopamine metabolisms, respectively, are two therapeutic targets of nicotine dependence.	Nicotine	172-180	monoamine oxidase A	Homo sapiens	63-68
25857233-3	2015	In the present study, we found eight active compounds isolated from V. cinerea that comprise inhibitory activity toward CYP2A6 and MAO-A and MAO-B enzymes using activity-guided assays, with coumarin as substrate of CYP2A6 and kynuramine of MAOs.	coumarin	190-198	monoamine oxidase A	Homo sapiens	131-136
25857233-3	2015	In the present study, we found eight active compounds isolated from V. cinerea that comprise inhibitory activity toward CYP2A6 and MAO-A and MAO-B enzymes using activity-guided assays, with coumarin as substrate of CYP2A6 and kynuramine of MAOs.	Kynuramine	226-236	monoamine oxidase A	Homo sapiens	131-136
25857233-8	2015	Flavonoids inhibited MAOs with variable degrees and were more prominent in inhibition toward MAO-A than hirsutinolides, while two of hirsutinolides inhibited MAO-B approximately comparable to two flavonoids.	Flavonoids	0-10	monoamine oxidase A	Homo sapiens	93-98
25613051-9	2015	Methylene blue and its metabolite, azure B, are potent, reversible inhibitors of monoamine oxidase A which is responsible for serotonin metabolism.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	81-100
25613051-9	2015	Methylene blue and its metabolite, azure B, are potent, reversible inhibitors of monoamine oxidase A which is responsible for serotonin metabolism.	Serotonin	126-135	monoamine oxidase A	Homo sapiens	81-100
25707011-1	2015	In this investigation, we searched for novel MAO-A inhibitors using a 3-benzylquinoxaline scaffold based on our earlier findings.	3-benzylquinoxaline	70-89	monoamine oxidase A	Homo sapiens	45-50
25701250-1	2015	Recent studies have found that phthalonitrile derivatives are remarkably potent inhibitors of human monoamine oxidase (MAO) A and B.	1,2-benzenedicarbonitrile	31-45	monoamine oxidase A	Homo sapiens	100-131
25701250-4	2015	For example, 3-chloro-2-(4-methylphenyl)-1H-indole-5,6-dicarbonitrile inhibited MAO-A and MAO-B with IC50 values of 0.014muM and 0.017muM, respectively.	CHEMBL3398531	13-69	monoamine oxidase A	Homo sapiens	80-85
25978392-2	2015	MAO, catalyzing the reaction of oxidative deamination of major neurotransmitter monoamines, exists in two highly homologous forms, MAO A and MAO B, distinguished by substrate specificity and inhibitor selectivity.	monoamines	80-90	monoamine oxidase A	Homo sapiens	131-136
25594603-0	2015	Parameter evaluation and fully-automated radiosynthesis of [(11)C]harmine for imaging of MAO-A for clinical trials.	[(11)c]harmine	59-73	monoamine oxidase A	Homo sapiens	89-94
25585152-2	2015	Monoamine oxidase A (MAOA), a mitochondria-bound enzyme, degrades monoamine neurotransmitters and dietary monoamines.	monoamine	66-75	monoamine oxidase A	Homo sapiens	0-19
25733484-3	2015	MAOA metabolizes monoamine neurotransmitters.	monoamine	17-26	monoamine oxidase A	Homo sapiens	0-4
25733484-9	2015	RESULTS: Infant monkeys with low-transcription MAOA polymorphisms more clearly demonstrated the following ID effects suggested in earlier studies: a 4% smaller head circumference, a 39% lower cortisol response to social separation, a 129% longer engagement with novel visual stimuli, and 33% lesser withdrawal in response to a human intruder.	Hydrocortisone	192-200	monoamine oxidase A	Homo sapiens	47-51
25794322-5	2015	METHODS: The MAOA genotype was determined in 371 male alcohol-dependent subjects and 236 male controls all of German descent.	Alcohols	54-61	monoamine oxidase A	Homo sapiens	13-17
25713771-4	2015	Harmaline, one of the main components of ayahuasca, is a selective and reversible MAO-A inhibitor and a serotonin reuptake inhibitor.	Harmaline	0-9	monoamine oxidase A	Homo sapiens	82-87
25585152-2	2015	Monoamine oxidase A (MAOA), a mitochondria-bound enzyme, degrades monoamine neurotransmitters and dietary monoamines.	monoamine	66-75	monoamine oxidase A	Homo sapiens	21-25
25585152-2	2015	Monoamine oxidase A (MAOA), a mitochondria-bound enzyme, degrades monoamine neurotransmitters and dietary monoamines.	monoamines	106-116	monoamine oxidase A	Homo sapiens	0-19
25585152-2	2015	Monoamine oxidase A (MAOA), a mitochondria-bound enzyme, degrades monoamine neurotransmitters and dietary monoamines.	monoamines	106-116	monoamine oxidase A	Homo sapiens	21-25
25585152-4	2015	MAOA induces epithelial-mesenchymal transition (EMT) and augments hypoxic effects by producing excess reactive oxygen species.	Reactive Oxygen Species	102-125	monoamine oxidase A	Homo sapiens	0-4
25585152-6	2015	Here we describe the design, synthesis, and in vitro and in vivo evaluation of NMI, a conjugate that combines a near-infrared dye for tumor targeting with the moiety derived from the MAOA inhibitor clorgyline.	Clorgyline	198-208	monoamine oxidase A	Homo sapiens	183-187
24809685-10	2015	However, the presently observed trend towards CpG-specific MAO-A gene hypomethylation-possibly via increased gene expression and consecutively decreased serotonin and/or norepinephrine availability-to potentially drive impaired antidepressant treatment response in female patients might be worthwhile to be followed up in larger pharmacoepigenetic studies.	Serotonin	153-162	monoamine oxidase A	Homo sapiens	59-64
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	imidazolyl	160-170	monoamine oxidase A	Homo sapiens	31-37
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	imidazolyl	160-170	monoamine oxidase A	Homo sapiens	32-37
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	2-Pyrazoline	266-278	monoamine oxidase A	Homo sapiens	31-37
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	2-Pyrazoline	266-278	monoamine oxidase A	Homo sapiens	32-37
25541201-4	2015	Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively.	7,8-diacetoxy-3-(4-nitrophenyl)coumarin	40-42	monoamine oxidase A	Homo sapiens	72-78
25541201-4	2015	Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively.	Hydrogen	87-95	monoamine oxidase A	Homo sapiens	72-78
25541201-4	2015	Molecular docking showed that compounds 7h and 12c were nicely bound to hMAO-A via two hydrogen bonds (SER209, GLU216), one Pi-Pi interaction and three hydrogen bonds (SER209, GLU216, TYR69), one Sigma-Pi interaction, respectively.	Hydrogen	152-160	monoamine oxidase A	Homo sapiens	72-78
25541203-0	2015	Selective binding to monoamine oxidase A: in vitro and in vivo evaluation of (18)F-labeled beta-carboline derivatives.	norharman	91-105	monoamine oxidase A	Homo sapiens	21-40
25541203-12	2015	In vitro binding assays revealed that 2-[(18)F]fluoroethyl-harmol (IC50=0.54+-0.06 nM) has a higher affinity than the (18)F-fluoro-d2-methylated ligand (IC50=12.2+-0.6 nM), making 2-[(18)F]fluoroethyl-harmol superior to the other evaluated compounds and a promising tracer for PET imaging of the MAO A.	2-[(18)f]fluoroethyl-harmol	38-65	monoamine oxidase A	Homo sapiens	296-301
25541203-12	2015	In vitro binding assays revealed that 2-[(18)F]fluoroethyl-harmol (IC50=0.54+-0.06 nM) has a higher affinity than the (18)F-fluoro-d2-methylated ligand (IC50=12.2+-0.6 nM), making 2-[(18)F]fluoroethyl-harmol superior to the other evaluated compounds and a promising tracer for PET imaging of the MAO A.	-fluoro-d2	123-133	monoamine oxidase A	Homo sapiens	296-301
26557867-0	2015	Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.	bavachinin	40-50	monoamine oxidase A	Homo sapiens	73-99
26557867-0	2015	Evaluation of the Inhibitory Effects of Bavachinin and Bavachin on Human Monoamine Oxidases A and B.	bavachin	40-48	monoamine oxidase A	Homo sapiens	73-99
26557867-7	2015	BNN competitively inhibited hMAO-A and hMAO-B, with a lower hMAO-B K i than hMAO-A K i by 10.33-fold, and reduced hMAO-B K m /V max efficiency ratio to be comparable to the standard selegiline.	bavachinin	0-3	monoamine oxidase A	Homo sapiens	28-34
26557867-7	2015	BNN competitively inhibited hMAO-A and hMAO-B, with a lower hMAO-B K i than hMAO-A K i by 10.33-fold, and reduced hMAO-B K m /V max efficiency ratio to be comparable to the standard selegiline.	bavachinin	0-3	monoamine oxidase A	Homo sapiens	76-82
25541201-2	2015	Among them, compounds 7h (IC50=2.40 muM) and 12c (IC50=2.00 muM) exhibited best inhibitory activity and selectivity against hMAO-A, surpassing that of the positive control Clorgyline (IC50=2.76 muM).	Clorgyline	172-182	monoamine oxidase A	Homo sapiens	124-130
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	piperidino	122-133	monoamine oxidase A	Homo sapiens	31-37
25541201-3	2015	Based on selective activity of hMAO-A, SAR analysis showed that the order of N1 substituent contribution was bromo (3)&gt;piperidinyl (4)&gt;morpholinyl (5)&gt;imidazolyl (6), and compounds with electron-withdrawing substituents (-F, -Cl) at C3 or C5 phenyl ring of 2-pyrazoline nucleus dedicated stronger MAO-A inhibitory activity.	piperidino	122-133	monoamine oxidase A	Homo sapiens	32-37
25249059-0	2015	Evidence that formulations of the selective MAO-B inhibitor, selegiline, which bypass first-pass metabolism, also inhibit MAO-A in the human brain.	Selegiline	61-71	monoamine oxidase A	Homo sapiens	122-127
25249059-7	2015	The 10 mg Zydis selegiline dose significantly inhibited MAO-A (36.9+-19.7%, range 11-70%, p&lt;0.007)) but not DAT; and while Emsam also inhibited MAO-A (33.2+-28.9 (range 9-68%) the difference did not reach significance (p=0.10)) presumably because of the small sample size.	Selegiline	16-26	monoamine oxidase A	Homo sapiens	56-61
25249059-7	2015	The 10 mg Zydis selegiline dose significantly inhibited MAO-A (36.9+-19.7%, range 11-70%, p&lt;0.007)) but not DAT; and while Emsam also inhibited MAO-A (33.2+-28.9 (range 9-68%) the difference did not reach significance (p=0.10)) presumably because of the small sample size.	Selegiline	16-26	monoamine oxidase A	Homo sapiens	147-152
25249059-8	2015	Our results provide the first direct evidence of brain MAO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verified to target brain MAO-A in addition to MAO-B.	Selegiline	101-111	monoamine oxidase A	Homo sapiens	55-60
25249059-8	2015	Our results provide the first direct evidence of brain MAO-A inhibition in humans by formulations of selegiline, which are currently postulated but not verified to target brain MAO-A in addition to MAO-B.	Selegiline	101-111	monoamine oxidase A	Homo sapiens	177-182
25242620-10	2015	Finally, plasma 5-HIAA increased in AS patients (74.64 +- 9.7 nM vs. 37.16 +- 4.1 nM; P = 0.0002) indicating a higher 5-HT degradation rate by MAO-A.	Hydroxyindoleacetic Acid	16-22	monoamine oxidase A	Homo sapiens	143-148
24809685-10	2015	However, the presently observed trend towards CpG-specific MAO-A gene hypomethylation-possibly via increased gene expression and consecutively decreased serotonin and/or norepinephrine availability-to potentially drive impaired antidepressant treatment response in female patients might be worthwhile to be followed up in larger pharmacoepigenetic studies.	Norepinephrine	170-184	monoamine oxidase A	Homo sapiens	59-64
25152370-0	2014	The monoamine oxidase-A inhibitor clorgyline promotes a mesenchymal-to-epithelial transition in the MDA-MB-231 breast cancer cell line.	Clorgyline	34-44	monoamine oxidase A	Homo sapiens	4-23
25541744-3	2015	MAO-A is related with metabolism of amine neurotransmitters in the brain whereas MAO-B is concerned with aging related neurodegenerative disorders.	Amines	36-41	monoamine oxidase A	Homo sapiens	0-5
25544115-3	2015	The compounds showed enhanced inhibition against MAO-A &amp; B as compared to reference compounds.	Adenosine Monophosphate	56-59	monoamine oxidase A	Homo sapiens	49-54
25544115-5	2015	The present investigation demonstrated that among piperidyl-thienyl chalcones, almost all the compounds exhibit significant MAO-A inhibition, thus may have antidepressant activity.	piperidyl-thienyl chalcones	50-77	monoamine oxidase A	Homo sapiens	124-129
25074638-3	2015	MAO-A is an enzyme that increases in density after estrogen decline, and has several functions including creating oxidative stress, influencing apoptosis and monoamine metabolism.	monoamine	158-167	monoamine oxidase A	Homo sapiens	0-5
24817649-9	2014	The major metabolic pathway was determined to be conversion into 5-hydroxyindole acetaldehyde catalyzed by the monoamine oxidase A (MAO-A).	hydroxyindoleacetaldehyde	65-93	monoamine oxidase A	Homo sapiens	111-130
24817649-9	2014	The major metabolic pathway was determined to be conversion into 5-hydroxyindole acetaldehyde catalyzed by the monoamine oxidase A (MAO-A).	hydroxyindoleacetaldehyde	65-93	monoamine oxidase A	Homo sapiens	132-137
26116123-0	2014	Strategy to develop a MAO-A-resistant 5-hydroxy-L-[beta-(11)C]tryptophan isotopologue based on deuterium kinetic isotope effects.	5-hydroxy-L-(beta-11C)tryptophan	38-72	monoamine oxidase A	Homo sapiens	22-27
26116123-0	2014	Strategy to develop a MAO-A-resistant 5-hydroxy-L-[beta-(11)C]tryptophan isotopologue based on deuterium kinetic isotope effects.	Deuterium	95-104	monoamine oxidase A	Homo sapiens	22-27
26116123-3	2014	METHODS: A synthesis method was developed for 5-hydroxy-L-[beta- (11)C(2)H]tryptophan ([(11)C]DHTP), an isotopologue of [(11)C]HTP, labeled with (11)C and (2)H at the beta-position adjacent to the carbon involved in MAO-A decarboxylation.	(2)h]tryptophan	70-85	monoamine oxidase A	Homo sapiens	216-221
26116123-3	2014	METHODS: A synthesis method was developed for 5-hydroxy-L-[beta- (11)C(2)H]tryptophan ([(11)C]DHTP), an isotopologue of [(11)C]HTP, labeled with (11)C and (2)H at the beta-position adjacent to the carbon involved in MAO-A decarboxylation.	5-hydroxy-l-[beta- (11)c	46-70	monoamine oxidase A	Homo sapiens	216-221
26116123-4	2014	MAO-A-mediated degradation of [(11)C]DHTP was evaluated and compared to non-deuterated [(11)C]HTP.	dihydrotestosterone propionate	37-41	monoamine oxidase A	Homo sapiens	0-5
25220264-1	2014	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines such as dopamine, serotonin and noradrenaline.	Amines	94-100	monoamine oxidase A	Homo sapiens	0-33
26116123-6	2014	Retention and resistance to MAO-A-mediated degradation of [(11)C]DHTP were increased in cells but not in non-human primate pancreas.	dihydrotestosterone propionate	65-69	monoamine oxidase A	Homo sapiens	28-33
25455893-6	2014	Trends regarding MAO A inhibition were explored among structural analogs, yielding the following ranking: amphetamine (Ki = 5.3 microM), AEPEA (Ki = 14.0 microM), methamphetamine (Ki = 17.2 microM), phentermine (Ki = 196 microM), and N,alpha-DEPEA (Ki = 251 microM).	Amphetamine	106-117	monoamine oxidase A	Homo sapiens	17-22
25455893-6	2014	Trends regarding MAO A inhibition were explored among structural analogs, yielding the following ranking: amphetamine (Ki = 5.3 microM), AEPEA (Ki = 14.0 microM), methamphetamine (Ki = 17.2 microM), phentermine (Ki = 196 microM), and N,alpha-DEPEA (Ki = 251 microM).	Methamphetamine	163-178	monoamine oxidase A	Homo sapiens	17-22
24356376-1	2014	Expression levels of monoamine oxidase A (MAOA), the enzyme that related to monoamine neurotransmitters metabolism such as serotonin, are related to schizophrenia and autism spectrum disorder.	monoamine	21-30	monoamine oxidase A	Homo sapiens	42-46
24356376-1	2014	Expression levels of monoamine oxidase A (MAOA), the enzyme that related to monoamine neurotransmitters metabolism such as serotonin, are related to schizophrenia and autism spectrum disorder.	Serotonin	123-132	monoamine oxidase A	Homo sapiens	21-40
24356376-1	2014	Expression levels of monoamine oxidase A (MAOA), the enzyme that related to monoamine neurotransmitters metabolism such as serotonin, are related to schizophrenia and autism spectrum disorder.	Serotonin	123-132	monoamine oxidase A	Homo sapiens	42-46
25455893-6	2014	Trends regarding MAO A inhibition were explored among structural analogs, yielding the following ranking: amphetamine (Ki = 5.3 microM), AEPEA (Ki = 14.0 microM), methamphetamine (Ki = 17.2 microM), phentermine (Ki = 196 microM), and N,alpha-DEPEA (Ki = 251 microM).	Phentermine	199-210	monoamine oxidase A	Homo sapiens	17-22
25455893-6	2014	Trends regarding MAO A inhibition were explored among structural analogs, yielding the following ranking: amphetamine (Ki = 5.3 microM), AEPEA (Ki = 14.0 microM), methamphetamine (Ki = 17.2 microM), phentermine (Ki = 196 microM), and N,alpha-DEPEA (Ki = 251 microM).	-depea	241-247	monoamine oxidase A	Homo sapiens	17-22
25227605-0	2014	[11C]befloxatone distribution is well correlated to monoamine oxidase A protein levels in the human brain.	Carbon-11	1-4	monoamine oxidase A	Homo sapiens	52-71
25227605-0	2014	[11C]befloxatone distribution is well correlated to monoamine oxidase A protein levels in the human brain.	befloxatone	5-16	monoamine oxidase A	Homo sapiens	52-71
25227605-1	2014	[(11)C]befloxatone is a positron emission tomography radioligand to image monoamine oxidase A (MAO-A) in the brain, which has been used in preclinical studies and in clinical protocols.	befloxatone	7-18	monoamine oxidase A	Homo sapiens	74-93
25227605-1	2014	[(11)C]befloxatone is a positron emission tomography radioligand to image monoamine oxidase A (MAO-A) in the brain, which has been used in preclinical studies and in clinical protocols.	befloxatone	7-18	monoamine oxidase A	Homo sapiens	95-100
25227605-2	2014	However, a recent study found that [(11)C]befloxatone binding potential (k(3)/k(4)) has a poor correlation with MAO-A protein levels measured in the human brain.	[(11)c]befloxatone	35-53	monoamine oxidase A	Homo sapiens	112-117
25227605-4	2014	In particular, the total volume of distribution of [(11)C]befloxatone shows a tight correlation with both protein and mRNA levels of MAO-A in the human brain.	[(11)c]befloxatone	51-69	monoamine oxidase A	Homo sapiens	133-138
25185897-0	2014	Imaging of monoamine oxidase-A in the human brain with [11C]befloxatone: quantification strategies and correlation with mRNA transcription maps.	[11C](5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	55-71	monoamine oxidase A	Homo sapiens	11-30
25185897-1	2014	INTRODUCTION: [C]Befloxatone is a highly specific, reversible, and selective radioligand for brain PET imaging of monoamine oxidase-A and can be quantified by a two-tissue compartment model (2TCM) and an arterial input function.	befloxatone	17-28	monoamine oxidase A	Homo sapiens	114-133
25220264-1	2014	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines such as dopamine, serotonin and noradrenaline.	Dopamine	109-117	monoamine oxidase A	Homo sapiens	0-33
25220264-1	2014	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines such as dopamine, serotonin and noradrenaline.	Serotonin	119-128	monoamine oxidase A	Homo sapiens	0-33
25220264-1	2014	Monoamine oxidases (MAOs) A and B are flavoenzymes responsible for the metabolism of biogenic amines such as dopamine, serotonin and noradrenaline.	Norepinephrine	133-146	monoamine oxidase A	Homo sapiens	0-33
25253656-0	2014	Profiling substrate specificity of two series of phenethylamine analogs at monoamine oxidase A and B.	phenethylamine	49-63	monoamine oxidase A	Homo sapiens	75-100
25253656-1	2014	The membrane bound enzyme monoamine oxidase exist in two splice variants designated A and B (MAO-A and MAO-B) and are key players in the oxidative metabolism of monoamines in mammalians.	monoamines	161-171	monoamine oxidase A	Homo sapiens	93-98
25253656-3	2014	In this study we present a systematic study of the MAO-A and MAO-B substrate specificity profile by probing two series of phenethylamine analogs.	phenethylamine	122-136	monoamine oxidase A	Homo sapiens	51-56
25253656-4	2014	Km and kcat values were determined for four N-alkyl analogs 2-5 and four aryl halide analogs 6-9 at MAO-A and MAO-B.	Nitrogen	44-45	monoamine oxidase A	Homo sapiens	100-105
25253656-4	2014	Km and kcat values were determined for four N-alkyl analogs 2-5 and four aryl halide analogs 6-9 at MAO-A and MAO-B.	aryl halide	73-84	monoamine oxidase A	Homo sapiens	100-105
25412041-4	2014	The dichloromethane extract of propolis showed potent inhibition of human MAO-A and MAO-B.	Methylene Chloride	4-19	monoamine oxidase A	Homo sapiens	74-79
24452523-1	2014	28 new 3-(4-fluorophenyl)-5-aryl-N-substituted-4,5-dihydro-1H-pyrazole-1-carbothioamide derivatives were synthesized and evaluated in vitro for their monoamine oxidase (MAO) A and B inhibitory activity and selectivity.	3-(4-fluorophenyl)-5-aryl-n-substituted-4,5-dihydro-1h-pyrazole-1-carbothioamide	7-87	monoamine oxidase A	Homo sapiens	150-181
25445435-10	2014	Small structural changes made to MB retain its antidepressant effect, even though the resulting phenothiazinium compound possesses reduced MAO-A inhibitory potency.	phenothiazinium	96-111	monoamine oxidase A	Homo sapiens	139-144
25405283-2	2014	In this paper, a series of 2-phenoxyacetamide analogues were synthesized, and their inhibitory potency towards monoamine oxidases A (MAO-A) and B (MAO-B) were evaluated using enzyme and cancer cell lysate.	2-Phenoxyacetamide	27-45	monoamine oxidase A	Homo sapiens	111-131
25405283-2	2014	In this paper, a series of 2-phenoxyacetamide analogues were synthesized, and their inhibitory potency towards monoamine oxidases A (MAO-A) and B (MAO-B) were evaluated using enzyme and cancer cell lysate.	2-Phenoxyacetamide	27-45	monoamine oxidase A	Homo sapiens	133-145
24452523-2	2014	The derivatives substituted by halogen on the fifth position of pyrazole ring, inhibited MAO-A enzyme with a high selectivity index.	Halogens	31-38	monoamine oxidase A	Homo sapiens	89-94
24452523-2	2014	The derivatives substituted by halogen on the fifth position of pyrazole ring, inhibited MAO-A enzyme with a high selectivity index.	pyrazole	64-72	monoamine oxidase A	Homo sapiens	89-94
25196265-5	2014	There is some recent evidence to suggest rasagiline also has monoamine oxidase-A (MAO-A) inhibiting properties, as well as different clinical and pharmacodynamic properties when compared with selegiline, and clinical benefits when used in combination with a dopamine agonist monotherapy.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	61-80
25173853-4	2014	The molecules were all found to covalently inhibit KDM1A and to become increasingly selective against human monoamine oxidases MAO A and MAO B through the introduction of bulkier substituents on the cyclopropylamine ring.	cyclopropylamine	199-215	monoamine oxidase A	Homo sapiens	127-132
25240617-4	2014	Furthermore we identified a modified lead structure as a potent DYRK1A inhibitor (IC50=130 nM) with significant selectivity against MAO-A, DYRK2, DYRK3, DYRK4 &amp; CLK2.	Adenosine Monophosphate	160-163	monoamine oxidase A	Homo sapiens	132-137
25378907-2	2014	The 3D-quantitative structure-activity relationship study was used to define 3D-pharmacophores for inhibition of MAO A/B, acetylcholinesterase (AChE), and butyrylcholinesterase (BuChE) enzymes and to design DPHs as novel multi-target drug candidates with potential impact in the therapy of AD.	dphs	207-211	monoamine oxidase A	Homo sapiens	113-120
25378907-6	2014	Concerning human monoamine oxidase (hMAO) A inhibition, only DPH9 and 5 proved active, compound DPH9 being the most potent (IC50 [MAO A] =5,700+-2,100 nM).	dph9	96-100	monoamine oxidase A	Homo sapiens	130-135
25196265-5	2014	There is some recent evidence to suggest rasagiline also has monoamine oxidase-A (MAO-A) inhibiting properties, as well as different clinical and pharmacodynamic properties when compared with selegiline, and clinical benefits when used in combination with a dopamine agonist monotherapy.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	82-87
25198178-6	2014	In vitro, cytotoxic chemotherapy induced the expression of MAOA and elevated MAOA levels enhanced cell survival following docetaxel exposure.	Docetaxel	122-131	monoamine oxidase A	Homo sapiens	59-63
23761378-1	2014	OBJECTIVES: Monoamine oxidase A (MAOA) modulates metabolism of serotonin and dopamine metabolism, neurotransmitters involved in regulation of appetite and food intake.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	12-31
23761378-1	2014	OBJECTIVES: Monoamine oxidase A (MAOA) modulates metabolism of serotonin and dopamine metabolism, neurotransmitters involved in regulation of appetite and food intake.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	33-37
23761378-1	2014	OBJECTIVES: Monoamine oxidase A (MAOA) modulates metabolism of serotonin and dopamine metabolism, neurotransmitters involved in regulation of appetite and food intake.	Dopamine	77-85	monoamine oxidase A	Homo sapiens	12-31
23761378-1	2014	OBJECTIVES: Monoamine oxidase A (MAOA) modulates metabolism of serotonin and dopamine metabolism, neurotransmitters involved in regulation of appetite and food intake.	Dopamine	77-85	monoamine oxidase A	Homo sapiens	33-37
25198178-6	2014	In vitro, cytotoxic chemotherapy induced the expression of MAOA and elevated MAOA levels enhanced cell survival following docetaxel exposure.	Docetaxel	122-131	monoamine oxidase A	Homo sapiens	77-81
25198178-7	2014	MAOA activity increased the levels of reactive oxygen species and increased the expression and nuclear translocation of HIF1alpha.	Reactive Oxygen Species	38-61	monoamine oxidase A	Homo sapiens	0-4
25198178-8	2014	The suppression of MAOA activity using the irreversible inhibitor clorgyline augmented the apoptotic responses induced by docetaxel.	Clorgyline	66-76	monoamine oxidase A	Homo sapiens	19-23
25198178-8	2014	The suppression of MAOA activity using the irreversible inhibitor clorgyline augmented the apoptotic responses induced by docetaxel.	Docetaxel	122-131	monoamine oxidase A	Homo sapiens	19-23
25198178-9	2014	In summary, we determined that the expression of MAOA is induced by exposure to cytotoxic chemotherapy, increases HIF1alpha, and contributes to docetaxel resistance.	Docetaxel	144-153	monoamine oxidase A	Homo sapiens	49-53
25198178-10	2014	As MAOA inhibitors have been approved for human use, regimens combining MAOA inhibitors with docetaxel may improve clinical outcomes.	Docetaxel	93-102	monoamine oxidase A	Homo sapiens	3-7
28962277-0	2014	Cellular uptake of quercetin and luteolin and their effects on monoamine oxidase-A in human neuroblastoma SH-SY5Y cells.	Quercetin	19-28	monoamine oxidase A	Homo sapiens	63-82
28962277-1	2014	Monoamine oxidase-A (MAO-A) is the main enzyme in the metabolism of the neurotransmitter serotonin (5-hydroxytryptamine).	Serotonin	89-98	monoamine oxidase A	Homo sapiens	0-19
28962277-1	2014	Monoamine oxidase-A (MAO-A) is the main enzyme in the metabolism of the neurotransmitter serotonin (5-hydroxytryptamine).	Serotonin	89-98	monoamine oxidase A	Homo sapiens	21-26
28962277-1	2014	Monoamine oxidase-A (MAO-A) is the main enzyme in the metabolism of the neurotransmitter serotonin (5-hydroxytryptamine).	Serotonin	100-119	monoamine oxidase A	Homo sapiens	0-19
28962277-1	2014	Monoamine oxidase-A (MAO-A) is the main enzyme in the metabolism of the neurotransmitter serotonin (5-hydroxytryptamine).	Serotonin	100-119	monoamine oxidase A	Homo sapiens	21-26
28962277-3	2014	Plant flavonoids, such as flavonol quercetin and flavone luteolin, have been suggested to be potential antidepressant compounds because they exert a suppressive effect on the MAO-A reaction.	Flavonoids	6-16	monoamine oxidase A	Homo sapiens	175-180
28962277-3	2014	Plant flavonoids, such as flavonol quercetin and flavone luteolin, have been suggested to be potential antidepressant compounds because they exert a suppressive effect on the MAO-A reaction.	3-hydroxyflavone	26-34	monoamine oxidase A	Homo sapiens	175-180
28962277-3	2014	Plant flavonoids, such as flavonol quercetin and flavone luteolin, have been suggested to be potential antidepressant compounds because they exert a suppressive effect on the MAO-A reaction.	Quercetin	35-44	monoamine oxidase A	Homo sapiens	175-180
28962277-3	2014	Plant flavonoids, such as flavonol quercetin and flavone luteolin, have been suggested to be potential antidepressant compounds because they exert a suppressive effect on the MAO-A reaction.	flavone	49-56	monoamine oxidase A	Homo sapiens	175-180
28962277-4	2014	We evaluated the effects of these flavonoids on MAO-A activity and protein level using SH-SY5Y as model serotoninergic nerve cells.	Flavonoids	34-44	monoamine oxidase A	Homo sapiens	48-53
28962277-8	2014	Luteolin and quercetin were incorporated into mitochondria fractions within 1-h incubation and attenuated MAO-A activity slightly but significantly.	Luteolin	0-8	monoamine oxidase A	Homo sapiens	106-111
28962277-8	2014	Luteolin and quercetin were incorporated into mitochondria fractions within 1-h incubation and attenuated MAO-A activity slightly but significantly.	Quercetin	13-22	monoamine oxidase A	Homo sapiens	106-111
28962277-11	2014	These data suggest that luteolin and quercetin can be direct inhibitors of MAO-A in nerve cells by targeting mitochondria.	Quercetin	37-46	monoamine oxidase A	Homo sapiens	75-80
25073638-4	2014	METHODS: We have searched for association between 119 SNPs in genes implicated in monoaminergic pathways [tryptophan hydroxylase 1 (TPH1), TPH2, tyrosine hydroxylase (TH), DOPA decarboxylase (DDC), dopamine beta-hydroxylase (DBH), catechol-O-methyltransferase (COMT), monoamine oxidase A (MAOA) and MAOB] and monoamine metabolite concentrations in CSF in 74 patients with psychotic disorder.	monoamine	82-91	monoamine oxidase A	Homo sapiens	268-287
24307270-1	2014	A computational study has suggested that phenformin, an oral hypoglycaemic drug, may bind to the active sites of the monoamine oxidase (MAO) A and B enzymes.	Phenformin	41-51	monoamine oxidase A	Homo sapiens	117-148
24307270-4	2014	Using recombinant human MAO-A and MAO-B, this study finds that phenformin acts as a moderately potent MAO-A selective inhibitor with an IC50 value of 41 microM.	Phenformin	63-73	monoamine oxidase A	Homo sapiens	24-29
24307270-4	2014	Using recombinant human MAO-A and MAO-B, this study finds that phenformin acts as a moderately potent MAO-A selective inhibitor with an IC50 value of 41 microM.	Phenformin	63-73	monoamine oxidase A	Homo sapiens	102-107
24307270-5	2014	Pentamidine, on the other hand, potently inhibits both MAO-A and MAO-B with IC50 values of 0.61 muM and 0.22 muM, respectively.	Pentamidine	0-11	monoamine oxidase A	Homo sapiens	55-60
24307270-7	2014	A kinetic analysis suggests that pentamidine acts as a competitive inhibitor with estimated Ki values of 0.41 muM and 0.22 muM for the inhibition of MAO-A and MAO-B, respectively.	Pentamidine	33-44	monoamine oxidase A	Homo sapiens	149-154
24307270-8	2014	Phenformin also exhibited a competitive mode of MAO-A inhibition with an estimated Ki value of 65 microM.	Phenformin	0-10	monoamine oxidase A	Homo sapiens	48-53
24986657-3	2014	With the exception of 5i, which was a selective MAO-B inhibitor, all derivatives inhibited hMAO-A potently and selectively.	carvone	22-24	monoamine oxidase A	Homo sapiens	91-97
24986657-4	2014	According to the experimental Ki values, compounds 6e and 6h exhibited the highest inhibitory activity towards the hMAO-A, whereas compound 5j, which carries a bromine atom at R(4) of the A ring of the pyrazoline, appeared to be the most selective MAO-A inhibitor.	pyrazoline	202-212	monoamine oxidase A	Homo sapiens	115-121
24986657-4	2014	According to the experimental Ki values, compounds 6e and 6h exhibited the highest inhibitory activity towards the hMAO-A, whereas compound 5j, which carries a bromine atom at R(4) of the A ring of the pyrazoline, appeared to be the most selective MAO-A inhibitor.	pyrazoline	202-212	monoamine oxidase A	Homo sapiens	116-121
24898155-0	2014	Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.	Carbon-11	75-84	monoamine oxidase A	Homo sapiens	8-27
24898155-0	2014	Greater monoamine oxidase a binding in perimenopausal age as measured with carbon 11-labeled harmine positron emission tomography.	Harmine	93-100	monoamine oxidase A	Homo sapiens	8-27
24898155-3	2014	Monoamine oxidase A (MAO-A) is an important brain enzyme that creates oxidative stress, influences apoptosis, and metabolizes monoamines.	monoamines	126-136	monoamine oxidase A	Homo sapiens	0-19
24898155-3	2014	Monoamine oxidase A (MAO-A) is an important brain enzyme that creates oxidative stress, influences apoptosis, and metabolizes monoamines.	monoamines	126-136	monoamine oxidase A	Homo sapiens	21-26
24607445-3	2014	More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clinical use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson"s disease (MAO-B inhibitors).	Amines	92-98	monoamine oxidase A	Homo sapiens	126-131
24607445-3	2014	More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clinical use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson"s disease (MAO-B inhibitors).	Amines	92-98	monoamine oxidase A	Homo sapiens	201-206
24607445-3	2014	More recently, the understanding that: a) potentiation of indirectly-acting sympathomimetic amines is caused by inhibitors of MAO-A but not by inhibitors of MAO-B, and b) that reversible inhibitors of MAO-A cause minimal tyramine potentiation, has led to their re-introduction to clinical use for treatment of depression (reversible MAO-A inhibitors and new dose form MAO-B inhibitor) and treatment of Parkinson"s disease (MAO-B inhibitors).	Amines	92-98	monoamine oxidase A	Homo sapiens	201-206
24449518-6	2014	Bacopaside I and bacoside A mixture inhibited the MAO-A and MAO-B enzymes.	bacopaside I	0-12	monoamine oxidase A	Homo sapiens	50-55
24449518-6	2014	Bacopaside I and bacoside A mixture inhibited the MAO-A and MAO-B enzymes.	bacoside A	17-27	monoamine oxidase A	Homo sapiens	50-55
24955776-4	2014	Replacement of the carboxamide linker with a methanimine spacer leading to (E)-N-(3,4-dichlorophenyl)-1-(1H-indazol-5-yl)methanimine (58) represents a further novel class of highly potent and selective MAO-B inhibitors (IC50 human MAO-B 0.612 nM, &gt;16000-fold selective versus MAO-A).	methyleneimine	45-56	monoamine oxidase A	Homo sapiens	279-284
24955776-4	2014	Replacement of the carboxamide linker with a methanimine spacer leading to (E)-N-(3,4-dichlorophenyl)-1-(1H-indazol-5-yl)methanimine (58) represents a further novel class of highly potent and selective MAO-B inhibitors (IC50 human MAO-B 0.612 nM, &gt;16000-fold selective versus MAO-A).	(e)-n-(3,4-dichlorophenyl)-1-(1h-indazol-5-yl)methanimine	75-132	monoamine oxidase A	Homo sapiens	279-284
24955776-5	2014	In N-(3,4-difluorophenyl-1H-indazole-5-carboxamide (30, PSB-1434, IC50 human MAO-B 1.59 nM, selectivity versus MAO-A&gt;6000-fold), high potency and selectivity are optimally combined with superior physicochemical properties.	n-(3,4-difluorophenyl-1h-indazole-5-carboxamide	3-50	monoamine oxidase A	Homo sapiens	111-116
24782464-3	2014	Here, two series of 3-phenylcoumarin derivatives were synthesized and evaluated against MAO-A and MAO-B.	3-Phenylcoumarin	20-36	monoamine oxidase A	Homo sapiens	88-93
24782464-5	2014	Only 6-chloro-4-hydroxy-3-(2"-hydroxyphenyl)coumarin exhibited activity against the MAO-A isoform, while still retaining good selectivity for MAO-B.	6-chloro-4-hydroxy-3-(2"-hydroxyphenyl)coumarin	5-52	monoamine oxidase A	Homo sapiens	84-89
25073638-4	2014	METHODS: We have searched for association between 119 SNPs in genes implicated in monoaminergic pathways [tryptophan hydroxylase 1 (TPH1), TPH2, tyrosine hydroxylase (TH), DOPA decarboxylase (DDC), dopamine beta-hydroxylase (DBH), catechol-O-methyltransferase (COMT), monoamine oxidase A (MAOA) and MAOB] and monoamine metabolite concentrations in CSF in 74 patients with psychotic disorder.	monoamine	82-91	monoamine oxidase A	Homo sapiens	289-293
24794105-1	2014	In the present study, a series of fifteen alpha-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	Tetralones	42-57	monoamine oxidase A	Homo sapiens	170-201
24115740-3	2014	This study investigated the effect of 5-IT on human MAO-A and -B isozymes using kynuramine as the substrate.	5-(2-aminopropyl)indole	38-42	monoamine oxidase A	Homo sapiens	52-64
24115740-5	2014	This method was employed to determine the extent of MAO inhibition (IC50 and Ki ) and it was found that 5-IT was a selective, competitive and reversible inhibitor of MAO-A.	5-(2-aminopropyl)indole	104-108	monoamine oxidase A	Homo sapiens	166-171
24115740-6	2014	5-IT revealed a relatively potent ability to inhibit MAO-A (IC50  =1.6 muM and Ki  =0.25 muM) while MAO-B inhibition was not observed (0-500 muM 5-IT).	5-(2-aminopropyl)indole	0-4	monoamine oxidase A	Homo sapiens	53-58
24115740-7	2014	Under identical experimental conditions, other established inhibitors of MAO-A and antidepressants provided the following IC50 values: clorgyline 16 nM, harmaline 20 nM, toloxatone 6.7 muM and moclobemide &gt;500 muM.	Clorgyline	135-145	monoamine oxidase A	Homo sapiens	73-78
24115740-7	2014	Under identical experimental conditions, other established inhibitors of MAO-A and antidepressants provided the following IC50 values: clorgyline 16 nM, harmaline 20 nM, toloxatone 6.7 muM and moclobemide &gt;500 muM.	Harmaline	153-162	monoamine oxidase A	Homo sapiens	73-78
24115740-7	2014	Under identical experimental conditions, other established inhibitors of MAO-A and antidepressants provided the following IC50 values: clorgyline 16 nM, harmaline 20 nM, toloxatone 6.7 muM and moclobemide &gt;500 muM.	toloxatone	170-180	monoamine oxidase A	Homo sapiens	73-78
24115740-7	2014	Under identical experimental conditions, other established inhibitors of MAO-A and antidepressants provided the following IC50 values: clorgyline 16 nM, harmaline 20 nM, toloxatone 6.7 muM and moclobemide &gt;500 muM.	Moclobemide	193-204	monoamine oxidase A	Homo sapiens	73-78
24865426-1	2014	Tumors from patients with high-grade aggressive prostate cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines.	monoamine	102-111	monoamine oxidase A	Homo sapiens	123-127
24865426-1	2014	Tumors from patients with high-grade aggressive prostate cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines.	Amines	207-213	monoamine oxidase A	Homo sapiens	102-121
24865426-1	2014	Tumors from patients with high-grade aggressive prostate cancer (PCa) exhibit increased expression of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines.	Amines	207-213	monoamine oxidase A	Homo sapiens	123-127
24865426-3	2014	Here, we found that MAOA functions to induce epithelial-to-mesenchymal transition (EMT) and stabilize the transcription factor HIF1alpha, which mediates hypoxia through an elevation of ROS, thus enhancing growth, invasiveness, and metastasis of PCa cells.	ros	185-188	monoamine oxidase A	Homo sapiens	20-24
24794105-1	2014	In the present study, a series of fifteen alpha-tetralone (3,4-dihydro-2H-naphthalen-1-one) derivatives were synthesised and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	Tetralones	59-90	monoamine oxidase A	Homo sapiens	170-201
24794105-4	2014	Although most compounds are selective inhibitors of MAO-B, the alpha-tetralones are also potent MAO-A inhibitors with ten compounds exhibiting IC50 values in the nanomolar range (&lt;792nM).	alpha-tetralones	63-79	monoamine oxidase A	Homo sapiens	96-101
24793878-1	2014	A series new 2H-chromene-3-carboxamide derivatives 4a-4t were synthesized and evaluated as monoamine oxidase A and B (MAO-A and MAO-B) inhibitors.	2H-chromene-3-carboxamide	13-38	monoamine oxidase A	Homo sapiens	91-116
24666288-14	2014	Imidazoline-2 (I-2) receptors interact with monoamine oxidase A and monoamine oxidase B leading to research that has focused on the effect of I-2 receptors and depression and the suggestion of a possible antidepressant action of the imidazolines.	Imidazolines	233-245	monoamine oxidase A	Homo sapiens	44-63
24313346-4	2014	METHODS: Employing the recombinant human enzymes, the potencies (IC50 values) by which the caffeine analogues inhibit MAO-A and MAO-B were measured.	Caffeine	91-99	monoamine oxidase A	Homo sapiens	118-123
23797843-4	2014	Targeted LC-MS/MS analysis of hepatocyte incubations using chemical inhibitors indicated that PQ was predominantly metabolized by CYPs 3A4, 1A2 and 2D6, MAO-A, -B and FMO-3.	Primaquine	94-96	monoamine oxidase A	Homo sapiens	153-158
23797843-6	2014	Small amounts of carboxyprimaquine (CPQ), the major observed PQ metabolite in vivo, were detected in recombinant MAO-A incubations along with another peak at m/z 261, and no significant formation of CPQ with any other recombinant enzymes was observed.	8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline	17-34	monoamine oxidase A	Homo sapiens	113-118
23797843-6	2014	Small amounts of carboxyprimaquine (CPQ), the major observed PQ metabolite in vivo, were detected in recombinant MAO-A incubations along with another peak at m/z 261, and no significant formation of CPQ with any other recombinant enzymes was observed.	8-(3-carboxy-1-methylpropylamino)-6-methoxyquinoline	36-39	monoamine oxidase A	Homo sapiens	113-118
23797843-6	2014	Small amounts of carboxyprimaquine (CPQ), the major observed PQ metabolite in vivo, were detected in recombinant MAO-A incubations along with another peak at m/z 261, and no significant formation of CPQ with any other recombinant enzymes was observed.	Primaquine	37-39	monoamine oxidase A	Homo sapiens	113-118
24169519-0	2014	20 ans apres: a second mutation in MAOA identified by targeted high-throughput sequencing in a family with altered behavior and cognition.	1-anilino-8-naphthalenesulfonate	3-6	monoamine oxidase A	Homo sapiens	35-39
24169519-7	2014	This novel missense mutation decreases MAOA enzymatic activity, leading to abnormal levels of urinary monoamines.	monoamines	102-112	monoamine oxidase A	Homo sapiens	39-43
24607627-1	2014	BACKGROUND &amp; AIMS: Monoamine oxidase A (MAOA), a catecholamine neurotransmitter degrading enzyme, is closely associated with neurological and psychiatric disorders.	Adenosine Monophosphate	12-15	monoamine oxidase A	Homo sapiens	23-42
24607627-1	2014	BACKGROUND &amp; AIMS: Monoamine oxidase A (MAOA), a catecholamine neurotransmitter degrading enzyme, is closely associated with neurological and psychiatric disorders.	Adenosine Monophosphate	12-15	monoamine oxidase A	Homo sapiens	44-48
24607627-1	2014	BACKGROUND &amp; AIMS: Monoamine oxidase A (MAOA), a catecholamine neurotransmitter degrading enzyme, is closely associated with neurological and psychiatric disorders.	Catecholamines	53-66	monoamine oxidase A	Homo sapiens	23-42
24607627-1	2014	BACKGROUND &amp; AIMS: Monoamine oxidase A (MAOA), a catecholamine neurotransmitter degrading enzyme, is closely associated with neurological and psychiatric disorders.	Catecholamines	53-66	monoamine oxidase A	Homo sapiens	44-48
24607627-7	2014	We then demonstrated that MAOA suppressed norepinephrine/epinephrine (NE/E)-induced HCC invasion and anoikis inhibition, and uncovered that the effects of NE/E on HCC behaviors were primarily mediated through alpha 1A (ADRA1A) and beta 2 adrenergic receptors (ADRB2).	Norepinephrine	42-56	monoamine oxidase A	Homo sapiens	26-30
24607627-7	2014	We then demonstrated that MAOA suppressed norepinephrine/epinephrine (NE/E)-induced HCC invasion and anoikis inhibition, and uncovered that the effects of NE/E on HCC behaviors were primarily mediated through alpha 1A (ADRA1A) and beta 2 adrenergic receptors (ADRB2).	Epinephrine	45-56	monoamine oxidase A	Homo sapiens	26-30
24269057-4	2014	We hypothesized that MAO-A VT, an index of MAO-A level, is elevated in the prefrontal cortex (PFC) during AD, because markers of greater oxidative stress and apoptosis are reported in the brain in AD and a microarray analysis reported greater MAO-A messenger RNA in the PFC of rodents exposed to alcohol vapor.	Alcohols	296-303	monoamine oxidase A	Homo sapiens	21-26
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	n-debutyl-dronedarone	0-21	monoamine oxidase A	Homo sapiens	116-121
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	Dronedarone	10-21	monoamine oxidase A	Homo sapiens	116-121
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	propionic acid	130-144	monoamine oxidase A	Homo sapiens	116-121
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	Dronedarone	56-67	monoamine oxidase A	Homo sapiens	116-121
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	Phenol	161-167	monoamine oxidase A	Homo sapiens	116-121
25505590-7	2014	N-debutyl-dronedarone was less rapidly metabolized than dronedarone, the major metabolic pathway being catalyzed by MAO-A to form propanoic acid-dronedarone and phenol-dronedarone.	Dronedarone	56-67	monoamine oxidase A	Homo sapiens	116-121
25611876-1	2014	Methylene blue, a drug used to treat vasoplegia and methemoglobinemia, also inhibits monoamine oxidase-A.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	85-104
24313346-7	2014	The most potent analogue, 8-(7-phenylheptyl)caffeine, exhibits IC50 values for the inhibition of MAO-A and MAO-B of 3.01 mum and 0.086 mum, respectively.	8-(7-phenylheptyl)caffeine	26-52	monoamine oxidase A	Homo sapiens	97-102
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	27-105	monoamine oxidase A	Homo sapiens	126-145
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	monoamine	37-46	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	monoamine	37-46	monoamine oxidase A	Homo sapiens	21-25
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Dopamine	75-83	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Dopamine	75-83	monoamine oxidase A	Homo sapiens	21-25
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	85-104	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	85-104	monoamine oxidase A	Homo sapiens	21-25
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	106-110	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	106-110	monoamine oxidase A	Homo sapiens	21-25
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	112-121	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Serotonin	112-121	monoamine oxidase A	Homo sapiens	21-25
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Norepinephrine	128-142	monoamine oxidase A	Homo sapiens	0-19
24510409-1	2014	Monoamine oxidase A (MAOA) catalyzes monoamine neurotransmitters including dopamine, 5-hydroxytryptamine (5-HT, serotonin), and norepinephrine.	Norepinephrine	128-142	monoamine oxidase A	Homo sapiens	21-25
24652311-3	2014	Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of amines, has been reported to be associated with aggression, impulsivity, depression, and mood changes.	Amines	82-88	monoamine oxidase A	Homo sapiens	0-19
24652311-3	2014	Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of amines, has been reported to be associated with aggression, impulsivity, depression, and mood changes.	Amines	82-88	monoamine oxidase A	Homo sapiens	21-25
24652311-4	2014	We hypothesized that MAOA can have a potential role in ADHD associated CD/ODD and analyzed 24 markers in a group of Indo-Caucasoid subjects.	Indomethacin	116-120	monoamine oxidase A	Homo sapiens	21-25
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	27-105	monoamine oxidase A	Homo sapiens	147-152
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	107-111	monoamine oxidase A	Homo sapiens	126-145
24304147-2	2014	In early discovery stages, 2-methyl-N-(2"-(pyrrolidinyl-1-ylsulfonyl)-[1,1"-biphenyl]-4-yl)propan-1-amine (PBPA) demonstrated monoamine oxidase A (MAO-A) and cytochrome P450 (CYP)-mediated clearance.	2-methyl-N-((2'-(pyrrolidin-1-ylsulfonyl)biphenyl-4-yl)methyl)propan-1-amine	107-111	monoamine oxidase A	Homo sapiens	147-152
24291416-3	2014	In the current study X-chromosomal gene, MAOA responsible for degradation of serotonin is investigated for possible association with ASD using population-based approach.	Serotonin	77-86	monoamine oxidase A	Homo sapiens	41-45
24601544-3	2014	MAO A also binds imidazolines but has a different active site structure.	Imidazolines	17-29	monoamine oxidase A	Homo sapiens	0-5
24601544-4	2014	Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B.	2-BFI hydrochloride	56-102	monoamine oxidase A	Homo sapiens	120-125
24601544-4	2014	Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B.	2-(2-benzofuranyl)-2-imidazoline	104-109	monoamine oxidase A	Homo sapiens	120-125
24601544-4	2014	Docking and molecular dynamics were used to explore how 2-(2-benzofuranyl)-2-imidazoline hydrochloride (2-BFI) binds to MAO A and to explain why tranylcypromine increases tight binding to MAO B.	Tranylcypromine	145-160	monoamine oxidase A	Homo sapiens	120-125
24601544-5	2014	The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity.	2-(2-benzofuranyl)-2-imidazoline	15-20	monoamine oxidase A	Homo sapiens	32-37
24601544-5	2014	The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity.	Tranylcypromine	65-80	monoamine oxidase A	Homo sapiens	32-37
24601544-5	2014	The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity.	Tranylcypromine	65-80	monoamine oxidase A	Homo sapiens	130-135
24601544-5	2014	The energy for 2-BFI binding to MAO A was comparable to that for tranylcypromine-modified MAO B, but the location of 2-BFI in the MAO A could be anywhere in the monopartite substrate cavity.	2-(2-benzofuranyl)-2-imidazoline	117-122	monoamine oxidase A	Homo sapiens	130-135
24355137-3	2014	RESULTS: Female heroin-dependent subjects with BPD have lower frequency of the high activity allele (L: 4 repeats (4R)) of MAOA-LPR than those female heroin-dependent subjects without BPD, and have higher 5-HTTVNTR 10R/10R genotype frequency than normal female controls, with adjusted P-value&lt;0.05 (after adjusted for multiple testing by 1000-fold permutation tests) respectively.	Heroin	16-22	monoamine oxidase A	Homo sapiens	123-127
24355137-3	2014	RESULTS: Female heroin-dependent subjects with BPD have lower frequency of the high activity allele (L: 4 repeats (4R)) of MAOA-LPR than those female heroin-dependent subjects without BPD, and have higher 5-HTTVNTR 10R/10R genotype frequency than normal female controls, with adjusted P-value&lt;0.05 (after adjusted for multiple testing by 1000-fold permutation tests) respectively.	Heroin	150-156	monoamine oxidase A	Homo sapiens	123-127
24355137-5	2014	CONCLUSION: 5-HTTVNTR and MAOA-LPR may have independent predictive effects on co-morbid BPD in female heroin-dependent patients; the gene-gene interactions between MAOA-LPR and 5-HTTVNTR, and among MAOA-LPR, 5-HTTVNTR and rs6311 might also be involved in the etiology of this co-morbidity.	Heroin	102-108	monoamine oxidase A	Homo sapiens	164-168
24355137-5	2014	CONCLUSION: 5-HTTVNTR and MAOA-LPR may have independent predictive effects on co-morbid BPD in female heroin-dependent patients; the gene-gene interactions between MAOA-LPR and 5-HTTVNTR, and among MAOA-LPR, 5-HTTVNTR and rs6311 might also be involved in the etiology of this co-morbidity.	Heroin	102-108	monoamine oxidase A	Homo sapiens	164-168
24165164-4	2014	Herein, we demonstrated that certain antitumor 1,4-NQs, including spermidine-1,4-NQ, lapachol, and nor-lapachol display inhibitory activity on human MAO-A and MAO-B.	1,4-naphthoquinone	47-54	monoamine oxidase A	Homo sapiens	149-154
24165164-4	2014	Herein, we demonstrated that certain antitumor 1,4-NQs, including spermidine-1,4-NQ, lapachol, and nor-lapachol display inhibitory activity on human MAO-A and MAO-B.	spermidine-1,4-nq	66-83	monoamine oxidase A	Homo sapiens	149-154
24165164-4	2014	Herein, we demonstrated that certain antitumor 1,4-NQs, including spermidine-1,4-NQ, lapachol, and nor-lapachol display inhibitory activity on human MAO-A and MAO-B.	lapachol	85-93	monoamine oxidase A	Homo sapiens	149-154
24165164-4	2014	Herein, we demonstrated that certain antitumor 1,4-NQs, including spermidine-1,4-NQ, lapachol, and nor-lapachol display inhibitory activity on human MAO-A and MAO-B.	norlapachol	99-111	monoamine oxidase A	Homo sapiens	149-154
24759925-3	2014	The purpose of the present study was to examine whether a cumulative genetic score (CGS) containing the monoamine oxidase A (MAOA) and the human serotonin transporter gene linked polymorphism (5-HTTLPR) was associated with IPV perpetration after accounting for the effects of alcohol problems, drug problems, age, and length of relationship.	Alcohols	276-283	monoamine oxidase A	Homo sapiens	125-129
24165164-7	2014	Furthermore, ability to inhibit both MAO-A and MAO-B can be potentialized by the formation of hydrogen bonds between these compounds and FAD and/or the residues in the active site.	Hydrogen	94-102	monoamine oxidase A	Homo sapiens	37-42
24165164-7	2014	Furthermore, ability to inhibit both MAO-A and MAO-B can be potentialized by the formation of hydrogen bonds between these compounds and FAD and/or the residues in the active site.	Flavin-Adenine Dinucleotide	137-140	monoamine oxidase A	Homo sapiens	37-42
24530494-4	2014	For the MAO inhibition, amides were not active, and among the amines, compound 14 was totally MAO A selective, while amines 15 and 16 were quite MAO A selective.	Amines	117-123	monoamine oxidase A	Homo sapiens	145-150
24530494-5	2014	Carboxylic acid derivatives 5 and 11 showed a multipotent moderate selective profile as EeACE and MAO A inhibitors.	Carboxylic Acids	0-15	monoamine oxidase A	Homo sapiens	98-103
24287819-12	2014	DAT and MAO-A/B, which are expressed by GCs, are prerequisites for a DA receptor-independent generation of ROS in GCs.	Reactive Oxygen Species	107-110	monoamine oxidase A	Homo sapiens	8-15
24560738-6	2014	Among the 7-hex-5-ynyloxy-coumarins, the 3-methoxycarbonyl derivative 36 was characterized as a dual-acting inhibitor with IC50 values of less than 10 nM towards MAO-A and MAO-B, and the 3-(4-methoxy)phenyl derivative 44 was shown to combine strong anti-MAO-B potency (IC50=3.0 nM) and selectivity for MAO-B over MAO-A (selectivity &gt;3400-fold).	7-hex-5-ynyloxy-coumarins	10-35	monoamine oxidase A	Homo sapiens	162-167
24560738-6	2014	Among the 7-hex-5-ynyloxy-coumarins, the 3-methoxycarbonyl derivative 36 was characterized as a dual-acting inhibitor with IC50 values of less than 10 nM towards MAO-A and MAO-B, and the 3-(4-methoxy)phenyl derivative 44 was shown to combine strong anti-MAO-B potency (IC50=3.0 nM) and selectivity for MAO-B over MAO-A (selectivity &gt;3400-fold).	7-hex-5-ynyloxy-coumarins	10-35	monoamine oxidase A	Homo sapiens	313-318
24443391-3	2014	Several genetic variations have been suggested to associate with AD and DE, particularly in genes involved in the serotonergic system such as the serotonin transporter (SERT/SLC6A4), responsible for the removal from the synaptic cleft, and the monoamine-oxidase-A (MAOA), responsible for the presynaptic degradation of serotonin.	Serotonin	146-155	monoamine oxidase A	Homo sapiens	244-263
24443391-3	2014	Several genetic variations have been suggested to associate with AD and DE, particularly in genes involved in the serotonergic system such as the serotonin transporter (SERT/SLC6A4), responsible for the removal from the synaptic cleft, and the monoamine-oxidase-A (MAOA), responsible for the presynaptic degradation of serotonin.	Serotonin	146-155	monoamine oxidase A	Homo sapiens	265-269
24635520-2	2014	In this study we synthesized and evaluated a new series of compounds, with benzo[f]coumarin structure, as potential inhibitors of MAO-A, MAO-B, AChE and BuChE.	benzo[f]coumarin	75-91	monoamine oxidase A	Homo sapiens	130-135
24287819-13	2014	Blockers of DAT and MAO-A/B, as well as an antioxidant, prevented the generation of ROS (P &lt; 0.05).	Reactive Oxygen Species	84-87	monoamine oxidase A	Homo sapiens	20-27
24287819-17	2014	In PCOS-derived follicular fluid, the levels of DA were higher (P &lt; 0.05) in GCs, the transcript levels of DAT and MAO-A/B in GCs were 2-fold higher (P &lt; 0.05) and the DA-induced ROS levels were found to be more than 4-fold increased (P &lt; 0.05) compared with non-PCOS cells.	Reactive Oxygen Species	185-188	monoamine oxidase A	Homo sapiens	118-125
24247011-0	2014	Exploring the structural basis of the selective inhibition of monoamine oxidase A by dicarbonitrile aminoheterocycles: role of Asn181 and Ile335 validated by spectroscopic and computational studies.	dicarbonitrile aminoheterocycles	85-117	monoamine oxidase A	Homo sapiens	62-81
24360188-7	2014	MAOA-uVNTR showed a significant association with ESS scores (p = 0.01): 3/3 genotype carriers had the lowest scores.	ESS	49-52	monoamine oxidase A	Homo sapiens	0-4
24525204-5	2014	Pancreatic uptake of (11)C-5-HTP in nonhuman primates was markedly decreased by inhibition of the enzyme dopa decarboxylase, which converts (11)C-5-HTP to (11)C-serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for serotonin degradation.	c-5-htp	25-32	monoamine oxidase A	Homo sapiens	205-224
24525204-5	2014	Pancreatic uptake of (11)C-5-HTP in nonhuman primates was markedly decreased by inhibition of the enzyme dopa decarboxylase, which converts (11)C-5-HTP to (11)C-serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for serotonin degradation.	)c-5-htp	24-32	monoamine oxidase A	Homo sapiens	205-224
24525204-5	2014	Pancreatic uptake of (11)C-5-HTP in nonhuman primates was markedly decreased by inhibition of the enzyme dopa decarboxylase, which converts (11)C-5-HTP to (11)C-serotonin and increased after inhibition of monoamine oxidase-A, the main enzyme responsible for serotonin degradation.	Carbon	25-26	monoamine oxidase A	Homo sapiens	205-224
24154665-4	2014	MAO-A VT (an index of MAO-A density) was measured using [(11)C]harmine positron emission tomography (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.	Harmine	63-70	monoamine oxidase A	Homo sapiens	0-5
24154665-4	2014	MAO-A VT (an index of MAO-A density) was measured using [(11)C]harmine positron emission tomography (PET) in 42 subjects with MDEs secondary to major depressive disorder and 37 healthy controls.	Harmine	63-70	monoamine oxidase A	Homo sapiens	22-27
24154665-8	2014	As MAO-A creates oxidative stress, facilitates apoptosis, and metabolizes monoamines, therapeutics opposing these processes are predicted to best treat MDE with greater severity and reversed neurovegetative symptoms.	monoamines	74-84	monoamine oxidase A	Homo sapiens	3-8
24393810-1	2014	A series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones (coumarins) have been synthesized and their inhibitory activity to human monoamine oxidase A (MAO A) and B (MAO B) determined.	6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones	12-65	monoamine oxidase A	Homo sapiens	139-158
24393810-1	2014	A series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones (coumarins) have been synthesized and their inhibitory activity to human monoamine oxidase A (MAO A) and B (MAO B) determined.	6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones	12-65	monoamine oxidase A	Homo sapiens	160-165
24393810-1	2014	A series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones (coumarins) have been synthesized and their inhibitory activity to human monoamine oxidase A (MAO A) and B (MAO B) determined.	Coumarins	67-76	monoamine oxidase A	Homo sapiens	139-158
24393810-1	2014	A series of 6-substituted 3-(pyrrolidin-1-ylmethyl)chromen-2-ones (coumarins) have been synthesized and their inhibitory activity to human monoamine oxidase A (MAO A) and B (MAO B) determined.	Coumarins	67-76	monoamine oxidase A	Homo sapiens	160-165
24393810-2	2014	Incorporation of a basic amino function in the C3 position together with substitution at the C6 position produced novel coumarin compounds with selectivity for the MAO A subtype.	coumarin	120-128	monoamine oxidase A	Homo sapiens	164-169
24247011-2	2014	Dicarbonitrile aminofurans were found to be potent, selective inhibitors against MAO A.	dicarbonitrile aminofurans	0-26	monoamine oxidase A	Homo sapiens	81-86
24247011-4	2014	Spectroscopic changes induced in MAO A by mono- and dicarbonitrile inhibitors were different, providing experimental evidence for distinct binding modes to the enzyme.	mono- and dicarbonitrile	42-66	monoamine oxidase A	Homo sapiens	33-38
24247011-5	2014	Similar differences were also found between the binding of dicarbonitrile compounds to MAO A and to MAO B.	dicarbonitrile	59-73	monoamine oxidase A	Homo sapiens	87-92
24660679-9	2014	Additionally, the hydantoin ring of 66 is able to interact by hydrogen bonds with two conserved water molecules in the MAO-A active site, while the methyl-thiohydantoin ring of 68 is within hydrogen bond distance from the hydrogen atom attached to the (N-5) of FAD cofactor.	Hydantoins	18-27	monoamine oxidase A	Homo sapiens	119-124
23701542-4	2014	An overlooked source of H2O2 in the mitochondrion is its production as a catalytic reaction product from the outer membrane enzymes: monoamine oxidases A and B.	Hydrogen Peroxide	24-28	monoamine oxidase A	Homo sapiens	133-159
23701542-5	2014	The literature is reviewed to document identified degenerative reactions attributed to H2O2 produced by MAO A and by MAO B catalysis.	Hydrogen Peroxide	87-91	monoamine oxidase A	Homo sapiens	104-109
24660679-10	2014	Taking together, our findings demonstrate that the indolyl-hydantoin and indolylmethyl-thiohydantoin rings might consists of good scaffolds for the development of new MAO-A inhibitors possessing neuroprotective properties.	indolyl hydantoin	51-68	monoamine oxidase A	Homo sapiens	167-172
24660679-10	2014	Taking together, our findings demonstrate that the indolyl-hydantoin and indolylmethyl-thiohydantoin rings might consists of good scaffolds for the development of new MAO-A inhibitors possessing neuroprotective properties.	indolylmethyl-thiohydantoin	73-100	monoamine oxidase A	Homo sapiens	167-172
24051032-1	2014	The study examined how the mitochondrial enzyme monoamine oxidase-A (MAO-A), which produces hydrogen peroxide as a catalytic by-product, influences death and survival mechanisms.	Hydrogen Peroxide	92-109	monoamine oxidase A	Homo sapiens	69-74
24008922-8	2014	The possibility that combined COMT and MAO-A genotype is a significant factor in determining an individual"s lifetime levodopa exposure warrants further investigation.	Levodopa	118-126	monoamine oxidase A	Homo sapiens	39-44
23319006-3	2014	Among these, the gene encoding monoamine oxidase A (MAOA) is noteworthy given that genetic variation has been demonstrated to influence gene expression and monoamine levels.	monoamine	31-40	monoamine oxidase A	Homo sapiens	52-56
24942140-7	2014	RESULTS: We found that functional polymorphisms in the genes encoding for dopamine-catabolizing enzymes (i.e. COMT and MAOA) are associated with motor RTV but not with sensory RTV, whereas vice versa the gene DRD2 influences sensory but not motor RTV.	Dopamine	74-82	monoamine oxidase A	Homo sapiens	119-123
23812646-7	2013	In addition, istradefylline hardly inhibited monoamine oxidase-A, monoamine oxidase-B, or catechol-O-methyl transferase.	istradefylline	13-27	monoamine oxidase A	Homo sapiens	45-64
24274579-0	2013	Kinetic analysis of [11C]befloxatone in the human brain, a selective radioligand to image monoamine oxidase A.	[11C](5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	20-36	monoamine oxidase A	Homo sapiens	90-109
24274579-1	2013	BACKGROUND: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain.	Carbon-11	13-16	monoamine oxidase A	Homo sapiens	64-83
24274579-1	2013	BACKGROUND: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain.	Carbon-11	13-16	monoamine oxidase A	Homo sapiens	85-90
24274579-1	2013	BACKGROUND: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain.	befloxatone	17-28	monoamine oxidase A	Homo sapiens	64-83
24274579-1	2013	BACKGROUND: [11C]Befloxatone measures the density of the enzyme monoamine oxidase A (MAO-A) in the brain.	befloxatone	17-28	monoamine oxidase A	Homo sapiens	85-90
24274579-12	2013	CONCLUSIONS: Binding of [11C]befloxatone to MAO-A can be quantified using an arterial input function and a two-compartment model or, in parametric images, with SA.	[11C](5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	24-40	monoamine oxidase A	Homo sapiens	44-49
23755928-0	2013	A MAOA gene*cocaine severity interaction on impulsivity and neuropsychological measures of orbitofrontal dysfunction: preliminary results.	Cocaine	12-19	monoamine oxidase A	Homo sapiens	2-6
23755928-5	2013	We computed the statistical significance of the prediction change yielded by each consecutive set, with "a priori" interest in the MAOA*cocaine severity interaction.	Cocaine	136-143	monoamine oxidase A	Homo sapiens	131-135
23755928-6	2013	RESULTS: We found significant effects of the MAOA gene*cocaine use severity interaction on the emotion recognition scores and the UPPS-P"s dimensions of Positive Urgency and Sensation Seeking: Low activity carriers with higher cocaine exposure had poorer emotion recognition and higher Positive Urgency and Sensation Seeking.	Cocaine	55-62	monoamine oxidase A	Homo sapiens	45-49
23755928-6	2013	RESULTS: We found significant effects of the MAOA gene*cocaine use severity interaction on the emotion recognition scores and the UPPS-P"s dimensions of Positive Urgency and Sensation Seeking: Low activity carriers with higher cocaine exposure had poorer emotion recognition and higher Positive Urgency and Sensation Seeking.	Cocaine	227-234	monoamine oxidase A	Homo sapiens	45-49
23755928-7	2013	CONCLUSION: Cocaine users carrying the MAOA low activity show a greater impact of cocaine use on impulsivity and behavioral measures of orbitofrontal cortex dysfunction.	Cocaine	12-19	monoamine oxidase A	Homo sapiens	39-43
23755928-7	2013	CONCLUSION: Cocaine users carrying the MAOA low activity show a greater impact of cocaine use on impulsivity and behavioral measures of orbitofrontal cortex dysfunction.	Cocaine	82-89	monoamine oxidase A	Homo sapiens	39-43
25322896-3	2014	In this study, two genes, 5HTR2a and MAO-A playing important roles in serotonin function, were analyzed in peripheral blood mononuclear cells (PBMCs) of individuals who had been exposed to air pollution and allergic asthmatic patients as well.	Serotonin	70-79	monoamine oxidase A	Homo sapiens	37-42
23858446-2	2013	The combined deficiency of MAO A and B results in significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-phenylethylamine; in humans and mice, these neurochemical changes are accompanied by neurodevelopmental perturbations as well as autistic-like responses.	Serotonin	83-92	monoamine oxidase A	Homo sapiens	27-38
23746540-4	2013	RESULTS: We demonstrate an association of ADHD symptoms with distinct blood oxygen level-dependent (BOLD) responses depending on MAOA genotype.	Oxygen	76-82	monoamine oxidase A	Homo sapiens	129-133
23677700-1	2013	Virtual screening of a library of drugs has suggested that esomeprazole, the S-enantiomer of omeprazole, may possess binding affinities for the active sites of the monoamine oxidase (MAO) A and B enzymes.	Esomeprazole	59-71	monoamine oxidase A	Homo sapiens	164-195
23677700-1	2013	Virtual screening of a library of drugs has suggested that esomeprazole, the S-enantiomer of omeprazole, may possess binding affinities for the active sites of the monoamine oxidase (MAO) A and B enzymes.	Omeprazole	61-71	monoamine oxidase A	Homo sapiens	164-195
23677700-3	2013	Using recombinant human MAO-A and MAO-B, IC50 values for the inhibition of these enzymes by esomeprazole were experimentally determined.	Esomeprazole	92-104	monoamine oxidase A	Homo sapiens	24-29
23677700-7	2013	The results document that esomeprazole inhibits both MAO-A and MAO-B with IC50 values of 23 microM and 48 microM, respectively.	Esomeprazole	26-38	monoamine oxidase A	Homo sapiens	53-58
23677700-8	2013	The interactions of esomeprazole with MAO-A and MAO-B are reversible and most likely competitive with Ki values for the inhibition of the respective enzymes of 8.99 microM and 31.7 microM.	Esomeprazole	20-32	monoamine oxidase A	Homo sapiens	38-43
24012182-1	2013	In the present study, a series of 3,4-dihydro-2(1H)-quinolinone derivatives were synthesized and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	3,4-dihydro-2(1H)-quinolinone	34-63	monoamine oxidase A	Homo sapiens	142-173
24012182-4	2013	The most potent MAO-B inhibitor, 7-(3-bromobenzyloxy)-3,4-dihydro-2(1H)-quinolinone, exhibits an IC50 value of 2.9 nM with a 2750-fold selectivity for MAO-B over the MAO-A isoform.	7-(3-bromobenzyloxy)-3,4-dihydro-2(1h)-quinolinone	33-83	monoamine oxidase A	Homo sapiens	166-171
24119940-3	2013	The current study aimed to determine whether maternal symptoms of depression or anxiety were associated with decreased placental expression of monoamine oxidase A (MAO A), the enzyme which metabolises 5-HT into 5-hydroxyindoleacetic acid.	Hydroxyindoleacetic Acid	211-237	monoamine oxidase A	Homo sapiens	143-162
24119940-3	2013	The current study aimed to determine whether maternal symptoms of depression or anxiety were associated with decreased placental expression of monoamine oxidase A (MAO A), the enzyme which metabolises 5-HT into 5-hydroxyindoleacetic acid.	Hydroxyindoleacetic Acid	211-237	monoamine oxidase A	Homo sapiens	164-169
23860591-4	2013	The most active compound, 2E-3-(5-chlorofuran-2-yl)-1-(3-chlorophenyl)prop-2-en-1-one, exhibited an IC50 value of 0.174 muM for the inhibition of MAO-B and 28.6 muM for the inhibition of MAO-A.	2e-3-(5-chlorofuran-2-yl)-1-(3-chlorophenyl)prop-2-en-1-one	26-85	monoamine oxidase A	Homo sapiens	187-192
23850513-1	2013	AIMS: Caffeine has been used as a scaffold for the design of inhibitors of monoamine oxidase (MAO) A and B.	Caffeine	6-14	monoamine oxidase A	Homo sapiens	75-106
23850513-7	2013	KEY FINDINGS: Caffeine acts as a MAO inhibitor with Ki values of 0.70 mM and 3.83 mM for the inhibition of MAO-A and MAO-B, respectively.	Caffeine	14-22	monoamine oxidase A	Homo sapiens	107-112
23850513-9	2013	SIGNIFICANCE: Although structural modifications of caffeine lead to highly potent MAO inhibitors, caffeine is a weak inhibitor of MAO-A and MAO-B.	Caffeine	98-106	monoamine oxidase A	Homo sapiens	130-135
23858446-2	2013	The combined deficiency of MAO A and B results in significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-phenylethylamine; in humans and mice, these neurochemical changes are accompanied by neurodevelopmental perturbations as well as autistic-like responses.	Serotonin	94-113	monoamine oxidase A	Homo sapiens	27-38
23858446-2	2013	The combined deficiency of MAO A and B results in significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-phenylethylamine; in humans and mice, these neurochemical changes are accompanied by neurodevelopmental perturbations as well as autistic-like responses.	Norepinephrine	116-130	monoamine oxidase A	Homo sapiens	27-38
23858446-2	2013	The combined deficiency of MAO A and B results in significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-phenylethylamine; in humans and mice, these neurochemical changes are accompanied by neurodevelopmental perturbations as well as autistic-like responses.	Dopamine	132-140	monoamine oxidase A	Homo sapiens	27-38
23858446-2	2013	The combined deficiency of MAO A and B results in significantly elevated levels of serotonin (5-hydroxytryptamine), norepinephrine, dopamine, and beta-phenylethylamine; in humans and mice, these neurochemical changes are accompanied by neurodevelopmental perturbations as well as autistic-like responses.	phenethylamine	146-167	monoamine oxidase A	Homo sapiens	27-38
23360763-3	2013	In the former case one of the new compounds, C624 (naphto [1,2-b]benzofuran-5,9-diol) displays a potency comparable to that of the first-in-class DYRK1A inhibitor, harmine, lacking however the drawback of drastically inhibiting monoamine oxidase-A (MAO-A) as harmine does.	c624	45-49	monoamine oxidase A	Homo sapiens	228-247
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	tedizolid	10-19	monoamine oxidase A	Homo sapiens	70-75
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	tedizolid	10-19	monoamine oxidase A	Homo sapiens	157-168
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase A	Homo sapiens	70-75
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	Linezolid	24-33	monoamine oxidase A	Homo sapiens	157-168
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	tedizolid	131-140	monoamine oxidase A	Homo sapiens	70-75
23612197-3	2013	In vitro, tedizolid and linezolid were reversible inhibitors of human MAO-A and MAO-B; the 50% inhibitory concentration (IC50) for tedizolid was 8.7 muM for MAO-A and 5.7 muM for MAO-B and 46.0 and 2.1 muM, respectively, with linezolid.	tedizolid	131-140	monoamine oxidase A	Homo sapiens	157-168
23612197-9	2013	In summary, tedizolid is a weak, reversible inhibitor of MAO-A and MAO-B in vitro.	tedizolid	12-21	monoamine oxidase A	Homo sapiens	57-62
23360763-3	2013	In the former case one of the new compounds, C624 (naphto [1,2-b]benzofuran-5,9-diol) displays a potency comparable to that of the first-in-class DYRK1A inhibitor, harmine, lacking however the drawback of drastically inhibiting monoamine oxidase-A (MAO-A) as harmine does.	c624	45-49	monoamine oxidase A	Homo sapiens	249-254
23360763-3	2013	In the former case one of the new compounds, C624 (naphto [1,2-b]benzofuran-5,9-diol) displays a potency comparable to that of the first-in-class DYRK1A inhibitor, harmine, lacking however the drawback of drastically inhibiting monoamine oxidase-A (MAO-A) as harmine does.	naphto [1,2-b]benzofuran-5,9-diol	51-84	monoamine oxidase A	Homo sapiens	228-247
23360763-3	2013	In the former case one of the new compounds, C624 (naphto [1,2-b]benzofuran-5,9-diol) displays a potency comparable to that of the first-in-class DYRK1A inhibitor, harmine, lacking however the drawback of drastically inhibiting monoamine oxidase-A (MAO-A) as harmine does.	naphto [1,2-b]benzofuran-5,9-diol	51-84	monoamine oxidase A	Homo sapiens	249-254
23403377-1	2013	Positron emission tomography (PET) imaging of monoamine oxidases (MAO-A: [(11)C]harmine, [(11)C]clorgyline, and [(11)C]befloxatone; MAO-B: [(11)C]deprenyl-D2) has been actively pursued given clinical importance of MAOs in human neuropsychiatric disorders.	Harmine	80-87	monoamine oxidase A	Homo sapiens	66-71
23950608-14	2013	Methylene blue would seem to have monoamine oxidase A inhibitory properties.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	34-53
23739004-4	2013	MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline.	rasagiline	72-82	monoamine oxidase A	Homo sapiens	0-5
23739004-4	2013	MAO-A mediates the induction of antiapoptotic bcl-2 and mao-a itself by rasagiline, whereas a different mechanism is associated with selegiline.	rasagiline	72-82	monoamine oxidase A	Homo sapiens	56-61
23670301-10	2013	Histamine stimulation of human umbilical vein endothelial cells to activate endothelial NO synthase resulted in an increase in cyclic GMP, which was almost abrogated by MAO-A exposure.	Histamine	0-9	monoamine oxidase A	Homo sapiens	169-174
23631427-5	2013	The best derivative was N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide (17, Ki human A2A, 39.5 nM; IC50 human MAO-B, 34.9 nM; selective versus other AR subtypes and MAO-A), which inhibited A2AAR-induced cAMP accumulation and showed competitive, reversible MAO-B inhibition.	N-(4-oxo-4H-3,1-benzothiazin-2-yl)-4-phenylbutanamide	24-77	monoamine oxidase A	Homo sapiens	172-177
23589499-8	2013	Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.	2-arylbenzofurans	158-175	monoamine oxidase A	Homo sapiens	69-74
23589499-8	2013	Docking experiments for the most active compounds into the MAO-B and MAO-A binding pockets highlighted different interactions between the derivative classes (2-arylbenzofurans and 3-arylcoumarins), and provided new information about the enzyme-inhibitor interaction and the potential therapeutic application of these scaffolds.	3-arylcoumarins	180-195	monoamine oxidase A	Homo sapiens	69-74
23403377-1	2013	Positron emission tomography (PET) imaging of monoamine oxidases (MAO-A: [(11)C]harmine, [(11)C]clorgyline, and [(11)C]befloxatone; MAO-B: [(11)C]deprenyl-D2) has been actively pursued given clinical importance of MAOs in human neuropsychiatric disorders.	Carbon	77-79	monoamine oxidase A	Homo sapiens	66-71
23242742-0	2013	Insights into the binding mode of new N-substituted pyrazoline derivatives to MAO-A: docking and quantum chemical calculations.	n-substituted pyrazoline	38-62	monoamine oxidase A	Homo sapiens	78-83
23417310-2	2013	The detailed molecular mechanism proposed for the MAO-catalyzed oxidation of amines has been controversial with the basic assumption that both MAO A and MAO B follow the same pathway for the C-H bond cleavage step.	Amines	77-83	monoamine oxidase A	Homo sapiens	143-148
23417310-3	2013	Using the mechanistic approach of investigation of electronic effects of various benzylamine ring substituents in experiments at pH 9.0, human MAO A exhibits a kinetic behavior characteristic of an H(+) abstraction, while human MAO B exhibits kinetic properties characteristic of a H(-) abstraction.	benzylamine	81-92	monoamine oxidase A	Homo sapiens	143-148
23242742-1	2013	The binding modes of four N-substituted pyrazoline derivatives as novel MAO-A inhibitory agents were investigated using docking and quantum chemical molecular modelling tools.	n-substituted pyrazoline	26-50	monoamine oxidase A	Homo sapiens	72-77
23242744-1	2013	Monoamine oxidases (MAO) A and B are flavin adenine dinucleotides containing enzymes bound to the mitochondrial outer membranes of the cells of the brain, liver, intestine, and placenta, as well as platelets.	Flavin-Adenine Dinucleotide	37-65	monoamine oxidase A	Homo sapiens	0-32
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	hydrazine	0-9	monoamine oxidase A	Homo sapiens	115-120
23361656-3	2013	MAO activities of the compounds were compared with moclobemide and selegiline and all the compounds were found to inhibit human MAO-A selectively.	Moclobemide	51-62	monoamine oxidase A	Homo sapiens	128-133
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	hydrazine	0-9	monoamine oxidase A	Homo sapiens	250-255
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	jl72	10-14	monoamine oxidase A	Homo sapiens	115-120
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	jl72	10-14	monoamine oxidase A	Homo sapiens	250-255
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	CHEMBL3040149	16-48	monoamine oxidase A	Homo sapiens	115-120
23263540-2	2013	Hydrazine JL72 (3-(3-hydrazinylpropyl)-1H-indole) showed a potent, reversible and non-time-dependent inhibition of MAO-A, which suggests its capacity in restoring serotoninergic neurotransmission being devoid of the side effects observed for classic MAO-A inhibitors.	CHEMBL3040149	16-48	monoamine oxidase A	Homo sapiens	250-255
23263540-0	2013	A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.	indole	60-66	monoamine oxidase A	Homo sapiens	162-189
23263540-0	2013	A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.	Isoniazid	79-89	monoamine oxidase A	Homo sapiens	162-189
23263540-0	2013	A therapeutic approach to cerebrovascular diseases based on indole substituted hydrazides and hydrazines able to interact with human vascular adhesion protein-1, monoamine oxidases (A and B), AChE and BuChE.	Hydrazines	94-104	monoamine oxidase A	Homo sapiens	162-189
23263540-1	2013	Herein, we report the biological evaluation of a series of indole substituted hydrazides and hydrazines throughout the assessment of their multipotent inhibitory potency towards monoamine oxidase (MAO) A and B, semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1), and the cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	indole	59-65	monoamine oxidase A	Homo sapiens	178-209
23263540-1	2013	Herein, we report the biological evaluation of a series of indole substituted hydrazides and hydrazines throughout the assessment of their multipotent inhibitory potency towards monoamine oxidase (MAO) A and B, semicarbazide-sensitive amine oxidase/vascular adhesion protein-1 (SSAO/VAP-1), and the cholinesterases, acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE).	Isoniazid	78-88	monoamine oxidase A	Homo sapiens	178-209
23361656-3	2013	MAO activities of the compounds were compared with moclobemide and selegiline and all the compounds were found to inhibit human MAO-A selectively.	Selegiline	67-77	monoamine oxidase A	Homo sapiens	128-133
23499958-1	2013	Resveratrol is known as an activator of SIRT1, which leads to the deacetylation of histone and non-histone protein substrates, but also has other pharmacological profiles such as the inhibition of monoamine oxidase (MAO)-A and MAO-B.	Resveratrol	0-11	monoamine oxidase A	Homo sapiens	197-222
23717621-6	2013	Importantly, E-PZ-iPS-like cells re-expressed basal epithelial cell markers (CD44, p63, MAO-A) in response to prostate-specific medium in spheroid culture.	e-pz-ips	13-21	monoamine oxidase A	Homo sapiens	88-93
23499958-6	2013	The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation.	Clorgyline	42-52	monoamine oxidase A	Homo sapiens	23-28
23454517-1	2013	A novel series of tacrine-selegiline hybrids was synthesised and evaluated for application as inhibitors of cholinesterase (AChE/BuChE) and monoamine oxidase (MAO-A/B).	Tacrine	18-25	monoamine oxidase A	Homo sapiens	159-166
23499958-6	2013	The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation.	Pargyline	57-66	monoamine oxidase A	Homo sapiens	23-28
23499958-6	2013	The inhibition of both MAO-A and MAO-B by clorgyline and pargyline, respectively, enhanced the effects of cocaine on DARPP-32 phosphorylation.	Cocaine	106-113	monoamine oxidase A	Homo sapiens	23-28
23499958-7	2013	The acute effect of resveratrol on cocaine-induced DARPP-32 phosphorylation was occluded with inhibition of MAO-A and MAO-B.	Resveratrol	20-31	monoamine oxidase A	Homo sapiens	108-113
23499958-7	2013	The acute effect of resveratrol on cocaine-induced DARPP-32 phosphorylation was occluded with inhibition of MAO-A and MAO-B.	Cocaine	35-42	monoamine oxidase A	Homo sapiens	108-113
23499958-9	2013	Thus, this study provides pharmacological evidence that acute resveratrol enhances cocaine-induced dopamine neurotransmission and behavioral responses, presumably via mechanisms involving the inhibition of dopamine catabolism by MAO-A and MAO-B.	Resveratrol	62-73	monoamine oxidase A	Homo sapiens	229-234
23499958-9	2013	Thus, this study provides pharmacological evidence that acute resveratrol enhances cocaine-induced dopamine neurotransmission and behavioral responses, presumably via mechanisms involving the inhibition of dopamine catabolism by MAO-A and MAO-B.	Cocaine	83-90	monoamine oxidase A	Homo sapiens	229-234
23499958-9	2013	Thus, this study provides pharmacological evidence that acute resveratrol enhances cocaine-induced dopamine neurotransmission and behavioral responses, presumably via mechanisms involving the inhibition of dopamine catabolism by MAO-A and MAO-B.	Dopamine	206-214	monoamine oxidase A	Homo sapiens	229-234
23474901-1	2013	A series of (coumarin-3-yl)carbamates was synthesized and evaluated in vitro as monoamine oxidase (MAO-A and MAO-B) inhibitors.	(coumarin-3-yl)carbamates	12-37	monoamine oxidase A	Homo sapiens	99-104
23437843-3	2013	6"-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM &lt; IC50 &lt; 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity.	sulfonyloxy	3-14	monoamine oxidase A	Homo sapiens	63-68
23437843-3	2013	6"-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM &lt; IC50 &lt; 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity.	sulfonyloxy	3-14	monoamine oxidase A	Homo sapiens	146-153
23437843-3	2013	6"-Sulfonyloxy derivatives exhibited outstanding affinities to MAO-A (7.0 nM &lt; IC50 &lt; 49 nM, much higher than moclobemide) and a pronounced MAO-A/B selectivity.	Moclobemide	116-127	monoamine oxidase A	Homo sapiens	63-68
22968599-3	2013	Recently, type A MAO (MAO-A) was found to mediate the induction of anti-apoptotic Bcl-2 by rasagiline, whereas MAO-A increases in neuronal death and also serves as a target of neurotoxins.	rasagiline	91-101	monoamine oxidase A	Homo sapiens	22-27
23355817-6	2013	The study aimed to show that schizotypy as measured by the O-LIFE can indeed be regarded as an endophenotype of schizophrenia in terms of genetic associations regarding relevant dopamine-related candidate polymorphisms of schizotypy [i.e., Val(158)Met-polymorphism of the COMT gene, uVNTR of the MAOA gene, Taq1A-polymorphism of the DRD2 gene, VNTR of the SLC6A3 (DAT) gene].	Dopamine	178-186	monoamine oxidase A	Homo sapiens	296-300
22968599-5	2013	This paper reports that rasagiline and selegiline increased the mRNA, protein and catalytic activity of MAO-A in SH-SY5Y cells.	rasagiline	24-34	monoamine oxidase A	Homo sapiens	104-109
22968599-5	2013	This paper reports that rasagiline and selegiline increased the mRNA, protein and catalytic activity of MAO-A in SH-SY5Y cells.	Selegiline	39-49	monoamine oxidase A	Homo sapiens	104-109
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	10-15
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-6	2013	Silencing MAO-A expression with small interfering (si)RNA suppressed rasagiline-dependent MAO-A expression, but MAO-B overexpression in SH-SY5Y cells did not affect, suggesting that MAO-A, not MAO-B, might be associated with MAO-A upregulation.	rasagiline	69-79	monoamine oxidase A	Homo sapiens	90-95
22968599-7	2013	Rasagiline reduced R1, a MAO-A specific repressor, but selegiline did not.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	25-30
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	Dactinomycin	48-61	monoamine oxidase A	Homo sapiens	141-146
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	104-114	monoamine oxidase A	Homo sapiens	141-146
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	104-114	monoamine oxidase A	Homo sapiens	188-193
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	169-179	monoamine oxidase A	Homo sapiens	141-146
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	rasagiline	169-179	monoamine oxidase A	Homo sapiens	188-193
22968599-8	2013	Mithramycin-A, an inhibitor of Sp1 binding, and actinomycin-D, a transcriptional inhibitor, reduced the rasagiline-dependent upregulation of MAO-A mRNA, indicating that rasagiline induced MAO-A transcriptionally through R1-Sp1 pathway, whereas selegiline by another non-defined pathway.	Selegiline	244-254	monoamine oxidase A	Homo sapiens	141-146
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	14-oxoprunifoleine	58-76	monoamine oxidase A	Homo sapiens	222-227
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Monoterpenes	17-28	monoamine oxidase A	Homo sapiens	154-159
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	beta-carboline alkaloids	15-39	monoamine oxidase A	Homo sapiens	103-108
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	beta-carboline alkaloids	15-39	monoamine oxidase A	Homo sapiens	222-227
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Monoterpenes	17-28	monoamine oxidase A	Homo sapiens	257-262
24140951-6	2013	The epsilon-amino group of Lys 305 of MAO A is proposed as possible target of the ITC group of the inhibitor.	Lysine	27-30	monoamine oxidase A	Homo sapiens	38-43
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Indole Alkaloids	29-45	monoamine oxidase A	Homo sapiens	154-159
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Indole Alkaloids	29-45	monoamine oxidase A	Homo sapiens	257-262
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	angustine	53-62	monoamine oxidase A	Homo sapiens	154-159
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Vallesiachotamine lactone	64-89	monoamine oxidase A	Homo sapiens	154-159
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	Vallesiachotamine lactone	64-89	monoamine oxidase A	Homo sapiens	257-262
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	e-vallesiachotamine	91-110	monoamine oxidase A	Homo sapiens	154-159
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	z-vallesiachotamine	115-134	monoamine oxidase A	Homo sapiens	154-159
23261030-4	2013	In addition, the monoterpene indole alkaloids (MIAs) angustine, vallesiachotamine lactone, E-vallesiachotamine and Z-vallesiachotamine inhibited BChE and MAO-A with IC(50) values ranging from 3.47 to 14 muM for BChE inhibition and from 0.85 to 2.14 muM for MAO-A inhibition.	z-vallesiachotamine	115-134	monoamine oxidase A	Homo sapiens	257-262
23261030-5	2013	Among the tested MIAs, angustine is able to inhibit MAO-A in a reversible and competitive way while the three vallesiachotamine-like alkaloids display a time-dependent inhibition on this target.	angustine	23-32	monoamine oxidase A	Homo sapiens	52-57
23261030-7	2013	Taken together, our findings established molecular details of AChE, BChE and MAO-A inhibition by quaternary beta-carboline alkaloids and MIAs from Psychotria, suggesting these secondary metabolites are scaffolds for the development of multifunctional compounds against neurodegeneration.	beta-carboline alkaloids	108-132	monoamine oxidase A	Homo sapiens	77-82
23044341-1	2013	BACKGROUND: Several studies have hypothesized that genes involved in the dopamine system, including dopamine type-2 receptor (DRD2)-related TaqIA polymorphism and monoamine oxidase-A upstream variable number tandem repeat (uVNTR), may be associated with alcoholism.	Dopamine	73-81	monoamine oxidase A	Homo sapiens	163-182
24533911-3	2013	Our study identified the detailed structure activity relationship, the structural requirement for enzyme interaction and the effect of chirality on the pyrazoline nucleus towards MAO-A and MAO-B.	pyrazoline	152-162	monoamine oxidase A	Homo sapiens	179-184
23116392-1	2013	Flavin-containing monoamine oxidases (MAO A and MAO B) located on the outer membrane of mitochondria oxidise amines and generate hydrogen peroxide.	Amines	109-115	monoamine oxidase A	Homo sapiens	38-43
23116392-1	2013	Flavin-containing monoamine oxidases (MAO A and MAO B) located on the outer membrane of mitochondria oxidise amines and generate hydrogen peroxide.	Hydrogen Peroxide	129-146	monoamine oxidase A	Homo sapiens	38-43
24140951-1	2013	New polyamine derivatives 1-8, related to the previously reported N(1),N(12)-dibenzyldodecane-1,12-diamine (Bis-Bza-Diado) and N(1)-benzyl-spermine (BD6), have been synthesized and used as "probes" (potential substrates or inhibitors) of the human monoamine oxidases (MAO A and MAO B) and Vascular-Adhesion-protein -1 (VAP-1).	Polyamines	4-13	monoamine oxidase A	Homo sapiens	268-273
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	Prunifoleine	41-53	monoamine oxidase A	Homo sapiens	103-108
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	Prunifoleine	41-53	monoamine oxidase A	Homo sapiens	222-227
23261030-2	2013	Two quaternary beta-carboline alkaloids, prunifoleine and 14-oxoprunifoleine, inhibited AChE, BChE and MAO-A with IC(50) values corresponding to 10 and 3.39 muM for AChE, 100 and 11 muM for BChE, and 7.41 and 6.92 muM for MAO-A, respectively.	14-oxoprunifoleine	58-76	monoamine oxidase A	Homo sapiens	103-108
23018753-3	2013	MAO-A metabolises monoamines, and greater metabolism of monoamines occurs when MAO-A is elevated in brain.	monoamines	18-28	monoamine oxidase A	Homo sapiens	0-5
23018753-3	2013	MAO-A metabolises monoamines, and greater metabolism of monoamines occurs when MAO-A is elevated in brain.	monoamines	56-66	monoamine oxidase A	Homo sapiens	79-84
23018753-6	2013	These results argue for a mechanism of lowering extracellular serotonin in the prefrontal and anterior cingulate cortex, consequent to elevated MAO-A level.	Serotonin	62-71	monoamine oxidase A	Homo sapiens	144-149
23207409-1	2013	Due to their role in the metabolism of monoamine neurotransmitters, MAO-A and MAO-B present a significant pharmacological interest.	monoamine	39-48	monoamine oxidase A	Homo sapiens	68-73
24231308-4	2013	In particular, the 7-metachlorobenzyloxy-4-oxyacetamido-2H-chromen-2-one (entry 62) showed single digit nanomolar MAO-B potency (IC50 = 3.1 nM) and high selectivity over the MAO-A isoform (selectivity ratio = 7244).	7-metachlorobenzyloxy-4-oxyacetamido-2h-chromen-2-one	19-72	monoamine oxidase A	Homo sapiens	174-179
23124025-10	2013	As evidence of differential regulation of gene function by IL-4 and IL-13, we further report that MAO-A-mediated reactive oxygen species generation is influenced by different Jaks.	Reactive Oxygen Species	113-136	monoamine oxidase A	Homo sapiens	98-103
23182697-1	2013	New series of bioactive 7-oxycoumarin derivatives were synthesized and tested for their in vitro and in vivo monoamine oxidase (MAO) A and B inhibitory effect.	7-hydroxycoumarin	24-37	monoamine oxidase A	Homo sapiens	109-134
23881096-10	2013	Interactions of transcription factor AP-2beta, COMT, and MAOA polymorphisms suggest higher leverage effects of transcription factor AP-2beta in subjects with high dopamine availability.	Dopamine	163-171	monoamine oxidase A	Homo sapiens	57-61
23182697-0	2013	Monoamine oxidase A and B inhibiting effect and molecular modeling of some synthesized coumarin derivatives.	coumarin	87-95	monoamine oxidase A	Homo sapiens	0-25
23122857-6	2012	Among the compounds evaluated, 4-[(4-bromobenzyl)sulfanyl]phthalonitrile is a particularly promising inhibitor since it displayed a high degree of selectivity (8720-fold) for MAO-B over MAO-A, and potent MAO-B inhibition (IC(50)=0.025 muM).	CHEMBL2204757	31-72	monoamine oxidase A	Homo sapiens	186-191
24112955-4	2013	RESULTS: NAC treatment inhibited fat accumulation and reduced the expression of obesity-related proteins, including monoamine oxidase A, heat shock protein 70 (HSP70), aminoacylase -1 (ACY-1), and transketolase.	Acetylcysteine	9-12	monoamine oxidase A	Homo sapiens	116-135
23221997-0	2013	TPH1, MAOA, serotonin receptor 2A and 2C genes in citalopram response: possible effect in melancholic and psychotic depression.	Citalopram	50-60	monoamine oxidase A	Homo sapiens	6-10
22925371-5	2012	The link between these testosterone induced endophenotypes and actual display of antisocial behavior is strongly modulated by different social (e.g., social rejection, low SES) and genetic (e.g., MAOA, 5HTT) risk factors that can disturb socio-, psycho-, and biological development and interact with testosterone in shaping behavior.	Testosterone	23-35	monoamine oxidase A	Homo sapiens	196-200
23122934-7	2012	Both the 8-sulfanylcaffeine and 8-sulfinylcaffeine analogues were found to be weak MAO-A inhibitors.	8-sulfanylcaffeine	9-27	monoamine oxidase A	Homo sapiens	83-88
23153282-0	2012	Synthesis of new 7-oxycoumarin derivatives as potent and selective monoamine oxidase A inhibitors.	7-hydroxycoumarin	17-30	monoamine oxidase A	Homo sapiens	67-86
23122934-7	2012	Both the 8-sulfanylcaffeine and 8-sulfinylcaffeine analogues were found to be weak MAO-A inhibitors.	8-sulfinylcaffeine	32-50	monoamine oxidase A	Homo sapiens	83-88
23153282-1	2012	New series of 4-methyl and 3,4-dimethyl-7-oxycoumarin derivatives (oxadiazoles, thiadiazoles, triazoles, and thiazolidinones) were designed, synthesized, and evaluated for their monoamine oxidase (MAO) A and B inhibiting effect.	4-methyl	14-22	monoamine oxidase A	Homo sapiens	178-203
23153282-1	2012	New series of 4-methyl and 3,4-dimethyl-7-oxycoumarin derivatives (oxadiazoles, thiadiazoles, triazoles, and thiazolidinones) were designed, synthesized, and evaluated for their monoamine oxidase (MAO) A and B inhibiting effect.	3,4-dimethyl-7-oxycoumarin	27-53	monoamine oxidase A	Homo sapiens	178-203
23153282-2	2012	All the synthesized compounds showed in vitro high affinity and selectivity toward MAO-A isoenzyme, compared to clorgyline and moclobemide, with Ki values on the picomolar range.	Clorgyline	112-122	monoamine oxidase A	Homo sapiens	83-88
23153282-2	2012	All the synthesized compounds showed in vitro high affinity and selectivity toward MAO-A isoenzyme, compared to clorgyline and moclobemide, with Ki values on the picomolar range.	Moclobemide	127-138	monoamine oxidase A	Homo sapiens	83-88
23153282-4	2012	The docking experiments carried out on MAO-A and MAO-B structures proved new information about the enzyme-inhibitor interaction and the potential therapeutic application of 7-oxycoumarin scaffold.	7-hydroxycoumarin	173-186	monoamine oxidase A	Homo sapiens	39-44
22954708-5	2012	These are MAOA, ENPP2, and ALOX15 producing 5-methoxy-indole acetate, lysophosphatidic acid (LPA) and 13-hydroxyoctadienoic acid (13-HODE), and/or 15-hydroxyeicosatetraenoic acid (15-HETE), respectively.	5-methoxyindoleacetic acid	44-68	monoamine oxidase A	Homo sapiens	10-14
23064123-1	2012	A series of C7-substituted chromone (1-benzopyran-4-one) derivatives were synthesized and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	Chromones	27-35	monoamine oxidase A	Homo sapiens	135-166
23064123-1	2012	A series of C7-substituted chromone (1-benzopyran-4-one) derivatives were synthesized and evaluated as inhibitors of recombinant human monoamine oxidase (MAO) A and B.	4-chromone	37-55	monoamine oxidase A	Homo sapiens	135-166
23064123-4	2012	While the chromone derivatives also exhibit affinities for MAO-A, with IC(50) values ranging from 0.495 to 8.03 muM, they are selective for the MAO-B isoform.	Chromones	10-18	monoamine oxidase A	Homo sapiens	59-64
23064123-7	2012	With the aid of modeling studies, potential binding orientations and interactions of selected chromone derivatives in the MAO-A and -B active sites are examined.	Chromones	94-102	monoamine oxidase A	Homo sapiens	122-127
22954708-5	2012	These are MAOA, ENPP2, and ALOX15 producing 5-methoxy-indole acetate, lysophosphatidic acid (LPA) and 13-hydroxyoctadienoic acid (13-HODE), and/or 15-hydroxyeicosatetraenoic acid (15-HETE), respectively.	lysophosphatidic acid	93-96	monoamine oxidase A	Homo sapiens	10-14
22954708-5	2012	These are MAOA, ENPP2, and ALOX15 producing 5-methoxy-indole acetate, lysophosphatidic acid (LPA) and 13-hydroxyoctadienoic acid (13-HODE), and/or 15-hydroxyeicosatetraenoic acid (15-HETE), respectively.	Coriolic acid	130-137	monoamine oxidase A	Homo sapiens	10-14
22954708-5	2012	These are MAOA, ENPP2, and ALOX15 producing 5-methoxy-indole acetate, lysophosphatidic acid (LPA) and 13-hydroxyoctadienoic acid (13-HODE), and/or 15-hydroxyeicosatetraenoic acid (15-HETE), respectively.	Eicosatetraenoic acid, 15-hydroxy-	147-178	monoamine oxidase A	Homo sapiens	10-14
22954708-5	2012	These are MAOA, ENPP2, and ALOX15 producing 5-methoxy-indole acetate, lysophosphatidic acid (LPA) and 13-hydroxyoctadienoic acid (13-HODE), and/or 15-hydroxyeicosatetraenoic acid (15-HETE), respectively.	15-Hete	180-187	monoamine oxidase A	Homo sapiens	10-14
21992679-3	2012	Oxidation of MPTP by human MAO-B was more efficient than by MAO-A.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	13-17	monoamine oxidase A	Homo sapiens	60-65
21992679-5	2012	Clorgyline and the beta-carbolines, harman and norharman, inhibited the oxidation of MPTP by MAO-A.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	93-98
21992679-5	2012	Clorgyline and the beta-carbolines, harman and norharman, inhibited the oxidation of MPTP by MAO-A.	Carbolines	19-34	monoamine oxidase A	Homo sapiens	93-98
21992679-5	2012	Clorgyline and the beta-carbolines, harman and norharman, inhibited the oxidation of MPTP by MAO-A.	norharman	47-56	monoamine oxidase A	Homo sapiens	93-98
21992679-5	2012	Clorgyline and the beta-carbolines, harman and norharman, inhibited the oxidation of MPTP by MAO-A.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	85-89	monoamine oxidase A	Homo sapiens	93-98
21992679-6	2012	Cigarette smoke, as well as the naturally occurring beta-carbolines (norharman and harman) isolated from smoke and coffee inhibited the oxidation of MPTP by MAO-B and/or MAO-A, suggesting protective effects against MPTP.	Carbolines	52-67	monoamine oxidase A	Homo sapiens	170-175
21992679-6	2012	Cigarette smoke, as well as the naturally occurring beta-carbolines (norharman and harman) isolated from smoke and coffee inhibited the oxidation of MPTP by MAO-B and/or MAO-A, suggesting protective effects against MPTP.	norharman	69-78	monoamine oxidase A	Homo sapiens	170-175
21992679-6	2012	Cigarette smoke, as well as the naturally occurring beta-carbolines (norharman and harman) isolated from smoke and coffee inhibited the oxidation of MPTP by MAO-B and/or MAO-A, suggesting protective effects against MPTP.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	149-153	monoamine oxidase A	Homo sapiens	170-175
23116433-6	2012	DNA methylation in the MAOA promoter region was quantified by bisulfite pyrosequencing using genomic DNA isolated from peripheral blood leukocytes.	hydrogen sulfite	62-71	monoamine oxidase A	Homo sapiens	23-27
23197227-11	2012	The ability of clorgyline (an MAO-A inhibitor) to counteract oncogenic pathways and promote differentiation suggests that MAO-A inhibitors, which have been used for many years in clinical practise for treating neurological disorders, could be therapeutic options for advanced stages of tumours.	Clorgyline	15-25	monoamine oxidase A	Homo sapiens	30-35
23197227-11	2012	The ability of clorgyline (an MAO-A inhibitor) to counteract oncogenic pathways and promote differentiation suggests that MAO-A inhibitors, which have been used for many years in clinical practise for treating neurological disorders, could be therapeutic options for advanced stages of tumours.	Clorgyline	15-25	monoamine oxidase A	Homo sapiens	122-127
22235061-3	2012	Rodent models have revealed that methylene blue is a potent, reversible inhibitor of monoamine oxidase A.	Methylene Blue	33-47	monoamine oxidase A	Homo sapiens	85-104
23197705-1	2012	Monoamine oxidase-A (MAO-A), a key brain enzyme which metabolizes monoamines, is implicated in the pathophysiology of stress-related illnesses, including major depressive disorder, addiction, and violent behavior.	monoamines	66-76	monoamine oxidase A	Homo sapiens	0-19
23197705-1	2012	Monoamine oxidase-A (MAO-A), a key brain enzyme which metabolizes monoamines, is implicated in the pathophysiology of stress-related illnesses, including major depressive disorder, addiction, and violent behavior.	monoamines	66-76	monoamine oxidase A	Homo sapiens	21-26
23197705-8	2012	Acute dexamethasone exposure in neuronal and glial cells significantly decreased MAO-A activity and protein levels.	Dexamethasone	6-19	monoamine oxidase A	Homo sapiens	81-86
23197705-10	2012	Since MAO-A metabolizes monoamines, this phenomenon may explain why acute stressors benefit healthy animals even though chronic stress is associated with illness.	monoamines	24-34	monoamine oxidase A	Homo sapiens	6-11
23010267-5	2012	The most potent inhibitor, 5-(benzylsulfanyl)phthalimide, exhibits an IC(50) value of 0.0045 muM for the inhibition of MAO-B with a 427-fold selectivity for MAO-B compared to MAO-A.	CHEMBL2158241	27-56	monoamine oxidase A	Homo sapiens	175-180
22791347-5	2012	As regards the genes that influence the drug"s pharmacodynamics, polymorphisms of SLC6A4, HTR1A and MAO-A seem to be involved in the response to fluoxetine, while the genes COMT, CRHR1, PDEA1, PDEA11 GSK3B and serpin-1 also seem to play a role.	Fluoxetine	145-155	monoamine oxidase A	Homo sapiens	100-105
22382901-0	2012	Aspartic acid substitutions in monoamine oxidase-A reveal both catalytic-dependent and -independent influences on cell viability and proliferation.	Aspartic Acid	0-13	monoamine oxidase A	Homo sapiens	31-50
22382901-3	2012	We substituted three aspartic acid (D) residues in human MAO-A that reside in putative Ca2+-binding motifs and overexpressed the individual proteins in the human HEK293 cell line.	Aspartic Acid	21-34	monoamine oxidase A	Homo sapiens	57-62
22382901-5	2012	Innate MAO-A catalytic activity (and the capacity for generating hydrogen peroxide) was unaffected by the D61A substitution, but inhibited moderately or completely by the D248A and D328G substitutions, respectively.	Hydrogen Peroxide	65-82	monoamine oxidase A	Homo sapiens	7-12
22382901-6	2012	The Ca2+-sensitive activities of wild-type and D248A MAO-A proteins were enhanced by treatment with the selective p38(MAPK) inhibitor, SB203580, but was completely abrogated by the D61A substitution.	SB 203580	135-143	monoamine oxidase A	Homo sapiens	53-58
22382901-8	2012	As expected, the catalytic-dead MAO-A(D328G) was not cytotoxic, but unexpectedly enhanced both MTT conversion and BrdU staining.	monooxyethylene trimethylolpropane tristearate	95-98	monoamine oxidase A	Homo sapiens	32-37
22382901-8	2012	As expected, the catalytic-dead MAO-A(D328G) was not cytotoxic, but unexpectedly enhanced both MTT conversion and BrdU staining.	Bromodeoxyuridine	114-118	monoamine oxidase A	Homo sapiens	32-37
22948232-3	2012	Here, we analyzed MAOA methylation in white blood cells (by bisulphite conversion of genomic DNA and subsequent sequencing of cloned DNA products) and measured brain MAO A levels (using PET and [(11)C]clorgyline, a radiotracer with specificity for MAO A) in 34 healthy non-smoking male volunteers.	hydrogen sulfite	60-70	monoamine oxidase A	Homo sapiens	18-22
22948532-4	2012	However, the enzyme monoamine oxidase-A (MAO-A),             which has a key role in the degradation of catecholamines, has been associated             with the pathophysiology and therapeutics of both MDD and CVD.	Catecholamines	104-118	monoamine oxidase A	Homo sapiens	20-39
22948532-4	2012	However, the enzyme monoamine oxidase-A (MAO-A),             which has a key role in the degradation of catecholamines, has been associated             with the pathophysiology and therapeutics of both MDD and CVD.	Catecholamines	104-118	monoamine oxidase A	Homo sapiens	41-46
23000748-16	2012	This observation offers perspectives for the development of a more selective PET tracer for beta-cell mass, based on an (11)C-hydroxytryptophan derivative with increased resistance toward degradation by MAO-A.	5-Hydroxytryptophan	126-143	monoamine oxidase A	Homo sapiens	203-208
22473857-1	2012	BACKGROUND: Amine catabolism by monoamine oxidase A (MAOA) contributes to oxidative stress, which plays a role in prostate cancer (PCa) development and progression.	Amines	12-17	monoamine oxidase A	Homo sapiens	32-51
22473857-1	2012	BACKGROUND: Amine catabolism by monoamine oxidase A (MAOA) contributes to oxidative stress, which plays a role in prostate cancer (PCa) development and progression.	Amines	12-17	monoamine oxidase A	Homo sapiens	53-57
22985508-6	2012	The second model was induced by the administration of clorgyline, an MAO-A inhibitor, and 5-hydroxy-l-tryptophan, a precursor of 5-HT.	Clorgyline	54-64	monoamine oxidase A	Homo sapiens	69-74
26593027-1	2012	Monoamine oxidase (MAO), which exists in two isozymic forms, MAO A and MAO B, is an important flavoenzyme responsible for the metabolism of amine neurotransmitters such as dopamine, serotonin, and norepinephrine.	Amines	4-9	monoamine oxidase A	Homo sapiens	61-66
26593027-1	2012	Monoamine oxidase (MAO), which exists in two isozymic forms, MAO A and MAO B, is an important flavoenzyme responsible for the metabolism of amine neurotransmitters such as dopamine, serotonin, and norepinephrine.	Dopamine	172-180	monoamine oxidase A	Homo sapiens	61-66
26593027-1	2012	Monoamine oxidase (MAO), which exists in two isozymic forms, MAO A and MAO B, is an important flavoenzyme responsible for the metabolism of amine neurotransmitters such as dopamine, serotonin, and norepinephrine.	Serotonin	182-191	monoamine oxidase A	Homo sapiens	61-66
26593027-1	2012	Monoamine oxidase (MAO), which exists in two isozymic forms, MAO A and MAO B, is an important flavoenzyme responsible for the metabolism of amine neurotransmitters such as dopamine, serotonin, and norepinephrine.	Norepinephrine	197-211	monoamine oxidase A	Homo sapiens	61-66
26593027-9	2012	Thus, we offer here theoretical evidence that the amine is most likely to be present in the active site in its protonated form, which is similar to the conclusion from experimental studies of MAO A (Jones et al.	Amines	50-55	monoamine oxidase A	Homo sapiens	192-197
22906985-2	2012	Monoamine oxidase A (MAOA), the degradation enzyme of serotonin and dopamine, is suppressed in cholangiocarcinoma via an unknown mechanism.	Serotonin	54-63	monoamine oxidase A	Homo sapiens	0-19
22906985-2	2012	Monoamine oxidase A (MAOA), the degradation enzyme of serotonin and dopamine, is suppressed in cholangiocarcinoma via an unknown mechanism.	Serotonin	54-63	monoamine oxidase A	Homo sapiens	21-25
22906985-2	2012	Monoamine oxidase A (MAOA), the degradation enzyme of serotonin and dopamine, is suppressed in cholangiocarcinoma via an unknown mechanism.	Dopamine	68-76	monoamine oxidase A	Homo sapiens	0-19
22906985-2	2012	Monoamine oxidase A (MAOA), the degradation enzyme of serotonin and dopamine, is suppressed in cholangiocarcinoma via an unknown mechanism.	Dopamine	68-76	monoamine oxidase A	Homo sapiens	21-25
22674756-4	2012	5-(4-Fluorophenyl)-3-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide (1.0 x 10(-3)  microM) was found to inhibit hMAO-A most selectively and potently.	5-(4-fluorophenyl)-3-(4-methoxyphenyl)-n-methyl-4,5-dihydro-1h-pyrazole-1-carbothioamide	0-88	monoamine oxidase A	Homo sapiens	133-139
22674756-5	2012	The binding mode of 5-(4-fluorophenyl)-3-(4-methoxyphenyl)-N-methyl-4,5-dihydro-1H-pyrazole-1-carbothioamide to hMAO-A was also predicted using docking studies.	5-(4-fluorophenyl)-3-(4-methoxyphenyl)-n-methyl-4,5-dihydro-1h-pyrazole-1-carbothioamide	20-108	monoamine oxidase A	Homo sapiens	112-118
22781190-5	2012	The compound (E)-5-[(6-bromo-1H-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one (3x) possessed an IC(50) of 5.6 nM at MAO-A and had a selectivity index of 80.24.	(e)-5-[(6-bromo-1h-indol-3-yl)methylene]-2-imino-1,3-dimethylimidazolidin-4-one	13-92	monoamine oxidase A	Homo sapiens	131-136
22569243-0	2012	Monoamine oxidase A down-regulation contributes to high metanephrine concentration in pheochromocytoma.	Metanephrine	56-68	monoamine oxidase A	Homo sapiens	0-19
22705191-1	2012	A recent study has reported that a series of 8-benzyloxycaffeines are potent and reversible inhibitors of both human monoamine oxidase (MAO) isoforms, MAO-A and -B.	8-benzyloxycaffeines	45-65	monoamine oxidase A	Homo sapiens	151-163
22714663-3	2012	A resulting product was converted into an MAO-A inhibitor, befloxatone.	befloxatone	59-70	monoamine oxidase A	Homo sapiens	42-47
22705191-8	2012	Using molecular docking experiments, this study also proposes possible binding orientations of selected caffeine derivatives in the active sites of MAO-A and -B.	Caffeine	104-112	monoamine oxidase A	Homo sapiens	148-160
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	monoamine	5-14	monoamine oxidase A	Homo sapiens	26-31
22547424-10	2012	CONCLUSIONS: These results suggest that genetically altered fatty acid metabolism predisposes to type 2 diabetes and propose a role for catecholamine-metabolizing enzymes like MAOA in the regulation of energy metabolism.	Fatty Acids	60-70	monoamine oxidase A	Homo sapiens	176-180
22547424-10	2012	CONCLUSIONS: These results suggest that genetically altered fatty acid metabolism predisposes to type 2 diabetes and propose a role for catecholamine-metabolizing enzymes like MAOA in the regulation of energy metabolism.	Catecholamines	136-149	monoamine oxidase A	Homo sapiens	176-180
21521428-2	2012	One of the major ingredients of BQ, arecoline, is known to affect the expression of monoamine oxidase A (MAO-A).	bulaquine	32-34	monoamine oxidase A	Homo sapiens	84-103
21521428-2	2012	One of the major ingredients of BQ, arecoline, is known to affect the expression of monoamine oxidase A (MAO-A).	bulaquine	32-34	monoamine oxidase A	Homo sapiens	105-110
21521428-2	2012	One of the major ingredients of BQ, arecoline, is known to affect the expression of monoamine oxidase A (MAO-A).	Arecoline	36-45	monoamine oxidase A	Homo sapiens	84-103
21521428-2	2012	One of the major ingredients of BQ, arecoline, is known to affect the expression of monoamine oxidase A (MAO-A).	Arecoline	36-45	monoamine oxidase A	Homo sapiens	105-110
21521428-6	2012	Our results indicate that arecoline and ANE inhibit MAO-A expression both in vitro and in vivo.	Arecoline	26-35	monoamine oxidase A	Homo sapiens	52-57
21521428-6	2012	Our results indicate that arecoline and ANE inhibit MAO-A expression both in vitro and in vivo.	ane	40-43	monoamine oxidase A	Homo sapiens	52-57
21521428-7	2012	In addition, we examined the correlation between plasma MAO-A activity and cumulative exposure to BQ in humans.	bulaquine	98-100	monoamine oxidase A	Homo sapiens	56-61
21521428-8	2012	We recruited 1307 aborigines from a large-scale community-based survey to determine whether MAO-A variants were associated with high BQ use and a preference for use with smoking or alcohol and whether gender bias existed.	bulaquine	133-135	monoamine oxidase A	Homo sapiens	92-97
21521428-10	2012	MAO-A activity levels in human plasma were positively correlated with the extent of BQ exposure, and individuals with at-risk alleles exhibited lower activity, although this result did not reach statistical significance.	bulaquine	84-86	monoamine oxidase A	Homo sapiens	0-5
21521428-14	2012	Our results suggest that two specific loci may confer a susceptibility to BQ abuse and affect MAO-A enzymatic activity.	bulaquine	74-76	monoamine oxidase A	Homo sapiens	94-99
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	Serotonin	131-140	monoamine oxidase A	Homo sapiens	5-24
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	Serotonin	131-140	monoamine oxidase A	Homo sapiens	26-31
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	Dopamine	142-150	monoamine oxidase A	Homo sapiens	5-24
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	Norepinephrine	156-170	monoamine oxidase A	Homo sapiens	5-24
22544010-0	2012	Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.	Olanzapine	65-75	monoamine oxidase A	Homo sapiens	37-41
22890201-2	2012	Both monoamine oxidase A (MAO-A) and monoamine oxidase B (MAO-B) regulate neurochemistry by degrading monoamine neurotransmitters (serotonin, dopamine, and norepinephrine).	Norepinephrine	156-170	monoamine oxidase A	Homo sapiens	26-31
22503231-1	2012	The synthesis, pharmacological evaluation and molecular modeling of heterocyclic substituted alkyl and cycloalkyl propargyl amines 1-7 of type I, and 9-12 of type II, designed as multipotent inhibitors able to simultaneously inhibit monoamine oxidases (MAO-A/B) as well as cholinesterase (AChE/BuChE) enzymes, as potential drugs for the treatment of Alzheimer"s disease, are described.	cycloalkyl propargyl amines	103-130	monoamine oxidase A	Homo sapiens	253-260
22544010-0	2012	Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.	Risperidone	77-88	monoamine oxidase A	Homo sapiens	37-41
22544010-0	2012	Different impacts of aquaporin 4 and MAOA allele variation among olanzapine, risperidone, and paliperidone in schizophrenia.	Paliperidone Palmitate	94-106	monoamine oxidase A	Homo sapiens	37-41
20641293-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Serotonin	30-39	monoamine oxidase A	Homo sapiens	0-5
22640768-8	2012	It is not surprising that the genes discovered so far act in a variety of ways: via altered metabolism of drug (the alcohol and nicotine metabolic gene variants), via altered function of a drug receptor (the nicotinic receptor, which may alter affinity for nicotine but as discussed may also alter circuitry of reward), and via general mechanisms of addiction (genes such as monoamine oxidase A and the serotonin transporter that modulate stress response, emotion, and behavioral control).	Alcohols	116-123	monoamine oxidase A	Homo sapiens	375-394
22640768-8	2012	It is not surprising that the genes discovered so far act in a variety of ways: via altered metabolism of drug (the alcohol and nicotine metabolic gene variants), via altered function of a drug receptor (the nicotinic receptor, which may alter affinity for nicotine but as discussed may also alter circuitry of reward), and via general mechanisms of addiction (genes such as monoamine oxidase A and the serotonin transporter that modulate stress response, emotion, and behavioral control).	Nicotine	128-136	monoamine oxidase A	Homo sapiens	375-394
22640768-8	2012	It is not surprising that the genes discovered so far act in a variety of ways: via altered metabolism of drug (the alcohol and nicotine metabolic gene variants), via altered function of a drug receptor (the nicotinic receptor, which may alter affinity for nicotine but as discussed may also alter circuitry of reward), and via general mechanisms of addiction (genes such as monoamine oxidase A and the serotonin transporter that modulate stress response, emotion, and behavioral control).	Nicotine	257-265	monoamine oxidase A	Homo sapiens	375-394
21628600-2	2012	Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine.	Tyramine	156-164	monoamine oxidase A	Homo sapiens	28-52
21628600-2	2012	Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine.	Tyramine	156-164	monoamine oxidase A	Homo sapiens	54-59
21628600-2	2012	Pharmacologic inhibition of monoamine oxidase type A (MAO-A), but not MAO-B, poses a risk of the "cheese effect," a hypertensive response to excess dietary tyramine, a biogenic sympathomimetic amine.	Amines	32-37	monoamine oxidase A	Homo sapiens	54-59
22065207-3	2012	Rasagiline and (-)deprenyl, and also befloxatone, a reversible MAO-A inhibitor, increased Bcl-2 mRNA and protein in SH-SY5Y cells.	befloxatone	37-48	monoamine oxidase A	Homo sapiens	63-68
22065207-4	2012	Silencing MAO-A expression with short interfering (si) RNA suppressed Bcl-2 induction by rasagiline, but not by (-)deprenyl.	rasagiline	89-99	monoamine oxidase A	Homo sapiens	10-15
22065207-6	2012	The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.	rasagiline	46-56	monoamine oxidase A	Homo sapiens	18-23
22065207-6	2012	The novel role of MAO-A in Bcl-2 induction by rasagiline is discussed with regard to the molecular mechanism underlying neuroprotection by the MAO inhibitors.	rasagiline	46-56	monoamine oxidase A	Homo sapiens	18-21
22365943-4	2012	Patients who lack both MAOA and MAOB have the most extreme laboratory values (urine, blood, and CSF serotonin 4-6 times normal, with elevated O-methylated amine metabolites and reduced deaminated metabolites) in addition to severe intellectual deficiency and behavioral problems.	Serotonin	100-109	monoamine oxidase A	Homo sapiens	23-27
22499122-6	2012	Moreover, we have newly identified the two genes that are down-regulated in ESCC: monoamine oxidase A, an enzyme that catalyzes monoamines oxidation and 15-hydroxyprostaglandin dehydrogenase [NAD+], a prostaglandin-synthesizing enzyme that physiologically antagonizes COX-2.	monoamines	128-138	monoamine oxidase A	Homo sapiens	82-101
22499122-6	2012	Moreover, we have newly identified the two genes that are down-regulated in ESCC: monoamine oxidase A, an enzyme that catalyzes monoamines oxidation and 15-hydroxyprostaglandin dehydrogenase [NAD+], a prostaglandin-synthesizing enzyme that physiologically antagonizes COX-2.	Prostaglandins	163-176	monoamine oxidase A	Homo sapiens	82-101
20641293-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Norepinephrine	44-57	monoamine oxidase A	Homo sapiens	0-5
20641293-6	2004	HAR is a carboline analog, which is a competitive and reversible inhibitor of MAO-A with a Ki of 5 nM (6).	Carbolines	9-18	monoamine oxidase A	Homo sapiens	78-83
22186668-0	2012	Dynamic, adaptive changes in MAO-A binding after alterations in substrate availability: an in vivo [(11)C]-harmine positron emission tomography study.	[(11)c]-harmine	99-114	monoamine oxidase A	Homo sapiens	29-34
22309913-4	2012	The chromones were also found to bind reversibly to MAO-A, but with lower affinities compared to MAO-B.	Chromones	4-13	monoamine oxidase A	Homo sapiens	52-57
22309913-6	2012	The results of this study are discussed with reference to possible binding orientations of a selected C6-substituted chromone in the active site cavities of MAO-A and -B.	Chromones	117-125	monoamine oxidase A	Homo sapiens	157-169
22186668-2	2012	We measured the effect of changes in MAO-A substrate on MAO-A binding in regions implicated in affective and neurodegenerative disease with [(11)C]-harmine positron emission tomography in healthy volunteers.	Harmine	146-155	monoamine oxidase A	Homo sapiens	56-61
22186668-3	2012	Monoamine oxidase A V(T), an index of MAO-A density, was decreased (mean: 14%+-9%) following tryptophan depletion in prefrontal cortex (P<0.031), and elevated (mean: 17%+-11%) in striatum following carbidopa-levodopa administration (P<0.007).	Tryptophan	93-103	monoamine oxidase A	Homo sapiens	0-19
22186668-3	2012	Monoamine oxidase A V(T), an index of MAO-A density, was decreased (mean: 14%+-9%) following tryptophan depletion in prefrontal cortex (P<0.031), and elevated (mean: 17%+-11%) in striatum following carbidopa-levodopa administration (P<0.007).	Carbidopa	198-207	monoamine oxidase A	Homo sapiens	0-19
22186668-3	2012	Monoamine oxidase A V(T), an index of MAO-A density, was decreased (mean: 14%+-9%) following tryptophan depletion in prefrontal cortex (P<0.031), and elevated (mean: 17%+-11%) in striatum following carbidopa-levodopa administration (P<0.007).	Levodopa	208-216	monoamine oxidase A	Homo sapiens	0-19
22186668-4	2012	These findings suggest an adaptive role for MAO-A in maintaining monoamine neurotransmitter homeostasis by rapidly compensating fluctuating monoamine levels.	monoamine	65-74	monoamine oxidase A	Homo sapiens	44-49
22396688-2	2012	The present study aimed to compare the treatment adherence of SAD patients who were taking either SSRIs or reversible inhibitors of MAO-A (moclobemide) by measuring treatment duration and all-cause discontinuation rates of pharmacotherapy in a natural clinical setting.	Moclobemide	139-150	monoamine oxidase A	Homo sapiens	132-137
22264472-0	2012	Inhibition of human monoamine oxidase A and B by 5-phenoxy 8-aminoquinoline analogs.	5-phenoxy-8-aminoquinoline	49-75	monoamine oxidase A	Homo sapiens	20-39
22225638-4	2012	We also found that derivatives of the natural product sulfuretin are potent MAO-A and MAO-B inhibitors.	sulfuretin	54-64	monoamine oxidase A	Homo sapiens	76-81
21570786-2	2012	We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity.	Serotonin	30-39	monoamine oxidase A	Homo sapiens	113-118
21570786-2	2012	We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity.	N-Methyl-3,4-methylenedioxyamphetamine	78-82	monoamine oxidase A	Homo sapiens	113-118
21570786-2	2012	We report four cases of fatal serotonin toxicity caused by the combination of MDMA and moclobemide, a reversible MAO-A inhibitor with potent serotonergic activity.	Moclobemide	87-98	monoamine oxidase A	Homo sapiens	113-118
22100142-6	2012	The phthalonitriles also interacted with human MAO-A, although with lower binding affinities compared to MAO-B.	1,2-benzenedicarbonitrile	4-19	monoamine oxidase A	Homo sapiens	47-52
22218074-6	2012	Second, measures related to mechanisms of monoamine loss, particularly elevated MAO-A binding in prefrontal and anterior cingulate cortex, are present in MDE and in high-risk states for MDE.	monoamine	42-51	monoamine oxidase A	Homo sapiens	80-85
21912392-0	2012	Genetically based reduced MAOA and COMT functioning is associated with the cortisol stress response: a replication study.	Hydrocortisone	75-83	monoamine oxidase A	Homo sapiens	26-30
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	monoamines	80-90	monoamine oxidase A	Homo sapiens	0-19
22197611-9	2012	These results suggest that azure B may be a hitherto under recognized contributor to the pharmacology and toxicology of MB by blocking central and peripheral MAO-A activity and as such needs to be considered during its use in humans and animals.	Azure B	27-34	monoamine oxidase A	Homo sapiens	158-163
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	monoamines	80-90	monoamine oxidase A	Homo sapiens	21-25
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	Dopamine	100-108	monoamine oxidase A	Homo sapiens	0-19
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	Dopamine	100-108	monoamine oxidase A	Homo sapiens	21-25
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	Serotonin	113-122	monoamine oxidase A	Homo sapiens	0-19
22162429-1	2012	Monoamine oxidase A (MAOA) is the enzyme responsible for degradation of several monoamines, such as dopamine and serotonin that are considered as being two of the most important neurotransmitters involved in the pathophysiology of schizophrenia.	Serotonin	113-122	monoamine oxidase A	Homo sapiens	21-25
22572099-3	2012	METHODS: With the use of quantitative real-time polymerase chain reaction and ELISA the expression of genes connected to the dopamine pathway (PAH, PCD, TH, DDC, DBH, PNMT, GPX1, MAOA, MAOB, COMT, DRD1-DRD5, VMAT1 and VMAT2) was observed in vitiligo patients" and control subjects" skin and blood.	Dopamine	125-133	monoamine oxidase A	Homo sapiens	179-183
23231394-2	2012	With both forms of monoamine oxidase (A and B), the production of hydrogen peroxide as a byproduct of the reaction between the monoamine oxidases and their monoamine substrates has also implicated monoamine oxidase-sensitive events in intrinsic cell death pathways, particularly those centered on oxidative stress and peroxyradical-mediated mechanisms.	Hydrogen Peroxide	66-83	monoamine oxidase A	Homo sapiens	19-45
22124705-1	2012	The aim of this study was to determine the correlation between total nitrite/nitrate concentrations (NOx) and the kinetic parameters of monoamine oxidase enzymes (MAO-A and MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) in human mesenteric arteries.	Nitrites	69-76	monoamine oxidase A	Homo sapiens	163-168
22124705-1	2012	The aim of this study was to determine the correlation between total nitrite/nitrate concentrations (NOx) and the kinetic parameters of monoamine oxidase enzymes (MAO-A and MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) in human mesenteric arteries.	Nitrates	77-84	monoamine oxidase A	Homo sapiens	163-168
22124705-1	2012	The aim of this study was to determine the correlation between total nitrite/nitrate concentrations (NOx) and the kinetic parameters of monoamine oxidase enzymes (MAO-A and MAO-B) and semicarbazide-sensitive amine oxidase (SSAO) in human mesenteric arteries.	nicotine 1-N-oxide	101-104	monoamine oxidase A	Homo sapiens	163-168
22572099-6	2012	We provide new data about changes of expression profile of the dopamine-synthesizing enzyme DDC, the dopamine-degrading enzymes MAOA and MAOB and the D1-like family dopamine receptors in vitiligo skin and blood sera.	Dopamine	101-109	monoamine oxidase A	Homo sapiens	128-132
22071524-8	2011	Additionally, docking studies suggest the phenyl side groups of Tyr407 and Tyr444 (for MAO-A) or Tyr398 and Tyr435 (for MAO-B) play an important role in the interaction of the enzyme with 1,4-NQ scaffold through forces of dispersion as verified for menadione, TMN and 1,4-NQ.	Vitamin K 3	249-258	monoamine oxidase A	Homo sapiens	87-92
22169038-5	2011	SIRT1 deacetylates the brain-specific helix-loop-helix transcription factor NHLH2 on lysine 49 to increase its activation of the MAO-A promoter.	Lysine	85-91	monoamine oxidase A	Homo sapiens	129-134
22071524-8	2011	Additionally, docking studies suggest the phenyl side groups of Tyr407 and Tyr444 (for MAO-A) or Tyr398 and Tyr435 (for MAO-B) play an important role in the interaction of the enzyme with 1,4-NQ scaffold through forces of dispersion as verified for menadione, TMN and 1,4-NQ.	1,4-naphthoquinone	188-194	monoamine oxidase A	Homo sapiens	87-92
23231395-8	2012	MAO-A is a target of an endogenous neurotoxin, Nmethyl( R)salsolinol, and MAO-A knockdown (KO) with short interfering (si)RNA protects neuronal death from apoptosis.	salsoline	47-68	monoamine oxidase A	Homo sapiens	0-5
23231397-4	2012	Differently substituted coumarins have been synthesized and evaluated as MAO-A and MAO-B inhibitors.	Coumarins	24-33	monoamine oxidase A	Homo sapiens	73-78
23231398-7	2012	For this reason, multiple scaffolds, such as substituted coumarins, indolylmethylamine or pyridazine derivatives were synthesized and assayed toward MAO-A and MAO-B inhibition.	Coumarins	57-66	monoamine oxidase A	Homo sapiens	149-154
23231398-7	2012	For this reason, multiple scaffolds, such as substituted coumarins, indolylmethylamine or pyridazine derivatives were synthesized and assayed toward MAO-A and MAO-B inhibition.	indolylmethylamine	68-86	monoamine oxidase A	Homo sapiens	149-154
23231398-7	2012	For this reason, multiple scaffolds, such as substituted coumarins, indolylmethylamine or pyridazine derivatives were synthesized and assayed toward MAO-A and MAO-B inhibition.	pyridazine	90-100	monoamine oxidase A	Homo sapiens	149-154
22055712-1	2011	In a recent study it was shown that 8-benzyloxycaffeine analogues act as potent reversible inhibitors of human monoamine oxidase (MAO) A and B.	8-Benzyloxycaffeine	36-55	monoamine oxidase A	Homo sapiens	111-142
22071524-8	2011	Additionally, docking studies suggest the phenyl side groups of Tyr407 and Tyr444 (for MAO-A) or Tyr398 and Tyr435 (for MAO-B) play an important role in the interaction of the enzyme with 1,4-NQ scaffold through forces of dispersion as verified for menadione, TMN and 1,4-NQ.	1,4-naphthoquinone	268-274	monoamine oxidase A	Homo sapiens	87-92
22055712-6	2011	While the sulfanylcaffeine analogues also exhibit affinities for MAO-A, they display in general a high degree of MAO-B selectivity.	sulfanylcaffeine	10-26	monoamine oxidase A	Homo sapiens	65-70
22055712-8	2011	The results of this study are discussed with reference to possible binding orientations of selected caffeine analogues within the active site cavities of MAO-A and -B.	Caffeine	100-108	monoamine oxidase A	Homo sapiens	154-166
22078410-0	2011	Time-dependent slowly-reversible inhibition of monoamine oxidase A by N-substituted 1,2,3,6-tetrahydropyridines.	n-substituted 1,2,3,6-tetrahydropyridines	70-111	monoamine oxidase A	Homo sapiens	47-66
22078410-1	2011	A novel class of N-substituted tetrahydropyridine derivatives was found to have multiple kinetic mechanisms of monoamine oxidase A inhibition.	n-substituted tetrahydropyridine	17-49	monoamine oxidase A	Homo sapiens	111-130
22078410-2	2011	Eleven structurally similar tetrahydropyridine derivatives were synthesized and evaluated as inhibitors of MAO-A and MAO-B.	Pyrrolidines	28-46	monoamine oxidase A	Homo sapiens	107-112
22078410-5	2011	Evidence that the slow-binding inhibition of MAO-A with 12 involves a covalent bond was gained from stabilizing a covalent reversible intermediate product by reduction with sodium borohydride.	sodium borohydride	173-191	monoamine oxidase A	Homo sapiens	45-50
22078410-8	2011	Two tetrahydropyridine analogs that selectively inhibited MAO-A were characterized by kinetic mechanisms differing from the kinetic mechanism of 12.	Pyrrolidines	4-22	monoamine oxidase A	Homo sapiens	58-63
22078410-9	2011	As reversible inhibitors of MAO-A, tetrahydropyridine analogs are at low risk of having an adverse effect of tyramine-induced hypertension.	Pyrrolidines	35-53	monoamine oxidase A	Homo sapiens	28-33
22078410-9	2011	As reversible inhibitors of MAO-A, tetrahydropyridine analogs are at low risk of having an adverse effect of tyramine-induced hypertension.	Tyramine	109-117	monoamine oxidase A	Homo sapiens	28-33
22005185-0	2011	2D MI-DRAGON: a new predictor for protein-ligands interactions and theoretic-experimental studies of US FDA drug-target network, oxoisoaporphine inhibitors for MAO-A and human parasite proteins.	oxoisoaporphine	129-144	monoamine oxidase A	Homo sapiens	160-165
22017497-0	2011	Novel reversible monoamine oxidase A inhibitors: highly potent and selective 3-(1H-pyrrol-3-yl)-2-oxazolidinones.	3-(1h-pyrrol-3-yl)-2-oxazolidinones	77-112	monoamine oxidase A	Homo sapiens	17-36
22017497-2	2011	Herein we report a novel series of 3-(1H-pyrrol-3-yl)-2-oxazolidinones 3-7 as reversible, highly potent and selective anti-MAO-A agents.	3-(1h-pyrrol-3-yl)-2-oxazolidinones	35-70	monoamine oxidase A	Homo sapiens	123-128
22018876-2	2011	Here, four new 5H-indeno[1,2-c]pyridazin-5-one derivatives containing lipophilic groups at both positions were synthesized and their inhibitory potency against human monoamine oxidase A and B were evaluated.	5h-indeno[1,2-c]pyridazin-5-one	15-46	monoamine oxidase A	Homo sapiens	166-191
22005185-17	2011	We reported the prediction, synthesis, and pharmacological assay of 10 different oxoisoaporphines with MAO-A inhibitory activity.	oxoisoaporphines	81-97	monoamine oxidase A	Homo sapiens	103-108
21978362-1	2011	The major structural difference between human monoamine oxidases A (MAO A) and B (MAO B) is that MAO A has a monopartite substrate cavity of ~550 A(3) volume and MAO B contains a dipartite cavity structure with volumes of ~290 A(3) (entrance cavity) and ~400 A(3) (substrate cavity).	dipartite	179-188	monoamine oxidase A	Homo sapiens	68-73
21978362-1	2011	The major structural difference between human monoamine oxidases A (MAO A) and B (MAO B) is that MAO A has a monopartite substrate cavity of ~550 A(3) volume and MAO B contains a dipartite cavity structure with volumes of ~290 A(3) (entrance cavity) and ~400 A(3) (substrate cavity).	dipartite	179-188	monoamine oxidase A	Homo sapiens	97-102
21978362-9	2011	The Ile199Ala-Tyr326Ala double mutant exhibits inhibitor binding properties more similar to those of MAO A than to MAO B.	ile199ala	4-13	monoamine oxidase A	Homo sapiens	101-106
21899930-4	2011	Analysis of the possible binding interactions of these inhibitors with active site models of human MAO-A and -B led to the design of phenolic and benzonitrile derivatives of 2c and 2d.	benzonitrile	146-158	monoamine oxidase A	Homo sapiens	99-111
21463543-0	2011	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John"s wort: an [11C]-harmine PET study.	Moclobemide	91-102	monoamine oxidase A	Homo sapiens	0-19
21463543-0	2011	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John"s wort: an [11C]-harmine PET study.	Carbon-11	127-130	monoamine oxidase A	Homo sapiens	0-19
21463543-0	2011	Monoamine oxidase A inhibitor occupancy during treatment of major depressive episodes with moclobemide or St. John"s wort: an [11C]-harmine PET study.	Harmine	132-139	monoamine oxidase A	Homo sapiens	0-19
21463543-1	2011	BACKGROUND: Monoamine oxidase A (MAO-A) inhibitor antidepressants raise levels of multiple monoamines, whereas the selective serotonin reuptake inhibitors (SSRIs) only raise extracellular serotonin.	monoamines	91-101	monoamine oxidase A	Homo sapiens	12-31
21463543-1	2011	BACKGROUND: Monoamine oxidase A (MAO-A) inhibitor antidepressants raise levels of multiple monoamines, whereas the selective serotonin reuptake inhibitors (SSRIs) only raise extracellular serotonin.	monoamines	91-101	monoamine oxidase A	Homo sapiens	33-38
21463543-8	2011	Monoamine oxidase A VT decreased significantly throughout all regions after moclobemide treatment in patients with MDD compared with controls (repeated-measures analysis of variance, F1,15 = 71.08-130.06, p &lt; 0.001 for all regions, mean occupancy 74% [standard deviation 6%]).	Moclobemide	76-87	monoamine oxidase A	Homo sapiens	0-19
21463543-13	2011	The magnitude of MAO-A blockade during moclobemide treatment exceeds the elevation of MAO-A binding during illness by at least 30%, suggesting that the treatment effect should exceed the disease effect when designing selective antidepressants for this target.	Moclobemide	39-50	monoamine oxidase A	Homo sapiens	17-22
21923181-1	2011	New series of 6-substituted-3-arylcoumarins displaying several alkyl, hydroxyl, halogen, and alkoxy groups in the two benzene rings have been designed, synthesized, and evaluated in vitro as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors.	6-substituted-3-arylcoumarins	14-43	monoamine oxidase A	Homo sapiens	197-222
21923181-1	2011	New series of 6-substituted-3-arylcoumarins displaying several alkyl, hydroxyl, halogen, and alkoxy groups in the two benzene rings have been designed, synthesized, and evaluated in vitro as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors.	6-substituted-3-arylcoumarins	14-43	monoamine oxidase A	Homo sapiens	224-230
22282722-5	2011	Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson"s patients.	Rosiglitazone	0-13	monoamine oxidase A	Homo sapiens	142-147
22282722-5	2011	Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson"s patients.	Troglitazone	28-40	monoamine oxidase A	Homo sapiens	142-147
22282722-5	2011	Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson"s patients.	Thiazolidinediones	4-13	monoamine oxidase A	Homo sapiens	142-147
22282722-5	2011	Rosiglitazone (Avandia) and troglitazone, other members of the glitazone class, are less selective in that they are weaker inhibitors of both MAO A and MAO B These results suggest that pioglitazone may have utility as a "re-purposed" neuro-protectant drug in retarding the progression of disease in Parkinson"s patients.	Pioglitazone	185-197	monoamine oxidase A	Homo sapiens	142-147
21877764-3	2011	Pirlindole is a selective and reversible inhibitor of monoamine oxidase (MAO) subtype A (MAO-A) that is approved in some European and non-European countries for the treatment of depression.	pirlindole	0-10	monoamine oxidase A	Homo sapiens	89-94
21775495-0	2011	Valproic acid induces monoamine oxidase A via Akt/forkhead box O1 activation.	Valproic Acid	0-13	monoamine oxidase A	Homo sapiens	22-41
21851116-1	2011	Monoamine oxidase (MAO) A is a flavoenzyme that catalyzes the oxidation of biologically important monoamines and is thought to be associated with psychiatric disorders.	monoamines	98-108	monoamine oxidase A	Homo sapiens	0-25
21775495-5	2011	MAO A is a key enzyme that degrades a number of monoamine neurotransmitters, including serotonin.	monoamine	48-57	monoamine oxidase A	Homo sapiens	0-5
21775495-5	2011	MAO A is a key enzyme that degrades a number of monoamine neurotransmitters, including serotonin.	Serotonin	87-96	monoamine oxidase A	Homo sapiens	0-5
21777011-1	2011	3-Acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles were designed, synthesized, and tested as inhibitors against human monoamine oxidase (MAO) A and B isoforms.	3-acetyl-2,5-diaryl-2,3-dihydro-1,3,4-oxadiazoles	0-49	monoamine oxidase A	Homo sapiens	117-148
21851116-3	2011	Our designed (19)F probe was oxidized expeditiously by hMAO-A to produce 2-fluoro-4-nitrophenol via a spontaneous beta-elimination mechanism.	2-fluoro-4-nitrophenol	73-95	monoamine oxidase A	Homo sapiens	55-61
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	monoamine	70-79	monoamine oxidase A	Homo sapiens	0-19
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	monoamine	70-79	monoamine oxidase A	Homo sapiens	21-25
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Serotonin	108-117	monoamine oxidase A	Homo sapiens	0-19
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Serotonin	108-117	monoamine oxidase A	Homo sapiens	21-25
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Norepinephrine	126-140	monoamine oxidase A	Homo sapiens	0-19
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Norepinephrine	126-140	monoamine oxidase A	Homo sapiens	21-25
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Dopamine	151-159	monoamine oxidase A	Homo sapiens	0-19
21761555-1	2011	Monoamine oxidase A (MAOA) plays a critical role in the metabolism of monoamine neurotransmitters including serotonin (5-HT), norepinephrine (NE), and dopamine (DA).	Dopamine	151-159	monoamine oxidase A	Homo sapiens	21-25
21697081-1	2011	Monoamine oxidases (MAO-A, MAO-B) metabolize biogenic amines and have been implicated in neuronal apoptosis.	Amines	54-60	monoamine oxidase A	Homo sapiens	20-25
21949471-2	2011	We examined the interaction of a stressor (receipt of public assistance) and a gene regulating the monoamine system (MAOA) in the prediction of change in adolescent depressive symptoms and body mass index (BMI).	monoamine	99-108	monoamine oxidase A	Homo sapiens	117-121
21778064-1	2011	Literature reports that isatin as well as C5- and C6-substituted isatin analogues are reversible inhibitors of human monoamine oxidase (MAO) A and B.	Isatin	24-30	monoamine oxidase A	Homo sapiens	117-148
21778064-1	2011	Literature reports that isatin as well as C5- and C6-substituted isatin analogues are reversible inhibitors of human monoamine oxidase (MAO) A and B.	Isatin	65-71	monoamine oxidase A	Homo sapiens	117-148
21778064-3	2011	Crystallographic and modeling studies suggest that the isatin ring binds to the substrate cavities of MAO-A and -B and is stabilized by hydrogen bond interactions between the NH and the C2 carbonyl oxygen of the dioxoindolyl moiety and water molecules present in the substrate cavities of MAO-A and -B.	Isatin	55-61	monoamine oxidase A	Homo sapiens	102-114
21778064-3	2011	Crystallographic and modeling studies suggest that the isatin ring binds to the substrate cavities of MAO-A and -B and is stabilized by hydrogen bond interactions between the NH and the C2 carbonyl oxygen of the dioxoindolyl moiety and water molecules present in the substrate cavities of MAO-A and -B.	Isatin	55-61	monoamine oxidase A	Homo sapiens	289-301
21778064-3	2011	Crystallographic and modeling studies suggest that the isatin ring binds to the substrate cavities of MAO-A and -B and is stabilized by hydrogen bond interactions between the NH and the C2 carbonyl oxygen of the dioxoindolyl moiety and water molecules present in the substrate cavities of MAO-A and -B.	dioxoindolyl	212-224	monoamine oxidase A	Homo sapiens	102-114
21778064-3	2011	Crystallographic and modeling studies suggest that the isatin ring binds to the substrate cavities of MAO-A and -B and is stabilized by hydrogen bond interactions between the NH and the C2 carbonyl oxygen of the dioxoindolyl moiety and water molecules present in the substrate cavities of MAO-A and -B.	dioxoindolyl	212-224	monoamine oxidase A	Homo sapiens	289-301
21778064-3	2011	Crystallographic and modeling studies suggest that the isatin ring binds to the substrate cavities of MAO-A and -B and is stabilized by hydrogen bond interactions between the NH and the C2 carbonyl oxygen of the dioxoindolyl moiety and water molecules present in the substrate cavities of MAO-A and -B.	Water	236-241	monoamine oxidase A	Homo sapiens	102-114
21697081-8	2011	Similar abnormalities were observed when embryos were cultured in the presence of the MAO-A inhibitor clorgyline or when the transcriptional inhibitor of MAO-A expression R1 was overexpressed.	Clorgyline	102-112	monoamine oxidase A	Homo sapiens	86-91
21621312-1	2011	Recently it was reported that a series of 8-benzyloxycaffeine analogues are potent reversible inhibitors of human monoamine oxidase (MAO) A and B.	8-Benzyloxycaffeine	42-61	monoamine oxidase A	Homo sapiens	114-145
21621312-2	2011	In an attempt to discover additional C8 oxy substituents of caffeine that lead to potent MAO inhibition, a series of related 8-aryl- and alkyloxycaffeine analogues were synthesized and their MAO-A and -B inhibition potencies were compared to those of the 8-benzyloxycaffeines.	Caffeine	60-68	monoamine oxidase A	Homo sapiens	191-203
21621312-8	2011	This study also reports possible binding orientations of selected oxy caffeines within the active site cavities of MAO-A and MAO-B.	oxy caffeines	66-79	monoamine oxidase A	Homo sapiens	115-120
21684743-4	2011	The presence or absence of a carbonyl group between the coumarin and the phenyl substituent in 3 position remarks, respectively, the MAO-A or MAO-B inhibitory activity.	coumarin	56-64	monoamine oxidase A	Homo sapiens	133-138
21696156-5	2011	Notably, chromone (19) exhibits an MAO-B IC(50) of 63 nM, greater than 1000-fold selectivity over MAO-A, and behaves as a quasi-reversible inhibitor.	Chromones	9-17	monoamine oxidase A	Homo sapiens	98-103
21601990-1	2011	Personality trait research has shown associations with many genes, prominently those of the catecholamine metabolism such as dopamine beta hydroxylase (DBH), catechol-O-methyltransferase (COMT), and monoamine oxidase A (MAOA).	Catecholamines	92-105	monoamine oxidase A	Homo sapiens	199-218
21601990-1	2011	Personality trait research has shown associations with many genes, prominently those of the catecholamine metabolism such as dopamine beta hydroxylase (DBH), catechol-O-methyltransferase (COMT), and monoamine oxidase A (MAOA).	Catecholamines	92-105	monoamine oxidase A	Homo sapiens	220-224
21527290-7	2011	The dopamine catabolizing enzyme genes, such as monoamine oxidase (MAO) A and catechol-O-methyltransferase (COMT) genes, have been linked to aggressive behaviors.	Dopamine	4-12	monoamine oxidase A	Homo sapiens	48-73
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	monoamines	79-89	monoamine oxidase A	Homo sapiens	12-31
21476070-12	2011	The results are contrary to the previous kinetic experiments and the computational study on the effect of p-substituents in the flavin reduction of MAO A by p-substituted benzylamine analogs.	4,6-dinitro-o-cresol	128-134	monoamine oxidase A	Homo sapiens	148-153
21476070-12	2011	The results are contrary to the previous kinetic experiments and the computational study on the effect of p-substituents in the flavin reduction of MAO A by p-substituted benzylamine analogs.	benzylamine	171-182	monoamine oxidase A	Homo sapiens	148-153
21354322-2	2011	zMAO oxidizes the neurotransmitter amines (serotonin, dopamine and tyramine) with k(cat) values that exceed those of hMAO A or of hMAO B.	zmao	0-4	monoamine oxidase A	Homo sapiens	117-123
21354322-3	2011	The enzyme is competitively inhibited by hMAO A selective reversible inhibitors with the exception of d-amphetamine where uncompetitive inhibition is exhibited.	Dextroamphetamine	102-115	monoamine oxidase A	Homo sapiens	41-47
21359973-1	2011	Monoamine oxidase (MAO) A and MAO B are a crucial pair of isoenzymes, which oxidatively deaminate monoamine neurotransmitters and dietary amines with a production of hydrogen peroxide.	monoamine	98-107	monoamine oxidase A	Homo sapiens	0-25
21359973-1	2011	Monoamine oxidase (MAO) A and MAO B are a crucial pair of isoenzymes, which oxidatively deaminate monoamine neurotransmitters and dietary amines with a production of hydrogen peroxide.	Amines	138-144	monoamine oxidase A	Homo sapiens	0-25
21359973-1	2011	Monoamine oxidase (MAO) A and MAO B are a crucial pair of isoenzymes, which oxidatively deaminate monoamine neurotransmitters and dietary amines with a production of hydrogen peroxide.	Hydrogen Peroxide	166-183	monoamine oxidase A	Homo sapiens	0-25
21373759-5	2011	The ability of the PS-1 substrate-competitor DAPT to induce MAO-A activity in cells expressing either PS-1 wildtype or PS-1(M146V) suggests the potential for a direct influence of PS-1 on MAO-A function.	dapt	45-49	monoamine oxidase A	Homo sapiens	60-65
21373759-5	2011	The ability of the PS-1 substrate-competitor DAPT to induce MAO-A activity in cells expressing either PS-1 wildtype or PS-1(M146V) suggests the potential for a direct influence of PS-1 on MAO-A function.	dapt	45-49	monoamine oxidase A	Homo sapiens	188-193
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Serotonin	98-107	monoamine oxidase A	Homo sapiens	12-31
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Serotonin	98-107	monoamine oxidase A	Homo sapiens	33-37
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Norepinephrine	109-123	monoamine oxidase A	Homo sapiens	12-31
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Norepinephrine	109-123	monoamine oxidase A	Homo sapiens	33-37
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Dopamine	128-136	monoamine oxidase A	Homo sapiens	12-31
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	Dopamine	128-136	monoamine oxidase A	Homo sapiens	33-37
20810002-7	2011	MAOA binding was measured with [11C]harmine positron emission tomography (PET) in prefrontal brain regions and personality traits were measured with the NEO Personality Inventory Revised (NEO PI-R).	Carbon-11	32-35	monoamine oxidase A	Homo sapiens	0-4
20810002-7	2011	MAOA binding was measured with [11C]harmine positron emission tomography (PET) in prefrontal brain regions and personality traits were measured with the NEO Personality Inventory Revised (NEO PI-R).	Harmine	36-43	monoamine oxidase A	Homo sapiens	0-4
20810002-1	2011	BACKGROUND: Monoamine oxidase A (MAOA) is an important enzyme that metabolizes monoamines such as serotonin, norepinephrine and dopamine in the brain.	monoamines	79-89	monoamine oxidase A	Homo sapiens	33-37
21341713-1	2011	TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928].	Pargyline	18-27	monoamine oxidase A	Homo sapiens	79-98
21397504-2	2011	Herein described is pharmacophore generation and atom-based 3D-QSAR analysis of previously reported pyrrole based MAO-A inhibitors in order to get insight into their structural requirements responsible for high affinity.	Pyrroles	100-107	monoamine oxidase A	Homo sapiens	114-119
21341713-1	2011	TEMPO-substituted pargyline analogues differentially inhibit recombinant human monoamine oxidase A (MAO A) and B (MAO B) in intact yeast mitochondria, suggesting these membrane-bound enzymes are located on differing faces of the mitochondrial outer membrane [Upadhyay, A., and Edmondson, D. E. (2009) Biochemistry 48, 3928].	Pargyline	18-27	monoamine oxidase A	Homo sapiens	100-105
21152968-3	2011	Weighted analyses accounting for over-sampling and clustering within schools as well as controlling for age and wave suggested that deviant peer affiliation and MAOA genotype were each significantly associated with levels of overt ASB across a 6-year period.	asb	231-234	monoamine oxidase A	Homo sapiens	161-165
20731636-0	2011	MAOA genotype, family relations and sexual abuse in relation to adolescent alcohol consumption.	Alcohols	75-82	monoamine oxidase A	Homo sapiens	0-4
20731636-1	2011	The aim of the present study was to investigate MAOA gene-environment (G*E) interactions in relation to adolescent alcohol consumption.	Alcohols	115-122	monoamine oxidase A	Homo sapiens	48-52
20731636-8	2011	Results showed that the MAOA u-VNTR, in interaction with psychosocial risk factors, such as the quality of family relations and sexual abuse, was related to high alcohol consumption among adolescents.	Alcohols	162-169	monoamine oxidase A	Homo sapiens	24-28
20731636-9	2011	Girls, carrying the long MAOA u-VNTR variant showed a higher risk of being high alcohol consumers, whereas among boys, the short allele was related to higher alcohol consumption.	Alcohols	80-87	monoamine oxidase A	Homo sapiens	25-29
20731636-9	2011	Girls, carrying the long MAOA u-VNTR variant showed a higher risk of being high alcohol consumers, whereas among boys, the short allele was related to higher alcohol consumption.	Alcohols	158-165	monoamine oxidase A	Homo sapiens	25-29
20731636-10	2011	The present study supports the hypothesis that there is a relation between MAOA u-VNTR and alcohol consumption and that this relation is modulated by environmental factors.	Alcohols	91-98	monoamine oxidase A	Homo sapiens	75-79
21316817-2	2011	Series of 3-indolyl and 3-thiophenylcoumarins were synthesized and evaluated as inhibitors of the two human MAO isoforms, hMAO-A and hMAO-B.	3-thiophenylcoumarins	24-45	monoamine oxidase A	Homo sapiens	122-139
21079379-2	2011	Because monoamine oxidase-A (MAO-A) is a potent degrading enzyme of these monoamines, we hypothesized that orexin-A may mediate its arousal-inducing effects through MAO-A.	monoamines	74-84	monoamine oxidase A	Homo sapiens	8-27
21079379-2	2011	Because monoamine oxidase-A (MAO-A) is a potent degrading enzyme of these monoamines, we hypothesized that orexin-A may mediate its arousal-inducing effects through MAO-A.	monoamines	74-84	monoamine oxidase A	Homo sapiens	29-34
21079379-3	2011	Therefore, we simultaneously injected clorgyline, a specific inhibitor of MAO-A, with orexin-A and examined behavior of chicks.	Clorgyline	38-48	monoamine oxidase A	Homo sapiens	74-79
21079379-6	2011	Therefore, we conclude that orexin-A-induced arousal is dependent upon monoamine neural activities stimulated by MAO-A in chicks.	monoamine	71-80	monoamine oxidase A	Homo sapiens	113-118
21152968-5	2011	Additionally, there was evidence suggestive of a gene-environment interaction (G x E) where the influence of deviant peer affiliation on overt ASB was significantly stronger among individuals with the high-activity MAOA genotype than the low-activity genotype.	asb	143-146	monoamine oxidase A	Homo sapiens	215-219
21302344-2	2011	Well-characterized common functional polymorphisms in the genes MAOA, COMT, and 5HTTLPR each have predictable effects on the availability of the monoamine neurotransmitters dopamine, noradrenaline, and serotonin.	monoamine	145-154	monoamine oxidase A	Homo sapiens	64-68
21302344-2	2011	Well-characterized common functional polymorphisms in the genes MAOA, COMT, and 5HTTLPR each have predictable effects on the availability of the monoamine neurotransmitters dopamine, noradrenaline, and serotonin.	Dopamine	173-181	monoamine oxidase A	Homo sapiens	64-68
21302344-2	2011	Well-characterized common functional polymorphisms in the genes MAOA, COMT, and 5HTTLPR each have predictable effects on the availability of the monoamine neurotransmitters dopamine, noradrenaline, and serotonin.	Norepinephrine	183-196	monoamine oxidase A	Homo sapiens	64-68
21302344-2	2011	Well-characterized common functional polymorphisms in the genes MAOA, COMT, and 5HTTLPR each have predictable effects on the availability of the monoamine neurotransmitters dopamine, noradrenaline, and serotonin.	Serotonin	202-211	monoamine oxidase A	Homo sapiens	64-68
21302344-3	2011	We hypothesized that 5HTTLPR genotype would show little association with prefrontal cognitive performance, but that COMT and MAOA would have interacting effects on cognition through their shared influence on prefrontal catecholamine availability.	Catecholamines	219-232	monoamine oxidase A	Homo sapiens	125-129
21302344-6	2011	In boys but not girls, there was a modest but statistically significant interaction between MAOA and COMT genotypes such that increased prefrontal catecholamine availability was associated with better working memory.	Catecholamines	147-160	monoamine oxidase A	Homo sapiens	92-96
21383264-11	2011	CONCLUSIONS: Long-term cocaine users with the low-repeat MAOA allele have enhanced sensitivity to gray matter loss, specifically in the orbitofrontal cortex, indicating that this genotype may exacerbate the deleterious effects of cocaine in the brain.	Cocaine	23-30	monoamine oxidase A	Homo sapiens	57-61
21383264-11	2011	CONCLUSIONS: Long-term cocaine users with the low-repeat MAOA allele have enhanced sensitivity to gray matter loss, specifically in the orbitofrontal cortex, indicating that this genotype may exacerbate the deleterious effects of cocaine in the brain.	Cocaine	230-237	monoamine oxidase A	Homo sapiens	57-61
20142303-7	2011	Recent human data showed that an intravenous dose of only 0.75 mg kg(-1) of methylene blue produced a peak plasma concentration of 500 ng ml(-1) (1.6 microM), indicating that the concentration in the central nervous system reaches a level that inhibits monoamine oxidase A.	Methylene Blue	76-90	monoamine oxidase A	Homo sapiens	253-272
20850185-2	2011	The efficacy of PCL-R in varying monoamine oxidase A (MAOA) genotypes is, however, unexamined.	pcl-r	16-21	monoamine oxidase A	Homo sapiens	33-52
20850185-2	2011	The efficacy of PCL-R in varying monoamine oxidase A (MAOA) genotypes is, however, unexamined.	pcl-r	16-21	monoamine oxidase A	Homo sapiens	54-58
20850185-8	2011	Results suggest that the efficacy of PCL-R is altered by MAOA genotype, alcohol exposure, and age, which seems important to note when PCL-R is used for risk assessments that will have legal or costly preventive work consequences.	pcl-r	37-42	monoamine oxidase A	Homo sapiens	57-61
20850185-8	2011	Results suggest that the efficacy of PCL-R is altered by MAOA genotype, alcohol exposure, and age, which seems important to note when PCL-R is used for risk assessments that will have legal or costly preventive work consequences.	pcl-r	134-139	monoamine oxidase A	Homo sapiens	57-61
21311414-10	2011	Flavonoids of several classes are inhibitors of monoamine oxidase A or B, thereby working as anti-depressants or to improve the conditions of Parkinson"s patients.	Flavonoids	0-10	monoamine oxidase A	Homo sapiens	48-72
21134756-1	2011	Previous studies have shown that (E)-5-styrylisatin and (E)-6-styrylisatin are reversible inhibitors of human monoamine oxidase (MAO) A and B.	(E)-5-Styrylisatin	33-51	monoamine oxidase A	Homo sapiens	110-141
20528162-6	2011	We identified a strong expression of the serotonin transporter and confirmed the high-affinity serotonin transporter-mediated uptake of serotonin (5-HT), along with uptake via the norepinephrine transporter, and an evidence of 5-HT breakdown due to the expression of the degradative enzymes monoamine oxidase A and B.	Serotonin	41-50	monoamine oxidase A	Homo sapiens	291-316
21183355-1	2011	Previous studies have shown that harmine is a reversible inhibitor of human monoamine oxidase A (MAO-A).	Harmine	33-40	monoamine oxidase A	Homo sapiens	76-95
21183355-1	2011	Previous studies have shown that harmine is a reversible inhibitor of human monoamine oxidase A (MAO-A).	Harmine	33-40	monoamine oxidase A	Homo sapiens	97-102
21134756-1	2011	Previous studies have shown that (E)-5-styrylisatin and (E)-6-styrylisatin are reversible inhibitors of human monoamine oxidase (MAO) A and B.	(E)-6-Styrylisatin	56-74	monoamine oxidase A	Homo sapiens	110-141
21183355-2	2011	Moreover, the crystal structure of human MAO-A in complex with harmine has been recently solved.	Harmine	63-70	monoamine oxidase A	Homo sapiens	41-46
21134756-7	2011	The most potent MAO-A inhibitor was found to be 5-phenylisatin with an IC(50) value of 562nM.	5-Phenylisatin	48-62	monoamine oxidase A	Homo sapiens	16-21
21183355-3	2011	This crystal structure shows that close to the methoxy group of the harmine moiety, a lipophilic pocket is left vacant within the binding site of human MAO-A.	Harmine	68-75	monoamine oxidase A	Homo sapiens	152-157
21183355-7	2011	The results show that O-alkylated compounds with lipophilic groups like cyclohexyl, phenyl and aliphatic chains increase the inhibition of MAO-A compared to harmine.	Harmine	157-164	monoamine oxidase A	Homo sapiens	139-144
21134756-9	2011	Possible binding orientations of selected isatin analogues within the active site cavities of MAO-A and MAO-B are proposed.	Isatin	42-48	monoamine oxidase A	Homo sapiens	94-99
21971009-2	2011	Ladostigil combines neuroprotective effects with monoamine oxidase-A and -B and cholinesterase inhibitory activities in a single molecule, presently in a Phase IIb clinical trial and intended for the treatment of Alzheimer"s disease, and dementia comorbid with extrapyramidal disorders and depression.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	monoamine oxidase A	Homo sapiens	49-75
21224199-5	2011	If MAO-A inhibition occurs, the body cannot protect itself from exogenous amines such as tyramine.	Tyramine	89-97	monoamine oxidase A	Homo sapiens	3-8
21103012-5	2010	Cellular treatment with the synthetic glucocorticoid, dexamethasone (a cellular stressor), has been reported to markedly increase both MAO A and MAO B catalytic activities, as well as apoptosis.	Dexamethasone	54-67	monoamine oxidase A	Homo sapiens	135-140
21647215-5	2011	This paper presents the preclinical profile of a novel I2 ligand (2-phenyl-6-(1H-imidazol-1yl) quinazoline; [CR4056]) that selectively inhibits the activity of human recombinant MAO-A in a concentration-dependent manner.	2-phenyl-6-(1h-imidazol-1yl) quinazoline	66-106	monoamine oxidase A	Homo sapiens	178-183
21647215-5	2011	This paper presents the preclinical profile of a novel I2 ligand (2-phenyl-6-(1H-imidazol-1yl) quinazoline; [CR4056]) that selectively inhibits the activity of human recombinant MAO-A in a concentration-dependent manner.	CR4056	109-115	monoamine oxidase A	Homo sapiens	178-183
21075154-10	2011	Deprenyl itself as well as the MAO-B antagonist rasagiline did effectively block the binding of the radioligand, whereas the MAO-A antagonist pirlindole did not affect it.	pirlindole	142-152	monoamine oxidase A	Homo sapiens	125-130
20445015-2	2010	This double-blind, placebo-controlled study determined the tyramine sensitivity factor (TSF) and degree of MAO-A inhibition (ie, reduction in plasma dihydroxyphenylglycol) in healthy volunteers who received phenelzine (15 mg, 3 times daily; positive control), selegiline (5 mg, twice daily), or rasagiline (1-6 mg, once daily) for 14 days or rasagiline 2 mg/d for 30 days.	dihydroxyphenylglycol	149-170	monoamine oxidase A	Homo sapiens	107-112
20934874-1	2010	A series of N-substituted-3-[(2"-hydroxy-4"-prenyloxy)-phenyl]-5-phenyl-4,5-dihydro-(1H)-pyrazolines were synthesized and tested on human monoamine oxidase-A and -B isoforms.	n-substituted-3-[(2"-hydroxy-4"-prenyloxy)-phenyl]-5-phenyl-4,5-dihydro-(1h)-pyrazolines	12-100	monoamine oxidase A	Homo sapiens	138-164
20843688-3	2010	Docking study was carried out to demonstrate the binding mode between a9 and MAO-A/B, and the result reveals that a9 localized in the "aromatic cage" and oriented to establish pi-pi stacking interactions with Tyr407, Tyr444 and FAD in MAO-A rather than in MAO-B.	Flavin-Adenine Dinucleotide	228-231	monoamine oxidase A	Homo sapiens	77-84
20843688-3	2010	Docking study was carried out to demonstrate the binding mode between a9 and MAO-A/B, and the result reveals that a9 localized in the "aromatic cage" and oriented to establish pi-pi stacking interactions with Tyr407, Tyr444 and FAD in MAO-A rather than in MAO-B.	Flavin-Adenine Dinucleotide	228-231	monoamine oxidase A	Homo sapiens	77-82
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Amines	248-254	monoamine oxidase A	Homo sapiens	157-176
20204405-1	2010	PURPOSE: Inhibitors of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades neurotransmitters including serotonin and norepinephrine, are commonly used to treat neurological conditions including depression.	Serotonin	116-125	monoamine oxidase A	Homo sapiens	23-42
20204405-1	2010	PURPOSE: Inhibitors of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades neurotransmitters including serotonin and norepinephrine, are commonly used to treat neurological conditions including depression.	Serotonin	116-125	monoamine oxidase A	Homo sapiens	44-48
20204405-1	2010	PURPOSE: Inhibitors of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades neurotransmitters including serotonin and norepinephrine, are commonly used to treat neurological conditions including depression.	Norepinephrine	130-144	monoamine oxidase A	Homo sapiens	23-42
20204405-1	2010	PURPOSE: Inhibitors of monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades neurotransmitters including serotonin and norepinephrine, are commonly used to treat neurological conditions including depression.	Norepinephrine	130-144	monoamine oxidase A	Homo sapiens	44-48
20204405-4	2010	An irreversible inhibitor of MAOA, clorgyline, induced secretory differentiation in primary cultures of normal basal epithelial cells and high-grade PCa.	Clorgyline	35-45	monoamine oxidase A	Homo sapiens	29-33
20204405-5	2010	Furthermore, clorgyline inhibited several oncogenic pathways in PCa cells, suggesting clinical value of MAOA inhibitors as a pro-differentiation and anti-oncogenic therapy for high-risk PCa.	Clorgyline	13-23	monoamine oxidase A	Homo sapiens	104-108
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Amines	248-254	monoamine oxidase A	Homo sapiens	178-183
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Serotonin	265-274	monoamine oxidase A	Homo sapiens	157-176
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Serotonin	265-274	monoamine oxidase A	Homo sapiens	178-183
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Dopamine	276-284	monoamine oxidase A	Homo sapiens	157-176
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Dopamine	276-284	monoamine oxidase A	Homo sapiens	178-183
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Norepinephrine	290-304	monoamine oxidase A	Homo sapiens	157-176
20679667-5	2010	Affected males in this family showed an inherited hemizygous deletion restricted to NDP and two immediately telomeric genes, monoamine oxidase-B (MAO-B) and monoamine oxidase-A (MAO-A), which encode closely related enzymes that metabolize biogenic amines including serotonin, dopamine, and norepinephrine.	Norepinephrine	290-304	monoamine oxidase A	Homo sapiens	178-183
20942780-3	2010	5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A).	Methoxydimethyltryptamines	0-9	monoamine oxidase A	Homo sapiens	184-203
20942780-3	2010	5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A).	Methoxydimethyltryptamines	0-9	monoamine oxidase A	Homo sapiens	205-210
20942780-3	2010	5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A).	Bufotenin	97-107	monoamine oxidase A	Homo sapiens	184-203
20942780-3	2010	5-MeO-DMT is O-demethylated by polymorphic cytochrome P450 2D6 (CYP2D6) to an active metabolite, bufotenine, while it is mainly inactivated through the deamination pathway mediated by monoamine oxidase A (MAO-A).	Bufotenin	97-107	monoamine oxidase A	Homo sapiens	205-210
20942780-4	2010	5-MeO-DMT is often used with MAO-A inhibitors such as harmaline.	Methoxydimethyltryptamines	0-9	monoamine oxidase A	Homo sapiens	29-34
20942780-4	2010	5-MeO-DMT is often used with MAO-A inhibitors such as harmaline.	Harmaline	54-63	monoamine oxidase A	Homo sapiens	29-34
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Serotonin	32-41	monoamine oxidase A	Homo sapiens	59-78
20485326-1	2010	Monoamine oxidases (MAO-A and MAO-B) have a key role in the degradation of amine neurotransmitters, such as dopamine, norepinephrine and serotonin.	Amines	4-9	monoamine oxidase A	Homo sapiens	20-25
20485326-1	2010	Monoamine oxidases (MAO-A and MAO-B) have a key role in the degradation of amine neurotransmitters, such as dopamine, norepinephrine and serotonin.	Dopamine	108-116	monoamine oxidase A	Homo sapiens	20-25
20485326-1	2010	Monoamine oxidases (MAO-A and MAO-B) have a key role in the degradation of amine neurotransmitters, such as dopamine, norepinephrine and serotonin.	Norepinephrine	118-132	monoamine oxidase A	Homo sapiens	20-25
20485326-1	2010	Monoamine oxidases (MAO-A and MAO-B) have a key role in the degradation of amine neurotransmitters, such as dopamine, norepinephrine and serotonin.	Serotonin	137-146	monoamine oxidase A	Homo sapiens	20-25
20652353-3	2010	To define an association between genetic profile and triptan response, we classified a migrainous population on the basis of triptan response and characterized it for polymorphisms in the genes coding for monoamine oxidase A, G protein beta3 and the cytochrome CYP1A2.	Tryptamines	53-60	monoamine oxidase A	Homo sapiens	205-241
20652353-4	2010	Analysis of the association between genotypic and allelic frequencies of the analyzed SNPs and the grade of response to triptan administration showed a significant correlation for MAOA uVNTR polymorphism.	Tryptamines	120-127	monoamine oxidase A	Homo sapiens	180-184
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Serotonin	32-41	monoamine oxidase A	Homo sapiens	80-85
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Hydrogen Peroxide	113-130	monoamine oxidase A	Homo sapiens	59-78
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Hydrogen Peroxide	113-130	monoamine oxidase A	Homo sapiens	80-85
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Hydrogen Peroxide	132-136	monoamine oxidase A	Homo sapiens	59-78
20073575-3	2010	We have recently shown that the serotonin-degrading enzyme monoamine oxidase A (MAO-A) generates large amount of hydrogen peroxide (H2O2) responsible for cell apoptosis.	Hydrogen Peroxide	132-136	monoamine oxidase A	Homo sapiens	80-85
20073575-4	2010	Hydrogen peroxide generation requires 5-HT internalization into the cell and its degradation by MAO-A.	Hydrogen Peroxide	0-17	monoamine oxidase A	Homo sapiens	96-101
20073575-5	2010	In the present study, we investigated whether MAO-A is expressed in MSCs and we defined its role in serotonin-dependent MSCs apoptosis.	Serotonin	100-109	monoamine oxidase A	Homo sapiens	46-51
20073575-7	2010	As shown by enzyme assays using [14C]serotonin or [14C]beta-phenylethylamine as selective MAO-A or MAO-B substrates, MAO-A is largely predominant in MSCs.	Carbon-14	33-36	monoamine oxidase A	Homo sapiens	117-122
20073575-7	2010	As shown by enzyme assays using [14C]serotonin or [14C]beta-phenylethylamine as selective MAO-A or MAO-B substrates, MAO-A is largely predominant in MSCs.	Serotonin	37-46	monoamine oxidase A	Homo sapiens	117-122
20073575-7	2010	As shown by enzyme assays using [14C]serotonin or [14C]beta-phenylethylamine as selective MAO-A or MAO-B substrates, MAO-A is largely predominant in MSCs.	Carbon-14	51-54	monoamine oxidase A	Homo sapiens	117-122
20073575-7	2010	As shown by enzyme assays using [14C]serotonin or [14C]beta-phenylethylamine as selective MAO-A or MAO-B substrates, MAO-A is largely predominant in MSCs.	phenethylamine	55-76	monoamine oxidase A	Homo sapiens	90-95
20073575-7	2010	As shown by enzyme assays using [14C]serotonin or [14C]beta-phenylethylamine as selective MAO-A or MAO-B substrates, MAO-A is largely predominant in MSCs.	phenethylamine	55-76	monoamine oxidase A	Homo sapiens	117-122
20073575-11	2010	In conclusion, these results show for the first time that the 5-HT-degrading enzyme MAO-A is an important source of H2O2 in MSCs and plays a major role in 5-HT-dependent MSCs apoptosis.	Hydrogen Peroxide	116-120	monoamine oxidase A	Homo sapiens	84-89
20595415-1	2010	OBJECTIVE: To use measures of cerebrospinal fluid (CSF) 5-hydroxyindoleacetic acid (5HIAA) and genotype of a functional polymorphism of the monoamine oxidase A gene promoter (MAOA-uVNTR) to study the role of central nervous system (CNS) serotonin in clustering of hostility, other psychosocial, metabolic and cardiovascular endophenotypes.	Serotonin	237-246	monoamine oxidase A	Homo sapiens	140-159
20659799-4	2010	Compounds 4 (IC(50)=11.05 nM), 5 (IC(50)=3.23 nM) and 6 (IC(50)=7.12 nM) show higher activity than selegiline (IC(50)=19.60 nM) and higher MAO-B selectivity, with more than 9050-fold, 30,960-fold and 14,045-fold inhibition levels, with respect to the MAO-A isoform.	Selegiline	99-109	monoamine oxidase A	Homo sapiens	251-256
20642018-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Serotonin	30-39	monoamine oxidase A	Homo sapiens	0-5
20497231-4	2010	Blood-oxygen-level-dependent response was measured with functional magnetic resonance imaging during a rejection-themed emotional Stroop task in 19 adolescents (aged 14-16) and 16 adults (aged 23-28) genotyped for MAOA polymorphism.	Oxygen	6-12	monoamine oxidase A	Homo sapiens	214-218
20642018-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Norepinephrine	44-57	monoamine oxidase A	Homo sapiens	0-5
20642018-5	2004	MAO-A is selectively inhibited by clorgyline, whereas MAO-B is selectively and irreversibly inhibited by L-depreny.	Clorgyline	34-44	monoamine oxidase A	Homo sapiens	0-5
23908775-6	2010	Although the exact distribution of MAO isoforms in different neurons and tissues is not known, dopamine behaves largely as a MAO-A substrate in vivo, but following loss of dopaminergic axonal varicosities from the striatum, metabolism by glial MAO-B becomes increasingly important.	Dopamine	95-103	monoamine oxidase A	Homo sapiens	125-130
20592043-3	2010	Genetic association studies suggest that variation within the genes of central neurotransmitter systems, particularly the serotonin (5-HTTLPR, MAOA-uVNTR) and opioid (OPRM1 A118G), are associated with individual differences in social sensitivity, which reflects the degree of emotional responsivity to social events and experiences.	Serotonin	122-131	monoamine oxidase A	Homo sapiens	143-147
20477771-3	2010	ANX/DEP ALC may be related to dopamine and serotonin, which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Dopamine	30-38	monoamine oxidase A	Homo sapiens	77-96
20477771-3	2010	ANX/DEP ALC may be related to dopamine and serotonin, which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Dopamine	30-38	monoamine oxidase A	Homo sapiens	98-102
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	Serotonin	52-61	monoamine oxidase A	Homo sapiens	0-19
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	Serotonin	52-61	monoamine oxidase A	Homo sapiens	21-25
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	Norepinephrine	74-88	monoamine oxidase A	Homo sapiens	0-19
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	Norepinephrine	74-88	monoamine oxidase A	Homo sapiens	21-25
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	monoamine	143-152	monoamine oxidase A	Homo sapiens	0-19
20332182-1	2010	Monoamine oxidase A (MAOA) and the transporters for serotonin (5-HTT) and norepinephrine (NET) may play important roles in regulating maternal monoamine neurotransmitters transferred across the placenta to the fetus.	monoamine	143-152	monoamine oxidase A	Homo sapiens	21-25
20332182-9	2010	These findings suggest that the three promoter polymorphisms of MAOA, 5-HTT, and NET influence gene expression levels and protein activity of these genes in human placentas, potentially leading to different fetal levels of maternal monoamine neurotransmitters, which may have an impact on fetal neurodevelopment.	monoamine	232-241	monoamine oxidase A	Homo sapiens	64-68
20477771-3	2010	ANX/DEP ALC may be related to dopamine and serotonin, which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Serotonin	43-52	monoamine oxidase A	Homo sapiens	77-96
20477771-3	2010	ANX/DEP ALC may be related to dopamine and serotonin, which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Serotonin	43-52	monoamine oxidase A	Homo sapiens	98-102
20421737-1	2010	Monoamine oxidase A (MAO A) is an enzyme that catalyzes the oxidation of neurotransmitter amines.	Amines	90-96	monoamine oxidase A	Homo sapiens	0-19
20421737-1	2010	Monoamine oxidase A (MAO A) is an enzyme that catalyzes the oxidation of neurotransmitter amines.	Amines	90-96	monoamine oxidase A	Homo sapiens	21-26
20421737-9	2010	(2) The uVNTR"s effect on the MAOA"s transcriptional activity might have epigenetic nature: this polymorphic region resides within the MAOA"s CGI and itself contains CpGs, thus, the number of repeating increments effectively changes the number of methylatable cytosines in the MAOA promoter.	Cytosine	260-269	monoamine oxidase A	Homo sapiens	30-34
20421737-9	2010	(2) The uVNTR"s effect on the MAOA"s transcriptional activity might have epigenetic nature: this polymorphic region resides within the MAOA"s CGI and itself contains CpGs, thus, the number of repeating increments effectively changes the number of methylatable cytosines in the MAOA promoter.	Cytosine	260-269	monoamine oxidase A	Homo sapiens	135-139
20421737-9	2010	(2) The uVNTR"s effect on the MAOA"s transcriptional activity might have epigenetic nature: this polymorphic region resides within the MAOA"s CGI and itself contains CpGs, thus, the number of repeating increments effectively changes the number of methylatable cytosines in the MAOA promoter.	Cytosine	260-269	monoamine oxidase A	Homo sapiens	135-139
19941049-2	2010	COMT and MAOA each contribute to the enzymatic degradation of dopamine and noradrenaline.	Dopamine	62-70	monoamine oxidase A	Homo sapiens	9-13
20439828-14	2010	CONCLUSIONS: Elevated MAO-A levels in the early postpartum period can be interpreted as a marker of a monoamine-lowering process that contributes to the mood change of postpartum blues.	monoamine	102-111	monoamine oxidase A	Homo sapiens	22-27
20382016-1	2010	Chromone carboxylic acids were evaluated as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors.	chromone-2-carboxylic acid	0-25	monoamine oxidase A	Homo sapiens	50-75
20382016-1	2010	Chromone carboxylic acids were evaluated as human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitors.	chromone-2-carboxylic acid	0-25	monoamine oxidase A	Homo sapiens	77-83
20382016-2	2010	The biological data indicated that only chromone-3-carboxylic acid is a potent hMAO-B inhibitor, with a high degree of selectivity for hMAO-B compared to hMAO-A.	Chromone-3-carboxylic acid	40-66	monoamine oxidase A	Homo sapiens	154-160
20201935-5	2010	RESULTS: Logistic regression analyses showed that both heavy drinking and CPA were significant independent predictors of recidivism in violent behavior (OR 5.2, p = 0.004 and OR 5.3, p = 0.003) among offenders having the high MAOA activity genotype (MAOA-H), but these predictors showed no effect among offenders carrying the low MAOA activity genotype (MAOA-L).	cpa	74-77	monoamine oxidase A	Homo sapiens	226-230
20201935-5	2010	RESULTS: Logistic regression analyses showed that both heavy drinking and CPA were significant independent predictors of recidivism in violent behavior (OR 5.2, p = 0.004 and OR 5.3, p = 0.003) among offenders having the high MAOA activity genotype (MAOA-H), but these predictors showed no effect among offenders carrying the low MAOA activity genotype (MAOA-L).	cpa	74-77	monoamine oxidase A	Homo sapiens	250-254
20201935-5	2010	RESULTS: Logistic regression analyses showed that both heavy drinking and CPA were significant independent predictors of recidivism in violent behavior (OR 5.2, p = 0.004 and OR 5.3, p = 0.003) among offenders having the high MAOA activity genotype (MAOA-H), but these predictors showed no effect among offenders carrying the low MAOA activity genotype (MAOA-L).	cpa	74-77	monoamine oxidase A	Homo sapiens	250-254
20201935-5	2010	RESULTS: Logistic regression analyses showed that both heavy drinking and CPA were significant independent predictors of recidivism in violent behavior (OR 5.2, p = 0.004 and OR 5.3, p = 0.003) among offenders having the high MAOA activity genotype (MAOA-H), but these predictors showed no effect among offenders carrying the low MAOA activity genotype (MAOA-L).	cpa	74-77	monoamine oxidase A	Homo sapiens	250-254
20201935-6	2010	CONCLUSION: Carriers of the MAOA-H allele have a high risk to commit severe recidivistic impulsive violent crimes after exposure to heavy drinking and CPA.	cpa	151-154	monoamine oxidase A	Homo sapiens	28-32
19941049-2	2010	COMT and MAOA each contribute to the enzymatic degradation of dopamine and noradrenaline.	Norepinephrine	75-88	monoamine oxidase A	Homo sapiens	9-13
20206656-4	2010	We have studied the relationship between the Val158Met polymorphism in catechol O-methyltransferase gene, variable tandem repeat polymorphisms in the monoamine oxidase A gene promoter, and plasma concentrations of 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxyphenylacetic acid and homovanillic acid in healthy control subjects as well as in untreated schizophrenic and bipolar patients.	Methoxyhydroxyphenylglycol	214-245	monoamine oxidase A	Homo sapiens	150-169
20206656-4	2010	We have studied the relationship between the Val158Met polymorphism in catechol O-methyltransferase gene, variable tandem repeat polymorphisms in the monoamine oxidase A gene promoter, and plasma concentrations of 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxyphenylacetic acid and homovanillic acid in healthy control subjects as well as in untreated schizophrenic and bipolar patients.	3,4-Dihydroxyphenylacetic Acid	251-277	monoamine oxidase A	Homo sapiens	150-169
20206656-4	2010	We have studied the relationship between the Val158Met polymorphism in catechol O-methyltransferase gene, variable tandem repeat polymorphisms in the monoamine oxidase A gene promoter, and plasma concentrations of 3-methoxy-4-hydroxyphenylglycol, 3,4-dihydroxyphenylacetic acid and homovanillic acid in healthy control subjects as well as in untreated schizophrenic and bipolar patients.	Homovanillic Acid	282-299	monoamine oxidase A	Homo sapiens	150-169
20036304-8	2010	Inhibition of MAO-A by seed extracts was quantitatively attributed to harmaline and harmine whereas inhibition by root extracts came from harmine with no additional interferences.	Harmaline	70-79	monoamine oxidase A	Homo sapiens	14-19
19777560-1	2010	Prior work using lymphoblast DNA prepared from 192 subjects from the Iowa Adoption Studies (IAS) demonstrated that decreased MAOA promoter methylation was associated with lifetime symptom count for nicotine dependence (ND) and provided suggestive evidence that the amount of methylation is genotype dependent.	Nicotine	198-206	monoamine oxidase A	Homo sapiens	125-129
20219660-14	2010	Among various constituents of Banisteriopsis caapi, harmine (7), harmaline (6) and tetrahydroharmine (5) are responsible for MAO-A inhibition, while two major proanthocyanidines, epicatechin (8) and procyanidine B2 (9) produce antioxidant effects.	Harmine	52-59	monoamine oxidase A	Homo sapiens	125-130
20219660-14	2010	Among various constituents of Banisteriopsis caapi, harmine (7), harmaline (6) and tetrahydroharmine (5) are responsible for MAO-A inhibition, while two major proanthocyanidines, epicatechin (8) and procyanidine B2 (9) produce antioxidant effects.	Harmaline	65-74	monoamine oxidase A	Homo sapiens	125-130
20219660-14	2010	Among various constituents of Banisteriopsis caapi, harmine (7), harmaline (6) and tetrahydroharmine (5) are responsible for MAO-A inhibition, while two major proanthocyanidines, epicatechin (8) and procyanidine B2 (9) produce antioxidant effects.	tetrahydroharmine	83-100	monoamine oxidase A	Homo sapiens	125-130
20149663-0	2010	Development of selective and reversible pyrazoline based MAO-A inhibitors: Synthesis, biological evaluation and docking studies.	pyrazoline	40-50	monoamine oxidase A	Homo sapiens	57-62
20036304-8	2010	Inhibition of MAO-A by seed extracts was quantitatively attributed to harmaline and harmine whereas inhibition by root extracts came from harmine with no additional interferences.	Harmine	84-91	monoamine oxidase A	Homo sapiens	14-19
20036304-10	2010	The potent inhibition of MAO-A by seed and root extracts of P. harmala containing beta-carbolines should contribute to the psychopharmacological and toxicological effects of this plant and could be the basis for its purported antidepressant actions.	Carbolines	82-97	monoamine oxidase A	Homo sapiens	25-30
20117937-0	2010	Design of novel nicotinamides as potent and selective monoamine oxidase a inhibitors.	Niacinamide	16-29	monoamine oxidase A	Homo sapiens	54-73
20218801-0	2010	Association of VNTR polymorphisms in the MAOA promoter and DRD4 exon 3 with heroin dependence in male Chinese addicts.	Heroin	76-82	monoamine oxidase A	Homo sapiens	41-45
20117937-3	2010	5-Chloro-6-hydroxy-N-(2-morpholinoethyl)nicotinamide (13) displayed the highest MAO-A inhibitory potency (IC(50)=0.045 microM) and a good selectivity.	chloro-6-hydroxy-n-(2-morpholinoethyl)nicotinamide	2-52	monoamine oxidase A	Homo sapiens	80-85
19890267-1	2010	Reversible inhibitors of monoamine oxidase-A (RIMA) inhibit the breakdown of three major neurotransmitters, serotonin, norepinephrine and dopamine, offering a multi-neurotransmitter strategy for the treatment of depression.	Serotonin	108-117	monoamine oxidase A	Homo sapiens	25-44
20045650-1	2010	A new series of synthetic flavones, thioflavones, and flavanones has been synthesized and evaluated as potential inhibitors of monoamine oxidase isoforms (MAO-A and -B).	Flavones	26-34	monoamine oxidase A	Homo sapiens	155-167
20045650-1	2010	A new series of synthetic flavones, thioflavones, and flavanones has been synthesized and evaluated as potential inhibitors of monoamine oxidase isoforms (MAO-A and -B).	thioflavone	36-48	monoamine oxidase A	Homo sapiens	155-167
19925626-3	2010	Metabolism by monoamine oxidase-A (MAO-A) leads to about 40% of the s.c. dose appearing in the urine as the inactive indole acetic acid.	indole	117-123	monoamine oxidase A	Homo sapiens	14-33
19925626-3	2010	Metabolism by monoamine oxidase-A (MAO-A) leads to about 40% of the s.c. dose appearing in the urine as the inactive indole acetic acid.	indole	117-123	monoamine oxidase A	Homo sapiens	35-40
19925626-3	2010	Metabolism by monoamine oxidase-A (MAO-A) leads to about 40% of the s.c. dose appearing in the urine as the inactive indole acetic acid.	Acetic Acid	124-135	monoamine oxidase A	Homo sapiens	14-33
19925626-3	2010	Metabolism by monoamine oxidase-A (MAO-A) leads to about 40% of the s.c. dose appearing in the urine as the inactive indole acetic acid.	Acetic Acid	124-135	monoamine oxidase A	Homo sapiens	35-40
19925626-4	2010	Product labeling states that co-administration of an inhibitor of MAO-A (a MAOI-A) causes a 2-fold increase in sumatriptan plasma concentrations, and a 40% increase in elimination half-life.	Sumatriptan	111-122	monoamine oxidase A	Homo sapiens	66-71
19925626-4	2010	Product labeling states that co-administration of an inhibitor of MAO-A (a MAOI-A) causes a 2-fold increase in sumatriptan plasma concentrations, and a 40% increase in elimination half-life.	Sumatriptan	111-122	monoamine oxidase A	Homo sapiens	75-81
19925626-5	2010	OBJECTIVE: The objective of this study is to determine whether MAOI-A therapy should deter the use of 6 mg s.c. sumatriptan on pharmacokinetic grounds.	Sumatriptan	112-123	monoamine oxidase A	Homo sapiens	63-69
19925626-16	2010	The dominance of the distribution phase and completeness of absorption of a 6 mg dose of s.c. sumatriptan explains the trivial effect size of the MAOI-A on plasma sumatriptan concentrations.	Sumatriptan	94-105	monoamine oxidase A	Homo sapiens	146-152
19925626-16	2010	The dominance of the distribution phase and completeness of absorption of a 6 mg dose of s.c. sumatriptan explains the trivial effect size of the MAOI-A on plasma sumatriptan concentrations.	Sumatriptan	163-174	monoamine oxidase A	Homo sapiens	146-152
19890267-1	2010	Reversible inhibitors of monoamine oxidase-A (RIMA) inhibit the breakdown of three major neurotransmitters, serotonin, norepinephrine and dopamine, offering a multi-neurotransmitter strategy for the treatment of depression.	Norepinephrine	119-133	monoamine oxidase A	Homo sapiens	25-44
19890267-1	2010	Reversible inhibitors of monoamine oxidase-A (RIMA) inhibit the breakdown of three major neurotransmitters, serotonin, norepinephrine and dopamine, offering a multi-neurotransmitter strategy for the treatment of depression.	Dopamine	138-146	monoamine oxidase A	Homo sapiens	25-44
19890267-6	2010	We found that 60 and 80 mg doses of CX157 produced a robust dose-related inhibition (47-72%) of [(11)C]clorgyline binding to brain MAO-A at 2 h after administration and that brain MAO-A recovered completely by 24 h post drug.	Clorgyline	103-113	monoamine oxidase A	Homo sapiens	131-136
19890267-8	2010	Thus, CX157 is the first agent in the RIMA class with documented reversible inhibition of human brain MAO-A, supporting its classification as a RIMA, and the first RIMA with observed plasma levels that can serve as a biomarker for the degree of brain MAO-A inhibition.	rima	38-42	monoamine oxidase A	Homo sapiens	102-107
19733607-5	2009	The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved.	Catecholamines	20-33	monoamine oxidase A	Homo sapiens	4-9
20410615-1	2010	A new series of benzylidene-prop-2-ynyl-amines analogues have been synthesized and evaluated for their monoamine oxidase A and B inhibitory activity by determination of IC(50) and selectivity index (SI).	benzylidene-prop-2-ynyl-amines	16-46	monoamine oxidase A	Homo sapiens	103-122
20410615-2	2010	Among these inhibitors, benzhydrylidene-prop-2-ynyl-amine (2, IC(50)=32 nM) and (3, 4-dimethoxy-benzylidene)-prop-2-ynyl-amine (10, IC(50)=14 nM) provide the highest inhibitory potency toward monoamine oxidase (MAO) A and B respectively.	(3, 4-dimethoxy-benzylidene)-prop-2-ynyl-amine	80-126	monoamine oxidase A	Homo sapiens	192-217
20410615-3	2010	(3,5-Dimethyl-1H-pyrrol-2-ylmethylene)-prop-2-ynyl-amine (1, SI=58.96) and compound (2, SI=0.34) were proved to be the superior selective inhibitors toward MAO-A and MAO-B respectively.	(3,5-dimethyl-1h-pyrrol-2-ylmethylene)-prop-2-ynyl-amine	0-56	monoamine oxidase A	Homo sapiens	156-161
20410615-4	2010	Docking studies show that the imine moiety is located in hydrophobic pocket, bringing the propargyl group close to FAD which indicates that the different inhibitory potency toward MAO-A may be ascribable to both the distance between alkynyl group and N5 of FAD, and hydrogen bonding interactions between inhibitors and enzymes.	Imines	30-35	monoamine oxidase A	Homo sapiens	180-185
20410615-4	2010	Docking studies show that the imine moiety is located in hydrophobic pocket, bringing the propargyl group close to FAD which indicates that the different inhibitory potency toward MAO-A may be ascribable to both the distance between alkynyl group and N5 of FAD, and hydrogen bonding interactions between inhibitors and enzymes.	Flavin-Adenine Dinucleotide	115-118	monoamine oxidase A	Homo sapiens	180-185
20410615-4	2010	Docking studies show that the imine moiety is located in hydrophobic pocket, bringing the propargyl group close to FAD which indicates that the different inhibitory potency toward MAO-A may be ascribable to both the distance between alkynyl group and N5 of FAD, and hydrogen bonding interactions between inhibitors and enzymes.	Flavin-Adenine Dinucleotide	257-260	monoamine oxidase A	Homo sapiens	180-185
20410615-4	2010	Docking studies show that the imine moiety is located in hydrophobic pocket, bringing the propargyl group close to FAD which indicates that the different inhibitory potency toward MAO-A may be ascribable to both the distance between alkynyl group and N5 of FAD, and hydrogen bonding interactions between inhibitors and enzymes.	Hydrogen	266-274	monoamine oxidase A	Homo sapiens	180-185
19506579-1	2009	We present a pharmacogenetic study of acute antipsychotic (AP)-induced extrapyramidal symptoms (EPS) using an extensive linkage disequilibrium mapping approach in seven-candidate genes with a well-established link to dopamine (DRD2, DRD3, ACE, COMT, DAT, MAO-A, MAO-B).	Dopamine	217-225	monoamine oxidase A	Homo sapiens	255-260
19996035-13	2009	CONCLUSIONS: Elevated MAO-A binding after SSRI treatment indicates persistence of a monoamine-lowering process not present in health.	monoamine	84-93	monoamine oxidase A	Homo sapiens	22-27
19996035-15	2009	Greater MAO-A binding in the prefrontal and anterior cingulate cortex in subjects with MDD in recovery and its association with subsequent recurrence argue that deficient monoamine neuromodulation may persist into recovery and contribute to recurrence.	monoamine	171-180	monoamine oxidase A	Homo sapiens	8-13
19733607-5	2009	The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved.	3,4-dihydroxyphenylglycol	45-49	monoamine oxidase A	Homo sapiens	4-9
19733607-5	2009	The MAO-A-dependent catecholamine metabolite DHPG levels did not change significantly during the study suggesting that rasagiline"s MAO-B selectivity was preserved.	rasagiline	119-129	monoamine oxidase A	Homo sapiens	4-9
19572987-8	2009	We hypothesize that alcohol can modulate SERT and MAO-A expression in DC, leading to reciprocal downregulation of 5-HT in extracellular medium.	Alcohols	20-27	monoamine oxidase A	Homo sapiens	50-55
19661285-1	2009	Monoamine oxidase A (MAO A), encoded by the X chromosome, catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions.	monoamine	97-106	monoamine oxidase A	Homo sapiens	0-19
19661285-1	2009	Monoamine oxidase A (MAO A), encoded by the X chromosome, catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions.	monoamine	97-106	monoamine oxidase A	Homo sapiens	21-26
19661285-1	2009	Monoamine oxidase A (MAO A), encoded by the X chromosome, catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions.	Serotonin	134-143	monoamine oxidase A	Homo sapiens	0-19
19661285-1	2009	Monoamine oxidase A (MAO A), encoded by the X chromosome, catalyzes the oxidative deamination of monoamine neurotransmitters, such as serotonin, and plays a critically important role in brain development and functions.	Serotonin	134-143	monoamine oxidase A	Homo sapiens	21-26
19615672-5	2009	Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine.	Norepinephrine	37-51	monoamine oxidase A	Homo sapiens	7-11
19615672-5	2009	Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine.	dihydroxyphenylglycol	53-74	monoamine oxidase A	Homo sapiens	7-11
19615672-5	2009	Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine.	3,4-Dihydroxyphenylacetic Acid	103-129	monoamine oxidase A	Homo sapiens	7-11
19615672-5	2009	Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine.	Hydroxytryptophol	146-173	monoamine oxidase A	Homo sapiens	7-11
19615672-5	2009	Plasma MAOA dependent metabolites of norepinephrine: dihydroxyphenylglycol; dopamine: homovanillic and dihydroxyphenylacetic acid; and serotonin: 5-hydroxy-indol acetic acid were measured at the end of the second trimester, at delivery, and in arterial cord blood along with plasma cotinine.	Cotinine	282-290	monoamine oxidase A	Homo sapiens	7-11
19615672-9	2009	Plasma markers of MAOA activity, in particular those reflecting dopamine"s catabolism, were significantly lower in SPW and in the arterial cord blood of their newborns than in NSPW and their newborns.	Dopamine	64-72	monoamine oxidase A	Homo sapiens	18-22
19763773-5	2009	Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	88-93
19763773-5	2009	Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors.	Selegiline	18-26	monoamine oxidase A	Homo sapiens	88-93
19763773-5	2009	Rasagiline and (-)deprenyl, type B MAO inhibitors of propagylamine-derivatives, bind to MAO-A to protect neuronal cells against apoptosis through induction of pro-survival Bcl-2 and neurotrophic factors.	propagylamine	53-66	monoamine oxidase A	Homo sapiens	88-93
19572987-12	2009	RESULTS: Dendritic cells treated with 0.1% alcohol for 24 hours showed significant upregulation of SERT and MAO-A expression compared with untreated DC.	Alcohols	43-50	monoamine oxidase A	Homo sapiens	108-113
19572987-14	2009	CONCLUSIONS: Our study suggests that alcohol upregulates SERT and MAO-A by elevating cyclic AMP, which may lead to decreased concentration of 5-HT in the extracellular medium.	Alcohols	37-44	monoamine oxidase A	Homo sapiens	66-71
19572987-14	2009	CONCLUSIONS: Our study suggests that alcohol upregulates SERT and MAO-A by elevating cyclic AMP, which may lead to decreased concentration of 5-HT in the extracellular medium.	Cyclic AMP	85-95	monoamine oxidase A	Homo sapiens	66-71
19666839-10	2009	Addition of serotonin to recombinant human MAO-A generated (O2*.-), and this effect was prevented by an MAO inhibitor.	Serotonin	12-21	monoamine oxidase A	Homo sapiens	43-48
19666839-11	2009	In conclusion, we have identified a novel mechanism whereby MAO-A can contribute to increased oxidative stress in human heart valves and pulmonary artery exposed to serotonin and dopamine.	Serotonin	165-174	monoamine oxidase A	Homo sapiens	60-65
19789505-3	2009	MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp.	Tritium	79-81	monoamine oxidase A	Homo sapiens	106-111
19666839-11	2009	In conclusion, we have identified a novel mechanism whereby MAO-A can contribute to increased oxidative stress in human heart valves and pulmonary artery exposed to serotonin and dopamine.	Dopamine	179-187	monoamine oxidase A	Homo sapiens	60-65
19669997-6	2009	6-Nitroindazole also inhibited MAO-A.	6-nitroindazole	0-15	monoamine oxidase A	Homo sapiens	31-36
19619137-7	2009	Further, inhibition of monoamine oxidase A prevents the degradation of serotonin in bipolar neurons, suggesting that monoamine oxidase A is present in these neurons.	Serotonin	71-80	monoamine oxidase A	Homo sapiens	23-42
19619137-7	2009	Further, inhibition of monoamine oxidase A prevents the degradation of serotonin in bipolar neurons, suggesting that monoamine oxidase A is present in these neurons.	Serotonin	71-80	monoamine oxidase A	Homo sapiens	117-136
19650872-0	2009	Serine 209 resides within a putative p38(MAPK) consensus motif and regulates monoamine oxidase-A activity.	Serine	0-6	monoamine oxidase A	Homo sapiens	77-96
19789505-3	2009	MATERIAL/METHODS: We investigated MAO labeling with mechanism-based inhibitor [3H]pargyline activities of MAO A, MAO B, and SSAO in healthy and inflamed human dental pulp.	Pargyline	82-91	monoamine oxidase A	Homo sapiens	106-111
19789505-5	2009	MAO activity assayed with 100 microM [14C]5HT or 10 microM [14C]PEA was sensitive to selective inhibitors of MAO A and MAO B, respectively.	14c]5ht	38-45	monoamine oxidase A	Homo sapiens	109-114
19789505-5	2009	MAO activity assayed with 100 microM [14C]5HT or 10 microM [14C]PEA was sensitive to selective inhibitors of MAO A and MAO B, respectively.	Carbon-14	38-41	monoamine oxidase A	Homo sapiens	109-114
19687003-3	2009	Moclobemide is a reversible inhibitor of monoamine oxidase (MAO)-A, selegiline is an irreversible selective inhibitor of MAO-B, and paroxetine is a selective serotonin reuptake inhibitor.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	41-66
19772578-1	2009	BACKGROUND: We previously reported risk haplotypes for two genes related with serotonin and dopamine metabolism: MAOA in migraine without aura and DDC in migraine with aura.	Serotonin	78-87	monoamine oxidase A	Homo sapiens	113-117
19772578-1	2009	BACKGROUND: We previously reported risk haplotypes for two genes related with serotonin and dopamine metabolism: MAOA in migraine without aura and DDC in migraine with aura.	Dopamine	92-100	monoamine oxidase A	Homo sapiens	113-117
19508883-1	2009	We present a schizophrenia association study using an extensive linkage disequilibrium (LD) mapping approach in seven candidate genes with a well established link to dopamine, including receptors (DRD2, DRD3) and genes involved in its metabolism and transport (ACE, COMT, DAT, MAO-A, MAO-B).	Dopamine	166-174	monoamine oxidase A	Homo sapiens	277-282
19691856-0	2009	Anti-oncogenic and pro-differentiation effects of clorgyline, a monoamine oxidase A inhibitor, on high grade prostate cancer cells.	Clorgyline	50-60	monoamine oxidase A	Homo sapiens	64-83
19691856-1	2009	BACKGROUND: Monoamine oxidase A (MAO-A), a mitochondrial enzyme that degrades monoamines including neurotransmitters, is highly expressed in basal cells of the normal human prostatic epithelium and in poorly differentiated (Gleason grades 4 and 5), aggressive prostate cancer (PCa).	monoamines	78-88	monoamine oxidase A	Homo sapiens	12-31
19691856-1	2009	BACKGROUND: Monoamine oxidase A (MAO-A), a mitochondrial enzyme that degrades monoamines including neurotransmitters, is highly expressed in basal cells of the normal human prostatic epithelium and in poorly differentiated (Gleason grades 4 and 5), aggressive prostate cancer (PCa).	monoamines	78-88	monoamine oxidase A	Homo sapiens	33-38
19691856-2	2009	Clorgyline, an MAO-A inhibitor, induces secretory differentiation of normal prostate cells.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	15-20
19645722-7	2009	Compared to purified wild-type and Ser209Ala MAO A proteins, the Ser209Glu MAO A mutant shows significant differences in covalent flavin fluorescence yield, CD spectra and thermal stability.	4,6-dinitro-o-cresol	130-136	monoamine oxidase A	Homo sapiens	75-80
19645722-7	2009	Compared to purified wild-type and Ser209Ala MAO A proteins, the Ser209Glu MAO A mutant shows significant differences in covalent flavin fluorescence yield, CD spectra and thermal stability.	Cadmium	157-159	monoamine oxidase A	Homo sapiens	75-80
19628387-1	2009	A series of 6-methyl-3-phenylcoumarins 3-6 were synthesized and evaluated as monoamine oxidase A and B (MAO-A and MAO-B) inhibitors.	6-methyl-3-phenylcoumarins	12-38	monoamine oxidase A	Homo sapiens	77-102
19628387-1	2009	A series of 6-methyl-3-phenylcoumarins 3-6 were synthesized and evaluated as monoamine oxidase A and B (MAO-A and MAO-B) inhibitors.	6-methyl-3-phenylcoumarins	12-38	monoamine oxidase A	Homo sapiens	104-109
19573521-1	2009	Monoamine oxidase (MAO) A is a critical enzyme in the catabolism of dopamine.	Dopamine	68-76	monoamine oxidase A	Homo sapiens	0-25
19539632-0	2009	Calcium alters monoamine oxidase-A parameters in human cerebellar and rat glial C6 cell extracts: possible influence by distinct signalling pathways.	Calcium	0-7	monoamine oxidase A	Homo sapiens	15-34
19539632-1	2009	AIMS: Calcium (Ca(2+)) is known to augment monoamine oxidase-A (MAO-A) activity in cell cultures as well as in brain extracts from several species.	Calcium	6-13	monoamine oxidase A	Homo sapiens	43-62
19539632-1	2009	AIMS: Calcium (Ca(2+)) is known to augment monoamine oxidase-A (MAO-A) activity in cell cultures as well as in brain extracts from several species.	Calcium	6-13	monoamine oxidase A	Homo sapiens	64-69
20000129-1	2009	The action of heterocyclic amides series (ethosuximide, phenytoin, primidone) on lipid peroxidation and membrane bound monoamine oxidases A and B under stress condition has been studied.	Ethosuximide	42-54	monoamine oxidase A	Homo sapiens	119-145
20000129-1	2009	The action of heterocyclic amides series (ethosuximide, phenytoin, primidone) on lipid peroxidation and membrane bound monoamine oxidases A and B under stress condition has been studied.	Amides	27-33	monoamine oxidase A	Homo sapiens	119-145
20000129-1	2009	The action of heterocyclic amides series (ethosuximide, phenytoin, primidone) on lipid peroxidation and membrane bound monoamine oxidases A and B under stress condition has been studied.	Phenytoin	56-65	monoamine oxidase A	Homo sapiens	119-145
20000129-1	2009	The action of heterocyclic amides series (ethosuximide, phenytoin, primidone) on lipid peroxidation and membrane bound monoamine oxidases A and B under stress condition has been studied.	Primidone	67-76	monoamine oxidase A	Homo sapiens	119-145
19506905-5	2009	Indeed, a series of recent studies, particularly concentrating on the serotonin and norepinephrine metabolising enzyme, monoamine oxidase A, has emphasised the necessity of examining gene by environmental interactions if the contributions of individual loci are to be understood.	Serotonin	70-79	monoamine oxidase A	Homo sapiens	120-139
19527191-5	2009	The selegiline transdermal system was developed to deliver sustained selegiline blood concentrations sufficient to selectively inhibit MAO-A and MAO-B in the brain, producing antidepressant effects, without substantially inhibiting MAO-A in the gastrointestinal tract, thereby reducing the risk of hypertensive crisis.	Selegiline	4-14	monoamine oxidase A	Homo sapiens	135-140
19506905-5	2009	Indeed, a series of recent studies, particularly concentrating on the serotonin and norepinephrine metabolising enzyme, monoamine oxidase A, has emphasised the necessity of examining gene by environmental interactions if the contributions of individual loci are to be understood.	Norepinephrine	84-98	monoamine oxidase A	Homo sapiens	120-139
19640356-0	2009	Randomized, crossover, single-blind, placebo-controlled, human pharmacology clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: multiple-dose pharmacokinetics.	3-deoxyvasicine	96-110	monoamine oxidase A	Homo sapiens	147-152
19309535-0	2009	MAOA is associated with methylphenidate improvement of oppositional symptoms in boys with attention deficit hyperactivity disorder.	Methylphenidate	24-39	monoamine oxidase A	Homo sapiens	0-4
19302089-0	2009	MAOA-uVNTR polymorphism may modify the protective effect of ALDH2 gene against alcohol dependence in antisocial personality disorder.	Alcohols	79-86	monoamine oxidase A	Homo sapiens	0-4
19302089-1	2009	BACKGROUND: Antisocial alcoholism is related to dopamine and serotonin which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Dopamine	48-56	monoamine oxidase A	Homo sapiens	94-113
19302089-1	2009	BACKGROUND: Antisocial alcoholism is related to dopamine and serotonin which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Dopamine	48-56	monoamine oxidase A	Homo sapiens	115-119
19302089-1	2009	BACKGROUND: Antisocial alcoholism is related to dopamine and serotonin which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Serotonin	61-70	monoamine oxidase A	Homo sapiens	94-113
19302089-1	2009	BACKGROUND: Antisocial alcoholism is related to dopamine and serotonin which are catalyzed by monoamine oxidase A (MAOA) and acetaldehyde dehydrogenase 2 (ALDH2).	Serotonin	61-70	monoamine oxidase A	Homo sapiens	115-119
19382113-0	2009	MAOA gene polymorphisms and response to mirtazapine in major depression.	Mirtazapine	40-51	monoamine oxidase A	Homo sapiens	0-4
19382113-2	2009	OBJECTIVE: To investigate the association of MAOA genetic polymorphisms and response to mirtazapine in patients with MDD.	Mirtazapine	88-99	monoamine oxidase A	Homo sapiens	45-49
19382113-6	2009	The patients" response to mirtazapine treatment was compared between those who had the long-form polymorphism in the MAOA gene promoter and the short-form polymorphism.	Mirtazapine	26-37	monoamine oxidase A	Homo sapiens	117-121
19382113-10	2009	CONCLUSION: The genetic polymorphisms in the MAOA promoter region may be associated with treatment response to mirtazapine.	Mirtazapine	111-122	monoamine oxidase A	Homo sapiens	45-49
19423346-1	2009	6-Methyl-3-phenylcoumarins 3-6 were designed, synthesized and evaluated as monoamine oxidase A and B (MAO-A and MAO-B) inhibitors.	6-methyl-3-phenylcoumarins	0-26	monoamine oxidase A	Homo sapiens	75-100
19423346-1	2009	6-Methyl-3-phenylcoumarins 3-6 were designed, synthesized and evaluated as monoamine oxidase A and B (MAO-A and MAO-B) inhibitors.	6-methyl-3-phenylcoumarins	0-26	monoamine oxidase A	Homo sapiens	102-107
19368859-0	2009	An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis.	Methamphetamine	72-87	monoamine oxidase A	Homo sapiens	24-43
19194374-10	2009	Monoamines such as noradrenalin and serotonin may modulate these relationships, given that their metabolism varies according to MAOA variants, and that they modulate both emotional brain systems and antisocial aggression.	monoamines	0-10	monoamine oxidase A	Homo sapiens	128-132
19194374-10	2009	Monoamines such as noradrenalin and serotonin may modulate these relationships, given that their metabolism varies according to MAOA variants, and that they modulate both emotional brain systems and antisocial aggression.	Norepinephrine	19-31	monoamine oxidase A	Homo sapiens	128-132
19194374-10	2009	Monoamines such as noradrenalin and serotonin may modulate these relationships, given that their metabolism varies according to MAOA variants, and that they modulate both emotional brain systems and antisocial aggression.	Serotonin	36-45	monoamine oxidase A	Homo sapiens	128-132
19368859-6	2009	As expected, there was a significant difference in the MAOA-u VNTR between males with persistent versus transient methamphetamine psychosis (p=0.018, odds ratio (OR)=2.76, 95% CI: 1.18-6.46).	Methamphetamine	114-129	monoamine oxidase A	Homo sapiens	55-59
19368859-7	2009	Our results suggest that the high-activity allele class of MAOA-u VNTR in males may be involved in susceptibility to a persistent course of methamphetamine psychosis.	Methamphetamine	140-155	monoamine oxidase A	Homo sapiens	59-63
19368859-0	2009	An association study of monoamine oxidase A (MAOA) gene polymorphism in methamphetamine psychosis.	Methamphetamine	72-87	monoamine oxidase A	Homo sapiens	45-49
19416630-0	2009	Berry anthocyanins and their aglycons inhibit monoamine oxidases A and B.	Anthocyanins	6-18	monoamine oxidase A	Homo sapiens	46-72
19296688-0	2009	Development of spin-labeled pargyline analogues as specific inhibitors of human monoamine oxidases A and B.	Pargyline	28-37	monoamine oxidase A	Homo sapiens	80-106
19378991-1	2009	A large series of substituted chalcones have been synthesized and tested in vitro for their ability to inhibit human monoamine oxidases A and B (hMAO-A and hMAO-B).	Chalcones	30-39	monoamine oxidase A	Homo sapiens	117-143
19378991-1	2009	A large series of substituted chalcones have been synthesized and tested in vitro for their ability to inhibit human monoamine oxidases A and B (hMAO-A and hMAO-B).	Chalcones	30-39	monoamine oxidase A	Homo sapiens	145-151
19342233-7	2009	The lower selectivity of the (E)-styrylisatin analogues between MAO-A and MAO-B, in contrast to CSC, is best explained by the differing relative geometries of the aromatic rings for these two classes of inhibitors.	(e)-styrylisatin	29-45	monoamine oxidase A	Homo sapiens	64-69
19223155-7	2009	According to our results, the higher serotonergic symptom score and cord blood DHPG concentration in rapid MAO-A metabolizers suggest that norepinephrine may modify the severity of perinatal serotonergic symptoms.	Norepinephrine	139-153	monoamine oxidase A	Homo sapiens	107-112
19416630-5	2009	For MAO A and B, IC(50) values in the low micromolar range were reached by anthocyanidins and anthocyanidin-3-glycosides, as opposed to values in the low millimolar range for phenolic acids.	Anthocyanins	75-89	monoamine oxidase A	Homo sapiens	4-9
19416630-5	2009	For MAO A and B, IC(50) values in the low micromolar range were reached by anthocyanidins and anthocyanidin-3-glycosides, as opposed to values in the low millimolar range for phenolic acids.	anthocyanidin-3-glycosides	94-120	monoamine oxidase A	Homo sapiens	4-9
19214141-0	2009	Association of MAOA gene functional promoter polymorphism with CSF dopamine turnover and atypical depression.	Dopamine	67-75	monoamine oxidase A	Homo sapiens	15-19
19267475-1	2009	A large series of 3-carboxamido-7-substituted coumarins have been synthesized and tested in vitro for their human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitory activity.	3-carboxamido-7-substituted coumarins	18-55	monoamine oxidase A	Homo sapiens	114-139
19267475-1	2009	A large series of 3-carboxamido-7-substituted coumarins have been synthesized and tested in vitro for their human monoamine oxidase A and B (hMAO-A and hMAO-B) inhibitory activity.	3-carboxamido-7-substituted coumarins	18-55	monoamine oxidase A	Homo sapiens	141-158
19214141-1	2009	OBJECTIVE: Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin.	Amines	15-20	monoamine oxidase A	Homo sapiens	32-37
19214141-1	2009	OBJECTIVE: Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin.	Dopamine	127-135	monoamine oxidase A	Homo sapiens	11-30
19214141-1	2009	OBJECTIVE: Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin.	Dopamine	127-135	monoamine oxidase A	Homo sapiens	32-37
19214141-1	2009	OBJECTIVE: Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin.	Serotonin	140-149	monoamine oxidase A	Homo sapiens	11-30
19214141-1	2009	OBJECTIVE: Monoamine oxidase-A (MAO-A) is a key mitochondrial enzyme that metabolizes biogenic amine neurotransmitters such as dopamine and serotonin.	Serotonin	140-149	monoamine oxidase A	Homo sapiens	32-37
19214141-8	2009	Moreover, the MAOA-uVNTR genotype significantly influenced the HVA concentration (P=0.01) and showed a strong trend in relation to 5-hydroxyindoleacetic acid concentration (P=0.057) in women.	Hydroxyindoleacetic Acid	131-157	monoamine oxidase A	Homo sapiens	14-18
19214141-10	2009	CONCLUSION: The association of the MAOA-uVNTR with both susceptibility to AD and dopamine metabolite (HVA) concentration lends further biological plausibility for high MAO-A enzyme activity as a mechanistic factor for genetic predisposition to AD through altered dopamine turnover.	Dopamine	81-89	monoamine oxidase A	Homo sapiens	168-173
19214141-10	2009	CONCLUSION: The association of the MAOA-uVNTR with both susceptibility to AD and dopamine metabolite (HVA) concentration lends further biological plausibility for high MAO-A enzyme activity as a mechanistic factor for genetic predisposition to AD through altered dopamine turnover.	Dopamine	263-271	monoamine oxidase A	Homo sapiens	35-39
19214141-10	2009	CONCLUSION: The association of the MAOA-uVNTR with both susceptibility to AD and dopamine metabolite (HVA) concentration lends further biological plausibility for high MAO-A enzyme activity as a mechanistic factor for genetic predisposition to AD through altered dopamine turnover.	Dopamine	263-271	monoamine oxidase A	Homo sapiens	168-173
19166596-12	2009	CONCLUSION: Along with anti-manic effects of lithium and the antidepressant effects of bright light, these findings suggest that perturbations of the circadian gene network at several levels may influence mood disorders, perhaps ultimately through regulation of MAOA and its modulation of dopamine transmission.	Lithium	45-52	monoamine oxidase A	Homo sapiens	262-266
18751929-2	2009	Ladostigil combines neuroprotective effects with monoamine oxidase (MAO)-A and MAO-B and cholinesterase (ChE) inhibitory activities in a single molecule, as a potential treatment for Alzheimer"s disease (AD) and Lewy body disease.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	monoamine oxidase A	Homo sapiens	49-74
19120058-2	2009	However, how MAOA-LPR modulates the effects of other factors such as alcohol consumption related to antisocial behavior is not completely understood.	Alcohols	69-76	monoamine oxidase A	Homo sapiens	13-17
19120058-9	2009	Finnish high activity MAOA genotyped risk alcoholics exhibiting antisocial behavior, high alcohol consumption, and abnormal alcohol-related impulsive and uncontrolled violence might represent an etiologically distinct alcohol dependence subtype.	Alcohols	42-49	monoamine oxidase A	Homo sapiens	22-26
19120058-9	2009	Finnish high activity MAOA genotyped risk alcoholics exhibiting antisocial behavior, high alcohol consumption, and abnormal alcohol-related impulsive and uncontrolled violence might represent an etiologically distinct alcohol dependence subtype.	Alcohols	90-97	monoamine oxidase A	Homo sapiens	22-26
19120058-9	2009	Finnish high activity MAOA genotyped risk alcoholics exhibiting antisocial behavior, high alcohol consumption, and abnormal alcohol-related impulsive and uncontrolled violence might represent an etiologically distinct alcohol dependence subtype.	Alcohols	90-97	monoamine oxidase A	Homo sapiens	22-26
19248248-3	2009	The enhanced component of 5-HT-induced tension development was eradicated by clorgyline (a MAO-A inhibitor).	Clorgyline	77-87	monoamine oxidase A	Homo sapiens	91-96
18810510-7	2009	Findings are discussed considering the metabolic association among DAT, 5-HTT and MAOA with special emphasis on the linked action of 5-HTT/MAOA in regulating serotonin metabolism of SIDS and SIUD infants.	Serotonin	158-167	monoamine oxidase A	Homo sapiens	139-143
19166596-12	2009	CONCLUSION: Along with anti-manic effects of lithium and the antidepressant effects of bright light, these findings suggest that perturbations of the circadian gene network at several levels may influence mood disorders, perhaps ultimately through regulation of MAOA and its modulation of dopamine transmission.	Dopamine	289-297	monoamine oxidase A	Homo sapiens	262-266
19091581-0	2009	New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.	pyrazoline	4-14	monoamine oxidase A	Homo sapiens	141-146
19091581-0	2009	New pyrazoline bearing 4(3H)-quinazolinone inhibitors of monoamine oxidase: synthesis, biological evaluation, and structural determinants of MAO-A and MAO-B selectivity.	4-hydroxyquinazoline	23-42	monoamine oxidase A	Homo sapiens	141-146
19091581-1	2009	A new series of pyrazoline derivatives were prepared starting from a quinazolinone ring and evaluated for antidepressant, anxiogenic and MAO-A and -B inhibitory activities by in vivo and in vitro tests, respectively.	pyrazoline	16-26	monoamine oxidase A	Homo sapiens	137-149
19091581-11	2009	The very high MAO-B selectivity for 4i can be also explained in terms of the distance between the FAD and the compound, which was greater in the complex of MAO-A-4i as compared to the corresponding MAO-B complex.	Flavin-Adenine Dinucleotide	98-101	monoamine oxidase A	Homo sapiens	156-161
19043245-0	2008	Synthesis of some pyridazinylacetic acid derivatives as a novel class of monoamine oxidase-A inhibitors.	pyridazinylacetic acid	18-40	monoamine oxidase A	Homo sapiens	73-92
19043245-3	2008	Computational study performed with a docking technique indicated the potential of these compounds in pyridazine-based MAO-A inhibitor drug development.	pyridazine	101-111	monoamine oxidase A	Homo sapiens	118-123
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Dopamine	80-88	monoamine oxidase A	Homo sapiens	0-19
19010890-5	2008	Specifically, there was an increased expression of tryptophan hydroxylase 1 and a suppression of monoamine oxidase A expression (enzymes responsible for the synthesis and degradation of serotonin, respectively) in cholangiocarcinoma.	Serotonin	186-195	monoamine oxidase A	Homo sapiens	97-116
18834112-5	2008	On the other hand, compounds 24 (IC 50 = 1.2 nM) and 28 (IC 50 = 1.5 nM) show higher activity than selegiline (IC 50 = 19.6 nM) and high MAO-B selectivity with 100-fold and 1600-fold inhibition levels, with respect to the MAO-A isoform.	Selegiline	99-109	monoamine oxidase A	Homo sapiens	222-227
18951803-0	2008	Synthesis, structure-activity relationships and molecular modeling studies of new indole inhibitors of monoamine oxidases A and B.	indole	82-88	monoamine oxidase A	Homo sapiens	103-129
18951803-4	2008	In molecular modeling studies, compounds 22, 24, 44, and 46 positioned the indole ring into an aromatic cavity of MAO-A, and established pi-pi stacking interactions with Tyr407, Tyr444, and FAD cofactor.	indole	75-81	monoamine oxidase A	Homo sapiens	114-119
18951803-5	2008	However, only compound 22 was able to form hydrogen bonds with FAD, a finding which was in accordance with its potent anti-MAO-A activity.	Flavin-Adenine Dinucleotide	63-66	monoamine oxidase A	Homo sapiens	123-128
18971477-3	2008	Monoamine oxidase A (MAO-A) is a key regulator of serotonin metabolism, and polymorphic variation in the X-linked MAO-A gene influences its expression.	Serotonin	50-59	monoamine oxidase A	Homo sapiens	0-19
18971477-3	2008	Monoamine oxidase A (MAO-A) is a key regulator of serotonin metabolism, and polymorphic variation in the X-linked MAO-A gene influences its expression.	Serotonin	50-59	monoamine oxidase A	Homo sapiens	21-26
18971477-3	2008	Monoamine oxidase A (MAO-A) is a key regulator of serotonin metabolism, and polymorphic variation in the X-linked MAO-A gene influences its expression.	Serotonin	50-59	monoamine oxidase A	Homo sapiens	114-119
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Dopamine	80-88	monoamine oxidase A	Homo sapiens	21-25
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Norepinephrine	90-104	monoamine oxidase A	Homo sapiens	0-19
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Norepinephrine	90-104	monoamine oxidase A	Homo sapiens	21-25
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Epinephrine	93-104	monoamine oxidase A	Homo sapiens	0-19
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Epinephrine	93-104	monoamine oxidase A	Homo sapiens	21-25
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Serotonin	123-132	monoamine oxidase A	Homo sapiens	0-19
18361446-1	2008	Monoamine oxidase A (MAOA) is an enzyme expressed in the brain that metabolizes dopamine, norepinephrine, epinephrine, and serotonin.	Serotonin	123-132	monoamine oxidase A	Homo sapiens	21-25
18506697-3	2008	Gas chromatography/mass spectrometry analysis of the extract identified N,N-dimethyltryptamine, a potent hallucinogen, and the beta-carboline alkaloids harmine and harmaline, revealing monoamine oxidase A-inhibiting properties.	Harmaline	164-173	monoamine oxidase A	Homo sapiens	185-204
18640844-1	2008	Part 5: Effects of electron-withdrawing or -donating aryl substituents on the inhibition of monoamine oxidases A and B by 2-aryl-2-fluoro-cyclopropylamines.	2-aryl-2-fluoro-cyclopropylamines	122-155	monoamine oxidase A	Homo sapiens	92-118
18639608-7	2008	Caregivers with MAOA-uVNTR alleles associated with less transcriptional activity (3-repeats) displayed a pattern of cortisol excretion -- a decrease from overnight to daytime -- that was suggestive of HPA axis blunting, as compared to non-caregivers and those caregivers with the more active alleles (3.5/4 repeats) (cortisol p&lt;.043).	Hydrocortisone	116-124	monoamine oxidase A	Homo sapiens	16-20
18248494-4	2008	Under differentiation-promoting conditions, clorgyline, an irreversible MAO-A inhibitor, induced secretory cell-like morphology and repressed expression of cytokeratin 14, a basal cell marker.	Clorgyline	44-54	monoamine oxidase A	Homo sapiens	72-77
18248494-8	2008	In turn, androgen decreased MAO-A expression in clorgyline-treated, secretory-like cells.	Clorgyline	48-58	monoamine oxidase A	Homo sapiens	28-33
18499710-4	2008	MAOA has been shown to catabolize catecholamines that were reported to regulate luteal function in CL and vasoconstriction in various organs.	Catecholamines	34-48	monoamine oxidase A	Homo sapiens	0-4
18281126-1	2008	A series of N1-propanoyl-3,5-diphenyl-4,5-dihydro-(1H)-pyrazole derivatives were synthesized and assayed as inhibitors of MAO-A and MAO-B isoforms.	n1-propanoyl-3,5-diphenyl-4,5-dihydro-(1h)-pyrazole	12-63	monoamine oxidase A	Homo sapiens	122-127
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	monoamines	166-176	monoamine oxidase A	Homo sapiens	0-19
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	monoamines	166-176	monoamine oxidase A	Homo sapiens	21-25
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	monoamines	166-176	monoamine oxidase A	Homo sapiens	124-128
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Serotonin	185-194	monoamine oxidase A	Homo sapiens	0-19
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Serotonin	185-194	monoamine oxidase A	Homo sapiens	21-25
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Serotonin	185-194	monoamine oxidase A	Homo sapiens	124-128
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Norepinephrine	199-213	monoamine oxidase A	Homo sapiens	0-19
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Norepinephrine	199-213	monoamine oxidase A	Homo sapiens	21-25
18437281-1	2008	Monoamine oxidase A (MAOA) abnormality has been suggested as a crucial factor in the pathogenesis of mood disorder, because MAOA is associated with the metabolism of monoamines such as serotonin and norepinephrine.	Norepinephrine	199-213	monoamine oxidase A	Homo sapiens	124-128
18454435-0	2008	MAOA methylation is associated with nicotine and alcohol dependence in women.	Nicotine	36-44	monoamine oxidase A	Homo sapiens	0-4
18596609-1	2008	The X-linked monoamine oxidase A (MAO A) gene, coding for an enzyme especially involved in the serotonin catabolism, presents a well-characterized functional polymorphism (long and short variants) in the promoter region that alters the transcriptional activity of the gene and hence the function of the corresponding proteins.	Serotonin	95-104	monoamine oxidase A	Homo sapiens	34-39
20641420-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Serotonin	30-39	monoamine oxidase A	Homo sapiens	0-5
20641420-2	2004	MAO-A preferentially oxidizes serotonin and noradrenaline, whereas MAO-B preferentially oxidizes phenethylamine.	Norepinephrine	44-57	monoamine oxidase A	Homo sapiens	0-5
20641420-5	2004	[(11)C]Harmine ([(11)C]HAR), a potent and selective MAO-A inhibitor, has been found to be a useful positron emission tomography (PET) imaging agent in the human brain.	[(11)c]harmine	0-14	monoamine oxidase A	Homo sapiens	52-57
20641420-7	2004	(5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone (befloxatone), an oxazolidinone derivative, is a potent, reversible, and competitive MAO-A inhibitor (7).	(5r)-5-(methoxymethyl)-3-[4-[(3r)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	0-89	monoamine oxidase A	Homo sapiens	175-180
20641420-7	2004	(5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone (befloxatone), an oxazolidinone derivative, is a potent, reversible, and competitive MAO-A inhibitor (7).	Oxazolidinones	76-89	monoamine oxidase A	Homo sapiens	175-180
18501009-1	2008	BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in degrading several different biological amines, including serotonin.	Amines	116-122	monoamine oxidase A	Homo sapiens	12-31
18501009-1	2008	BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in degrading several different biological amines, including serotonin.	Amines	116-122	monoamine oxidase A	Homo sapiens	33-37
18501009-1	2008	BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in degrading several different biological amines, including serotonin.	Serotonin	134-143	monoamine oxidase A	Homo sapiens	12-31
20641420-8	2004	[(11)C]Befloxatone is being developed as a next-generation PET agent for the non-invasive study of brain MAO-A distribution and concentration in patients with psychiatric and neurologic disorders as well as for PET imaging in the heart.	befloxatone	7-18	monoamine oxidase A	Homo sapiens	105-110
18501009-1	2008	BACKGROUND: Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in degrading several different biological amines, including serotonin.	Serotonin	134-143	monoamine oxidase A	Homo sapiens	33-37
18242989-0	2008	Facile synthesis of substituted trans-2-arylcyclopropylamine inhibitors of the human histone demethylase LSD1 and monoamine oxidases A and B.	trans-2-arylcyclopropylamine	32-60	monoamine oxidase A	Homo sapiens	114-140
18426226-0	2008	Structural and mechanistic studies of arylalkylhydrazine inhibition of human monoamine oxidases A and B.	arylalkylhydrazine	38-56	monoamine oxidase A	Homo sapiens	77-103
18426226-3	2008	Benzylhydrazine is bound more tightly to MAO B than to MAO A, and phenylhydrazine is bound weakly by either enzyme.	benzylhydrazine	0-15	monoamine oxidase A	Homo sapiens	55-60
18426226-4	2008	Phenylethylhydrazine stoichiometrically reduces the covalent FAD moieties of MAO A and of MAO B.	Phenelzine	0-20	monoamine oxidase A	Homo sapiens	77-82
18426226-5	2008	Molecular oxygen is required for the inhibition reactions, and the level of O2 consumption for phenylethylhydrazine is 6-7-fold higher with either MAO A or MAO B than for the corresponding reactions with benzylhydrazine or phenylhydrazine.	Oxygen	10-16	monoamine oxidase A	Homo sapiens	147-152
18426226-5	2008	Molecular oxygen is required for the inhibition reactions, and the level of O2 consumption for phenylethylhydrazine is 6-7-fold higher with either MAO A or MAO B than for the corresponding reactions with benzylhydrazine or phenylhydrazine.	Oxygen	76-78	monoamine oxidase A	Homo sapiens	147-152
18426226-5	2008	Molecular oxygen is required for the inhibition reactions, and the level of O2 consumption for phenylethylhydrazine is 6-7-fold higher with either MAO A or MAO B than for the corresponding reactions with benzylhydrazine or phenylhydrazine.	Phenelzine	95-115	monoamine oxidase A	Homo sapiens	147-152
18426226-5	2008	Molecular oxygen is required for the inhibition reactions, and the level of O2 consumption for phenylethylhydrazine is 6-7-fold higher with either MAO A or MAO B than for the corresponding reactions with benzylhydrazine or phenylhydrazine.	benzylhydrazine	204-219	monoamine oxidase A	Homo sapiens	147-152
18242989-1	2008	A facile synthetic route to substituted trans-2-arylcyclopropylamines was developed to provide access to mechanism-based inhibitors of the human flavoenzyme oxidase lysine-specific histone demethylase LSD1 and related enzyme family members such as monoamine oxidases A and B.	trans-2-arylcyclopropylamines	40-69	monoamine oxidase A	Homo sapiens	248-274
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	monoamine	24-33	monoamine oxidase A	Homo sapiens	45-50
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Norepinephrine	112-126	monoamine oxidase A	Homo sapiens	24-43
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Norepinephrine	112-126	monoamine oxidase A	Homo sapiens	45-50
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Serotonin	128-137	monoamine oxidase A	Homo sapiens	24-43
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Serotonin	128-137	monoamine oxidase A	Homo sapiens	45-50
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Dopamine	143-151	monoamine oxidase A	Homo sapiens	24-43
18463263-1	2008	The genetic deletion of monoamine oxidase A (MAO A), an enzyme that breaks down the monoamine neurotransmitters norepinephrine, serotonin, and dopamine, produces aggressive phenotypes across species.	Dopamine	143-151	monoamine oxidase A	Homo sapiens	45-50
18463263-4	2008	Here, we hypothesized that in healthy adult males the gene product of MAO A in the brain, rather than the gene per se, would be associated with regulating the concentration of brain amines involved in trait aggression.	Amines	182-188	monoamine oxidase A	Homo sapiens	70-75
18463263-5	2008	Brain MAO A activity was measured in vivo in healthy nonsmoking men with positron emission tomography using a radioligand specific for MAO A (clorgyline labeled with carbon 11).	Clorgyline	142-152	monoamine oxidase A	Homo sapiens	135-140
18463263-7	2008	Here we report for the first time that brain MAO A correlates inversely with the MPQ trait measure of aggression (but not with other personality traits) such that the lower the MAO A activity in cortical and subcortical brain regions, the higher the self-reported aggression (in both MAOA genotype groups) contributing to more than one-third of the variability.	mpq	81-84	monoamine oxidase A	Homo sapiens	45-50
18463263-7	2008	Here we report for the first time that brain MAO A correlates inversely with the MPQ trait measure of aggression (but not with other personality traits) such that the lower the MAO A activity in cortical and subcortical brain regions, the higher the self-reported aggression (in both MAOA genotype groups) contributing to more than one-third of the variability.	mpq	81-84	monoamine oxidase A	Homo sapiens	177-182
18463263-7	2008	Here we report for the first time that brain MAO A correlates inversely with the MPQ trait measure of aggression (but not with other personality traits) such that the lower the MAO A activity in cortical and subcortical brain regions, the higher the self-reported aggression (in both MAOA genotype groups) contributing to more than one-third of the variability.	mpq	81-84	monoamine oxidase A	Homo sapiens	284-288
18508575-2	2008	Ladostigil combines neuroprotective effects with monoamine oxidase -A and -B and cholinesterase inhibitory activities in a single molecule, as a potential treatment for Alzheimer"s disease (AD) and Lewy Body disease.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-10	monoamine oxidase A	Homo sapiens	49-76
18177231-2	2008	Patients produce little IKAP, the gene product of the affected mutated gene, and have low levels of monoamine oxidase A (MAO A), whose reduced presence appears to result in an increased accumulation of biogenic amines, which is a trigger for hypertensive crises.	Amines	211-217	monoamine oxidase A	Homo sapiens	100-119
18237459-6	2008	We suggest that the neuroprotective effect of selegiline is predominantly associated with neurotrophic actions but not MAO-B inhibition, because SH-SY 5Y human neuroblastoma cells only contain MAO-A.	Selegiline	46-56	monoamine oxidase A	Homo sapiens	193-198
18391214-6	2008	The results confirm that the inhibitor selectivity of MAOA and MAOB is caused by the structural differences arising from Ile-335 in MAOA vs. Tyr-326 in MAOB.	Isoleucine	121-124	monoamine oxidase A	Homo sapiens	54-58
18391214-6	2008	The results confirm that the inhibitor selectivity of MAOA and MAOB is caused by the structural differences arising from Ile-335 in MAOA vs. Tyr-326 in MAOB.	Isoleucine	121-124	monoamine oxidase A	Homo sapiens	132-136
18391214-6	2008	The results confirm that the inhibitor selectivity of MAOA and MAOB is caused by the structural differences arising from Ile-335 in MAOA vs. Tyr-326 in MAOB.	Tyrosine	141-144	monoamine oxidase A	Homo sapiens	54-58
18177231-2	2008	Patients produce little IKAP, the gene product of the affected mutated gene, and have low levels of monoamine oxidase A (MAO A), whose reduced presence appears to result in an increased accumulation of biogenic amines, which is a trigger for hypertensive crises.	Amines	211-217	monoamine oxidase A	Homo sapiens	121-126
18177231-3	2008	As ingestion of tocotrienols elevates IKAP and MAO A in FD patients, we examined their impact on the frequency of hypertensive crises and cardiac function.	Tocotrienols	16-28	monoamine oxidase A	Homo sapiens	47-52
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Amines	59-65	monoamine oxidase A	Homo sapiens	0-19
18294618-2	2008	The X-linked Mono-Amine Oxidase A (MAO A) gene, coding for an enzyme especially involved in the serotonin (5-HT) catabolism, presents a well-characterized functional polymorphism consisting in a variable number of tandem repeats (VNTR) in the promoter region with high activity and low activity variants.	Serotonin	96-105	monoamine oxidase A	Homo sapiens	35-40
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Amines	59-65	monoamine oxidase A	Homo sapiens	21-25
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Norepinephrine	74-88	monoamine oxidase A	Homo sapiens	0-19
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Norepinephrine	74-88	monoamine oxidase A	Homo sapiens	21-25
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Dopamine	90-98	monoamine oxidase A	Homo sapiens	0-19
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Dopamine	90-98	monoamine oxidase A	Homo sapiens	21-25
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Serotonin	104-113	monoamine oxidase A	Homo sapiens	0-19
18388730-1	2008	Monoamine oxidase A (MAOA) enzymatically degrades biogenic amines such as norepinephrine, dopamine, and serotonin, and plays a key role in the regulation of their neurotransmission.	Serotonin	104-113	monoamine oxidase A	Homo sapiens	21-25
18366702-7	2008	RESULTS: Our analysis found that significant downregulation of MAO-A, the enzyme that metabolizes serotonin, occurred in multiple tissues from humans, rodents, and fish.	Serotonin	98-107	monoamine oxidase A	Homo sapiens	63-68
18560630-0	2008	Phase I clinical trial with desoxypeganine, a new cholinesterase and selective MAO-A inhibitor: tolerance and pharmacokinetics study of escalating single oral doses.	3-deoxyvasicine	28-42	monoamine oxidase A	Homo sapiens	79-84
17519928-2	2008	To identify these circuits, we used a combined genetic and imaging approach focused on Monoamine Oxidase A (MAOA), encoding a key enzyme for monoamine metabolism previously associated with temperament and antisocial behavior.	monoamine	141-150	monoamine oxidase A	Homo sapiens	87-106
17519928-2	2008	To identify these circuits, we used a combined genetic and imaging approach focused on Monoamine Oxidase A (MAOA), encoding a key enzyme for monoamine metabolism previously associated with temperament and antisocial behavior.	monoamine	141-150	monoamine oxidase A	Homo sapiens	108-112
18560630-1	2008	Desoxypeganine (DOP) is a natural alkaloid that has been characterized as a cholinesterase inhibitor and a selective inhibitor of monoamine oxidase A.	3-deoxyvasicine	0-14	monoamine oxidase A	Homo sapiens	130-149
18560630-1	2008	Desoxypeganine (DOP) is a natural alkaloid that has been characterized as a cholinesterase inhibitor and a selective inhibitor of monoamine oxidase A.	3-deoxyvasicine	16-19	monoamine oxidase A	Homo sapiens	130-149
17429405-0	2008	A non-additive interaction of a functional MAO-A VNTR and testosterone predicts antisocial behavior.	Testosterone	58-70	monoamine oxidase A	Homo sapiens	43-48
17592478-14	2008	The MAOA-LPR low activity allele appears to confer increased vulnerability to the adverse psychosocial consequences of CSA.	Cyclosporine	119-122	monoamine oxidase A	Homo sapiens	4-8
18198902-1	2008	Human monoamine oxidase A (hMAOA) is considered to be unique among mammalian MAOs in having a non-conservative Glu-X-Lys mutation (X being 151 in MAOAs and 142 in MAOB"s), which is suggested to be the reason for its monomeric structure.	Glutamic Acid	111-114	monoamine oxidase A	Homo sapiens	6-25
18198902-1	2008	Human monoamine oxidase A (hMAOA) is considered to be unique among mammalian MAOs in having a non-conservative Glu-X-Lys mutation (X being 151 in MAOAs and 142 in MAOB"s), which is suggested to be the reason for its monomeric structure.	Glutamic Acid	111-114	monoamine oxidase A	Homo sapiens	27-32
18198902-1	2008	Human monoamine oxidase A (hMAOA) is considered to be unique among mammalian MAOs in having a non-conservative Glu-X-Lys mutation (X being 151 in MAOAs and 142 in MAOB"s), which is suggested to be the reason for its monomeric structure.	Lysine	117-120	monoamine oxidase A	Homo sapiens	6-25
18198902-1	2008	Human monoamine oxidase A (hMAOA) is considered to be unique among mammalian MAOs in having a non-conservative Glu-X-Lys mutation (X being 151 in MAOAs and 142 in MAOB"s), which is suggested to be the reason for its monomeric structure.	Lysine	117-120	monoamine oxidase A	Homo sapiens	27-32
17885758-10	2008	In conclusion, it seems plausible to say that MAOA-dependent metabolism of the biological amines may be partly related to high-activated MAO-A, allele 3, in the occurrence of FS among Turkish population.	Amines	90-96	monoamine oxidase A	Homo sapiens	46-50
17885758-10	2008	In conclusion, it seems plausible to say that MAOA-dependent metabolism of the biological amines may be partly related to high-activated MAO-A, allele 3, in the occurrence of FS among Turkish population.	Amines	90-96	monoamine oxidase A	Homo sapiens	137-142
18029114-0	2008	The MAO-A gene, platelet MAO-B activity and psychosocial environment in adolescent female alcohol-related problem behaviour.	Alcohols	90-97	monoamine oxidase A	Homo sapiens	4-9
18029114-2	2008	It has been suggested that antisocial behaviour, associated with alcohol consumption in males, is related to a variation in the monoamine oxidase A gene (MAO-A) promoter.	Alcohols	65-72	monoamine oxidase A	Homo sapiens	128-147
18029114-2	2008	It has been suggested that antisocial behaviour, associated with alcohol consumption in males, is related to a variation in the monoamine oxidase A gene (MAO-A) promoter.	Alcohols	65-72	monoamine oxidase A	Homo sapiens	154-159
18029114-4	2008	Aims of the present study were to: (1) investigate possible interactions between the MAO-A polymorphism, family relations and maltreatment/sexual abuse on adolescent alcohol-related problem behaviour among female adolescents; (2) to investigate if platelet MAO-B enzyme activity interacted with environment to predict female alcohol-related problems.	Alcohols	166-173	monoamine oxidase A	Homo sapiens	85-90
18029114-6	2008	RESULTS: In contrast to what has been reported in males, presence of the long (4-repeat) variant of the MAO-A gene in females interacted significantly with an unfavourable environment (poor family relations or maltreatment/abuse/sexual abuse) to increase the risk for high scores of alcohol-related problems.	Alcohols	283-290	monoamine oxidase A	Homo sapiens	104-109
18029114-8	2008	CONCLUSIONS: Poor psychosocial environment interacts with the high activity MAO-A genotype and low platelet MAO-B enzyme activity to increase vulnerability for female adolescent alcohol-related problem behaviour.	Alcohols	178-185	monoamine oxidase A	Homo sapiens	76-81
17429405-5	2008	The MAOA/testosterone interaction also predicted low levels of CSF MHPG, which tentatively suggests the possibility that the interaction may be mediated by a direct effect on gene transcription.	Testosterone	9-21	monoamine oxidase A	Homo sapiens	4-8
17429405-5	2008	The MAOA/testosterone interaction also predicted low levels of CSF MHPG, which tentatively suggests the possibility that the interaction may be mediated by a direct effect on gene transcription.	Methoxyhydroxyphenylglycol	67-71	monoamine oxidase A	Homo sapiens	4-8
18258310-5	2008	We propose that the MAOA-L, by causing an ontogenic excess of 5-hydroxytryptamine, labilizes critical neural circuitry for social evaluation and emotion regulation (the "socioaffective scaffold"), thereby amplifying the effects of adverse early-life experience and creating deleterious sociocognitive biases.	Serotonin	62-81	monoamine oxidase A	Homo sapiens	20-24
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Serotonin	112-121	monoamine oxidase A	Homo sapiens	16-35
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Serotonin	112-121	monoamine oxidase A	Homo sapiens	37-41
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Norepinephrine	123-137	monoamine oxidase A	Homo sapiens	16-35
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Norepinephrine	123-137	monoamine oxidase A	Homo sapiens	37-41
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Dopamine	143-151	monoamine oxidase A	Homo sapiens	16-35
18227761-1	2008	BACKGROUND: The monoamine oxidase-A (MAOA) gene plays a vital role in the metabolism of neurotransmitters, e.g, serotonin, norepinephrine, and dopamine.	Dopamine	143-151	monoamine oxidase A	Homo sapiens	37-41
18405062-6	2008	In addition, when TPH-cc and MAOA-4 were combined as "high 5HT" genotypes, a correlative increase in PSL was observed with the increase in the number of "high 5HT" genotypes.	Serotonin	59-62	monoamine oxidase A	Homo sapiens	29-33
18405062-6	2008	In addition, when TPH-cc and MAOA-4 were combined as "high 5HT" genotypes, a correlative increase in PSL was observed with the increase in the number of "high 5HT" genotypes.	Serotonin	159-162	monoamine oxidase A	Homo sapiens	29-33
17429405-2	2008	Testosterone analogues are known to interact with the MAOA promoter in vitro to influence gene transcription as well as in vivo to influence CSF levels of the MAO metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in human males.	Testosterone	0-12	monoamine oxidase A	Homo sapiens	54-58
17429405-2	2008	Testosterone analogues are known to interact with the MAOA promoter in vitro to influence gene transcription as well as in vivo to influence CSF levels of the MAO metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in human males.	Methoxyhydroxyphenylglycol	174-205	monoamine oxidase A	Homo sapiens	54-58
17429405-2	2008	Testosterone analogues are known to interact with the MAOA promoter in vitro to influence gene transcription as well as in vivo to influence CSF levels of the MAO metabolite 3-methoxy-4-hydroxyphenylglycol (MHPG) in human males.	Methoxyhydroxyphenylglycol	207-211	monoamine oxidase A	Homo sapiens	54-58
17884271-5	2008	The present results suggest that high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression.	Serotonin	99-108	monoamine oxidase A	Homo sapiens	47-52
17884271-5	2008	The present results suggest that high-activity MAO-A genotypes possibly by consecutively decreased serotonin and/or norepinephrine availability negatively influence antidepressant treatment response during the first six weeks of pharmacological treatment in female patients with Major Depression.	Norepinephrine	116-130	monoamine oxidase A	Homo sapiens	47-52
17881661-9	2007	Clorgyline, a specific inhibitor of MAO-A, was less effective in inhibiting M12 formation.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	36-41
18044898-0	2007	Characterization of the covalently bound anionic flavin radical in monoamine oxidase a by electron paramagnetic resonance.	flavin radical	49-63	monoamine oxidase A	Homo sapiens	67-86
18044898-12	2007	DAAO contains a noncovalently bound flavin whereas MAO A contains a flavin covalently bound to a cysteinyl residue at C8alpha.	4,6-dinitro-o-cresol	68-74	monoamine oxidase A	Homo sapiens	51-56
18044898-12	2007	DAAO contains a noncovalently bound flavin whereas MAO A contains a flavin covalently bound to a cysteinyl residue at C8alpha.	lysyl-cysteinyl-cysteinyl-arginyl-cysteinyl-lysine	97-106	monoamine oxidase A	Homo sapiens	51-56
17883400-3	2007	In this study, we describe the MAO-A isoform as functional in apoptosis induced by staurosporine (STS) in human dopaminergic neuroblastoma cells (SH-SY5Y).	Staurosporine	98-101	monoamine oxidase A	Homo sapiens	31-36
17883400-10	2007	Therefore our data provide evidence that MAO-A, through its production of reactive oxygen species as a by-product of its catalytic activity on the mitochondrial surface, is recruited by the cell to enhance apoptotic signalling.	Reactive Oxygen Species	74-97	monoamine oxidase A	Homo sapiens	41-46
17883400-0	2007	Monoamine oxidase-A modulates apoptotic cell death induced by staurosporine in human neuroblastoma cells.	Staurosporine	62-75	monoamine oxidase A	Homo sapiens	0-19
17721552-0	2007	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	53-72
17883400-3	2007	In this study, we describe the MAO-A isoform as functional in apoptosis induced by staurosporine (STS) in human dopaminergic neuroblastoma cells (SH-SY5Y).	Staurosporine	83-96	monoamine oxidase A	Homo sapiens	31-36
17721552-0	2007	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.	Methylene Blue	0-14	monoamine oxidase A	Homo sapiens	74-79
17721552-0	2007	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.	Serotonin	19-28	monoamine oxidase A	Homo sapiens	53-72
17721552-0	2007	Methylene blue and serotonin toxicity: inhibition of monoamine oxidase A (MAO A) confirms a theoretical prediction.	Serotonin	19-28	monoamine oxidase A	Homo sapiens	74-79
17721552-5	2007	KEY RESULTS: MB was a potent (tight binding) inhibitor for MAO A.	Methylene Blue	13-15	monoamine oxidase A	Homo sapiens	59-64
17721552-7	2007	Interactions of MB with the active site of MAO A were confirmed by its action both as an oxidising substrate and as a one-electron reductant.	Methylene Blue	16-18	monoamine oxidase A	Homo sapiens	43-48
17721552-8	2007	CONCLUSIONS AND IMPLICATIONS: MB is a potent reversible inhibitor of MAO A with implications for gut uptake of amines when administered orally.	Amines	111-117	monoamine oxidase A	Homo sapiens	69-74
17721552-10	2007	This inhibition of MAO A would be expected to lead to perturbations of 5-hydroxytryptamine metabolism and hence account for ST occurring when administered to patients on SSRI treatment.	Serotonin	71-90	monoamine oxidase A	Homo sapiens	19-24
17824599-1	2007	Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity.	safinamide	0-10	monoamine oxidase A	Homo sapiens	299-318
17883257-8	2007	beta-Carbolines were isolated from raisins and acted as good competitive inhibitors of MAO-A (harman) and MAO-B (norharman) isozymes.	Carbolines	0-15	monoamine oxidase A	Homo sapiens	87-92
17824599-1	2007	Safinamide, (S)-N2-{4-[(3-fluorobenzyl)oxy]benzyl}alaninamide methanesulfonate, which is in phase III clinical trials as an anti-Parkinson drug, and a library of alkanamidic analogues were prepared through an expeditious solid-phase synthesis and evaluated for their monoamine oxidase B (MAO-B) and monoamine oxidase A (MAO-A) inhibitory activity and selectivity.	safinamide	0-10	monoamine oxidase A	Homo sapiens	320-325
17868200-3	2007	An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B.	Tyramine	95-103	monoamine oxidase A	Homo sapiens	180-185
17868200-3	2007	An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B.	Tyramine	95-103	monoamine oxidase A	Homo sapiens	197-202
17868200-3	2007	An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B.	Tyramine	110-118	monoamine oxidase A	Homo sapiens	180-185
17868200-3	2007	An exception is the extensive investigation carried out on the inhibition of the metabolism of tyramine, when tyramine-containing food is ingested by subjects taking inhibitors of MAO A or of both MAO A and B.	Tyramine	110-118	monoamine oxidase A	Homo sapiens	197-202
17692293-3	2007	Increased pineal MAOA activity might contribute to the reduced pineal melatonin production in AD.	Melatonin	70-79	monoamine oxidase A	Homo sapiens	17-21
17885625-1	2007	OBJECTIVE: The genes of catalytic enzymes of dopamine, including monoamine oxidase (MAOA and MAOB) and catechol-O-methyltransferase (COMT), have been major candidates for genes that affect smoking behavior.	Dopamine	45-53	monoamine oxidase A	Homo sapiens	84-88
17141746-3	2007	METHODS: Brain MAO A activity was measured with positron emission tomography and [(11)C]clorgyline in 38 healthy adult male nonsmokers genotyped for MAO A polymorphism.	[(11)c]clorgyline	81-98	monoamine oxidase A	Homo sapiens	15-20
17614182-6	2007	STS allows the targeted inhibition of the monoamine A (MAO-A) and MAO-B isoenzymes with minimal effects on the MAO-A in the gastrointestinal and hepatic systems.	monoamine a	42-53	monoamine oxidase A	Homo sapiens	55-60
17573034-0	2007	Structural insights into the mechanism of amine oxidation by monoamine oxidases A and B.	Amines	42-47	monoamine oxidase A	Homo sapiens	61-87
17573034-1	2007	Due to their pharmacological importance in the oxidation of amine neurotransmitters, the membrane-bound flavoenzymes monoamine oxidase A and monoamine oxidase B have attracted numerous investigations and, as a result, two different mechanisms; the single electron transfer and the polar nucleophilic mechanisms, have been proposed to describe their catalytic mechanisms.	Amines	60-65	monoamine oxidase A	Homo sapiens	117-136
17554106-2	2007	Medications that inhibit monoamine oxidase type A can augment the pressor effects of sympathomimetic amines, increasing the potential for hypertensive crisis.	Amines	101-107	monoamine oxidase A	Homo sapiens	25-49
17561096-0	2007	MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway.	Reactive Oxygen Species	49-72	monoamine oxidase A	Homo sapiens	0-5
17561096-0	2007	MAO-A-induced mitogenic signaling is mediated by reactive oxygen species, MMP-2, and the sphingolipid pathway.	Sphingolipids	89-101	monoamine oxidase A	Homo sapiens	0-5
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Amines	28-34	monoamine oxidase A	Homo sapiens	38-57
17561096-2	2007	This study aimed to investigate the role of ROS in the mitogenic signaling activated during tyramine and serotonin oxidation by MAO-A in smooth muscle cells (SMC).	Serotonin	105-114	monoamine oxidase A	Homo sapiens	128-133
17561096-4	2007	Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required.	Pargyline	60-69	monoamine oxidase A	Homo sapiens	10-15
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Amines	28-34	monoamine oxidase A	Homo sapiens	59-64
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Reactive Oxygen Species	76-99	monoamine oxidase A	Homo sapiens	38-57
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Reactive Oxygen Species	76-99	monoamine oxidase A	Homo sapiens	59-64
17561096-4	2007	Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required.	Ro 41-1049	74-83	monoamine oxidase A	Homo sapiens	10-15
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Reactive Oxygen Species	101-104	monoamine oxidase A	Homo sapiens	38-57
17561096-4	2007	Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required.	Reactive Oxygen Species	200-203	monoamine oxidase A	Homo sapiens	10-15
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Reactive Oxygen Species	101-104	monoamine oxidase A	Homo sapiens	59-64
17561096-4	2007	Silencing MAO-A by siRNA, pharmacological MAO-A inhibitors (pargyline and Ro41-1049), and the antioxidant/ROS scavenger butylated hydroxytoluene (BHT) inhibited the signaling cascade, suggesting that ROS generated during tyramine oxidation by MAO-A are required.	Tyramine	221-229	monoamine oxidase A	Homo sapiens	10-15
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Serotonin	127-136	monoamine oxidase A	Homo sapiens	38-57
17561096-7	2007	These findings demonstrate that H(2)O(2)-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall.	Hydrogen Peroxide	32-40	monoamine oxidase A	Homo sapiens	80-85
17561096-7	2007	These findings demonstrate that H(2)O(2)-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall.	Tyramine	58-66	monoamine oxidase A	Homo sapiens	80-85
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Serotonin	127-136	monoamine oxidase A	Homo sapiens	59-64
17561096-7	2007	These findings demonstrate that H(2)O(2)-generated during tyramine oxidation by MAO-A triggers a stress-induced mitogenic signaling via the MMP2/sphingolipid pathway, which could participate in excessive remodeling and alteration of the vascular wall.	Sphingolipids	145-157	monoamine oxidase A	Homo sapiens	80-85
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Tyramine	141-149	monoamine oxidase A	Homo sapiens	38-57
17561096-1	2007	The degradation of biogenic amines by monoamine oxidase A (MAO-A) generates reactive oxygen species (ROS) which participate in serotonin and tyramine signaling.	Tyramine	141-149	monoamine oxidase A	Homo sapiens	59-64
17561096-2	2007	This study aimed to investigate the role of ROS in the mitogenic signaling activated during tyramine and serotonin oxidation by MAO-A in smooth muscle cells (SMC).	Reactive Oxygen Species	44-47	monoamine oxidase A	Homo sapiens	128-133
17944104-3	2007	5-HT2A and MAOA genes, regulating activity of serotonin, influence on subjective time flow.	Serotonin	46-55	monoamine oxidase A	Homo sapiens	11-15
17674808-2	2007	The MAO-A inhibitory activity expressed as IC50 of the xanthones is known to correlate with E-state, molecular connectivity, shape indices and in this contribution it is shown that the orientation of nodes in their occupied pi orbitals explain a further large portion of the variance in their inhibitory activity.	Xanthones	55-64	monoamine oxidase A	Homo sapiens	4-9
17440951-3	2007	Drawing on the life course perspective, we predicted a stronger association between the polymorphisms in 5HTT, DAT1, DRD4, DRD2, and MAOA and alcohol consumption in young adulthood than adolescence.	Alcohols	142-149	monoamine oxidase A	Homo sapiens	133-137
17417058-1	2007	OBJECTIVE: Monoamine oxidase A is a mitochondrial enzyme involved in the degradation of certain neurotransmitter amines: serotonin and norepinephrine.	Serotonin	121-130	monoamine oxidase A	Homo sapiens	11-30
17563839-2	2007	These genetic differences could be explained by various genes, the HTR1B, encoding the 5-HT(1) receptor subtype, MAOA gene that encodes the monoamino-oxidase, the main metabolic enzyme of this triptan, SLC6A4 (gene encoding the serotonin transporter) and DRD(2) (gene encoding the D(2) receptor), both involved in the pathogenesis of migraine.	Tryptamines	193-200	monoamine oxidase A	Homo sapiens	113-117
17417058-1	2007	OBJECTIVE: Monoamine oxidase A is a mitochondrial enzyme involved in the degradation of certain neurotransmitter amines: serotonin and norepinephrine.	Amines	113-119	monoamine oxidase A	Homo sapiens	11-30
17417058-1	2007	OBJECTIVE: Monoamine oxidase A is a mitochondrial enzyme involved in the degradation of certain neurotransmitter amines: serotonin and norepinephrine.	Norepinephrine	135-149	monoamine oxidase A	Homo sapiens	11-30
17295220-4	2007	Common alleles of some serotonin pathway genes, including those involved in its degradation (monoamine oxidase A, MAOA), or its re-uptake into pre-synaptic neurones (serotonin transporter, SERT) have been shown to confer functional variation.	Serotonin	23-32	monoamine oxidase A	Homo sapiens	114-118
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Serotonin	106-115	monoamine oxidase A	Homo sapiens	4-23
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Serotonin	106-115	monoamine oxidase A	Homo sapiens	25-29
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Serotonin	106-115	monoamine oxidase A	Homo sapiens	195-199
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Norepinephrine	117-131	monoamine oxidase A	Homo sapiens	4-23
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Norepinephrine	117-131	monoamine oxidase A	Homo sapiens	25-29
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Norepinephrine	117-131	monoamine oxidase A	Homo sapiens	195-199
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Dopamine	137-145	monoamine oxidase A	Homo sapiens	4-23
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Dopamine	137-145	monoamine oxidase A	Homo sapiens	25-29
17585061-2	2007	The monoamine oxidase-A (MAOA) gene, which plays a vital role in degradation of neurotransmitters such as serotonin, norepinephrine, and dopamine, contains a polymorphism in its promoter region (MAOA-uVNTR) that affects transcriptional efficiency.	Dopamine	137-145	monoamine oxidase A	Homo sapiens	195-199
17192957-0	2007	The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.	Mirtazapine	65-76	monoamine oxidase A	Homo sapiens	4-8
17192957-0	2007	The MAOA T941G polymorphism and short-term treatment response to mirtazapine and paroxetine in major depression.	Paroxetine	81-91	monoamine oxidase A	Homo sapiens	4-8
17192957-1	2007	This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial.	Mirtazapine	125-136	monoamine oxidase A	Homo sapiens	56-60
17192957-1	2007	This study investigated the possible association of the MAOA T941G gene variant with differential antidepressant response to mirtazapine and/or paroxetine in 102 patients with major depression (DSM-IV criteria) participating in a randomized double-blind controlled clinical trial.	Paroxetine	144-154	monoamine oxidase A	Homo sapiens	56-60
17192957-5	2007	Time course of response and antidepressant efficacy of mirtazapine, but not paroxetine, seem to be influenced in a clinically relevant manner by this allelic variation within the MAOA gene, at least in female patients.	Mirtazapine	55-66	monoamine oxidase A	Homo sapiens	179-183
17256833-1	2007	A series of new pyrrole derivatives have been synthesized and evaluated for their monoamine oxidase (MAO) A and B inhibitory activity and selectivity.	Pyrroles	16-23	monoamine oxidase A	Homo sapiens	82-113
17256833-7	2007	The slightly different binding pose of 18 into the MAO-B active site seems to be forced by a bulkier Tyr residue, which replaces a smaller Ile residue present in MAO-A.	Isoleucine	139-142	monoamine oxidase A	Homo sapiens	162-167
17298646-0	2007	The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behaviour during male adolescent alcohol consumption.	Alcohols	133-140	monoamine oxidase A	Homo sapiens	4-23
17298646-0	2007	The monoamine oxidase A (MAO-A) gene, family function and maltreatment as predictors of destructive behaviour during male adolescent alcohol consumption.	Alcohols	133-140	monoamine oxidase A	Homo sapiens	25-30
17298646-1	2007	AIM: To investigate possible interactions between a polymorphism in the monoamine oxidase A (MAO-A) gene promoter, family relations and maltreatment/sexual abuse on adolescent alcohol-related problem behaviour among male adolescents.	Alcohols	176-183	monoamine oxidase A	Homo sapiens	72-91
17298646-1	2007	AIM: To investigate possible interactions between a polymorphism in the monoamine oxidase A (MAO-A) gene promoter, family relations and maltreatment/sexual abuse on adolescent alcohol-related problem behaviour among male adolescents.	Alcohols	176-183	monoamine oxidase A	Homo sapiens	93-98
17298646-5	2007	FINDINGS: Boys with the short (three-repeat) variant of the MAO-A gene, who had been maltreated/abused or came from families with poor relations, showed significantly higher scores of alcohol-related problems.	Alcohols	184-191	monoamine oxidase A	Homo sapiens	60-65
17298646-7	2007	CONCLUSIONS: The results suggest that both maltreatment and MAO-A genotype may be useful for the understanding of male adolescent alcohol-related problem behaviour.	Alcohols	130-137	monoamine oxidase A	Homo sapiens	60-65
17295220-4	2007	Common alleles of some serotonin pathway genes, including those involved in its degradation (monoamine oxidase A, MAOA), or its re-uptake into pre-synaptic neurones (serotonin transporter, SERT) have been shown to confer functional variation.	Serotonin	23-32	monoamine oxidase A	Homo sapiens	93-112
17346675-3	2007	In contrast to MPTP, human MAO-A or -B were not able to oxidize 2-Me-THbetaC to pyridinium-like cations.	2-methyltryptoline	64-76	monoamine oxidase A	Homo sapiens	27-38
17367163-7	2007	2-PCPA shows limited selectivity for human MAOs versus LSD1, with kinact/KI values only 16-fold and 2.4-fold higher for MAO B and MAO A, respectively.	Tranylcypromine	0-6	monoamine oxidase A	Homo sapiens	130-135
17480205-3	2007	When purified human monoamine oxidase A was used to examine the interaction with the active site, inhibition by guanabenz, 2-(2-benzofuranyl)-2-imidazoline and idazoxan was competitive with kynuramine as substrate, giving K(i) values of 3 microM, 26 microM and 125 microM, respectively.	Idazoxan	160-168	monoamine oxidase A	Homo sapiens	20-39
17480205-3	2007	When purified human monoamine oxidase A was used to examine the interaction with the active site, inhibition by guanabenz, 2-(2-benzofuranyl)-2-imidazoline and idazoxan was competitive with kynuramine as substrate, giving K(i) values of 3 microM, 26 microM and 125 microM, respectively.	Kynuramine	190-200	monoamine oxidase A	Homo sapiens	20-39
17480205-0	2007	Interactions of imidazoline ligands with the active site of purified monoamine oxidase A.	Imidazolines	16-27	monoamine oxidase A	Homo sapiens	69-88
17480205-1	2007	The two forms of monoamine oxidase, monoamine oxidase A and monoamine oxidase B, have been associated with imidazoline-binding sites (type 2).	Imidazolines	107-118	monoamine oxidase A	Homo sapiens	36-55
17480205-4	2007	Titration of monoamine oxidase A with imidazoline ligands induced spectral changes that were used to measure the binding affinities for guanabenz (19.3 +/- 3.9 microM) and 2-(2-benzofuranyl)-2-imidazoline (49 +/- 8 microM).	Imidazolines	38-49	monoamine oxidase A	Homo sapiens	13-32
17480205-3	2007	When purified human monoamine oxidase A was used to examine the interaction with the active site, inhibition by guanabenz, 2-(2-benzofuranyl)-2-imidazoline and idazoxan was competitive with kynuramine as substrate, giving K(i) values of 3 microM, 26 microM and 125 microM, respectively.	Guanabenz	112-121	monoamine oxidase A	Homo sapiens	20-39
17480205-3	2007	When purified human monoamine oxidase A was used to examine the interaction with the active site, inhibition by guanabenz, 2-(2-benzofuranyl)-2-imidazoline and idazoxan was competitive with kynuramine as substrate, giving K(i) values of 3 microM, 26 microM and 125 microM, respectively.	2-(2-benzofuranyl)-2-imidazoline	123-155	monoamine oxidase A	Homo sapiens	20-39
17480205-4	2007	Titration of monoamine oxidase A with imidazoline ligands induced spectral changes that were used to measure the binding affinities for guanabenz (19.3 +/- 3.9 microM) and 2-(2-benzofuranyl)-2-imidazoline (49 +/- 8 microM).	Guanabenz	136-145	monoamine oxidase A	Homo sapiens	13-32
17480205-4	2007	Titration of monoamine oxidase A with imidazoline ligands induced spectral changes that were used to measure the binding affinities for guanabenz (19.3 +/- 3.9 microM) and 2-(2-benzofuranyl)-2-imidazoline (49 +/- 8 microM).	2-(2-benzofuranyl)-2-imidazoline	172-204	monoamine oxidase A	Homo sapiens	13-32
17480205-6	2007	Agmatine, a putative endogenous ligand for some imidazoline sites, reduced monoamine oxidase A under anaerobic conditions, indicating that it binds close to the flavin in the active site.	Agmatine	0-8	monoamine oxidase A	Homo sapiens	75-94
17480205-6	2007	Agmatine, a putative endogenous ligand for some imidazoline sites, reduced monoamine oxidase A under anaerobic conditions, indicating that it binds close to the flavin in the active site.	Imidazolines	48-59	monoamine oxidase A	Homo sapiens	75-94
17480205-6	2007	Agmatine, a putative endogenous ligand for some imidazoline sites, reduced monoamine oxidase A under anaerobic conditions, indicating that it binds close to the flavin in the active site.	4,6-dinitro-o-cresol	161-167	monoamine oxidase A	Homo sapiens	75-94
17266193-1	2007	A series of 3,5-diaryl pyrazoles were prepared and assayed for their ability to inhibit reversibly monoamine oxidase-A (MAO-A) and monoamine oxidase B (MAO-B).	3,5-diaryl pyrazoles	12-32	monoamine oxidase A	Homo sapiens	99-118
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Amines	69-75	monoamine oxidase A	Homo sapiens	0-19
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Amines	69-75	monoamine oxidase A	Homo sapiens	21-26
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Norepinephrine	113-127	monoamine oxidase A	Homo sapiens	0-19
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Norepinephrine	113-127	monoamine oxidase A	Homo sapiens	21-26
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Dopamine	129-137	monoamine oxidase A	Homo sapiens	0-19
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Dopamine	129-137	monoamine oxidase A	Homo sapiens	21-26
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Serotonin	142-151	monoamine oxidase A	Homo sapiens	0-19
17328795-3	2007	Monoamine oxidase A (MAO-A) encodes an enzyme that degrades biogenic amines, including neurotransmitters such as norepinephrine, dopamine and serotonin.	Serotonin	142-151	monoamine oxidase A	Homo sapiens	21-26
17266193-1	2007	A series of 3,5-diaryl pyrazoles were prepared and assayed for their ability to inhibit reversibly monoamine oxidase-A (MAO-A) and monoamine oxidase B (MAO-B).	3,5-diaryl pyrazoles	12-32	monoamine oxidase A	Homo sapiens	120-125
17192761-2	2007	A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier.	Selegiline	2-12	monoamine oxidase A	Homo sapiens	159-178
16806099-5	2007	RESULTS: A suggestive association of sequence variations in genes responsible for the synthesis (TPH), recognition (5-HTR2A), and degradation (MAOA) of serotonin with depression symptomatology was found, although the effect was generally restricted to men.	Serotonin	152-161	monoamine oxidase A	Homo sapiens	143-147
17098208-6	2007	And in the fourth phase, coincident with the decrease in heme-containing cytochrome c protein, a transcriptional induction of the heme-dependent transcripts ALAS1 and MAOA occurred.	Heme	57-61	monoamine oxidase A	Homo sapiens	167-171
17192761-2	2007	A selegiline transdermal system (STS) was developed to provide antidepressant concentrations of selegiline in the brain, while preserving the gastrointestinal monoamine oxidase A (MAO-A) barrier.	Selegiline	2-12	monoamine oxidase A	Homo sapiens	180-185
17348765-3	2007	The first-generation MAOIs such as phenelzine and isocarboxazid were largely nonselective inhibitors of both subtypes of MAO, MAO(A) and MAO(B).	Phenelzine	35-45	monoamine oxidase A	Homo sapiens	126-132
17284087-2	2007	However, MAO-A is also inhibited at the high oral dosages needed to effectively treat depression (not an approved indication), necessitating a tyramine-restricted diet.	Tyramine	143-151	monoamine oxidase A	Homo sapiens	9-14
17348765-3	2007	The first-generation MAOIs such as phenelzine and isocarboxazid were largely nonselective inhibitors of both subtypes of MAO, MAO(A) and MAO(B).	Isocarboxazid	50-63	monoamine oxidase A	Homo sapiens	126-132
17348765-6	2007	At higher doses, selegiline loses selectivity and inhibits both MAO(A) and MAO(B).	Selegiline	17-27	monoamine oxidase A	Homo sapiens	64-70
17401530-2	2007	With the exception of the inhibition of the metabolism of tyramine ingested by subjects taking inhibitors of MAO-A or of both MAO-A and -B, which has been extensively investigated, the involvement of the monoamine oxidases in xenobiotic amine metabolism (drugs in particular) has been largely neglected.	Tyramine	58-66	monoamine oxidase A	Homo sapiens	109-114
17401530-2	2007	With the exception of the inhibition of the metabolism of tyramine ingested by subjects taking inhibitors of MAO-A or of both MAO-A and -B, which has been extensively investigated, the involvement of the monoamine oxidases in xenobiotic amine metabolism (drugs in particular) has been largely neglected.	Tyramine	58-66	monoamine oxidase A	Homo sapiens	126-138
17393065-0	2007	Kinetic properties of recombinant MAO-A on incorporation into phospholipid nanodisks.	Phospholipids	62-74	monoamine oxidase A	Homo sapiens	34-39
17417741-1	2007	Dopamine behaves mainly as a MAO-A substrate in rodent brain, but selective inhibition of MAO-B results in an increased turning activity following L-DOPA administration in hemi-Parkinsonian rodents.	Dopamine	0-8	monoamine oxidase A	Homo sapiens	29-34
17393065-3	2007	Purified MAO-A incorporates into pre-formed nanodiscs which are approximately 10 nm in diameter and exhibit the thickness expected for a phospholipid bilayer.	Phospholipids	137-149	monoamine oxidase A	Homo sapiens	9-14
17401535-2	2007	The pH dependence of the kinetic parameters for kynuramine oxidation by purified human MAO-A and for phenylethylamine oxidation by MAO-B in granulocytes at pH values from 5 to 10 was consistent with the protonated amine being used.	Kynuramine	48-58	monoamine oxidase A	Homo sapiens	87-92
17393065-4	2007	Nanodisc assemblies of MAO-A are water-soluble, yield increased enzyme stability relative to detergent solutions, are catalytically active, and reactive with acetylenic inhibitors.	Water	33-38	monoamine oxidase A	Homo sapiens	23-28
17417741-4	2007	MAO-B as well as MAO-A may contribute to deamination of dopamine produced from L-DOPA.	Dopamine	56-64	monoamine oxidase A	Homo sapiens	17-22
17417741-4	2007	MAO-B as well as MAO-A may contribute to deamination of dopamine produced from L-DOPA.	Levodopa	79-85	monoamine oxidase A	Homo sapiens	17-22
17393065-6	2007	Also, nanodisc bound MAO-A binds various inhibitors with K (i) values that are 2-4 fold lower than MAO-A in reduced Triton X-100 solutions.	Octoxynol	116-128	monoamine oxidase A	Homo sapiens	21-26
17393065-6	2007	Also, nanodisc bound MAO-A binds various inhibitors with K (i) values that are 2-4 fold lower than MAO-A in reduced Triton X-100 solutions.	Octoxynol	116-128	monoamine oxidase A	Homo sapiens	99-104
17401535-2	2007	The pH dependence of the kinetic parameters for kynuramine oxidation by purified human MAO-A and for phenylethylamine oxidation by MAO-B in granulocytes at pH values from 5 to 10 was consistent with the protonated amine being used.	Amines	53-58	monoamine oxidase A	Homo sapiens	87-92
17401535-4	2007	The K(i) values for two oxazolidinone inhibitors of MAO-A gave opposite pH-dependence indicating that the uncharged form of each inhibitor bound better than the charged form.	Oxazolidinones	24-37	monoamine oxidase A	Homo sapiens	52-57
17401535-5	2007	Decreased pH induced a blue shift in the spectral maximum of MAO-A indicative of a more hydrophobic environment around the flavin, and also influenced the redox properties of the flavin.	4,6-dinitro-o-cresol	123-129	monoamine oxidase A	Homo sapiens	61-66
17401535-5	2007	Decreased pH induced a blue shift in the spectral maximum of MAO-A indicative of a more hydrophobic environment around the flavin, and also influenced the redox properties of the flavin.	4,6-dinitro-o-cresol	179-185	monoamine oxidase A	Homo sapiens	61-66
17401536-2	2007	The results presented here provide additional new insights into the interactions that take place on activation of the amine substrate by the aromatic cage residues in MAO-B catalysis and have relevance to the MAO-A catalytic mechanism.	Amines	118-123	monoamine oxidase A	Homo sapiens	209-214
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Amines	75-81	monoamine oxidase A	Homo sapiens	0-19
19300583-5	2007	Delivery of selegiline transdermally (EMSAM((R))) bypasses hepatic first pass metabolism, thereby avoiding significant inhibition of gastrointestinal and hepatic MAO-A activity (ie, reduced risk of tyramine-provoked events) while still providing sufficient levels of selegiline in the brain to produce an antidepressant effect.	Selegiline	12-22	monoamine oxidase A	Homo sapiens	162-167
17056035-0	2006	The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.	Imidazolines	4-15	monoamine oxidase A	Homo sapiens	57-62
17056035-0	2006	The imidazoline I2-site ligands BU 224 and 2-BFI inhibit MAO-A and MAO-B activities, hydrogen peroxide production, and lipolysis in rodent and human adipocytes.	2-(2-benzofuranyl)-2-imidazoline	43-48	monoamine oxidase A	Homo sapiens	57-62
17056035-5	2006	BU 224 and 2-BFI behaved as reversible inhibitors of both MAO-A and -B, as demonstrated by total inhibition of tyramine oxidation in human adipocytes and platelets or in liver from rats previously treated with selective MAO-inhibitors.	Busulfan	0-2	monoamine oxidase A	Homo sapiens	58-70
17056035-5	2006	BU 224 and 2-BFI behaved as reversible inhibitors of both MAO-A and -B, as demonstrated by total inhibition of tyramine oxidation in human adipocytes and platelets or in liver from rats previously treated with selective MAO-inhibitors.	2-(2-benzofuranyl)-2-imidazoline	11-16	monoamine oxidase A	Homo sapiens	58-70
17020906-5	2006	The second objective was to examine the endometrial expression of MAO-A during the receptive phase induced by exogenous estradiol (E(2)) and progesterone in patients whose endometrium was shown to have been either receptive or non-receptive to embryo implantation in repeated cycles of oocyte donation.	Estradiol	120-129	monoamine oxidase A	Homo sapiens	66-71
17020906-7	2006	Immunofluorescent labelling demonstrated MAO-A localization to the glandular and luminal epithelium with an increasing positive score between LH+3 and LH+7.	Luteinizing Hormone	151-153	monoamine oxidase A	Homo sapiens	41-46
17106424-0	2006	Allele distribution of a monoamine oxidase A gene promoter polymorphism in German alcoholics and in subgroups with severe forms of alcohol withdrawal and its influence on plasma homovanillic acid.	Alcohols	82-89	monoamine oxidase A	Homo sapiens	25-44
17106424-0	2006	Allele distribution of a monoamine oxidase A gene promoter polymorphism in German alcoholics and in subgroups with severe forms of alcohol withdrawal and its influence on plasma homovanillic acid.	Homovanillic Acid	178-195	monoamine oxidase A	Homo sapiens	25-44
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	monoamines	58-68	monoamine oxidase A	Homo sapiens	0-19
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	monoamines	58-68	monoamine oxidase A	Homo sapiens	21-26
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Serotonin	78-87	monoamine oxidase A	Homo sapiens	0-19
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Serotonin	78-87	monoamine oxidase A	Homo sapiens	21-26
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Norepinephrine	89-103	monoamine oxidase A	Homo sapiens	0-19
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Norepinephrine	89-103	monoamine oxidase A	Homo sapiens	21-26
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Dopamine	109-117	monoamine oxidase A	Homo sapiens	0-19
17088501-2	2006	Monoamine oxidase A (MAO-A) is an enzyme that metabolizes monoamines, such as serotonin, norepinephrine, and dopamine.	Dopamine	109-117	monoamine oxidase A	Homo sapiens	21-26
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	82-87
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	142-147
17088501-8	2006	MAIN OUTCOME MEASURE: Harmine labeled with carbon 11, a radioligand selective for MAO-A and positron emission tomography, was used to measure MAO-A DVS (specific distribution volume), an index of MAO-A density, in different brain regions (prefrontal cortex, anterior cingulate cortex, posterior cingulate cortex, caudate, putamen, thalamus, anterior temporal cortex, midbrain, hippocampus, and parahippocampus).	Harmine	22-29	monoamine oxidase A	Homo sapiens	142-147
17088501-10	2006	The MAO-A DVS was elevated on average by 34% (2 SDs) throughout the brain during major depression.	Sodium Dodecyl Sulfate	48-51	monoamine oxidase A	Homo sapiens	4-9
17088501-11	2006	CONCLUSIONS: The sizable magnitude of this finding and the absence of other compelling explanations for monoamine loss during major depressive episodes led to the conclusion that elevated MAO-A density is the primary monoamine-lowering process during major depression.	monoamine	104-113	monoamine oxidase A	Homo sapiens	188-193
17088501-11	2006	CONCLUSIONS: The sizable magnitude of this finding and the absence of other compelling explanations for monoamine loss during major depressive episodes led to the conclusion that elevated MAO-A density is the primary monoamine-lowering process during major depression.	monoamine	217-226	monoamine oxidase A	Homo sapiens	188-193
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Amines	75-81	monoamine oxidase A	Homo sapiens	21-25
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Norepinephrine	118-132	monoamine oxidase A	Homo sapiens	0-19
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Norepinephrine	118-132	monoamine oxidase A	Homo sapiens	21-25
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Serotonin	137-146	monoamine oxidase A	Homo sapiens	0-19
16896926-1	2006	Monoamine oxidase A (MAOA) catalyses the oxidative deamination of biogenic amines including neurotransmitters, mainly norepinephrine and serotonin in the brain and peripheral tissues.	Serotonin	137-146	monoamine oxidase A	Homo sapiens	21-25
16770335-2	2006	Monoamine oxidase A deaminates the monoamine neurotransmitters serotonin, dopamine (DA), and noradrenaline.	Dopamine	74-82	monoamine oxidase A	Homo sapiens	0-19
16207390-11	2006	Moreover, MAOA gene haplotypes were associated significantly with nicotine dependence in every group.	Nicotine	66-74	monoamine oxidase A	Homo sapiens	10-14
16207390-12	2006	In conclusion, there is an important association between MAOA polymorphisms and smoking status, suggesting a possible role of MAOA gene variants in nicotine dependence.	Nicotine	148-156	monoamine oxidase A	Homo sapiens	57-61
16207390-12	2006	In conclusion, there is an important association between MAOA polymorphisms and smoking status, suggesting a possible role of MAOA gene variants in nicotine dependence.	Nicotine	148-156	monoamine oxidase A	Homo sapiens	126-130
16770335-0	2006	A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index.	Dopamine	80-88	monoamine oxidase A	Homo sapiens	33-37
16770335-0	2006	A functional polymorphism in the MAOA gene promoter (MAOA-LPR) predicts central dopamine function and body mass index.	Dopamine	80-88	monoamine oxidase A	Homo sapiens	53-57
16770335-2	2006	Monoamine oxidase A deaminates the monoamine neurotransmitters serotonin, dopamine (DA), and noradrenaline.	Dopamine	84-86	monoamine oxidase A	Homo sapiens	0-19
16770335-2	2006	Monoamine oxidase A deaminates the monoamine neurotransmitters serotonin, dopamine (DA), and noradrenaline.	monoamine	35-44	monoamine oxidase A	Homo sapiens	0-19
16770335-2	2006	Monoamine oxidase A deaminates the monoamine neurotransmitters serotonin, dopamine (DA), and noradrenaline.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	0-19
16770335-2	2006	Monoamine oxidase A deaminates the monoamine neurotransmitters serotonin, dopamine (DA), and noradrenaline.	Norepinephrine	93-106	monoamine oxidase A	Homo sapiens	0-19
16770335-4	2006	Our goals were to test (1) whether MAOA-LPR contributes to interindividual variation in monoamine activity, assessed using levels of cerebrospinal fluid (CSF) monoamine metabolites; and (2) whether MAOA-LPR genotype influences alcoholism and/or body mass index (BMI).	monoamine	88-97	monoamine oxidase A	Homo sapiens	35-39
16770335-10	2006	Specifically, the genotype conferring high MAOA activity was associated with lower HVA levels in both alcoholics and controls, a finding that persisted after accounting for the potential confounds of alcoholism, BMI, height, and smoking.	Homovanillic Acid	83-86	monoamine oxidase A	Homo sapiens	43-47
16884303-1	2006	A new series of 3-, 4-, 7-polysubstituted coumarins have been designed and evaluated for their monoamine oxidase A and monoamine oxidase B (MAO-A and MAO-B) inhibitory potency.	3-, 4-, 7-polysubstituted coumarins	16-51	monoamine oxidase A	Homo sapiens	95-114
16884303-1	2006	A new series of 3-, 4-, 7-polysubstituted coumarins have been designed and evaluated for their monoamine oxidase A and monoamine oxidase B (MAO-A and MAO-B) inhibitory potency.	3-, 4-, 7-polysubstituted coumarins	16-51	monoamine oxidase A	Homo sapiens	140-145
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Serotonin	37-46	monoamine oxidase A	Homo sapiens	0-19
16944667-5	2006	We hypothesized that the risk of sleep disturbance is, at least in part, influenced by the availability of serotonin used for melatonin synthesis secondary to polymorphic variation at the enzyme monoamine oxidase A (MAO-A).	Serotonin	107-116	monoamine oxidase A	Homo sapiens	195-214
16944667-5	2006	We hypothesized that the risk of sleep disturbance is, at least in part, influenced by the availability of serotonin used for melatonin synthesis secondary to polymorphic variation at the enzyme monoamine oxidase A (MAO-A).	Serotonin	107-116	monoamine oxidase A	Homo sapiens	216-221
16944667-5	2006	We hypothesized that the risk of sleep disturbance is, at least in part, influenced by the availability of serotonin used for melatonin synthesis secondary to polymorphic variation at the enzyme monoamine oxidase A (MAO-A).	Melatonin	126-135	monoamine oxidase A	Homo sapiens	216-221
17723508-1	2006	An optical bio-sniffer for methyl mercaptan (MM) one of major odorous chemicals in halitosis (bad breath) was constructed by immobilizing monoamine oxidase type A (MAO-A) onto a tip of a fiber optic oxygen sensor (od: 1.59 mm) with an oxygen sensitive ruthenium organic complex (excitation: 470 nm, fluorescent: 600 nm).	methylmercaptan	27-43	monoamine oxidase A	Homo sapiens	138-162
17723508-1	2006	An optical bio-sniffer for methyl mercaptan (MM) one of major odorous chemicals in halitosis (bad breath) was constructed by immobilizing monoamine oxidase type A (MAO-A) onto a tip of a fiber optic oxygen sensor (od: 1.59 mm) with an oxygen sensitive ruthenium organic complex (excitation: 470 nm, fluorescent: 600 nm).	methylmercaptan	27-43	monoamine oxidase A	Homo sapiens	164-169
17723508-1	2006	An optical bio-sniffer for methyl mercaptan (MM) one of major odorous chemicals in halitosis (bad breath) was constructed by immobilizing monoamine oxidase type A (MAO-A) onto a tip of a fiber optic oxygen sensor (od: 1.59 mm) with an oxygen sensitive ruthenium organic complex (excitation: 470 nm, fluorescent: 600 nm).	Oxygen	199-205	monoamine oxidase A	Homo sapiens	164-169
17723508-1	2006	An optical bio-sniffer for methyl mercaptan (MM) one of major odorous chemicals in halitosis (bad breath) was constructed by immobilizing monoamine oxidase type A (MAO-A) onto a tip of a fiber optic oxygen sensor (od: 1.59 mm) with an oxygen sensitive ruthenium organic complex (excitation: 470 nm, fluorescent: 600 nm).	Oxygen	235-241	monoamine oxidase A	Homo sapiens	164-169
17723508-1	2006	An optical bio-sniffer for methyl mercaptan (MM) one of major odorous chemicals in halitosis (bad breath) was constructed by immobilizing monoamine oxidase type A (MAO-A) onto a tip of a fiber optic oxygen sensor (od: 1.59 mm) with an oxygen sensitive ruthenium organic complex (excitation: 470 nm, fluorescent: 600 nm).	ruthenium organic complex	252-277	monoamine oxidase A	Homo sapiens	164-169
17723508-3	2006	In order to amplify the bio-sniffer output, a substrate regeneration cycle caused by coupling MAO-A with l-ascorbic acid (AsA) as reducing reaction with reagent system was applied to the sensor system.	Ascorbic Acid	122-125	monoamine oxidase A	Homo sapiens	94-99
17723508-5	2006	The optical bio-sniffer was applied to detect the oxygen consumption induced by MAO-A enzymatic reaction (and AsA chemical reduction) with gaseous MM application.	Oxygen	50-56	monoamine oxidase A	Homo sapiens	80-85
16679384-0	2006	Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes.	Nomifensine	14-25	monoamine oxidase A	Homo sapiens	106-125
16679384-0	2006	Metabolism of nomifensine to a dihydroisoquinolinium ion metabolite by human myeloperoxidase, hemoglobin, monoamine oxidase A, and cytochrome P450 enzymes.	dihydroisoquinolinium	31-52	monoamine oxidase A	Homo sapiens	106-125
16679384-5	2006	Monoamine oxidase A, but not monoamine oxidase B, catalyzed this reaction, as well as human hemoglobin supplemented with H2O2.	Hydrogen Peroxide	121-125	monoamine oxidase A	Homo sapiens	0-19
16885013-0	2006	CHF3381, a N-methyl-D-aspartate receptor antagonist and monoamine oxidase-A inhibitor, attenuates secondary hyperalgesia in a human pain model.	indantadol	0-7	monoamine oxidase A	Homo sapiens	56-75
16885013-1	2006	UNLABELLED: CHF3381 is a new low-affinity, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor.	indantadol	12-19	monoamine oxidase A	Homo sapiens	121-140
16885013-1	2006	UNLABELLED: CHF3381 is a new low-affinity, noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor.	indantadol	12-19	monoamine oxidase A	Homo sapiens	142-147
16885013-10	2006	PERSPECTIVE: This article presents the antihyperalgesic effect of CHF3381, a new NMDA receptor antagonist and reversible MAO-A inhibitor, in a human pain model and might guide the proper selection of CHF3381 doses to be used in Phase 2 studies in patients with neuropathic pain.	indantadol	66-73	monoamine oxidase A	Homo sapiens	121-126
16885013-10	2006	PERSPECTIVE: This article presents the antihyperalgesic effect of CHF3381, a new NMDA receptor antagonist and reversible MAO-A inhibitor, in a human pain model and might guide the proper selection of CHF3381 doses to be used in Phase 2 studies in patients with neuropathic pain.	indantadol	200-207	monoamine oxidase A	Homo sapiens	121-126
16728402-1	2006	Monoamine oxidase (MAO) A is a key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine.	Serotonin	83-92	monoamine oxidase A	Homo sapiens	0-25
16728402-1	2006	Monoamine oxidase (MAO) A is a key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine.	Norepinephrine	94-108	monoamine oxidase A	Homo sapiens	0-25
16728402-1	2006	Monoamine oxidase (MAO) A is a key enzyme for the degradation of neurotransmitters serotonin, norepinephrine, and dopamine.	Dopamine	114-122	monoamine oxidase A	Homo sapiens	0-25
16728402-4	2006	Luciferase assays show that glucocorticoid (dexamethasone) and androgen (R1881) increase MAO A promoter and catalytic activities in human neuroblastoma and glioblastoma cells.	Dexamethasone	44-57	monoamine oxidase A	Homo sapiens	89-94
16848906-3	2006	RESULTS: Variations in the catecholamine metabolizing enzyme genes (MAOA and COMT) showed significant associations with the maximum post-operative pain rating while the serotonin transporter gene (SLC6A4) showed association with the onset time of post-operative pain.	Catecholamines	27-40	monoamine oxidase A	Homo sapiens	68-72
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Serotonin	37-46	monoamine oxidase A	Homo sapiens	21-26
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Norepinephrine	48-62	monoamine oxidase A	Homo sapiens	0-19
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Norepinephrine	48-62	monoamine oxidase A	Homo sapiens	21-26
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Dopamine	68-76	monoamine oxidase A	Homo sapiens	0-19
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Dopamine	68-76	monoamine oxidase A	Homo sapiens	21-26
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Oxygen	99-105	monoamine oxidase A	Homo sapiens	0-19
16829576-1	2006	Monoamine oxidase A (MAO A) degrades serotonin, norepinephrine, and dopamine and produces reactive oxygen that may cause neuronal cell death.	Oxygen	99-105	monoamine oxidase A	Homo sapiens	21-26
16584839-1	2006	Catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAOA) are both involved in the degradation of various biogenic amines which have been hypothesized to have a relationship with personality traits.	Amines	124-130	monoamine oxidase A	Homo sapiens	40-59
16725119-2	2006	Norepinephrine is degraded by monoamine oxidase A (MAOA) and catechol-O-methyl transferase (COMT).	Norepinephrine	0-14	monoamine oxidase A	Homo sapiens	30-49
16725119-2	2006	Norepinephrine is degraded by monoamine oxidase A (MAOA) and catechol-O-methyl transferase (COMT).	Norepinephrine	0-14	monoamine oxidase A	Homo sapiens	51-55
16386263-5	2006	Several beta-carbolines such as tryptoline (1,2,3,4-tetrahydro-beta-carboline) and 1-methyltryptoline (1-methyl-1,2,3,4-tetrahydro-beta-carboline) were inhibitors of MAO-A; instead their corresponding 6-hydroxy-derivatives (6-hydroxytryptoline and 6-hydroxy-1-methyltryptoline) lacked this activity.	tryptoline	44-77	monoamine oxidase A	Homo sapiens	166-171
16386263-5	2006	Several beta-carbolines such as tryptoline (1,2,3,4-tetrahydro-beta-carboline) and 1-methyltryptoline (1-methyl-1,2,3,4-tetrahydro-beta-carboline) were inhibitors of MAO-A; instead their corresponding 6-hydroxy-derivatives (6-hydroxytryptoline and 6-hydroxy-1-methyltryptoline) lacked this activity.	tetrahydroharmane	103-145	monoamine oxidase A	Homo sapiens	166-171
16386263-8	2006	Two tetrahydro-beta-carbolines (i.e. tryptoline and 1-methyltryptoline) occurring in foods were isolated by solid-phase extraction (SPE) and RP-HPLC from selected samples of sausages and the corresponding extracts exhibited good inhibition properties over MAO-A.	tryptoline	4-30	monoamine oxidase A	Homo sapiens	256-261
16386263-8	2006	Two tetrahydro-beta-carbolines (i.e. tryptoline and 1-methyltryptoline) occurring in foods were isolated by solid-phase extraction (SPE) and RP-HPLC from selected samples of sausages and the corresponding extracts exhibited good inhibition properties over MAO-A.	tryptoline	37-47	monoamine oxidase A	Homo sapiens	256-261
16386263-8	2006	Two tetrahydro-beta-carbolines (i.e. tryptoline and 1-methyltryptoline) occurring in foods were isolated by solid-phase extraction (SPE) and RP-HPLC from selected samples of sausages and the corresponding extracts exhibited good inhibition properties over MAO-A.	1-methyltryptoline	52-70	monoamine oxidase A	Homo sapiens	256-261
16702990-2	2006	Moclobemide (MB) is an antidepressant drug that selectively and reversibly inhibits monoamine oxidase-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	84-103
16702990-2	2006	Moclobemide (MB) is an antidepressant drug that selectively and reversibly inhibits monoamine oxidase-A.	Moclobemide	13-15	monoamine oxidase A	Homo sapiens	84-103
16584839-1	2006	Catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAOA) are both involved in the degradation of various biogenic amines which have been hypothesized to have a relationship with personality traits.	Amines	124-130	monoamine oxidase A	Homo sapiens	61-65
16631124-5	2006	On the other hand, both c-RESV and t-RESV (5-200 microM) concentration-dependently inhibited the enzymatic activity of commercial (human recombinant) MAO isoform (MAO-A and MAO-B) activity, c-RESV being slightly less effective than t-RESV.	c-resv	24-30	monoamine oxidase A	Homo sapiens	163-168
16631124-5	2006	On the other hand, both c-RESV and t-RESV (5-200 microM) concentration-dependently inhibited the enzymatic activity of commercial (human recombinant) MAO isoform (MAO-A and MAO-B) activity, c-RESV being slightly less effective than t-RESV.	Resveratrol	26-30	monoamine oxidase A	Homo sapiens	163-168
16652315-3	2006	The concomitant administration of nonselective MAO inhibitors or MAO-A inhibitors with drugs that increase serotonin concentrations is associated with serotonin toxicity.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	65-70
16723097-5	2006	The K(m) value of serotonin to MAO-A was 1.66 micromol/L, while that of benzylamine to MAO-B was 0.80 micromol/L.	Serotonin	18-27	monoamine oxidase A	Homo sapiens	31-36
16723097-6	2006	The IC(50) value of clorgyline to MAO-A was 2.99 nmol/L, and that of deprenyl to MAO-B was 7.04 nmol/L, matching those obtained from traditional spectrometric assays.	Clorgyline	20-30	monoamine oxidase A	Homo sapiens	34-39
16652315-3	2006	The concomitant administration of nonselective MAO inhibitors or MAO-A inhibitors with drugs that increase serotonin concentrations is associated with serotonin toxicity.	Serotonin	151-160	monoamine oxidase A	Homo sapiens	65-70
16427095-1	2006	Monoamine oxidase (MAO), a mitochondrial flavine containing enzyme, exists in two isoenzymes, MAO-A and MAO-B.	3,6-DIAMINO-10-METHYLACRIDINIUM CHLORIDE	41-48	monoamine oxidase A	Homo sapiens	94-99
16252076-2	2006	Here, using extracts from cultured astrocytes, containing both monoamine oxidase (MAO) A and B activity, we demonstrate that ADT concentration-dependently inhibits MAO-B activity in a clinically relevant concentration range (0.03-30 microM, IC-50 = 0.5 microM) without affecting MAO A activity.	adt	125-128	monoamine oxidase A	Homo sapiens	63-94
16674552-2	2006	Dopamine availability is controlled largely by three enzymes: COMT, MAOA and MAOB, and by the dopamine transporter SLC6A3, and each gene has a well-characterized functional variant.	Dopamine	0-8	monoamine oxidase A	Homo sapiens	68-72
16674552-9	2006	In implicating both the MAOA and MOAB variants, however, this study provides the first indication that dopamine availability (as opposed to other effects of MAOA) is involved in human obesity.	Dopamine	103-111	monoamine oxidase A	Homo sapiens	24-28
16574383-5	2006	Dopaminechrome, a product of dopamine oxidation, was found to be a MAO-A inhibitor and a strong oxidizer of NADH and NADPH in a cell-free system.	dopaminechrome	0-14	monoamine oxidase A	Homo sapiens	67-72
16574383-5	2006	Dopaminechrome, a product of dopamine oxidation, was found to be a MAO-A inhibitor and a strong oxidizer of NADH and NADPH in a cell-free system.	Dopamine	29-37	monoamine oxidase A	Homo sapiens	67-72
16252076-2	2006	Here, using extracts from cultured astrocytes, containing both monoamine oxidase (MAO) A and B activity, we demonstrate that ADT concentration-dependently inhibits MAO-B activity in a clinically relevant concentration range (0.03-30 microM, IC-50 = 0.5 microM) without affecting MAO A activity.	adt	125-128	monoamine oxidase A	Homo sapiens	279-284
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	flavin-dependent amine	38-60	monoamine oxidase A	Homo sapiens	95-121
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	flavin-dependent amine	38-60	monoamine oxidase A	Homo sapiens	123-128
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	Amino Acids, Aromatic	145-164	monoamine oxidase A	Homo sapiens	95-121
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	Amino Acids, Aromatic	145-164	monoamine oxidase A	Homo sapiens	123-128
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	4,6-dinitro-o-cresol	38-44	monoamine oxidase A	Homo sapiens	95-121
16605246-1	2006	Current structural results of several flavin-dependent amine oxidizing enzymes including human monoamine oxidases A and B (MAO A and MAO B) show aromatic amino acid residues oriented approximately perpendicular to the flavin ring, suggesting a functional role in catalysis.	4,6-dinitro-o-cresol	38-44	monoamine oxidase A	Homo sapiens	123-128
16356714-0	2006	Synthesis of 3-benzyl-2-substituted quinoxalines as novel monoamine oxidase A inhibitors.	3-benzyl-2-substituted quinoxalines	13-48	monoamine oxidase A	Homo sapiens	58-77
16400710-1	2006	The 2-oxidation activity on the pyrimidine ring of RS-8359, a MAO-A inhibitor, is the major metabolic pathway catalysed by aldehyde oxidase.	RS 8359	51-58	monoamine oxidase A	Homo sapiens	62-67
16400710-0	2006	Species differences in enantioselective 2-oxidations of RS-8359, a selective and reversible MAO-A inhibitor, and cinchona alkaloids by aldehyde oxidase.	RS 8359	56-63	monoamine oxidase A	Homo sapiens	92-97
16400710-1	2006	The 2-oxidation activity on the pyrimidine ring of RS-8359, a MAO-A inhibitor, is the major metabolic pathway catalysed by aldehyde oxidase.	pyrimidine	32-42	monoamine oxidase A	Homo sapiens	62-67
16719786-8	2006	The molecular modeling work was carried out combining the Glide docking approach with CoMFA with the aim to rationalize the structure-activity relationships of each pyrazoline inhibitor toward MAO-A and MAO-B isoforms and to derive a suitable selectivity model.	pyrazoline	165-175	monoamine oxidase A	Homo sapiens	193-198
16522074-2	2006	By modifying the amino group and the central core of luciferin derivatives, we have developed a series of substrates useful for assays of MAO A or B, or both.	D-luciferin	53-62	monoamine oxidase A	Homo sapiens	138-143
16611214-0	2006	Synthesis and molecular modelling of novel substituted-4,5-dihydro-(1H)-pyrazole derivatives as potent and highly selective monoamine oxidase-A inhibitors.	-4,5-dihydro-(1h)-pyrazole	54-80	monoamine oxidase A	Homo sapiens	124-143
16079787-0	2006	Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.	Carbon-11	48-51	monoamine oxidase A	Homo sapiens	72-91
16079787-0	2006	Positron emission tomography quantification of [11C]-harmine binding to monoamine oxidase-A in the human brain.	Harmine	53-60	monoamine oxidase A	Homo sapiens	72-91
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Carbon-11	47-53	monoamine oxidase A	Homo sapiens	74-93
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Carbon-11	47-53	monoamine oxidase A	Homo sapiens	95-100
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Harmine	55-62	monoamine oxidase A	Homo sapiens	74-93
16079787-1	2006	This article describes the kinetic modeling of [(11)C]-harmine binding to monoamine oxidase A (MAO-A) binding sites in the human brain using positron emission tomography (PET).	Harmine	55-62	monoamine oxidase A	Homo sapiens	95-100
16079787-8	2006	Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	44-49
16079787-8	2006	Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	150-155
16079787-8	2006	Moclobemide treatment leads to a 64% to 79% MAO-A blockade across brain regions, a result that supports the specificity of [(11)C]-harmine binding to MAO-A.	Harmine	131-138	monoamine oxidase A	Homo sapiens	150-155
16079787-10	2006	These results indicate the suitability of using [(11)C]-harmine for quantitative evaluation of MAO-A densities using PET and should enable further studies of potential MAO-A dysregulation in several psychiatric and neurologic illnesses.	[(11)c]-harmine	48-63	monoamine oxidase A	Homo sapiens	95-100
16079787-10	2006	These results indicate the suitability of using [(11)C]-harmine for quantitative evaluation of MAO-A densities using PET and should enable further studies of potential MAO-A dysregulation in several psychiatric and neurologic illnesses.	[(11)c]-harmine	48-63	monoamine oxidase A	Homo sapiens	168-173
16467939-6	2006	These results agree with the previous kinetic experiments on the effect of p-substituents on the reduction of MAO-A by benzylamine analogs.	benzylamine	119-130	monoamine oxidase A	Homo sapiens	110-115
16467939-7	2006	In addition, the calculated rate constants showed a correlation with the rate of reduction of the flavin in MAO-A.	4,6-dinitro-o-cresol	98-104	monoamine oxidase A	Homo sapiens	108-113
16202396-2	2006	The monoamine oxidase-A (MAO-A) gene, coding for an enzyme primarily involved in serotonin and noradrenaline catabolism, presents a well-characterized functional polymorphism consisting of a variable number of tandem repeats in the promoter region, with high-activity and low-activity variants.	Serotonin	81-90	monoamine oxidase A	Homo sapiens	4-23
16202396-2	2006	The monoamine oxidase-A (MAO-A) gene, coding for an enzyme primarily involved in serotonin and noradrenaline catabolism, presents a well-characterized functional polymorphism consisting of a variable number of tandem repeats in the promoter region, with high-activity and low-activity variants.	Serotonin	81-90	monoamine oxidase A	Homo sapiens	25-30
16202396-2	2006	The monoamine oxidase-A (MAO-A) gene, coding for an enzyme primarily involved in serotonin and noradrenaline catabolism, presents a well-characterized functional polymorphism consisting of a variable number of tandem repeats in the promoter region, with high-activity and low-activity variants.	Norepinephrine	95-108	monoamine oxidase A	Homo sapiens	4-23
16202396-2	2006	The monoamine oxidase-A (MAO-A) gene, coding for an enzyme primarily involved in serotonin and noradrenaline catabolism, presents a well-characterized functional polymorphism consisting of a variable number of tandem repeats in the promoter region, with high-activity and low-activity variants.	Norepinephrine	95-108	monoamine oxidase A	Homo sapiens	25-30
16139309-3	2006	In this paper, "ready to drink" coffee brews exhibited inhibitory properties on recombinant human MAO A and B isozymes catalyzing the oxidative deamination of kynuramine, suggesting that coffee contains compounds acting as MAO inhibitors.	Kynuramine	159-169	monoamine oxidase A	Homo sapiens	98-103
16139309-5	2006	Subsequently, the pyrido-indole (beta-carboline) alkaloids, norharman and harman, were identified and isolated from MAO-inhibiting coffee, and were good inhibitors on MAO A (harman and norharman) and MAO B (norharman) isozymes.	pyrido-indole (beta-carboline) alkaloids	18-58	monoamine oxidase A	Homo sapiens	167-172
16139309-5	2006	Subsequently, the pyrido-indole (beta-carboline) alkaloids, norharman and harman, were identified and isolated from MAO-inhibiting coffee, and were good inhibitors on MAO A (harman and norharman) and MAO B (norharman) isozymes.	norharman	60-69	monoamine oxidase A	Homo sapiens	167-172
16139309-5	2006	Subsequently, the pyrido-indole (beta-carboline) alkaloids, norharman and harman, were identified and isolated from MAO-inhibiting coffee, and were good inhibitors on MAO A (harman and norharman) and MAO B (norharman) isozymes.	norharman	185-194	monoamine oxidase A	Homo sapiens	167-172
16139309-5	2006	Subsequently, the pyrido-indole (beta-carboline) alkaloids, norharman and harman, were identified and isolated from MAO-inhibiting coffee, and were good inhibitors on MAO A (harman and norharman) and MAO B (norharman) isozymes.	norharman	185-194	monoamine oxidase A	Homo sapiens	167-172
16360899-4	2006	In the present study, we investigated the association between personality traits and systematic combination of functional polymorphisms in three genes that regulate the metabolism of catecholamines, namely, tyrosine hydroxylase (TH), monoamine oxidase A (MAOA), and catechol-O-methyltransferase (COMT).	Catecholamines	183-197	monoamine oxidase A	Homo sapiens	234-253
16360899-4	2006	In the present study, we investigated the association between personality traits and systematic combination of functional polymorphisms in three genes that regulate the metabolism of catecholamines, namely, tyrosine hydroxylase (TH), monoamine oxidase A (MAOA), and catechol-O-methyltransferase (COMT).	Catecholamines	183-197	monoamine oxidase A	Homo sapiens	255-259
21901055-6	2006	Of the MAO inhibitors, the propargylamine derivative clorgyline, an irreversible MAO-A inhibitor, effectively blocks METH-induced hyperlocomotion and behavioral sensitization in rodents.	propargylamine	27-41	monoamine oxidase A	Homo sapiens	81-86
21901055-6	2006	Of the MAO inhibitors, the propargylamine derivative clorgyline, an irreversible MAO-A inhibitor, effectively blocks METH-induced hyperlocomotion and behavioral sensitization in rodents.	Clorgyline	53-63	monoamine oxidase A	Homo sapiens	81-86
21901055-6	2006	Of the MAO inhibitors, the propargylamine derivative clorgyline, an irreversible MAO-A inhibitor, effectively blocks METH-induced hyperlocomotion and behavioral sensitization in rodents.	Methamphetamine	117-121	monoamine oxidase A	Homo sapiens	81-86
17447417-9	2006	MAO-B oxidized dopamine with production of hydrogen peroxide, whereas in control cells expressing only MAO-A, dopamine autoxidation produced superoxide and dopamine-quinone, and induced mitochondrial permeability transition and apoptosis.	Dopamine	110-118	monoamine oxidase A	Homo sapiens	103-108
16336631-3	2006	An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, an MAO-A inhibitor, reduced membrane potential, DeltaPsim, in isolated mitochondria, and induced apoptosis in the cells, which 5-hydroxytryptamine, an MAO-A substrate, prevented.	salsoline	39-60	monoamine oxidase A	Homo sapiens	65-70
16336631-3	2006	An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, an MAO-A inhibitor, reduced membrane potential, DeltaPsim, in isolated mitochondria, and induced apoptosis in the cells, which 5-hydroxytryptamine, an MAO-A substrate, prevented.	salsoline	39-60	monoamine oxidase A	Homo sapiens	213-218
16336631-3	2006	An endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, an MAO-A inhibitor, reduced membrane potential, DeltaPsim, in isolated mitochondria, and induced apoptosis in the cells, which 5-hydroxytryptamine, an MAO-A substrate, prevented.	Serotonin	189-208	monoamine oxidase A	Homo sapiens	65-70
16336631-6	2006	RNA interference targeting MAO-A significantly reduced the binding of N-methyl(R)salsolinol with simultaneous reduction in the MAO activity.	salsoline	70-91	monoamine oxidase A	Homo sapiens	27-32
16336631-6	2006	RNA interference targeting MAO-A significantly reduced the binding of N-methyl(R)salsolinol with simultaneous reduction in the MAO activity.	salsoline	70-91	monoamine oxidase A	Homo sapiens	27-30
15843867-6	2006	N-Propargylamine inhibited MAO-A in competition to substrate with the apparent K(i) value of 28 microM, which was significantly higher than the concentration required for neuroprotection.	n-propargylamine	0-16	monoamine oxidase A	Homo sapiens	27-32
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	monoamine	110-119	monoamine oxidase A	Homo sapiens	0-26
17447417-9	2006	MAO-B oxidized dopamine with production of hydrogen peroxide, whereas in control cells expressing only MAO-A, dopamine autoxidation produced superoxide and dopamine-quinone, and induced mitochondrial permeability transition and apoptosis.	Dopamine	110-118	monoamine oxidase A	Homo sapiens	103-108
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	monoamine	110-119	monoamine oxidase A	Homo sapiens	28-43
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Dopamine	147-155	monoamine oxidase A	Homo sapiens	0-26
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Dopamine	147-155	monoamine oxidase A	Homo sapiens	28-43
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Dopamine	157-159	monoamine oxidase A	Homo sapiens	0-26
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Dopamine	157-159	monoamine oxidase A	Homo sapiens	28-43
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Norepinephrine	162-175	monoamine oxidase A	Homo sapiens	0-26
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Norepinephrine	162-175	monoamine oxidase A	Homo sapiens	28-43
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Serotonin	181-190	monoamine oxidase A	Homo sapiens	0-26
17447417-10	2006	Rasagiline and other MAO-B inhibitors prevent the activation of apoptotic cascade and induce prosurvival genes, such as bcl-2 and glial cell line-derived neurotrophic factor, in MAO-A-containing cells.	rasagiline	0-10	monoamine oxidase A	Homo sapiens	178-183
17447416-1	2006	Monoamine oxidases A and B (MAO A and MAO B) are the major enzymes that catalyze the oxidative deamination of monoamine neurotaransmitters such as dopamine (DA), noradrenaline, and serotonin in the central and peripheral nervous systems.	Serotonin	181-190	monoamine oxidase A	Homo sapiens	28-43
17447417-2	2006	Monoamine oxidase (MAO) in the mitochondrial outer membrane produces hydrogen peroxide by oxidation of monoamine substrates, and induces oxidative stress resulting in neuronal degeneration.	Hydrogen Peroxide	69-86	monoamine oxidase A	Homo sapiens	19-22
16366596-3	2005	In this study, we investigate the inhibition of recombinant human MAO A and MAO B by several rasagiline analogues.	rasagiline	93-103	monoamine oxidase A	Homo sapiens	66-71
17447417-2	2006	Monoamine oxidase (MAO) in the mitochondrial outer membrane produces hydrogen peroxide by oxidation of monoamine substrates, and induces oxidative stress resulting in neuronal degeneration.	monoamine	103-112	monoamine oxidase A	Homo sapiens	19-22
17447417-7	2006	Type A MAO (MAO-A) was found to bind an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, and induce apoptosis in dopaminergic SH-SY5Y cells containing only MAO-A.	n-methyl	76-84	monoamine oxidase A	Homo sapiens	7-10
17447417-7	2006	Type A MAO (MAO-A) was found to bind an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, and induce apoptosis in dopaminergic SH-SY5Y cells containing only MAO-A.	n-methyl	76-84	monoamine oxidase A	Homo sapiens	12-17
17447417-7	2006	Type A MAO (MAO-A) was found to bind an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, and induce apoptosis in dopaminergic SH-SY5Y cells containing only MAO-A.	salsolinol	84-97	monoamine oxidase A	Homo sapiens	7-10
17447417-7	2006	Type A MAO (MAO-A) was found to bind an endogenous dopaminergic neurotoxin, N-methyl(R)salsolinol, and induce apoptosis in dopaminergic SH-SY5Y cells containing only MAO-A.	salsolinol	84-97	monoamine oxidase A	Homo sapiens	12-17
16763378-8	2006	Taken together, in alcohol-dependent heavily smoking men there is evidence for a MAO-A gene-associated effect on the quantity that is smoked as reflected by the daily number of cigarettes consumed.	Alcohols	19-26	monoamine oxidase A	Homo sapiens	81-86
16366596-7	2005	1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B.	(r)-aminoindan	1-15	monoamine oxidase A	Homo sapiens	102-107
16366596-7	2005	1(R)-Aminoindan, the major metabolic product of rasagiline, and its analogues reversibly inhibit both MAO A and MAO B.	rasagiline	48-58	monoamine oxidase A	Homo sapiens	102-107
16265597-4	2005	MAO A and B can be imaged in the human brain and certain peripheral organs using PET and carbon-11 (half-life 20.4 minutes) labeled mechanism-based irreversible inhibitors, clorgyline and L -deprenyl, respectively.	Carbon-11	89-98	monoamine oxidase A	Homo sapiens	0-11
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Serotonin	117-126	monoamine oxidase A	Homo sapiens	0-19
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Serotonin	117-126	monoamine oxidase A	Homo sapiens	21-26
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Norepinephrine	132-145	monoamine oxidase A	Homo sapiens	0-19
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Norepinephrine	132-145	monoamine oxidase A	Homo sapiens	21-26
16222369-4	2005	The tip of the electrode covered with MAO-A membrane was placed into the liquid compartment as touching to the PTFE diaphragm membrane.	Polytetrafluoroethylene	111-115	monoamine oxidase A	Homo sapiens	38-43
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	monoamine	71-80	monoamine oxidase A	Homo sapiens	0-19
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	monoamine	71-80	monoamine oxidase A	Homo sapiens	21-26
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Dopamine	107-115	monoamine oxidase A	Homo sapiens	0-19
16139427-1	2005	Monoamine oxidase A (MAO-A) is an enzyme involved in the metabolism of monoamine neurotransmitters such as dopamine, serotonin, and noradrenaline in the brain.	Dopamine	107-115	monoamine oxidase A	Homo sapiens	21-26
16265597-4	2005	MAO A and B can be imaged in the human brain and certain peripheral organs using PET and carbon-11 (half-life 20.4 minutes) labeled mechanism-based irreversible inhibitors, clorgyline and L -deprenyl, respectively.	Clorgyline	173-183	monoamine oxidase A	Homo sapiens	0-11
16265597-4	2005	MAO A and B can be imaged in the human brain and certain peripheral organs using PET and carbon-11 (half-life 20.4 minutes) labeled mechanism-based irreversible inhibitors, clorgyline and L -deprenyl, respectively.	Selegiline	188-199	monoamine oxidase A	Homo sapiens	0-11
16125677-5	2005	FD-derived cells, stimulated with tocotrienols or EGCG to produce increased levels of functional IKAP, express increased amounts of MAO A mRNA transcript and protein.	Tocotrienols	34-46	monoamine oxidase A	Homo sapiens	132-137
16125677-5	2005	FD-derived cells, stimulated with tocotrienols or EGCG to produce increased levels of functional IKAP, express increased amounts of MAO A mRNA transcript and protein.	epigallocatechin gallate	50-54	monoamine oxidase A	Homo sapiens	132-137
16125677-6	2005	Administration of tocotrienol to individuals with FD results in increased expression of both functional IKAP and MAO A transcripts in their peripheral blood cells.	Tocotrienols	18-29	monoamine oxidase A	Homo sapiens	113-118
16157521-0	2005	Imaging MAO-A levels by PET using the deuterium isotope effect.	Deuterium	38-47	monoamine oxidase A	Homo sapiens	8-13
16129825-1	2005	The three-dimensional structure of recombinant human monoamine oxidase A (hMAO A) as its clorgyline-inhibited adduct is described.	Clorgyline	89-99	monoamine oxidase A	Homo sapiens	53-72
16129825-1	2005	The three-dimensional structure of recombinant human monoamine oxidase A (hMAO A) as its clorgyline-inhibited adduct is described.	Clorgyline	89-99	monoamine oxidase A	Homo sapiens	74-80
16129825-6	2005	In addition to serving as a basis for the development of hMAO A specific inhibitors, these data support the proposal that hMAO A involves a change from the dimeric to the monomeric form through a Glu-151 --&gt; Lys mutation that is specific of hMAO A [Andres, A. M., Soldevila, M., Navarro, A., Kidd, K. K., Oliva, B.	Glutamic Acid	196-199	monoamine oxidase A	Homo sapiens	122-128
16129825-6	2005	In addition to serving as a basis for the development of hMAO A specific inhibitors, these data support the proposal that hMAO A involves a change from the dimeric to the monomeric form through a Glu-151 --&gt; Lys mutation that is specific of hMAO A [Andres, A. M., Soldevila, M., Navarro, A., Kidd, K. K., Oliva, B.	Glutamic Acid	196-199	monoamine oxidase A	Homo sapiens	122-128
16129825-6	2005	In addition to serving as a basis for the development of hMAO A specific inhibitors, these data support the proposal that hMAO A involves a change from the dimeric to the monomeric form through a Glu-151 --&gt; Lys mutation that is specific of hMAO A [Andres, A. M., Soldevila, M., Navarro, A., Kidd, K. K., Oliva, B.	Lysine	211-214	monoamine oxidase A	Homo sapiens	122-128
16129825-6	2005	In addition to serving as a basis for the development of hMAO A specific inhibitors, these data support the proposal that hMAO A involves a change from the dimeric to the monomeric form through a Glu-151 --&gt; Lys mutation that is specific of hMAO A [Andres, A. M., Soldevila, M., Navarro, A., Kidd, K. K., Oliva, B.	Lysine	211-214	monoamine oxidase A	Homo sapiens	122-128
15956990-1	2005	Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of biogenic amines, may be implicated in the pathogenesis of major depressive disorder (MDD) and be related to the therapeutic effects of antidepressants.	Amines	91-97	monoamine oxidase A	Homo sapiens	0-19
16127378-12	2005	Modification of multiple thiols results in inactivation but mutation of a single thiol, cysteine 374 in MAO A to alanine, decreased the catalytic potency (kcat/Km) by 30%.	Sulfhydryl Compounds	25-31	monoamine oxidase A	Homo sapiens	104-109
16127378-12	2005	Modification of multiple thiols results in inactivation but mutation of a single thiol, cysteine 374 in MAO A to alanine, decreased the catalytic potency (kcat/Km) by 30%.	Sulfhydryl Compounds	25-30	monoamine oxidase A	Homo sapiens	104-109
16127378-12	2005	Modification of multiple thiols results in inactivation but mutation of a single thiol, cysteine 374 in MAO A to alanine, decreased the catalytic potency (kcat/Km) by 30%.	Cysteine	88-96	monoamine oxidase A	Homo sapiens	104-109
16127378-12	2005	Modification of multiple thiols results in inactivation but mutation of a single thiol, cysteine 374 in MAO A to alanine, decreased the catalytic potency (kcat/Km) by 30%.	Alanine	113-120	monoamine oxidase A	Homo sapiens	104-109
15956990-1	2005	Monoamine oxidase A (MAOA), a mitochondrial enzyme involved in the degradation of biogenic amines, may be implicated in the pathogenesis of major depressive disorder (MDD) and be related to the therapeutic effects of antidepressants.	Amines	91-97	monoamine oxidase A	Homo sapiens	21-25
16002749-6	2005	Treatment with SB224289 (selective antagonist of 5-HT1B), fluoxetine (SERT inhibitor), SERT RNA-interference, and iproniazid (monoamine oxidase-A inhibitor), blocked 5-HT-induced S100A4/Mts1.	Iproniazid	114-124	monoamine oxidase A	Homo sapiens	126-145
16094253-3	2005	A dinucleotide repeat in intron 2 of the gene (monoamine oxidase A-CAn) has been described previously, and is in linkage disequilibrium with the variable number of tandom repeats (VNTR).	Dinucleoside Phosphates	2-14	monoamine oxidase A	Homo sapiens	47-66
15950194-2	2005	By synthesizing novel dimerised derivatives with identical substitution of the two C-5 side chains, we have obtained experimental evidence for the orientation of oxazolidinones in the active site of MAO A.	Oxazolidinones	162-176	monoamine oxidase A	Homo sapiens	199-204
15950194-3	2005	Two types of spectral changes, either increasing the absorbance at 510 nm or decreasing it at 495 nm depending on the group nearest to the flavin cofactor, were seen on ligand binding to MAO A.	4,6-dinitro-o-cresol	139-145	monoamine oxidase A	Homo sapiens	187-192
15946989-5	2005	MAO-A is the primary enzyme metabolizing catecholamines and dietary amines, and its role in skeletal muscle remains largely unexplored.	Catecholamines	41-55	monoamine oxidase A	Homo sapiens	0-5
15946989-5	2005	MAO-A is the primary enzyme metabolizing catecholamines and dietary amines, and its role in skeletal muscle remains largely unexplored.	Amines	49-55	monoamine oxidase A	Homo sapiens	0-5
15946989-6	2005	Dexamethasone induced dose- and time-dependent increases of MAO-A gene and protein expression, while its effects on MAO-B were minimal.	Dexamethasone	0-13	monoamine oxidase A	Homo sapiens	60-65
15946989-7	2005	Both the glucocorticoid receptor (GR) and the Sp1 transcription factor were required for dexamethasone-induced MAO-A mRNA expression, as blockade of the GR with RU 486 or ablation of Sp1 binding with mithramycin abrogated MAO-A mRNA induction.	Dexamethasone	89-102	monoamine oxidase A	Homo sapiens	111-116
15946989-7	2005	Both the glucocorticoid receptor (GR) and the Sp1 transcription factor were required for dexamethasone-induced MAO-A mRNA expression, as blockade of the GR with RU 486 or ablation of Sp1 binding with mithramycin abrogated MAO-A mRNA induction.	Dexamethasone	89-102	monoamine oxidase A	Homo sapiens	222-227
15946989-7	2005	Both the glucocorticoid receptor (GR) and the Sp1 transcription factor were required for dexamethasone-induced MAO-A mRNA expression, as blockade of the GR with RU 486 or ablation of Sp1 binding with mithramycin abrogated MAO-A mRNA induction.	Plicamycin	200-211	monoamine oxidase A	Homo sapiens	111-116
16049371-7	2005	A similar isoform-specific expression of MAO-A mRNA was observed when U937 cells were transfected with 15-LOX1 or when the cells were incubated with primary 15-LOX1 products (hydroperoxy fatty acids) or H2O2.	hydroperoxy fatty acids	175-198	monoamine oxidase A	Homo sapiens	41-46
16049371-7	2005	A similar isoform-specific expression of MAO-A mRNA was observed when U937 cells were transfected with 15-LOX1 or when the cells were incubated with primary 15-LOX1 products (hydroperoxy fatty acids) or H2O2.	Hydrogen Peroxide	203-207	monoamine oxidase A	Homo sapiens	41-46
16049371-9	2005	CONCLUSIONS: These data indicate that increased intracellular peroxide concentrations (oxidative stress) induce MAO-A expression in monocytes/macrophages, which normally do not express the enzyme.	Peroxides	62-70	monoamine oxidase A	Homo sapiens	112-117
15908219-1	2005	The in vitro monoamine oxidase inhibitory (MAOI) activities of 11 heteroarylisopropylamines vis-a-vis MAO-A and MAO-B were described and interpreted in terms of possible interactions with the enzyme active site.	heteroarylisopropylamines	66-91	monoamine oxidase A	Homo sapiens	102-107
15936529-2	2005	Noradrenaline (NA) is catabolized by monoamine oxidase A (MAOA) and cathecol-O-methyl transferase (COMT).	Norepinephrine	0-13	monoamine oxidase A	Homo sapiens	37-56
15936529-2	2005	Noradrenaline (NA) is catabolized by monoamine oxidase A (MAOA) and cathecol-O-methyl transferase (COMT).	Norepinephrine	0-13	monoamine oxidase A	Homo sapiens	58-62
15908219-2	2005	Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin.	1-(2-benzofuryl)-2-aminopropane	111-142	monoamine oxidase A	Homo sapiens	76-81
15908219-2	2005	Molecular dynamics simulations allowed a comparison between the most active MAO-A inhibitor of the series, the 1-(2-benzofuryl)-2-aminopropane, and the specific, analogous MAO-A substrate serotonin.	Serotonin	188-197	monoamine oxidase A	Homo sapiens	172-177
15982583-2	2005	More recently, we have estimated MAO A and B activity in other organs using the deuterium isotope effect to determine binding specificity for MAO and a three-compartment model to estimate k(3), the model term proportional to MAO A activity.	Deuterium	80-89	monoamine oxidase A	Homo sapiens	33-38
15833896-4	2005	In vitro, befloxatone inhibits selectively, competitively, and reversibly MAO-A in human tissues.	befloxatone	10-21	monoamine oxidase A	Homo sapiens	74-79
15982583-13	2005	k(3) was found to be significantly lower in smokers; for CLG, a 50% reduction in MAO A for both CLG and D CLG was observed.	Clorgyline	57-60	monoamine oxidase A	Homo sapiens	81-86
15982583-13	2005	k(3) was found to be significantly lower in smokers; for CLG, a 50% reduction in MAO A for both CLG and D CLG was observed.	Clorgyline	96-99	monoamine oxidase A	Homo sapiens	81-86
15982583-13	2005	k(3) was found to be significantly lower in smokers; for CLG, a 50% reduction in MAO A for both CLG and D CLG was observed.	d clg	104-109	monoamine oxidase A	Homo sapiens	81-86
15671203-0	2005	Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.	indantadol	60-67	monoamine oxidase A	Homo sapiens	179-198
16149329-1	2005	Harmine, a major alkaloid in ayahuasca (hoasca), is a selective and reversible inhibitor of the enzyme monoamine oxidase-A (MAO-A).	Harmine	0-7	monoamine oxidase A	Homo sapiens	103-122
16149329-1	2005	Harmine, a major alkaloid in ayahuasca (hoasca), is a selective and reversible inhibitor of the enzyme monoamine oxidase-A (MAO-A).	Harmine	0-7	monoamine oxidase A	Homo sapiens	124-129
15848762-0	2005	Mutation of surface cysteine 374 to alanine in monoamine oxidase A alters substrate turnover and inactivation by cyclopropylamines.	cyclopropylamine	113-130	monoamine oxidase A	Homo sapiens	47-66
15974574-1	2005	Pyrrolylethanoneamines 1-12, 18-23 and related amino alcohols 13-15, 24-27 were synthesized and tested against monoamine oxidases A and B (MAO-A and MAO-B) enzymes.	pyrrolylethanoneamines	0-22	monoamine oxidase A	Homo sapiens	139-144
15974574-2	2005	In general, aminoketones 1-12, 18-23 were found to be potent and selective MAO-A inhibitors.	aminoketones	12-24	monoamine oxidase A	Homo sapiens	75-80
15671203-0	2005	Mechanistic pharmacokinetic and pharmacodynamic modeling of CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride), a novel N-methyl-D-aspartate antagonist and monoamine oxidase-A inhibitor in healthy subjects.	2-[(2,3-dihydro-1h-inden-2-yl)amino]acetamide monohydrochloride	69-132	monoamine oxidase A	Homo sapiens	179-198
15671203-1	2005	CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride) is a new N-methyl-D-aspartate antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor in development for the treatment of neuropathic pain.	indantadol	0-7	monoamine oxidase A	Homo sapiens	130-149
15671203-1	2005	CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride) is a new N-methyl-D-aspartate antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor in development for the treatment of neuropathic pain.	indantadol	0-7	monoamine oxidase A	Homo sapiens	151-156
15671203-1	2005	CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride) is a new N-methyl-D-aspartate antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor in development for the treatment of neuropathic pain.	2-[(2,3-dihydro-1h-inden-2-yl)amino]acetamide monohydrochloride	9-72	monoamine oxidase A	Homo sapiens	130-149
15671203-1	2005	CHF3381 (2-[(2,3-dihydro-1H-inden-2-yl)amino]acetamide monohydrochloride) is a new N-methyl-D-aspartate antagonist and reversible monoamine oxidase-A (MAO-A) inhibitor in development for the treatment of neuropathic pain.	2-[(2,3-dihydro-1h-inden-2-yl)amino]acetamide monohydrochloride	9-72	monoamine oxidase A	Homo sapiens	151-156
15671203-2	2005	This study developed a mechanistic model to describe the pharmacokinetics of CHF3381 and of its two metabolites, the relationship with MAO-A activity and heart rate.	indantadol	77-84	monoamine oxidase A	Homo sapiens	135-140
15671203-4	2005	MAO-A activity was estimated by measuring concentrations of 3,4-dihydroxyphenylglycol (DHPG), a stable metabolite of norepinephrine.	3,4-dihydroxyphenylglycol	60-85	monoamine oxidase A	Homo sapiens	0-5
15671203-4	2005	MAO-A activity was estimated by measuring concentrations of 3,4-dihydroxyphenylglycol (DHPG), a stable metabolite of norepinephrine.	3,4-dihydroxyphenylglycol	87-91	monoamine oxidase A	Homo sapiens	0-5
15671203-4	2005	MAO-A activity was estimated by measuring concentrations of 3,4-dihydroxyphenylglycol (DHPG), a stable metabolite of norepinephrine.	Norepinephrine	117-131	monoamine oxidase A	Homo sapiens	0-5
15710600-3	2005	In contrast, the reversible competitive inhibitor isatin binds to all known MAO B and MAO A with similar affinities.	Isatin	50-56	monoamine oxidase A	Homo sapiens	86-91
15710600-7	2005	Phe is conserved in the analogous position in MAO A sequences.	Phenylalanine	0-3	monoamine oxidase A	Homo sapiens	46-51
15710600-2	2005	The following compounds: 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene, and trans,trans-farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K(i) values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A.	8-(3-chlorostyryl)caffeine	25-51	monoamine oxidase A	Homo sapiens	280-285
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Amines	62-68	monoamine oxidase A	Homo sapiens	0-26
15710600-2	2005	The following compounds: 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene, and trans,trans-farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K(i) values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A.	1,4-diphenyl-2-butene	53-74	monoamine oxidase A	Homo sapiens	280-285
15710600-2	2005	The following compounds: 8-(3-chlorostyryl)caffeine, 1,4-diphenyl-2-butene, and trans,trans-farnesol are shown to inhibit competitively human, horse, rat, and mouse MAO B with K(i) values in the low micromolar range but are without effect on either bovine or sheep MAO B or human MAO A.	Farnesol	80-100	monoamine oxidase A	Homo sapiens	280-285
15804499-5	2005	In humans, co-administration of MDMA with the reversible MAO-A inhibitor moclobemide has led to increased apparent toxicity with ensuing fatalities.	N-Methyl-3,4-methylenedioxyamphetamine	32-36	monoamine oxidase A	Homo sapiens	57-62
15804499-5	2005	In humans, co-administration of MDMA with the reversible MAO-A inhibitor moclobemide has led to increased apparent toxicity with ensuing fatalities.	Moclobemide	73-84	monoamine oxidase A	Homo sapiens	57-62
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Amines	62-68	monoamine oxidase A	Homo sapiens	28-33
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Dopamine	77-85	monoamine oxidase A	Homo sapiens	0-26
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Dopamine	77-85	monoamine oxidase A	Homo sapiens	28-33
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Serotonin	90-99	monoamine oxidase A	Homo sapiens	0-26
15717295-2	2005	Monoamine oxidases A and B (MAO-A and MAO-B) degrade biogenic amines such as dopamine and serotonin and thereby control the levels of these neurotransmitters in the central nervous system.	Serotonin	90-99	monoamine oxidase A	Homo sapiens	28-33
15801935-1	2005	AIMS: To evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of CHF3381, a dual NMDA and MAO-A inhibitor, after multiple oral doses in healthy subjects.	indantadol	92-99	monoamine oxidase A	Homo sapiens	117-122
15755651-3	2005	Unlike the parent 1-phenylcyclopropylamine, which is a selective inhibitor of MAO B, both (E)- and (Z)-diastereomers of derivatives having fluorine at the 2-position of the cyclopropane ring were potent and selective irreversible inhibitors of MAO A.	1-phenylcyclopropylamine	18-42	monoamine oxidase A	Homo sapiens	244-249
15755651-6	2005	Surprisingly, (1S,2R)-2-fluoro-1-phenylcyclopropylamine and the (1R,2S)-enantiomer were essential equally potent as inhibitors of MAO A and MAO B.	(1s,2r)-2-fluoro-1-phenylcyclopropylamine	14-55	monoamine oxidase A	Homo sapiens	130-135
15801935-4	2005	MAO-A activity in plasma was estimated by measuring plasma concentrations of 3,4-dihydroxyphenylglycol.	3,4-dihydroxyphenylglycol	77-102	monoamine oxidase A	Homo sapiens	0-5
15654081-7	2005	The transfection of R1 in a human neuroblastoma cell line, SK-N-BE (2)-C, inhibited the monoamine oxidase A promoter and enzymatic activity.	sk-n-be (2)-c	59-72	monoamine oxidase A	Homo sapiens	88-107
20711287-1	2005	BACKGROUND: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA).	Moclobemide	12-23	monoamine oxidase A	Homo sapiens	67-86
20711287-1	2005	BACKGROUND: Moclobemide, a benzamide, is one of the new-generation monoamine oxidase-A inhibitors (MAO-AIs) which belongs to the class of reversible inhibitors of monoamine oxidase (RIMA).	benzamide	27-36	monoamine oxidase A	Homo sapiens	67-86
16787307-0	2005	3-(1H-pyrrol-2-yl)-2-oxazolidinones as novel monoamine oxidase type A inhibitors.	3-(1h-pyrrol-2-yl)-2-oxazolidinones	0-35	monoamine oxidase A	Homo sapiens	45-69
15784243-1	2005	Novel 2-alkylsulfanyl-1-benzyl-5-imidazolecarboxylic acid hydrazides (15a,b) were synthesized as analogues of isocarboxazide, which is a known nonselective irreversible monoamine oxidase inhibitor and tested for monoamine oxidase A and B inhibitory activity.	Isocarboxazid	110-124	monoamine oxidase A	Homo sapiens	212-231
15694196-2	2005	Monoamine oxidase A and B (MAO-A and -B) regulate the levels of monoamine neurotransmitters, so changes in their activity could participate in migraine pathogenesis.	monoamine	64-73	monoamine oxidase A	Homo sapiens	0-25
15694196-2	2005	Monoamine oxidase A and B (MAO-A and -B) regulate the levels of monoamine neurotransmitters, so changes in their activity could participate in migraine pathogenesis.	monoamine	64-73	monoamine oxidase A	Homo sapiens	27-39
15547048-5	2005	Purified human monoamine oxidases A and B also catalyzed sertraline deamination with comparable K(m) values (230-270 microM).	Sertraline	57-67	monoamine oxidase A	Homo sapiens	15-41
15556933-0	2005	A stable tyrosyl radical in monoamine oxidase A.	Tyrosyl radical	9-24	monoamine oxidase A	Homo sapiens	28-47
15556933-1	2005	We present spectroscopic evidence consistent with the presence of a stable tyrosyl radical in partially reduced human monoamine oxidase (MAO) A.	Tyrosyl radical	75-90	monoamine oxidase A	Homo sapiens	118-143
15556933-2	2005	The radical forms following single electron donation to MAO A and exists in equilibrium with the FAD flavosemiquinone.	fad flavosemiquinone	97-117	monoamine oxidase A	Homo sapiens	56-61
15635592-0	2005	Serotonin transporter promoter polymorphism and monoamine oxidase type A VNTR allelic variants together influence alcohol binge drinking risk in young women.	Alcohols	114-121	monoamine oxidase A	Homo sapiens	48-72
15658863-0	2005	Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A.	4-substituted 1,2,3-triazoles	18-47	monoamine oxidase A	Homo sapiens	122-141
15658863-0	2005	Identification of 4-substituted 1,2,3-triazoles as novel oxazolidinone antibacterial agents with reduced activity against monoamine oxidase A.	Oxazolidinones	57-70	monoamine oxidase A	Homo sapiens	122-141
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Oxazolidinones	5-19	monoamine oxidase A	Homo sapiens	80-99
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Oxazolidinones	5-19	monoamine oxidase A	Homo sapiens	101-106
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	31-40	monoamine oxidase A	Homo sapiens	80-99
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	31-40	monoamine oxidase A	Homo sapiens	101-106
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	54-59	monoamine oxidase A	Homo sapiens	80-99
15658863-3	2005	Many oxazolidinones, including linezolid (marketed as Zyvox), are inhibitors of monoamine oxidase A (MAO-A), which presents an undesired side effect.	Linezolid	54-59	monoamine oxidase A	Homo sapiens	101-106
15658863-5	2005	We now disclose the finding that 1,2,3-triazoles bearing a substituent like methyl, small substituted methyl, bromo, or a linear (sp-hybridized) group at the 4 position (compounds such as 5, 16, 19, and 21) are good antibacterials with reduced or no activity, within the detection limit of the assay, against MAO-A.	1,2,3-triazoles	33-48	monoamine oxidase A	Homo sapiens	309-314
15457497-0	2005	Relationship of MAO-A promoter (u-VNTR) and COMT (V158M) gene polymorphisms to CSF monoamine metabolites levels in a psychiatric sample of caucasians: A preliminary report.	monoamine	83-92	monoamine oxidase A	Homo sapiens	16-21
15582589-8	2005	Norharman was an inhibitor of MAO-A (K(i)=1.2+/-0.18 microM) and MAO-B (K(i)=1.12+/-0.19 microM), and harman of MAO-A (K(i)=55.54+/-5.3nM).	norharman	0-9	monoamine oxidase A	Homo sapiens	30-35
15582589-8	2005	Norharman was an inhibitor of MAO-A (K(i)=1.2+/-0.18 microM) and MAO-B (K(i)=1.12+/-0.19 microM), and harman of MAO-A (K(i)=55.54+/-5.3nM).	norharman	0-9	monoamine oxidase A	Homo sapiens	112-117
15762767-18	2005	Almotriptan clearance was reduced, to a modest degree, by moclobemide and verapamil, which was consistent with the contribution of monoamine oxidase-A and CYP3A4 to the metabolic clearance of almotriptan.	almotriptan	192-203	monoamine oxidase A	Homo sapiens	131-150
15817751-3	2004	Two major enzymes are responsible for catecholamine catabolism in the brain: catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAOA).	Catecholamines	38-51	monoamine oxidase A	Homo sapiens	117-136
15907150-5	2005	Second-line treatments include MAOIs (e.g. phenelzine) and reversible inhibitors of monoamine oxidase A (e.g. moclobemide), while some benzodiazepines and antiepileptics (e.g. clonazepam and pregabalin) may also be useful.	Moclobemide	110-121	monoamine oxidase A	Homo sapiens	84-103
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Dopamine	84-92	monoamine oxidase A	Homo sapiens	0-19
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Dopamine	84-92	monoamine oxidase A	Homo sapiens	21-25
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Serotonin	94-103	monoamine oxidase A	Homo sapiens	0-19
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Serotonin	94-103	monoamine oxidase A	Homo sapiens	21-25
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Norepinephrine	108-122	monoamine oxidase A	Homo sapiens	0-19
15990460-1	2005	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine and these neurotransmitters are hypothesized to be involved in the cognitive function of humans.	Norepinephrine	108-122	monoamine oxidase A	Homo sapiens	21-25
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Amines	85-91	monoamine oxidase A	Homo sapiens	0-19
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Amines	85-91	monoamine oxidase A	Homo sapiens	21-25
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Norepinephrine	102-116	monoamine oxidase A	Homo sapiens	0-19
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Norepinephrine	102-116	monoamine oxidase A	Homo sapiens	21-25
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Dopamine	118-126	monoamine oxidase A	Homo sapiens	0-19
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Dopamine	118-126	monoamine oxidase A	Homo sapiens	21-25
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Serotonin	131-140	monoamine oxidase A	Homo sapiens	0-19
16110245-1	2005	Monoamine oxidase A (MAOA), a mitochondrial outer membrane enzyme, degrades biogenic amines including norepinephrine, dopamine and serotonin, which have been implicated in the expression of personality traits.	Serotonin	131-140	monoamine oxidase A	Homo sapiens	21-25
15817751-3	2004	Two major enzymes are responsible for catecholamine catabolism in the brain: catechol-O-methyltransferase (COMT) and monoamine oxidase A (MAOA).	Catecholamines	38-51	monoamine oxidase A	Homo sapiens	138-142
15817751-5	2004	If aggressive behavior is enhanced by catecholaminergic activity, then the lower activity of COMT and MAOA (resulting in a slower inactivation of catecholamines) should indirectly enhance aggression.	Catecholamines	146-160	monoamine oxidase A	Homo sapiens	102-106
15490317-1	2004	In the course of a screening of plant extracts for potential CNS and anti-inflammatory activities, a dichloromethane extract of Salvia miltiorrhiza showed a pronounced inhibitory effect on recombinant monoamine oxidase A (MAO A) and on inducible NO synthase (iNOS) induction in Raw 267.4 cells.	Methylene Chloride	101-116	monoamine oxidase A	Homo sapiens	222-227
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Amines	165-171	monoamine oxidase A	Homo sapiens	0-19
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Amines	165-171	monoamine oxidase A	Homo sapiens	21-25
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Serotonin	204-213	monoamine oxidase A	Homo sapiens	0-19
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Serotonin	204-213	monoamine oxidase A	Homo sapiens	21-25
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Norepinephrine	215-228	monoamine oxidase A	Homo sapiens	0-19
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Norepinephrine	215-228	monoamine oxidase A	Homo sapiens	21-25
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Dopamine	233-241	monoamine oxidase A	Homo sapiens	0-19
15564894-1	2004	Monoamine oxidase A (MAOA) has been suggested to be involved in human behaviour and physiology due to its key role in the metabolism of several different biological amines including the neurotransmitters serotonin, norepinephrin and dopamine.Recently, a 30 bp repeat in the MAOA gene promoter (uMAOA) has been demonstrated to be polymorphic and to affect transcriptional activity.	Dopamine	233-241	monoamine oxidase A	Homo sapiens	21-25
15482934-1	2004	This work presents a study QSAR among the MAO A inhibitory activity (IMAO A) of a xanthones series correlated with descriptors like the E-state index (S(i)), molecular connectivity (chi) and shape (k) descriptors.	imao a	69-75	monoamine oxidase A	Homo sapiens	42-47
15482934-1	2004	This work presents a study QSAR among the MAO A inhibitory activity (IMAO A) of a xanthones series correlated with descriptors like the E-state index (S(i)), molecular connectivity (chi) and shape (k) descriptors.	Xanthones	82-91	monoamine oxidase A	Homo sapiens	42-47
15482934-2	2004	The xanthones group (9-H-xanton-9-onas) are of natural or synthetic origin, they present eight positions for the substitution and their MAO A inhibitory activity is reported in the work from Gnerre et al.	Xanthones	4-13	monoamine oxidase A	Homo sapiens	136-141
15521893-1	2004	AIMS: To investigate the effect of monoamine oxidase A inhibition from a single oral dose of linezolid on the pressor response to intravenous (i.v.)	Linezolid	93-102	monoamine oxidase A	Homo sapiens	35-54
15349769-1	2004	Monoamine oxidase A (MAOA) is the X-linked gene responsible for deamination and subsequent degradation of several neurotransmitters and other amines.	Amines	142-148	monoamine oxidase A	Homo sapiens	0-19
15349769-1	2004	Monoamine oxidase A (MAOA) is the X-linked gene responsible for deamination and subsequent degradation of several neurotransmitters and other amines.	Amines	142-148	monoamine oxidase A	Homo sapiens	21-25
15199371-1	2004	In the monkey dorsal raphe, we reported that 1-month (mo) of estrogen replacement, with or without progesterone supplementation for 14 days, significantly increased tryptophan hydroxylase-1 (TPH-1) mRNA; decreased serotonin reuptake transporter (SERT) mRNA and decreased monoamine oxidase (MAO)-A mRNA, but had no effect on MAO-B mRNA.	Progesterone	99-111	monoamine oxidase A	Homo sapiens	271-296
15490317-3	2004	The IC50 of the most active compound, 15,16-dihydrotanshinone I, on human recombinant MAO A was at 23 microM, and 2.4 microM on lipopolysaccharide-mediated iNOS induction in Raw 267.4 cells.	15,16-dihydrotanshinone	38-61	monoamine oxidase A	Homo sapiens	86-91
15279562-1	2004	Monoamine oxidases A and B (MAO A and MAO B) are mitochondrial outer membrane-bound flavoproteins that catalyze the oxidative deamination of neurotransmitters and biogenic amines.	Amines	172-178	monoamine oxidase A	Homo sapiens	0-26
15498245-4	2004	Polymerase chain reaction (PCR) and 2.5% agarose gel electrophoresisi were adopted to detect the polymorphism of functional 30 bp-uVNTR in the promoter region of the X-chromosomal MAOA gene and their frequencies of varied genotypes were estimated.	Sepharose	41-48	monoamine oxidase A	Homo sapiens	180-184
15246083-1	2004	Twenty-nine arylisopropylamines, substituted at the beta-position of their side chain by an oxo, hydroxy, or methoxy group, were evaluated in vitro as MAO-A and MAO-B inhibitors.	arylisopropylamines	12-31	monoamine oxidase A	Homo sapiens	151-156
15246083-2	2004	The oxo derivatives ("cathinones") were in general less active as MAO-A inhibitors than the corresponding arylisopropylamines, but exhibited an interesting MAO-B inhibiting activity, which was absent in the hydroxy, methoxy, and beta-unsubstituted analogues.	cathinone	22-32	monoamine oxidase A	Homo sapiens	66-71
15052272-14	2004	Although these data should be interpreted cautiously due to the small sample size, these results implicate TPH1 and SLC6A4 in general response, and HTR2A, TPH2, and MAOA in the specificity of response to fluoxetine.	Fluoxetine	204-214	monoamine oxidase A	Homo sapiens	165-169
15279562-1	2004	Monoamine oxidases A and B (MAO A and MAO B) are mitochondrial outer membrane-bound flavoproteins that catalyze the oxidative deamination of neurotransmitters and biogenic amines.	Amines	172-178	monoamine oxidase A	Homo sapiens	28-33
15082228-8	2004	Although, the MAO-mediated metabolism of DA increases MAO-B activity, the presence of iron inhibits both MAO-A and MAO-B activities.	Iron	86-90	monoamine oxidase A	Homo sapiens	105-110
15203146-5	2004	The coumarin-3-acyl chlorides 3a-e showed high pIC(50) values against both MAO-A and MAO-B isoforms, 3d being the highest against MAO-B with a pIC(50) value of 8.00.	coumarin-3-acyl chlorides	4-29	monoamine oxidase A	Homo sapiens	75-80
15110846-2	2004	Fluorinated phenylcyclopropylamines and alkylamines were examined as inhibitors of recombinant human liver monoamine oxidase A (MAO A) and B (MAO B).	alkylamines	40-51	monoamine oxidase A	Homo sapiens	128-133
15251892-5	2004	Sequence variation within serotonin system genes, for example, a repeat polymorphism in the transcriptional control region of the monoamine oxidase gene (MAOA-LPR), increases the propensity for adolescent males to consume alcohol.	Serotonin	26-35	monoamine oxidase A	Homo sapiens	154-158
15251892-5	2004	Sequence variation within serotonin system genes, for example, a repeat polymorphism in the transcriptional control region of the monoamine oxidase gene (MAOA-LPR), increases the propensity for adolescent males to consume alcohol.	Alcohols	222-229	monoamine oxidase A	Homo sapiens	154-158
15110846-5	2004	(1S,2S)-2-Fluoro-2-phenylcyclopropylamine was a more potent inhibitor of both MAO A and B than was the (1R,2R)-enantiomer, indicating that the presence of fluorine has no influence on the enantioselectivity of MAO inhibition, since a similar effect of stereochemistry has been reported for tranylcypromine.	Tranylcypromine	290-305	monoamine oxidase A	Homo sapiens	78-83
15110846-3	2004	For a series of trans- and cis-2-fluoro-2-phenylcyclopropylamine analogues, the presence of fluorine attached to a cyclopropane ring was found to result in an increase in inhibitory activity towards both MAO A and B.	trans- and cis-2-fluoro-2-phenylcyclopropylamine	16-64	monoamine oxidase A	Homo sapiens	204-209
15110846-6	2004	Interestingly, fluorination at the 2-position of 1-phenycyclopropylamine, which is known as a selective inhibitor of MAO B relative to MAO A, reversed the selectivity and resulted in a potent inhibitor selective for MAO A.	1-phenycyclopropylamine	49-72	monoamine oxidase A	Homo sapiens	135-140
15110846-3	2004	For a series of trans- and cis-2-fluoro-2-phenylcyclopropylamine analogues, the presence of fluorine attached to a cyclopropane ring was found to result in an increase in inhibitory activity towards both MAO A and B.	Fluorine	92-100	monoamine oxidase A	Homo sapiens	204-209
15110846-6	2004	Interestingly, fluorination at the 2-position of 1-phenycyclopropylamine, which is known as a selective inhibitor of MAO B relative to MAO A, reversed the selectivity and resulted in a potent inhibitor selective for MAO A.	1-phenycyclopropylamine	49-72	monoamine oxidase A	Homo sapiens	216-221
15110846-7	2004	All inhibitors showed time- and concentration-dependent inhibition for both enzymes, with the exception of trans-2-fluoro-2-phenylcyclopropyl ethylamine, which acts as a competitive and reversible MAO A selective inhibitor.	trans-2-fluoro-2-phenylcyclopropyl ethylamine	107-152	monoamine oxidase A	Homo sapiens	197-202
15110846-3	2004	For a series of trans- and cis-2-fluoro-2-phenylcyclopropylamine analogues, the presence of fluorine attached to a cyclopropane ring was found to result in an increase in inhibitory activity towards both MAO A and B.	cyclopropane	115-127	monoamine oxidase A	Homo sapiens	204-209
15110846-5	2004	(1S,2S)-2-Fluoro-2-phenylcyclopropylamine was a more potent inhibitor of both MAO A and B than was the (1R,2R)-enantiomer, indicating that the presence of fluorine has no influence on the enantioselectivity of MAO inhibition, since a similar effect of stereochemistry has been reported for tranylcypromine.	(1s,2s)-2-fluoro-2-phenylcyclopropylamine	0-41	monoamine oxidase A	Homo sapiens	78-83
15110846-5	2004	(1S,2S)-2-Fluoro-2-phenylcyclopropylamine was a more potent inhibitor of both MAO A and B than was the (1R,2R)-enantiomer, indicating that the presence of fluorine has no influence on the enantioselectivity of MAO inhibition, since a similar effect of stereochemistry has been reported for tranylcypromine.	Fluorine	155-163	monoamine oxidase A	Homo sapiens	78-83
15024015-1	2004	Monoamine oxidases (MAO) A and B catalyze the oxidative deamination of many biogenic and dietary amines.	Amines	97-103	monoamine oxidase A	Homo sapiens	0-26
15088153-3	2004	One of the key enzymes in the degradation of serotonin and to a lesser extent of dopamine is monoamine oxidase A (MAO-A).	Serotonin	45-54	monoamine oxidase A	Homo sapiens	114-119
15056494-3	2004	CD spectra of MAO A indicate that a small inhibitor such d-amphetamine perturbs the aromatic residues very little, but binding of the larger pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride) causes spectral changes consistent with the alteration of the environment of tyrosine and tryptophan residues in particular.	d-amphetamine perturbs	57-79	monoamine oxidase A	Homo sapiens	14-19
15088153-3	2004	One of the key enzymes in the degradation of serotonin and to a lesser extent of dopamine is monoamine oxidase A (MAO-A).	Serotonin	45-54	monoamine oxidase A	Homo sapiens	93-112
15088153-3	2004	One of the key enzymes in the degradation of serotonin and to a lesser extent of dopamine is monoamine oxidase A (MAO-A).	Dopamine	81-89	monoamine oxidase A	Homo sapiens	93-112
15088153-3	2004	One of the key enzymes in the degradation of serotonin and to a lesser extent of dopamine is monoamine oxidase A (MAO-A).	Dopamine	81-89	monoamine oxidase A	Homo sapiens	114-119
15088153-7	2004	Moreover, effectiveness of the potent serotonergic antimigraine agents, triptans, which are metabolized by MAO-A, was clinically not affected by the MAO-A-LPR in our patients.	Tryptamines	72-80	monoamine oxidase A	Homo sapiens	107-112
15088154-0	2004	Analysis of monoamine oxidase A (MAO-A) promoter polymorphism in male heroin-dependent subjects: behavioural and personality correlates.	Heroin	70-76	monoamine oxidase A	Homo sapiens	12-31
15088154-0	2004	Analysis of monoamine oxidase A (MAO-A) promoter polymorphism in male heroin-dependent subjects: behavioural and personality correlates.	Heroin	70-76	monoamine oxidase A	Homo sapiens	33-38
15088154-2	2004	The repeat number of the MAO-A polymorphism was assessed in 199 male subjects of Italian descent, a sample comprising 95 healthy subjects and 104 heroin-dependent subjects including 52 addicted individuals with violent behaviour and antisocial personality disorder.	Heroin	146-152	monoamine oxidase A	Homo sapiens	25-30
15056494-3	2004	CD spectra of MAO A indicate that a small inhibitor such d-amphetamine perturbs the aromatic residues very little, but binding of the larger pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride) causes spectral changes consistent with the alteration of the environment of tyrosine and tryptophan residues in particular.	pirlindole	141-153	monoamine oxidase A	Homo sapiens	14-19
15056494-3	2004	CD spectra of MAO A indicate that a small inhibitor such d-amphetamine perturbs the aromatic residues very little, but binding of the larger pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride) causes spectral changes consistent with the alteration of the environment of tyrosine and tryptophan residues in particular.	2,3,3a,4,5,6-hexahydro-8-methyl-1h-pyrazino[3,2,1-j,k]carbazole hydrochloride	153-230	monoamine oxidase A	Homo sapiens	14-19
15056494-3	2004	CD spectra of MAO A indicate that a small inhibitor such d-amphetamine perturbs the aromatic residues very little, but binding of the larger pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride) causes spectral changes consistent with the alteration of the environment of tyrosine and tryptophan residues in particular.	Tyrosine	309-317	monoamine oxidase A	Homo sapiens	14-19
15056494-3	2004	CD spectra of MAO A indicate that a small inhibitor such d-amphetamine perturbs the aromatic residues very little, but binding of the larger pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-j,k]carbazole hydrochloride) causes spectral changes consistent with the alteration of the environment of tyrosine and tryptophan residues in particular.	Tryptophan	322-332	monoamine oxidase A	Homo sapiens	14-19
14962671-3	2004	The monoamine oxidases A and B (MAO-A and -B) genes, which are involved in serotonin and dopamine metabolism, are possible candidate genes for susceptibility to PD.	Serotonin	75-84	monoamine oxidase A	Homo sapiens	32-44
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	64-74	monoamine oxidase A	Homo sapiens	4-29
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	64-74	monoamine oxidase A	Homo sapiens	31-42
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	64-74	monoamine oxidase A	Homo sapiens	31-36
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	76-79	monoamine oxidase A	Homo sapiens	4-29
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	76-79	monoamine oxidase A	Homo sapiens	31-42
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	76-79	monoamine oxidase A	Homo sapiens	31-36
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Deuterium	119-128	monoamine oxidase A	Homo sapiens	31-42
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Deuterium	119-128	monoamine oxidase A	Homo sapiens	31-36
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	151-154	monoamine oxidase A	Homo sapiens	4-29
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	151-154	monoamine oxidase A	Homo sapiens	31-42
15028243-1	2004	The monoamine oxidase A and B (MAO A and B) radiotracers [(11)C]clorgyline (CLG) and [(11)C]L-deprenyl (DEP) and their deuterium labeled counterparts (CLG-D and DEP-D) were compared to determine whether their distribution and kinetics in humans are consistent with their physical, chemical and pharmacological properties and the reported ratios of MAO A:MAO B in post-mortem human tissues.	Clorgyline	151-154	monoamine oxidase A	Homo sapiens	31-36
15027867-0	2004	Inactivation of purified human recombinant monoamine oxidases A and B by rasagiline and its analogues.	rasagiline	73-83	monoamine oxidase A	Homo sapiens	43-69
15027867-5	2004	MAO B and MAO A are more selective for the R-enantiomer (rasagiline) compared to the S-enantiomer (S-PAI) by 2500-fold and 17-fold, respectively.	rasagiline	57-67	monoamine oxidase A	Homo sapiens	10-15
14962671-3	2004	The monoamine oxidases A and B (MAO-A and -B) genes, which are involved in serotonin and dopamine metabolism, are possible candidate genes for susceptibility to PD.	Dopamine	89-97	monoamine oxidase A	Homo sapiens	32-44
15048616-1	2004	BACKGROUND: Moclobemide, a reversible and selective inhibitor of the MAO-A isoenzyme, is marketed as an antidepressant that lacks autonomic and cognitive side effects.	Moclobemide	12-23	monoamine oxidase A	Homo sapiens	69-74
15094788-4	2004	In this study, we used a family-based association approach to investigate the implication of dopamine-related candidate genes, which had been previously reported as possibly associated with TS [genes that encode for the dopamine receptors DRD2, DRD3 and DRD4, the dopamine transporter 1 (SLC6A3) and the monoamine oxidase-A (MAO-A).	Dopamine	93-101	monoamine oxidase A	Homo sapiens	304-323
15094788-4	2004	In this study, we used a family-based association approach to investigate the implication of dopamine-related candidate genes, which had been previously reported as possibly associated with TS [genes that encode for the dopamine receptors DRD2, DRD3 and DRD4, the dopamine transporter 1 (SLC6A3) and the monoamine oxidase-A (MAO-A).	Dopamine	93-101	monoamine oxidase A	Homo sapiens	325-330
15094788-4	2004	In this study, we used a family-based association approach to investigate the implication of dopamine-related candidate genes, which had been previously reported as possibly associated with TS [genes that encode for the dopamine receptors DRD2, DRD3 and DRD4, the dopamine transporter 1 (SLC6A3) and the monoamine oxidase-A (MAO-A).	Dopamine	220-228	monoamine oxidase A	Homo sapiens	304-323
15094788-4	2004	In this study, we used a family-based association approach to investigate the implication of dopamine-related candidate genes, which had been previously reported as possibly associated with TS [genes that encode for the dopamine receptors DRD2, DRD3 and DRD4, the dopamine transporter 1 (SLC6A3) and the monoamine oxidase-A (MAO-A).	Dopamine	220-228	monoamine oxidase A	Homo sapiens	325-330
14697878-1	2004	Monoamine oxidase (MAO) A and B play important roles in the metabolism of catecholamines and xenobiotics in the central nervous system and peripheral tissues.	Catecholamines	74-88	monoamine oxidase A	Homo sapiens	0-25
14755456-1	2004	Monoamine oxidase A (MAOA) locus is an attractive candidate for exploring genetic contribution to the variation in the risk for substance use disorders (SUD) because of its important role in the metabolism of neurotransmitters, including dopamine and serotonin.	Dopamine	238-246	monoamine oxidase A	Homo sapiens	0-19
14755456-1	2004	Monoamine oxidase A (MAOA) locus is an attractive candidate for exploring genetic contribution to the variation in the risk for substance use disorders (SUD) because of its important role in the metabolism of neurotransmitters, including dopamine and serotonin.	Dopamine	238-246	monoamine oxidase A	Homo sapiens	21-25
14755456-1	2004	Monoamine oxidase A (MAOA) locus is an attractive candidate for exploring genetic contribution to the variation in the risk for substance use disorders (SUD) because of its important role in the metabolism of neurotransmitters, including dopamine and serotonin.	Serotonin	251-260	monoamine oxidase A	Homo sapiens	0-19
14755456-1	2004	Monoamine oxidase A (MAOA) locus is an attractive candidate for exploring genetic contribution to the variation in the risk for substance use disorders (SUD) because of its important role in the metabolism of neurotransmitters, including dopamine and serotonin.	Serotonin	251-260	monoamine oxidase A	Homo sapiens	21-25
14697793-1	2004	A new molecule, the 4-methyl-thio-phenyl-propylamine (PrNH(2)) was synthesized and its biological interaction with different amine oxidases such as semicarbazide sensitive amine oxidase (SSAO) [E.C.1.4.3.6], and monoamine oxidase [E.C.1.4.3.4] under its two isoforms, MAO A and MAO B, has been assessed.	prnh(2)	54-61	monoamine oxidase A	Homo sapiens	268-273
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Dopamine	84-92	monoamine oxidase A	Homo sapiens	0-19
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Dopamine	84-92	monoamine oxidase A	Homo sapiens	21-25
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Serotonin	94-103	monoamine oxidase A	Homo sapiens	0-19
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Serotonin	94-103	monoamine oxidase A	Homo sapiens	21-25
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Norepinephrine	108-122	monoamine oxidase A	Homo sapiens	0-19
15539858-2	2004	Monoamine oxidase A (MAOA) is a mitochondrial enzyme involved in the degradation of dopamine, serotonin and norepinephrine.	Norepinephrine	108-122	monoamine oxidase A	Homo sapiens	21-25
14697876-3	2004	MAO-A is inhibited by clorgyline; and MAO-B, by deprenyl.	Clorgyline	22-32	monoamine oxidase A	Homo sapiens	0-5
14697876-3	2004	MAO-A is inhibited by clorgyline; and MAO-B, by deprenyl.	Selegiline	48-56	monoamine oxidase A	Homo sapiens	0-5
14697878-6	2004	The presence of repeat units within the 2 kb human MAO A promoter which is associated with promoter activity and enzymatic activity in human fibroblast culture provided a tool to study human population with abnormal behaviors related to serotonin and other neurotransmitters.	Serotonin	237-246	monoamine oxidase A	Homo sapiens	51-56
14697876-10	2004	MAO-A oxidizes noradrenaline and serotonin; and MAO-B, mainly beta-phenylethylamine.	Norepinephrine	15-28	monoamine oxidase A	Homo sapiens	0-5
14697876-10	2004	MAO-A oxidizes noradrenaline and serotonin; and MAO-B, mainly beta-phenylethylamine.	Serotonin	33-42	monoamine oxidase A	Homo sapiens	0-5
14697881-0	2004	The FAD binding sites of human monoamine oxidases A and B.	Flavin-Adenine Dinucleotide	4-7	monoamine oxidase A	Homo sapiens	31-57
14697899-4	2004	However irreversible MAO-A inhibitors continue to induce a cheese reaction, whereas MAO-B inhibitors at their selective dosage did not and led to introduction of L-deprenyl (selegiline) as an anti-Parkinson drug, since dopamine is equally well metabolized by both enzyme forms.	Selegiline	162-172	monoamine oxidase A	Homo sapiens	21-26
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	45-48	monoamine oxidase A	Homo sapiens	66-85
14697899-4	2004	However irreversible MAO-A inhibitors continue to induce a cheese reaction, whereas MAO-B inhibitors at their selective dosage did not and led to introduction of L-deprenyl (selegiline) as an anti-Parkinson drug, since dopamine is equally well metabolized by both enzyme forms.	Selegiline	174-184	monoamine oxidase A	Homo sapiens	21-26
14697899-5	2004	The cheese reaction is a consequence of inhibition of MAO-A, the enzyme responsible for metabolism of noradrenaline and serotonin, located in peripheral adrenergic neurons.	Norepinephrine	102-115	monoamine oxidase A	Homo sapiens	54-59
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	45-48	monoamine oxidase A	Homo sapiens	87-92
14697899-5	2004	The cheese reaction is a consequence of inhibition of MAO-A, the enzyme responsible for metabolism of noradrenaline and serotonin, located in peripheral adrenergic neurons.	Serotonin	120-129	monoamine oxidase A	Homo sapiens	54-59
14697899-6	2004	The consequence of these findings were the development of reversible MAO-A inhibitors (RIMA), moclobemide and brofaromin, as antidepressants and possible anti-Parkinson activity, with limited tyramine potentiation, since the amine can displace the inhibitor from its binding site on the enzyme.	rima	87-91	monoamine oxidase A	Homo sapiens	69-74
14697899-6	2004	The consequence of these findings were the development of reversible MAO-A inhibitors (RIMA), moclobemide and brofaromin, as antidepressants and possible anti-Parkinson activity, with limited tyramine potentiation, since the amine can displace the inhibitor from its binding site on the enzyme.	Amines	195-200	monoamine oxidase A	Homo sapiens	69-74
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	45-48	monoamine oxidase A	Homo sapiens	139-144
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	119-122	monoamine oxidase A	Homo sapiens	66-85
14697904-8	2004	2-N-(phenylethylamino)-acetoamide was the good substrate for MAO-A and MAO-B same as milacemide.	2-n-(phenylethylamino)-acetoamide	0-33	monoamine oxidase A	Homo sapiens	61-66
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	119-122	monoamine oxidase A	Homo sapiens	87-92
14697904-8	2004	2-N-(phenylethylamino)-acetoamide was the good substrate for MAO-A and MAO-B same as milacemide.	milacemide	85-95	monoamine oxidase A	Homo sapiens	61-66
14697881-3	2004	Since those amino acids interacting with the FAD are conserved in monoamine oxidase A (MAO A), it is proposed that the FAD binding site in MAO A is quite similar to that in MAO B.	Flavin-Adenine Dinucleotide	119-122	monoamine oxidase A	Homo sapiens	139-144
14697881-7	2004	This structural information is then used to explain previous studies on flavin analog incorporation into either MAO B or into MAO A.	4,6-dinitro-o-cresol	72-78	monoamine oxidase A	Homo sapiens	126-131
14697882-1	2004	Monoamine oxidases A and B (MAO A and B) are the major enzymes in mammals that catalyze the oxidative deamination or oxidation of neurotransmitters, peripheral vasoactive amines, and xenobiotics (e.g. MPTP).	Amines	171-177	monoamine oxidase A	Homo sapiens	0-26
14697882-1	2004	Monoamine oxidases A and B (MAO A and B) are the major enzymes in mammals that catalyze the oxidative deamination or oxidation of neurotransmitters, peripheral vasoactive amines, and xenobiotics (e.g. MPTP).	Amines	171-177	monoamine oxidase A	Homo sapiens	28-39
14697882-1	2004	Monoamine oxidases A and B (MAO A and B) are the major enzymes in mammals that catalyze the oxidative deamination or oxidation of neurotransmitters, peripheral vasoactive amines, and xenobiotics (e.g. MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	201-205	monoamine oxidase A	Homo sapiens	0-26
14697882-1	2004	Monoamine oxidases A and B (MAO A and B) are the major enzymes in mammals that catalyze the oxidative deamination or oxidation of neurotransmitters, peripheral vasoactive amines, and xenobiotics (e.g. MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	201-205	monoamine oxidase A	Homo sapiens	28-39
14671188-7	2003	The precursor of melatonin, serotonin was stepwise depleted during the course of AD, as indicated by the up-regulated monoamine oxidase A mRNA and activity (5-hydroxyindoleacetic acid:serotonin ratio).	Melatonin	17-26	monoamine oxidase A	Homo sapiens	118-137
15095350-2	2004	The method used kynuramine as a common substrate for both MAO-A and MAO-B in incubations, and the 4-hydroxyquinoline (4-HQ) resulting from deamination of kynuramine followed by intramolecular condensation was analyzed using LC/MS/MS; formation of 4-HQ was used as the marker of MAO activity to evaluate the effects of test compounds.	Kynuramine	16-26	monoamine oxidase A	Homo sapiens	58-63
22033639-8	2003	Three double-blind, placebo-controlled trials have been conducted showing promising results for the selective serotonin reuptake inhibitors (SSRIs) sertraline and fluoxetine, as well as for moclobemide, a reversible inhibitor of monoamine oxidase A.	Moclobemide	190-201	monoamine oxidase A	Homo sapiens	229-248
14508509-3	2003	Since monoamine oxidase A metabolises noradrenalin, a positive association with the MAOA gene would be biologically plausible.	Norepinephrine	38-50	monoamine oxidase A	Homo sapiens	6-25
14508509-3	2003	Since monoamine oxidase A metabolises noradrenalin, a positive association with the MAOA gene would be biologically plausible.	Norepinephrine	38-50	monoamine oxidase A	Homo sapiens	84-88
14671188-7	2003	The precursor of melatonin, serotonin was stepwise depleted during the course of AD, as indicated by the up-regulated monoamine oxidase A mRNA and activity (5-hydroxyindoleacetic acid:serotonin ratio).	Serotonin	28-37	monoamine oxidase A	Homo sapiens	118-137
14671188-7	2003	The precursor of melatonin, serotonin was stepwise depleted during the course of AD, as indicated by the up-regulated monoamine oxidase A mRNA and activity (5-hydroxyindoleacetic acid:serotonin ratio).	Hydroxyindoleacetic Acid	157-183	monoamine oxidase A	Homo sapiens	118-137
14671188-7	2003	The precursor of melatonin, serotonin was stepwise depleted during the course of AD, as indicated by the up-regulated monoamine oxidase A mRNA and activity (5-hydroxyindoleacetic acid:serotonin ratio).	Serotonin	184-193	monoamine oxidase A	Homo sapiens	118-137
14671188-8	2003	We conclude that a dysfunction of noradrenergic regulation and the depletion of serotonin by increased monoamine oxidase A result in the loss of melatonin rhythm already in preclinical AD.	Serotonin	80-89	monoamine oxidase A	Homo sapiens	103-122
14671188-8	2003	We conclude that a dysfunction of noradrenergic regulation and the depletion of serotonin by increased monoamine oxidase A result in the loss of melatonin rhythm already in preclinical AD.	Melatonin	145-154	monoamine oxidase A	Homo sapiens	103-122
12855685-1	2003	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine.	monoamines	94-104	monoamine oxidase A	Homo sapiens	0-25
12958079-14	2003	This 4.96 Mb region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are involved in the oxidative deamination of several neurotransmitters, including dopamine and serotonin.	Dopamine	187-195	monoamine oxidase A	Homo sapiens	58-77
12958079-14	2003	This 4.96 Mb region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are involved in the oxidative deamination of several neurotransmitters, including dopamine and serotonin.	Dopamine	187-195	monoamine oxidase A	Homo sapiens	79-83
12958079-14	2003	This 4.96 Mb region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are involved in the oxidative deamination of several neurotransmitters, including dopamine and serotonin.	Serotonin	200-209	monoamine oxidase A	Homo sapiens	58-77
12958079-14	2003	This 4.96 Mb region contains, among others, the genes for monoamine oxidase A (MAOA) and B (MAOB), which are involved in the oxidative deamination of several neurotransmitters, including dopamine and serotonin.	Serotonin	200-209	monoamine oxidase A	Homo sapiens	79-83
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	phenethylamine	129-150	monoamine oxidase A	Homo sapiens	51-75
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	phenethylamine	129-150	monoamine oxidase A	Homo sapiens	77-82
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	phenethylamine	152-155	monoamine oxidase A	Homo sapiens	51-75
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	phenethylamine	152-155	monoamine oxidase A	Homo sapiens	77-82
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	Hydroxyindoleacetic Acid	169-195	monoamine oxidase A	Homo sapiens	51-75
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	Hydroxyindoleacetic Acid	169-195	monoamine oxidase A	Homo sapiens	77-82
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	Hydroxyindoleacetic Acid	197-203	monoamine oxidase A	Homo sapiens	51-75
14628189-4	2003	Inhibition of monoamine-oxidase type B (MAO-B) and monoamine oxidase type A (MAO-A) activity was determined by measurement of as beta-phenylethylamine (PEA) by GCMS and 5-hydroxyindoleacetic acid (5-HIAA) by High Performance Liquid Chromatography (HPLC) assays.	Hydroxyindoleacetic Acid	197-203	monoamine oxidase A	Homo sapiens	77-82
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	rizatriptan	82-93	monoamine oxidase A	Homo sapiens	23-33
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	rizatriptan	82-93	monoamine oxidase A	Homo sapiens	35-40
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	rizatriptan	95-98	monoamine oxidase A	Homo sapiens	23-33
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	rizatriptan	95-98	monoamine oxidase A	Homo sapiens	35-40
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	Serotonin	117-136	monoamine oxidase A	Homo sapiens	23-33
14651728-3	2003	We aimed to assess the MAO type A (MAO-A) involvement in the metabolic pathway of rizatriptan (RIZ), an antimigraine 5-hydroxytryptamine (5-HT)1B/1D agonist, and the interethnic difference in MAO activities between Caucasians and Japanese using RIZ as a model drug in in vitro experiments.	Serotonin	117-136	monoamine oxidase A	Homo sapiens	35-40
14651728-7	2003	The oxidative deaminase activities of RIZ were inhibited completely by the nanomolar-order concentration of clorgyline and Ro 41-1049 (MAO-A selective inhibitors), but not by that of Ro 16-6491 (MAO-B selective inhibitor).	Ro 41-1049	123-133	monoamine oxidase A	Homo sapiens	135-140
14651728-10	2003	CONCLUSIONS: RIZ is mainly metabolized by MAO-A and the in vitro oxidative deaminase activities mediated via MAO-A and -B do not appear to differ between Japanese and Caucasians.	rizatriptan	13-16	monoamine oxidase A	Homo sapiens	42-47
12855685-1	2003	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine.	Serotonin	113-122	monoamine oxidase A	Homo sapiens	0-25
12855685-1	2003	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine.	Tyramine	124-132	monoamine oxidase A	Homo sapiens	0-25
12855685-1	2003	Monoamine oxidase (MAO) A and B catalyze the oxidative deamination of neuroactive and dietary monoamines such as serotonin, tyramine, and phenylethylamine.	Phenethylamines	138-154	monoamine oxidase A	Homo sapiens	0-25
14502756-1	2003	Twelve new 1-N-substituted thiocarbomoyl-3-phenyl-5-thienyl-2-pyrazoline derivatives were synthesized and evaluated their for antidepressant, anxiogenic and mammalian monoamine oxidase (MAO)-A and Binhibitory activities by in vivo and in vitro tests.	1-n-substituted thiocarbomoyl-3-phenyl-5-thienyl-2-pyrazoline	11-72	monoamine oxidase A	Homo sapiens	167-192
14606950-3	2003	However, only two of them, NO donors (7-nitro-benzotetrazine-1,3-dioxide (7-NBTDO) and benzodifuroxan), caused nonselective inhibition of MAO A and MAO B with IC(50) values of 1.3-1.6 and 6.8-6.3 microM, respectively.	7-nitro-benzotetrazine-1,3-dioxide	38-72	monoamine oxidase A	Homo sapiens	138-143
14606950-3	2003	However, only two of them, NO donors (7-nitro-benzotetrazine-1,3-dioxide (7-NBTDO) and benzodifuroxan), caused nonselective inhibition of MAO A and MAO B with IC(50) values of 1.3-1.6 and 6.8-6.3 microM, respectively.	benzo(1,2-c:3,4-c')bis(1,2,5)oxadiazole-1,6-dioxide	87-101	monoamine oxidase A	Homo sapiens	138-143
14606950-7	2003	The data suggest that nonselective inhibition of MAO A and MAO B by benzodifuroxan and 7-NBTDO can be attributed to the properties of the chemical structures of these compounds.	benzo(1,2-c:3,4-c')bis(1,2,5)oxadiazole-1,6-dioxide	68-82	monoamine oxidase A	Homo sapiens	49-54
14606950-7	2003	The data suggest that nonselective inhibition of MAO A and MAO B by benzodifuroxan and 7-NBTDO can be attributed to the properties of the chemical structures of these compounds.	7-nitro-benzotetrazine-1,3-dioxide	87-94	monoamine oxidase A	Homo sapiens	49-54
14606950-3	2003	However, only two of them, NO donors (7-nitro-benzotetrazine-1,3-dioxide (7-NBTDO) and benzodifuroxan), caused nonselective inhibition of MAO A and MAO B with IC(50) values of 1.3-1.6 and 6.8-6.3 microM, respectively.	7-nitro-benzotetrazine-1,3-dioxide	74-81	monoamine oxidase A	Homo sapiens	138-143
12729662-0	2003	Synthesis and in vivo imaging properties of [11C]befloxatone: a novel highly potent positron emission tomography ligand for mono-amine oxidase-A.	[11C](5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	44-60	monoamine oxidase A	Homo sapiens	124-144
12833310-0	2003	Pharmacological treatment of frontotemporal dementia: treatment response to the MAO-A inhibitor moclobemide.	Moclobemide	96-107	monoamine oxidase A	Homo sapiens	80-85
12781338-0	2003	Monoamine oxidase A inhibitory potency and flavin perturbation are influenced by different aspects of pirlindole inhibitor structure.	pirlindole	102-112	monoamine oxidase A	Homo sapiens	0-19
12781338-3	2003	The kinetic, spectral, and thermodynamic changes induced by four closely related pirlindole analogues have been determined to investigate their interaction with the FAD in the active site of MAO A.	pirlindole	81-91	monoamine oxidase A	Homo sapiens	191-196
12781338-8	2003	All inhibitors stabilised the semiquinone of the FAD when MAO A was titrated with dithionite and prevented further reduction.	Dithionite	82-92	monoamine oxidase A	Homo sapiens	58-63
12781338-9	2003	These results indicate that the active site of MAO A is far more sensitive to structural variation than would be predicted by the simple flavin stacking model.	4,6-dinitro-o-cresol	137-143	monoamine oxidase A	Homo sapiens	47-52
12777388-0	2003	Structural comparison of human monoamine oxidases A and B: mass spectrometry monitoring of cysteine reactivities.	Cysteine	91-99	monoamine oxidase A	Homo sapiens	31-57
12777388-1	2003	Monoamine oxidases (MAO) A and B are approximately 60-kDa outer mitochondrial membrane flavoenzymes catalyzing the degradation of neurotransmitters and xenobiotic arylalkyl amines.	xenobiotic arylalkyl amines	152-179	monoamine oxidase A	Homo sapiens	0-32
12777388-3	2003	Human MAO A and MAO B each contain 9 cysteine residues (7 in conserved sequence locations).	Cysteine	37-45	monoamine oxidase A	Homo sapiens	6-11
12777388-4	2003	MAO A is inactivated by N-ethylmaleimide (NEM) much faster (tau(1/2) = approximately 3 min) than MAO B (tau(1/2) = approximately 8 h).	Ethylmaleimide	24-40	monoamine oxidase A	Homo sapiens	0-5
12777388-4	2003	MAO A is inactivated by N-ethylmaleimide (NEM) much faster (tau(1/2) = approximately 3 min) than MAO B (tau(1/2) = approximately 8 h).	Ethylmaleimide	42-45	monoamine oxidase A	Homo sapiens	0-5
12777388-7	2003	Cys5 and Cys266 were identified as the only residues modified by biotin-derivatized NEM in clorgyline-inactivated MAO A and pargyline-inactivated MAO B, respectively.	Biotin	65-71	monoamine oxidase A	Homo sapiens	114-119
12777388-7	2003	Cys5 and Cys266 were identified as the only residues modified by biotin-derivatized NEM in clorgyline-inactivated MAO A and pargyline-inactivated MAO B, respectively.	Clorgyline	91-101	monoamine oxidase A	Homo sapiens	114-119
12777388-14	2003	These thiol residues are also modified by biotin-derivatized NEM in the mitochondrial membrane-bound MAO A and MAO B.	Sulfhydryl Compounds	6-11	monoamine oxidase A	Homo sapiens	101-106
12777388-14	2003	These thiol residues are also modified by biotin-derivatized NEM in the mitochondrial membrane-bound MAO A and MAO B.	Biotin	42-48	monoamine oxidase A	Homo sapiens	101-106
12777388-15	2003	This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes.	Clorgyline	89-99	monoamine oxidase A	Homo sapiens	26-31
12777388-15	2003	This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes.	Clorgyline	89-99	monoamine oxidase A	Homo sapiens	130-141
12777388-15	2003	This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes.	Pargyline	104-113	monoamine oxidase A	Homo sapiens	26-31
12777388-15	2003	This study shows that the MAO A structure is "more flexible" than that of MAO B and that clorgyline and pargyline inactivation of MAO A and B, respectively, increases the structural stability of both enzymes.	Pargyline	104-113	monoamine oxidase A	Homo sapiens	130-141
12729662-1	2003	Befloxatone (1, (5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone) is an oxazolidinone derivative belonging to a new generation of reversible and selective mono-amine oxidase-A (MAO-A) inhibitors.	befloxatone	0-11	monoamine oxidase A	Homo sapiens	196-216
12729662-1	2003	Befloxatone (1, (5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone) is an oxazolidinone derivative belonging to a new generation of reversible and selective mono-amine oxidase-A (MAO-A) inhibitors.	befloxatone	0-11	monoamine oxidase A	Homo sapiens	218-223
12729662-1	2003	Befloxatone (1, (5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone) is an oxazolidinone derivative belonging to a new generation of reversible and selective mono-amine oxidase-A (MAO-A) inhibitors.	1, (5r)-5-(methoxymethyl)-3-[4-[(3r)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	13-105	monoamine oxidase A	Homo sapiens	196-216
12729662-1	2003	Befloxatone (1, (5R)-5-(methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone) is an oxazolidinone derivative belonging to a new generation of reversible and selective mono-amine oxidase-A (MAO-A) inhibitors.	1, (5r)-5-(methoxymethyl)-3-[4-[(3r)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	13-105	monoamine oxidase A	Homo sapiens	218-223
12729662-2	2003	In vitro and ex vivo studies have demonstrated that befloxatone is a potent, reversible and competitive MAO-A inhibitor with potential antidepressant properties.	befloxatone	52-63	monoamine oxidase A	Homo sapiens	104-109
12729662-5	2003	The results obtained in vivo with carbon-11-labelled befloxatone not only confirm the biochemical and pharmacological profile of befloxatone found in rodent and in human tissues but also point out [(11)C]befloxatone as an excellent tool for the assessment of MAO-A binding sites using positron emission tomography, a high-resolution, sensitive, non-invasive and quantitative imaging technique.	Carbon-11	34-43	monoamine oxidase A	Homo sapiens	259-264
12606609-13	2003	These results indicate that [(11)C]befloxatone will be an excellent probe for the study of MAO-A in humans using PET.	Carbon-11	28-34	monoamine oxidase A	Homo sapiens	91-96
12853332-2	2003	TV3326 also inhibits monoamine oxidase (MAO)-A and B, while its S-isomer, TV3279, lacks MAO-inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	monoamine oxidase A	Homo sapiens	21-52
12606609-0	2003	Mapping the cerebral monoamine oxidase type A: positron emission tomography characterization of the reversible selective inhibitor [11C]befloxatone.	[11C](5R)-5-(Methoxymethyl)-3-[4-[(3R)-4,4,4-trifluoro-3-hydroxybutoxy]phenyl]-2-oxazolidinone	131-147	monoamine oxidase A	Homo sapiens	21-45
12606609-13	2003	These results indicate that [(11)C]befloxatone will be an excellent probe for the study of MAO-A in humans using PET.	befloxatone	35-46	monoamine oxidase A	Homo sapiens	91-96
12606609-1	2003	Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A).	befloxatone	0-11	monoamine oxidase A	Homo sapiens	57-76
12606609-1	2003	Befloxatone is a competitive and reversible inhibitor of monoamine oxidase-A (MAOI-A).	befloxatone	0-11	monoamine oxidase A	Homo sapiens	78-84
12642466-6	2003	Almotriptan is also metabolized at the dimethylaminoethyl group by N-demethylation, a reaction that is carried out by five different cytochrome P450s, flavin monooxygenase-3 mediated N-oxidation, and MAO-A catalyzed oxidative deamination to form the indole acetic acid and the indole ethyl alcohol derivatives of almotriptan.	almotriptan	0-11	monoamine oxidase A	Homo sapiens	200-205
12606609-2	2003	The aim of the study was to characterize the in vivo properties of [(11)C]befloxatone and to validate its use as a ligand for the study of MAO-A by positron emission tomography (PET).	[(11)c]befloxatone	67-85	monoamine oxidase A	Homo sapiens	139-144
12606609-9	2003	), a selective MAOI-B but is completely blocked by a pretreatment with moclobemide (MAOI-A; 10 mg/kg).	Moclobemide	71-82	monoamine oxidase A	Homo sapiens	84-90
12679138-1	2003	We have previously shown that pirlindole and dehydropirlindole, two monoamine oxidase type-A inhibitors, protect cultured brain cells against iron-induced toxicity through a mechanism unrelated to monoamine oxidase type-A inhibition.	pirlindole	30-40	monoamine oxidase A	Homo sapiens	68-92
12679138-1	2003	We have previously shown that pirlindole and dehydropirlindole, two monoamine oxidase type-A inhibitors, protect cultured brain cells against iron-induced toxicity through a mechanism unrelated to monoamine oxidase type-A inhibition.	3,3a-dehydropyrazidol	45-62	monoamine oxidase A	Homo sapiens	68-92
12679138-1	2003	We have previously shown that pirlindole and dehydropirlindole, two monoamine oxidase type-A inhibitors, protect cultured brain cells against iron-induced toxicity through a mechanism unrelated to monoamine oxidase type-A inhibition.	Iron	142-146	monoamine oxidase A	Homo sapiens	68-92
12642466-6	2003	Almotriptan is also metabolized at the dimethylaminoethyl group by N-demethylation, a reaction that is carried out by five different cytochrome P450s, flavin monooxygenase-3 mediated N-oxidation, and MAO-A catalyzed oxidative deamination to form the indole acetic acid and the indole ethyl alcohol derivatives of almotriptan.	Nitrogen	67-68	monoamine oxidase A	Homo sapiens	200-205
12642466-7	2003	The use of human liver mitochondria confirmed the contribution of MAO-A to the metabolism of almotriptan.	almotriptan	93-104	monoamine oxidase A	Homo sapiens	66-71
12642466-9	2003	In addition, different clinical trials conducted to study the effects of CYP3A4, CYP2D6, and MAO-A on the pharmacokinetics of almotriptan confirmed the involvement of these enzymes in the metabolic clearance of this drug and that no dose changes are required in the presence of inhibitors of these enzymes.	almotriptan	126-137	monoamine oxidase A	Homo sapiens	93-98
12620419-0	2003	Synthesis and biological evaluation of enantiomerically pure pyrrolyl-oxazolidinones as a new class of potent and selective monoamine oxidase type A inhibitors.	pyrrolyl-oxazolidinones	61-84	monoamine oxidase A	Homo sapiens	124-148
12620068-0	2003	Simple, potent, and selective pyrrole inhibitors of monoamine oxidase types A and B.	Pyrroles	30-37	monoamine oxidase A	Homo sapiens	52-83
12620068-1	2003	N-Benzyl- and N-propargyl-1H-pyrrole-2-carboxyamides and some related methylenamines were synthesized and tested for their monoamine oxidase types A and B inhibitory activity.	n-benzyl- and n-propargyl-1h-pyrrole-2-carboxyamides	0-52	monoamine oxidase A	Homo sapiens	123-154
12620068-2	2003	2-(N-Methyl-N-propargylaminomethyl)-1H-pyrrole (24) was the most potent MAO-A inhibitor of the series [K(i)(MAO-A) = 0.0054 microM], but it was not selective.	2-(n-methyl-n-propargylaminomethyl)-1h-pyrrole	0-46	monoamine oxidase A	Homo sapiens	72-77
12620068-2	2003	2-(N-Methyl-N-propargylaminomethyl)-1H-pyrrole (24) was the most potent MAO-A inhibitor of the series [K(i)(MAO-A) = 0.0054 microM], but it was not selective.	2-(n-methyl-n-propargylaminomethyl)-1h-pyrrole	0-46	monoamine oxidase A	Homo sapiens	108-113
12620419-2	2003	Among selective MAOIs, MAO-A inhibitors (e.g. clorgyline) are used as antidepressant and antianxiety drugs and are claimed to protect neuronal cells against apoptosis, and selective MAO-B inhibitors (e.g. L-deprenyl) can be used in the treatment of Parkinson"s disease either alone or in combination with L-DOPA.	Clorgyline	46-56	monoamine oxidase A	Homo sapiens	23-28
12620419-5	2003	Among these molecules, the most representative are toloxatone and befloxatone, two selective and reversible MAO-A inhibitors used in therapy as antidepressant drugs.	toloxatone	51-61	monoamine oxidase A	Homo sapiens	108-113
12620419-5	2003	Among these molecules, the most representative are toloxatone and befloxatone, two selective and reversible MAO-A inhibitors used in therapy as antidepressant drugs.	befloxatone	66-77	monoamine oxidase A	Homo sapiens	108-113
12629534-2	2003	Our objective in this study was to determine whether functional polymorphisms of the genes that encode for the serotonin transporter promoter (5HTTLPR) and monoamine oxidase A (MAOA-uVNTR) are associated with CNS serotonin turnover-indexed by cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (5-HIAA)-in a community sample of healthy adults.	Serotonin	111-120	monoamine oxidase A	Homo sapiens	177-181
12765230-1	2003	The antidepressant moclobemide (Aurorix) is a reversible inhibitor of monoamine oxidase-A.	Moclobemide	19-30	monoamine oxidase A	Homo sapiens	70-89
12765230-1	2003	The antidepressant moclobemide (Aurorix) is a reversible inhibitor of monoamine oxidase-A.	Moclobemide	32-39	monoamine oxidase A	Homo sapiens	70-89
12629534-2	2003	Our objective in this study was to determine whether functional polymorphisms of the genes that encode for the serotonin transporter promoter (5HTTLPR) and monoamine oxidase A (MAOA-uVNTR) are associated with CNS serotonin turnover-indexed by cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (5-HIAA)-in a community sample of healthy adults.	Hydroxyindoleacetic Acid	273-299	monoamine oxidase A	Homo sapiens	156-175
12765230-6	2003	Although dietary restrictions during moclobemide therapy are not considered necessary, the combination of large quantities of moclobemide and tyramine-containing products seems to be lethal, probably because monoamine oxidase-A selectivity is overwhelmed after massive overdoses.	Moclobemide	126-137	monoamine oxidase A	Homo sapiens	208-227
12765230-6	2003	Although dietary restrictions during moclobemide therapy are not considered necessary, the combination of large quantities of moclobemide and tyramine-containing products seems to be lethal, probably because monoamine oxidase-A selectivity is overwhelmed after massive overdoses.	Tyramine	142-150	monoamine oxidase A	Homo sapiens	208-227
12629534-2	2003	Our objective in this study was to determine whether functional polymorphisms of the genes that encode for the serotonin transporter promoter (5HTTLPR) and monoamine oxidase A (MAOA-uVNTR) are associated with CNS serotonin turnover-indexed by cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (5-HIAA)-in a community sample of healthy adults.	Hydroxyindoleacetic Acid	273-299	monoamine oxidase A	Homo sapiens	177-181
12629534-2	2003	Our objective in this study was to determine whether functional polymorphisms of the genes that encode for the serotonin transporter promoter (5HTTLPR) and monoamine oxidase A (MAOA-uVNTR) are associated with CNS serotonin turnover-indexed by cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (5-HIAA)-in a community sample of healthy adults.	Hydroxyindoleacetic Acid	301-307	monoamine oxidase A	Homo sapiens	156-175
12629534-2	2003	Our objective in this study was to determine whether functional polymorphisms of the genes that encode for the serotonin transporter promoter (5HTTLPR) and monoamine oxidase A (MAOA-uVNTR) are associated with CNS serotonin turnover-indexed by cerebrospinal fluid levels of 5-hydroxyindoleacetic acid (5-HIAA)-in a community sample of healthy adults.	Hydroxyindoleacetic Acid	301-307	monoamine oxidase A	Homo sapiens	177-181
12633131-2	2003	A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme.	Selegiline	2-12	monoamine oxidase A	Homo sapiens	164-169
12633131-2	2003	A selegiline transdermal system (STS) has been developed with unique pharmacokinetic and pharmacodynamic properties that allow inhibition of central nervous system MAO-A and MAO-B enzymes while substantially avoiding inhibition of intestinal and liver MAO-A enzyme.	Selegiline	2-12	monoamine oxidase A	Homo sapiens	252-257
12665046-1	2002	This randomized, prospective, double-blind study evaluated the efficacy and tolerability of moclobemide, a reversible, selective inhibitor of monoamine oxidase-A, in reducing the frequency and severity of hot flashes.	Moclobemide	92-103	monoamine oxidase A	Homo sapiens	142-161
12538805-4	2003	Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH.	tryptamine	0-10	monoamine oxidase A	Homo sapiens	78-83
12538805-4	2003	Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH.	indole-3-acetaldehyde	27-48	monoamine oxidase A	Homo sapiens	78-83
12538805-4	2003	Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH.	indole-3-acetaldehyde	113-134	monoamine oxidase A	Homo sapiens	78-83
12538805-4	2003	Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH.	tryptophol	158-168	monoamine oxidase A	Homo sapiens	78-83
12538805-4	2003	Tryptamine was oxidized to indole-3-acetaldehyde by HLM and recombinant human MAO-A in the absence of NADPH, and indole-3-acetaldehyde was further reduced to tryptophol by aldehyde reductase in HLM in the presence of NADPH.	NADP	217-222	monoamine oxidase A	Homo sapiens	78-83
12538805-6	2003	The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A.	bufuralol	22-31	monoamine oxidase A	Homo sapiens	211-216
12538805-6	2003	The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A.	Debrisoquin	36-48	monoamine oxidase A	Homo sapiens	211-216
12538805-6	2003	The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A.	indole-3-acetaldehyde	148-169	monoamine oxidase A	Homo sapiens	211-216
12538805-6	2003	The CYP2D6 substrates bufuralol and debrisoquine showed strong inhibition of both tryptophol production from tryptamine in HLM and the formation of indole-3-acetaldehyde from tryptamine catalyzed by recombinant MAO-A.	tryptamine	175-185	monoamine oxidase A	Homo sapiens	211-216
12538805-9	2003	This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A.	tryptamine	68-78	monoamine oxidase A	Homo sapiens	96-101
12538805-9	2003	This is the first unequivocal report of the selective conversion of tryptamine to tryptophol by MAO-A.	tryptophol	82-92	monoamine oxidase A	Homo sapiens	96-101
14531724-18	2003	Linezolid is a mild, reversible, inhibitor of monoamine oxidases A and B.	Linezolid	0-9	monoamine oxidase A	Homo sapiens	46-72
15035814-0	2003	Interactions of D-amphetamine with the active site of monoamine oxidase-A.	Dextroamphetamine	16-29	monoamine oxidase A	Homo sapiens	54-73
12445480-1	2002	Monoamine oxidase A (MAO A) catalyses the oxidation of both neurotransmitter and ingested amines.	Amines	90-96	monoamine oxidase A	Homo sapiens	0-19
12445480-1	2002	Monoamine oxidase A (MAO A) catalyses the oxidation of both neurotransmitter and ingested amines.	Amines	90-96	monoamine oxidase A	Homo sapiens	21-26
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	Dextroamphetamine	16-29	monoamine oxidase A	Homo sapiens	134-139
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	Harmine	31-38	monoamine oxidase A	Homo sapiens	134-139
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	tetrindole	40-50	monoamine oxidase A	Homo sapiens	134-139
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	befloxatone	56-67	monoamine oxidase A	Homo sapiens	134-139
12445480-5	2002	The inhibitors, D-amphetamine, harmine, tetrindole, and befloxatone all induce similar (but not identical) changes in the spectrum of MAO A, consistent with stacking of inhibitor with the flavin in the active site.	4,6-dinitro-o-cresol	188-194	monoamine oxidase A	Homo sapiens	134-139
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	Dextroamphetamine	0-13	monoamine oxidase A	Homo sapiens	97-102
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	Harmine	15-22	monoamine oxidase A	Homo sapiens	97-102
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	tetrindole	28-38	monoamine oxidase A	Homo sapiens	97-102
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	semiquinone	53-64	monoamine oxidase A	Homo sapiens	97-102
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	Flavin-Adenine Dinucleotide	73-76	monoamine oxidase A	Homo sapiens	97-102
12445480-6	2002	D-Amphetamine, harmine, and tetrindole stabilise the semiquinone form of FAD during reduction of MAO A by dithionite and no further reduction of these inhibitor-MAO A complexes has been observed.	Dithionite	106-116	monoamine oxidase A	Homo sapiens	97-102
12445480-7	2002	In contrast, semiquinone is never observed during reduction of the befloxatone-MAO A complex.	semiquinone	13-24	monoamine oxidase A	Homo sapiens	79-84
12445480-7	2002	In contrast, semiquinone is never observed during reduction of the befloxatone-MAO A complex.	befloxatone	67-78	monoamine oxidase A	Homo sapiens	79-84
12504917-3	2002	Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.	Reserpine	0-9	monoamine oxidase A	Homo sapiens	101-106
12504917-3	2002	Reserpine-induced ptosis was reversed by rasagiline at doses above 2 mg x kg(-1) i.p., which inhibit MAO-A as well as MAO-B, but not at MAO-B-selective doses.	rasagiline	41-51	monoamine oxidase A	Homo sapiens	101-106
12502014-1	2002	Monoamine oxidase A (MAOA) and tryptophan hydroxylase (TPH) are the staple enzymes in the metabolism of serotonin (5-HT).	Serotonin	104-113	monoamine oxidase A	Homo sapiens	0-19
12502014-1	2002	Monoamine oxidase A (MAOA) and tryptophan hydroxylase (TPH) are the staple enzymes in the metabolism of serotonin (5-HT).	Serotonin	104-113	monoamine oxidase A	Homo sapiens	21-25
12502014-5	2002	The present study fails to demonstrate that the genetic polymorphisms of MAOA-VNTR and TPH-A218C affect the antidepressant effect of fluvoxamine in Japanese patients with major depressive disorder.	Fluvoxamine	133-144	monoamine oxidase A	Homo sapiens	73-77
12439294-0	2002	Strategy for the formation of parametric images under conditions of low injected radioactivity applied to PET studies with the irreversible monoamine oxidase A tracers [11C]clorgyline and deuterium-substituted [11C]clorgyline.	Carbon-11	169-172	monoamine oxidase A	Homo sapiens	140-159
12439294-0	2002	Strategy for the formation of parametric images under conditions of low injected radioactivity applied to PET studies with the irreversible monoamine oxidase A tracers [11C]clorgyline and deuterium-substituted [11C]clorgyline.	Clorgyline	173-183	monoamine oxidase A	Homo sapiens	140-159
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	11c]clorgyline	97-111	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	11c]clorgyline	97-111	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Clorgyline	113-116	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Clorgyline	113-116	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Carbon-11	97-100	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Carbon-11	97-100	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Clorgyline	101-111	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Clorgyline	101-111	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	clg-d	161-166	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	clg-d	161-166	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	clg-d	299-304	monoamine oxidase A	Homo sapiens	55-74
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	clg-d	299-304	monoamine oxidase A	Homo sapiens	76-81
12439294-4	2002	A comparison was recently reported of the irreversible monoamine oxidase A (MAO A) radiotracers [11C]clorgyline (CLG) and deuterium-substituted [11C]clorgyline (CLG-D) in the human brain using region of interest (ROI) analysis in which the authors observed an unexpected loss of image contrast with CLG-D compared with CLG.	Clorgyline	161-164	monoamine oxidase A	Homo sapiens	76-81
12110326-0	2002	Synthesis and biological evaluation of MAO-A selective 1,4-disubstituted-1,2,3,6-tetrahydropyridinyl substrates.	1,4-disubstituted-1,2,3,6-tetrahydropyridinyl	55-100	monoamine oxidase A	Homo sapiens	39-44
12206996-2	2002	TV3326 also inhibits monoamine oxidase (MAO)-A and -B, whereas its S-isomer, TV3279, lacks MAO inhibitory activity.	(N-propargyl-(3R) aminoindan-5-yl)-ethyl methyl carbamate	0-6	monoamine oxidase A	Homo sapiens	21-53
12110326-4	2002	Kinetic parameters and MAO-A selectivity indicate that 1-allyl- and 1-propyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine should be good candidates to develop a robust spectrophotometric-based assay that is selective for MAO-A.	1-allyl- and 1-propyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	55-127	monoamine oxidase A	Homo sapiens	23-28
12110326-4	2002	Kinetic parameters and MAO-A selectivity indicate that 1-allyl- and 1-propyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine should be good candidates to develop a robust spectrophotometric-based assay that is selective for MAO-A.	1-allyl- and 1-propyl-4-(1-methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	55-127	monoamine oxidase A	Homo sapiens	227-232
12170473-2	2002	METHODS: The MAO-A gene EcoRV polymorphism was detected with PCR-RFLP method in 110 PD patients and 182 healthy controls, furthermore, statistical analysis was performed to investigate association between EcoR V polymorphism and PD onset.	ecor v	205-211	monoamine oxidase A	Homo sapiens	13-18
12131599-3	2002	A randomized placebo-controlled, double-blind multi-site trial of moclobemide, a reversible inhibitor of monoamine oxidase A, was undertaken with 390 subjects.	Moclobemide	66-77	monoamine oxidase A	Homo sapiens	105-124
12183115-4	2002	Both MAO A and B can be imaged and quantified in the living human brain using positron emission tomography (PET) and radiotracers labeled with carbon-11.	Carbon-11	143-152	monoamine oxidase A	Homo sapiens	5-10
11956220-1	2002	Monoamine oxidases (MAO) A and B deaminate a number of biogenic amines.	Amines	64-70	monoamine oxidase A	Homo sapiens	0-32
12473970-5	2002	Transdermal delivery of selegiline bypasses first-pass metabolism and avoids impairment of the gastrointestinal barrier provided by MAO-A of the gastrointestinal mucosa.	Selegiline	24-34	monoamine oxidase A	Homo sapiens	132-137
12163988-0	2002	Moclobemide response in depressed patients: association study with a functional polymorphism in the monoamine oxidase A promoter.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	100-119
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Lysine	114-117	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tryptophan	123-126	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	132-135	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Lysine	114-117	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	132-135	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Lysine	209-212	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Lysine	209-212	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tryptophan	218-221	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tryptophan	218-221	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tryptophan	123-126	monoamine oxidase A	Homo sapiens	61-72
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-66
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-72
12036014-2	2002	Among them, 5-[4-(2-iodobenzyloxy)phenyl]-3-(cyanoethyl)-1,3,4-oxadiazole-2(3H)one (2-IBPO) was found to have high inhibitory potency and selectivity toward MAO-B (IC50=2.0 nM, MAO-A/MAO-B &gt;50000).	5-[4-(2-iodobenzyloxy)phenyl]-3-(cyanoethyl)-1,3,4-oxadiazole-2(3h)one	12-82	monoamine oxidase A	Homo sapiens	177-182
11861643-3	2002	We have recently generated 14 site-directed mutants of human MAO A and B, and we found that four key amino acids, Lys-305, Trp-397, Tyr-407, and Tyr-444, in MAO A and their corresponding amino acids in MAO B, Lys-296, Trp-388, Tyr-398, and Tyr-435, play important roles in MAO catalytic activity.	Tyrosine	145-148	monoamine oxidase A	Homo sapiens	61-66
11861643-4	2002	Based on the polyamine oxidase three-dimensional crystal structure, it is suggested that Lys-305, Trp-397, and Tyr-407 in MAO A and Lys-296, Trp-388, and Tyr-398 in MAO B may be involved in the non-covalent binding to FAD.	Lysine	89-92	monoamine oxidase A	Homo sapiens	122-127
11861643-4	2002	Based on the polyamine oxidase three-dimensional crystal structure, it is suggested that Lys-305, Trp-397, and Tyr-407 in MAO A and Lys-296, Trp-388, and Tyr-398 in MAO B may be involved in the non-covalent binding to FAD.	Tryptophan	98-101	monoamine oxidase A	Homo sapiens	122-127
11861643-4	2002	Based on the polyamine oxidase three-dimensional crystal structure, it is suggested that Lys-305, Trp-397, and Tyr-407 in MAO A and Lys-296, Trp-388, and Tyr-398 in MAO B may be involved in the non-covalent binding to FAD.	Tyrosine	111-114	monoamine oxidase A	Homo sapiens	122-127
11861643-5	2002	Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding.	Tyrosine	0-3	monoamine oxidase A	Homo sapiens	23-28
11861643-5	2002	Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding.	Tyrosine	12-15	monoamine oxidase A	Homo sapiens	23-28
11861643-5	2002	Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding.	Tyrosine	12-15	monoamine oxidase A	Homo sapiens	23-28
11861643-5	2002	Tyr-407 and Tyr-444 in MAO A (Tyr-398 and Tyr-435 in MAO B) may form an aromatic sandwich that stabilizes the substrate binding.	Tyrosine	12-15	monoamine oxidase A	Homo sapiens	23-28
11861643-6	2002	Asp-132 in MAO A (Asp-123 in MAO B) located at the entrance of the U-shaped substrate-binding site has no effect on MAO A nor MAO B catalytic activity.	Aspartic Acid	0-3	monoamine oxidase A	Homo sapiens	11-16
11861643-6	2002	Asp-132 in MAO A (Asp-123 in MAO B) located at the entrance of the U-shaped substrate-binding site has no effect on MAO A nor MAO B catalytic activity.	Aspartic Acid	18-21	monoamine oxidase A	Homo sapiens	11-16
12036014-2	2002	Among them, 5-[4-(2-iodobenzyloxy)phenyl]-3-(cyanoethyl)-1,3,4-oxadiazole-2(3H)one (2-IBPO) was found to have high inhibitory potency and selectivity toward MAO-B (IC50=2.0 nM, MAO-A/MAO-B &gt;50000).	2-ibpo	84-90	monoamine oxidase A	Homo sapiens	177-182
12017403-2	2002	In vitro studies have suggested that sumatriptan is metabolized primarily by the monoamine oxidase-A isozyme and not by CYP3A4.	Sumatriptan	37-48	monoamine oxidase A	Homo sapiens	81-100
11999916-1	2002	Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	41-60
11999916-1	2002	Moclobemide is a specific and reversible monoamine oxidase-A (MAO-A) inhibitor.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	62-67
11911838-0	2002	Phentermine inhibition of recombinant human liver monoamine oxidases A and B.	Phentermine	0-11	monoamine oxidase A	Homo sapiens	50-76
11881986-0	2002	3-(1H-Pyrrol-1-yl)-2-oxazolidinones as reversible, highly potent, and selective inhibitors of monoamine oxidase type A.	3-(1h-pyrrol-1-yl)-2-oxazolidinones	0-35	monoamine oxidase A	Homo sapiens	94-118
11881986-1	2002	3-(1H-Pyrrol-1-yl)-2-oxazolidinones 1aminus signi have been synthesized as pyrrole analogues of toloxatone (Humoryl), an antidepressant agent belonging to the 3-phenyl-2-oxazolidinone class, and their monoamine oxidase (MAO) type A and B inhibitory activities have been evaluated.	3-(1h-pyrrol-1-yl)-2-oxazolidinones	0-35	monoamine oxidase A	Homo sapiens	201-237
11881986-1	2002	3-(1H-Pyrrol-1-yl)-2-oxazolidinones 1aminus signi have been synthesized as pyrrole analogues of toloxatone (Humoryl), an antidepressant agent belonging to the 3-phenyl-2-oxazolidinone class, and their monoamine oxidase (MAO) type A and B inhibitory activities have been evaluated.	toloxatone	96-106	monoamine oxidase A	Homo sapiens	201-237
11911838-2	2002	Since there are known differences between rats and humans in substrate and inhibitor specificities of MAOs, the interactions of phentermine with recombinant human purified preparations of MAO A and MAO B were determined.	Phentermine	128-139	monoamine oxidase A	Homo sapiens	188-193
11911838-3	2002	Human MAO A was competitively inhibited by phentermine with a K(I) value of 498+/-60 microM, a value approximately 6-fold weaker than that observed for the rat enzyme.	Phentermine	43-54	monoamine oxidase A	Homo sapiens	6-11
11911838-6	2002	Difference absorption spectral studies showed similar perturbations of the covalent FAD moieties of both human MAO A and MAO B, which suggests a similar mode of binding in both enzymes.	Flavin-Adenine Dinucleotide	84-87	monoamine oxidase A	Homo sapiens	111-116
11911838-7	2002	These data suggest that phentermine inhibition of human MAO A (or of MAO B) is too weak to be of pharmacological relevance.	Phentermine	24-35	monoamine oxidase A	Homo sapiens	56-61
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Fluvoxamine	177-188	monoamine oxidase A	Homo sapiens	66-85
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Fluvoxamine	177-188	monoamine oxidase A	Homo sapiens	87-91
12057029-1	2002	The aim of the present study was to test a possible effect of the monoamine oxidase A (MAOA) and serotonin receptor 2A (5-HT-2A) gene variants on the antidepressant activity of fluvoxamine and paroxetine in a sample of major (n = 248) and bipolar (n = 195) depressives, with or without psychotic features.	Paroxetine	193-203	monoamine oxidase A	Homo sapiens	66-85
11889496-0	2002	Ovarian steroid regulation of monoamine oxidase-A and -B mRNAs in the macaque dorsal raphe and hypothalamic nuclei.	Steroids	8-15	monoamine oxidase A	Homo sapiens	30-56
11889496-5	2002	OBJECTIVES: We questioned the effect of ovarian steroid hormones on MAO-A and MAO-B mRNA expression in the dorsal raphe nucleus and hypothalamus using in situ hybridization in non-human primates.	Steroids	48-55	monoamine oxidase A	Homo sapiens	68-73
11889496-14	2002	CONCLUSIONS: Ovarian steroids decreased MAO-A, but not B, in the raphe nucleus.	Steroids	21-29	monoamine oxidase A	Homo sapiens	40-45
11801236-5	2002	Among the reversible inhibitors of monoamine oxidase A, brofaromine may also be an effective drug, while moclobemide appears to be less potent.	brofaromine	56-67	monoamine oxidase A	Homo sapiens	35-54
12188024-0	2002	Charge-transfer interactions in the inhibition of MAO-A by phenylisopropylamines--a QSAR study.	phenylisopropylamines--a	59-83	monoamine oxidase A	Homo sapiens	50-55
12188024-1	2002	The HOMO energies and the charges on the aromatic carbons of two sets of MAO-A-inhibiting phenylisopropylamines, one containing 4-amino substituents, were calculated by the AM1 method, in order to evaluate the importance of charge-transfer interactions between drug and enzyme.	Carbon	50-57	monoamine oxidase A	Homo sapiens	73-78
12188024-1	2002	The HOMO energies and the charges on the aromatic carbons of two sets of MAO-A-inhibiting phenylisopropylamines, one containing 4-amino substituents, were calculated by the AM1 method, in order to evaluate the importance of charge-transfer interactions between drug and enzyme.	Amphetamine	90-111	monoamine oxidase A	Homo sapiens	73-78
11945082-1	2002	A feature of pre-eclampsia is that circulating levels of maternal serotonin (5-hydroxytryptamine) are elevated and placental monoamine oxidase-A (MAO-A) activity, the major factor in the regulation of serotonin levels in pregnancy, is reduced.	Serotonin	201-210	monoamine oxidase A	Homo sapiens	125-144
11945082-1	2002	A feature of pre-eclampsia is that circulating levels of maternal serotonin (5-hydroxytryptamine) are elevated and placental monoamine oxidase-A (MAO-A) activity, the major factor in the regulation of serotonin levels in pregnancy, is reduced.	Serotonin	201-210	monoamine oxidase A	Homo sapiens	146-151
11945082-2	2002	It is not known whether this is due to a reduced MAO-A protein content or a reduced catalytic turnover of the serotonin by MAO-A; this question has been addressed in the present work.	Serotonin	110-119	monoamine oxidase A	Homo sapiens	123-128
11812236-6	2002	The amino termini of both P. pastoris- and S. cerevisiae-expressed MAO-A are acetylated on the N-terminal methionine.	Methionine	106-116	monoamine oxidase A	Homo sapiens	67-72
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	phenethylamine	153-167	monoamine oxidase A	Homo sapiens	61-66
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	phenethylamine	153-167	monoamine oxidase A	Homo sapiens	115-120
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	p-cf(3)-benzylamine	169-188	monoamine oxidase A	Homo sapiens	61-66
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	p-cf(3)-benzylamine	169-188	monoamine oxidase A	Homo sapiens	115-120
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Dopamine	190-198	monoamine oxidase A	Homo sapiens	61-66
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Dopamine	190-198	monoamine oxidase A	Homo sapiens	115-120
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Serotonin	200-209	monoamine oxidase A	Homo sapiens	61-66
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Serotonin	200-209	monoamine oxidase A	Homo sapiens	115-120
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Kynuramine	215-225	monoamine oxidase A	Homo sapiens	61-66
11812236-7	2002	The steady-state kinetic properties of P. pastoris-expressed MAO-A are similar to those of S. cerevisiae-expressed MAO-A using the following substrates: phenethylamine, p-CF(3)-benzylamine, dopamine, serotonin, and kynuramine.	Kynuramine	215-225	monoamine oxidase A	Homo sapiens	115-120
11801236-5	2002	Among the reversible inhibitors of monoamine oxidase A, brofaromine may also be an effective drug, while moclobemide appears to be less potent.	Moclobemide	105-116	monoamine oxidase A	Homo sapiens	35-54
11739617-0	2001	Non-MAO A binding of clorgyline in white matter in human brain.	Clorgyline	21-31	monoamine oxidase A	Homo sapiens	4-9
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Amines	84-90	monoamine oxidase A	Homo sapiens	0-19
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Amines	84-90	monoamine oxidase A	Homo sapiens	21-26
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Dopamine	101-109	monoamine oxidase A	Homo sapiens	0-19
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Dopamine	101-109	monoamine oxidase A	Homo sapiens	21-26
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Norepinephrine	111-125	monoamine oxidase A	Homo sapiens	0-19
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Norepinephrine	111-125	monoamine oxidase A	Homo sapiens	21-26
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Serotonin	130-139	monoamine oxidase A	Homo sapiens	0-19
12140786-1	2002	Monoamine oxidase A (MAO A) is located on the X chromosome and metabolizes biogenic amines including dopamine, norepinephrine and serotonin.	Serotonin	130-139	monoamine oxidase A	Homo sapiens	21-26
12190330-11	2002	Sumatriptan is metabolised by monoamine oxidase (MAO; predominantly the A isozyme, MAO-A) to an inactive metabolite.	Sumatriptan	0-11	monoamine oxidase A	Homo sapiens	83-88
12190330-12	2002	Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated.	Moclobemide	41-52	monoamine oxidase A	Homo sapiens	24-29
12190330-12	2002	Coadministration with a MAO-A inhibitor, moclobemide, leads to a significant increase in sumatriptan plasma concentrations and is contraindicated.	Sumatriptan	89-100	monoamine oxidase A	Homo sapiens	24-29
11840311-7	2002	Apparent Km and Vmax of S-citalopram biotransformation in human frontal cortex by monoamine oxidase B were found to be 266 microM and 6.0 pmol min(-1) mg(-1) protein and by monoamine oxidase A 856 microM and 6.4 pmol min(-1) mg(-1) protein, respectively.	Citalopram	24-36	monoamine oxidase A	Homo sapiens	173-192
11732903-0	2001	Loss of serotonin oxidation as a component of the altered substrate specificity in the Y444F mutant of recombinant human liver MAO A.	Serotonin	8-17	monoamine oxidase A	Homo sapiens	127-132
11732903-2	2001	All mutant enzymes were expressed and exhibited lower specific activities as compared to WT MAO A using kynuramine as substrate.	Kynuramine	104-114	monoamine oxidase A	Homo sapiens	92-97
11732903-5	2001	Both mutant enzymes are irreversibly inhibited by the MAO A inhibitor clorgyline and exhibit binding stoichiometries of 0.54 (Y407F) and 0.95 (Y444F) as compared to 1.05 for WT MAO A.	Clorgyline	70-80	monoamine oxidase A	Homo sapiens	54-59
11732903-5	2001	Both mutant enzymes are irreversibly inhibited by the MAO A inhibitor clorgyline and exhibit binding stoichiometries of 0.54 (Y407F) and 0.95 (Y444F) as compared to 1.05 for WT MAO A.	Clorgyline	70-80	monoamine oxidase A	Homo sapiens	177-182
11732903-6	2001	Y444F MAO A oxidizes kynuramine with a k(cat) &lt;2% of WT enzyme and is greater than 100-fold slower in catalyzing the oxidation of phenylethylamine or of serotonin.	Kynuramine	21-31	monoamine oxidase A	Homo sapiens	6-11
11732903-6	2001	Y444F MAO A oxidizes kynuramine with a k(cat) &lt;2% of WT enzyme and is greater than 100-fold slower in catalyzing the oxidation of phenylethylamine or of serotonin.	Phenethylamines	133-149	monoamine oxidase A	Homo sapiens	6-11
11732903-6	2001	Y444F MAO A oxidizes kynuramine with a k(cat) &lt;2% of WT enzyme and is greater than 100-fold slower in catalyzing the oxidation of phenylethylamine or of serotonin.	Serotonin	156-165	monoamine oxidase A	Homo sapiens	6-11
11732903-7	2001	In contrast, Y444F MAO A oxidizes p-CF(3)-benzylamine at a rate 25% that of WT enzyme.	p-cf(3)-benzylamine	34-53	monoamine oxidase A	Homo sapiens	19-24
11732903-8	2001	Steady state and reductive half-reaction stopped-flow data using a series of para-substituted benzylamine analogues show Y444F MAO A exhibits quantitative structure activity relationships (QSAR) properties on analogue binding and rates of substrate oxidation very similar to that exhibited by the WT enzyme (Miller and Edmondson (1999) Biochemistry 38, 13670): log K(d) = -(0.37 +/- ()()0.07)V(W)(x0.1) - 4.5 +/- 0.1; log k(red) = +(2.43 +/- 0.19)sigma + 0.17 +/- 0.05.	para-substituted benzylamine	77-105	monoamine oxidase A	Homo sapiens	127-132
11732903-9	2001	The Y444F MAO A mutant also exhibits similar QSAR properties on the binding of phenylalkyl side chain amine analogues as WT enzyme: log K(i) = (4.37 +/- 0.51)E(S) + 1.21 +/- 0.77.	Amines	102-107	monoamine oxidase A	Homo sapiens	10-15
11732903-10	2001	These data show that mutation of Y444F in MAO A results in a mutant that has lost its ability to efficiently oxidize serotonin (its physiological substrate) but, however, exhibits unaltered quantitative structure-activity parameters in the binding and rate of benzylamine analogues.	Serotonin	117-126	monoamine oxidase A	Homo sapiens	42-47
11732903-10	2001	These data show that mutation of Y444F in MAO A results in a mutant that has lost its ability to efficiently oxidize serotonin (its physiological substrate) but, however, exhibits unaltered quantitative structure-activity parameters in the binding and rate of benzylamine analogues.	benzylamine	260-271	monoamine oxidase A	Homo sapiens	42-47
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	43-60
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	62-67
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	146-151
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Carbon-11	97-106	monoamine oxidase A	Homo sapiens	43-60
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Carbon-11	97-106	monoamine oxidase A	Homo sapiens	62-67
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Carbon-11	108-112	monoamine oxidase A	Homo sapiens	43-60
11739617-1	2001	Clorgyline is an irreversible inhibitor of monoamine oxidase (MAO A) which has been labeled with carbon-11 (C-11) and used to measure human brain MAO A with positron emission tomography (PET).	Carbon-11	108-112	monoamine oxidase A	Homo sapiens	62-67
11739617-5	2001	The percentages of the total binding attributable to MAO A is largest for the thalamus and smallest for the white matter and this is clearly seen in PET images with [11C]clorgyline-D2.	clorgyline-d2	170-183	monoamine oxidase A	Homo sapiens	53-58
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	Deuterium	5-14	monoamine oxidase A	Homo sapiens	67-72
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	Deuterium	5-14	monoamine oxidase A	Homo sapiens	138-143
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	[11c]clorgyline	27-42	monoamine oxidase A	Homo sapiens	67-72
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	[11c]clorgyline	27-42	monoamine oxidase A	Homo sapiens	138-143
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	Clorgyline	32-42	monoamine oxidase A	Homo sapiens	67-72
11739617-6	2001	Thus deuterium-substituted [11C]clorgyline selectively reduces the MAO A binding component of clorgyline in the human brain revealing non-MAO A binding which is most apparent in the white matter.	Clorgyline	32-42	monoamine oxidase A	Homo sapiens	138-143
11761322-1	2001	The midpoint potentials for the reduction of the cysteinyl-flavin adenine dinucleotide (FAD) in monoamine oxidases (MAO) A and B in the absence and presence of ligands have been determined.	cysteinyl-flavin adenine dinucleotide	49-86	monoamine oxidase A	Homo sapiens	96-128
11761322-1	2001	The midpoint potentials for the reduction of the cysteinyl-flavin adenine dinucleotide (FAD) in monoamine oxidases (MAO) A and B in the absence and presence of ligands have been determined.	Flavin-Adenine Dinucleotide	88-91	monoamine oxidase A	Homo sapiens	96-128
11761322-3	2001	The midpoint potentials for the oxidized/semiquinone and semiquinone/reduced couples were -159+/-4 mV and -262+/-3 mV for MAO A and -167+/-4 mV and -275+/-3 mV for MAO B.	semiquinone	41-52	monoamine oxidase A	Homo sapiens	122-127
11761328-4	2001	Current knowledge on the mechanism of covalent flavin attachment is discussed based on studies on the 8alpha-S-cysteinylFAD of monoamine oxidases A and B, as well as studies on other flavoenzymes.	4,6-dinitro-o-cresol	47-53	monoamine oxidase A	Homo sapiens	127-153
11702062-4	2001	In addition to identifying both the phenotype and the associated mutation found by Brunner et al., we also wished to test the hypothesis that mutations elsewhere in the MAO-A gene could cause the low intelligence quotient/personality disorder phenotype associated with low urinary catecholamine degradation products.	Catecholamines	281-294	monoamine oxidase A	Homo sapiens	169-174
11600577-10	2001	Double labeling with an antiserum against chromogranin A showed that MAO-A was actually contained in chromaffin cells.	chromaffin	101-111	monoamine oxidase A	Homo sapiens	69-74
11600577-13	2001	Our data also indicate that 5-HT is metabolized by MAO-A located in intracortical chromaffin cells.	chromaffin	82-92	monoamine oxidase A	Homo sapiens	51-56
11578898-1	2001	[11C]Clorgyline selectively binds to MAO A in the human brain.	Carbon-11	1-4	monoamine oxidase A	Homo sapiens	37-42
11578898-1	2001	[11C]Clorgyline selectively binds to MAO A in the human brain.	Clorgyline	5-15	monoamine oxidase A	Homo sapiens	37-42
11478921-8	2001	In contrast to vinpocetine, the selective MAO-A inhibitor, clorgyline, increases DA and decreases DOPAC formation.	Clorgyline	59-69	monoamine oxidase A	Homo sapiens	42-47
11478921-8	2001	In contrast to vinpocetine, the selective MAO-A inhibitor, clorgyline, increases DA and decreases DOPAC formation.	amsonic acid	81-83	monoamine oxidase A	Homo sapiens	42-47
11478921-8	2001	In contrast to vinpocetine, the selective MAO-A inhibitor, clorgyline, increases DA and decreases DOPAC formation.	3,4-Dihydroxyphenylacetic Acid	98-103	monoamine oxidase A	Homo sapiens	42-47
11430877-3	2001	However, alpha-MeHA inhibited MAO-A more potently than MAO-B at high concentrations in all three species.	alpha-methylhistamine	9-19	monoamine oxidase A	Homo sapiens	30-35
11430877-5	2001	In contrast, rat, monkey and human brain MAO-B activities were inhibited by thioperamide, with respective K(i) values of 174.6, 8.2 and 10.8 microM, more potently than MAO-A activity.	thioperamide	76-88	monoamine oxidase A	Homo sapiens	168-173
11445194-7	2001	Following acute treatment, igmesine lacked activity for monoamine oxidase (MAO) A or B (IC(50)&gt;10 microM).	igmesine	27-35	monoamine oxidase A	Homo sapiens	56-81
11453892-14	2001	CONCLUSIONS: These results suggest that propranolol increases plasma concentrations of rizatriptan by inhibiting monoamine oxidase-A.	Propranolol	40-51	monoamine oxidase A	Homo sapiens	113-132
11453892-14	2001	CONCLUSIONS: These results suggest that propranolol increases plasma concentrations of rizatriptan by inhibiting monoamine oxidase-A.	rizatriptan	87-98	monoamine oxidase A	Homo sapiens	113-132
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	cupric ion	0-4	monoamine oxidase A	Homo sapiens	74-93
11465638-1	2001	RATIONALE AND OBJECTIVES: We tested the hypothesis that the selective reversible MAO-A inhibitor moclobemide has a specific therapeutic effect on erectile dysfunction independent of its antidepressive properties.	Moclobemide	97-108	monoamine oxidase A	Homo sapiens	81-86
11422001-0	2001	Effect of MAO-A inhibition on the pharmacokinetics of almotriptan, an antimigraine agent in humans.	almotriptan	54-65	monoamine oxidase A	Homo sapiens	10-15
11422001-1	2001	AIMS: To assess the effect of a reversible MAO-A inhibitor, moclobemide, on the single-dose pharmacokinetics of almotriptan and assess the clinical consequences of any interaction.	Moclobemide	60-71	monoamine oxidase A	Homo sapiens	43-48
11422001-1	2001	AIMS: To assess the effect of a reversible MAO-A inhibitor, moclobemide, on the single-dose pharmacokinetics of almotriptan and assess the clinical consequences of any interaction.	almotriptan	112-123	monoamine oxidase A	Homo sapiens	43-48
11481866-8	2001	In vivo microdialysis studies showed that the irreversible monoamine oxidase A inhibitor clorgyline and the irreversible monoamine oxidase B inhibitor selegiline induced a mild increase and no increase in extracellular serotonin, respectively.	Clorgyline	89-99	monoamine oxidase A	Homo sapiens	59-78
11336106-2	2001	Because linezolid also competitively inhibits human monoamine oxidase-A (MAO-A; Ki = 55 microM), we monitored its effects on the cardiovascular responses to tyramine and amine cold remedies in comparison with standard MAO inhibitors.	Linezolid	8-17	monoamine oxidase A	Homo sapiens	52-71
11336106-2	2001	Because linezolid also competitively inhibits human monoamine oxidase-A (MAO-A; Ki = 55 microM), we monitored its effects on the cardiovascular responses to tyramine and amine cold remedies in comparison with standard MAO inhibitors.	Linezolid	8-17	monoamine oxidase A	Homo sapiens	73-78
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	phenethylamine	77-98	monoamine oxidase A	Homo sapiens	7-12
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Serotonin	138-147	monoamine oxidase A	Homo sapiens	7-12
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Serotonin	138-147	monoamine oxidase A	Homo sapiens	112-117
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Serotonin	138-147	monoamine oxidase A	Homo sapiens	112-117
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Serotonin	149-168	monoamine oxidase A	Homo sapiens	7-12
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	cupric ion	0-4	monoamine oxidase A	Homo sapiens	95-100
11331009-4	2001	Use of the fungal enzyme, MAO N, which lacks the covalent attachment to the flavin adenine dinucleotide (FAD) cofactor present in the mammalian forms MAO A and MAO B, has allowed for the isolation and further structural identification of the flavin-inactivator adduct.	Flavin-Adenine Dinucleotide	105-108	monoamine oxidase A	Homo sapiens	150-155
11400918-1	2001	In this study, we investigated whether treatment with L-deprenyl, a selective monoamine oxidase B (MAO B) inhibitor, also inhibits MAO A or the dopamine transporter in the human brain.	Selegiline	54-64	monoamine oxidase A	Homo sapiens	131-136
11309556-1	2001	BACKGROUND: Moclobemide, an antidepressant with selective monoamine oxidase-A inhibitory action, is known to be metabolized by CYP2C19 and is also reported to be an inhibitor of CYP2C19, CYP2D6, and CYP1A2.	Moclobemide	12-23	monoamine oxidase A	Homo sapiens	58-77
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Selegiline	200-208	monoamine oxidase A	Homo sapiens	7-12
11134050-5	2001	Mutant MAO A-I335Y became like MAO B, which exhibits a higher preference for beta-phenylethylamine than for the MAO A preferred substrate serotonin (5-hydroxytryptamine), and became more sensitive to deprenyl (MAO B-specific inhibitor) than to clorgyline (MAO A-specific inhibitor).	Clorgyline	244-254	monoamine oxidase A	Homo sapiens	7-12
11134050-9	2001	Our results indicate that Ile-335 in MAO A and Tyr-326 in MAO B play a critical role in determining substrate and inhibitor specificities in human MAO A and B.	Isoleucine	26-29	monoamine oxidase A	Homo sapiens	37-42
11134050-9	2001	Our results indicate that Ile-335 in MAO A and Tyr-326 in MAO B play a critical role in determining substrate and inhibitor specificities in human MAO A and B.	Isoleucine	26-29	monoamine oxidase A	Homo sapiens	147-158
11134050-9	2001	Our results indicate that Ile-335 in MAO A and Tyr-326 in MAO B play a critical role in determining substrate and inhibitor specificities in human MAO A and B.	Tyrosine	47-50	monoamine oxidase A	Homo sapiens	147-158
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	Flavin-Adenine Dinucleotide	30-57	monoamine oxidase A	Homo sapiens	74-93
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	Flavin-Adenine Dinucleotide	30-57	monoamine oxidase A	Homo sapiens	95-100
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	Flavin-Adenine Dinucleotide	59-62	monoamine oxidase A	Homo sapiens	74-93
11263670-8	2001	Cu2+ dose-dependently reduced flavin adenine dinucleotide (FAD)-dependent monoamine oxidase A (MAO-A) activity in a time-independent manner, with an IC50 value approximately 20 microM, whereas Mn2+ had no effect.	Flavin-Adenine Dinucleotide	59-62	monoamine oxidase A	Homo sapiens	95-100
11263670-10	2001	Cu2+ appears to exert an inhibitory effect on both NAD and FAD-dependent enzymes, but predominantly against the latter, including MAO-A and succinate dehydrogenase.	cupric ion	0-4	monoamine oxidase A	Homo sapiens	130-135
11294480-2	2001	This study examines the relation between baseline clinical characteristics in patients with posttraumatic stress disorder (PTSD) and response to treatment with a reversible monoamine oxidase A inhibitor (RIMA), brofaromine.	rima	204-208	monoamine oxidase A	Homo sapiens	173-192
11157075-1	2001	Deficiency in the monoamine degradation enzyme monoamine oxidase A (MAOA) or prenatal exposure to the monoamine uptake inhibitor cocaine alters behavior in humans and rodents, but the mechanisms are unclear.	monoamine	18-27	monoamine oxidase A	Homo sapiens	47-66
11157075-1	2001	Deficiency in the monoamine degradation enzyme monoamine oxidase A (MAOA) or prenatal exposure to the monoamine uptake inhibitor cocaine alters behavior in humans and rodents, but the mechanisms are unclear.	monoamine	18-27	monoamine oxidase A	Homo sapiens	68-72
11157075-1	2001	Deficiency in the monoamine degradation enzyme monoamine oxidase A (MAOA) or prenatal exposure to the monoamine uptake inhibitor cocaine alters behavior in humans and rodents, but the mechanisms are unclear.	monoamine	47-56	monoamine oxidase A	Homo sapiens	68-72
11157075-1	2001	Deficiency in the monoamine degradation enzyme monoamine oxidase A (MAOA) or prenatal exposure to the monoamine uptake inhibitor cocaine alters behavior in humans and rodents, but the mechanisms are unclear.	Cocaine	129-136	monoamine oxidase A	Homo sapiens	47-66
11294480-2	2001	This study examines the relation between baseline clinical characteristics in patients with posttraumatic stress disorder (PTSD) and response to treatment with a reversible monoamine oxidase A inhibitor (RIMA), brofaromine.	brofaromine	211-222	monoamine oxidase A	Homo sapiens	173-192
11195257-1	2001	A 6-week double-blind placebo-controlled trial was carried out to examine the efficacy and tolerability of moclobemide, a monoamine oxidase type A selective and reversible inhibitor, in the treatment of bulimia nervosa.	Moclobemide	107-118	monoamine oxidase A	Homo sapiens	122-146
11460889-9	2001	Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems.	Tryptamines	14-21	monoamine oxidase A	Homo sapiens	36-55
11460889-9	2001	Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems.	Moclobemide	73-84	monoamine oxidase A	Homo sapiens	36-55
11460889-9	2001	Inhibition of triptan metabolism by monoamine oxidase A inhibitors, e.g. moclobemide, may raise circulating triptan concentrations, although this does not yet seem to have led to reported clinical problems.	Tryptamines	108-115	monoamine oxidase A	Homo sapiens	36-55
11106506-0	2000	Structure-activity relations in the oxidation of phenethylamine analogues by recombinant human liver monoamine oxidase A.	phenethylamine	49-63	monoamine oxidase A	Homo sapiens	101-120
11106506-1	2000	The interaction of recombinant human liver monoamine oxidase A (MAO A) with a series of phenethylamine substrate analogues has been investigated by steady-state and stopped-flow kinetic techniques.	phenethylamine	88-102	monoamine oxidase A	Homo sapiens	43-62
11123983-2	2000	Most of the compounds acted preferentially on MAO-B with IC(50) values in the micromolar to low-nanomolar range; high inhibitory activities toward MAO-A were also measured for sulfonic acid esters.	sulfonic acid esters	176-196	monoamine oxidase A	Homo sapiens	147-152
11106506-1	2000	The interaction of recombinant human liver monoamine oxidase A (MAO A) with a series of phenethylamine substrate analogues has been investigated by steady-state and stopped-flow kinetic techniques.	phenethylamine	88-102	monoamine oxidase A	Homo sapiens	64-69
11106506-5	2000	Phenethylamine oxidation by MAO A can be described as the C-H bond cleavage step being rate limiting in catalysis and with oxygen reacting with the reduced enzyme-imine complex.	phenethylamine	0-14	monoamine oxidase A	Homo sapiens	28-33
11106506-5	2000	Phenethylamine oxidation by MAO A can be described as the C-H bond cleavage step being rate limiting in catalysis and with oxygen reacting with the reduced enzyme-imine complex.	Oxygen	123-129	monoamine oxidase A	Homo sapiens	28-33
11106506-5	2000	Phenethylamine oxidation by MAO A can be described as the C-H bond cleavage step being rate limiting in catalysis and with oxygen reacting with the reduced enzyme-imine complex.	Imines	163-168	monoamine oxidase A	Homo sapiens	28-33
11106506-7	2000	The binding affinities of a series of para-substituted phenethylamine analogues to MAO A show an increase in affinity of the deprotonated amine with increasing van der Waals volume of the substituent.	4-dichlorobenzene	38-42	monoamine oxidase A	Homo sapiens	83-88
11106506-7	2000	The binding affinities of a series of para-substituted phenethylamine analogues to MAO A show an increase in affinity of the deprotonated amine with increasing van der Waals volume of the substituent.	phenethylamine	55-69	monoamine oxidase A	Homo sapiens	83-88
11106506-7	2000	The binding affinities of a series of para-substituted phenethylamine analogues to MAO A show an increase in affinity of the deprotonated amine with increasing van der Waals volume of the substituent.	Amines	64-69	monoamine oxidase A	Homo sapiens	83-88
11106506-8	2000	The limiting rate of enzyme reduction decreases with increasing van der Waals volume of the substituent in a linear manner with no observable electronic contribution as observed previously with benzylamine reduction of MAO A [Miller, J. R., and Edmondson, D. E. (1999) Biochemistry 38, 13670-13683].	benzylamine	194-205	monoamine oxidase A	Homo sapiens	219-224
11106506-12	2000	These results suggest that the binding site for the aryl ring is identical for phenethylamine and for benzylamine analogues and that steric interactions of the alkyl side chain with the enzyme strongly contribute to the binding affinities of a series of reversible inhibitors of MAO A.	benzylamine	102-113	monoamine oxidase A	Homo sapiens	279-284
11115741-6	2000	Acute treatment with the monoamine oxidase A inhibitor clorgyline, acute moderate NE reduction (alpha-methyl-p-tyrosine treatment) or less severe depletion for 3 weeks have no effect on the gene expression of the transporters.	Clorgyline	55-65	monoamine oxidase A	Homo sapiens	25-44
10794685-1	2000	A series of indolylmethylamine derivatives were assayed toward MAO-A and MAO-B inhibition.	indolylmethylamine	12-30	monoamine oxidase A	Homo sapiens	63-68
10936214-0	2000	Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat.	Phenylalanine	0-3	monoamine oxidase A	Homo sapiens	31-56
10936214-0	2000	Phe(208) and Ile(199) in human monoamine oxidase A and B do not determine substrate and inhibitor specificities as in rat.	Isoleucine	13-16	monoamine oxidase A	Homo sapiens	31-56
10936214-3	2000	When compared with MAO A, MAO A-F208I showed a sixfold decrease in the specificity constant k(cat)/K(m) for both the MAO A- and the MAO B-preferring substrates 5-hydroxytryptamine and beta-phenylethylamine, respectively.	Serotonin	160-179	monoamine oxidase A	Homo sapiens	19-24
10936214-3	2000	When compared with MAO A, MAO A-F208I showed a sixfold decrease in the specificity constant k(cat)/K(m) for both the MAO A- and the MAO B-preferring substrates 5-hydroxytryptamine and beta-phenylethylamine, respectively.	Serotonin	160-179	monoamine oxidase A	Homo sapiens	26-31
10936214-3	2000	When compared with MAO A, MAO A-F208I showed a sixfold decrease in the specificity constant k(cat)/K(m) for both the MAO A- and the MAO B-preferring substrates 5-hydroxytryptamine and beta-phenylethylamine, respectively.	Serotonin	160-179	monoamine oxidase A	Homo sapiens	26-31
10936214-3	2000	When compared with MAO A, MAO A-F208I showed a sixfold decrease in the specificity constant k(cat)/K(m) for both the MAO A- and the MAO B-preferring substrates 5-hydroxytryptamine and beta-phenylethylamine, respectively.	phenethylamine	184-205	monoamine oxidase A	Homo sapiens	26-31
10936214-3	2000	When compared with MAO A, MAO A-F208I showed a sixfold decrease in the specificity constant k(cat)/K(m) for both the MAO A- and the MAO B-preferring substrates 5-hydroxytryptamine and beta-phenylethylamine, respectively.	phenethylamine	184-205	monoamine oxidase A	Homo sapiens	26-31
10936214-7	2000	The results suggest that Phe(208) in MAO A and amino acid segments 159-214 and 150-205 in MAO A and B, respectively, influence the enzyme active site.	Phenylalanine	25-28	monoamine oxidase A	Homo sapiens	37-42
10936214-7	2000	The results suggest that Phe(208) in MAO A and amino acid segments 159-214 and 150-205 in MAO A and B, respectively, influence the enzyme active site.	Phenylalanine	25-28	monoamine oxidase A	Homo sapiens	90-101
11081224-2	2000	Results of the biochemical analysis of the MAO A activity with serotonin or noradrenaline as substrates revealed a seasonal dependence of the substrate specific changes of this enzyme activity in hibernating animals.	Serotonin	63-72	monoamine oxidase A	Homo sapiens	43-48
11081224-2	2000	Results of the biochemical analysis of the MAO A activity with serotonin or noradrenaline as substrates revealed a seasonal dependence of the substrate specific changes of this enzyme activity in hibernating animals.	Norepinephrine	76-89	monoamine oxidase A	Homo sapiens	43-48
11030484-3	2000	METHOD: Ninety patients with chronic fatigue syndrome, diagnosed with our system that approximates CDC criteria, participated in a randomized, placebo-controlled, double-blind trial of 450 to 600 mg/day of moclobemide, a novel reversible inhibitor of monoamine oxidase-A.	Moclobemide	206-217	monoamine oxidase A	Homo sapiens	251-270
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Flavin-Adenine Dinucleotide	4-7	monoamine oxidase A	Homo sapiens	36-55
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Flavin-Adenine Dinucleotide	4-7	monoamine oxidase A	Homo sapiens	57-62
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Flavin-Adenine Dinucleotide	136-139	monoamine oxidase A	Homo sapiens	36-55
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Flavin-Adenine Dinucleotide	136-139	monoamine oxidase A	Homo sapiens	57-62
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Cysteine	152-155	monoamine oxidase A	Homo sapiens	36-55
10877844-1	2000	The FAD binding site of human liver monoamine oxidase A (MAO A) has been investigated by mutagenesis of the amino acid site of covalent FAD attachment (Cys-406) to an alanyl residue.	Cysteine	152-155	monoamine oxidase A	Homo sapiens	57-62
10877844-4	2000	C406A MAO A was expressed in a rib 5(-) strain of S. cerevisiae in the presence of 16 different riboflavin analogues.	Riboflavin	96-106	monoamine oxidase A	Homo sapiens	6-11
10877844-5	2000	Inactive apoC406A MAO A is formed by induction of the enzyme in the absence of riboflavin.	Riboflavin	79-89	monoamine oxidase A	Homo sapiens	18-23
10877844-8	2000	Analogues with substituents on the pyrimidine ring bind to C406A MAO A more weakly than normal FAD, suggesting specific interactions with the N(3) and N(1) positions.	pyrimidine	35-45	monoamine oxidase A	Homo sapiens	65-70
10831475-2	2000	Given the link between abnormalities in serotonergic neurotransmission and bipolar disorder, a candidate gene association approach was applied to study the involvement of the monoamine oxidase A (MAOA) gene, which codes for a catabolic enzyme of serotonin, in the susceptibility to bipolar disorder.	Serotonin	246-255	monoamine oxidase A	Homo sapiens	175-194
10831475-2	2000	Given the link between abnormalities in serotonergic neurotransmission and bipolar disorder, a candidate gene association approach was applied to study the involvement of the monoamine oxidase A (MAOA) gene, which codes for a catabolic enzyme of serotonin, in the susceptibility to bipolar disorder.	Serotonin	246-255	monoamine oxidase A	Homo sapiens	196-200
10794685-4	2000	Comparison of MAO-A and MAO-B CoMFA models showed that both the steric and electrostatic properties at the 5 position of the indole ring are determinant for MAO selectivity.	indole	125-131	monoamine oxidase A	Homo sapiens	14-19
10794685-5	2000	Computational simulations of the complex between this part of the ligand and Phe-208 of MAO-A or Ile-199 of MAO-B, experimentally identified as responsible for substrate selectivity, allowed us to further characterize the nature of these enzyme-inhibitor interactions.	Phenylalanine	77-80	monoamine oxidase A	Homo sapiens	88-93
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Homovanillic Acid	156-173	monoamine oxidase A	Homo sapiens	98-117
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Homovanillic Acid	156-173	monoamine oxidase A	Homo sapiens	119-123
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Homovanillic Acid	175-178	monoamine oxidase A	Homo sapiens	98-117
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Hydroxyindoleacetic Acid	181-207	monoamine oxidase A	Homo sapiens	98-117
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Methoxyhydroxyphenylglycol	222-253	monoamine oxidase A	Homo sapiens	98-117
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Methoxyhydroxyphenylglycol	222-253	monoamine oxidase A	Homo sapiens	119-123
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Methoxyhydroxyphenylglycol	255-259	monoamine oxidase A	Homo sapiens	98-117
10867119-2	2000	We investigated possible relationships between a putative functional promoter polymorphism in the monoamine oxidase A (MAOA) gene and CSF concentrations of homovanillic acid (HVA), 5-hydroxyindoleacetic acid (5-HIAA), and 3-methoxy-4-hydroxyphenylglycol (MHPG) in healthy volunteers (n=88).	Methoxyhydroxyphenylglycol	255-259	monoamine oxidase A	Homo sapiens	119-123
10867119-5	2000	The results suggest that MAOA genotypes may participate differentially in the regulation of dopamine and serotonin turnover rates under presumed steady state in the central nervous system.	Dopamine	92-100	monoamine oxidase A	Homo sapiens	25-29
10867119-5	2000	The results suggest that MAOA genotypes may participate differentially in the regulation of dopamine and serotonin turnover rates under presumed steady state in the central nervous system.	Serotonin	105-114	monoamine oxidase A	Homo sapiens	25-29
10643794-2	2000	The A form of monoamine oxidase (MAO-A) shares with MAO-B many characteristics that could be relevant to PD, especially proneuroxicant bioactivation and dopamine metabolism.	Dopamine	153-161	monoamine oxidase A	Homo sapiens	33-38
10760560-3	2000	Little is known on the immune effects of moclobemide, a reversible monoamine oxidase A inhibitor.	Moclobemide	41-52	monoamine oxidase A	Homo sapiens	67-86
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	eletriptan	0-10	monoamine oxidase A	Homo sapiens	127-144
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	eletriptan	0-10	monoamine oxidase A	Homo sapiens	146-151
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	naratriptan	12-23	monoamine oxidase A	Homo sapiens	127-144
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	naratriptan	12-23	monoamine oxidase A	Homo sapiens	146-151
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	rizatriptan	25-36	monoamine oxidase A	Homo sapiens	127-144
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	rizatriptan	25-36	monoamine oxidase A	Homo sapiens	146-151
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	zolmitriptan	41-53	monoamine oxidase A	Homo sapiens	127-144
11249525-2	2000	Eletriptan, naratriptan, rizatriptan and zolmitriptan display both increased stability to first pass metabolic inactivation by monoamine oxidase (MAO-A) and enhanced lipophilicity (4- to &gt; 120-fold more than sumatriptan), leading to increased oral bioavailability (2- to 5-fold more than the 14% reported for oral sumatriptan).	zolmitriptan	41-53	monoamine oxidase A	Homo sapiens	146-151
11249525-5	2000	Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels).	Fluvoxamine	191-202	monoamine oxidase A	Homo sapiens	83-88
11249525-5	2000	Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels).	quinilone	211-220	monoamine oxidase A	Homo sapiens	83-88
11249525-5	2000	Differences in the metabolic balance between hepatic P450 (especially CYP 1A2) and MAO-A inactivation lead to potential drug interactions for all TELs with the oral contraceptive pill (OCP), fluvoxamine and the quinilone antibiotics (with increased triptan levels).	Tryptamines	249-256	monoamine oxidase A	Homo sapiens	83-88
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	Propranolol	67-78	monoamine oxidase A	Homo sapiens	25-30
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	rizatriptan	83-94	monoamine oxidase A	Homo sapiens	25-30
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	rizatriptan	135-146	monoamine oxidase A	Homo sapiens	25-30
11249525-6	2000	An important but complex MAO-A interaction between a metabolite of propranolol and rizatriptan mandates dosage reduction (to 5 mg) for rizatriptan in the presence of propranolol treatment.	Propranolol	166-177	monoamine oxidase A	Homo sapiens	25-30
11249525-7	2000	There is also an absolute contraindication for the concurrent administration of the MAO-A inhibitor moclobemide and rizatriptan.	Moclobemide	100-111	monoamine oxidase A	Homo sapiens	84-89
10606764-0	2000	The FAD binding sites of human liver monoamine oxidases A and B: investigation of the role of flavin ribityl side chain hydroxyl groups in the covalent flavinylation reaction and catalytic activities.	4,6-dinitro-o-cresol	94-100	monoamine oxidase A	Homo sapiens	37-63
10606764-1	2000	The role of ribityl side chain hydroxyl groups of the flavin moiety in the covalent flavinylation reaction and catalytic activities of recombinant human liver monoamine oxidases (MAO) A and B have been investigated using the riboflavin analogue: N(10)-omega-hydroxypentyl-isoalloxazine.	4,6-dinitro-o-cresol	54-60	monoamine oxidase A	Homo sapiens	159-191
10606764-1	2000	The role of ribityl side chain hydroxyl groups of the flavin moiety in the covalent flavinylation reaction and catalytic activities of recombinant human liver monoamine oxidases (MAO) A and B have been investigated using the riboflavin analogue: N(10)-omega-hydroxypentyl-isoalloxazine.	Riboflavin	225-235	monoamine oxidase A	Homo sapiens	159-191
10606764-1	2000	The role of ribityl side chain hydroxyl groups of the flavin moiety in the covalent flavinylation reaction and catalytic activities of recombinant human liver monoamine oxidases (MAO) A and B have been investigated using the riboflavin analogue: N(10)-omega-hydroxypentyl-isoalloxazine.	n(10)-omega-hydroxypentyl-isoalloxazine	246-285	monoamine oxidase A	Homo sapiens	159-191
10606764-2	2000	Using a rib5 disrupted strain of Saccharomyces cerevisiae which is auxotrophic for riboflavin, MAO A and MAO B were expressed separately under control of a galactose inducible GAL10/CYC1 promoter in the presence of N(10)-omega-hydroxypentyl-isoalloxazine as the only available riboflavin analogue.	Galactose	156-165	monoamine oxidase A	Homo sapiens	95-100
10606764-4	2000	Catalytic activities, as monitored by kynuramine oxidation, are equivalent to (MAO A) or 2-fold greater (MAO B) than control preparations expressed in the presence of riboflavin.	Kynuramine	38-48	monoamine oxidase A	Homo sapiens	79-84
10649964-5	2000	Fractionation of extracts from flue-cured tobacco leaves led to the isolation of a competitive inhibitor of human MAO-A (K(i) = 3 microM) and MAO-B (K(i) = 6 microM), the structure of which could be assigned by classical spectroscopic analysis and confirmed by synthesis.	flue	31-35	monoamine oxidase A	Homo sapiens	114-119
11008880-2	2000	Among the various chemical classes of monoamine oxidase A inhibitors, phenyloxazolidinone represent one of the major series.	phenyloxazolidinone	70-89	monoamine oxidase A	Homo sapiens	38-57
10729753-5	2000	These findings suggest that the higher plasma-free serotonin levels observed in severe pre-eclampsia are mainly due to a reduction in MAO-A activity and not limited by the rate of serotonin uptake into the cells.	Serotonin	51-60	monoamine oxidase A	Homo sapiens	134-139
11061215-3	2000	Among various isatin analogues with nearllanar structure selective MAO B inhibitors fit to 3D box of 8.5x5.1x1.8 A, whereas 3D box of 14.2x5.6x1.8 A accommodates selective MAO A inhibitors.	Isatin	14-20	monoamine oxidase A	Homo sapiens	172-177
11061215-7	2000	3D-QSAR with CoMFA of isatin and pirlindole analogues of MAO A and B revealed differences in the models of MAO A and B.	Isatin	22-28	monoamine oxidase A	Homo sapiens	57-62
11008880-3	2000	The purpose of this paper is to review the experimental (X-ray diffraction, NMR, electronic absorption spectroscopy, lipophilicity studies) and theoretical (quantum chemistry, molecular mechanics, molecular dynamics) studies which have led to the description of the mode of interaction between phenyloxazolidinone inhibitors and the MAO-A enzyme.	phenyloxazolidinone	294-313	monoamine oxidase A	Homo sapiens	333-338
11061215-7	2000	3D-QSAR with CoMFA of isatin and pirlindole analogues of MAO A and B revealed differences in the models of MAO A and B.	pirlindole	33-43	monoamine oxidase A	Homo sapiens	57-62
11061215-7	2000	3D-QSAR with CoMFA of isatin and pirlindole analogues of MAO A and B revealed differences in the models of MAO A and B.	pirlindole	33-43	monoamine oxidase A	Homo sapiens	57-68
11139753-2	2000	This structural similarity explains in part the MAO-A metabolism of certain triptan drugs used in human medicine.	Tryptamines	76-83	monoamine oxidase A	Homo sapiens	48-53
23531135-6	2000	Inhibitors of MAO A are clinically useful to treat anxiety and depression since they are expected to increase both noradrenalin and serotonin levels in the brain.	Norepinephrine	115-127	monoamine oxidase A	Homo sapiens	14-19
23531135-6	2000	Inhibitors of MAO A are clinically useful to treat anxiety and depression since they are expected to increase both noradrenalin and serotonin levels in the brain.	Serotonin	132-141	monoamine oxidase A	Homo sapiens	14-19
10647887-7	1999	The uVNTR genotype may be a common genetic determinant of significant individual differences in oxidizing capacity for critical MAO-A substrates, which include serotonin, norepinephrine, and tyramine.	Norepinephrine	171-185	monoamine oxidase A	Homo sapiens	128-133
10571247-4	1999	Characterization of the enzyme isoforms by inhibition profiles of [14C]tyramine oxidation and Western and Northern blot analyses showed that mRNAs and proteins related to both monoamine oxidases A and B were expressed in adipocytes.	Carbon-14	67-70	monoamine oxidase A	Homo sapiens	176-202
10571247-4	1999	Characterization of the enzyme isoforms by inhibition profiles of [14C]tyramine oxidation and Western and Northern blot analyses showed that mRNAs and proteins related to both monoamine oxidases A and B were expressed in adipocytes.	Tyramine	71-79	monoamine oxidase A	Homo sapiens	176-202
10647887-7	1999	The uVNTR genotype may be a common genetic determinant of significant individual differences in oxidizing capacity for critical MAO-A substrates, which include serotonin, norepinephrine, and tyramine.	Serotonin	160-169	monoamine oxidase A	Homo sapiens	128-133
10647887-7	1999	The uVNTR genotype may be a common genetic determinant of significant individual differences in oxidizing capacity for critical MAO-A substrates, which include serotonin, norepinephrine, and tyramine.	Tyramine	191-199	monoamine oxidase A	Homo sapiens	128-133
10641793-2	1999	Clorgyline and deprenyl in fact represent archetypal MAO-A and MAO-B inhibitors respectively.	Selegiline	15-23	monoamine oxidase A	Homo sapiens	53-58
10641793-2	1999	Clorgyline and deprenyl in fact represent archetypal MAO-A and MAO-B inhibitors respectively.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	53-58
10521274-0	1999	Structure-activity relationships in the oxidation of para-substituted benzylamine analogues by recombinant human liver monoamine oxidase A.	benzylamine	70-81	monoamine oxidase A	Homo sapiens	119-138
10564737-2	1999	Monoamine oxidase A (MAO-A) is a key enzyme in the catabolism of biogenic amines and is expressed in brain noradrenergic neurons.	Amines	74-80	monoamine oxidase A	Homo sapiens	0-19
10564737-2	1999	Monoamine oxidase A (MAO-A) is a key enzyme in the catabolism of biogenic amines and is expressed in brain noradrenergic neurons.	Amines	74-80	monoamine oxidase A	Homo sapiens	21-26
10564737-3	1999	In this study, the binding of [3H]Ro41-1049 to MAO-A was measured by quantitative autoradiography at multiple levels along the rostral-caudal axis of the noradrenergic locus coeruleus from subjects with major depression and age- and postmortem interval-matched control subjects who were psychiatrically normal.	Tritium	31-33	monoamine oxidase A	Homo sapiens	47-52
10564737-4	1999	[3H]Ro41-1049 binding to MAO-A was unevenly distributed along the axis of the locus coeruleus, paralleling an uneven number of neuromelanin-containing (noradrenergic) neurons throughout the nucleus.	Tritium	1-3	monoamine oxidase A	Homo sapiens	25-30
10641793-3	1999	In the present study several ring-substituted deprenyl structural analogues were synthesized and alterations of selectivity and potency towards MAO-A and MAO-B activities were found.	Selegiline	46-54	monoamine oxidase A	Homo sapiens	144-149
10641793-5	1999	i.e. by attaching either an extra propargyl or a methyl group to the nitrogen atom, the potency of inhibition of MAO-B activity was drastically reduced and inhibition of MAO-A activity substantially increased.	Nitrogen	69-77	monoamine oxidase A	Homo sapiens	170-175
10525109-0	1999	Species-dependent differences in monoamine oxidase A and B-catalyzed oxidation of various C4 substituted 1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl derivatives.	1-methyl-4-phenyl-1,2,3, 6-tetrahydropyridinyl	105-151	monoamine oxidase A	Homo sapiens	33-52
10525109-1	1999	In an attempt to provide a better understanding of the scope and limitations of animal models used in some drug development programs and to further our understanding of potential metabolic bioactivation reactions, we have undertaken studies to profile the monoamine oxidase A and B (MAO-A and -B, respectively) activities in liver and brain mitochondrial preparations obtained from a variety of species using a series of 1-methyl-4-aryl-1,2,3, 6-tetrahydropyridinyl substrates.	methyl-4-aryl-1,2,3, 6-tetrahydropyridinyl	423-465	monoamine oxidase A	Homo sapiens	283-295
10521274-1	1999	Monoamine oxidase A (MAO A) plays a central role in the oxidation of amine neurotransmitters.	Amines	4-9	monoamine oxidase A	Homo sapiens	21-26
10521274-5	1999	The reaction rates and binding affinities of 17 para-substituted benzylamine analogues with purified MAO A were determined by steady state and stopped flow kinetic experiments.	benzylamine	65-76	monoamine oxidase A	Homo sapiens	101-106
10521274-13	1999	Quantitative structure-activity relationship (QSAR) analysis of dissociation constants shows that the binding of para-substituted benzylamine analogues to MAO A is best correlated with the van der Waals volume of the substituent, with larger substituents binding most tightly.	benzylamine	130-141	monoamine oxidase A	Homo sapiens	155-160
10438531-0	1999	Influence of flavin analogue structure on the catalytic activities and flavinylation reactions of recombinant human liver monoamine oxidases A and B.	4,6-dinitro-o-cresol	13-19	monoamine oxidase A	Homo sapiens	122-148
10438531-9	1999	A flavin peptide was isolated from MAO A containing 7-nor-7-bromo-FAD and was demonstrated to be covalently attached to Cys-406 by an 8alpha-S-thioether linkage by sequence analysis and by matrix-assisted laser desorption ionization time of flight mass spectroscopy.	flavin peptide	2-16	monoamine oxidase A	Homo sapiens	35-40
10504491-9	1999	MAO activity measured in intact cells showed that after accumulation into mesangial cells, [14C]serotonin was metabolized by MAO-A.	Carbon-14	92-95	monoamine oxidase A	Homo sapiens	125-130
10504491-9	1999	MAO activity measured in intact cells showed that after accumulation into mesangial cells, [14C]serotonin was metabolized by MAO-A.	Serotonin	96-105	monoamine oxidase A	Homo sapiens	125-130
10438531-4	1999	Expression levels of both MAO A and B are invariant with the presence or absence of riboflavin or riboflavin analogues in the growth medium.	Riboflavin	84-94	monoamine oxidase A	Homo sapiens	26-31
10438531-9	1999	A flavin peptide was isolated from MAO A containing 7-nor-7-bromo-FAD and was demonstrated to be covalently attached to Cys-406 by an 8alpha-S-thioether linkage by sequence analysis and by matrix-assisted laser desorption ionization time of flight mass spectroscopy.	7-nor-7-bromo-fad	52-69	monoamine oxidase A	Homo sapiens	35-40
10438531-9	1999	A flavin peptide was isolated from MAO A containing 7-nor-7-bromo-FAD and was demonstrated to be covalently attached to Cys-406 by an 8alpha-S-thioether linkage by sequence analysis and by matrix-assisted laser desorption ionization time of flight mass spectroscopy.	Cysteine	120-123	monoamine oxidase A	Homo sapiens	35-40
10438531-4	1999	Expression levels of both MAO A and B are invariant with the presence or absence of riboflavin or riboflavin analogues in the growth medium.	Riboflavin	98-108	monoamine oxidase A	Homo sapiens	26-31
10438531-9	1999	A flavin peptide was isolated from MAO A containing 7-nor-7-bromo-FAD and was demonstrated to be covalently attached to Cys-406 by an 8alpha-S-thioether linkage by sequence analysis and by matrix-assisted laser desorption ionization time of flight mass spectroscopy.	8alpha-s-thioether	134-152	monoamine oxidase A	Homo sapiens	35-40
10438531-10	1999	MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	8-nor-8-chlororiboflavin	45-69	monoamine oxidase A	Homo sapiens	0-5
10438531-6	1999	The selectivities of MAO A and MAO B for flavin analogue incorporation are found to be similar, although 8alpha-methylation of the flavin resulted in a higher level of catalytic activity for MAO B than for MAO A.	4,6-dinitro-o-cresol	41-47	monoamine oxidase A	Homo sapiens	21-26
10438531-10	1999	MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	4,6-dinitro-o-cresol	63-69	monoamine oxidase A	Homo sapiens	0-5
10438531-10	1999	MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	8-nor-8-s-thioflavin	140-160	monoamine oxidase A	Homo sapiens	0-5
10438531-10	1999	MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	quinone	229-236	monoamine oxidase A	Homo sapiens	0-5
10438531-10	1999	MAO A partially purified from yeast grown on 8-nor-8-chlororiboflavin exhibited an absorption spectrum indicating the covalent flavin is an 8-nor-8-S-thioflavin, suggesting a nucleophilic displacement mechanism that supports the quinone-methide mechanism previously suggested as a general mechanism for covalent flavin attachment.	4,6-dinitro-o-cresol	127-133	monoamine oxidase A	Homo sapiens	0-5
10438531-6	1999	The selectivities of MAO A and MAO B for flavin analogue incorporation are found to be similar, although 8alpha-methylation of the flavin resulted in a higher level of catalytic activity for MAO B than for MAO A.	4,6-dinitro-o-cresol	131-137	monoamine oxidase A	Homo sapiens	21-26
10438531-6	1999	The selectivities of MAO A and MAO B for flavin analogue incorporation are found to be similar, although 8alpha-methylation of the flavin resulted in a higher level of catalytic activity for MAO B than for MAO A.	4,6-dinitro-o-cresol	131-137	monoamine oxidase A	Homo sapiens	206-211
10417495-3	1999	Antidepressants such as the MAO-A inhibitor moclobemide may be used in patients with chronic headache syndromes.	Moclobemide	44-55	monoamine oxidase A	Homo sapiens	28-33
10417495-14	1999	CONCLUSIONS: Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A.	Moclobemide	13-24	monoamine oxidase A	Homo sapiens	129-134
10417495-14	1999	CONCLUSIONS: Moclobemide inhibited the metabolism of rizatriptan and its active N-monodesmethyl metabolite through inhibition of MAO-A.	rizatriptan	53-64	monoamine oxidase A	Homo sapiens	129-134
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmala Alkaloids	64-81	monoamine oxidase A	Homo sapiens	151-156
10482460-0	1999	A reversible monoamine oxidase A inhibitor, befloxatone: structural approach of its mechanism of action.	befloxatone	44-55	monoamine oxidase A	Homo sapiens	13-32
10482460-1	1999	Experimental and theoretical physico-chemical methods were used to investigate the interaction between several reversible monoamine oxidase A inhibitors in the oxazolidinone series and the active site of the enzyme.	Oxazolidinones	160-173	monoamine oxidase A	Homo sapiens	122-141
10482460-7	1999	As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site.	befloxatone	88-99	monoamine oxidase A	Homo sapiens	79-84
10482460-7	1999	As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site.	Flavin-Adenine Dinucleotide	152-179	monoamine oxidase A	Homo sapiens	79-84
10482460-7	1999	As a result of this work, a model is proposed for the reversible inhibition of MAO A by befloxatone via long distance, reversible interactions with the flavin adenine dinucleotide (FAD) cofactor of the enzyme and with specific amino acids of the active site.	Flavin-Adenine Dinucleotide	181-184	monoamine oxidase A	Homo sapiens	79-84
10553725-12	1999	Clorgyline</protein-id>, a selective inhibitor of monoamine oxidase A (MAO-A), markedly inhibited the microsomal formation of the indole ethyl alcohol derivative.	indole ethyl alcohol	130-150	monoamine oxidase A	Homo sapiens	50-69
10553725-12	1999	Clorgyline</protein-id>, a selective inhibitor of monoamine oxidase A (MAO-A), markedly inhibited the microsomal formation of the indole ethyl alcohol derivative.	indole ethyl alcohol	130-150	monoamine oxidase A	Homo sapiens	71-76
10553725-14	1999	Primary metabolism of zolmitriptan is dependent mainly on CYP1A2, whereas MAO-A is responsible for further metabolism of N-desmethyl-zolmitriptan, the active metabolite.	N-Desmethyl zolmitriptan	121-145	monoamine oxidase A	Homo sapiens	74-79
10553725-15	1999	Since the in vivo clearance of zolmitriptan is primarily dependent on metabolism, interactions with drugs that induce or inhibit CYP1A2 or MAO-A may be anticipated.	zolmitriptan	31-43	monoamine oxidase A	Homo sapiens	139-144
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmine	89-96	monoamine oxidase A	Homo sapiens	130-149
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmine	89-96	monoamine oxidase A	Homo sapiens	151-156
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmaline	101-110	monoamine oxidase A	Homo sapiens	130-149
10404423-2	1999	Such beverages are characterized by the presence of these three harmala alkaloids, where harmine and harmaline reversibly inhibit monoamine oxidase A (MAO-A) while tetrahydroharmine weakly inhibits the uptake of serotonin.	Harmaline	101-110	monoamine oxidase A	Homo sapiens	151-156
10359483-2	1999	The repeat number (3-5) of the MAOA polymorphism was assessed in 488 male subjects of German descent, a sample comprising 185 psychiatrically screened control subjects and 303 alcohol-dependent subjects including 59 alcoholics with antisocial personality disorder.	Alcohols	176-183	monoamine oxidase A	Homo sapiens	31-35
10498294-1	1999	Monoamine oxidase (MAO) A and B are mitochondrial enzymes involved in the oxidative deamination of endogenous and exogenous amines.	Amines	124-130	monoamine oxidase A	Homo sapiens	0-31
10498294-5	1999	Our results showed that cell incubation with tyramine (50 micromol/l) led to a time-dependent H2O2 generation which was fully inhibited by MAO A (clorgyline and RO 41-1049) and MAO B (selegiline and RO 19-6327) inhibitors.	Tyramine	45-53	monoamine oxidase A	Homo sapiens	139-144
10498294-5	1999	Our results showed that cell incubation with tyramine (50 micromol/l) led to a time-dependent H2O2 generation which was fully inhibited by MAO A (clorgyline and RO 41-1049) and MAO B (selegiline and RO 19-6327) inhibitors.	Hydrogen Peroxide	94-98	monoamine oxidase A	Homo sapiens	139-144
10498294-5	1999	Our results showed that cell incubation with tyramine (50 micromol/l) led to a time-dependent H2O2 generation which was fully inhibited by MAO A (clorgyline and RO 41-1049) and MAO B (selegiline and RO 19-6327) inhibitors.	Selegiline	184-194	monoamine oxidase A	Homo sapiens	139-144
10331110-5	1999	In this report, we use 110 nuclear OCD families to analyze the inheritance of variants of COMT and monoamine oxidase-A (MAOA), another gene modulating monoamine metabolism.	monoamine	99-108	monoamine oxidase A	Homo sapiens	120-124
10359483-5	1999	Our findings suggest that the low-activity 3-repeat allele of the MAOA promoter polymorphism confers increased susceptibility to antisocial behavior rather than alcohol dependence per se in alcohol-dependent males.	Alcohols	161-168	monoamine oxidase A	Homo sapiens	66-70
10334000-2	1999	Effects of 150-400 mg/day of moclobemide, a reversible monoamine oxidase A inhibitor, were studied in a 3-month open design in 10 MS patient with DSM-IV-diagnosed depression.	Moclobemide	29-40	monoamine oxidase A	Homo sapiens	55-74
10027835-7	1999	The data thus suggest that selective MAO-A inhibitors such as esuprone may be an interesting new approach for the treatment of epilepsy.	esuprone	62-70	monoamine oxidase A	Homo sapiens	37-42
16160936-1	1999	Synthelabo is developing befloxatone, a long-acting selective and reversible monoamine oxidase A (MAO-A) inhibitor, for the treatment of depression, social phobias and panic disorders.	befloxatone	25-36	monoamine oxidase A	Homo sapiens	77-96
16160936-1	1999	Synthelabo is developing befloxatone, a long-acting selective and reversible monoamine oxidase A (MAO-A) inhibitor, for the treatment of depression, social phobias and panic disorders.	befloxatone	25-36	monoamine oxidase A	Homo sapiens	98-103
16160936-10	1999	[11C]-befloxatone was evaluated and found to be an excellent ligand for the study of MAO-A by positron emission tomography.	[11c]-befloxatone	0-17	monoamine oxidase A	Homo sapiens	85-90
10335547-0	1999	MAOA: association and linkage studies with lithium responsive bipolar disorder.	Lithium	43-50	monoamine oxidase A	Homo sapiens	0-4
10063483-0	1999	Meta-analysis of the reversible inhibitors of monoamine oxidase type A moclobemide and brofaromine for the treatment of depression.	Moclobemide	71-82	monoamine oxidase A	Homo sapiens	46-70
10063483-1	1999	The reversible inhibitors of monoamine oxidase type A (RIMAs) are a newer group of antidepressants that have had much less impact on clinical psychopharmacology than another contemporary class of medications, the selective serotonin reuptake-inhibitors (SSRIs).	Serotonin	223-232	monoamine oxidase A	Homo sapiens	29-53
10333164-0	1999	Undesirable blood pressure changes under naturalistic treatment with moclobemide, a reversible MAO-A inhibitor--results of the drug utilization observation studies.	Moclobemide	69-80	monoamine oxidase A	Homo sapiens	95-100
10335547-5	1999	In this study, we investigated the role of MAOA in lithium responsive bipolar patients using association and linkage study designs.	Lithium	51-58	monoamine oxidase A	Homo sapiens	43-47
9878889-0	1999	Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer"s disease: mechanism of neuron death.	3,4-dihydroxyphenylglycolaldehyde	16-49	monoamine oxidase A	Homo sapiens	66-85
10050962-5	1999	When available, plasma samples were evaluated first for levels of 3-methoxy, 4-hydroxyphenolglycol (MHPG), a metabolite of norepinephrine which serves as the most sensitive index of MAO-A activity in humans.	Norepinephrine	123-137	monoamine oxidase A	Homo sapiens	182-187
10065374-0	1999	Benzylamine analog binding studies as probes of the substrate sites of monoamine oxidases A and B.	benzylamine	0-11	monoamine oxidase A	Homo sapiens	71-97
9878889-0	1999	Accumulation of 3,4-dihydroxyphenylglycolaldehyde, the neurotoxic monoamine oxidase A metabolite of norepinephrine, in locus ceruleus cell bodies in Alzheimer"s disease: mechanism of neuron death.	Norepinephrine	100-114	monoamine oxidase A	Homo sapiens	66-85
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	3,4-dihydroxyphenylglycolaldehyde	0-33	monoamine oxidase A	Homo sapiens	62-81
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	3,4-dihydroxyphenylglycolaldehyde	0-33	monoamine oxidase A	Homo sapiens	83-88
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	3,4-dihydroxyphenylglycolaldehyde	35-42	monoamine oxidase A	Homo sapiens	62-81
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	3,4-dihydroxyphenylglycolaldehyde	35-42	monoamine oxidase A	Homo sapiens	83-88
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	Norepinephrine	104-118	monoamine oxidase A	Homo sapiens	62-81
9878889-1	1999	3,4-Dihydroxyphenylglycolaldehyde (DOPEGAL) is the neurotoxic monoamine oxidase A (MAO-A) metabolite of norepinephrine (NE).	Norepinephrine	104-118	monoamine oxidase A	Homo sapiens	83-88
10591049-1	1999	A series of pirlindole analogues were tested as inhibitors of monoamine oxidase A and B.	pirlindole	12-22	monoamine oxidase A	Homo sapiens	62-87
10216976-2	1999	This method allowed the simultaneous determination of antidepressants belonging to different classes: tricyclic antidepressants (TADs), selective serotonin reuptake inhibitors (SSRIs) and selective inhibitors of monoamine oxidase A (IMAOs).	imaos	233-238	monoamine oxidase A	Homo sapiens	212-231
10410765-1	1999	Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	47-51
10410765-1	1999	Moclobemide, the first reversible inhibitor of MAOA (so-called RIMA) to become widely available for clinical use, is an effective and well-tolerated antidepressant.	rima	63-67	monoamine oxidase A	Homo sapiens	47-51
9987207-1	1999	OBJECTIVE: To determine the efficacy of substituting moclobemide, a reversible monoamine oxidase-A inhibitor, for fluoxetine to reverse fluoxetine-induced sexual dysfunction in patients with depression.	Moclobemide	53-64	monoamine oxidase A	Homo sapiens	79-98
11741212-1	1999	Benzazoles containing two or three nitrogen atoms were screened for their inhibitory activity toward monoamine oxidases MAO-A and MAO-B.	benzazoles	0-10	monoamine oxidase A	Homo sapiens	120-125
9829163-3	1998	While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction.	Phenelzine	67-77	monoamine oxidase A	Homo sapiens	320-339
10333984-1	1998	Clinical pharmacology studies of befloxatone, a new selective reversible inhibitor of monoamine oxidase-A (MAO-A), have addressed safety, with special emphasis on tyramine interactions, and have also investigated pharmacokinetics (PK) and pharmacodynamics in terms of both MAO-A inhibition (using 3,4-dihydroxyphenylglycol, DHPG, as a pharmacological activity marker) and effects on psychomotor and cognitive function, in young and elderly healthy volunteers.	befloxatone	33-44	monoamine oxidase A	Homo sapiens	86-105
10333984-1	1998	Clinical pharmacology studies of befloxatone, a new selective reversible inhibitor of monoamine oxidase-A (MAO-A), have addressed safety, with special emphasis on tyramine interactions, and have also investigated pharmacokinetics (PK) and pharmacodynamics in terms of both MAO-A inhibition (using 3,4-dihydroxyphenylglycol, DHPG, as a pharmacological activity marker) and effects on psychomotor and cognitive function, in young and elderly healthy volunteers.	befloxatone	33-44	monoamine oxidase A	Homo sapiens	107-112
10333984-1	1998	Clinical pharmacology studies of befloxatone, a new selective reversible inhibitor of monoamine oxidase-A (MAO-A), have addressed safety, with special emphasis on tyramine interactions, and have also investigated pharmacokinetics (PK) and pharmacodynamics in terms of both MAO-A inhibition (using 3,4-dihydroxyphenylglycol, DHPG, as a pharmacological activity marker) and effects on psychomotor and cognitive function, in young and elderly healthy volunteers.	befloxatone	33-44	monoamine oxidase A	Homo sapiens	273-278
9829163-3	1998	While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction.	Phenelzine	67-77	monoamine oxidase A	Homo sapiens	341-346
9829163-3	1998	While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction.	Tranylcypromine	82-97	monoamine oxidase A	Homo sapiens	320-339
9829163-3	1998	While the classical, nonselective and nonreversible MAOIs, such as phenelzine and tranylcypromine, are characterised by the risk of inducing a hypertensive crisis when dietary tyramine is ingested, the selective monoamine oxidase-B (MAO-B) inhibitor selegiline (deprenyl) and, even more so, the selective and reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide, are free from this potential interaction.	Tranylcypromine	82-97	monoamine oxidase A	Homo sapiens	341-346
9793841-5	1998	The inhibition of MAO by clorgyline and deprenyl by use of 5-HT, tyramine and PEA as substrates showed that the MAO-A inhibitor clorgyline was more effective than the MAO-B inhibitor deprenyl for both catfish tissues; a single form was present since inhibition by clorgyline or deprenyl with 1000 microM PEA showed single phase sigmoid curves.	Selegiline	40-48	monoamine oxidase A	Homo sapiens	112-117
9748356-5	1998	Thus, while most of the condensed pyridazines were reversible inhibitors of MAO-B with little or no MAO-A effects, the pyrimidine derivatives proved to be reversible and selective MAO-A inhibitors.	pyrimidine	119-129	monoamine oxidase A	Homo sapiens	180-185
9728902-0	1998	Cognitive performance in elderly subjects after a single dose of befloxatone, a new reversible selective monoamine oxidase A inhibitor.	befloxatone	65-76	monoamine oxidase A	Homo sapiens	105-124
9728902-4	1998	Befloxatone is a new antidepressant with a potent, selective, competitive, and reversible inhibitory activity on the A isoform of monoamine oxidase (MAO-A).	befloxatone	0-11	monoamine oxidase A	Homo sapiens	130-147
9728902-4	1998	Befloxatone is a new antidepressant with a potent, selective, competitive, and reversible inhibitory activity on the A isoform of monoamine oxidase (MAO-A).	befloxatone	0-11	monoamine oxidase A	Homo sapiens	149-154
9728902-8	1998	MAO-A inhibition was estimated by multiple titrations of 3,4-dihydrophenylglycol (DHPG) in plasma.	3,4-dihydrophenylglycol	57-80	monoamine oxidase A	Homo sapiens	0-5
9728902-8	1998	MAO-A inhibition was estimated by multiple titrations of 3,4-dihydrophenylglycol (DHPG) in plasma.	dhpg	82-86	monoamine oxidase A	Homo sapiens	0-5
9793841-5	1998	The inhibition of MAO by clorgyline and deprenyl by use of 5-HT, tyramine and PEA as substrates showed that the MAO-A inhibitor clorgyline was more effective than the MAO-B inhibitor deprenyl for both catfish tissues; a single form was present since inhibition by clorgyline or deprenyl with 1000 microM PEA showed single phase sigmoid curves.	Clorgyline	128-138	monoamine oxidase A	Homo sapiens	112-117
9793841-5	1998	The inhibition of MAO by clorgyline and deprenyl by use of 5-HT, tyramine and PEA as substrates showed that the MAO-A inhibitor clorgyline was more effective than the MAO-B inhibitor deprenyl for both catfish tissues; a single form was present since inhibition by clorgyline or deprenyl with 1000 microM PEA showed single phase sigmoid curves.	Clorgyline	128-138	monoamine oxidase A	Homo sapiens	112-117
9698084-8	1998	Monoamine oxidases (MAO) type A and B and aldehyde oxidase were identified as the probable enzymes involved in the formation of CIT-PROP from CIT, DCIT and DDCIT.	cit-prop	128-136	monoamine oxidase A	Homo sapiens	0-37
9704592-0	1998	Role of monoamine oxidase type A and B on the dopamine metabolism in discrete regions of the primate brain.	Dopamine	46-54	monoamine oxidase A	Homo sapiens	8-38
9704592-1	1998	The role of monoamine oxidase (MAO) type A and B on the metabolism of dopamine (DA) in discrete regions of the monkey brain was studied.	Dopamine	70-78	monoamine oxidase A	Homo sapiens	12-48
9704592-6	1998	Clorgyline administration resulted in MAO-A inhibition by more than 87% but failed to increase DA levels in any of the brain regions studied.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	38-43
9704873-1	1998	The onset of action (during the first 2 weeks of treatment) of moclobemide (450 mg/day), a reversible MAO-A inhibitor, was compared in a double-blind, multi-center trial with clomipramine (150 mg/day) on dimensional and global depressive symptoms in 124 hospitalized patients suffering from a major depressive episode according to DSM-III-R criteria and with blunted affect and retardation.	Moclobemide	63-74	monoamine oxidase A	Homo sapiens	102-107
9698084-8	1998	Monoamine oxidases (MAO) type A and B and aldehyde oxidase were identified as the probable enzymes involved in the formation of CIT-PROP from CIT, DCIT and DDCIT.	Citalopram	128-131	monoamine oxidase A	Homo sapiens	0-37
9698084-8	1998	Monoamine oxidases (MAO) type A and B and aldehyde oxidase were identified as the probable enzymes involved in the formation of CIT-PROP from CIT, DCIT and DDCIT.	dcit	147-151	monoamine oxidase A	Homo sapiens	0-37
9698084-8	1998	Monoamine oxidases (MAO) type A and B and aldehyde oxidase were identified as the probable enzymes involved in the formation of CIT-PROP from CIT, DCIT and DDCIT.	ddcit	156-161	monoamine oxidase A	Homo sapiens	0-37
9698084-9	1998	Indeed, the irreversible monoamine oxidase type A inhibitor clorgyline and the irreversible monoamine oxidase type B inhibitor selegiline (both at 0.5 microM in the incubation mixture) inhibited CIT-PROP formation, depending on the substrate, up to 70% and 88%, respectively.	Clorgyline	60-70	monoamine oxidase A	Homo sapiens	25-49
9698084-9	1998	Indeed, the irreversible monoamine oxidase type A inhibitor clorgyline and the irreversible monoamine oxidase type B inhibitor selegiline (both at 0.5 microM in the incubation mixture) inhibited CIT-PROP formation, depending on the substrate, up to 70% and 88%, respectively.	cit-prop	195-203	monoamine oxidase A	Homo sapiens	25-49
9622553-2	1998	1-Substituted phenoxathiin inhibitors containing no nitrogen that inhibit MAO A by binding it to a hydrophobic site.	phenoxathiin	14-26	monoamine oxidase A	Homo sapiens	74-79
9642149-1	1998	Monoamine oxidase (MAO), which exists in two forms (MAOA and MAOB), plays an important role in the oxidative metabolism of neurotransmitters such as dopamine, and has been implicated in the etiology of Parkinson"s disease (PD).	Dopamine	149-157	monoamine oxidase A	Homo sapiens	52-56
9603903-1	1998	Mitochondrial monoamine oxidases A and B (MAO A and MAO B) are ubiquitous homodimeric FAD-containing oxidases that catalyze the oxidation of biogenic amines.	Amines	150-156	monoamine oxidase A	Homo sapiens	42-47
9603903-4	1998	The experiments reported here show that both MAO A and MAO B contain a redox-active disulfide at the catalytic center.	Disulfides	84-93	monoamine oxidase A	Homo sapiens	45-50
9622553-3	1998	It is believed that a monoamine oxidase (MAO) inhibitor specific for MAO A, which is reversibly bound to this enzyme and displaceable by tyramine, will be an antidepressant which will not cause a rise in blood pressure when tyramine-containing foods are ingested.	Tyramine	137-145	monoamine oxidase A	Homo sapiens	69-74
9622553-3	1998	It is believed that a monoamine oxidase (MAO) inhibitor specific for MAO A, which is reversibly bound to this enzyme and displaceable by tyramine, will be an antidepressant which will not cause a rise in blood pressure when tyramine-containing foods are ingested.	Tyramine	224-232	monoamine oxidase A	Homo sapiens	69-74
9703624-4	1998	The administration of MAO a inhibitor pyrazidol promoted the increase in brain serotonin content, normalized brain catecholamine contents and demonstrated positive effect on the animal state.	pirlindole	38-47	monoamine oxidase A	Homo sapiens	22-27
9663810-22	1998	CONCLUSIONS: The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals.	Tyramine	33-41	monoamine oxidase A	Homo sapiens	113-118
9663810-22	1998	CONCLUSIONS: The potentiation of tyramine-evoked mydriasis by moclobemide is likely to reflect the inhibition of MAO-A activity in the iris, consistent with the activity of this enzyme in sympathetic nerve terminals.	Moclobemide	62-73	monoamine oxidase A	Homo sapiens	113-118
9871778-0	1998	Molecular lipophilicity potential by CLIP, a reliable tool for the description of the 3D distribution of lipophilicity: application to 3-phenyloxazolidin-2-one, a prototype series of reversible MAOA inhibitors.	3-Phenyl-2-oxazolidinone	135-159	monoamine oxidase A	Homo sapiens	194-198
9663810-24	1998	The effects of the two drugs on platelet MAO activity and plasma DHPG concentration are in agreement with previous reports and consistent with the relative selectivity of moclobemide for MAO-A and of selegiline for MAO-B.	Moclobemide	171-182	monoamine oxidase A	Homo sapiens	187-192
9682221-4	1998	The levels of MAo and B were assayed: MAO A showed a K(m) of 137.1 +/- 16.2 microM and a V(m) of 10.4 +/- 2.5 nmol mg-1 min-1 for serotonin; MAo B had a K(m) of 9.9 +/- 1.6 microM and V(m) of 4.3 +/- 1.1 nmol mg-1 min-1 for beta-phenylethylamine (mean +/- SE of seven hearts).	Serotonin	130-139	monoamine oxidase A	Homo sapiens	38-43
9682221-4	1998	The levels of MAo and B were assayed: MAO A showed a K(m) of 137.1 +/- 16.2 microM and a V(m) of 10.4 +/- 2.5 nmol mg-1 min-1 for serotonin; MAo B had a K(m) of 9.9 +/- 1.6 microM and V(m) of 4.3 +/- 1.1 nmol mg-1 min-1 for beta-phenylethylamine (mean +/- SE of seven hearts).	phenethylamine	224-245	monoamine oxidase A	Homo sapiens	38-43
9703624-4	1998	The administration of MAO a inhibitor pyrazidol promoted the increase in brain serotonin content, normalized brain catecholamine contents and demonstrated positive effect on the animal state.	Serotonin	79-88	monoamine oxidase A	Homo sapiens	22-27
9703624-4	1998	The administration of MAO a inhibitor pyrazidol promoted the increase in brain serotonin content, normalized brain catecholamine contents and demonstrated positive effect on the animal state.	Catecholamines	115-128	monoamine oxidase A	Homo sapiens	22-27
9730267-0	1998	The role of MAO-A and MAO-B in the metabolic degradation of noradrenaline in human arteries.	Norepinephrine	60-73	monoamine oxidase A	Homo sapiens	12-17
9730267-9	1998	Both clorgyline (a selective MAO-A inhibitor) and selegiline (a selective MAO-B inhibitor) reduced the formation of dihydroxyphenylglycol (DOPEG), DOMA and O-methylated-deaminated metabolites (OMDA), and increased that of normetanephrine (NMN).	Clorgyline	5-15	monoamine oxidase A	Homo sapiens	29-34
9730267-9	1998	Both clorgyline (a selective MAO-A inhibitor) and selegiline (a selective MAO-B inhibitor) reduced the formation of dihydroxyphenylglycol (DOPEG), DOMA and O-methylated-deaminated metabolites (OMDA), and increased that of normetanephrine (NMN).	Selegiline	50-60	monoamine oxidase A	Homo sapiens	29-34
9730267-9	1998	Both clorgyline (a selective MAO-A inhibitor) and selegiline (a selective MAO-B inhibitor) reduced the formation of dihydroxyphenylglycol (DOPEG), DOMA and O-methylated-deaminated metabolites (OMDA), and increased that of normetanephrine (NMN).	dihydroxyphenylglycol	116-137	monoamine oxidase A	Homo sapiens	29-34
9730267-12	1998	In conclusion, three major differences distinguish the metabolism of noradrenaline by human arteries from that observed in other species: (1) the large predominance of deamination over O-methylation; (2) the extremely high formation of DOMA; and (3) the relative lack of selectivity of clorgyline and selegiline for MAO-A and B, respectively.	Norepinephrine	69-82	monoamine oxidase A	Homo sapiens	316-327
9534836-1	1998	BACKGROUND: Moclobemide, a reversible inhibitor of monoamine oxidase A, previously has been reported to have efficacy in the treatment of social phobia.	Moclobemide	12-23	monoamine oxidase A	Homo sapiens	51-70
9579294-0	1998	The therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, in Parkinson"s disease.	Moclobemide	26-37	monoamine oxidase A	Homo sapiens	62-81
9579294-1	1998	In this open study, the therapeutic effect of moclobemide, a reversible selective monoamine oxidase A inhibitor, was tested in 20 patients with Parkinson"s disease who developed levodopa-induced motor response complications.	Moclobemide	46-57	monoamine oxidase A	Homo sapiens	82-101
9754371-19	1998	Inactivation of catecholamines is mediated by catechol-O-methyltransferase and by the monoamine oxidases A and B.	Catecholamines	16-30	monoamine oxidase A	Homo sapiens	86-112
9564606-2	1998	In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B &gt; MAO-A inhibitor used in doses of 90 mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied.	Pargyline	86-95	monoamine oxidase A	Homo sapiens	111-116
9656095-2	1998	First, two social phobia studies which used the monoamine oxidase type A inhibitors brofaromine and moclobemide are considered.	brofaromine	84-95	monoamine oxidase A	Homo sapiens	48-72
9656095-2	1998	First, two social phobia studies which used the monoamine oxidase type A inhibitors brofaromine and moclobemide are considered.	Moclobemide	100-111	monoamine oxidase A	Homo sapiens	48-72
9794145-5	1998	The relative risk with different drug combinations is assessed from available evidence and argued to be strongly associated with the degree of elevation of 5-hydroxytryptamine, which is greatest following combinations of irreversible inhibitors of monoamine oxidase A and B with potent serotonin reuptake inhibitors.	Serotonin	156-175	monoamine oxidase A	Homo sapiens	248-267
9564616-1	1998	The rate of oxidation by monoamine oxidase (MAO) of a particular amine in a given cell depends on the levels of MAO-A and MAO-B expressed in the mitochondrial outer membranes, on the amine concentration and the oxygen concentration.	Amines	29-34	monoamine oxidase A	Homo sapiens	112-117
9564606-2	1998	In comparative studies with other, structurally similar acetylenic inhibitors of MAO, pargyline, an MAO-B &gt; MAO-A inhibitor used in doses of 90 mg/day for three or more weeks, produced elevations in these trace amines which were similar to those found with the highest dose of selegiline studied.	Amines	214-220	monoamine oxidase A	Homo sapiens	111-116
9564616-1	1998	The rate of oxidation by monoamine oxidase (MAO) of a particular amine in a given cell depends on the levels of MAO-A and MAO-B expressed in the mitochondrial outer membranes, on the amine concentration and the oxygen concentration.	Amines	65-70	monoamine oxidase A	Homo sapiens	112-117
9564619-4	1998	Conversely, the catalytic properties and specificity of MAO-A were insensitive to substitution of both the NH2-(up to position 112) and COOH-termini (from residue 395), but further modification of the central sequence of MAO-A was not compatible with activity.	Carbonic Acid	136-140	monoamine oxidase A	Homo sapiens	56-61
9564603-5	1998	The results demonstrate that the characteristic abnormalities in the excretion of biogenic amines and their metabolites were faithfully present in every one of 12 independent samples obtained from the MAO-A deficient males over the two-week study period.	Amines	91-97	monoamine oxidase A	Homo sapiens	201-206
9564605-1	1998	Lack of monoamine oxidase A (MAO-A) due to either Xp chromosomal deletions or alterations in the coding sequence of the gene for this enzyme are associated with marked changes in monoamine metabolism and appear to be associated with variable cognitive deficits and behavioral changes in humans and in transgenic mice.	monoamine	8-17	monoamine oxidase A	Homo sapiens	29-34
9564606-3	1998	Clorgyline, a selective inhibitor of MAO-A used in doses of 30 mg/day for three or more weeks (a dose/time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) &gt; 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	37-42
9564606-0	1998	Differential trace amine alterations in individuals receiving acetylenic inhibitors of MAO-A (clorgyline) or MAO-B (selegiline and pargyline).	Amines	19-24	monoamine oxidase A	Homo sapiens	87-92
9564621-1	1998	The deamination of 5-hydroxytryptamine, phenylethylamine and benzylamine by monoamine oxidases (MAO-A and B) and semicarbazide sensitive amine oxidase (SSAO) respectively has been studied in homogenates of human cystic and colonic arteries by radiochemical assays.	Serotonin	19-38	monoamine oxidase A	Homo sapiens	96-107
9564621-1	1998	The deamination of 5-hydroxytryptamine, phenylethylamine and benzylamine by monoamine oxidases (MAO-A and B) and semicarbazide sensitive amine oxidase (SSAO) respectively has been studied in homogenates of human cystic and colonic arteries by radiochemical assays.	Phenethylamines	40-56	monoamine oxidase A	Homo sapiens	96-107
9564621-1	1998	The deamination of 5-hydroxytryptamine, phenylethylamine and benzylamine by monoamine oxidases (MAO-A and B) and semicarbazide sensitive amine oxidase (SSAO) respectively has been studied in homogenates of human cystic and colonic arteries by radiochemical assays.	benzylamine	61-72	monoamine oxidase A	Homo sapiens	96-107
9564636-0	1998	The influence of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase A and GABAA receptor binding.	pirlindole	36-46	monoamine oxidase A	Homo sapiens	93-112
9564606-3	1998	Clorgyline, a selective inhibitor of MAO-A used in doses of 30 mg/day for three or more weeks (a dose/time regimen previously reported to reduce urinary, plasma, and cerebrospinal fluid 3-methoxy-4-hydroxyphenylethyleneglycol (MHPG) &gt; 80%, indicating a marked inhibitory effect on MAO-A in humans in vivo) produced negligible changes in trace amine excretion.	Clorgyline	0-10	monoamine oxidase A	Homo sapiens	284-289
9564636-6	1998	Data obtained suggest that in contrast to pirlindole dehydro-pirlindole may act not only as a MAO-A inhibitor but also as a potent GABAA receptor blocker.	pirlindole dehydro-pirlindole	42-71	monoamine oxidase A	Homo sapiens	94-99
9564606-6	1998	Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO-B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.	Amines	15-20	monoamine oxidase A	Homo sapiens	305-310
9564606-6	1998	Overall, trace amine elevations in individuals receiving the highest dose of deprenyl or receiving pargyline were approximately three to five-fold lower than the elevations observed in individuals lacking the genes for both MAO-A and MAO-B, suggesting that these drug doses yield incomplete inhibition of MAO-A and MAO-B.	Selegiline	77-85	monoamine oxidase A	Homo sapiens	305-310
9564607-2	1998	In part, this oxidative stress is the result of the oxidation of dopamine by the action of monoamine oxidases (MAO) A and B to generate hydrogen peroxide and subsequent oxygen free radicals.	Dopamine	65-73	monoamine oxidase A	Homo sapiens	91-123
9564607-2	1998	In part, this oxidative stress is the result of the oxidation of dopamine by the action of monoamine oxidases (MAO) A and B to generate hydrogen peroxide and subsequent oxygen free radicals.	Hydrogen Peroxide	136-153	monoamine oxidase A	Homo sapiens	91-123
9564607-2	1998	In part, this oxidative stress is the result of the oxidation of dopamine by the action of monoamine oxidases (MAO) A and B to generate hydrogen peroxide and subsequent oxygen free radicals.	Oxygen	169-175	monoamine oxidase A	Homo sapiens	91-123
18591080-1	1997	Moclobemide, a potent reversible monoamine-oxidase A (MAO-A) inhibitor, is an effective antidepressant that does not cause impairment of cognitive function in elderly patients and might be beneficial to motor deficits in Parkinson"s disease (PD).	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	33-52
18591080-1	1997	Moclobemide, a potent reversible monoamine-oxidase A (MAO-A) inhibitor, is an effective antidepressant that does not cause impairment of cognitive function in elderly patients and might be beneficial to motor deficits in Parkinson"s disease (PD).	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	54-59
9399014-5	1997	Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	15-34
9452885-3	1997	Cell extracts from epidermal suction blister roofs revealed only half the normal activity of phenylethanolamine-N-methyl transferase (PNMT) together with a threefold induction of the norepinephrine-degrading enzyme monoamine oxidase A (MAO-A).	Norepinephrine	183-197	monoamine oxidase A	Homo sapiens	215-234
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Serotonin	32-41	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Serotonin	43-46	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Harmine	80-87	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Clorgyline	92-102	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	phenethylamine	142-156	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	benzylamine	161-172	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Selegiline	206-217	monoamine oxidase A	Homo sapiens	0-5
9503561-4	1997	MAO-A preferentially deaminates serotonin (5HT) and is selectively inhibited by harmine and clorgyline, while MAO-B preferentially deaminates phenethylamine and benzylamine, and is selectively inhibited by (-)deprenyl as well as low concentrations of pargyline.	Pargyline	251-260	monoamine oxidase A	Homo sapiens	0-5
9503563-1	1997	MAO A and MAO B follow the same chemical mechanism to oxidise primary, secondary, and tertiary amines, but they are distinguished by differences in their substrate and inhibitor specificities and in their kinetic behaviour.	Amines	95-101	monoamine oxidase A	Homo sapiens	0-5
9503566-2	1997	Although tyramine is a substrate for both MAO-A and -B, it is only inhibitors of the former enzyme, which are also the effective antidepressants, that give rise to the cheese reaction.	Tyramine	9-17	monoamine oxidase A	Homo sapiens	42-54
9503566-5	1997	The development of reversible inhibitors of monoamine oxidase-A (RIMAs) has reduced this hypertensive response since rising tyramine concentrations can displace the inhibitor from the enzyme and thus allow some metabolism to occur.	Tyramine	124-132	monoamine oxidase A	Homo sapiens	44-63
9399014-5	1997	Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	36-41
9399014-5	1997	Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91.	zolmitriptan	81-93	monoamine oxidase A	Homo sapiens	15-34
9399014-5	1997	Moclobemide, a monoamine oxidase A (MAO-A) inhibitor, decreased the clearance of zolmitriptan and, in particular, 183C91.	zolmitriptan	81-93	monoamine oxidase A	Homo sapiens	36-41
9399014-6	1997	This suggests that MAO-A is involved in the metabolism of 183C91 and it may be prudent to limit the daily zolmitriptan dose in migraine patients maintained on a MAO-A inhibitor.	zolmitriptan	106-118	monoamine oxidase A	Homo sapiens	19-24
9466163-1	1997	RS-8359 is a new reversible inhibitor of monoamine oxidase A (RIMA).	RS 8359	0-7	monoamine oxidase A	Homo sapiens	41-60
9466172-1	1997	Moclobemide is a reversible selective inhibitor of monoamine oxidase A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	51-70
9466167-1	1997	The safety, tolerability and a preliminary assessment of the efficacy of the new reversible inhibitor of monoamine oxidase A, RS-8359, were evaluated in two studies in hospitalized, depressed patients.	RS 8359	126-133	monoamine oxidase A	Homo sapiens	105-124
9272198-0	1997	Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression.	pirlindole	124-134	monoamine oxidase A	Homo sapiens	92-111
9304853-2	1997	Moclobemide is a selective and reversible inhibitor of monoamine oxidase type A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	55-79
9390776-2	1997	[3H]Ro41-1049 and [3H]lazabemide were used as selective radioligands to image and quantify MAO-A and MAO-B respectively by enzyme autoradiography.	Tritium	1-3	monoamine oxidase A	Homo sapiens	91-96
9390776-2	1997	[3H]Ro41-1049 and [3H]lazabemide were used as selective radioligands to image and quantify MAO-A and MAO-B respectively by enzyme autoradiography.	[3h]lazabemide	18-32	monoamine oxidase A	Homo sapiens	91-96
9273760-2	1997	Moclobemide is a reversible inhibitor of the monoamine oxidase type A (RIMA).	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	45-69
9273760-2	1997	Moclobemide is a reversible inhibitor of the monoamine oxidase type A (RIMA).	rima	71-75	monoamine oxidase A	Homo sapiens	45-69
9272198-0	1997	Double-blind randomized controlled study of the efficacy and tolerability of two reversible monoamine oxidase A inhibitors, pirlindole and moclobemide, in the treatment of depression.	Moclobemide	139-150	monoamine oxidase A	Homo sapiens	92-111
9272198-1	1997	The aim of this double-blind randomized study was to compare the efficacy and the tolerability of moclobemide (300-600 mg daily) and pirlindole (150-300 mg daily), two reversible inhibitors of MAO-A (RIMAs), in the treatment of depression.	pirlindole	133-143	monoamine oxidase A	Homo sapiens	193-198
9272198-1	1997	The aim of this double-blind randomized study was to compare the efficacy and the tolerability of moclobemide (300-600 mg daily) and pirlindole (150-300 mg daily), two reversible inhibitors of MAO-A (RIMAs), in the treatment of depression.	rimas	200-205	monoamine oxidase A	Homo sapiens	193-198
9259175-14	1997	Moclobemide is a selective inhibitor of monoamine oxidase type A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	40-64
8987145-1	1997	Monoamine oxidases A and B (MAOA and MAOB) are the major catabolic isoenzymes of catecholamines and serotonin in the mammalian brain.	Catecholamines	81-95	monoamine oxidase A	Homo sapiens	0-26
9347378-2	1997	An international, multicenter, placebo-controlled study was undertaken to determine the safety and antidepressant efficacy of moclobemide, a new reversible inhibitor of monoamine oxidase A, and imipramine in the treatment of dysthymia (DSM-III-R).	Moclobemide	126-137	monoamine oxidase A	Homo sapiens	169-188
9347385-2	1997	Moclobemide, which is a reversible inhibitor of monoamine oxidase-A, is relatively free of these limitations and is therefore potentially useful in the treatment of post-traumatic stress disorder.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	48-67
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Norepinephrine	19-33	monoamine oxidase A	Homo sapiens	244-263
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Norepinephrine	19-33	monoamine oxidase A	Homo sapiens	265-270
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Serotonin	54-63	monoamine oxidase A	Homo sapiens	244-263
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Serotonin	54-63	monoamine oxidase A	Homo sapiens	265-270
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	mociobemide	68-79	monoamine oxidase A	Homo sapiens	244-263
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	mociobemide	68-79	monoamine oxidase A	Homo sapiens	265-270
9116581-0	1997	Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B.	Imidazolines	21-32	monoamine oxidase A	Homo sapiens	65-90
9116581-0	1997	Relationship between imidazoline/guanidinium receptive sites and monoamine oxidase A and B.	Guanidine	33-44	monoamine oxidase A	Homo sapiens	65-90
9116581-8	1997	Additional experiments indicate that the imidazoline binding domains on MAO-A and -B exhibit different ligand recognition properties.	Imidazolines	41-52	monoamine oxidase A	Homo sapiens	72-84
9116585-1	1997	I2-imidazoline binding site (I2BS) has been identified with a regulatory site located on a sub-population of monoamine oxidase (MAO)-A and -B.	Imidazolines	3-14	monoamine oxidase A	Homo sapiens	109-141
9324719-3	1997	The selective and reversible monoamine oxidase inhibitor type A (MAO-A inhibitor), moclobemide (Aurorix), is much better tolerated and safer to use.	Moclobemide	83-94	monoamine oxidase A	Homo sapiens	65-70
9324719-3	1997	The selective and reversible monoamine oxidase inhibitor type A (MAO-A inhibitor), moclobemide (Aurorix), is much better tolerated and safer to use.	Moclobemide	96-103	monoamine oxidase A	Homo sapiens	65-70
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	Carbon	68-74	monoamine oxidase A	Homo sapiens	4-30
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	Carbon	68-74	monoamine oxidase A	Homo sapiens	32-37
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	4-substituted 1-methyl-1,2,3,6-tetrahydropyridine	101-150	monoamine oxidase A	Homo sapiens	4-30
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	4-substituted 1-methyl-1,2,3,6-tetrahydropyridine	101-150	monoamine oxidase A	Homo sapiens	32-37
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	2,3-dihydropyridinium	190-211	monoamine oxidase A	Homo sapiens	4-30
9377092-1	1997	The monoamine oxidases A and B (MAO-A and MAO-B) catalyze the alpha-carbon oxidation of a variety of 4-substituted 1-methyl-1,2,3,6-tetrahydropyridine derivatives to yield the corresponding 2,3-dihydropyridinium species.	2,3-dihydropyridinium	190-211	monoamine oxidase A	Homo sapiens	32-37
9377092-3	1997	In this paper we summarize our efforts to exploit this metabolic pathway to develop latent nitrogen mustard derivatives related to the oxazaphosphorine antitumor agent cyclophosphamide which may target MAO-A and/or MAO-B rich cells.	Nitrogen	91-99	monoamine oxidase A	Homo sapiens	202-207
9377092-3	1997	In this paper we summarize our efforts to exploit this metabolic pathway to develop latent nitrogen mustard derivatives related to the oxazaphosphorine antitumor agent cyclophosphamide which may target MAO-A and/or MAO-B rich cells.	oxazaphosphorine	135-151	monoamine oxidase A	Homo sapiens	202-207
9377092-3	1997	In this paper we summarize our efforts to exploit this metabolic pathway to develop latent nitrogen mustard derivatives related to the oxazaphosphorine antitumor agent cyclophosphamide which may target MAO-A and/or MAO-B rich cells.	Cyclophosphamide	168-184	monoamine oxidase A	Homo sapiens	202-207
9241569-1	1997	Brofaromine is a selective and reversible inhibitor of monoamine oxidase A.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	55-74
9207939-0	1997	Probing the active sites of monoamine oxidase A and B with 1,4-disubstituted tetrahydropyridine substrates and inactivators.	1,4-disubstituted tetrahydropyridine	59-95	monoamine oxidase A	Homo sapiens	28-47
9207939-1	1997	As part of our efforts to characterize more fully the structural features of the monoamine oxidase (MAO) A and B active sites, we have examined the substrate and inhibitor properties of several 1-methyl- and 1-cyclopropyl-4-aryl-1,2,3,6-tetrahydropyridine derivatives with the human placental A and beef liver B forms of the enzyme.	1-methyl- and 1-cyclopropyl-4-aryl-1,2,3,6-tetrahydropyridine	194-255	monoamine oxidase A	Homo sapiens	81-106
9131641-2	1997	Stress enhances excretion of adrenaline, which is deaminated by monoamine oxidase and methylamine is formed.	Epinephrine	29-39	monoamine oxidase A	Homo sapiens	64-81
9131641-6	1997	Methylamine was confirmed to be a product of adrenaline catalyzed by type A monoamine oxidase (MAO-A).	methylamine	0-11	monoamine oxidase A	Homo sapiens	76-93
9131641-6	1997	Methylamine was confirmed to be a product of adrenaline catalyzed by type A monoamine oxidase (MAO-A).	methylamine	0-11	monoamine oxidase A	Homo sapiens	95-100
9131641-6	1997	Methylamine was confirmed to be a product of adrenaline catalyzed by type A monoamine oxidase (MAO-A).	Epinephrine	45-55	monoamine oxidase A	Homo sapiens	76-93
9131641-6	1997	Methylamine was confirmed to be a product of adrenaline catalyzed by type A monoamine oxidase (MAO-A).	Epinephrine	45-55	monoamine oxidase A	Homo sapiens	95-100
9408857-3	1997	Through all species, the protein binding of sumatriptan is similar (14-16%), and its metabolic pathway undergoes extensive oxidative deamination involving the monoamine oxidase A isoenzyme.	Sumatriptan	44-55	monoamine oxidase A	Homo sapiens	159-178
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Amines	170-175	monoamine oxidase A	Homo sapiens	244-263
9112832-3	1997	Superimposition of norepinephrine and gauche forms of serotonin and mociobemide suggest that the phenyl ring, electronegative group attached to the aromatic ring and the amine terminal group may serve as the recognition elements for binding to monoamine oxidase-A (MAO-A).	Amines	170-175	monoamine oxidase A	Homo sapiens	265-270
9074307-2	1997	This review examines the evidence in support of classical monoamine oxidase inhibitor (MAOI) agents and the selective reversible monoamine oxidase type A inhibitor moclobemide in continuation and maintenance therapy.	Moclobemide	164-175	monoamine oxidase A	Homo sapiens	129-153
8990278-0	1997	Inhibition of monoamine oxidase A by beta-carboline derivatives.	norharman	37-51	monoamine oxidase A	Homo sapiens	14-33
8990278-2	1997	The interaction of nine beta-carboline derivatives and four 3,4-dihydro forms with purified MAO A was investigated.	norharman	24-38	monoamine oxidase A	Homo sapiens	92-97
8990278-4	1997	The oxidation of kynuramine by MAO A in the presence of the more effective inhibitors showed a lag period before reaching the steady state.	Kynuramine	17-27	monoamine oxidase A	Homo sapiens	31-36
8990278-6	1997	Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively.	Harmine	0-7	monoamine oxidase A	Homo sapiens	116-121
8990278-6	1997	Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively.	2-methylharminium	9-26	monoamine oxidase A	Homo sapiens	116-121
8990278-6	1997	Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively.	2,9-dimethylharminium	28-49	monoamine oxidase A	Homo sapiens	116-121
8990278-6	1997	Harmine, 2-methylharminium, 2,9-dimethylharminium, and harmaline were the most effective inhibitors of the purified MAO A, with low Ki values of 5, 69, 15, and 48 nM, respectively.	Harmaline	55-64	monoamine oxidase A	Homo sapiens	116-121
9174681-0	1997	MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.	esuprone	44-52	monoamine oxidase A	Homo sapiens	0-5
9174681-0	1997	MAO-A inhibition in brain after dosing with esuprone, moclobemide and placebo in healthy volunteers: in vivo studies with positron emission tomography.	Moclobemide	54-65	monoamine oxidase A	Homo sapiens	0-5
9174681-7	1997	RESULTS: PET showed a high degree of binding of [11C]harmine, a high-affinity ligand for MAO-A, before the start of treatment, and a marked and similar reduction after treatment with esuprone and moclobemide.	UNII-C06QCS6OX3	48-60	monoamine oxidase A	Homo sapiens	89-94
9174681-10	1997	Plasma kinetics of esuprone showed a rapid elimination with a half-life of about 4 h. CONCLUSION: The study demonstrates that esuprone was comparable to moclobemide in its effect on MAO-A inhibition in the brain at the doses given.	esuprone	126-134	monoamine oxidase A	Homo sapiens	182-187
8987145-1	1997	Monoamine oxidases A and B (MAOA and MAOB) are the major catabolic isoenzymes of catecholamines and serotonin in the mammalian brain.	Catecholamines	81-95	monoamine oxidase A	Homo sapiens	28-32
8987145-1	1997	Monoamine oxidases A and B (MAOA and MAOB) are the major catabolic isoenzymes of catecholamines and serotonin in the mammalian brain.	Serotonin	100-109	monoamine oxidase A	Homo sapiens	0-26
8987145-1	1997	Monoamine oxidases A and B (MAOA and MAOB) are the major catabolic isoenzymes of catecholamines and serotonin in the mammalian brain.	Serotonin	100-109	monoamine oxidase A	Homo sapiens	28-32
9038453-1	1996	We report a case of low thoracic epidural and general anaesthesia in a patient receiving moclobemide, a new selective inhibitor of monoamine oxidase A.	Moclobemide	89-100	monoamine oxidase A	Homo sapiens	131-150
8978500-3	1996	Both MAO-A and MAO-B have relatively equivalent affinities for dopamine, and since PC12 primarily express the A and not the B form of the enzyme, this allowed us to distinguish the transgenic MAO activity in these cells from endogenous using the MAO-B specific substrate PEA.	Dopamine	63-71	monoamine oxidase A	Homo sapiens	5-10
9020990-0	1996	A double-blind randomized placebo-controlled study of the efficacy and safety of pirlindole, a reversible monoamine oxidase A inhibitor, in the treatment of depression.	pirlindole	81-91	monoamine oxidase A	Homo sapiens	106-125
9020990-1	1996	The efficacy and safety of pirlindole (300 mg/day), a new reversible inhibitor of monoamine oxidase A, have been evaluated in a multicentre placebo-controlled double-blind randomized trial in 103 in-patients suffering from unipolar major depression (DSM-III-R 296.2, 296.3) over a 42-day period after a run-in placebo period of 6 days.	pirlindole	27-37	monoamine oxidase A	Homo sapiens	82-101
8953568-6	1996	In contrast to pirlindole, dehydro-pirlindole may act not only as MAO-A inhibitor but also as a clozapine-like selective GABAA receptor blocker, preferentially blocking a subset of GABAA receptors that are not sensitive to DMCM or Ro 5-4864.	3,3a-dehydropyrazidol	27-45	monoamine oxidase A	Homo sapiens	66-71
8961085-0	1996	Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.	Ephedrine	46-55	monoamine oxidase A	Homo sapiens	74-93
8961085-0	1996	Modification of the cardiovascular effects of ephedrine by the reversible monoamine oxidase A-inhibitor moclobemide.	Moclobemide	104-115	monoamine oxidase A	Homo sapiens	74-93
8961085-2	1996	This study investigated the safety and tolerability of concomitant administration to 12 healthy subjects of both genders (aged 19-36 years) of ephedrine and moclobemide, a reversible MAO-A inhibitor.	Moclobemide	157-168	monoamine oxidase A	Homo sapiens	183-188
8953568-0	1996	Effects of the antidepressant pirlindole and its dehydro-derivative on the activity of monoamine oxidase-A and on GABAA receptors.	pirlindole	30-40	monoamine oxidase A	Homo sapiens	87-106
8889283-9	1996	Several variables (DHPG, platelet serotonin) suggested that selegiline has some MAO-A inhibitory activity.	Selegiline	60-70	monoamine oxidase A	Homo sapiens	80-85
8941389-2	1996	We have attempted to adapt this metabolic pathway to the preparation of amine-containing prodrugs that may target the central nervous system which is rich in monoamine oxidase A and B.	Amines	72-77	monoamine oxidase A	Homo sapiens	158-183
8941389-4	1996	These carbamates are selective monoamine oxidase A substrates.	Carbamates	6-16	monoamine oxidase A	Homo sapiens	31-50
8780428-3	1996	RESULTS: Significant associations of alcohol dependence with MAOA alleles (RFLP and DNRP) were found among the Han Chinese, but not among the aboriginal groups.	Alcohols	37-44	monoamine oxidase A	Homo sapiens	61-65
8889283-8	1996	The most reliable variables to assess inhibition of MAO-A and -B in humans proved to be DHPG in plasma and serotonin in platelets and MAO-B activity in platelets, respectively.	Serotonin	107-116	monoamine oxidase A	Homo sapiens	52-64
8930782-0	1996	Effects of befloxatone, a reversible selective monoamine oxidase-A inhibitor, on psychomotor function and memory in healthy subjects.	befloxatone	11-22	monoamine oxidase A	Homo sapiens	47-66
8930782-1	1996	Befloxatone is a new reversible and selective monoamine oxidase (MAO-A) inhibitor that has been shown to have antidepressant activity in various animal models.	befloxatone	0-11	monoamine oxidase A	Homo sapiens	46-63
8930782-1	1996	Befloxatone is a new reversible and selective monoamine oxidase (MAO-A) inhibitor that has been shown to have antidepressant activity in various animal models.	befloxatone	0-11	monoamine oxidase A	Homo sapiens	65-70
8923574-0	1996	Initial monoamine oxidase-A inhibition by moclobemide does not predict the therapeutic response in patients with major depression.	Moclobemide	42-53	monoamine oxidase A	Homo sapiens	8-27
8923574-3	1996	In order to evaluate the predictive ability of monoamine oxidase-A inhibition for therapeutic efficacy, the start of treatment effects of moclobemide, a selective, reversible monoamine oxidase-A inhibitor, on plasma concentrations of monoamines and monoamine metabolites were determined.	Moclobemide	138-149	monoamine oxidase A	Homo sapiens	175-194
8780428-3	1996	RESULTS: Significant associations of alcohol dependence with MAOA alleles (RFLP and DNRP) were found among the Han Chinese, but not among the aboriginal groups.	dnrp	84-88	monoamine oxidase A	Homo sapiens	61-65
8875133-2	1996	Unlike older monoamine oxidase inhibitors, which irreversibly and nonselectively bind monoamine oxidase (MAO), moclobemide is a reversible and selective inhibitor of the MAO-A isozyme.	Moclobemide	111-122	monoamine oxidase A	Homo sapiens	170-175
8835705-2	1996	In this study, the SSRI fluvoxamine (Fluv) was compared with the MAO-A-I brofaromine (Brof).	brofaromine	73-84	monoamine oxidase A	Homo sapiens	65-70
8880082-1	1996	The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan.	Moclobemide	22-33	monoamine oxidase A	Homo sapiens	92-116
8880082-1	1996	The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan.	Moclobemide	22-33	monoamine oxidase A	Homo sapiens	118-123
8880082-1	1996	The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan.	Moclobemide	35-45	monoamine oxidase A	Homo sapiens	92-116
8880082-1	1996	The metabolic fate of moclobemide (Ro 11-1163), a new reversible and selective inhibitor of monoamine oxidase type A (MAO-A), has been assessed in a pilot study in 2 debrisoquine poor metabolizers (PM) and 4 extensive metabolizers (EM) after multiple oral dosings of moclobemide with and without co-medication of dextromethorphan.	Moclobemide	35-45	monoamine oxidase A	Homo sapiens	118-123
8835705-10	1996	The selective and reversible MAO-A-I brofaromine and the SSRI fluvoxamine are equally effective in the treatment of PD.	brofaromine	37-48	monoamine oxidase A	Homo sapiens	29-34
8695909-1	1996	Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA.	monoamine	27-36	monoamine oxidase A	Homo sapiens	201-205
8981559-1	1996	Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline) is a naturally occurring compound in the mammalian body which inhibits serotonin (5-hydroxytryptamine) uptake and monoamine oxidase-A activity.	6-methoxytryptoline	0-8	monoamine oxidase A	Homo sapiens	169-188
8981559-1	1996	Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline) is a naturally occurring compound in the mammalian body which inhibits serotonin (5-hydroxytryptamine) uptake and monoamine oxidase-A activity.	6-methoxytryptoline	10-53	monoamine oxidase A	Homo sapiens	169-188
8981559-1	1996	Pinoline (6-methoxy-1,2,3,4-tetrahydro-beta-carboline) is a naturally occurring compound in the mammalian body which inhibits serotonin (5-hydroxytryptamine) uptake and monoamine oxidase-A activity.	Serotonin	126-135	monoamine oxidase A	Homo sapiens	169-188
8695909-1	1996	Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA.	Octopamine	76-86	monoamine oxidase A	Homo sapiens	201-205
8695909-1	1996	Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA.	Norepinephrine	91-105	monoamine oxidase A	Homo sapiens	201-205
8695909-6	1996	The maoA gene forms an operon with the maoC gene, which has similarity to a dehydrogenase involved in the tyramine metabolism.	Tyramine	106-114	monoamine oxidase A	Homo sapiens	4-8
8695909-1	1996	Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA.	Tyramine	56-64	monoamine oxidase A	Homo sapiens	201-205
8695909-1	1996	Bacterial cells respond to monoamine compounds, such as tyramine, dopamine, octopamine, or norepinephrine, and induce the syntheses of tyramine oxidase encoded by tynA and monoamine oxidase encoded by maoA.	Dopamine	66-74	monoamine oxidase A	Homo sapiens	201-205
8923113-4	1996	A reversible inhibitor of monoamine oxidase A, moclobemide, is better tolerated and safer than the irreversible monoamine oxidase inhibitors and placebo-controlled studies have also demonstrated efficacy for this compound; moreover, positive results from a small study of brofaromine also support the efficacy of this class of compounds.	Moclobemide	47-58	monoamine oxidase A	Homo sapiens	26-45
8923113-4	1996	A reversible inhibitor of monoamine oxidase A, moclobemide, is better tolerated and safer than the irreversible monoamine oxidase inhibitors and placebo-controlled studies have also demonstrated efficacy for this compound; moreover, positive results from a small study of brofaromine also support the efficacy of this class of compounds.	brofaromine	272-283	monoamine oxidase A	Homo sapiens	26-45
8923114-3	1996	Moclobemide is a reversible inhibitor of monoamine oxidase A (RIMA) which has an established place in the treatment of depression.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	41-60
8804132-1	1996	Monoamine oxidases (MAO) A and B, which are encoded by two distinct genes located on the human X chromosome, are both involved in the oxidative metabolism of dopamine.	Dopamine	158-166	monoamine oxidase A	Homo sapiens	0-32
8677764-3	1996	MAO-A and -B activities were radiometrically measured using 14C-5-hydroxytriptamine for MAO-A substrate and 14C-benzylamine for MAO-B substrate.	14c-5-hydroxytriptamine	60-83	monoamine oxidase A	Homo sapiens	0-12
8677764-3	1996	MAO-A and -B activities were radiometrically measured using 14C-5-hydroxytriptamine for MAO-A substrate and 14C-benzylamine for MAO-B substrate.	14c-5-hydroxytriptamine	60-83	monoamine oxidase A	Homo sapiens	0-5
8677764-3	1996	MAO-A and -B activities were radiometrically measured using 14C-5-hydroxytriptamine for MAO-A substrate and 14C-benzylamine for MAO-B substrate.	14c-benzylamine	108-123	monoamine oxidase A	Homo sapiens	0-12
8677764-3	1996	MAO-A and -B activities were radiometrically measured using 14C-5-hydroxytriptamine for MAO-A substrate and 14C-benzylamine for MAO-B substrate.	14c-benzylamine	108-123	monoamine oxidase A	Homo sapiens	0-5
9005342-2	1996	With the introduction of moclobemide as the first reversible and selective inhibitor of monoamine oxidase (type A), the therapeutic principle of monoamine oxidase inhibition gained new importance.	Moclobemide	25-36	monoamine oxidase A	Homo sapiens	88-113
8860658-1	1996	Monoamine oxidases (MAO-A and MAO-B) are enzymes that play a key role in the degradation of endogenous and dietary monoamines.	monoamines	115-125	monoamine oxidase A	Homo sapiens	20-25
8627609-4	1996	The previous paper had developed structure-activity relationships (SAR) for in vitro MAO A inhibition by tricyclic N-arylamides.	n-arylamides	115-127	monoamine oxidase A	Homo sapiens	85-90
9005353-4	1996	The development of new serotonin selective antidepressants and selective reversible inhibitors of monoamine oxidase A has led to the use of more and more substances that can cause these life-threatening complications if they are taken in too high doses or together with other drugs.	Serotonin	23-32	monoamine oxidase A	Homo sapiens	98-117
9148606-5	1996	Esters of indoleacetic and 4-hydroxyphenylacetic acids and 4-hydroxyphenyletanol selectively inhibit monoamine oxidase A.	Esters	0-6	monoamine oxidase A	Homo sapiens	101-120
8713690-7	1996	Although the selective MAO-A inhibitor, clorgiline (clorgyline), was found to be effective in the treatment of depression, it still retained the potential to cause hypertensive reactions.	Clorgyline	40-50	monoamine oxidase A	Homo sapiens	23-28
8713690-7	1996	Although the selective MAO-A inhibitor, clorgiline (clorgyline), was found to be effective in the treatment of depression, it still retained the potential to cause hypertensive reactions.	Clorgyline	52-62	monoamine oxidase A	Homo sapiens	23-28
8713690-8	1996	Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy.	Moclobemide	126-137	monoamine oxidase A	Homo sapiens	84-89
8713690-8	1996	Recently, agents that are not only selective, but reversible in their inhibition of MAO-A (RIMAs) have been synthesised (e.g. moclobemide and toloxatone), and have proven antidepressant efficacy.	toloxatone	142-152	monoamine oxidase A	Homo sapiens	84-89
8861736-1	1996	The objective of this study was to assess the tyramine pressor sensitivity during combined administration of selective and reversible inhibitors of monoamine oxidase A and B, viz.	Tyramine	46-54	monoamine oxidase A	Homo sapiens	148-173
8861736-14	1996	The low amount of oral tyramine needed (51 + or - 20 mg) to induce relevant increases in blood pressure indicates that dietary precautions are needed when both MAO-A and B are inhibited by 2 reversible inhibitors.	Tyramine	23-31	monoamine oxidase A	Homo sapiens	160-171
8661341-4	1996	As expected, the development of the fluorescence was inhibited by both clorgyline (an MAO-A inhibitor) and deprenyl (an MAO-B inhibitor).	Clorgyline	71-81	monoamine oxidase A	Homo sapiens	86-91
9148606-5	1996	Esters of indoleacetic and 4-hydroxyphenylacetic acids and 4-hydroxyphenyletanol selectively inhibit monoamine oxidase A.	4-hydroxyphenylacetic acid	27-54	monoamine oxidase A	Homo sapiens	101-120
9148606-5	1996	Esters of indoleacetic and 4-hydroxyphenylacetic acids and 4-hydroxyphenyletanol selectively inhibit monoamine oxidase A.	4-hydroxyphenyletanol	59-80	monoamine oxidase A	Homo sapiens	101-120
8965658-1	1996	The distribution of mRNAs encoding the isoenzymes monoamine oxidase A and B (MAO-A and MAO-B) in monkey locus coeruleus and dorsal raphe nucleus was studied by in situ hybridization histochemistry using 35S-labelled oligodeoxynucleotide probes complementary to cloned human sequences.	Oligodeoxyribonucleotides	216-236	monoamine oxidase A	Homo sapiens	50-75
8965658-5	1996	They also suggest the coexistence of the isoenzymes in raphe neurons as well as the potential role of MAO-A in metabolizing serotonin in vivo.	Serotonin	124-133	monoamine oxidase A	Homo sapiens	102-107
8965658-0	1996	Detection of MAO-A and MAO-B mRNAs in monkey brainstem by cross-hybridization with human oligonucleotide probes.	Oligonucleotides	89-104	monoamine oxidase A	Homo sapiens	13-18
8618686-7	1996	The post-levodopa rise of plasma DOPAC was only slightly attenuated with deprenyl therapy, consistent with a predominant MAO-A effect in the circulation and peripheral organs.	Selegiline	73-81	monoamine oxidase A	Homo sapiens	121-126
8965658-1	1996	The distribution of mRNAs encoding the isoenzymes monoamine oxidase A and B (MAO-A and MAO-B) in monkey locus coeruleus and dorsal raphe nucleus was studied by in situ hybridization histochemistry using 35S-labelled oligodeoxynucleotide probes complementary to cloned human sequences.	Sulfur-35	203-206	monoamine oxidase A	Homo sapiens	50-75
8613523-6	1996	In MAO-A-deficient subjects, there is a marked decrease in deaminated catecholamine metabolites and a concomitant marked elevation of O-methylated amine metabolites.	Catecholamines	70-83	monoamine oxidase A	Homo sapiens	3-8
8678123-1	1996	The monoamine oxidases (MAO-A and MAO-B) are the enzymes primarily responsible for the degradation of amine neurotransmitters, such as dopamine, norepinephrine, and serotonin.	Amines	8-13	monoamine oxidase A	Homo sapiens	24-29
8678123-1	1996	The monoamine oxidases (MAO-A and MAO-B) are the enzymes primarily responsible for the degradation of amine neurotransmitters, such as dopamine, norepinephrine, and serotonin.	Dopamine	135-143	monoamine oxidase A	Homo sapiens	24-29
8678123-1	1996	The monoamine oxidases (MAO-A and MAO-B) are the enzymes primarily responsible for the degradation of amine neurotransmitters, such as dopamine, norepinephrine, and serotonin.	Norepinephrine	145-159	monoamine oxidase A	Homo sapiens	24-29
8678123-1	1996	The monoamine oxidases (MAO-A and MAO-B) are the enzymes primarily responsible for the degradation of amine neurotransmitters, such as dopamine, norepinephrine, and serotonin.	Serotonin	165-174	monoamine oxidase A	Homo sapiens	24-29
8613523-6	1996	In MAO-A-deficient subjects, there is a marked decrease in deaminated catecholamine metabolites and a concomitant marked elevation of O-methylated amine metabolites.	Amines	78-83	monoamine oxidase A	Homo sapiens	3-8
8613523-9	1996	The differences in neurochemical profiles indicate that, under normal conditions, MAO-A is considerably more important than MAO-B in the metabolism of biogenic amines, a factor likely to contribute to the different clinical phenotypes.	Amines	160-166	monoamine oxidase A	Homo sapiens	82-87
8929994-3	1996	We have carried out allelic association studies of PD with monoamine oxidase type A (MAOA) and monoamine oxidase type B (MAOB) gene loci using dinucleotide repeat polymorphisms.	Dinucleoside Phosphates	143-155	monoamine oxidase A	Homo sapiens	59-83
9033760-1	1996	We report a case of severe serotonin syndrome after self-poisoning with two antidepressant drugs, paroxetine (a selective inhibitor of serotonin reuptake) and moclobemide (a reversible inhibitor of MAO-A).	Moclobemide	159-170	monoamine oxidase A	Homo sapiens	198-203
8592154-1	1996	Monoamine oxidase (MAO) A and B play important roles in the metabolism of neurotransmitters and dietary amines.	Amines	104-110	monoamine oxidase A	Homo sapiens	0-25
9045087-11	1996	We conclude that [3H]Ro41-1049 and [3H]azabemide are extremely useful radioligands for high-resolution analyses of the abundance and distribution of catalytic sites of monoamine oxidases A and B, respectively, in human brain sections.	Tritium	18-20	monoamine oxidase A	Homo sapiens	168-194
9045087-11	1996	We conclude that [3H]Ro41-1049 and [3H]azabemide are extremely useful radioligands for high-resolution analyses of the abundance and distribution of catalytic sites of monoamine oxidases A and B, respectively, in human brain sections.	3h]azabemide	36-48	monoamine oxidase A	Homo sapiens	168-194
8876663-3	1996	[3H]Ro41-1049 and [3H]lazabemide, two recently characterized selective radioligands were used to map MAO-A and MAO-B respectively.	[3h]lazabemide	18-32	monoamine oxidase A	Homo sapiens	101-106
8866634-1	1996	OBJECTIVE: The pharmacokinetics of brofaromine, a selective inhibitor of monoamine oxidase A, was evaluated in 12 frail elderly patients (66-92 y) and 12 healthy volunteers (20-35 y).	brofaromine	35-46	monoamine oxidase A	Homo sapiens	73-92
8632725-1	1996	Monoamine oxidase (MAO) A and B are flavoenzymes that catalyze the oxidative deamination of biogenic and xenobiotic amines.	xenobiotic amines	105-122	monoamine oxidase A	Homo sapiens	0-31
8632725-6	1996	Serotonin (5-HT), a preferred substrate for MAO-A, was not oxidized by AB(161-375)A or wild-type MAO-B.	Serotonin	0-9	monoamine oxidase A	Homo sapiens	44-49
8632725-7	1996	Furthermore, (AB161-375)A was more sensitive to the MAO-B specific inhibitor deprenyl (IC50 2.7 +/- 0.4 x 10(-8) M) than to the MAO-A specific inhibitor clorgyline (IC50 5.4 +/- 0.8 x 10(-7) M).	Clorgyline	153-163	monoamine oxidase A	Homo sapiens	128-133
8750929-5	1996	Both human keratinocytes and melanocytes expressed significant levels of monoamine oxidase A (MAO-A) activities as shown using 14C-labelled 5-hydroxytryptamine as substrate and immunohistochemical staining with mouse monoclonal antibody.	Carbon-14	127-130	monoamine oxidase A	Homo sapiens	73-92
8750929-5	1996	Both human keratinocytes and melanocytes expressed significant levels of monoamine oxidase A (MAO-A) activities as shown using 14C-labelled 5-hydroxytryptamine as substrate and immunohistochemical staining with mouse monoclonal antibody.	Carbon-14	127-130	monoamine oxidase A	Homo sapiens	94-99
8750929-5	1996	Both human keratinocytes and melanocytes expressed significant levels of monoamine oxidase A (MAO-A) activities as shown using 14C-labelled 5-hydroxytryptamine as substrate and immunohistochemical staining with mouse monoclonal antibody.	Serotonin	140-159	monoamine oxidase A	Homo sapiens	73-92
8750929-5	1996	Both human keratinocytes and melanocytes expressed significant levels of monoamine oxidase A (MAO-A) activities as shown using 14C-labelled 5-hydroxytryptamine as substrate and immunohistochemical staining with mouse monoclonal antibody.	Serotonin	140-159	monoamine oxidase A	Homo sapiens	94-99
8750929-8	1996	Based on these results, it can be concluded that defective catecholamine synthesis in the epidermis of patients with vitiligo leads to increased levels of norepinephrine with a concomitant increase in MAO-A activity.	Catecholamines	59-72	monoamine oxidase A	Homo sapiens	201-206
9026374-5	1996	Biochemical and pharmacological aspects will be reviewed, showing that brofaromine is a selective and reversible inhibitor of monoamine oxidase type A with additional serotonin reuptake inhibiting properties.	brofaromine	71-82	monoamine oxidase A	Homo sapiens	126-150
8904739-0	1996	Pharmacoelectroencephalographic profile of befloxatone, a new reversible MAO-A inhibitor, in healthy subjects.	befloxatone	43-54	monoamine oxidase A	Homo sapiens	73-78
8776746-0	1996	Different modes of data processing and statistical testing applied to the same set of pharmaco-EEG recordings: effects on the evaluation of a selective and reversible MAO A inhibitor (brofaromine).	brofaromine	184-195	monoamine oxidase A	Homo sapiens	167-172
8776746-2	1996	Brofaromine (CGP 11,305 A), a new selective and reversible monoamine oxidase type A inhibitor was used as an example for investigating a potentially antidepressant drug in clinical development.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	59-83
8904739-1	1996	The pharmaco-EEG profile and the effects on P300 and CNV of befloxatone, a new selective and reversible MAO-A inhibitor, were assessed in a randomized, double-blind, placebo-controlled, 4-way crossover study.	befloxatone	60-71	monoamine oxidase A	Homo sapiens	104-109
8530333-3	1995	METHOD: Fifty-seven patients with social phobia completed a 12-week double-blind, placebo-controlled trial with the reversible and selective monoamine oxidase A inhibitor brofaromine 150 mg/day.	brofaromine	171-182	monoamine oxidase A	Homo sapiens	141-160
8851820-2	1996	The metabolism of 1-ethylphenoxathiin-10,10-dioxide (BW1370U87), an experimental compound designed as an inhibitor of monoamine oxidase-A for use as a possible anti-depression agent, has been studied in a human liver microsome preparation.	1-ethylphenoxathiin 10,10-dioxide	53-62	monoamine oxidase A	Homo sapiens	118-137
8771218-0	1995	A dinucleotide repeat polymorphism at the gene for monoamine oxidase A and measures of aggressiveness.	Dinucleoside Phosphates	2-14	monoamine oxidase A	Homo sapiens	51-70
8771218-1	1995	The relationship between measures of aggressiveness (personality questionnaire scales, conduct disorder diagnosis, and symptom count) and a recently discovered dinucleotide repeat length polymorphism at the monoamine oxidase type A (MAOA) gene (MAOCA-1) as a candidate locus was examined in adolescents using polymerase chain reaction.	Dinucleoside Phosphates	160-172	monoamine oxidase A	Homo sapiens	207-231
8771218-1	1995	The relationship between measures of aggressiveness (personality questionnaire scales, conduct disorder diagnosis, and symptom count) and a recently discovered dinucleotide repeat length polymorphism at the monoamine oxidase type A (MAOA) gene (MAOCA-1) as a candidate locus was examined in adolescents using polymerase chain reaction.	Dinucleoside Phosphates	160-172	monoamine oxidase A	Homo sapiens	233-237
7586937-0	1995	A reversible monoamine oxidase A inhibitor (moclobemide) facilitates smoking cessation and abstinence in heavy, dependent smokers.	Moclobemide	44-55	monoamine oxidase A	Homo sapiens	13-32
8557884-2	1995	The results demonstrated that in agitated-anxious depressive patients (defined by HAMD factor score or HAMD item 9) a nonsedative, reversible MAO-A inhibitor moclobemide has about equal efficacy as imipramine or sedative antidepressants.	Moclobemide	158-169	monoamine oxidase A	Homo sapiens	142-147
8848950-2	1995	The efficacy and the safety of moclobemide (400-600 mg/day), a reversible and selective inhibitor of monoamine oxidase-A (RIMA) and of clomipramine (100-150 mg/day) were compared respectively in 98 and 93 nonmelancholic, nonpsychotic out-patients with a DSM-III major depressive episode over 6 weeks and up to 3 months, in a multi-center double-blind trial.	Moclobemide	31-42	monoamine oxidase A	Homo sapiens	101-120
8582117-0	1995	Clinical pharmacokinetics of the monoamine oxidase-A inhibitor moclobemide.	Moclobemide	63-74	monoamine oxidase A	Homo sapiens	33-52
8582117-4	1995	Moclobemide is an example of a reversible MAO-A inhibitor which has been extensively studied and whose pharmacokinetic, clinical pharmacological and toxicological profiles have been thoroughly defined.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	42-47
7593725-2	1995	For the purpose of this analysis of the antidepressant efficacy of the reversible inhibitor of monoamine oxidase A moclobemide, all hospitalized cases were selected from the current database of comparative studies and compared with the standard tricyclics imipramine and clomipramine.	Moclobemide	115-126	monoamine oxidase A	Homo sapiens	95-114
8570762-3	1995	To reevaluate this question, we examined the results of two large-scale controlled clinical trials comparing the selective and reversible inhibitor of monoamine oxidase type A (MAO-A) brofaromine with the standard tricyclic compound imipramine.	brofaromine	184-195	monoamine oxidase A	Homo sapiens	151-175
8570762-3	1995	To reevaluate this question, we examined the results of two large-scale controlled clinical trials comparing the selective and reversible inhibitor of monoamine oxidase type A (MAO-A) brofaromine with the standard tricyclic compound imipramine.	brofaromine	184-195	monoamine oxidase A	Homo sapiens	177-182
7562919-1	1995	A large series (66 compounds) of indeno[1,2-c]pyridazin-5-ones (IPs) were synthesized and tested on their monoamine oxidase-A (MAO-A) and MAO-B inhibitory activity.	IPS	64-67	monoamine oxidase A	Homo sapiens	127-132
21597803-0	1995	Mao-a enzyme binding in bladder-cancer characterized with [C-11] harmine in frozen-section autoradiography.	[c-11] harmine	58-72	monoamine oxidase A	Homo sapiens	0-5
21597803-1	1995	Operative specimens from 7 patients with urinary bladder cancer and with only inflammatory tissue in the operative sample from one patient, were used for frozen section autoradiography using [C-11]harmine to characterize the expression of the enzyme monoamine oxidase A (MAO-A).	Carbon	192-193	monoamine oxidase A	Homo sapiens	250-269
21597803-10	1995	With the availability of [C-11]harmine and positron emission tomography (PET) it is reasonable to believe that in vivo characterization of MAO-A in bladder cancer is feasible and could be used for diagnostic purposes or for treatment monitoring.	[c-11]harmine	25-38	monoamine oxidase A	Homo sapiens	139-144
7560704-2	1995	DESIGN: This study was part of a larger n-of-1 clinical trial to investigate the efficacy and safety of a MAO/A inhibitor (Brofaromine) in patients with Alzheimer"s disease.	brofaromine	123-134	monoamine oxidase A	Homo sapiens	106-111
7572258-1	1995	A total of 56 patients attending a general practitioner for treatment of depression, most of whom met the criteria for major depression, were included in this double-blind, parallel group, 6-week study, in which the selective MAO-A inhibitor moclobemide (MOC; maximum dose 600 mg) was compared with the tricyclic antidepressant doxepin (DOX; maximum dose 250 mg).	Moclobemide	242-253	monoamine oxidase A	Homo sapiens	226-231
7593732-0	1995	The therapeutic potential of moclobemide, a reversible selective monoamine oxidase A inhibitor in Parkinson"s disease.	Moclobemide	29-40	monoamine oxidase A	Homo sapiens	65-84
7593732-1	1995	Dopamine is equally well deaminated oxidatively by monoamine oxidase (MAO) A and B types.	Dopamine	0-8	monoamine oxidase A	Homo sapiens	51-76
7770050-6	1995	Analysis of the deduced amino acid sequence indicates that MAO-N is structurally related to the human monoamine oxidases MAO-A and MAO-B.	spizofurone	59-64	monoamine oxidase A	Homo sapiens	121-126
7792602-1	1995	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family.	Serotonin	66-75	monoamine oxidase A	Homo sapiens	14-33
7792602-1	1995	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family.	Serotonin	66-75	monoamine oxidase A	Homo sapiens	35-39
7792602-1	1995	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family.	Norepinephrine	80-94	monoamine oxidase A	Homo sapiens	14-33
7792602-1	1995	Deficiency in monoamine oxidase A (MAOA), an enzyme that degrades serotonin and norepinephrine, has recently been shown to be associated with aggressive behavior in men of a Dutch family.	Norepinephrine	80-94	monoamine oxidase A	Homo sapiens	35-39
7781267-1	1995	The reversible monoamine oxidase A inhibitor moclobemide was given in single (300 mg) and multiple doses (600 mg/day) to 11 male and four female healthy volunteers (age range, 23 to 27) who were either poor metabolizers of S-mephenytoin (n = 7) or extensive metabolizers of S-mephenytoin (n = 8).	Moclobemide	45-56	monoamine oxidase A	Homo sapiens	15-34
7665725-0	1995	Pressor effect of oral tyramine during treatment with befloxatone, a new reversible monoamine oxidase-A inhibitor, in healthy subjects.	befloxatone	54-65	monoamine oxidase A	Homo sapiens	84-103
7665725-1	1995	The interaction between tyramine and befloxatone, a new selective, reversible monoamine oxidase-A (MAO-A) inhibitor, was studied in a single-blind, parallel-group study in 30 healthy male volunteers whose fasting tyramine 30 dose (Tyr30) was 400 or 600 mg. Each subject completed a placebo run-in period followed by a befloxatone period.	befloxatone	37-48	monoamine oxidase A	Homo sapiens	99-104
7573127-4	1995	Recombination events identify a 55.6 cM interval between DXS1068 and DXS454, while a one unit support interval identifies 40 cM between MAOA and DXS458.	dxs458	145-151	monoamine oxidase A	Homo sapiens	136-140
7601156-5	1995	Whereas exchange of the ADP-binding sequence did not modify the catalytic properties of either MAO isoforms, chimeras with increasing length of the NH2-terminus of MAO-A (up to residue 256) showed a marked decrease in affinity towards the MAO-B substrate phenylethylamine and the inhibitor N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide .	Phenethylamines	255-271	monoamine oxidase A	Homo sapiens	164-169
7601156-5	1995	Whereas exchange of the ADP-binding sequence did not modify the catalytic properties of either MAO isoforms, chimeras with increasing length of the NH2-terminus of MAO-A (up to residue 256) showed a marked decrease in affinity towards the MAO-B substrate phenylethylamine and the inhibitor N-(2-aminoethyl)-5-chloro-2-pyridine carboxamide .	lazabemide	290-338	monoamine oxidase A	Homo sapiens	164-169
7783122-0	1995	Studies on the monoamine oxidase (MAO)-catalyzed oxidation of phenyl-substituted 1-methyl-4-phenoxy-1,2,3,6-tetrahydropyridine derivatives: factors contributing to MAO-A and MAO-B selectivity.	phenyl-substituted 1-methyl-4-phenoxy-1,2,3,6-tetrahydropyridine	62-126	monoamine oxidase A	Homo sapiens	164-169
7783122-6	1995	The best defined structural parameter relating to selectivity again was the relatively better MAO-A substrate properties of tetrahydropyridine derivatives bearing bulky C-4 substituents.	tetrahydropyridine derivatives	124-154	monoamine oxidase A	Homo sapiens	94-99
7663405-0	1995	Interaction of indole derivatives with monoamine oxidase A and B.	indole	15-21	monoamine oxidase A	Homo sapiens	39-64
7663405-5	1995	The QSAR analysis revealed the requirement of co-planar structure of substituents at C2 and C3 of indole ring for selective MAO-A inhibition, whilst type of bond was less essential.	indole	98-104	monoamine oxidase A	Homo sapiens	124-129
7663405-6	1995	The presence of hydroxy group at C5 of isatin increased selectivity of MAO-A inhibition, however simultaneous insertion of substituents into both positions of indole ring (5-hydroxy-2-phenylindole) led to a decrease of MAO-A inhibition.	Isatin	39-45	monoamine oxidase A	Homo sapiens	71-76
7663405-6	1995	The presence of hydroxy group at C5 of isatin increased selectivity of MAO-A inhibition, however simultaneous insertion of substituents into both positions of indole ring (5-hydroxy-2-phenylindole) led to a decrease of MAO-A inhibition.	Isatin	39-45	monoamine oxidase A	Homo sapiens	219-224
7663405-6	1995	The presence of hydroxy group at C5 of isatin increased selectivity of MAO-A inhibition, however simultaneous insertion of substituents into both positions of indole ring (5-hydroxy-2-phenylindole) led to a decrease of MAO-A inhibition.	5-hydroxy-2-phenylindole	172-196	monoamine oxidase A	Homo sapiens	219-224
7717091-1	1995	This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO-A) moclobemide, which has now received extensive evaluation.	Moclobemide	107-118	monoamine oxidase A	Homo sapiens	79-98
7796873-4	1995	Monoamine oxidase A and B inhibitors, tranylcypromine and clorgyline but not l-deprenyl increased the extent of 6-hydroxydopamine induced inhibition of complex I.	Oxidopamine	112-129	monoamine oxidase A	Homo sapiens	0-25
7767310-0	1995	Evaluation of radioiodinated iodoclorgyline as a SPECT radiopharmaceutical for MAO-A in the brain.	6-iodoclorgyline	29-43	monoamine oxidase A	Homo sapiens	79-84
7767310-1	1995	An in vivo estimation of the newly synthesized MAO-A specific inhibitor, [125I]-labeled N-[3(2,4-dichloro-6-iodophenoxy)propyl]-N-methyl-2- propynylamine ([125I]-iodoclorgyline), was performed.	6-iodoclorgyline	88-153	monoamine oxidase A	Homo sapiens	47-52
7767310-1	1995	An in vivo estimation of the newly synthesized MAO-A specific inhibitor, [125I]-labeled N-[3(2,4-dichloro-6-iodophenoxy)propyl]-N-methyl-2- propynylamine ([125I]-iodoclorgyline), was performed.	125i]-iodoclorgyline	156-176	monoamine oxidase A	Homo sapiens	47-52
7767310-3	1995	Pretreatments with clorgyline and l-deprenyl showed selective binding of [125I]-iodoclorgyline to MAO-A in the brain at 24 h post-injection.	Clorgyline	19-29	monoamine oxidase A	Homo sapiens	98-103
7767310-3	1995	Pretreatments with clorgyline and l-deprenyl showed selective binding of [125I]-iodoclorgyline to MAO-A in the brain at 24 h post-injection.	Selegiline	34-44	monoamine oxidase A	Homo sapiens	98-103
7767310-3	1995	Pretreatments with clorgyline and l-deprenyl showed selective binding of [125I]-iodoclorgyline to MAO-A in the brain at 24 h post-injection.	[125i]-iodoclorgyline	73-94	monoamine oxidase A	Homo sapiens	98-103
7767310-4	1995	Moreover, a good correlation (r = 0.907) between the uptake of [125I]-iodoclorgyline and MAO-A enzyme activity in the cortex was observed in the pretreatment study with several doses of clorgyline.	[125i]-iodoclorgyline	63-84	monoamine oxidase A	Homo sapiens	89-94
7767310-4	1995	Moreover, a good correlation (r = 0.907) between the uptake of [125I]-iodoclorgyline and MAO-A enzyme activity in the cortex was observed in the pretreatment study with several doses of clorgyline.	Clorgyline	74-84	monoamine oxidase A	Homo sapiens	89-94
7767310-5	1995	Although improvement to increase the brain/blood ratio is desirable because of slow blood clearance of the radioactivity, radioiodinated iodoclorgyline may serve as a useful SPECT radiopharmaceutical for quantitative analysis of MAO-A in the brain.	6-iodoclorgyline	137-151	monoamine oxidase A	Homo sapiens	229-234
7485245-0	1995	Preliminary evidence for an association of a dinucleotide repeat polymorphism at the MAOA gene with early onset alcoholism/substance abuse.	Dinucleoside Phosphates	45-57	monoamine oxidase A	Homo sapiens	85-89
7485245-1	1995	An association between the liability to early onset alcoholism/substance abuse and a recently discovered dinucleotide repeat length polymorphism at the MAOA gene (MAOCA-1) was examined using polymerase chain reaction (PCR).	Dinucleoside Phosphates	105-117	monoamine oxidase A	Homo sapiens	152-156
7727530-8	1995	From substrate specificity and inhibitor susceptibility, it is suggested that the monoamine oxidase from A. niger (MAO-N) is a prototype of the two mammalian enzymes, MAO-A and MAO-B.	mao-n	115-120	monoamine oxidase A	Homo sapiens	167-172
7714227-2	1995	A switch in treatment from TCAs to moclobemide, a reversible and selective inhibitor of MAO-A, was investigated in a double-blind, placebo-controlled study in healthy volunteers.	Moclobemide	35-46	monoamine oxidase A	Homo sapiens	88-93
7717091-1	1995	This article reviews efficacy studies of the reversible selective inhibitor of monoamine oxidase A (MAO-A) moclobemide, which has now received extensive evaluation.	Moclobemide	107-118	monoamine oxidase A	Homo sapiens	100-105
7772614-8	1995	Thus far only a small number of studies with selective MAO-A inhibitors, such as moclobemide and brofaromine, have been conducted in social phobia, and the results indicate that both compounds are effective.	Moclobemide	81-92	monoamine oxidase A	Homo sapiens	55-60
7599386-8	1995	The involved epidermis produces hydrogen peroxide due to defective tetrahydrobiopterin recycling and increased monoamine oxidase A activity, whereupon catalase is inactivated.	Hydrogen Peroxide	32-49	monoamine oxidase A	Homo sapiens	111-130
7772614-8	1995	Thus far only a small number of studies with selective MAO-A inhibitors, such as moclobemide and brofaromine, have been conducted in social phobia, and the results indicate that both compounds are effective.	brofaromine	97-108	monoamine oxidase A	Homo sapiens	55-60
8584674-1	1995	Monoamine oxidase (MAO) A (EC 1.4.3.4) oxidizes norepinephrine and serotonin and is expressed in a cell type-specific manner.	Norepinephrine	48-62	monoamine oxidase A	Homo sapiens	0-25
8527006-5	1995	IC50 values for MAO A were found to be 44 microM (105 microM for methyl indole-3-propionate), 88 microM and 120 microM, respectively, whilst those for MAO B were each greater than 1 mM.	Methyl 3-(1H-indol-3-yl)propanoate	65-91	monoamine oxidase A	Homo sapiens	16-21
8695059-7	1995	A correlation, though rather weak, was obtained between MAO-A activity and MHPG concentration (P = 0.045).	Methoxyhydroxyphenylglycol	75-79	monoamine oxidase A	Homo sapiens	56-61
8584674-1	1995	Monoamine oxidase (MAO) A (EC 1.4.3.4) oxidizes norepinephrine and serotonin and is expressed in a cell type-specific manner.	Serotonin	67-76	monoamine oxidase A	Homo sapiens	0-25
7884022-1	1994	The effect of a short treatment (7 days) with the reversible monoamine oxidase type A inhibitor toloxatone on the reactivity to the inhalation of 35% CO2 was evaluated in 18 panic patients who responded to 35% CO2 inhalation with panic before treatment.	toloxatone	96-106	monoamine oxidase A	Homo sapiens	61-85
7891891-5	1994	Previous reports have described the accumulation of the 5HT metabolite 5-hydroxyindoleacetic acid and increased activities of the 5HT-metabolizing enzyme MAOA in this same material from patients with hepatic encephalopathy.	Serotonin	130-133	monoamine oxidase A	Homo sapiens	154-158
7808446-8	1994	When 5-HT is used as a substrate, trout MAO is more sensitive to clorgyline (IC50, 2.8 +/- 0.2 x 10(-8) M) than deprenyl (IC50, 1.0 +/- 0.1 x 10(-6) M), a result similar to the inhibition selectivity of human MAO-A.	Clorgyline	65-75	monoamine oxidase A	Homo sapiens	209-214
7918350-1	1994	Women with bulimia nervosa undergoing treatment with the reversible monoamine oxidase type A inhibitor, brofaromine, were rated for mood and eating behaviour and their plasma and urine were assessed for phenylacetic acid (unconjugated and total) and unconjugated phenylethylamine prior to and after four weeks of drug treatment.	brofaromine	104-115	monoamine oxidase A	Homo sapiens	68-92
7953696-6	1994	In contrast to the effects of deprenyl and pargyline, co-administration of the MAO-A selective inhibitor clorgyline (1 mg/kg) did not alter binding.	Clorgyline	105-115	monoamine oxidase A	Homo sapiens	79-84
7953696-9	1994	Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities.	Selegiline	18-26	monoamine oxidase A	Homo sapiens	69-74
7953696-9	1994	Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities.	Selegiline	18-26	monoamine oxidase A	Homo sapiens	118-123
7953696-9	1994	Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities.	Pargyline	30-39	monoamine oxidase A	Homo sapiens	69-74
7953696-9	1994	Administration of deprenyl or pargyline, together with pCA, itself a MAO-A inhibitor, will lead to inhibition of both MAO-A and MAO-B activities.	Pargyline	30-39	monoamine oxidase A	Homo sapiens	118-123
8056992-2	1994	The reversible, selective monoamine oxidase A inhibitor moclobemide (450 mg daily) was compared with imipramine (150 mg daily) and placebo in a multicentre, controlled clinical trial lasting 6 weeks.	Moclobemide	56-67	monoamine oxidase A	Homo sapiens	26-45
7829762-0	1994	A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression.	brofaromine	67-78	monoamine oxidase A	Homo sapiens	103-108
7519662-1	1994	Monoamine oxidase (MAO) A (EC 1.4.3.4) oxidizes norepinephrine and serotonin and is expressed in a cell type-specific manner.	Norepinephrine	48-62	monoamine oxidase A	Homo sapiens	0-25
7519662-1	1994	Monoamine oxidase (MAO) A (EC 1.4.3.4) oxidizes norepinephrine and serotonin and is expressed in a cell type-specific manner.	Serotonin	67-76	monoamine oxidase A	Homo sapiens	0-25
7816197-4	1994	Using tritiated monoamine oxidase inhibitors (Ro41-1049 and lazabemide)--as high affinity substrates selective for monoamine oxidases A and B, respectively--it was found that monoamine oxidase B activity increased up to three-fold exclusively in temporal, parietal and frontal cortices of Alzheimer disease cases compared with controls.	Ro 41-1049	46-55	monoamine oxidase A	Homo sapiens	115-141
7816197-4	1994	Using tritiated monoamine oxidase inhibitors (Ro41-1049 and lazabemide)--as high affinity substrates selective for monoamine oxidases A and B, respectively--it was found that monoamine oxidase B activity increased up to three-fold exclusively in temporal, parietal and frontal cortices of Alzheimer disease cases compared with controls.	lazabemide	60-70	monoamine oxidase A	Homo sapiens	115-141
7816197-7	1994	[3H]Ro41-1049 binding (i.e. monoamine oxidase A) was unchanged in all tissues of diseased versus control brains.	Tritium	1-3	monoamine oxidase A	Homo sapiens	28-47
7816197-7	1994	[3H]Ro41-1049 binding (i.e. monoamine oxidase A) was unchanged in all tissues of diseased versus control brains.	Ro 41-1049	4-13	monoamine oxidase A	Homo sapiens	28-47
8027990-5	1994	A group of N-arylacetamides are highly specific inhibitors of MAO A, some with IC50 values in the 10-100 nM range.	n-arylacetamides	11-27	monoamine oxidase A	Homo sapiens	62-67
7972347-1	1994	In a controlled, double-blind, comparative four-week trial on reactive or neurotic major depressed inpatients, the efficacy and safety of the new selective and reversible inhibitor of monoamine oxidase type A, brofaromine, was evaluated in three dose steps (50 mg/day [N = 13], 100 mg/day [N = 12], and 150 mg/day [N = 11]) versus 20 mg tranylcypromine/day (N = 11).	brofaromine	210-221	monoamine oxidase A	Homo sapiens	184-208
7952273-8	1994	These differences prompted the further characterization of [3H]SR 95531 binding in the LC, revealing a significant affinity for monoamine oxidase type A (MAO-A), which is highly concentrated in this nucleus.	Tritium	60-62	monoamine oxidase A	Homo sapiens	154-159
7952273-9	1994	In a competition binding study, a reduction of up to 25% of the [3H]SR 95531 binding was observed with MAO-A but not MAO-B inhibitors, at concentrations which produce maximum but selective enzyme inhibition.	Tritium	65-67	monoamine oxidase A	Homo sapiens	103-108
7952273-10	1994	Correspondingly, 2 h after the oral administration of supramaximal doses of the MAO-A inhibitors moclobemide and Ro 41-1049 (but not the MAO-B inhibitor lazabemide) the in vitro binding of [3H]SR 95531 was markedly reduced (by 77 and 82% of controls respectively).	Moclobemide	97-108	monoamine oxidase A	Homo sapiens	80-85
7952273-10	1994	Correspondingly, 2 h after the oral administration of supramaximal doses of the MAO-A inhibitors moclobemide and Ro 41-1049 (but not the MAO-B inhibitor lazabemide) the in vitro binding of [3H]SR 95531 was markedly reduced (by 77 and 82% of controls respectively).	Ro 41-1049	113-123	monoamine oxidase A	Homo sapiens	80-85
7952273-11	1994	Moreover, enzyme radioautography with [3H]Ro 41-1049 revealed that SR 95531 has a significant affinity for MAO-A (IC50 values were 10(-5) and 4 x 10(-6) M in the LC and dentate gyrus respectively) but not for MAO-B ([3H]lazabemide binding).	Tritium	217-219	monoamine oxidase A	Homo sapiens	107-112
7952273-11	1994	Moreover, enzyme radioautography with [3H]Ro 41-1049 revealed that SR 95531 has a significant affinity for MAO-A (IC50 values were 10(-5) and 4 x 10(-6) M in the LC and dentate gyrus respectively) but not for MAO-B ([3H]lazabemide binding).	lazabemide	220-230	monoamine oxidase A	Homo sapiens	107-112
7519866-0	1994	Monoamine oxidase-A: pharmacodynamics in humans of moclobemide, a reversible and selective inhibitor.	Moclobemide	51-62	monoamine oxidase A	Homo sapiens	0-19
7527564-1	1994	The main metabolites of noradrenalin, dopamine, and serotonin-3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), respectively--were estimated in plasma of 21 depressed patients before and after 2 and 4 weeks of treatment with the monoamine oxidase-type A (MAO-A) inhibitor moclobemide (mean final daily dose = 8.9 mg/kg body weight).	serotonin-3-methoxy-4-hydroxyphenylglycol	52-93	monoamine oxidase A	Homo sapiens	285-309
7527564-1	1994	The main metabolites of noradrenalin, dopamine, and serotonin-3-methoxy-4-hydroxyphenylglycol (MHPG), homovanillic acid (HVA), and 5-hydroxyindoleacetic acid (5-HIAA), respectively--were estimated in plasma of 21 depressed patients before and after 2 and 4 weeks of treatment with the monoamine oxidase-type A (MAO-A) inhibitor moclobemide (mean final daily dose = 8.9 mg/kg body weight).	serotonin-3-methoxy-4-hydroxyphenylglycol	52-93	monoamine oxidase A	Homo sapiens	311-316
7519866-2	1994	Single oral doses of 300, 450 and 600 mg moclobemide, a monoamine oxidase type A inhibitor, were administered in a cross-over design to eight healthy male volunteers.	Moclobemide	41-52	monoamine oxidase A	Homo sapiens	56-80
7519866-5	1994	A physiological pharmacokinetic-pharmacodynamic model was used to describe MAO-A inhibition as reflected in the alterations of monoamine metabolites.	monoamine	127-136	monoamine oxidase A	Homo sapiens	75-80
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Carbon-14	105-108	monoamine oxidase A	Homo sapiens	140-145
7514408-2	1994	The in vitro studies confirmed that 4-amino-alpha-methylphenethylamine derivatives are highly selective and reversible MAO-A inhibitors.	4-amino-alpha-methylphenethylamine	36-70	monoamine oxidase A	Homo sapiens	119-124
8151621-0	1994	Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.	4-(aryloxy)tetrahydropyridine	6-35	monoamine oxidase A	Homo sapiens	55-74
8151621-0	1994	Novel 4-(aryloxy)tetrahydropyridine analogs of MPTP as monoamine oxidase A and B substrates.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	47-51	monoamine oxidase A	Homo sapiens	55-74
8151621-2	1994	The expected dihydropyridinium metabolites generated from these MAO-A- and MAO-B-catalyzed oxidations of the 4-(aryloxy)tetrahydropyridine analogs were found to undergo rapid hydrolytic cleavage to yield the corresponding arenol and 1-methyl-2,3-dihydro-4-pyridone, a species that could be monitored spectrophotometrically.	dihydropyridinium	13-30	monoamine oxidase A	Homo sapiens	64-69
8151621-2	1994	The expected dihydropyridinium metabolites generated from these MAO-A- and MAO-B-catalyzed oxidations of the 4-(aryloxy)tetrahydropyridine analogs were found to undergo rapid hydrolytic cleavage to yield the corresponding arenol and 1-methyl-2,3-dihydro-4-pyridone, a species that could be monitored spectrophotometrically.	4-(aryloxy)tetrahydropyridine	109-138	monoamine oxidase A	Homo sapiens	64-69
8151621-2	1994	The expected dihydropyridinium metabolites generated from these MAO-A- and MAO-B-catalyzed oxidations of the 4-(aryloxy)tetrahydropyridine analogs were found to undergo rapid hydrolytic cleavage to yield the corresponding arenol and 1-methyl-2,3-dihydro-4-pyridone, a species that could be monitored spectrophotometrically.	Arenol	222-228	monoamine oxidase A	Homo sapiens	64-69
8151621-2	1994	The expected dihydropyridinium metabolites generated from these MAO-A- and MAO-B-catalyzed oxidations of the 4-(aryloxy)tetrahydropyridine analogs were found to undergo rapid hydrolytic cleavage to yield the corresponding arenol and 1-methyl-2,3-dihydro-4-pyridone, a species that could be monitored spectrophotometrically.	1-methyl-2,3-dihydro-4-pyridone	233-264	monoamine oxidase A	Homo sapiens	64-69
8151621-3	1994	We have exploited this reaction sequence to probe the active sites of beef liver MAO-B and human placental MAO-A with a variety of 4-(aryloxy)-1-methyl-1,2,3,6-tetrahydropyridine derivatives.	4-(aryloxy)-1-methyl-1,2,3,6-tetrahydropyridine	131-178	monoamine oxidase A	Homo sapiens	107-112
8151621-4	1994	The results are discussed in relationship to recently published reports describing the MAO-A vs MAO-B selectivity of various 4-(arylmethyl)tetrahydropyridine derivatives.	4-(arylmethyl)tetrahydropyridine	125-157	monoamine oxidase A	Homo sapiens	87-92
8161354-3	1994	The metabolism of [14C]sumatriptan was therefore investigated in vitro in a preparation derived from human liver, which was shown, by the use of the probe substrates [14C]testosterone (P450), [3H]5HT (MAO-A) and [14C]benzylamine (MAO-B) to be a rich source of both enzyme systems.	Sumatriptan	23-34	monoamine oxidase A	Homo sapiens	201-206
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Clorgyline	16-26	monoamine oxidase A	Homo sapiens	61-66
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Selegiline	31-39	monoamine oxidase A	Homo sapiens	61-66
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Selegiline	31-39	monoamine oxidase A	Homo sapiens	140-145
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Sumatriptan	109-120	monoamine oxidase A	Homo sapiens	61-66
8161354-4	1994	Incubation with clorgyline and deprenyl, probe inhibitors of MAO-A and MAO-B, respectively, showed that [14C]sumatriptan was metabolized by MAO-A; there was no evidence of P450 involvement in its metabolism.	Sumatriptan	109-120	monoamine oxidase A	Homo sapiens	140-145
8161354-5	1994	The data in this study therefore indicate that the enzyme MAO-A is the major enzyme responsible for the metabolism of sumatriptan in human liver.	Sumatriptan	118-129	monoamine oxidase A	Homo sapiens	58-63
8208985-2	1994	Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	152-171
8208985-2	1994	Moclobemide (Aurorix) is a newly developed, effective, short-acting well tolerable and safe antidepressant which belongs to the new class of reversible monoamine-oxidase-A inhibitors.	Moclobemide	13-20	monoamine oxidase A	Homo sapiens	152-171
8151007-0	1994	The use of the reversible monoamine oxidase-A inhibitor brofaromine in social phobia complicated by panic disorder with or without agoraphobia.	brofaromine	56-67	monoamine oxidase A	Homo sapiens	26-45
8289189-0	1994	Interaction of tetrahydrostilbazoles with monoamine oxidase A and B.	tetrahydrostilbazoles	15-36	monoamine oxidase A	Homo sapiens	42-67
8289189-4	1994	The corresponding pyridinium forms of trans-MTHS and its analogs were more potent inhibitors of MAO A (Ki values between 0.3 and 5 microM) than of MAO B, for which the Ki values varied greatly.	pyridine	18-28	monoamine oxidase A	Homo sapiens	96-101
9160569-2	1994	Following screening and placebo washout, patients received brofaromine (a combined MAO-A inhibitor/5-HT transport inhibitor) or placebo in a flexible dosing design.	brofaromine	59-70	monoamine oxidase A	Homo sapiens	83-88
7954485-1	1994	Moclobemide, a novel monoamine oxidase-A reversible inhibitor with demonstrated antidepressive efficacy, was administered double-blind versus imipramine to aged depressive subjects.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	21-40
7865179-0	1994	Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.	brofaromine	53-64	monoamine oxidase A	Homo sapiens	36-41
8828003-4	1994	Although the molecular identity of the I1 binding site remains unknown, an I2 receptive site has been reported to be encoded by monoamine oxidase genes (both MAO-A and MAO-B), suggesting a novel explanation for the antidepressant efficacy of idazoxan, a prototypic I2 ligand.	Idazoxan	242-250	monoamine oxidase A	Homo sapiens	158-163
7865179-0	1994	Monoamine oxidase inhibition by the MAO-A inhibitors brofaromine and clorgyline in healthy volunteers.	Clorgyline	69-79	monoamine oxidase A	Homo sapiens	36-41
7865179-1	1994	The present study compared the extent and duration of MAO inhibition by the selective and reversible MAO-A inhibitor brofaromine with the selective and irreversible MAO-A inhibitor clorgyline using amine pressor tests and excretion of urinary amine metabolites (MHPG, tryptamine).	brofaromine	117-128	monoamine oxidase A	Homo sapiens	101-106
7865179-1	1994	The present study compared the extent and duration of MAO inhibition by the selective and reversible MAO-A inhibitor brofaromine with the selective and irreversible MAO-A inhibitor clorgyline using amine pressor tests and excretion of urinary amine metabolites (MHPG, tryptamine).	Clorgyline	181-191	monoamine oxidase A	Homo sapiens	165-170
7931241-1	1994	N-Methyl-N-propargyl-3-(4-phenoxy)phenoxypropylamine, an analogue of the MAO-A-selective irreversible inhibitor clorgyline in which the 2,4-dichloro- substitution in clorgyline was replaced by a 2-H atom and a 4-phenoxy group, has been synthesised and assessed as an inhibitor of monoamine oxidase (MAO).	N-methyl-N-propargyl-3-(4-phenoxy)phenoxypropylamine	0-52	monoamine oxidase A	Homo sapiens	73-78
7931233-1	1994	Six months of administration of the selective MAO-B inhibitor, selegiline (l-deprenyl 0.25 mg/kg, s.c.) to aged female Fisher 344N rats suppressed MAO-A as well as MAO-B activity and increased serotonin (substrate for melatonin biosynthesis) and N-acetylserotonin (immediate melatonin precursor) levels in pineal glands taken from the animals during the night.	Selegiline	63-73	monoamine oxidase A	Homo sapiens	147-152
7865179-2	1994	The pharmacological characterization of clorgyline as an irreversible and brofaromine as a reversible MAO-A inhibitor in clinically effective doses was confirmed in humans.	brofaromine	74-85	monoamine oxidase A	Homo sapiens	102-107
7931233-1	1994	Six months of administration of the selective MAO-B inhibitor, selegiline (l-deprenyl 0.25 mg/kg, s.c.) to aged female Fisher 344N rats suppressed MAO-A as well as MAO-B activity and increased serotonin (substrate for melatonin biosynthesis) and N-acetylserotonin (immediate melatonin precursor) levels in pineal glands taken from the animals during the night.	Selegiline	75-85	monoamine oxidase A	Homo sapiens	147-152
7931241-1	1994	N-Methyl-N-propargyl-3-(4-phenoxy)phenoxypropylamine, an analogue of the MAO-A-selective irreversible inhibitor clorgyline in which the 2,4-dichloro- substitution in clorgyline was replaced by a 2-H atom and a 4-phenoxy group, has been synthesised and assessed as an inhibitor of monoamine oxidase (MAO).	Clorgyline	112-122	monoamine oxidase A	Homo sapiens	73-78
7931257-3	1994	MDL 72974A (E)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride is a potent (IC50 = 10(-9) M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A.	mofegiline	0-10	monoamine oxidase A	Homo sapiens	167-172
7931241-1	1994	N-Methyl-N-propargyl-3-(4-phenoxy)phenoxypropylamine, an analogue of the MAO-A-selective irreversible inhibitor clorgyline in which the 2,4-dichloro- substitution in clorgyline was replaced by a 2-H atom and a 4-phenoxy group, has been synthesised and assessed as an inhibitor of monoamine oxidase (MAO).	2,4-dichloro	136-148	monoamine oxidase A	Homo sapiens	73-78
7931241-6	1994	In the case of the initial, non-covalent, inhibition all these compounds were competitive inhibitors of MAO-A, with respect to the amine substrate, and the affinity for inhibitor binding increased with carbon chain length.	Amines	131-136	monoamine oxidase A	Homo sapiens	104-109
7931241-6	1994	In the case of the initial, non-covalent, inhibition all these compounds were competitive inhibitors of MAO-A, with respect to the amine substrate, and the affinity for inhibitor binding increased with carbon chain length.	Carbon	202-208	monoamine oxidase A	Homo sapiens	104-109
7931241-10	1994	The time-dependent irreversible inhibition (measured as the IC50 values after 60 min enzyme-inhibitor preincubation) showed that the potency towards MAO-A increased when the side-chain length was increased from 2 to 3 carbons but that there was no significant difference between the 3 and 4 carbon-chain compounds.	Carbon	218-225	monoamine oxidase A	Homo sapiens	149-154
7931241-10	1994	The time-dependent irreversible inhibition (measured as the IC50 values after 60 min enzyme-inhibitor preincubation) showed that the potency towards MAO-A increased when the side-chain length was increased from 2 to 3 carbons but that there was no significant difference between the 3 and 4 carbon-chain compounds.	Carbon	218-224	monoamine oxidase A	Homo sapiens	149-154
7931244-3	1994	The calculation using ab initio molecular orbital methods of the electronic properties of flavin and befloxatone, a reversible inhibitor of MAO A, led to a description of the interaction between aryl-oxazolidinones and the cofactor of the enzyme.	4,6-dinitro-o-cresol	90-96	monoamine oxidase A	Homo sapiens	140-145
7931244-3	1994	The calculation using ab initio molecular orbital methods of the electronic properties of flavin and befloxatone, a reversible inhibitor of MAO A, led to a description of the interaction between aryl-oxazolidinones and the cofactor of the enzyme.	befloxatone	101-112	monoamine oxidase A	Homo sapiens	140-145
7931244-3	1994	The calculation using ab initio molecular orbital methods of the electronic properties of flavin and befloxatone, a reversible inhibitor of MAO A, led to a description of the interaction between aryl-oxazolidinones and the cofactor of the enzyme.	aryl-oxazolidinones	195-214	monoamine oxidase A	Homo sapiens	140-145
7931233-3	1994	The data suggest that stimulation of pineal melatonin biosynthesis might be one of the consequences of MAO-A inhibition contributing to life span prolongation induced by chronic selegiline treatment.	Melatonin	44-53	monoamine oxidase A	Homo sapiens	103-108
7931233-3	1994	The data suggest that stimulation of pineal melatonin biosynthesis might be one of the consequences of MAO-A inhibition contributing to life span prolongation induced by chronic selegiline treatment.	Selegiline	178-188	monoamine oxidase A	Homo sapiens	103-108
7931238-4	1994	The kinetic behaviour of the parent amines as MAO A and MAO B inhibitors and substrates was determined.	Amines	36-42	monoamine oxidase A	Homo sapiens	46-51
7931238-6	1994	These parameters will allow us to establish the correlation with structural features that predetermine one compound to be a good MAO substrate or a good MAO A and MAO B inhibitor.	predetermine	90-102	monoamine oxidase A	Homo sapiens	153-158
7931257-3	1994	MDL 72974A (E)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride is a potent (IC50 = 10(-9) M) inhibitor of both MAO-B and SSAO, with 190-fold lower affinity for MAO-A.	e)-2-(4-fluorophenethyl)-3-fluoroallylamine hydrochloride	12-69	monoamine oxidase A	Homo sapiens	167-172
7931265-2	1994	Kinetic considerations show that the rate of reaction of MAO-A with low concentrations of free pargyline will be very much slower than that of MAO-B.	Pargyline	95-104	monoamine oxidase A	Homo sapiens	57-62
7931265-3	1994	Failure to use adequate reaction times for the concentration of pargyline added can lead to gross underestimation of the quantity of MAO-A present.	Pargyline	64-73	monoamine oxidase A	Homo sapiens	133-138
8122400-1	1994	Increase of serotonin content and decrease in 5-hydroxyindolyl acetic acid (5-HIAA) were observed under hypoxic conditions (9,000 m, 3 hrs) which correlated with inhibition of monoamine oxidase A.	Serotonin	12-21	monoamine oxidase A	Homo sapiens	176-195
7527888-5	1994	Since MAO (monoamine oxidase A and B are the major H2O2 generating enzymes in the SN much attention has been paid to their selective inhibitors as symptomatic and neuroprotective agents in PD.	Hydrogen Peroxide	51-55	monoamine oxidase A	Homo sapiens	11-36
7800155-0	1994	Effects of long-term treatment with the MAO-A inhibitor moclobemide on sleep EEG and nocturnal hormonal secretion in normal men.	Moclobemide	56-67	monoamine oxidase A	Homo sapiens	40-45
7800155-1	1994	Sleep EEG, nocturnal penile tumescence (NPT) and nocturnal hormone secretion were studied in four normal males during placebo, under up to 300 mg per day of moclobemide, the short-acting and reversible inhibitor of monoamine oxidase (type A), and after withdrawal.	Moclobemide	157-168	monoamine oxidase A	Homo sapiens	215-240
8122400-1	1994	Increase of serotonin content and decrease in 5-hydroxyindolyl acetic acid (5-HIAA) were observed under hypoxic conditions (9,000 m, 3 hrs) which correlated with inhibition of monoamine oxidase A.	Hydroxyindoleacetic Acid	76-82	monoamine oxidase A	Homo sapiens	176-195
8120155-3	1993	Brofaromine, a selective and reversible inhibitor of monoamine oxidase-A was selected for a double-blind, placebo-controlled evaluation because of previous demonstrated monoamine oxidase inhibitor efficacy in BN and because of its safer adverse reaction profile.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	53-72
10607101-0	1993	Treatment of narcolepsy-cataplexy syndrome with the new selective and reversible MAO-A inhibitor brofaromine-a pilot study.	brofaromine	97-108	monoamine oxidase A	Homo sapiens	81-86
10607101-1	1993	Eighteen narcoleptic patients were treated in a single-blind study with brofaromine, a new selective and reversible MAO-A-inhibitor.	brofaromine	72-83	monoamine oxidase A	Homo sapiens	116-121
8296582-2	1993	A comparison of the selective monoamine oxidase A inhibitor moclobemide and placebo.	Moclobemide	60-71	monoamine oxidase A	Homo sapiens	30-49
7505890-1	1993	Brofaromine, a selective and reversible inhibitor of monoamine oxidase-A (MAO-A) was given to 19 women while 17 received placebo for 8 weeks.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	53-72
7505890-1	1993	Brofaromine, a selective and reversible inhibitor of monoamine oxidase-A (MAO-A) was given to 19 women while 17 received placebo for 8 weeks.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	74-79
7505890-10	1993	This study verifies that brofaromine complies with predicted MAO-A inhibiting patterns in a clinical population.	brofaromine	25-36	monoamine oxidase A	Homo sapiens	61-66
8296582-3	1993	Thirty-four patients with seasonal affective disorder, winter depression type (WD) were randomly distributed to receive the selective monoamine oxidase-A inhibitor moclobemide (400 mg daily) or placebo in a double-blind, parallel group study lasting for up to 14 weeks.	Moclobemide	164-175	monoamine oxidase A	Homo sapiens	134-153
7905288-0	1993	Biochemistry and pharmacology of reversible inhibitors of MAO-A agents: focus on moclobemide.	Moclobemide	81-92	monoamine oxidase A	Homo sapiens	58-63
8293522-0	1993	Synthesis and characterization of 11C-labeled fluoroclorgyline: a monoamine oxidase A specific inhibitor for positron emission tomography.	Carbon-11	34-37	monoamine oxidase A	Homo sapiens	66-85
8293522-0	1993	Synthesis and characterization of 11C-labeled fluoroclorgyline: a monoamine oxidase A specific inhibitor for positron emission tomography.	fluoroclorgyline	46-62	monoamine oxidase A	Homo sapiens	66-85
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	[11c]fluoroclorgyline	56-77	monoamine oxidase A	Homo sapiens	22-46
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	[11c]fluoroclorgyline	56-77	monoamine oxidase A	Homo sapiens	48-53
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	Carbon-11	57-60	monoamine oxidase A	Homo sapiens	22-46
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	Carbon-11	57-60	monoamine oxidase A	Homo sapiens	48-53
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	methyl iodide	161-174	monoamine oxidase A	Homo sapiens	22-46
8293522-1	1993	A new radioligand for monoamine oxidase type A (MAO-A), [11C]fluoroclorgyline, was synthesized from its desmethyl precursor by N-methylation reaction using [11C]methyl iodide with a radiochemical yield of 75-85%.	methyl iodide	161-174	monoamine oxidase A	Homo sapiens	48-53
8293522-4	1993	A selective interaction with MAO-A in the accumulation of [11C]fluorclorgyline was confirmed by a competition experiment performed with the MAO-A specific inhibitor,clorgyline, and MAO-B specific inhibitor, l-deprenyl.	[11c]fluorclorgyline	58-78	monoamine oxidase A	Homo sapiens	29-34
8293522-4	1993	A selective interaction with MAO-A in the accumulation of [11C]fluorclorgyline was confirmed by a competition experiment performed with the MAO-A specific inhibitor,clorgyline, and MAO-B specific inhibitor, l-deprenyl.	[11c]fluorclorgyline	58-78	monoamine oxidase A	Homo sapiens	140-145
8293522-4	1993	A selective interaction with MAO-A in the accumulation of [11C]fluorclorgyline was confirmed by a competition experiment performed with the MAO-A specific inhibitor,clorgyline, and MAO-B specific inhibitor, l-deprenyl.	Clorgyline	68-78	monoamine oxidase A	Homo sapiens	29-34
8293522-4	1993	A selective interaction with MAO-A in the accumulation of [11C]fluorclorgyline was confirmed by a competition experiment performed with the MAO-A specific inhibitor,clorgyline, and MAO-B specific inhibitor, l-deprenyl.	Clorgyline	68-78	monoamine oxidase A	Homo sapiens	140-145
8293522-4	1993	A selective interaction with MAO-A in the accumulation of [11C]fluorclorgyline was confirmed by a competition experiment performed with the MAO-A specific inhibitor,clorgyline, and MAO-B specific inhibitor, l-deprenyl.	Selegiline	207-217	monoamine oxidase A	Homo sapiens	29-34
8293522-5	1993	These very desirable characteristics of [11C]fluoroclorgyline suggested that its 18F labeled counterpart, [18F]fluoroclorgyline, would have great potential as a longer-lived alternative to 11C labeled clorgyline for in vivo studies of MAO-A in the human brain with positron emission tomography (PET).	[18f]fluoroclorgyline	106-127	monoamine oxidase A	Homo sapiens	235-240
7905288-1	1993	Moclobemide, p-chloro-N-[morpholinoethyl]benzamide, is a prototype of RIMA (reversible inhibitor of MAO-A) agents.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	100-105
7905288-1	1993	Moclobemide, p-chloro-N-[morpholinoethyl]benzamide, is a prototype of RIMA (reversible inhibitor of MAO-A) agents.	p-chloro-n-[morpholinoethyl]benzamide	13-50	monoamine oxidase A	Homo sapiens	100-105
7905288-1	1993	Moclobemide, p-chloro-N-[morpholinoethyl]benzamide, is a prototype of RIMA (reversible inhibitor of MAO-A) agents.	rima	70-74	monoamine oxidase A	Homo sapiens	100-105
8127928-1	1993	Moclobemide is the first of a new generation of reversible inhibitors of monoamine oxidase-A (RIMA) with no clinically relevant potentiation of the hypertensive actions of dietary tyramine.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	73-92
8211186-5	1993	In each of five affected males, a point mutation was identified in the eighth exon of the MAOA structural gene, which changes a glutamine to a termination codon.	Glutamine	128-137	monoamine oxidase A	Homo sapiens	90-94
8369275-0	1993	Oxidation of tetrahydrostilbazole by monoamine oxidase A demonstrates the effect of alternate pathways in the kinetic mechanism.	tetrahydrostilbazole	13-33	monoamine oxidase A	Homo sapiens	37-56
8405291-1	1993	The activity of three catecholamine-metabolizing enzymes, monoamine oxidase type A and type B (MAO-A and MAO-B) as well as catechol-O-methyltransferase (COMT), were estimated in homogenates of human spinal cord using radiometric assays.	Catecholamines	22-35	monoamine oxidase A	Homo sapiens	58-93
8242348-2	1993	Activities of both MAOA and MAOB were significantly increased in frontal cortex and caudate nucleus, two brain regions shown previously to be the site of functional and morphological alterations of astrocytes and increased concentrations of the acid metabolites of dopamine and serotonin.	Dopamine	265-273	monoamine oxidase A	Homo sapiens	19-23
8242348-2	1993	Activities of both MAOA and MAOB were significantly increased in frontal cortex and caudate nucleus, two brain regions shown previously to be the site of functional and morphological alterations of astrocytes and increased concentrations of the acid metabolites of dopamine and serotonin.	Serotonin	278-287	monoamine oxidase A	Homo sapiens	19-23
8369275-1	1993	The steady-state kinetics for the oxidation of 1-methyl-1,2,3,6-tetrahydrostilbazole (MTHS) by purified human liver monoamine oxidase A yielded biphasic double-reciprocal plots.	1-methyl-1,2,3,6-tetrahydrostilbazole	47-84	monoamine oxidase A	Homo sapiens	116-135
8369275-1	1993	The steady-state kinetics for the oxidation of 1-methyl-1,2,3,6-tetrahydrostilbazole (MTHS) by purified human liver monoamine oxidase A yielded biphasic double-reciprocal plots.	1-methyl-1,2,3,6-tetrahydrostilbazole	86-90	monoamine oxidase A	Homo sapiens	116-135
7504824-0	1993	The effect of the MAO-A selective inhibitor brofaromine on the plasma and urine concentrations of some biogenic amines and their acidic metabolites in bulimia nervosa.	brofaromine	44-55	monoamine oxidase A	Homo sapiens	18-23
8232718-1	1993	Phenelzine [2-phenylethylhydrazine] (PLZ), a potent inhibitor of monoamine oxidase (MAO)-A and -B, is used widely in psychiatry.	phenelzine [2-phenylethylhydrazine]	0-35	monoamine oxidase A	Homo sapiens	65-97
8232718-1	1993	Phenelzine [2-phenylethylhydrazine] (PLZ), a potent inhibitor of monoamine oxidase (MAO)-A and -B, is used widely in psychiatry.	4-[({3-Hydroxy-2-Methyl-5-[(Phosphonooxy)methyl]pyridin-4-Yl}methyl)amino]butanoic Acid	37-40	monoamine oxidase A	Homo sapiens	65-97
8517863-6	1993	Those compounds where the acetylenic side chain was substituted at position 2 of the heterocyclic ring and selective inhibitors of monoamine oxidase A were more potent than those with the side chain in position 3.	acetylenic	26-36	monoamine oxidase A	Homo sapiens	131-150
8255982-2	1993	Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	57-76
8255982-2	1993	Moclobemide is a novel benzamide reversible inhibitor of monoamine oxidase A and has clinical efficacy in a wide spectrum of depressive illness including endogenous and non-endogenous depression, in younger adults and in the elderly.	benzamide	23-32	monoamine oxidase A	Homo sapiens	57-76
8363632-0	1993	Suicide inhibition of monoamine oxidases A and B by (-)-deprenyl.	Selegiline	52-64	monoamine oxidase A	Homo sapiens	22-48
8363632-2	1993	An analytical solution to the differential equations describing the kinetics of the suicide inhibition of a two-enzyme system has been derived and the modelling of suicide inhibition of the monoamine oxidases A and B (MAO A and B, EC 1.4.3.4) by a quasi-selective agent, (-)-deprenyl, is presented as an example.	Selegiline	271-283	monoamine oxidase A	Homo sapiens	190-216
8363632-2	1993	An analytical solution to the differential equations describing the kinetics of the suicide inhibition of a two-enzyme system has been derived and the modelling of suicide inhibition of the monoamine oxidases A and B (MAO A and B, EC 1.4.3.4) by a quasi-selective agent, (-)-deprenyl, is presented as an example.	Selegiline	271-283	monoamine oxidase A	Homo sapiens	218-229
8363632-3	1993	A new parameter, the specificity index is defined and used in a model which describes the specific and non-specific binding of (-)-deprenyl to MAO B and MAO A, respectively.	Selegiline	127-139	monoamine oxidase A	Homo sapiens	153-158
8376621-0	1993	The selective reversible monoamine oxidase-A inhibitor brofaromine and sleep.	brofaromine	55-66	monoamine oxidase A	Homo sapiens	25-44
8415406-0	1993	Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors.	Xanthones	12-21	monoamine oxidase A	Homo sapiens	50-69
8415406-0	1993	Substituted xanthones as selective and reversible monoamine oxidase A (MAO-A) inhibitors.	Xanthones	12-21	monoamine oxidase A	Homo sapiens	71-76
8408980-2	1993	In a double-blind study the selective monoamine oxidase-A inhibitor brofaromine was compared with the classical MAOI tranylcypromine in 39 patients with major depression resistant to treatment with tricyclic antidepressants.	brofaromine	68-79	monoamine oxidase A	Homo sapiens	38-57
8316221-0	1993	Site-directed mutagenesis of monoamine oxidase A and B: role of cysteines.	Cysteine	64-73	monoamine oxidase A	Homo sapiens	29-54
8354766-0	1993	Moclobemide: a reversible MAO-A-inhibitor showing weaker antidepressant effect than clomipramine in a controlled multicenter study.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	26-31
8316221-1	1993	Nine cysteines are found in the deduced amino acid sequences of both human liver monoamine oxidase (MAO)-A and MAO-B.	Cysteine	5-14	monoamine oxidase A	Homo sapiens	81-106
8316221-2	1993	The role of these cysteine residues in MAO-A and -B catalytic activity was studied by site-directed mutagenesis, whereby each cysteine residue was converted to serine.	Cysteine	18-26	monoamine oxidase A	Homo sapiens	39-51
8316221-2	1993	The role of these cysteine residues in MAO-A and -B catalytic activity was studied by site-directed mutagenesis, whereby each cysteine residue was converted to serine.	Cysteine	126-134	monoamine oxidase A	Homo sapiens	39-51
8316221-2	1993	The role of these cysteine residues in MAO-A and -B catalytic activity was studied by site-directed mutagenesis, whereby each cysteine residue was converted to serine.	Serine	160-166	monoamine oxidase A	Homo sapiens	39-51
8316221-3	1993	The wild-type and mutant cDNAs were then transiently transfected into COS cells and assayed for MAO-A and -B catalytic activity using 5-[3H]hydroxytryptamine and [14C]phenylethylamine, respectively, as substrates.	5-[3h]hydroxytryptamine	134-157	monoamine oxidase A	Homo sapiens	96-108
8316221-4	1993	Catalytic activities were retained in seven MAO-A cysteine to serine mutants (mutations at residues 165, 210, 266, 306, 321, 323, and 398) and in six MAO-B cysteine to serine mutants (mutations at residues 5, 172, 192, 297, 312, and 389).	Serine	62-68	monoamine oxidase A	Homo sapiens	44-49
8316221-6	1993	Substitution of MAO-A Cys-374 and -406 and MAO-B Cys-156, -365, and -397 with serine resulted in complete loss of MAO-A and -B catalytic activity.	Cysteine	22-25	monoamine oxidase A	Homo sapiens	16-21
8316221-6	1993	Substitution of MAO-A Cys-374 and -406 and MAO-B Cys-156, -365, and -397 with serine resulted in complete loss of MAO-A and -B catalytic activity.	Cysteine	22-25	monoamine oxidase A	Homo sapiens	114-126
8316221-6	1993	Substitution of MAO-A Cys-374 and -406 and MAO-B Cys-156, -365, and -397 with serine resulted in complete loss of MAO-A and -B catalytic activity.	Cysteine	49-52	monoamine oxidase A	Homo sapiens	114-126
8316221-6	1993	Substitution of MAO-A Cys-374 and -406 and MAO-B Cys-156, -365, and -397 with serine resulted in complete loss of MAO-A and -B catalytic activity.	Serine	78-84	monoamine oxidase A	Homo sapiens	16-21
8316221-6	1993	Substitution of MAO-A Cys-374 and -406 and MAO-B Cys-156, -365, and -397 with serine resulted in complete loss of MAO-A and -B catalytic activity.	Serine	78-84	monoamine oxidase A	Homo sapiens	114-126
8316221-8	1993	The loss of catalytic activity in the MAO-A Ser-406 and MAO-B Ser-397 mutants may be due to the prevention of covalent binding of the enzyme to the cofactor FAD, which is necessary for catalytic activity.	Serine	44-47	monoamine oxidase A	Homo sapiens	38-43
8316221-8	1993	The loss of catalytic activity in the MAO-A Ser-406 and MAO-B Ser-397 mutants may be due to the prevention of covalent binding of the enzyme to the cofactor FAD, which is necessary for catalytic activity.	Serine	62-65	monoamine oxidase A	Homo sapiens	38-43
8316221-9	1993	The loss of catalytic activity of MAO-A Ser-374 and MAO-B Ser-156 and -365 suggests that these cysteines are important for catalytic activity, but whether they are involved in forming the active site or are important for the appropriate conformation of MAO-A and -B remains to be studied.	Serine	40-43	monoamine oxidase A	Homo sapiens	34-39
8316221-9	1993	The loss of catalytic activity of MAO-A Ser-374 and MAO-B Ser-156 and -365 suggests that these cysteines are important for catalytic activity, but whether they are involved in forming the active site or are important for the appropriate conformation of MAO-A and -B remains to be studied.	Serine	40-43	monoamine oxidase A	Homo sapiens	253-265
8316221-9	1993	The loss of catalytic activity of MAO-A Ser-374 and MAO-B Ser-156 and -365 suggests that these cysteines are important for catalytic activity, but whether they are involved in forming the active site or are important for the appropriate conformation of MAO-A and -B remains to be studied.	Cysteine	95-104	monoamine oxidase A	Homo sapiens	34-39
8316221-9	1993	The loss of catalytic activity of MAO-A Ser-374 and MAO-B Ser-156 and -365 suggests that these cysteines are important for catalytic activity, but whether they are involved in forming the active site or are important for the appropriate conformation of MAO-A and -B remains to be studied.	Cysteine	95-104	monoamine oxidase A	Homo sapiens	253-265
8490690-0	1993	Moclobemide: a reversible inhibitor of monoamine oxidase type A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	39-63
8487265-0	1993	Molecular size and flexibility as determinants of selectivity in the oxidation of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine analogs by monoamine oxidase A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	82-126	monoamine oxidase A	Homo sapiens	138-163
8487265-1	1993	The introduction of a methylene bridge between the phenyl and tetrahydropyridyl moieties of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in increased selectivity for monoamine oxidase B (MAO B) over monoamine oxidase A (MAO A).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	92-136	monoamine oxidase A	Homo sapiens	214-233
8487265-1	1993	The introduction of a methylene bridge between the phenyl and tetrahydropyridyl moieties of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in increased selectivity for monoamine oxidase B (MAO B) over monoamine oxidase A (MAO A).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	92-136	monoamine oxidase A	Homo sapiens	235-240
8487265-1	1993	The introduction of a methylene bridge between the phenyl and tetrahydropyridyl moieties of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in increased selectivity for monoamine oxidase B (MAO B) over monoamine oxidase A (MAO A).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	138-142	monoamine oxidase A	Homo sapiens	214-233
8487265-1	1993	The introduction of a methylene bridge between the phenyl and tetrahydropyridyl moieties of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) results in increased selectivity for monoamine oxidase B (MAO B) over monoamine oxidase A (MAO A).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	138-142	monoamine oxidase A	Homo sapiens	235-240
8487265-3	1993	In the present study, a number of isomeric 4-naphthyl-, 4-(naphthylalkyl)-, 4-thienyl-, and 4-(thienylalkyl)tetrahydropyridines, conformationally restrained and flexible analogs of MPTP, were synthesized and evaluated as potential selective substrates of MAO A and B.	, 4-thienyl-, and 4-(thienylalkyl)tetrahydropyridines	74-127	monoamine oxidase A	Homo sapiens	255-260
8487265-4	1993	In terms of the parameter (turnover number)/Km, the bulky naphthyl analogs were invariably better substrates of MAO A than kynuramine, the reference substrate for this enzyme.	Kynuramine	123-133	monoamine oxidase A	Homo sapiens	112-117
8490690-2	1993	Moclobemide, the first reversible inhibitor of monoamine oxidase type A to enter widespread clinical use, has a number of advantages over traditional monoamine oxidase inhibitors and represents a valuable addition to the antidepressant armamentarium.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	47-71
8488751-1	1993	The clinical efficacy of the monoamine oxidase A inhibitor moclobemide and its effect on the dexamethasone suppression test (DST) and plasma and urine methoxyhydroxyphenylglycol (MHPG) were investigated in 26 depressed patients during a 4-week clinical trial.	Moclobemide	59-70	monoamine oxidase A	Homo sapiens	29-48
8313394-3	1993	However, BW 1370U87 differs from most other MAO inhibitors in that its mechanism of action follows simple competitive kinetics, so that an unusually high concentration of tyramine in peripheral tissues may displace the inhibitor from MAO-A sites in the intestine and liver.	Tyramine	171-179	monoamine oxidase A	Homo sapiens	234-239
8490109-0	1993	Influence of food on the disposition of the monoamine oxidase-A inhibitor brofaromine in healthy volunteers.	brofaromine	74-85	monoamine oxidase A	Homo sapiens	44-63
8430214-0	1993	Newer aspects of the reversible inhibitor of MAO-A and serotonin reuptake, brofaromine.	brofaromine	75-86	monoamine oxidase A	Homo sapiens	45-50
8430214-5	1993	Earlier data from in vitro and some ex vivo experiments had suggested an irreversible interaction of brofaromine with MAO-A, whereas the short duration of action, the absence of cumulation of effect and the displaceability by endogenously released substrates indicated reversibility.	brofaromine	101-112	monoamine oxidase A	Homo sapiens	118-123
8428624-1	1993	Monoamine oxidase (MAO)-A and MAO-B are FAD-containing mitochondrial enzymes which catabolize biogenic and xenobiotic amines.	Flavin-Adenine Dinucleotide	40-43	monoamine oxidase A	Homo sapiens	0-25
8428624-1	1993	Monoamine oxidase (MAO)-A and MAO-B are FAD-containing mitochondrial enzymes which catabolize biogenic and xenobiotic amines.	xenobiotic amines	107-124	monoamine oxidase A	Homo sapiens	0-25
8443155-1	1993	Monoamine oxidases A and B have identical flavin sites but different, although overlapping, amine substrate specificity.	4,6-dinitro-o-cresol	42-48	monoamine oxidase A	Homo sapiens	0-26
8443155-4	1993	The second-order rate constant for the reoxidation was highest with monoamine oxidase A when kynuramine was the ligand (508 x 10(3) M-1 s-1) compared to 4 x 10(3) M-1 s-1 in its absence.	Kynuramine	93-103	monoamine oxidase A	Homo sapiens	68-87
8348033-3	1993	The action of terindole is related to its ability to exert reversible inhibitory effects on MAO A activity.	terindole	14-23	monoamine oxidase A	Homo sapiens	92-97
8518326-0	1993	Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.	brofaromine	38-49	monoamine oxidase A	Homo sapiens	22-27
8518326-0	1993	Metabolism of the new MAO-A inhibitor brofaromine in poor and extensive metabolizers of debrisoquine.	Debrisoquin	88-100	monoamine oxidase A	Homo sapiens	22-27
8443037-8	1993	Thus, neurotransmitters in the central nervous system which are substrate for MAO-A (i.e. noradrenaline, 5-HT) may be involved in the control of capsaicin-induced reflex bronchoconstriction.	Norepinephrine	90-103	monoamine oxidase A	Homo sapiens	78-83
8443037-8	1993	Thus, neurotransmitters in the central nervous system which are substrate for MAO-A (i.e. noradrenaline, 5-HT) may be involved in the control of capsaicin-induced reflex bronchoconstriction.	Capsaicin	145-154	monoamine oxidase A	Homo sapiens	78-83
8313394-0	1993	Preclinical and early clinical studies with BW 1370U87, a reversible competitive monoamine oxidase-A inhibitor.	1370u87	47-54	monoamine oxidase A	Homo sapiens	81-100
8313394-2	1993	Like other MAO-A inhibitors, BW 1370U87 elevates neurotransmitter amines in the brain over the same dose range at which it exhibits positive activities in animal models of depressive illness.	1370u87	32-39	monoamine oxidase A	Homo sapiens	11-16
8313396-4	1993	The introduction of reversible inhibitors of monoamine oxidase-A (RIMAs) has greatly reduced both the number and severity of these interactions and, in particular, the risk of hypertensive crises following the ingestion of tyramine (the "cheese effect").	Tyramine	223-231	monoamine oxidase A	Homo sapiens	45-64
8313399-3	1993	Moclobemide is the first reversible MAO-A inhibitor to be widely marketed and is currently approved for marketing in approximately 50 countries.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	36-41
8313400-2	1993	This article reviews studies on the efficacy of both the classical MAOIs and the new, selective monoamine oxidase-A (MAO-A) inhibitor brofaromine in patients with resistant major depression.	brofaromine	134-145	monoamine oxidase A	Homo sapiens	96-115
8313400-2	1993	This article reviews studies on the efficacy of both the classical MAOIs and the new, selective monoamine oxidase-A (MAO-A) inhibitor brofaromine in patients with resistant major depression.	brofaromine	134-145	monoamine oxidase A	Homo sapiens	117-122
8313400-5	1993	More studies on the benefits of the new MAO-A inhibitors in resistant depression are indicated, not only with brofaromine but also with moclobemide, which to date has not been studied in this indication.	brofaromine	110-121	monoamine oxidase A	Homo sapiens	40-45
8313400-5	1993	More studies on the benefits of the new MAO-A inhibitors in resistant depression are indicated, not only with brofaromine but also with moclobemide, which to date has not been studied in this indication.	Moclobemide	136-147	monoamine oxidase A	Homo sapiens	40-45
8313401-2	1993	The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated.	brofaromine	67-78	monoamine oxidase A	Homo sapiens	35-40
8313401-2	1993	The new, selective, and reversible MAO-A inhibitors exemplified by brofaromine and moclobemide do not require dietary restrictions, have fewer drug interactions, and are better tolerated.	Moclobemide	83-94	monoamine oxidase A	Homo sapiens	35-40
8461277-1	1993	Monoamine oxidase (MAO) A and B play an important role in regulating levels of biogenic amines.	Amines	88-94	monoamine oxidase A	Homo sapiens	0-31
8468439-2	1993	However, moclobemide, a selective reversible inhibitor of MAO-A, has a low propensity for producing drug interactions.	Moclobemide	9-20	monoamine oxidase A	Homo sapiens	58-63
8390270-0	1993	Dopamine metabolism and neurotransmission in primate brain in relationship to monoamine oxidase A and B inhibition.	Dopamine	0-8	monoamine oxidase A	Homo sapiens	78-103
8390270-1	1993	The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors.	Amines	81-87	monoamine oxidase A	Homo sapiens	171-196
8390270-1	1993	The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors.	Amines	81-87	monoamine oxidase A	Homo sapiens	283-288
8390270-1	1993	The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors.	Tyramine	96-104	monoamine oxidase A	Homo sapiens	171-196
8390270-1	1993	The "cheese effect", potentiation of sympathomimetic action of indirectly acting amines such as tyramine, the main side effect of irreversible non-selective and selective monoamine oxidase (MAO) A inhibitors, has largely been eliminated in the new generation of reversible selective MAO-A and B and irreversible MAO-B inhibitors.	Tyramine	96-104	monoamine oxidase A	Homo sapiens	283-288
8469735-1	1993	Specific 2-propynylamine inhibitors of monoamine oxidase (MAO) pargyline and especially chlorgyline, a selective inhibitor of MAO A (but not deprenyl, a selective inhibitor of MAO B) increase the radioprotective effect of small doses of O-methyltyramine and phenylephrine and do not change the efficacy of large doses.	propargylamine	9-24	monoamine oxidase A	Homo sapiens	126-131
8469735-1	1993	Specific 2-propynylamine inhibitors of monoamine oxidase (MAO) pargyline and especially chlorgyline, a selective inhibitor of MAO A (but not deprenyl, a selective inhibitor of MAO B) increase the radioprotective effect of small doses of O-methyltyramine and phenylephrine and do not change the efficacy of large doses.	O-methyltyramine	237-253	monoamine oxidase A	Homo sapiens	126-131
8469735-1	1993	Specific 2-propynylamine inhibitors of monoamine oxidase (MAO) pargyline and especially chlorgyline, a selective inhibitor of MAO A (but not deprenyl, a selective inhibitor of MAO B) increase the radioprotective effect of small doses of O-methyltyramine and phenylephrine and do not change the efficacy of large doses.	Phenylephrine	258-271	monoamine oxidase A	Homo sapiens	126-131
7871061-4	1993	In this study 30 patients with PD with or without agoraphobia (DSM-III-R) were treated with the selective and reversible MAO-A inhibitor brofaromine (150 mg daily) in a 12-week double-blind placebo controlled design.	brofaromine	137-148	monoamine oxidase A	Homo sapiens	121-126
8469735-1	1993	Specific 2-propynylamine inhibitors of monoamine oxidase (MAO) pargyline and especially chlorgyline, a selective inhibitor of MAO A (but not deprenyl, a selective inhibitor of MAO B) increase the radioprotective effect of small doses of O-methyltyramine and phenylephrine and do not change the efficacy of large doses.	Clorgyline	88-99	monoamine oxidase A	Homo sapiens	126-131
1432104-1	1992	Monoamine oxidase A and B (MAO A and B) play important roles in the metabolism of biogenic and dietary amines and are encoded by two genes derived from a common ancestral gene.	Amines	103-109	monoamine oxidase A	Homo sapiens	0-25
1432104-1	1992	Monoamine oxidase A and B (MAO A and B) play important roles in the metabolism of biogenic and dietary amines and are encoded by two genes derived from a common ancestral gene.	Amines	103-109	monoamine oxidase A	Homo sapiens	27-38
1417632-2	1992	Moclobemide is a specific monoamine oxidase-A inhibitor which does not bind irreversibly to the enzyme, unlike the currently available MAOIs.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	26-45
1282522-6	1992	The results support other reports of comparable antidepressant efficacy for brofaromine and phenelzine, both inhibitors of MAO-A in humans.	brofaromine	76-87	monoamine oxidase A	Homo sapiens	123-128
1282522-6	1992	The results support other reports of comparable antidepressant efficacy for brofaromine and phenelzine, both inhibitors of MAO-A in humans.	Phenelzine	92-102	monoamine oxidase A	Homo sapiens	123-128
1494591-0	1992	Brofaromine in panic disorder: a pilot study with a new reversible inhibitor of monoamine oxidase-A.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	80-99
1494591-1	1992	The therapeutic efficacy of brofaromine--a new reversible and short acting MAO-A inhibitor--was evaluated in 14 inpatients with a panic disorder.	brofaromine	28-39	monoamine oxidase A	Homo sapiens	75-80
1494591-6	1992	Our findings suggest that the MAO-A inhibitor brofaromine is an effective drug in the treatment of anxiety disorders.	brofaromine	46-57	monoamine oxidase A	Homo sapiens	30-35
1424410-0	1992	Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects.	toloxatone	56-66	monoamine oxidase A	Homo sapiens	85-104
1639424-0	1992	Characterization of a highly polymorphic region near the first exon of the human MAOA gene containing a GT dinucleotide and a novel VNTR motif.	gt dinucleotide	104-119	monoamine oxidase A	Homo sapiens	81-85
1393304-2	1992	In a double-blind, parallel group trial, 78 subjects with social phobia received moclobemide (a new reversible inhibitor of monoamine oxidase A) phenelzine, or placebo.	Moclobemide	81-92	monoamine oxidase A	Homo sapiens	124-143
1427834-10	1992	Two multiply informative crossovers are consistent with CSNB lying proximal to MAOA and distal to DXS426, respectively.	csnb	56-60	monoamine oxidase A	Homo sapiens	79-83
1394030-2	1992	Moclobemide represents a new class of drug, the so-called RIMA compounds--reversible inhibitors of MAO-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	99-104
1510706-0	1992	Inhibitory potency of some isatin analogues on human monoamine oxidase A and B.	Isatin	27-33	monoamine oxidase A	Homo sapiens	53-78
1510706-2	1992	In this study a range of isatin analogues were tested for their in vitro inhibition of human MAO A and B.	Isatin	25-31	monoamine oxidase A	Homo sapiens	93-104
1510706-4	1992	Hydroxylation of the aromatic ring changed the inhibitory potency in favour of MAO A, with 5-hydroxyisatin being a potent and selective MAO A inhibitor (IC50 8 microM).	5-hydroxyisatin	91-106	monoamine oxidase A	Homo sapiens	136-141
1504260-3	1992	A quantitative structure-metabolism relationship (QSMR) study of MPTP and analogues based on literature data was undertaken in order to determine the key features eliciting MAO-A and MAO-B reactivity and selectivity and influencing toxication.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	65-69	monoamine oxidase A	Homo sapiens	173-178
1610807-0	1992	Interaction of flexible analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of N-methyl-4-phenylpyridinium with highly purified monoamine oxidase A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	35-79	monoamine oxidase A	Homo sapiens	136-161
1610807-0	1992	Interaction of flexible analogs of N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and of N-methyl-4-phenylpyridinium with highly purified monoamine oxidase A and B.	1-Methyl-4-phenylpyridinium	87-114	monoamine oxidase A	Homo sapiens	136-161
1610807-1	1992	Sixteen analogs of N-methyl-1,2,3,6-tetrahydropyridine (MPTP) of varying degrees of flexibility have been studied as substrates of highly purified monoamine oxidases (MAO) A and B.	n-methyl-1,2,3,6-tetrahydropyridine	19-54	monoamine oxidase A	Homo sapiens	147-179
1610807-1	1992	Sixteen analogs of N-methyl-1,2,3,6-tetrahydropyridine (MPTP) of varying degrees of flexibility have been studied as substrates of highly purified monoamine oxidases (MAO) A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	56-60	monoamine oxidase A	Homo sapiens	147-179
1610807-2	1992	The relative effectiveness of the various tetrahydropyridines as substrates of MAO A and B were evaluated in terms of the function turnover number/Km, as determined by initial rate measurements.	Pyrrolidines	42-61	monoamine oxidase A	Homo sapiens	79-84
1610807-3	1992	The insertion of a methylene bridge between the phenyl and tetrahydropyridine moieties of MPTP to yield N-methyl-4-benzyl-1,2,3,6-tetrahydropyridine, rendering the molecule more flexible, greatly enhances reactivity with MAO B, but not with MAO A, as compared with MPTP itself, in accord with data in the literature (Youngster et al., 1989a).	acetophenone	48-54	monoamine oxidase A	Homo sapiens	241-246
1610807-3	1992	The insertion of a methylene bridge between the phenyl and tetrahydropyridine moieties of MPTP to yield N-methyl-4-benzyl-1,2,3,6-tetrahydropyridine, rendering the molecule more flexible, greatly enhances reactivity with MAO B, but not with MAO A, as compared with MPTP itself, in accord with data in the literature (Youngster et al., 1989a).	Pyrrolidines	59-77	monoamine oxidase A	Homo sapiens	241-246
1610807-3	1992	The insertion of a methylene bridge between the phenyl and tetrahydropyridine moieties of MPTP to yield N-methyl-4-benzyl-1,2,3,6-tetrahydropyridine, rendering the molecule more flexible, greatly enhances reactivity with MAO B, but not with MAO A, as compared with MPTP itself, in accord with data in the literature (Youngster et al., 1989a).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	90-94	monoamine oxidase A	Homo sapiens	241-246
1610807-3	1992	The insertion of a methylene bridge between the phenyl and tetrahydropyridine moieties of MPTP to yield N-methyl-4-benzyl-1,2,3,6-tetrahydropyridine, rendering the molecule more flexible, greatly enhances reactivity with MAO B, but not with MAO A, as compared with MPTP itself, in accord with data in the literature (Youngster et al., 1989a).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	265-269	monoamine oxidase A	Homo sapiens	241-246
1609337-6	1992	The reversible inhibitors of monoamine oxidase A (RIMAs) are a group of drugs that, by producing inhibition selectively of monoamine oxidase A (MOA-A), still allow metabolism of tyramine by MAO-B.	Tyramine	178-186	monoamine oxidase A	Homo sapiens	29-48
1609337-6	1992	The reversible inhibitors of monoamine oxidase A (RIMAs) are a group of drugs that, by producing inhibition selectively of monoamine oxidase A (MOA-A), still allow metabolism of tyramine by MAO-B.	Tyramine	178-186	monoamine oxidase A	Homo sapiens	123-142
1303171-1	1992	It has been shown from pulsed-field gel electrophoresis (PFGE) that the monoamine oxidase genes A and B (MAOA &amp; MAOB) and DXS7 loci are physically very close.	Adenosine Monophosphate	111-114	monoamine oxidase A	Homo sapiens	105-109
1413647-2	1992	Activity of MAO-A with serotonin as a substrate was statistically distinctly lower (by 22%) in placenta within early periods of pregnancy as compared which the mature placenta during the delivery time.	Serotonin	23-32	monoamine oxidase A	Homo sapiens	12-17
1349639-10	1992	By using the MAOA-specific inhibitor clorgyline and the MAOB-specific inhibitor deprenyl we were able to confirm that the MAOA form of the enzyme is involved in DA metabolism in this preparation.	Clorgyline	37-47	monoamine oxidase A	Homo sapiens	13-17
1349639-10	1992	By using the MAOA-specific inhibitor clorgyline and the MAOB-specific inhibitor deprenyl we were able to confirm that the MAOA form of the enzyme is involved in DA metabolism in this preparation.	Clorgyline	37-47	monoamine oxidase A	Homo sapiens	122-126
1349639-10	1992	By using the MAOA-specific inhibitor clorgyline and the MAOB-specific inhibitor deprenyl we were able to confirm that the MAOA form of the enzyme is involved in DA metabolism in this preparation.	Selegiline	80-88	monoamine oxidase A	Homo sapiens	122-126
1349639-10	1992	By using the MAOA-specific inhibitor clorgyline and the MAOB-specific inhibitor deprenyl we were able to confirm that the MAOA form of the enzyme is involved in DA metabolism in this preparation.	Dopamine	161-163	monoamine oxidase A	Homo sapiens	13-17
1349639-10	1992	By using the MAOA-specific inhibitor clorgyline and the MAOB-specific inhibitor deprenyl we were able to confirm that the MAOA form of the enzyme is involved in DA metabolism in this preparation.	Dopamine	161-163	monoamine oxidase A	Homo sapiens	122-126
1301161-8	1992	The apparent order of these loci is telomere ... DXS7-MAOA-MAOB-NDP-dc12-YMAO.AluR ... centromere.	dc12-ymao	68-77	monoamine oxidase A	Homo sapiens	54-58
1638170-0	1992	Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor.	brofaromine	86-97	monoamine oxidase A	Homo sapiens	111-116
1580888-7	1992	Moclobemide, a specific, reversible inhibitor of MAO-A, has been extensively evaluated in depressive illness.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	49-54
1638170-2	1992	In this study 30 patients with social phobia (DSM-IIIR) were treated with the selective and reversible MAO-A inhibitor brofaromine, using a 12-week double-blind placebo controlled design.	brofaromine	119-130	monoamine oxidase A	Homo sapiens	103-108
1498863-0	1992	Brofaromine, a drug inhibiting MAO-A and 5-HT uptake.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	31-42
1413625-4	1992	In the system containing membrane bound MAO from human placenta, where the MAO-A is predominating, the modulators studied mostly inhibited deamination of 14C-serotonin.	Carbon-14	154-157	monoamine oxidase A	Homo sapiens	75-80
1413625-4	1992	In the system containing membrane bound MAO from human placenta, where the MAO-A is predominating, the modulators studied mostly inhibited deamination of 14C-serotonin.	Serotonin	158-167	monoamine oxidase A	Homo sapiens	75-80
1354041-0	1992	Preclinical and early clinical studies with BW 1370U87, a reversible competitive MAO-A inhibitor.	1370u87	47-54	monoamine oxidase A	Homo sapiens	81-86
1418864-0	1992	Effect of the selective MAO-A inhibitors brofaromine, clorgyline and moclobemide on human platelet MAO-B activity.	Moclobemide	69-80	monoamine oxidase A	Homo sapiens	24-29
1483487-1	1992	An open study was carried out to examine the effect of moclobemide, a new antidepressant reversible inhibitor of MAO-A, on the pressor response induced by oral tyramine added to meals of different lipid and protein composition, and to correlate the blood pressure increase in the tyramine test with that obtained during an exercise test.	Moclobemide	55-66	monoamine oxidase A	Homo sapiens	113-118
1483487-1	1992	An open study was carried out to examine the effect of moclobemide, a new antidepressant reversible inhibitor of MAO-A, on the pressor response induced by oral tyramine added to meals of different lipid and protein composition, and to correlate the blood pressure increase in the tyramine test with that obtained during an exercise test.	Tyramine	160-168	monoamine oxidase A	Homo sapiens	113-118
1609114-5	1992	In the central nervous system of man MAO-A seems to be mainly involved in the metabolism of 5 HT and noradrenaline, whereas 2-phenylethylamine and probably dopamine are predominantly deaminated by MAO-B.	Norepinephrine	101-114	monoamine oxidase A	Homo sapiens	37-42
1609114-6	1992	In the intestinal tract tyramine is mainly metabolized by MAO-A.	Tyramine	24-32	monoamine oxidase A	Homo sapiens	58-63
1812674-0	1991	[Effectiveness and tolerance of the selective MAO-A inhibitor moclobemide in children with hyperkinetic syndrome].	Moclobemide	62-73	monoamine oxidase A	Homo sapiens	46-51
1347658-3	1992	A new class of RIMA (Reversible Inhibitors of MAO-A) represented by moclobemide requires a change in clinical thinking on antidepressants.	rima	15-19	monoamine oxidase A	Homo sapiens	46-51
1347658-3	1992	A new class of RIMA (Reversible Inhibitors of MAO-A) represented by moclobemide requires a change in clinical thinking on antidepressants.	Moclobemide	68-79	monoamine oxidase A	Homo sapiens	46-51
1347659-5	1992	The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA.	Moclobemide	27-38	monoamine oxidase A	Homo sapiens	42-47
1347659-5	1992	The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA.	3,4-dihydroxyphenylglycol	116-120	monoamine oxidase A	Homo sapiens	42-47
1347659-5	1992	The inhibitory activity of moclobemide on MAO-A was reflected in significant reductions of plasma concentrations of DHPG and 5-HIAA.	Hydroxyindoleacetic Acid	125-131	monoamine oxidase A	Homo sapiens	42-47
1347659-9	1992	Thus, single oral doses of 300, 450 and 600 mg moclobemide demonstrated marked inhibition of MAO-A activity, whereas a single dose of 300 mg induced a near-maximum effect.	Moclobemide	47-58	monoamine oxidase A	Homo sapiens	93-98
1843597-1	1991	One hundred and one depressed inpatients were treated by the authors with a second-generation antidepressive original molecule: Toloxatone, a specific and reversible MAO A inhibitor.	toloxatone	128-138	monoamine oxidase A	Homo sapiens	166-171
1546120-1	1992	Monoamine oxidases A and B (MAO-A and B) catalyze the oxidative catabolism of biogenic amines and xenobiotics.	Amines	87-93	monoamine oxidase A	Homo sapiens	0-26
1546120-1	1992	Monoamine oxidases A and B (MAO-A and B) catalyze the oxidative catabolism of biogenic amines and xenobiotics.	Amines	87-93	monoamine oxidase A	Homo sapiens	28-39
1546127-1	1992	Moclobemide is a reversible inhibitor of the monoamine oxidase type A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	45-69
1546129-3	1992	To test this, moclobemide, a new and reversible inhibitor of monoamine oxidase-A, was administered to 12 children between the ages of 6 and 13 years, diagnosed as attention deficit hyperactive according to DSM III-R, in a 4-week study.	Moclobemide	14-25	monoamine oxidase A	Homo sapiens	61-80
1546132-0	1992	Mode of action and characteristics of monoamine oxidase-A inhibition by moclobemide.	Moclobemide	72-83	monoamine oxidase A	Homo sapiens	38-57
1546132-1	1992	The mode of interaction of the reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide with the enzyme was investigated.	Moclobemide	80-91	monoamine oxidase A	Homo sapiens	42-61
1546132-1	1992	The mode of interaction of the reversible monoamine oxidase-A (MAO-A) inhibitor moclobemide with the enzyme was investigated.	Moclobemide	80-91	monoamine oxidase A	Homo sapiens	63-68
1546132-2	1992	The inhibition of rat brain or human placenta MAO-A by moclobemide showed an initial competitive phase, with a relatively low affinity (KI = 0.2-0.4 mM).	Moclobemide	55-66	monoamine oxidase A	Homo sapiens	46-51
1546132-4	1992	The time-dependent component of the association of moclobemide with MAO-A followed pseudo-first order kinetics.	Moclobemide	51-62	monoamine oxidase A	Homo sapiens	68-73
1546132-6	1992	Even though some aspects of the moclobemide interaction with MAO-A are still not completely elucidated, this compound seems to have the characteristics of a slow-binding inhibitor.	Moclobemide	32-43	monoamine oxidase A	Homo sapiens	61-66
1546142-7	1992	It may be explained by moclobemide"s selective and reversible inhibition of monoamine oxidase A, as well as by the lack of any anticholinergic action.	Moclobemide	23-34	monoamine oxidase A	Homo sapiens	76-95
1546143-1	1992	RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro.	rima	0-4	monoamine oxidase A	Homo sapiens	88-93
1546143-1	1992	RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro.	rima	0-4	monoamine oxidase A	Homo sapiens	198-203
1546143-1	1992	RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro.	Moclobemide	95-106	monoamine oxidase A	Homo sapiens	88-93
1546143-1	1992	RIMA is a term for reversible inhibitors of monoamine oxidase (MAO) with preference for MAO-A; moclobemide is a prototype of this new class of antidepressants and is a highly selective inhibitor of MAO-A in vitro.	Moclobemide	95-106	monoamine oxidase A	Homo sapiens	198-203
1546143-4	1992	Potentiation of the cardiovascular effects of tyramine is less pronounced after taking moclobemide than after irreversible MAO-A inhibitors.	Tyramine	46-54	monoamine oxidase A	Homo sapiens	123-128
1546152-4	1992	The design of controlled clinical trials to compare the effects of moclobemide, a new and selective monoamine oxidase-A inhibitor, with those of standard tricyclic antidepressant drugs involved the refinement of selection strategies, formulation of hypotheses, means of statistical analysis and clinical interpretation.	Moclobemide	67-78	monoamine oxidase A	Homo sapiens	100-119
1812674-4	1991	In an open clinical study we administered moclobemide, a new reversible MAO-A inhibitor, to children who fulfilled the diagnostic criteria for hyperkinetic syndrome according to ICD-9 (314).	Moclobemide	42-53	monoamine oxidase A	Homo sapiens	72-77
1741773-6	1991	Therefore, clorgyline titration can seriously overestimate the concentration of MAO A protein in mitochondrial preparations.	Clorgyline	11-21	monoamine oxidase A	Homo sapiens	80-85
1686901-0	1991	Synthesis, biological evaluation and quantitative structure activity relationship analysis of nuclear-substituted pargylines as competitive inhibitors of MAO-A and MAO-B.	Pargyline	114-124	monoamine oxidase A	Homo sapiens	154-159
1686901-1	1991	A series of nuclear substituted derivatives of pargyline has been prepared and tested (under controlled conditions designed to measure the competitive component of the inhibition) as competitive inhibitors of MAO-A and -B.	Pargyline	47-56	monoamine oxidase A	Homo sapiens	209-221
1687486-0	1991	Successful treatment of tardive akathisia with moclobemide, a reversible and selective monoamine-oxidase-A inhibitor.	Moclobemide	47-58	monoamine oxidase A	Homo sapiens	87-106
1687486-4	1991	In this case report, TA that occurred in the course of a tardive dyskinesia (TD) was successfully treated with the monoamine-oxidase-A inhibitor moclobemide.	Moclobemide	145-156	monoamine oxidase A	Homo sapiens	115-134
1741773-8	1991	The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23).	Serotonin	85-94	monoamine oxidase A	Homo sapiens	11-16
1741773-8	1991	The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23).	tryptamine	115-125	monoamine oxidase A	Homo sapiens	11-16
1741773-8	1991	The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23).	Tyramine	146-154	monoamine oxidase A	Homo sapiens	11-16
1741773-8	1991	The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23).	Dopamine	176-184	monoamine oxidase A	Homo sapiens	11-16
1741773-8	1991	The ratio, MAO A molecular activity:MAO B molecular activity decreased in the order: serotonin (35:1) greater than tryptamine (12:1) greater than tyramine (3.3:1) greater than dopamine (2.4:1) greater than benzylamine (1:23).	benzylamine	206-217	monoamine oxidase A	Homo sapiens	11-16
2021654-2	1991	In this study, with use of purified monoamine oxidase A, steady-state data for the inhibition by D-amphetamine of the oxidation of primary amines indicate the possibility of a ternary complex mechanism for monoamine oxidase A also.	Dextroamphetamine	97-110	monoamine oxidase A	Homo sapiens	36-55
1685185-11	1991	In MAO A, the pocket P2"-A is oriented 45-135 degrees relative to the plane of the tetrahydropyridine moiety, with a radius of 3.1 A from C2" of the phenyl ring.	Pyrrolidines	83-101	monoamine oxidase A	Homo sapiens	3-8
1759390-7	1991	In deprenyl pretreated mitochondria the potency of MAO-A-dependent effects of these amines was: serotonin greater than tyramine much greater than much greater than 2-phenylethylamine.	Amines	84-90	monoamine oxidase A	Homo sapiens	51-56
1759390-7	1991	In deprenyl pretreated mitochondria the potency of MAO-A-dependent effects of these amines was: serotonin greater than tyramine much greater than much greater than 2-phenylethylamine.	Serotonin	96-105	monoamine oxidase A	Homo sapiens	51-56
1759390-7	1991	In deprenyl pretreated mitochondria the potency of MAO-A-dependent effects of these amines was: serotonin greater than tyramine much greater than much greater than 2-phenylethylamine.	Tyramine	119-127	monoamine oxidase A	Homo sapiens	51-56
1759390-7	1991	In deprenyl pretreated mitochondria the potency of MAO-A-dependent effects of these amines was: serotonin greater than tyramine much greater than much greater than 2-phenylethylamine.	phenethylamine	164-182	monoamine oxidase A	Homo sapiens	51-56
1759390-8	1991	The data obtained suggest that the product(s) of oxidative deamination of biogenic amines (probably the aldehydes) catalyzed by both types of MAO (MAO-A and MAO-B) are able to regulate the energy functions of mitochondria.	Amines	83-89	monoamine oxidase A	Homo sapiens	147-152
1759390-8	1991	The data obtained suggest that the product(s) of oxidative deamination of biogenic amines (probably the aldehydes) catalyzed by both types of MAO (MAO-A and MAO-B) are able to regulate the energy functions of mitochondria.	Aldehydes	104-113	monoamine oxidase A	Homo sapiens	147-152
1886775-7	1991	Exon 12 (bearing the codon for cysteine, which carries the covalently bound FAD cofactor) and exon 13 are highly conserved between human MAOA and MAOB genes (92% at the amino acid level).	Cysteine	31-39	monoamine oxidase A	Homo sapiens	137-141
1922929-2	1991	Pretreatment with type A monoamine oxidase (MAO-A) inhibitors, clorgyline and RS-8359 ((+)-4-(4-cyanoanilino)-7-hydroxycyclopenta (3,2-e) pyrimidine) decreased significantly the number of necrotic neurons and inhibited changes in the dopamine metabolite contents during and after transient ischemia.	(+)-4-(4-cyanoanilino)-7-hydroxycyclopenta (3,2-e) pyrimidine	87-148	monoamine oxidase A	Homo sapiens	44-49
1922929-4	1991	The results suggest that the activation of dopamine metabolism after transient ischemia was mainly mediated by MAO-A and partly by MAO-B and suggest a possible role of dopamine deamination by MAO in the development of ischemic neuronal necrosis.	Dopamine	43-51	monoamine oxidase A	Homo sapiens	111-116
1904620-2	1991	Moclobemide belongs to a new class of substances called RIMA (Reversible Inhibitor of the monoamine oxidase type A).	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	90-114
1904620-2	1991	Moclobemide belongs to a new class of substances called RIMA (Reversible Inhibitor of the monoamine oxidase type A).	rima	56-60	monoamine oxidase A	Homo sapiens	90-114
2021654-2	1991	In this study, with use of purified monoamine oxidase A, steady-state data for the inhibition by D-amphetamine of the oxidation of primary amines indicate the possibility of a ternary complex mechanism for monoamine oxidase A also.	Dextroamphetamine	97-110	monoamine oxidase A	Homo sapiens	206-225
2021654-2	1991	In this study, with use of purified monoamine oxidase A, steady-state data for the inhibition by D-amphetamine of the oxidation of primary amines indicate the possibility of a ternary complex mechanism for monoamine oxidase A also.	Amines	139-145	monoamine oxidase A	Homo sapiens	36-55
2021654-2	1991	In this study, with use of purified monoamine oxidase A, steady-state data for the inhibition by D-amphetamine of the oxidation of primary amines indicate the possibility of a ternary complex mechanism for monoamine oxidase A also.	Amines	139-145	monoamine oxidase A	Homo sapiens	206-225
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	279-283	monoamine oxidase A	Homo sapiens	28-32
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	4,6-dinitro-o-cresol	86-92	monoamine oxidase A	Homo sapiens	0-26
2023912-3	1991	Exon 12 codes for the covalent FAD-binding-site and is the most conserved exon; the MAOA and MAOB exon 12 products share 93.9% peptide identity.	Flavin-Adenine Dinucleotide	31-34	monoamine oxidase A	Homo sapiens	84-88
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	4,6-dinitro-o-cresol	86-92	monoamine oxidase A	Homo sapiens	28-32
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	Amines	184-190	monoamine oxidase A	Homo sapiens	0-26
1988553-8	1991	In conclusion, we suggest that [3H]harman binding is a biochemical tool as a selective marker to quantify MAO-A in the CNS of different mammalian species as well as in extraneuronal tissues.	Tritium	32-34	monoamine oxidase A	Homo sapiens	106-111
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	Amines	184-190	monoamine oxidase A	Homo sapiens	28-32
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	233-277	monoamine oxidase A	Homo sapiens	0-26
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	233-277	monoamine oxidase A	Homo sapiens	28-32
2023912-1	1991	Monoamine oxidases A and B [MAOA and MAOB; amine:oxygen oxidoreductase (deaminating) (flavin-containing), EC 1.4.3.4] play important roles in the metabolism of neuroactive, vasoactive amines and the Parkinsonism-producing neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP).	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	279-283	monoamine oxidase A	Homo sapiens	0-26
1893487-0	1991	Synthesis of fluorine and iodine analogues of clorgyline and selective inhibition of monoamine oxidase A.	Fluorine	13-21	monoamine oxidase A	Homo sapiens	85-104
1893487-0	1991	Synthesis of fluorine and iodine analogues of clorgyline and selective inhibition of monoamine oxidase A.	Iodine	26-32	monoamine oxidase A	Homo sapiens	85-104
1893487-1	1991	A series of fluorine and iodine analogues of clorgyline was synthesized and evaluated for inhibitory potency and selectivity toward monoamine oxidase A (MAO-A).	Clorgyline	45-55	monoamine oxidase A	Homo sapiens	132-151
1893487-1	1991	A series of fluorine and iodine analogues of clorgyline was synthesized and evaluated for inhibitory potency and selectivity toward monoamine oxidase A (MAO-A).	Clorgyline	45-55	monoamine oxidase A	Homo sapiens	153-158
1852792-0	1991	Brofaromine--a selective, reversible, and short-acting MAO-A inhibitor: review of the pharmacological and clinical findings.	brofaromine--a	0-14	monoamine oxidase A	Homo sapiens	55-60
1852792-3	1991	Brofaromine, a newly developed MAO inhibitor of the second generation, is a selective, reversible, and short-acting MAO-A inhibitor.	brofaromine	0-11	monoamine oxidase A	Homo sapiens	116-121
2011543-0	1991	Dinucleotide repeat polymorphism at the MAOA locus.	Dinucleoside Phosphates	0-12	monoamine oxidase A	Homo sapiens	40-44
1905757-3	1991	Both molecular forms of MAO, MAO A and MAO B, were found using specific inhibitors clorgyline and deprenyl.	Clorgyline	83-93	monoamine oxidase A	Homo sapiens	29-34
1905757-3	1991	Both molecular forms of MAO, MAO A and MAO B, were found using specific inhibitors clorgyline and deprenyl.	Selegiline	98-106	monoamine oxidase A	Homo sapiens	29-34
1988238-0	1991	Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.	Cimetidine	0-10	monoamine oxidase A	Homo sapiens	50-69
1988238-0	1991	Cimetidine alters the disposition kinetics of the monoamine oxidase-A inhibitor moclobemide.	Moclobemide	80-91	monoamine oxidase A	Homo sapiens	50-69
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	Moclobemide	88-99	monoamine oxidase A	Homo sapiens	45-69
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	Moclobemide	88-99	monoamine oxidase A	Homo sapiens	71-76
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	3,4-dihydroxyphenylglycol	115-119	monoamine oxidase A	Homo sapiens	45-69
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	3,4-dihydroxyphenylglycol	115-119	monoamine oxidase A	Homo sapiens	71-76
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	Methoxyhydroxyphenylglycol	138-142	monoamine oxidase A	Homo sapiens	45-69
1646924-4	1991	In contrast, a single dose of the reversible monoamine oxidase type A (MAO-A) inhibitor moclobemide reduced plasma DHPG levels by 78% and MHPG levels by 51%.	Methoxyhydroxyphenylglycol	138-142	monoamine oxidase A	Homo sapiens	71-76
1646924-5	1991	It is concluded that the plasma concentrations of DHPG and MHPG are largely determined by intraneuronal, MAO-A-dependent metabolism of NE, and do not accurately reflect acute alterations in neuronal NE release.	3,4-dihydroxyphenylglycol	50-54	monoamine oxidase A	Homo sapiens	105-110
1646924-5	1991	It is concluded that the plasma concentrations of DHPG and MHPG are largely determined by intraneuronal, MAO-A-dependent metabolism of NE, and do not accurately reflect acute alterations in neuronal NE release.	Methoxyhydroxyphenylglycol	59-63	monoamine oxidase A	Homo sapiens	105-110
2003865-1	1991	Monoamine oxidase A and B (MAO A and B) catalyze the oxidative deamination of a number of biogenic and xenobiotic amines with different substrate and inhibitor specificities.	xenobiotic amines	103-120	monoamine oxidase A	Homo sapiens	0-25
2003865-1	1991	Monoamine oxidase A and B (MAO A and B) catalyze the oxidative deamination of a number of biogenic and xenobiotic amines with different substrate and inhibitor specificities.	xenobiotic amines	103-120	monoamine oxidase A	Homo sapiens	27-38
2244915-1	1990	It is well established that 1-methyl-4-phenylpyridinium (MPP), the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and most of its analogs are good competitive inhibitors of monoamine oxidase A, with Ki values in the micromolar range, but they inhibit monoamine oxidase B only at much higher concentrations.	1-Methyl-4-phenylpyridinium	28-55	monoamine oxidase A	Homo sapiens	214-233
2125217-0	1990	Catalytically active monoamine oxidase type A from human liver expressed in Saccharomyces cerevisiae contains covalent FAD.	Flavin-Adenine Dinucleotide	119-122	monoamine oxidase A	Homo sapiens	21-45
1705137-12	1990	Before the next drug intake, MAO-A inhibition, as judged by the decrease of plasma DHPG concentration, was significantly different from placebo with moclobemide but not with toloxatone.	Moclobemide	149-160	monoamine oxidase A	Homo sapiens	29-34
2244915-1	1990	It is well established that 1-methyl-4-phenylpyridinium (MPP), the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and most of its analogs are good competitive inhibitors of monoamine oxidase A, with Ki values in the micromolar range, but they inhibit monoamine oxidase B only at much higher concentrations.	1-Methyl-4-phenylpyridinium	57-60	monoamine oxidase A	Homo sapiens	214-233
2244915-1	1990	It is well established that 1-methyl-4-phenylpyridinium (MPP), the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and most of its analogs are good competitive inhibitors of monoamine oxidase A, with Ki values in the micromolar range, but they inhibit monoamine oxidase B only at much higher concentrations.	methyl radical	29-37	monoamine oxidase A	Homo sapiens	214-233
2244915-1	1990	It is well established that 1-methyl-4-phenylpyridinium (MPP), the neurotoxic bioactivation product of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and most of its analogs are good competitive inhibitors of monoamine oxidase A, with Ki values in the micromolar range, but they inhibit monoamine oxidase B only at much higher concentrations.	3,6-tetrahydropyridine	125-147	monoamine oxidase A	Homo sapiens	214-233
2143389-3	1990	Inhibition of MAO-A increased the accumulation of newly-formed DA and reduced DOPAC formation; by contrast, the inhibition of monoamine oxidase, MAO-B, only resulted in a decrease in DOPAC formation.	Dopamine	63-65	monoamine oxidase A	Homo sapiens	14-19
2398352-1	1990	Monoamine oxidase (MAO) A and B play important roles in the metabolism of biogenic amines.	Amines	83-89	monoamine oxidase A	Homo sapiens	0-25
2398352-2	1990	Northern analysis using 32P-labeled subfragments of human liver MAO A and B cDNA clones detected a 5- and a 3-kb transcript, respectively, in most human tissues examined.	Phosphorus-32	24-27	monoamine oxidase A	Homo sapiens	64-69
2083287-0	1990	[The effect of monoamine oxidase type A inhibitors on chemoluminescence of blood serum in the presence of divalent iron ions].	Iron	115-119	monoamine oxidase A	Homo sapiens	15-39
2253761-4	1990	A large number of MPTP analogs substituted in the aromatic (but not in the pyridine) ring are also oxidized by monoamine oxidase A or B, is in some cases faster than any previously recognized substrate.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	18-22	monoamine oxidase A	Homo sapiens	111-135
1967018-4	1990	The behavioral and physiological phenomena could not be antagonized by brofaromine, a putative antidepressant reversibly and selectively inhibiting monoamine oxidase A (MAO-A), contrasting to the complete inhibition by the central cholinolytic scopolamine.	brofaromine	71-82	monoamine oxidase A	Homo sapiens	169-174
2143389-3	1990	Inhibition of MAO-A increased the accumulation of newly-formed DA and reduced DOPAC formation; by contrast, the inhibition of monoamine oxidase, MAO-B, only resulted in a decrease in DOPAC formation.	3,4-Dihydroxyphenylacetic Acid	78-83	monoamine oxidase A	Homo sapiens	14-19
2366877-4	1990	(4) The results show that a 70% depletion of monoamine content by chemical denervation resulted only in a 23% reduction of MAO-A activity in the renal cortex, whereas MAO-B was unaffected either in the cortical or the medullary zones; in the renal medulla MAO-A activity was not changed by denervation.	monoamine	45-54	monoamine oxidase A	Homo sapiens	123-128
2338548-6	1990	Recently it has been demonstrated in human brain that neurons in regions rich in catecholamines are positive for MAO-A.	Catecholamines	81-95	monoamine oxidase A	Homo sapiens	113-118
2344359-0	1990	Mechanism-based inactivation of monoamine oxidases A and B by tetrahydropyridines and dihydropyridines.	Pyrrolidines	62-81	monoamine oxidase A	Homo sapiens	32-58
2344359-0	1990	Mechanism-based inactivation of monoamine oxidases A and B by tetrahydropyridines and dihydropyridines.	Dihydropyridines	86-102	monoamine oxidase A	Homo sapiens	32-58
2344359-1	1990	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its primary oxidation product, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), are mechanism-based inhibitors of monoamine oxidases A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	0-44	monoamine oxidase A	Homo sapiens	170-196
2344359-1	1990	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its primary oxidation product, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), are mechanism-based inhibitors of monoamine oxidases A and B.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	46-50	monoamine oxidase A	Homo sapiens	170-196
2344359-1	1990	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its primary oxidation product, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), are mechanism-based inhibitors of monoamine oxidases A and B.	,3-dihydropyridinium	106-126	monoamine oxidase A	Homo sapiens	170-196
2344359-1	1990	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) and its primary oxidation product, 1-methyl-4-phenyl-2,3-dihydropyridinium (MPDP+), are mechanism-based inhibitors of monoamine oxidases A and B.	1-methyl-4-phenyl-2,3-dihydropyridinium	128-133	monoamine oxidase A	Homo sapiens	170-196
2344359-4	1990	The dihydropyridiniums were poor substrates for monoamine oxidase A and, consequently, inactivated the enzyme only slowly, despite partition coefficients lower than those for the tetrahydropyridines.	dihydropyridiniums	4-22	monoamine oxidase A	Homo sapiens	48-67
2344359-4	1990	The dihydropyridiniums were poor substrates for monoamine oxidase A and, consequently, inactivated the enzyme only slowly, despite partition coefficients lower than those for the tetrahydropyridines.	Pyrrolidines	179-198	monoamine oxidase A	Homo sapiens	48-67
2344359-6	1990	Substitutions in the aromatic ring had no major effect on the inactivation of monoamine oxidase B, but the 2"-ethyl- and 3"-chloro-substituted compounds were very poor mechanism-based inactivators of monoamine oxidase A.	2"-ethyl- and 3"-chloro	107-130	monoamine oxidase A	Homo sapiens	200-219
2366877-4	1990	(4) The results show that a 70% depletion of monoamine content by chemical denervation resulted only in a 23% reduction of MAO-A activity in the renal cortex, whereas MAO-B was unaffected either in the cortical or the medullary zones; in the renal medulla MAO-A activity was not changed by denervation.	monoamine	45-54	monoamine oxidase A	Homo sapiens	256-261
2123366-0	1990	Tolerability of moclobemide, a new reversible inhibitor of monoamine oxidase-A, compared with other antidepressants and placebo.	Moclobemide	16-27	monoamine oxidase A	Homo sapiens	59-78
1689378-5	1990	The concentration of 5-HIAA in CSF correlated with the plasma 5-HIAA/5-HT ratio (r = 0.405, p less than 0.026) (which can be taken as an index of monoamine oxidase type A activity in peripheral tissues) and with the platelet 5-HT/plasma 5-HT ratio (r = 0.375, p less than 0.05).	Hydroxyindoleacetic Acid	21-27	monoamine oxidase A	Homo sapiens	146-170
2106391-4	1990	Plasma DOPAC levels were unaffected, suggesting that the majority of peripheral DOPAC is generated by action of MAO-A.	3,4-Dihydroxyphenylacetic Acid	80-85	monoamine oxidase A	Homo sapiens	112-117
2314388-0	1990	Characterization of the binding of [3H]Ro 41-1049 to the active site of human monoamine oxidase-A.	Tritium	36-38	monoamine oxidase A	Homo sapiens	78-97
2314388-1	1990	The novel reversible and selective inhibitor of monoamine oxidase-A (MAO-A) Ro 41-1049 [N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide HCl] shows inhibition characteristics similar to those of the structurally related reversible MAO-B inhibitors Ro 16-6491 and Ro 19-6327.	Ro 41-1049	76-86	monoamine oxidase A	Homo sapiens	48-67
2314388-1	1990	The novel reversible and selective inhibitor of monoamine oxidase-A (MAO-A) Ro 41-1049 [N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide HCl] shows inhibition characteristics similar to those of the structurally related reversible MAO-B inhibitors Ro 16-6491 and Ro 19-6327.	Ro 41-1049	76-86	monoamine oxidase A	Homo sapiens	69-74
2314388-1	1990	The novel reversible and selective inhibitor of monoamine oxidase-A (MAO-A) Ro 41-1049 [N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide HCl] shows inhibition characteristics similar to those of the structurally related reversible MAO-B inhibitors Ro 16-6491 and Ro 19-6327.	n-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide hcl	88-150	monoamine oxidase A	Homo sapiens	48-67
2314388-1	1990	The novel reversible and selective inhibitor of monoamine oxidase-A (MAO-A) Ro 41-1049 [N-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide HCl] shows inhibition characteristics similar to those of the structurally related reversible MAO-B inhibitors Ro 16-6491 and Ro 19-6327.	n-(2-aminoethyl)-5-(m-fluorophenyl)-4-thiazole carboxamide hcl	88-150	monoamine oxidase A	Homo sapiens	69-74
2314388-2	1990	In the present study, tritiated Ro 41-1049 was used as a high affinity ligand to study the binding characteristics of this inhibitor to MAO-A and its interactions with the enzyme.	Ro 41-1049	32-42	monoamine oxidase A	Homo sapiens	136-141
2314388-9	1990	Among the various drugs tested, only inhibitors of MAO-A were able to effectively prevent [3H]Ro 41-1049 specific binding.	Tritium	91-93	monoamine oxidase A	Homo sapiens	51-56
2314388-14	1990	The presence of MAO-A- but not MAO-B-selective inhibitors prevented the covalent incorporation of [3H]Ro 41-1049.	Tritium	99-101	monoamine oxidase A	Homo sapiens	16-21
2314388-14	1990	The presence of MAO-A- but not MAO-B-selective inhibitors prevented the covalent incorporation of [3H]Ro 41-1049.	Ro 41-1049	102-112	monoamine oxidase A	Homo sapiens	16-21
2314388-15	1990	The present results indicate that [3H]Ro 41-1049 is incorporated into a subunit of MAO-A, in the presence of NaBH3CN, and modifies a protein domain that is essential for the enzyme activity.	Tritium	35-37	monoamine oxidase A	Homo sapiens	83-88
2314388-15	1990	The present results indicate that [3H]Ro 41-1049 is incorporated into a subunit of MAO-A, in the presence of NaBH3CN, and modifies a protein domain that is essential for the enzyme activity.	sodium cyanoborohydride	109-116	monoamine oxidase A	Homo sapiens	83-88
2248061-6	1990	Since the concentration of Ro 16-6491 in human plasma remains below the limit of detection, only a very weak inhibition of MAO-B is produced in human platelets, and moclobemide can thus be considered a selective MAO-A inhibitor in humans.	Moclobemide	165-176	monoamine oxidase A	Homo sapiens	212-217
2248084-5	1990	Moclobemide and clorgyline were found to be the most highly selective MAO-A inhibitors, although both also inhibited 30% of platelet MAO-B activity.	Clorgyline	16-26	monoamine oxidase A	Homo sapiens	70-75
2248084-6	1990	Potentiation of the tyramine pressor effect is mainly influenced by the irreversibility and degree of MAO-A inhibition.	Tyramine	20-28	monoamine oxidase A	Homo sapiens	102-107
2123366-1	1990	Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	57-76
2248084-7	1990	Tyramine sensitivity was raised (a factor of 10-30) by all irreversible MAO inhibitors in doses inhibiting MAO-A; it diminished with increasing reversibility.	Tyramine	0-8	monoamine oxidase A	Homo sapiens	107-112
2248062-1	1990	The acute psychomotor effects of moclobemide, a reversible inhibitor of MAO-A antidepressant (100 and 300 mg) compared with amitriptyline (25 and 75 mg) showed that moclobemide caused no significant impairment in contrast with amitriptyline, which caused significant impairment at both doses.	Moclobemide	33-44	monoamine oxidase A	Homo sapiens	72-77
2123366-1	1990	Moclobemide, a new selective and reversible inhibitor of monoamine oxidase A (RIMA), has been compared with various tricyclic antidepressants (TCAs) in numerous controlled studies.	rima	78-82	monoamine oxidase A	Homo sapiens	57-76
2248063-2	1990	Moclobemide, a reversible inhibitor of monoamine oxidase (RIMA), preferentially inhibits MAO-A.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	89-94
2296014-0	1990	Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines.	Isoquinolines	158-171	monoamine oxidase A	Homo sapiens	14-40
2248082-9	1990	The authors conclude that, because of the short-lasting, reversible and selective MAO-A-inhibiting effect of moclobemide, there is no marked interaction with tyramine given by i.v.	Moclobemide	109-120	monoamine oxidase A	Homo sapiens	82-87
2248084-1	1990	The pharmacodynamic properties of moclobemide, a reversible inhibitor of MAO-A (RIMA), were compared with the properties of other reversible as well as older irreversible MAO inhibitors in human subjects.	Moclobemide	34-45	monoamine oxidase A	Homo sapiens	73-78
2248084-3	1990	Toloxatone and low doses of deprenyl (a MAO-B inhibitor) caused 20% and 17% inhibition respectively; higher doses of deprenyl, however, strongly inhibited MAO-A.	Selegiline	117-125	monoamine oxidase A	Homo sapiens	155-160
2248084-5	1990	Moclobemide and clorgyline were found to be the most highly selective MAO-A inhibitors, although both also inhibited 30% of platelet MAO-B activity.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	70-75
1965198-1	1990	The effect of chronic treatment with the selective and reversible MAO-A-inhibitor moclobemide (MOC) vs. the norepinephrine reuptake inhibitor maprotiline (MAP) on alpha 2-adrenoceptor responsivity was studied by clonidine (CLON)-evoked growth hormone (GH) release in major depressive disorder.	Moclobemide	82-93	monoamine oxidase A	Homo sapiens	66-71
2089088-0	1990	Psychometric alterations in treatment with the MAO-A-inhibitor moclobemide.	Moclobemide	63-74	monoamine oxidase A	Homo sapiens	47-52
2089089-0	1990	Clinical, biochemical and psychometric findings with the new MAO-A-inhibitors moclobemide and brofaromine in patients with major depressive disorder.	Moclobemide	78-89	monoamine oxidase A	Homo sapiens	61-66
2089089-1	1990	N = 53 inpatients with major depressive disorder have been treated with the reversible, selective MAO-A-inhibitors moclobemide (double-blind versus maprotiline) and brofaromine (open study), respectively.	Moclobemide	115-126	monoamine oxidase A	Homo sapiens	98-103
2089104-1	1990	Northern analysis using 32P-labeled subfragments of human liver MAO-A and B cDNA clones detected 5Kb and 3Kb transcripts, respectively in fetal tissues and adult brains.	Phosphorus-32	24-27	monoamine oxidase A	Homo sapiens	64-69
2128498-3	1990	In the present study we point out that several analogs of MPTP are good substrates not only for MAO-B but also for MAO-A.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	58-62	monoamine oxidase A	Homo sapiens	115-120
2128498-4	1990	In addition, we point out that with long-term administration to rodents, deprenyl loses its selectivity as an inhibitor of MAO-B and also inhibits MAO-A.	Selegiline	73-81	monoamine oxidase A	Homo sapiens	147-152
2193111-0	1990	From moclobemide to Ro 19-6327 and Ro 41-1049: the development of a new class of reversible, selective MAO-A and MAO-B inhibitors.	Moclobemide	5-16	monoamine oxidase A	Homo sapiens	103-108
2193111-1	1990	This study describes the serendipitous discovery of moclobemide, a short-acting MAO-A inhibitor which is in an advanced stage of clinical development as an antidepressant.	Moclobemide	52-63	monoamine oxidase A	Homo sapiens	80-85
2193111-2	1990	The short duration of action of this MAO inhibitor containing a morpholine ring moiety is due to the complete reversibility (probably by metabolism of the inhibitory molecular species) of MAO-A inhibition.	morpholine	64-74	monoamine oxidase A	Homo sapiens	188-193
2358804-5	1990	Substitution of a methyl group at the 6-position of the heterocyclic ring of MPTP prevented it from acting as a substrate for MAO-B and greatly decreased its potency as an inhibitor of that form of MAO, although it remained a good competitive inhibitor of MAO-A.	1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine	77-81	monoamine oxidase A	Homo sapiens	256-261
2250565-0	1990	Evidence that the reversible MAO-A inhibitor moclobemide increases prolactin secretion by a serotonergic mechanism in healthy male volunteers.	Moclobemide	45-56	monoamine oxidase A	Homo sapiens	29-34
2250565-1	1990	The serotonin receptor antagonist methysergide was used to investigate the mechanism mediating stimulation of prolactin release after single doses of the reversible MAO-A inhibitor moclobemide.	Methysergide	34-46	monoamine oxidase A	Homo sapiens	165-170
2250565-1	1990	The serotonin receptor antagonist methysergide was used to investigate the mechanism mediating stimulation of prolactin release after single doses of the reversible MAO-A inhibitor moclobemide.	Moclobemide	181-192	monoamine oxidase A	Homo sapiens	165-170
2250565-3	1990	MAO-A inhibition, as evidenced by up to 80% decreases in the plasma concentration of 3,4-dihydroxyphenylglycol, a deaminated metabolite of norepinephrine, was similar after both pretreatments.	3,4-dihydroxyphenylglycol	85-110	monoamine oxidase A	Homo sapiens	0-5
2250565-3	1990	MAO-A inhibition, as evidenced by up to 80% decreases in the plasma concentration of 3,4-dihydroxyphenylglycol, a deaminated metabolite of norepinephrine, was similar after both pretreatments.	Norepinephrine	139-153	monoamine oxidase A	Homo sapiens	0-5
2362546-0	1990	Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine by human monoamine oxidases A and B.	1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol	37-83	monoamine oxidase A	Homo sapiens	180-206
2362546-0	1990	Studies of the in vitro oxidation of 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine by human monoamine oxidases A and B.	1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	112-170	monoamine oxidase A	Homo sapiens	180-206
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol	104-150	monoamine oxidase A	Homo sapiens	53-78
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol	104-150	monoamine oxidase A	Homo sapiens	80-91
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol	152-156	monoamine oxidase A	Homo sapiens	53-78
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol	152-156	monoamine oxidase A	Homo sapiens	80-91
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	186-244	monoamine oxidase A	Homo sapiens	53-78
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	186-244	monoamine oxidase A	Homo sapiens	80-91
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	246-250	monoamine oxidase A	Homo sapiens	53-78
2362546-1	1990	The ability of highly purified preparations of human monoamine oxidase A and B (MAO A and B) to utilize 1-methyl-4-(1-methylpyrrol-2-yl)-4-piperidinol (MMPP) and its dehydration product 1,2,3,6-tetrahydro-1-methyl-4-(methylpyrrol-2-yl) pyridine (TMMP) as substrates was investigated.	1-methyl-4-(methylpyrrol-2-yl)-1,2,3,6-tetrahydropyridine	246-250	monoamine oxidase A	Homo sapiens	80-91
2099892-9	1990	In humans, both the MAO-A selective inhibitor clorgyline and the non-selective inhibitor tranylcypromine increase serum melatonin levels.	Clorgyline	46-56	monoamine oxidase A	Homo sapiens	20-25
2099892-9	1990	In humans, both the MAO-A selective inhibitor clorgyline and the non-selective inhibitor tranylcypromine increase serum melatonin levels.	Melatonin	120-129	monoamine oxidase A	Homo sapiens	20-25
2296014-0	1990	Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines.	isoquinoline alkaloids	51-73	monoamine oxidase A	Homo sapiens	14-40
2296014-0	1990	Inhibition of monoamine oxidases A and B by simple isoquinoline alkaloids: racemic and optically active 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines.	1,2,3,4-tetrahydro-, 3,4-dihydro-, and	104-142	monoamine oxidase A	Homo sapiens	14-40
2296014-1	1990	A series of 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines were tested as substrates and/or inactivators of highly purified human monoamine oxidase A and B (MAO A and B).	1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines	12-79	monoamine oxidase A	Homo sapiens	151-176
2296014-1	1990	A series of 1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines were tested as substrates and/or inactivators of highly purified human monoamine oxidase A and B (MAO A and B).	1,2,3,4-tetrahydro-, 3,4-dihydro-, and fully aromatic isoquinolines	12-79	monoamine oxidase A	Homo sapiens	178-189
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	Isoquinolines	71-84	monoamine oxidase A	Homo sapiens	118-123
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	Isoquinolines	71-84	monoamine oxidase A	Homo sapiens	172-177
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsolinol	253-263	monoamine oxidase A	Homo sapiens	118-123
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsolinol	253-263	monoamine oxidase A	Homo sapiens	172-177
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsoline	282-291	monoamine oxidase A	Homo sapiens	118-123
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsoline	282-291	monoamine oxidase A	Homo sapiens	172-177
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsolidine	310-321	monoamine oxidase A	Homo sapiens	118-123
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	salsolidine	310-321	monoamine oxidase A	Homo sapiens	172-177
1691454-1	1990	Isatin (Tribulin) produced a dose-dependent inhibition of both MAO A and MAO B in broken cell preparations from rat brain and pineal.	Isatin	0-6	monoamine oxidase A	Homo sapiens	63-68
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	carnegine	343-352	monoamine oxidase A	Homo sapiens	118-123
2296014-2	1990	None were found to be a substrate for either enzyme, but many of these isoquinolines could selectively inhibit either MAO A or B. Stereoselective competitive inhibition of MAO A was found with the R enantiomer of all the stereoisomers tested, including salsolinol (Ki = 31 microM), salsoline (Ki = 77 microM), salsolidine (Ki = 6 microM), and carnegine (Ki = 2 microM).	carnegine	343-352	monoamine oxidase A	Homo sapiens	172-177
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	Isoniazid	35-44	monoamine oxidase A	Homo sapiens	52-56
2300680-0	1990	Moclobemide, an inhibitor of MAO-A, does not increase daytime plasma melatonin levels in normal humans.	Moclobemide	0-11	monoamine oxidase A	Homo sapiens	29-34
33815093-2	2021	Monoamine oxidase A (MAOA) is an enzyme located on the outer mitochondrial membrane that catalyzes the oxidative deamination of DA.	Dopamine	128-130	monoamine oxidase A	Homo sapiens	0-19
33815093-2	2021	Monoamine oxidase A (MAOA) is an enzyme located on the outer mitochondrial membrane that catalyzes the oxidative deamination of DA.	Dopamine	128-130	monoamine oxidase A	Homo sapiens	21-25
33588721-9	2021	The function of risk genes is described: COMT and MAO A/B genes, with a reduced activity in the corresponding enzymes, are associated with a decrease in dopamine degradation and hence dopamine hyperactivity occurred via D2 receptors.	Dopamine	153-161	monoamine oxidase A	Homo sapiens	50-57
33588721-9	2021	The function of risk genes is described: COMT and MAO A/B genes, with a reduced activity in the corresponding enzymes, are associated with a decrease in dopamine degradation and hence dopamine hyperactivity occurred via D2 receptors.	Dopamine	184-192	monoamine oxidase A	Homo sapiens	50-57
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	Isoniazid	35-44	monoamine oxidase A	Homo sapiens	231-235
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	heptamethine	135-147	monoamine oxidase A	Homo sapiens	231-235
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	Carbocyanines	148-160	monoamine oxidase A	Homo sapiens	231-235
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	Hydrazones	185-194	monoamine oxidase A	Homo sapiens	231-235
32797765-2	2020	Here, we choose the small molecule isoniazid as the MAOA inhibition functionality and incorporated it in the tumor-targeting moiety of heptamethine carbocyanine dyes via a pH sensitive hydrazone bond to design and synthesize novel MAOA inhibitor isoniazid-heptamethine carbocyanine dye conjugates.	isoniazid-heptamethine carbocyanine	246-281	monoamine oxidase A	Homo sapiens	231-235
25497297-7	2015	RESULTS: Results suggest that MAOA promoter hypermethylation is associated with ASPD and may contribute to downregulation of MAOA gene expression, as indicated by functional assays in vitro, and regression analysis with whole-blood serotonin levels in offenders with ASPD.	Serotonin	232-241	monoamine oxidase A	Homo sapiens	30-34
1821707-1	1991	The tolerability and antidepressive effect of brofaromine, a selective MAO-A inhibitor was tested in 14 depressive patients.	brofaromine	46-57	monoamine oxidase A	Homo sapiens	71-76
2312783-0	1990	Disposition kinetics of moclobemide, a new MAO-A inhibitor, in subjects with impaired renal function.	Moclobemide	24-35	monoamine oxidase A	Homo sapiens	43-48
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Dopamine	69-77	monoamine oxidase A	Homo sapiens	13-32
34801597-4	2022	Our in vitro and in vivo functional and mechanistic assays revealed that EV-mediated release of miR-378a-3p from tumor cells was upregulated in bone-metastatic PCa, maintaining low intracellular miR-378a-3p concentration to promote proliferation and MAOA-mediated epithelial-to-mesenchymal transition.	mir-378a-	96-105	monoamine oxidase A	Homo sapiens	250-254
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Dopamine	69-77	monoamine oxidase A	Homo sapiens	34-38
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Norepinephrine	79-93	monoamine oxidase A	Homo sapiens	13-32
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Norepinephrine	79-93	monoamine oxidase A	Homo sapiens	34-38
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Serotonin	99-108	monoamine oxidase A	Homo sapiens	13-32
34923109-2	2022	Among these, Monoamine oxidase A (MAOA) catalyzes the degradation of dopamine, norepinephrine, and serotonin into their inactive metabolites.	Serotonin	99-108	monoamine oxidase A	Homo sapiens	34-38
34952543-1	2021	The monoamine oxidase A (MAO-A) is integral to monoamine metabolism and is thus relevant to the pathophysiology of various neuropsychiatric disorders; however, associated gene-enzyme relations are not well understood.	monoamine	47-56	monoamine oxidase A	Homo sapiens	4-23
34814086-0	2022	Monoamine oxidase A and B inhibitory activities of 3,5-diphenyl-1,2,4-triazole substituted (1,2,4)triazolo(3,4-b)(1,3,4)thiadiazole derivatives.	3,5-Diphenyl-4H-1,2,4-triazole	51-78	monoamine oxidase A	Homo sapiens	0-25
34814086-0	2022	Monoamine oxidase A and B inhibitory activities of 3,5-diphenyl-1,2,4-triazole substituted (1,2,4)triazolo(3,4-b)(1,3,4)thiadiazole derivatives.	1,2,4-triazolo-(3,4-b)-1,3,4-thiadiazoles	91-131	monoamine oxidase A	Homo sapiens	0-25
34952543-1	2021	The monoamine oxidase A (MAO-A) is integral to monoamine metabolism and is thus relevant to the pathophysiology of various neuropsychiatric disorders; however, associated gene-enzyme relations are not well understood.	monoamine	47-56	monoamine oxidase A	Homo sapiens	25-30
34952543-3	2021	Therefore, 18 179 mRNA expression maps (based on the Allen Human Brain Atlas) were correlated with the cerebral distribution volume (VT) of MAO-A assessed in 36 healthy subjects (mean age +- standard deviation: 32.9 +- 8.8 years, 18 female) using (11C)harmine positron emission tomography scans.	Harmine	252-259	monoamine oxidase A	Homo sapiens	140-145
34782122-4	2022	Monoamine oxidase A (MAOA) (X p11.23) plays a crucial role in the metabolism of monoamines.	monoamines	80-90	monoamine oxidase A	Homo sapiens	0-19
34829725-0	2021	MicroRNA Sequencing Analysis in Obstructive Sleep Apnea and Depression: Anti-Oxidant and MAOA-Inhibiting Effects of miR-15b-5p and miR-92b-3p through Targeting PTGS1-NF-kappaB-SP1 Signaling.	mir-15b-5p	116-126	monoamine oxidase A	Homo sapiens	89-93
34829725-10	2021	Down-regulated miR-15b-5p/miR-92b-3p in OSA patients could contribute to IHR-induced oxidative stress and MAOA hyperactivity through the eicosanoid inflammatory pathway via directly targeting PTGS1-NF-kappaB-SP1 signaling.	Eicosanoids	137-147	monoamine oxidase A	Homo sapiens	106-110
34795483-1	2021	Background: Monoamine oxidase-A (MAO-A) decomposes dopamine and serotonin, and decreased MAO-A expression increases monoamine levels and is related to the pathophysiology of schizophrenia.	Dopamine	51-59	monoamine oxidase A	Homo sapiens	12-31
34795483-1	2021	Background: Monoamine oxidase-A (MAO-A) decomposes dopamine and serotonin, and decreased MAO-A expression increases monoamine levels and is related to the pathophysiology of schizophrenia.	Dopamine	51-59	monoamine oxidase A	Homo sapiens	33-38
34795483-1	2021	Background: Monoamine oxidase-A (MAO-A) decomposes dopamine and serotonin, and decreased MAO-A expression increases monoamine levels and is related to the pathophysiology of schizophrenia.	Serotonin	64-73	monoamine oxidase A	Homo sapiens	12-31
34795483-1	2021	Background: Monoamine oxidase-A (MAO-A) decomposes dopamine and serotonin, and decreased MAO-A expression increases monoamine levels and is related to the pathophysiology of schizophrenia.	Serotonin	64-73	monoamine oxidase A	Homo sapiens	33-38
34782122-4	2022	Monoamine oxidase A (MAOA) (X p11.23) plays a crucial role in the metabolism of monoamines.	monoamines	80-90	monoamine oxidase A	Homo sapiens	21-25
34782122-6	2022	METHODS: In the present study, methylation rates of CpG dinucleotides in the MAOA promoter and exon 1 region were determined from DNA derived from whole blood samples of PWS patients (n = 32) and controls (n = 14) matched for age, sex and BMI via bisulfite sequencing.	cytidylyl-3'-5'-guanosine	52-69	monoamine oxidase A	Homo sapiens	77-81
34492558-7	2021	4-Bromo-2-((prop-2-yn-1-ylimino)methyl)phenol 4a was the most potent inhibitor of MAOs (IC50 of 3.95 and  10 microM for MAO-B and MAO-A, respectively) along with a balanced inhibition of both cholinesterases being a real MTDL.	4-bromo-2-((prop-2-yn-1-ylimino)methyl)phenol	0-45	monoamine oxidase A	Homo sapiens	130-135
34560070-4	2021	In vivo, by HE and TUNEL staining, we found that cisplatin-induced renal lesions and apoptotic regions, which were located in proximal tubular epithelial cells, were also the regions in which tryptophan hydroxylase 1 (Tph1), aromatic l-amino acid decarboxylase (AADC), 5-HT2A receptor (5-HT2AR) and monoamine oxidase A (MAO-A) were overexpressed, as determined by immunohistochemistry.	Cisplatin	49-58	monoamine oxidase A	Homo sapiens	299-318
34560070-4	2021	In vivo, by HE and TUNEL staining, we found that cisplatin-induced renal lesions and apoptotic regions, which were located in proximal tubular epithelial cells, were also the regions in which tryptophan hydroxylase 1 (Tph1), aromatic l-amino acid decarboxylase (AADC), 5-HT2A receptor (5-HT2AR) and monoamine oxidase A (MAO-A) were overexpressed, as determined by immunohistochemistry.	Cisplatin	49-58	monoamine oxidase A	Homo sapiens	320-325
34560070-8	2021	Additionally, similar to the combination of SH and CDP, the MAO-A inhibitor clorgyline could also abolish the effects of cisplatin challenge.	Clorgyline	76-86	monoamine oxidase A	Homo sapiens	60-65
34560070-8	2021	Additionally, similar to the combination of SH and CDP, the MAO-A inhibitor clorgyline could also abolish the effects of cisplatin challenge.	Cisplatin	121-130	monoamine oxidase A	Homo sapiens	60-65
34560070-9	2021	More importantly, by western blotting, we detected that the upregulation of Tph1, AADC and MAO-A expression induced by cisplatin both in vivo and in vitro could be obviously suppressed by SH to decrease 5-HT synthesis and mitochondrial 5-HT degradation.	Cisplatin	119-128	monoamine oxidase A	Homo sapiens	91-96
34560070-9	2021	More importantly, by western blotting, we detected that the upregulation of Tph1, AADC and MAO-A expression induced by cisplatin both in vivo and in vitro could be obviously suppressed by SH to decrease 5-HT synthesis and mitochondrial 5-HT degradation.	Serotonin	203-207	monoamine oxidase A	Homo sapiens	91-96
34560070-9	2021	More importantly, by western blotting, we detected that the upregulation of Tph1, AADC and MAO-A expression induced by cisplatin both in vivo and in vitro could be obviously suppressed by SH to decrease 5-HT synthesis and mitochondrial 5-HT degradation.	Serotonin	236-240	monoamine oxidase A	Homo sapiens	91-96
34607159-9	2021	MAO-A activation-impaired mitochondrial homeostasis resulted in ROS accumulation and NF-kappaB activation, thereby enhancing expression of atherogenic and proinflammatory molecules in ECs.	Reactive Oxygen Species	64-67	monoamine oxidase A	Homo sapiens	0-5
34503991-3	2021	Catecholamines are metabolized by two isoforms of monoamine oxidase, MAO-A and MAO-B; and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically.	Catecholamines	0-14	monoamine oxidase A	Homo sapiens	69-74
34503991-3	2021	Catecholamines are metabolized by two isoforms of monoamine oxidase, MAO-A and MAO-B; and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically.	Catecholamines	0-14	monoamine oxidase A	Homo sapiens	128-133
34503991-3	2021	Catecholamines are metabolized by two isoforms of monoamine oxidase, MAO-A and MAO-B; and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically.	Catecholamines	0-14	monoamine oxidase A	Homo sapiens	302-307
34503991-3	2021	Catecholamines are metabolized by two isoforms of monoamine oxidase, MAO-A and MAO-B; and although the anatomic localization of MAO-A and MAO-B and substrate specificities of enzyme inhibitors are well characterized, relative susceptibilities of the endogenous catecholamines to enzymatic oxidation by MAO-A and MAO-B have not been studied systematically.	Catecholamines	261-275	monoamine oxidase A	Homo sapiens	302-307
34503991-5	2021	In this study we exploited the technical ability to assay DOPAL and DOPEGAL simultaneously with the substrate catecholamines to compare DA, NE, and EPI in their metabolism by MAO-A and MAO-B.	Dopamine	136-138	monoamine oxidase A	Homo sapiens	175-180
34503991-5	2021	In this study we exploited the technical ability to assay DOPAL and DOPEGAL simultaneously with the substrate catecholamines to compare DA, NE, and EPI in their metabolism by MAO-A and MAO-B.	Epinephrine	148-151	monoamine oxidase A	Homo sapiens	175-180
34503991-7	2021	Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intra-neuronal enzymatic oxidation of catecholamines is via MAO-A.	Catecholamines	133-147	monoamine oxidase A	Homo sapiens	71-76
34503991-7	2021	Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intra-neuronal enzymatic oxidation of catecholamines is via MAO-A.	Catecholamines	133-147	monoamine oxidase A	Homo sapiens	258-263
34503991-7	2021	Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intra-neuronal enzymatic oxidation of catecholamines is via MAO-A.	Catecholamines	236-250	monoamine oxidase A	Homo sapiens	47-52
34503991-7	2021	Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intra-neuronal enzymatic oxidation of catecholamines is via MAO-A.	Catecholamines	236-250	monoamine oxidase A	Homo sapiens	71-76
34503991-7	2021	Since catecholaminergic neurons express mainly MAO-A, the finding that MAO-A is more efficient than MAO-B in metabolizing endogenous catecholamines reinforces the view that the predominant route of intra-neuronal enzymatic oxidation of catecholamines is via MAO-A.	Catecholamines	236-250	monoamine oxidase A	Homo sapiens	258-263
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Catecholamines	34-48	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	catecholaldehydes	115-132	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	3,4-dihydroxyphenylacetaldehyde	133-164	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	3,4-dihydroxyphenylacetaldehyde	166-171	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Dopamine	178-186	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Dopamine	188-190	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	3,4-dihydroxyphenylglycolaldehyde	196-229	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	3,4-dihydroxyphenylglycolaldehyde	231-238	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Norepinephrine	245-259	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Epinephrine	269-280	monoamine oxidase A	Homo sapiens	68-100
34503991-10	2021	Significance Statement Endogenous catecholamines are metabolized by monoamine oxidase (MAO)-A and -B, yielding the catecholaldehydes 3,4-dihydroxyphenylacetaldehyde (DOPAL) from dopamine (DA) and 3,4-dihydroxyphenylglycolaldehyde (DOPEGAL) from norepinephrine (NE) and epinephrine (EPI).	Epinephrine	282-285	monoamine oxidase A	Homo sapiens	68-100
34503991-11	2021	Based on measurements of DOPAL and DOPEGAL production, DA is a better substrate than NE or EPI for both MAO isoforms, and MAO-A is more efficient than MAO-B in metabolizing DA, NE, and EPI.	3,4-dihydroxyphenylacetaldehyde	25-30	monoamine oxidase A	Homo sapiens	122-127
34503991-11	2021	Based on measurements of DOPAL and DOPEGAL production, DA is a better substrate than NE or EPI for both MAO isoforms, and MAO-A is more efficient than MAO-B in metabolizing DA, NE, and EPI.	3,4-dihydroxyphenylglycolaldehyde	35-42	monoamine oxidase A	Homo sapiens	122-127
34503991-11	2021	Based on measurements of DOPAL and DOPEGAL production, DA is a better substrate than NE or EPI for both MAO isoforms, and MAO-A is more efficient than MAO-B in metabolizing DA, NE, and EPI.	Dopamine	173-175	monoamine oxidase A	Homo sapiens	122-127
34503991-12	2021	MAO-A is the main route of intra-neuronal metabolism of endogenous catecholamines.	Catecholamines	67-81	monoamine oxidase A	Homo sapiens	0-5
34416504-0	2021	High-dose testosterone treatment reduces monoamine oxidase A levels in the human brain: A preliminary report.	Testosterone	10-22	monoamine oxidase A	Homo sapiens	41-60
34416504-3	2021	Here, we investigated the effects of GHT on levels of monoamine oxidase A (MAO-A), another key target of antidepressant treatment.	6a,7-Dehydroboldine	37-40	monoamine oxidase A	Homo sapiens	54-73
34416504-4	2021	Participants underwent PET with the radioligand (11C)harmine to assess cerebral MAO-A distribution volumes (VT) before and four months after initiation of GHT.	(11c)harmine	48-60	monoamine oxidase A	Homo sapiens	80-85
34416504-6	2021	Preliminary analysis of available data revealed statistically significant MAO-A VT reductions in TM under testosterone treatment in six of twelve a priori defined regions of interest (middle frontal cortex (-10%), anterior cingulate cortex (-9%), medial cingulate cortex (-10.5%), insula (-8%), amygdala (-9%) and hippocampus (-8.5%, all p<0.05)).	Testosterone	106-118	monoamine oxidase A	Homo sapiens	74-79
34416504-9	2021	Considering MAO-A"s central role in regulation of serotonergic neurotransmission, changes to MAO-A VT should be further investigated as a possible mechanism by which testosterone mediates risk for, symptomatology of, and treatment response in affective disorders.	Testosterone	166-178	monoamine oxidase A	Homo sapiens	12-17
34416504-9	2021	Considering MAO-A"s central role in regulation of serotonergic neurotransmission, changes to MAO-A VT should be further investigated as a possible mechanism by which testosterone mediates risk for, symptomatology of, and treatment response in affective disorders.	Testosterone	166-178	monoamine oxidase A	Homo sapiens	93-98
34445126-0	2021	MAO-A Inhibition by Metaxalone Reverts IL-1beta-Induced Inflammatory Phenotype in Microglial Cells.	metaxalone	20-30	monoamine oxidase A	Homo sapiens	0-5
34682298-3	2021	Compounds alternariol (AT), 5"-hydroxy-alternariol (HAT), and mycoepoxydiene (MED), isolated from the extract, had potent inhibitory activities against hMAO-A with IC50 values of 0.020, 0.31, and 8.68 microM, respectively.	5"-hydroxy-alternariol	28-50	monoamine oxidase A	Homo sapiens	152-158
34682298-3	2021	Compounds alternariol (AT), 5"-hydroxy-alternariol (HAT), and mycoepoxydiene (MED), isolated from the extract, had potent inhibitory activities against hMAO-A with IC50 values of 0.020, 0.31, and 8.68 microM, respectively.	hat	52-55	monoamine oxidase A	Homo sapiens	152-158
34682298-3	2021	Compounds alternariol (AT), 5"-hydroxy-alternariol (HAT), and mycoepoxydiene (MED), isolated from the extract, had potent inhibitory activities against hMAO-A with IC50 values of 0.020, 0.31, and 8.68 microM, respectively.	mycoepoxydiene	62-76	monoamine oxidase A	Homo sapiens	152-158
34682298-3	2021	Compounds alternariol (AT), 5"-hydroxy-alternariol (HAT), and mycoepoxydiene (MED), isolated from the extract, had potent inhibitory activities against hMAO-A with IC50 values of 0.020, 0.31, and 8.68 microM, respectively.	mycoepoxydiene	78-81	monoamine oxidase A	Homo sapiens	152-158
34682298-6	2021	The relative tight binding might result from a hydrogen bond interaction of the three compounds with a Tyr444 residue in hMAO-A, whereas no hydrogen bond interaction was proposed in hMAO-B.	Hydrogen	47-55	monoamine oxidase A	Homo sapiens	121-127
34116327-0	2021	Halting colorectal cancer metastasis via novel dual nanomolar MMP-9/MAO-A quinoxaline-based inhibitors; design, synthesis, and evaluation.	Quinoxalines	74-85	monoamine oxidase A	Homo sapiens	68-73
34116327-2	2021	Novel series of quinoxaline-based dual MMP-9/MAO-A inhibitors were synthesized to suppress CRC progression.	Quinoxalines	16-27	monoamine oxidase A	Homo sapiens	45-50
34116327-7	2021	Enzymatic assays revealed that the selected derivatives were superior to the reference MMP-9 and MAO-A inhibitors (quercetin and clorgyline, respectively).	Quercetin	115-124	monoamine oxidase A	Homo sapiens	97-102
34311047-4	2021	At very high concentrations of RDV, there was partial inhibition of complex I- (IC50 675 micromol/L, residual activity 39.4 %) and complex II-linked (IC50 81.8 micromol/L, residual activity 40.7 %) respiration, without inhibition of complex IV-linked respiration, and partial inhibition both of MAO-A (IC50 26.6 micromol/L, residual activity 35.2 %) and MAO-B (IC50 89.8 micromol/L, residual activity 34.0 %) activity.	remdesivir	31-34	monoamine oxidase A	Homo sapiens	295-300
34455780-4	2021	Furthermore, two MAO-A screening assays based on (1) human-recombinant MAO-A and (2) displacement of 2-fluoro-ethyl-harmine from mouse brain homogenate were employed.	2-fluoro-ethyl-harmine	101-123	monoamine oxidase A	Homo sapiens	17-22
34674410-0	2022	Novel thiazolyl-hydrazone derivatives including piperazine ring: synthesis, in vitro evaluation, and molecular docking as selective MAO-A inhibitor.	thiazolyl-hydrazone	6-25	monoamine oxidase A	Homo sapiens	132-137
34674410-0	2022	Novel thiazolyl-hydrazone derivatives including piperazine ring: synthesis, in vitro evaluation, and molecular docking as selective MAO-A inhibitor.	Piperazine	48-58	monoamine oxidase A	Homo sapiens	132-137
34674410-7	2022	Based on this view, new thiazolyl-hydrazone compounds were synthesized, characterized, and screened for their hMAO-A and hMAO-B inhibitory activity by an in vitro fluorometric method.	thiazolyl-hydrazone	24-43	monoamine oxidase A	Homo sapiens	110-116
34674410-9	2022	The compound including 2,4-dimethyl substituent (3i) were found to be the most effective agents in the series against MAO-A enzyme with the IC50 value of 0.080 +- 0.003 microM.	2,4-dimethyl	23-35	monoamine oxidase A	Homo sapiens	118-123
34280394-5	2021	LO2 cells were treated with CCl4, 5-HT or 2,5-dimethoxy-4-idopametamine and pretreated with SH, CDP or the monoamine oxidase A (MAO-A) inhibitor clorgyline.	Clorgyline	145-155	monoamine oxidase A	Homo sapiens	128-133
34280394-7	2021	5-HT2A receptors, 5-HT synthetase and MAO-A were expressed in hepatocytes; their gene and protein expression were upregulated by CCl4, which led to the degradation of mitochondrial 5-HT and overproduction of reactive oxygen species (ROS).	Carbon Tetrachloride	129-133	monoamine oxidase A	Homo sapiens	38-43
34280394-7	2021	5-HT2A receptors, 5-HT synthetase and MAO-A were expressed in hepatocytes; their gene and protein expression were upregulated by CCl4, which led to the degradation of mitochondrial 5-HT and overproduction of reactive oxygen species (ROS).	Serotonin	181-185	monoamine oxidase A	Homo sapiens	38-43
34174267-4	2021	A docking study of gamma-decanolactone has been carried out with the molecular targets of MAO-A and MAO-B isoforms.	decan-4-olide	19-38	monoamine oxidase A	Homo sapiens	90-95
34174267-11	2021	The molecular docking study show that the gamma-decanolactone ligand adopts a relatively compact conformation in the active site of hMAO-B, while we note an extended conformation of gamma-decanolactone ligand in the hMAO-A isoform.	decan-4-olide	182-201	monoamine oxidase A	Homo sapiens	216-222
34102520-4	2021	Compounds 2a, 2k, 4a and 4i showed significant inhibitory activity against MAO-A, with IC50 value in the range of 0.084-0.207 microM compared to reference drug moclobemide (IC50 value = 6.061 microM).	Moclobemide	160-171	monoamine oxidase A	Homo sapiens	75-80
34097996-0	2021	Induction of monoamine oxidase A-mediated oxidative stress and impairment of NRF2-antioxidant defence response by polyphenol-rich fraction of Bergenia ligulata sensitizes prostate cancer cells in vitro and in vivo.	Polyphenols	114-124	monoamine oxidase A	Homo sapiens	13-32
34097996-5	2021	Further investigation revealed that PFBL mediates its function through upregulating ROS production by enhanced catalytic activity of monoamine oxidase A (MAO-A).	pfbl	36-40	monoamine oxidase A	Homo sapiens	133-152
34097996-5	2021	Further investigation revealed that PFBL mediates its function through upregulating ROS production by enhanced catalytic activity of monoamine oxidase A (MAO-A).	pfbl	36-40	monoamine oxidase A	Homo sapiens	154-159
34097996-5	2021	Further investigation revealed that PFBL mediates its function through upregulating ROS production by enhanced catalytic activity of monoamine oxidase A (MAO-A).	ros	84-87	monoamine oxidase A	Homo sapiens	133-152
34097996-5	2021	Further investigation revealed that PFBL mediates its function through upregulating ROS production by enhanced catalytic activity of monoamine oxidase A (MAO-A).	ros	84-87	monoamine oxidase A	Homo sapiens	154-159
34167949-3	2021	Here we report that monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, reciprocally interacts with AR in PC.	monoamine	85-94	monoamine oxidase A	Homo sapiens	20-39
34167949-3	2021	Here we report that monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, reciprocally interacts with AR in PC.	monoamine	85-94	monoamine oxidase A	Homo sapiens	41-45
34167949-3	2021	Here we report that monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, reciprocally interacts with AR in PC.	Amines	125-131	monoamine oxidase A	Homo sapiens	20-39
34167949-3	2021	Here we report that monoamine oxidase A (MAOA), a mitochondrial enzyme that degrades monoamine neurotransmitters and dietary amines, reciprocally interacts with AR in PC.	Amines	125-131	monoamine oxidase A	Homo sapiens	41-45
34167949-7	2021	Finally, genetic or pharmacologic targeting of MAOA enhanced the growth-inhibition efficacy of enzalutamide, darolutamide, and apalutamide in both androgen-dependent and castration-resistant PC cells.	enzalutamide	95-107	monoamine oxidase A	Homo sapiens	47-51
34167949-7	2021	Finally, genetic or pharmacologic targeting of MAOA enhanced the growth-inhibition efficacy of enzalutamide, darolutamide, and apalutamide in both androgen-dependent and castration-resistant PC cells.	darolutamide	109-121	monoamine oxidase A	Homo sapiens	47-51
34167949-7	2021	Finally, genetic or pharmacologic targeting of MAOA enhanced the growth-inhibition efficacy of enzalutamide, darolutamide, and apalutamide in both androgen-dependent and castration-resistant PC cells.	apalutamide	127-138	monoamine oxidase A	Homo sapiens	47-51
34445126-2	2021	Metaxalone is an FDA-approved muscle relaxant that has been reported to inhibit monoamine oxidase A (MAO-A).	metaxalone	0-10	monoamine oxidase A	Homo sapiens	80-99
34445126-2	2021	Metaxalone is an FDA-approved muscle relaxant that has been reported to inhibit monoamine oxidase A (MAO-A).	metaxalone	0-10	monoamine oxidase A	Homo sapiens	101-106
34445126-9	2021	Metaxalone decreased MAO-A activity and expression, reduced NF-kB, TNF-alpha, and IL-6, enhanced IL-13, and also increased PPARgamma, PGC-1alpha, and Nrf2 expression.	metaxalone	0-10	monoamine oxidase A	Homo sapiens	21-26
34356625-2	2021	Lipophilic tanshinones are major phytoconstituents in the dried roots of Salvia miltiorrhiza that have demonstrated neuroprotective effects against dopaminergic neurotoxins and the inhibition of MAO-A.	tanshinone	11-22	monoamine oxidase A	Homo sapiens	195-200
34439627-4	2021	Childhood trauma and functional genetic polymorphisms in catecholamines converting enzymes, such as mono-amino-oxidase A (MAO-A) and catechol-o-methyltransferase (COMT) have been suggested to augment an aggressive behavioral response in adulthood.	Catecholamines	57-71	monoamine oxidase A	Homo sapiens	100-120
34439627-4	2021	Childhood trauma and functional genetic polymorphisms in catecholamines converting enzymes, such as mono-amino-oxidase A (MAO-A) and catechol-o-methyltransferase (COMT) have been suggested to augment an aggressive behavioral response in adulthood.	Catecholamines	57-71	monoamine oxidase A	Homo sapiens	122-127
34356625-4	2021	In our study, tanshinone I (1) exhibited the highest potency against hMAO-A, followed by tanshinone IIA and cryptotanshinone, with an IC50 less than 10 microM.	tanshinone	14-26	monoamine oxidase A	Homo sapiens	69-75
34356625-6	2021	Although tanshinones are known to inhibit hMAO-A, their enzyme inhibition mechanism and binding sites have yet to be investigated.	tanshinone	9-20	monoamine oxidase A	Homo sapiens	42-48
34071665-2	2021	Pyrazoline/halogenated pyrazolines were investigated for their inhibitory activities against human monoamine oxidase-A and -B.	pyrazoline	0-10	monoamine oxidase A	Homo sapiens	99-125
34112755-8	2021	We further demonstrate that MAO-A promotes TAM immunosuppressive polarization via upregulating oxidative stress.	tam	43-46	monoamine oxidase A	Homo sapiens	28-33
34112755-9	2021	Together, these data identify MAO-A as a critical regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunotherapy.	tams	63-67	monoamine oxidase A	Homo sapiens	30-35
34112755-9	2021	Together, these data identify MAO-A as a critical regulator of TAMs and support repurposing MAOIs for TAM reprogramming to improve cancer immunotherapy.	tam	102-105	monoamine oxidase A	Homo sapiens	30-35
34201128-3	2021	Six compounds inhibited MAO-B more effectively than MAO-A, and the 2",3",4"-methoxy moiety in CH4-CH6 was more effective for MAO-B inhibition than the 2",4",6"-methoxy moiety in CH1-CH3.	2",3",4"-methoxy	67-83	monoamine oxidase A	Homo sapiens	52-57
34201128-3	2021	Six compounds inhibited MAO-B more effectively than MAO-A, and the 2",3",4"-methoxy moiety in CH4-CH6 was more effective for MAO-B inhibition than the 2",4",6"-methoxy moiety in CH1-CH3.	ch4-ch6	94-101	monoamine oxidase A	Homo sapiens	52-57
34201128-3	2021	Six compounds inhibited MAO-B more effectively than MAO-A, and the 2",3",4"-methoxy moiety in CH4-CH6 was more effective for MAO-B inhibition than the 2",4",6"-methoxy moiety in CH1-CH3.	2",4",6"-methoxy	151-167	monoamine oxidase A	Homo sapiens	52-57
34071665-2	2021	Pyrazoline/halogenated pyrazolines were investigated for their inhibitory activities against human monoamine oxidase-A and -B.	pyrazolines	23-34	monoamine oxidase A	Homo sapiens	99-125
34477522-8	2021	Chalcones, generally, are potential and more selective towards MAO-B inhibitions whereas pyrazolines derived from chalcones turned into selective towards MAO-A inhibitions due to maybe the presence of two nitrogen heteroatoms.	pyrazolines	89-100	monoamine oxidase A	Homo sapiens	154-159
34779368-0	2021	Physicochemical, Interaction & Topological Descriptors vs. hMAO-A Inhibition of Aplysinopsin Analogs: A Boulevard to the Discovery of Semi-Synthetic Anti-Depression Agents.	aplysinopsin	80-92	monoamine oxidase A	Homo sapiens	59-65
34477522-8	2021	Chalcones, generally, are potential and more selective towards MAO-B inhibitions whereas pyrazolines derived from chalcones turned into selective towards MAO-A inhibitions due to maybe the presence of two nitrogen heteroatoms.	Chalcones	114-123	monoamine oxidase A	Homo sapiens	154-159
34779368-2	2021	OBJECTIVE: This study aimed to model a 2D-QSAR equation that can facilitate the researchers to design better aplysinopsin analogs with potent hMAO-A inhibition.	aplysinopsin	109-121	monoamine oxidase A	Homo sapiens	142-148
34477522-8	2021	Chalcones, generally, are potential and more selective towards MAO-B inhibitions whereas pyrazolines derived from chalcones turned into selective towards MAO-A inhibitions due to maybe the presence of two nitrogen heteroatoms.	Nitrogen	205-213	monoamine oxidase A	Homo sapiens	154-159
34779368-13	2021	This model can be used for the design of a more potent hMAO-A inhibitor having an aplysinopsin scaffold, which can then contribute to the treatment of depression and other neurological disorders.	aplysinopsin	82-94	monoamine oxidase A	Homo sapiens	55-61
34477522-10	2021	Our group has already documented the importance of pyrazolines towards MAO-A inhibition in 2013.	pyrazolines	51-62	monoamine oxidase A	Homo sapiens	71-76
35447344-4	2022	An important consideration is that selegiline and rasagiline display specificity for MAO-B over the MAO-A isoform thus reducing the risk of tyramine-induced changes in blood-pressure.	rasagiline	50-60	monoamine oxidase A	Homo sapiens	100-105
34158725-1	2020	Linezolid is an oxazolidinone antibiotic, which is a weak, reversible, nonselective monoamine oxidase A and B inhibitor; is known to increase serotonin levels, and has been implicated in the development of serotonin syndrome (SS).	Linezolid	0-9	monoamine oxidase A	Homo sapiens	84-109
34158725-1	2020	Linezolid is an oxazolidinone antibiotic, which is a weak, reversible, nonselective monoamine oxidase A and B inhibitor; is known to increase serotonin levels, and has been implicated in the development of serotonin syndrome (SS).	Oxazolidinones	16-29	monoamine oxidase A	Homo sapiens	84-109
35472505-1	2022	Monoamine oxidases A and B (MAO-A and MAO-B) play important roles in biogenic amine metabolism, oxidative stress, and chronic inflammation.	Amines	78-83	monoamine oxidase A	Homo sapiens	0-26
35472505-1	2022	Monoamine oxidases A and B (MAO-A and MAO-B) play important roles in biogenic amine metabolism, oxidative stress, and chronic inflammation.	Amines	78-83	monoamine oxidase A	Homo sapiens	28-33
35472505-3	2022	Herein, novel 3,6-disubstituted isobenzofuran-1(3H)-ones were designed, synthesized and evaluated in vitro as inhibitors of monoamine oxidases A and B.	3,6-disubstituted isobenzofuran-1(3h)-ones	14-56	monoamine oxidase A	Homo sapiens	124-150
35500503-0	2022	Quinazolinone-based benzenesulfonamides with low toxicity and high affinity as monoamine oxidase-A inhibitors: Synthesis, biological evaluation and induced-fit docking studies.	Quinazolinones	0-13	monoamine oxidase A	Homo sapiens	79-98
35500503-0	2022	Quinazolinone-based benzenesulfonamides with low toxicity and high affinity as monoamine oxidase-A inhibitors: Synthesis, biological evaluation and induced-fit docking studies.	benzenesulfonamide	20-39	monoamine oxidase A	Homo sapiens	79-98
35447344-6	2022	The in vitro human MAO inhibition properties of this compound were measured and the results showed that 2-PAT is a 20-fold more potent inhibitor of MAO-A (IC50 = 0.721 microM) compared to MAO-B (IC50 = 14.6 microM).	2-PAT	104-109	monoamine oxidase A	Homo sapiens	148-153
35447344-7	2022	Interestingly, dialysis studies found that 2-PAT is a reversible MAO-A inhibitor, while acting as an inactivator of MAO-B.	2-PAT	43-48	monoamine oxidase A	Homo sapiens	65-70
35447344-8	2022	Since reversible MAO-A inhibitors are much less liable to potentiate tyramine-induced side effects than MAO-A inactivators, it is reasonable to suggest that 2-PAT could be a useful and safe therapeutic agent for disorders such as Parkinson"s disease and depression.	2-PAT	157-162	monoamine oxidase A	Homo sapiens	17-22
35447344-8	2022	Since reversible MAO-A inhibitors are much less liable to potentiate tyramine-induced side effects than MAO-A inactivators, it is reasonable to suggest that 2-PAT could be a useful and safe therapeutic agent for disorders such as Parkinson"s disease and depression.	2-PAT	157-162	monoamine oxidase A	Homo sapiens	104-109
35349822-6	2022	In particular, Enz was found to induce NED via the MAOA/mTOR/HIF-1alpha signaling axis.	ned	39-42	monoamine oxidase A	Homo sapiens	51-55
35621378-10	2022	In these compounds, huperzine B, huperzinine, lycoposerramine U N-oxide, 12-epilycodine N-oxide showed strongly inhibit the five AChE, BuChE, MAO A, BACE 1 and NMDA targets for Alzheimer"s treatment.	huperzine B	20-31	monoamine oxidase A	Homo sapiens	142-147
35621378-10	2022	In these compounds, huperzine B, huperzinine, lycoposerramine U N-oxide, 12-epilycodine N-oxide showed strongly inhibit the five AChE, BuChE, MAO A, BACE 1 and NMDA targets for Alzheimer"s treatment.	huperzinine	33-44	monoamine oxidase A	Homo sapiens	142-147
35621378-10	2022	In these compounds, huperzine B, huperzinine, lycoposerramine U N-oxide, 12-epilycodine N-oxide showed strongly inhibit the five AChE, BuChE, MAO A, BACE 1 and NMDA targets for Alzheimer"s treatment.	Lycoposerramine U N-oxide	46-71	monoamine oxidase A	Homo sapiens	142-147
35621378-10	2022	In these compounds, huperzine B, huperzinine, lycoposerramine U N-oxide, 12-epilycodine N-oxide showed strongly inhibit the five AChE, BuChE, MAO A, BACE 1 and NMDA targets for Alzheimer"s treatment.	12-epilycodine	73-87	monoamine oxidase A	Homo sapiens	142-147
35349822-7	2022	Further analyses revealed that the MAOA inhibitor clorgyline(CLG) may bring multiple benefits to CRPC patients, including better therapeutic effect and delays NED.	Clorgyline	50-60	monoamine oxidase A	Homo sapiens	35-39
35202708-1	2022	Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A receptor, and 5-HT synthases in hepatocytes.	Carbon Tetrachloride	78-98	monoamine oxidase A	Homo sapiens	194-213
35621378-10	2022	In these compounds, huperzine B, huperzinine, lycoposerramine U N-oxide, 12-epilycodine N-oxide showed strongly inhibit the five AChE, BuChE, MAO A, BACE 1 and NMDA targets for Alzheimer"s treatment.	n-oxide	88-95	monoamine oxidase A	Homo sapiens	142-147
35626478-6	2022	Docking interaction analysis revealed that Soyasapogenol B bound effectively to all of the targeted proteins (AChE, BuChE MAO-A, MAO-B, GSK3beta, and NMDA), in contrast to other screened abrineurin natural inducers and inhibitors.	soyasapogenol B	43-58	monoamine oxidase A	Homo sapiens	122-127
35596745-2	2022	Due to structural similarities of flortaucipir with some monoamine oxidase A (MAO-A) inhibitors, this study aimed to evaluate flortaucipir binding to MAO-A and MAO-B and any potential impact on PET interpretation.	7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	126-138	monoamine oxidase A	Homo sapiens	150-155
35596745-7	2022	(18F)Flortaucipir bound with low nanomolar affinity to human MAO-A in a microsomal preparation in vitro but with a fast dissociation rate relative to MAO-A ligand fluoroethyl-harmol, consistent with no observed in vivo binding in rats of (18F)flortaucipir to MAO-A.	7-(6-fluoropyridin-3-yl)-5H-pyrido(4,3-b)indole	5-17	monoamine oxidase A	Homo sapiens	61-66
35566238-2	2022	Monoamine Oxidase-A (MAO-A) enzyme mediates the production of reactive oxygen species (ROS) that trigger DNA damage and oxidative injury of cells resulting in tumor initiation and progression.	Reactive Oxygen Species	62-85	monoamine oxidase A	Homo sapiens	0-19
35566238-2	2022	Monoamine Oxidase-A (MAO-A) enzyme mediates the production of reactive oxygen species (ROS) that trigger DNA damage and oxidative injury of cells resulting in tumor initiation and progression.	Reactive Oxygen Species	62-85	monoamine oxidase A	Homo sapiens	21-26
35566238-2	2022	Monoamine Oxidase-A (MAO-A) enzyme mediates the production of reactive oxygen species (ROS) that trigger DNA damage and oxidative injury of cells resulting in tumor initiation and progression.	Reactive Oxygen Species	87-90	monoamine oxidase A	Homo sapiens	0-19
35566238-2	2022	Monoamine Oxidase-A (MAO-A) enzyme mediates the production of reactive oxygen species (ROS) that trigger DNA damage and oxidative injury of cells resulting in tumor initiation and progression.	Reactive Oxygen Species	87-90	monoamine oxidase A	Homo sapiens	21-26
35298131-11	2022	Network pharmacology and molecular docking revealed that CYP1A2, CYP2A6, CYP2E1, MAOA, PLA2G2A, PTGS1, and XDH were critical targets for PBZ hepatorenal toxicity.	paclobutrazol	137-140	monoamine oxidase A	Homo sapiens	81-85
35457272-2	2022	However, this traditional belief has been challenged by demonstrating that it is not MAOB but MAOA which mediates dopamine degradation.	Dopamine	114-122	monoamine oxidase A	Homo sapiens	94-98
35202708-1	2022	Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A receptor, and 5-HT synthases in hepatocytes.	Carbon Tetrachloride	78-98	monoamine oxidase A	Homo sapiens	215-220
35202708-1	2022	Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A receptor, and 5-HT synthases in hepatocytes.	Serotonin	148-152	monoamine oxidase A	Homo sapiens	194-213
35202708-1	2022	Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A receptor, and 5-HT synthases in hepatocytes.	Serotonin	148-152	monoamine oxidase A	Homo sapiens	215-220
35202708-1	2022	Previously we found that acute liver injury (ALI) with inflammation caused by carbon tetrachloride (CCl4) was associated with the activation of the 5-HT degradation system (5DS), which includes monoamine oxidase A (MAO-A), the 5-HT2A receptor, and 5-HT synthases in hepatocytes.	Serotonin	248-252	monoamine oxidase A	Homo sapiens	215-220
35202708-4	2022	Suppression of 5DS with the 5-HT2A receptor antagonist, MAO-A inhibitor, or gene silencing MAO-A significantly reduced the CCl4-induced production of mitochondrial reactive oxygen species (ROS).	Reactive Oxygen Species	164-187	monoamine oxidase A	Homo sapiens	56-61
35202708-4	2022	Suppression of 5DS with the 5-HT2A receptor antagonist, MAO-A inhibitor, or gene silencing MAO-A significantly reduced the CCl4-induced production of mitochondrial reactive oxygen species (ROS).	Reactive Oxygen Species	164-187	monoamine oxidase A	Homo sapiens	91-96
35202708-4	2022	Suppression of 5DS with the 5-HT2A receptor antagonist, MAO-A inhibitor, or gene silencing MAO-A significantly reduced the CCl4-induced production of mitochondrial reactive oxygen species (ROS).	Reactive Oxygen Species	189-192	monoamine oxidase A	Homo sapiens	56-61
35202708-4	2022	Suppression of 5DS with the 5-HT2A receptor antagonist, MAO-A inhibitor, or gene silencing MAO-A significantly reduced the CCl4-induced production of mitochondrial reactive oxygen species (ROS).	Reactive Oxygen Species	189-192	monoamine oxidase A	Homo sapiens	91-96
35350344-0	2022	Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease.	indole	40-46	monoamine oxidase A	Homo sapiens	158-179
35350344-0	2022	Design, Synthesis, and Bioevaluation of Indole Core Containing 2-Arylidine Derivatives of Thiazolopyrimidine as Multitarget Inhibitors of Cholinesterases and Monoamine Oxidase A/B for the Treatment of Alzheimer Disease.	thiazolopyrimidine	90-108	monoamine oxidase A	Homo sapiens	158-179
35051709-3	2022	Particularly, FY-56 was identified to be a highly potent LSD1 inhibitor (IC50 = 42 nM) and showed high selectivity over monoamine oxidases (MAO-A/B).	fy-56	14-19	monoamine oxidase A	Homo sapiens	140-147
35005974-0	2022	N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.	N-Methylpropargylamine	0-22	monoamine oxidase A	Homo sapiens	73-92
35168478-3	2022	A recent study has shown that coumarins tend to be more selective towards MAO-B than MAO-A when connected to a hex-5-ynyloxy chain at position 6 in contrast to their C7-isomers.	Coumarins	30-39	monoamine oxidase A	Homo sapiens	85-90
35168478-8	2022	Molecular dynamics revealed that the C7-isomer is relatively stable in both MAO isoforms through the simulation duration, whereas the C6-isomer deemed unstable for MAO-A which may be due to the bulky Phe-208 residue in MAO-A.	Phenylalanine	200-203	monoamine oxidase A	Homo sapiens	164-169
35168478-8	2022	Molecular dynamics revealed that the C7-isomer is relatively stable in both MAO isoforms through the simulation duration, whereas the C6-isomer deemed unstable for MAO-A which may be due to the bulky Phe-208 residue in MAO-A.	Phenylalanine	200-203	monoamine oxidase A	Homo sapiens	219-224
35005974-0	2022	N-Methylpropargylamine-Conjugated Hydroxamic Acids as Dual Inhibitors of Monoamine Oxidase A and Histone Deacetylase for Glioma Treatment.	Hydroxamic Acids	34-50	monoamine oxidase A	Homo sapiens	73-92
35005974-4	2022	We have synthesized and evaluated N-methylpropargylamine-conjugated hydroxamic acids as dual inhibitors of MAO A and HDAC.	N-Methylpropargylamine	34-56	monoamine oxidase A	Homo sapiens	107-112
35005974-4	2022	We have synthesized and evaluated N-methylpropargylamine-conjugated hydroxamic acids as dual inhibitors of MAO A and HDAC.	Hydroxamic Acids	68-84	monoamine oxidase A	Homo sapiens	107-112
35049267-3	2022	(S)-6 showed higher binding affinity to MAO-B and lower binding affinity to MAO-A than (R)-6, demonstrating a higher selectivity ratio (MAO-B/MAO-A).	(r)-6	87-92	monoamine oxidase A	Homo sapiens	76-81
35049267-3	2022	(S)-6 showed higher binding affinity to MAO-B and lower binding affinity to MAO-A than (R)-6, demonstrating a higher selectivity ratio (MAO-B/MAO-A).	(r)-6	87-92	monoamine oxidase A	Homo sapiens	142-147
35049267-3	2022	(S)-6 showed higher binding affinity to MAO-B and lower binding affinity to MAO-A than (R)-6, demonstrating a higher selectivity ratio (MAO-B/MAO-A).	(s)-6	0-5	monoamine oxidase A	Homo sapiens	76-81
35049267-3	2022	(S)-6 showed higher binding affinity to MAO-B and lower binding affinity to MAO-A than (R)-6, demonstrating a higher selectivity ratio (MAO-B/MAO-A).	(s)-6	0-5	monoamine oxidase A	Homo sapiens	142-147